-DOCSTART- -X- -X- -X- O

A	O
41	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
with	O
weight	B-Sign_symptom
loss	I-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
vomiting	B-Sign_symptom
,	O
and	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
was	O
referred	O
for	O
an	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
to	O
rule	O
out	O
intraabdominal	B-Disease_disorder
pathology	I-Disease_disorder
.	O

A	O
dedicated	O
CT	B-Diagnostic_procedure
of	O
the	O
abdomen	B-Biological_structure
was	O
performed	O
at	O
our	O
institution	B-Nonbiological_location
according	O
to	O
our	O
standard	B-Detailed_description
venous	I-Detailed_description
phase	I-Detailed_description
protocol	I-Detailed_description
.	O

Following	O
ingestion	O
of	O
positive	B-Diagnostic_procedure
oral	I-Diagnostic_procedure
contrast	I-Diagnostic_procedure
material	O
(	O
barium	B-Medication
sulfate	I-Medication
suspension	I-Medication
2	B-Dosage
.	I-Dosage
1	I-Dosage
%	I-Dosage
w	I-Dosage
/	I-Dosage
v	I-Dosage
,	O
Mallinckrodt	B-Detailed_description
)	O
and	O
injection	O
of	O
125	B-Dosage
ml	I-Dosage
of	O
iopromide	B-Medication
,	O
300	B-Dosage
mg	I-Dosage
I	I-Dosage
/	I-Dosage
mL	I-Dosage
(	O
Ultravist	B-Detailed_description
,	I-Detailed_description
Bayer	I-Detailed_description
HealthCare	I-Detailed_description
)	O
,	O
helical	B-Detailed_description
CT	O
was	O
obtained	O
with	O
a	O
65	B-Detailed_description
-	I-Detailed_description
s	I-Detailed_description
delays	I-Detailed_description
using	O
a	O
64	B-Detailed_description
-	I-Detailed_description
slice	I-Detailed_description
GE	I-Detailed_description
Lightspeed	I-Detailed_description
VCT	I-Detailed_description
scanner	I-Detailed_description
(	O
GE	B-Detailed_description
Medical	I-Detailed_description
Systems	I-Detailed_description
;	I-Detailed_description
Milwaukee	I-Detailed_description
,	I-Detailed_description
WI	I-Detailed_description
)	O
.	O

Axial	B-Diagnostic_procedure
sections	I-Diagnostic_procedure
of	O
the	O
abdomen	B-Biological_structure
showed	O
a	O
large	B-Lab_value
(	O
18	B-Volume
×	I-Volume
22	I-Volume
×	I-Volume
22	I-Volume
cm	I-Volume
)	O
heterogeneous	B-Detailed_description
retroperitoneal	B-Biological_structure
mass	B-Sign_symptom
probably	O
arising	O
from	O
the	O
left	B-Biological_structure
adrenal	I-Biological_structure
gland	I-Biological_structure
containing	O
multiple	B-Detailed_description
areas	I-Detailed_description
of	I-Detailed_description
macroscopic	I-Detailed_description
fat	I-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
patient	O
had	O
no	O
documented	O
clinical	O
or	O
laboratory	O
evidence	O
of	O
adrenal	O
hormonal	O
excess	O
.	O

On	O
the	O
basis	O
of	O
the	O
clinical	O
history	O
and	O
CT	O
findings	O
,	O
the	O
patient	O
underwent	O
surgical	B-Therapeutic_procedure
resection	I-Therapeutic_procedure
of	O
the	O
left	B-Biological_structure
adrenal	I-Biological_structure
mass	B-Sign_symptom
,	O
which	O
was	O
found	O
on	O
pathologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
to	O
represent	O
a	O
low	B-Severity
-	I-Severity
grade	I-Severity
adrenocortical	B-Disease_disorder
carcinoma	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
61	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
patient	O
had	O
a	O
history	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
under	O
regular	O
bronchodilator	O
treatment	O
.	O

In	O
2014	O
,	O
he	O
suffered	O
from	O
severe	B-Severity
productive	B-Detailed_description
cough	B-Sign_symptom
with	O
mucus	B-Detailed_description
sputum	I-Detailed_description
for	B-Duration
several	I-Duration
months	I-Duration
and	O
unintentional	B-Detailed_description
body	O
weight	B-Sign_symptom
loss	I-Sign_symptom
6	B-Lab_value
kg	I-Lab_value
within	B-Duration
6	I-Duration
months	I-Duration
.	O

After	O
sputum	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
and	O
chest	B-Biological_structure
imaging	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
in	O
May	O
2014	O
,	O
he	O
was	O
diagnosed	O
of	O
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
in	O
right	B-Biological_structure
upper	I-Biological_structure
lobe	I-Biological_structure
lung	I-Biological_structure
(	O
cT3N2M0	B-Lab_value
,	O
stage	B-Lab_value
IIIa	I-Lab_value
)	O
.	O

Then	O
he	O
received	O
neoadjuvant	B-Detailed_description
chemoradiotherapy	B-Therapeutic_procedure
(	O
etoposide	B-Medication
70	B-Dosage
mg	I-Dosage
[	I-Dosage
45	I-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
]	I-Dosage
+	O
cisplatin	B-Medication
79	B-Dosage
mg	I-Dosage
[	I-Dosage
50	I-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
]	I-Dosage
;	O
4500	B-Dosage
cGY	I-Dosage
in	I-Dosage
25	I-Dosage
fractions	I-Dosage
)	O
from	B-Duration
June	I-Duration
to	I-Duration
July	I-Duration
2014	I-Duration
.	O

In	O
October	O
2014	O
,	O
surgical	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
was	O
arranged	O
.	O

Because	O
the	O
tumor	B-Sign_symptom
was	O
located	O
at	O
right	B-Biological_structure
hilum	I-Biological_structure
and	O
invaded	O
main	B-Biological_structure
bronchus	I-Biological_structure
and	O
major	B-Biological_structure
vessels	I-Biological_structure
,	O
video	B-Detailed_description
-	I-Detailed_description
assisted	I-Detailed_description
thoracoscopic	B-Detailed_description
surgery	B-Therapeutic_procedure
with	O
right	B-Detailed_description
side	I-Detailed_description
intrapericardial	B-Biological_structure
pneumonectomy	B-Therapeutic_procedure
was	O
performed	O
.	O

Postoperatively	O
,	O
pathological	B-Diagnostic_procedure
exams	I-Diagnostic_procedure
revealed	O
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
,	O
T3N0M0	B-Lab_value
,	O
stage	B-Lab_value
IIB	I-Lab_value
.	O

The	O
postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
smooth	B-Lab_value
but	O
he	O
suffered	O
from	O
severe	B-Severity
cough	B-Sign_symptom
and	O
right	B-Biological_structure
chest	I-Biological_structure
pain	B-Sign_symptom
one	O
month	O
later	O
.	O

Laboratory	B-Diagnostic_procedure
exams	I-Diagnostic_procedure
revealed	O
leukocytosis	B-Sign_symptom
(	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cells	I-Diagnostic_procedure
=	O
21,860	B-Lab_value
μL	I-Lab_value
)	O
and	O
elevated	B-Lab_value
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
to	O
23	B-Lab_value
.	I-Lab_value
94	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
cavitary	B-Detailed_description
lesion	B-Sign_symptom
and	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
showed	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
and	O
fluid	B-Sign_symptom
collection	I-Sign_symptom
with	O
mottled	B-Detailed_description
gas	I-Detailed_description
appearance	I-Detailed_description
in	O
the	O
dependent	B-Biological_structure
portion	I-Biological_structure
of	I-Biological_structure
right	I-Biological_structure
hemithorax	I-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
.	O

According	O
to	O
the	O
patient	O
`	O
s	O
history	O
,	O
results	O
of	O
laboratory	O
exams	O
,	O
and	O
imaging	O
findings	O
,	O
postpneumonectomy	B-Detailed_description
empyema	B-Sign_symptom
was	O
diagnosed	O
and	O
bronchopleural	B-Disease_disorder
fistula	I-Disease_disorder
was	O
highly	O
suspected	O
.	O

After	O
admission	O
,	O
chest	B-Biological_structure
tube	B-Therapeutic_procedure
drainage	I-Therapeutic_procedure
was	O
inserted	O
and	O
bronchoscopic	B-Detailed_description
tissue	B-Therapeutic_procedure
glue	I-Therapeutic_procedure
sealing	I-Therapeutic_procedure
was	O
performed	O
.	O

However	O
,	O
persistent	B-Detailed_description
air	B-Sign_symptom
leakage	I-Sign_symptom
was	O
presented	O
and	O
we	O
decided	O
to	O
repair	B-Therapeutic_procedure
the	O
bronchial	B-Biological_structure
stump	I-Biological_structure
with	O
flap	B-Therapeutic_procedure
coverage	I-Therapeutic_procedure
.	O

Because	O
the	O
patient	O
just	O
received	O
neoadjuvant	B-Detailed_description
chemoradiotherapy	B-Therapeutic_procedure
a	O
few	O
months	O
ago	O
,	O
the	O
flaps	O
harvested	O
from	O
chest	O
area	O
were	O
not	O
appropriate	O
because	O
the	O
pedicle	O
arteries	O
might	O
have	O
been	O
injured	O
by	O
irradiation	O
.	O

After	O
discussing	O
with	O
the	O
plastic	O
surgeon	O
,	O
we	O
decided	O
to	O
repair	B-Therapeutic_procedure
the	O
bronchial	B-Biological_structure
stump	I-Biological_structure
by	O
a	O
TRAM	B-Therapeutic_procedure
flap	I-Therapeutic_procedure
.	O

Intraoperatively	O
,	O
the	O
patient	O
was	O
placed	B-Therapeutic_procedure
in	I-Therapeutic_procedure
supine	I-Therapeutic_procedure
.	O

Right	B-Detailed_description
side	I-Detailed_description
exploratory	B-Detailed_description
thoracotomy	B-Diagnostic_procedure
was	O
performed	O
and	O
the	O
bronchial	B-Biological_structure
stump	I-Biological_structure
was	O
located	O
.	O

The	O
superior	B-Biological_structure
epigastric	I-Biological_structure
vascular	I-Biological_structure
artery	I-Biological_structure
and	O
right	B-Biological_structure
rectus	I-Biological_structure
abdominis	I-Biological_structure
muscle	I-Biological_structure
was	O
identified	O
and	O
the	O
location	O
of	O
the	O
TRAM	B-Therapeutic_procedure
flap	I-Therapeutic_procedure
was	O
marked	B-Detailed_description
on	I-Detailed_description
the	I-Detailed_description
skin	I-Detailed_description
(	O
Fig	O
.	O
2A	O
)	O
.	O

Then	O
the	O
TRAM	B-Therapeutic_procedure
flap	I-Therapeutic_procedure
was	O
harvested	B-Therapeutic_procedure
from	O
right	B-Biological_structure
rectus	I-Biological_structure
abdominis	I-Biological_structure
(	O
Fig	O
.	O
2B	O
)	O
and	O
was	O
deepithelialized	B-Therapeutic_procedure
(	O
Fig	O
.	O
2C	O
)	O
.	O

Through	O
a	O
subcutaneous	B-Therapeutic_procedure
tunnel	I-Therapeutic_procedure
,	O
the	O
TRAM	B-Therapeutic_procedure
flap	I-Therapeutic_procedure
was	O
moved	O
toward	O
the	O
right	B-Biological_structure
thoracic	I-Biological_structure
space	I-Biological_structure
with	O
no	O
tension	B-Sign_symptom
or	O
kinking	B-Sign_symptom
on	O
the	O
pedicle	B-Biological_structure
(	O
Fig	O
.	O
2D	O
)	O
.	O

Then	O
the	O
TRAM	B-Therapeutic_procedure
flap	I-Therapeutic_procedure
was	O
fixed	O
to	O
posterior	B-Biological_structure
chest	I-Biological_structure
wall	I-Biological_structure
to	O
cover	O
the	O
bronchial	B-Biological_structure
stump	I-Biological_structure
(	O
Fig	O
.	O
2E	O
)	O
and	O
the	O
tissue	B-Therapeutic_procedure
glue	I-Therapeutic_procedure
was	O
also	O
applied	O
to	O
the	O
bronchial	B-Biological_structure
stump	I-Biological_structure
under	O
bronchoscope	B-Diagnostic_procedure
.	O

The	O
donor	B-Biological_structure
site	I-Biological_structure
of	I-Biological_structure
flap	I-Biological_structure
was	O
closed	O
with	O
mesh	B-Therapeutic_procedure
repair	I-Therapeutic_procedure
.	O

The	O
postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
smooth	B-Lab_value
and	O
the	O
air	B-Sign_symptom
leak	I-Sign_symptom
was	O
diminished	B-Lab_value
gradually	O
.	O

Then	O
the	O
patient	O
was	O
discharge	O
under	O
stable	B-Sign_symptom
condition	I-Sign_symptom
and	O
was	O
free	O
from	O
air	B-Sign_symptom
leak	I-Sign_symptom
after	O
following	O
for	O
12	O
months	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

The	O
patient	O
provided	O
written	O
informed	O
consent	O
for	O
publication	O
of	O
this	O
report	O
and	O
all	O
accompanying	O
images	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
53	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
to	O
our	O
institution	B-Nonbiological_location
with	O
progressive	B-Detailed_description
abdominal	B-Biological_structure
distention	B-Sign_symptom
and	O
irregular	B-Detailed_description
vaginal	B-Biological_structure
bleeding	B-Sign_symptom
of	O
several	B-Duration
weeks	I-Duration
`	O
duration	O
.	O

A	O
contrast	B-Detailed_description
CT	B-Diagnostic_procedure
abdomen	B-Biological_structure
and	O
pelvis	B-Biological_structure
revealed	O
an	O
ill	B-Detailed_description
-	I-Detailed_description
defined	I-Detailed_description
,	O
irregular	B-Detailed_description
mass	B-Sign_symptom
in	O
the	O
lower	B-Biological_structure
uterine	I-Biological_structure
/	O
cervical	B-Biological_structure
region	I-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

There	O
were	O
multiple	B-Detailed_description
peritoneal	B-Biological_structure
and	O
omental	B-Biological_structure
masses	B-Sign_symptom
,	O
enlarged	B-Sign_symptom
pelvic	B-Biological_structure
and	O
paraaortic	B-Biological_structure
lymph	B-Biological_structure
nodes	I-Biological_structure
,	O
and	O
large	B-Detailed_description
-	I-Detailed_description
volume	I-Detailed_description
ascites	B-Sign_symptom
.	O

The	O
initial	O
CBC	B-Diagnostic_procedure
was	O
significant	O
for	O
hemoglobin	B-Diagnostic_procedure
of	O
9	B-Lab_value
.	I-Lab_value
2	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
leukocytosis	B-Sign_symptom
of	O
36	B-Lab_value
790	I-Lab_value
per	I-Lab_value
microliter	I-Lab_value
,	O
and	O
thrombocytosis	B-Sign_symptom
of	O
625	B-Lab_value
000	I-Lab_value
per	I-Lab_value
microliter	I-Lab_value
.	O

Serum	B-Biological_structure
calcium	B-Diagnostic_procedure
was	O
elevated	B-Lab_value
at	O
13	B-Lab_value
.	I-Lab_value
1	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

BUN	B-Diagnostic_procedure
and	O
creatinine	B-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

Hepatic	B-Diagnostic_procedure
function	I-Diagnostic_procedure
was	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

A	O
pelvic	B-Diagnostic_procedure
exam	I-Diagnostic_procedure
revealed	O
a	O
fungating	B-Detailed_description
vaginal	B-Biological_structure
mass	B-Sign_symptom
.	O

The	O
patient	O
underwent	O
biopsies	B-Diagnostic_procedure
of	O
the	O
endometrium	B-Biological_structure
and	O
the	O
vaginal	B-Biological_structure
mass	O
,	O
which	O
revealed	O
a	O
high	B-Severity
-	I-Severity
grade	I-Severity
tumor	B-Sign_symptom
with	O
predominantly	B-Detailed_description
oval	I-Detailed_description
-	I-Detailed_description
shaped	I-Detailed_description
cells	I-Detailed_description
.	O

Immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
was	O
positive	B-Lab_value
for	O
vimentin	B-Diagnostic_procedure
,	O
CD10	B-Diagnostic_procedure
,	O
and	O
cyclin	B-Diagnostic_procedure
D1	I-Diagnostic_procedure
,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
high	B-Severity
-	I-Severity
grade	I-Severity
endometrial	B-Disease_disorder
stromal	I-Disease_disorder
sarcoma	I-Disease_disorder
(	O
Figure	O
2	O
)	O
.	O

The	O
tumor	O
was	O
negative	B-Lab_value
for	O
ER	B-Diagnostic_procedure
,	O
with	O
rare	B-Detailed_description
cells	I-Detailed_description
positive	B-Lab_value
for	O
PR	B-Diagnostic_procedure
.	O

Although	O
immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
for	O
cytokeratins	B-Diagnostic_procedure
was	O
negative	B-Lab_value
,	O
a	O
biphasic	B-Sign_symptom
component	I-Sign_symptom
could	O
not	O
be	O
entirely	O
ruled	O
out	O
given	O
the	O
small	O
size	O
of	O
the	O
biopsy	O
specimen	O
relative	O
to	O
the	O
tumor	O
.	O

The	O
patient	O
`	O
s	O
Ca125	B-Diagnostic_procedure
was	O
markedly	O
elevated	B-Lab_value
at	O
1624	B-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
nl	O
≤	O
34	O
)	O
.	O

Contrast	B-Detailed_description
CT	B-Diagnostic_procedure
chest	B-Biological_structure
revealed	O
a	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
but	O
no	O
suspicious	B-Detailed_description
nodules	B-Sign_symptom
or	O
lymphadenopathy	B-Disease_disorder
.	O

The	O
patient	O
was	O
deemed	O
to	O
have	O
operable	B-Disease_disorder
disease	I-Disease_disorder
and	O
was	O
scheduled	O
for	O
debulking	B-Therapeutic_procedure
surgery	I-Therapeutic_procedure
.	O

However	O
,	O
preoperative	O
laboratory	B-Diagnostic_procedure
studies	I-Diagnostic_procedure
showed	O
that	O
her	O
serum	B-Biological_structure
calcium	B-Diagnostic_procedure
had	O
further	O
increased	B-Lab_value
to	O
19	B-Lab_value
.	I-Lab_value
2	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

She	O
had	O
also	O
developed	O
evidence	O
of	O
acute	B-Detailed_description
kidney	B-Biological_structure
injury	B-Disease_disorder
,	O
with	O
her	O
BUN	B-Diagnostic_procedure
rising	B-Lab_value
to	O
37	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
and	O
creatinine	B-Diagnostic_procedure
to	O
1	B-Lab_value
.	I-Lab_value
81	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

On	O
physical	B-Diagnostic_procedure
exam	I-Diagnostic_procedure
,	O
she	O
was	O
noted	O
to	O
be	O
lethargic	B-Sign_symptom
,	O
with	O
dry	B-Sign_symptom
mucous	B-Biological_structure
membranes	I-Biological_structure
.	O

The	O
surgery	B-Therapeutic_procedure
was	O
cancelled	O
due	O
to	O
the	O
patient	O
`	O
s	O
medical	B-Disease_disorder
instability	I-Disease_disorder
.	O

Further	O
workup	O
revealed	O
an	O
elevated	B-Lab_value
PTHrP	B-Diagnostic_procedure
of	O
301	B-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
nl	O
14	O
-	O
27	O
)	O
,	O
a	O
depressed	B-Lab_value
PTH	B-Diagnostic_procedure
level	O
of	O
3	B-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
nl	O
15	O
-	O
65	O
)	O
,	O
and	O
a	O
depressed	B-Lab_value
25	B-Diagnostic_procedure
-	I-Diagnostic_procedure
OH	I-Diagnostic_procedure
vitamin	I-Diagnostic_procedure
D	I-Diagnostic_procedure
level	O
of	O
16	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
nl	O
30	O
-	O
100	O
)	O
,	O
consistent	O
with	O
humoral	B-Disease_disorder
hypercalcemia	I-Disease_disorder
of	I-Disease_disorder
malignancy	I-Disease_disorder
.	O

The	O
patient	O
was	O
treated	O
with	O
pamidronate	B-Medication
,	O
calcitonin	B-Medication
,	O
and	O
intravenous	O
fluids	B-Medication
.	O

She	O
eventually	O
required	O
temporary	B-Detailed_description
hemodialysis	B-Therapeutic_procedure
and	O
denosumab	B-Medication
for	O
refractory	B-Detailed_description
hypercalcemia	B-Sign_symptom
.	O

The	O
patient	O
improved	O
with	O
regard	O
to	O
her	O
electrolyte	O
abnormalities	O
.	O

Given	O
the	O
extent	O
of	O
her	O
disease	O
,	O
she	O
was	O
planned	O
for	O
neoadjuvant	O
chemotherapy	B-Medication
followed	O
by	O
surgery	B-Therapeutic_procedure
if	O
a	O
good	O
response	O
was	O
achieved	O
.	O

She	O
was	O
started	O
on	O
a	O
regimen	O
of	O
carboplatin	B-Medication
and	O
paclitaxel	B-Medication
,	O
which	O
she	O
received	O
for	O
3	B-Dosage
cycles	I-Dosage
.	O

She	O
also	O
had	O
palliative	O
radiation	B-Therapeutic_procedure
to	O
the	O
uterus	B-Biological_structure
to	O
control	O
bleeding	B-Sign_symptom
.	O

However	O
,	O
her	O
disease	O
failed	O
to	O
respond	O
significantly	O
to	O
chemotherapy	O
,	O
and	O
she	O
ultimately	O
died	O
from	O
complications	B-Disease_disorder
of	I-Disease_disorder
malignancy	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
67	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
sent	O
to	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
because	O
of	O
fever	B-Sign_symptom
and	O
sore	B-Sign_symptom
throat	B-Biological_structure
.	O

Her	O
medical	O
history	O
included	O
ESRD	B-Disease_disorder
with	O
regular	O
hemodialysis	B-Therapeutic_procedure
3	B-Frequency
times	I-Frequency
per	I-Frequency
week	I-Frequency
for	O
15	B-Duration
years	I-Duration
,	O
hyperuricemia	O
and	O
gout	O
.	O

She	O
also	O
had	O
comorbidity	O
such	O
as	O
dyslipidemia	O
,	O
hypertension	O
,	O
secondary	B-Detailed_description
hyperparathyroidism	O
,	O
and	O
diabetes	O
.	O

The	O
hemogram	B-Diagnostic_procedure
revealed	O
a	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
(	O
WBC	B-Diagnostic_procedure
)	O
of	O
700	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
,	O
with	O
2	B-Lab_value
%	I-Lab_value
neutrophils	B-Diagnostic_procedure
,	O
94	B-Lab_value
%	I-Lab_value
lymphocytes	B-Diagnostic_procedure
and	O
2	B-Lab_value
%	I-Lab_value
monocytes	B-Diagnostic_procedure
,	O
hemoglobin	B-Diagnostic_procedure
11	B-Lab_value
.	I-Lab_value
1	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
and	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
131,000	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
.	O

Under	O
the	O
impression	O
of	O
febrile	B-Detailed_description
neutropenia	B-Sign_symptom
and	O
acute	B-Detailed_description
pharyngitis	B-Disease_disorder
,	O
she	O
was	O
admitted	O
to	O
our	O
hematologic	B-Nonbiological_location
ward	I-Nonbiological_location
for	O
further	O
survey	O
and	O
management	O
.	O

Broad	B-Detailed_description
-	I-Detailed_description
spectrum	I-Detailed_description
antibiotics	B-Medication
with	O
piperacillin	B-Medication
2	B-Dosage
g	I-Dosage
and	O
tazobactam	B-Medication
0	B-Dosage
.	I-Dosage
25	I-Dosage
gm	I-Dosage
i	O
.	O
v	O
.	O

q8h	B-Dosage
had	O
been	O
administered	O
and	O
her	O
infection	B-Sign_symptom
sign	I-Sign_symptom
resolved	O
gradually	O
.	O

Upon	O
admission	O
,	O
we	O
reviewed	O
her	O
oral	O
medication	O
:	O
glipizide	B-Medication
5	B-Dosage
mg	I-Dosage
tid	I-Dosage
,	O
saxagliptin	B-Medication
2	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
qd	I-Dosage
,	O
fenofibrate	B-Medication
600	B-Dosage
mg	I-Dosage
qd	I-Dosage
,	O
aluminum	B-Medication
hydroxide	I-Medication
324	B-Dosage
mg	I-Dosage
tid	I-Dosage
,	O
folic	B-Medication
acid	I-Medication
5	B-Dosage
mg	I-Dosage
qd	I-Dosage
,	O
calcium	B-Medication
carbonate	I-Medication
1000	B-Dosage
mg	I-Dosage
tid	I-Dosage
,	O
and	O
febuxostat	B-Medication
40	B-Dosage
mg	I-Dosage
qd	I-Dosage
.	O

Besides	O
,	O
she	O
also	O
received	O
epoetin	B-Medication
-	I-Medication
beta	I-Medication
2000	B-Dosage
iu	I-Dosage
i	O
.	O
v	O
.	O
tiw	B-Dosage
.	O

Except	O
for	O
febuxostat	B-Medication
,	O
all	O
the	O
other	O
drugs	O
had	O
been	O
used	O
for	O
more	B-Duration
than	I-Duration
1	I-Duration
year	I-Duration
.	O

Febuxostat	B-Medication
was	O
administered	O
2	O
1/2	O
months	O
before	O
admission	O
for	O
inadequate	O
serum	O
uric	O
acid	O
control	O
by	O
allopurinol	B-Medication
50	B-Dosage
mg	I-Dosage
qd	I-Dosage
.	O

Two	O
weeks	O
before	O
febuxostat	O
exposure	O
,	O
routine	O
laboratory	B-Diagnostic_procedure
test	I-Diagnostic_procedure
revealed	O
WBC	B-Diagnostic_procedure
6000	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
and	O
serum	B-Detailed_description
uric	B-Diagnostic_procedure
acid	I-Diagnostic_procedure
level	O
9	B-Lab_value
.	I-Lab_value
8	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Febuxostat	B-Medication
was	O
discontinued	O
thereafter	O
due	O
to	O
the	O
causal	O
relationship	O
of	O
agranulocytosis	B-Disease_disorder
can	O
not	O
be	O
excluded	O
.	O

Besides	O
,	O
we	O
also	O
surveyed	O
viral	O
infection	O
and	O
autoimmune	O
disorder	O
.	O

There	O
were	O
no	O
clinical	O
or	O
laboratory	O
evidence	O
of	O
Epstein	B-Detailed_description
-	I-Detailed_description
Barr	I-Detailed_description
virus	I-Detailed_description
,	O
cytomegalovirus	B-Detailed_description
,	O
or	O
human	B-Detailed_description
immunodeficiency	I-Detailed_description
virus	I-Detailed_description
infections	B-Disease_disorder
;	O
antinuclear	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
(	O
ANA	B-Diagnostic_procedure
)	O
and	O
antiextractable	B-Diagnostic_procedure
nuclear	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ENA	I-Diagnostic_procedure
)	O
were	O
both	O
negative	B-Lab_value
.	O

Bone	B-Diagnostic_procedure
marrow	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
during	O
hospitalization	O
showed	O
hypocellular	B-Sign_symptom
marrow	B-Biological_structure
with	O
a	O
marked	O
decrease	B-Lab_value
in	O
myeloid	B-Diagnostic_procedure
component	I-Diagnostic_procedure
but	O
no	O
evidence	O
of	O
hematologic	B-Biological_structure
neoplasms	B-Sign_symptom
.	O

Chromosome	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
of	O
bone	B-Biological_structure
marrow	I-Biological_structure
was	O
normal	B-Lab_value
karyotype	I-Lab_value
.	O

The	O
patient	O
denied	O
history	O
of	O
radiation	O
or	O
chemicals	O
exposure	O
.	O

After	O
stopping	O
febuxostat	B-Medication
for	O
17	B-Duration
days	I-Duration
,	O
her	O
neutropenia	B-Sign_symptom
improved	O
significantly	O
(	O
WBC	B-Diagnostic_procedure
2100	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
,	O
and	O
neutrophil	B-Diagnostic_procedure
66	B-Lab_value
%	I-Lab_value
)	O
,	O
without	O
any	O
granulocyte	B-Medication
colony	I-Medication
-	I-Medication
stimulating	I-Medication
factor	I-Medication
(	O
G	O
-	O
CSF	O
)	O
support	O
.	O

After	O
discharge	O
,	O
her	O
WBC	B-Diagnostic_procedure
and	O
differential	B-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
completely	O
normal	B-Lab_value
during	O
follow	O
-	O
up	O
(	O
Fig	O
.	O
1	O
)	O
.	O

This	O
study	O
was	O
approved	O
by	O
our	O
institutional	O
review	O
board	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
52	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
(	O
body	O
surface	O
area	O
:	O
1	O
.	O
3	O
m2	O
)	O
known	O
to	O
have	O
dilated	O
cardiomyopathy	O
(	O
DCM	B-Disease_disorder
)	O
,	O
was	O
admitted	O
for	O
worsening	O
heart	B-Disease_disorder
failure	I-Disease_disorder
(	O
NYHA	B-Lab_value
class	I-Lab_value
IV	I-Lab_value
)	O
.	O

He	O
presented	O
with	O
a	O
5	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
cough	B-Sign_symptom
,	O
progressive	B-Detailed_description
dyspnoea	B-Sign_symptom
,	O
orthopnea	B-Sign_symptom
and	O
recurrent	B-Detailed_description
upper	B-Biological_structure
abdominal	I-Biological_structure
pain	B-Sign_symptom
started	O
from	B-Duration
2	I-Duration
months	I-Duration
ago	I-Duration
.	O

On	O
examination	B-Diagnostic_procedure
his	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
37	B-Lab_value
°C	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
80	B-Lab_value
/	I-Lab_value
40	I-Lab_value
mmHg	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
24	B-Lab_value
breaths	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
,	O
and	O
electrocardiogram	B-Diagnostic_procedure
showed	O
atrial	B-Disease_disorder
fibrillation	I-Disease_disorder
with	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
50	B-Lab_value
beats	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
the	O
jugular	B-Biological_structure
venous	I-Biological_structure
distension	B-Sign_symptom
,	O
significant	B-Severity
tender	B-Detailed_description
hepatomegaly	B-Sign_symptom
and	O
bilateral	B-Detailed_description
pitting	B-Detailed_description
edema	B-Sign_symptom
at	O
lower	B-Biological_structure
limbs	I-Biological_structure
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
elevated	B-Lab_value
pro	B-Diagnostic_procedure
-	I-Diagnostic_procedure
NT	I-Diagnostic_procedure
brain	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
of	O
22145	B-Lab_value
pg	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
(	O
normal	O
0	O
to	O
227	O
pg	O
/	O
ml	O
)	O
and	O
unremarkable	B-Lab_value
D	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimer	I-Diagnostic_procedure
.	O

X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
and	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
of	O
the	O
chest	B-Biological_structure
demonstrated	O
consolidation	B-Sign_symptom
of	O
bilateral	B-Biological_structure
lower	I-Biological_structure
lobes	I-Biological_structure
with	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
,	O
while	O
his	O
venous	B-Biological_structure
Doppler	B-Diagnostic_procedure
of	O
lower	B-Biological_structure
extremities	I-Biological_structure
was	O
normal	B-Lab_value
.	O

Based	O
on	O
his	O
clinical	O
condition	O
,	O
echocardiography	B-Diagnostic_procedure
was	O
immediately	O
inserted	O
.	O

There	O
were	O
severe	B-Severity
dilated	B-Sign_symptom
cardiac	I-Sign_symptom
chambers	I-Sign_symptom
,	O
especially	O
enlargement	B-Sign_symptom
of	O
the	O
left	B-Biological_structure
ventricle	I-Biological_structure
(	O
LV	B-Biological_structure
)	O
(	O
58	B-Lab_value
mm	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
)	O
with	O
spherical	B-Sign_symptom
shape	I-Sign_symptom
,	O
decreased	B-Sign_symptom
wall	I-Sign_symptom
thickness	I-Sign_symptom
,	O
impaired	B-Lab_value
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
22	B-Lab_value
%	I-Lab_value
and	O
severe	B-Severity
mitral	B-Sign_symptom
regurgitation	I-Sign_symptom
on	O
two	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
transthoracic	I-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
2DTTE	B-Diagnostic_procedure
)	O
.	O

Parasternal	O
short	O
axis	O
and	O
subxyphoid	O
view	O
(	O
Figure	O
1	O
)	O
showed	O
the	O
mobile	B-Detailed_description
right	B-Biological_structure
atrial	I-Biological_structure
mass	B-Sign_symptom
highly	O
suspicious	O
of	O
a	O
thrombus	B-Disease_disorder
traversing	O
the	O
right	B-Biological_structure
atrial	I-Biological_structure
cavity	I-Biological_structure
during	O
the	O
cardiac	O
cycle	O
accompanying	O
with	O
free	B-Detailed_description
-	I-Detailed_description
floating	I-Detailed_description
small	B-Detailed_description
parts	I-Detailed_description
of	O
the	O
thrombi	B-Disease_disorder
.	O

Real	B-Diagnostic_procedure
-	I-Diagnostic_procedure
time	I-Diagnostic_procedure
three	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
transthoracic	I-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
RT	B-Diagnostic_procedure
-	I-Diagnostic_procedure
3DTTE	I-Diagnostic_procedure
)	O
was	O
performed	O
to	O
further	O
confirm	O
the	O
nature	O
of	O
mass	B-Sign_symptom
.	O

It	O
showed	O
a	O
highly	B-Detailed_description
mobile	I-Detailed_description
thrombus	B-Disease_disorder
,	O
irregular	B-Shape
in	I-Shape
contour	I-Shape
,	O
measured	O
2	B-Area
.	I-Area
6	I-Area
×	I-Area
1	I-Area
.	I-Area
0	I-Area
cm	I-Area
which	O
floating	O
around	O
the	O
orifice	B-Biological_structure
of	I-Biological_structure
inferior	I-Biological_structure
vena	I-Biological_structure
cava	I-Biological_structure
and	O
protruding	B-Biological_structure
into	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
atrial	I-Biological_structure
cavity	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

In	O
addition	O
,	O
RT	B-Diagnostic_procedure
-	I-Diagnostic_procedure
3DTTE	I-Diagnostic_procedure
evaluated	O
right	B-Biological_structure
ventricle	I-Biological_structure
(	O
RV	B-Biological_structure
)	O
systolic	B-Sign_symptom
dysfunction	I-Sign_symptom
with	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
15	B-Lab_value
.	I-Lab_value
7	I-Lab_value
%	I-Lab_value
(	O
Figure	O
3	O
)	O
.	O

He	O
was	O
maintained	O
on	O
digoxin	B-Medication
,	O
spironolactone	B-Medication
,	O
furosemide	B-Medication
,	O
sotalol	B-Medication
and	O
dopamine	B-Medication
.	O

At	O
the	O
same	O
time	O
therapeutic	B-Therapeutic_procedure
anticoagulation	I-Therapeutic_procedure
was	O
started	O
with	O
low	B-Detailed_description
-	I-Detailed_description
molecular	I-Detailed_description
-	I-Detailed_description
weight	I-Detailed_description
heparin	B-Medication
and	O
warfarin	B-Medication
.	O

The	O
patient	O
had	O
an	O
uneventful	B-Lab_value
hospital	B-Therapeutic_procedure
course	I-Therapeutic_procedure
and	O
one	O
week	O
follow	O
-	O
up	O
echocardiography	B-Diagnostic_procedure
confirmed	O
adequate	O
removal	O
of	O
the	O
thrombus	B-Disease_disorder
(	O
Figures	O
4A	O
and	O
4B	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
75	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
presented	O
in	O
the	O
Emergency	B-Nonbiological_location
Department	I-Nonbiological_location
of	I-Nonbiological_location
Ilfov	I-Nonbiological_location
Clinical	I-Nonbiological_location
Hospital	I-Nonbiological_location
,	I-Nonbiological_location
Bucharest	I-Nonbiological_location
,	I-Nonbiological_location
Romania	I-Nonbiological_location
,	O
with	O
dyspnea	B-Sign_symptom
,	O
orthopnea	B-Sign_symptom
,	O
lower	B-Biological_structure
extremities	I-Biological_structure
swelling	B-Sign_symptom
,	O
palpitations	B-Sign_symptom
.	O

She	O
had	O
a	O
3	B-Duration
years	I-Duration
history	O
of	O
atrial	B-Sign_symptom
fibrillation	I-Sign_symptom
diagnosed	O
by	O
her	O
family	O
doctor	O
and	O
one	B-Duration
-	I-Duration
year	I-Duration
history	O
of	O
cardiac	B-Disease_disorder
failure	I-Disease_disorder
NYHA	B-Lab_value
(	I-Lab_value
New	I-Lab_value
York	I-Lab_value
Heart	I-Lab_value
Association	I-Lab_value
)	I-Lab_value
class	I-Lab_value
Ⅱ	I-Lab_value
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
an	O
irregular	B-Sign_symptom
pulse	I-Sign_symptom
80	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
100	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mmHg	I-Lab_value
,	O
bi	B-Sign_symptom
-	I-Sign_symptom
basal	I-Sign_symptom
crackles	I-Sign_symptom
on	O
chest	B-Biological_structure
auscultation	B-Diagnostic_procedure
,	O
lower	B-Biological_structure
extremities	I-Biological_structure
swelling	O
.	O

Heart	B-Diagnostic_procedure
sounds	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
IVth	B-Lab_value
degree	I-Lab_value
pansystolic	B-Sign_symptom
murmur	I-Sign_symptom
at	O
the	O
left	B-Biological_structure
border	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
stern	I-Biological_structure
.	O

The	O
jugular	B-Biological_structure
veins	I-Biological_structure
were	O
dilated	B-Sign_symptom
.	O

The	O
patient	O
complained	O
of	O
pain	B-Sign_symptom
in	O
the	O
upper	B-Biological_structure
right	I-Biological_structure
abdominal	I-Biological_structure
region	I-Biological_structure
,	O
enhanced	B-Detailed_description
by	I-Detailed_description
palpation	I-Detailed_description
.	O

The	O
liver	B-Diagnostic_procedure
margin	I-Diagnostic_procedure
was	O
tender	B-Texture
,	O
round	B-Shape
,	O
of	O
6	B-Distance
cm	I-Distance
below	I-Distance
the	I-Distance
costal	I-Distance
rib	I-Distance
,	O
with	O
a	O
smooth	B-Texture
liver	B-Diagnostic_procedure
surface	I-Diagnostic_procedure
.	O

The	O
spleen	O
could	O
not	O
be	O
felt	O
.	O

EKG	B-Diagnostic_procedure
:	O
atrial	B-Sign_symptom
fibrillation	I-Sign_symptom
of	O
80	B-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
right	B-Sign_symptom
bundle	I-Sign_symptom
branch	I-Sign_symptom
block	I-Sign_symptom
,	O
infero	B-Biological_structure
-	I-Biological_structure
lateral	I-Biological_structure
ischemia	B-Sign_symptom
.	O

Transabdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
showed	O
a	O
homogenous	B-Detailed_description
,	O
enlarged	B-Sign_symptom
liver	I-Sign_symptom
.	O

The	O
suprahepatic	B-Biological_structure
veins	I-Biological_structure
were	O
dilated	B-Sign_symptom
,	O
as	O
well	O
as	O
the	O
inferior	B-Biological_structure
vena	I-Biological_structure
cava	I-Biological_structure
(	O
30	B-Lab_value
mm	I-Lab_value
,	O
without	O
respiratory	O
variations	O
)	O
.	O

Transthoracic	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
revealed	O
a	O
dilated	B-Sign_symptom
right	B-Biological_structure
atrium	I-Biological_structure
of	O
74,2	B-Lab_value
mm	I-Lab_value
(	O
Figure	O
1	O
)	O
,	O
dilated	B-Sign_symptom
left	B-Biological_structure
atrium	I-Biological_structure
of	O
55,2	B-Lab_value
mm	I-Lab_value
,	O
dilated	B-Sign_symptom
left	B-Biological_structure
ventricle	I-Biological_structure
of	O
64	B-Lab_value
/	I-Lab_value
72,3	I-Lab_value
mm	I-Lab_value
,	O
dilated	B-Sign_symptom
right	B-Biological_structure
ventricle	I-Biological_structure
of	O
44,4	B-Lab_value
mm	I-Lab_value
.	O

Atrial	B-Disease_disorder
septal	I-Disease_disorder
defect	I-Disease_disorder
ostium	B-Detailed_description
secundum	I-Detailed_description
type	I-Detailed_description
,	O
of	O
6	B-Distance
cm	I-Distance
(	O
Figure	O
2	O
)	O
,	O
with	O
left	B-Sign_symptom
-	I-Sign_symptom
to	I-Sign_symptom
-	I-Sign_symptom
right	I-Sign_symptom
shunt	I-Sign_symptom
.	O

Severe	B-Severity
tricuspid	B-Disease_disorder
insufficiency	I-Disease_disorder
with	O
maximum	O
gradient	O
of	O
55,4	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

4th	B-Lab_value
degree	I-Lab_value
mitral	B-Disease_disorder
insufficiency	I-Disease_disorder
.	O

Severe	B-Severity
pulmonary	B-Biological_structure
hypertension	B-Sign_symptom
of	O
75	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

The	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
29	B-Lab_value
%	I-Lab_value
.	O

Atrial	B-Sign_symptom
fibrillation	I-Sign_symptom
.	O

Interventricular	B-Biological_structure
sept	I-Biological_structure
with	O
paradoxical	B-Sign_symptom
motion	I-Sign_symptom
.	O

Flattening	B-Sign_symptom
of	O
the	O
interventricular	B-Biological_structure
septum	I-Biological_structure
(	O
Figure	O
3	O
)	O
.	O

The	O
diagnosis	O
was	O
IVth	B-Lab_value
degree	I-Lab_value
chronic	B-Disease_disorder
heart	I-Disease_disorder
failure	I-Disease_disorder
NYHA	O
.	O

Atrial	O
septal	O
defect	O
ostium	O
secundum	O
type	O
with	O
left	O
-	O
to	O
-	O
right	O
shunt	O
.	O

Severe	O
tricuspid	O
insufficiency	O
.	O

4th	O
degree	O
mitral	O
insufficiency	O
.	O

Severe	O
pulmonary	O
hypertension	O
of	O
75	O
mm	O
Hg	O
.	O

Chronic	O
atrial	O
fibrillation	O
.	O

Right	O
bundle	O
branch	O
block	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
34	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
,	O
1	O
week	O
postpartum	O
,	O
presented	O
to	O
our	O
dermatology	B-Nonbiological_location
clinic	I-Nonbiological_location
with	O
an	O
intensely	B-Severity
pruritic	B-Detailed_description
generalized	B-Detailed_description
rash	B-Sign_symptom
.	O

Two	O
days	O
after	O
delivery	O
of	O
her	O
child	O
,	O
the	O
patient	O
developed	O
an	O
itchy	B-Detailed_description
rash	B-Sign_symptom
on	O
the	O
abdomen	B-Biological_structure
.	O

On	O
discharge	O
,	O
she	O
was	O
instructed	O
to	O
follow	O
up	O
with	O
the	O
dermatology	O
department	O
if	O
the	O
rash	O
did	O
not	O
resolve	O
.	O

After	O
leaving	O
the	O
hospital	O
,	O
she	O
reported	O
that	O
the	O
eruption	B-Sign_symptom
had	O
progressively	B-Detailed_description
spread	I-Detailed_description
to	O
the	O
buttocks	B-Biological_structure
and	O
legs	B-Biological_structure
and	O
the	O
itching	B-Sign_symptom
seemed	O
to	O
be	O
worse	O
.	O

The	O
patient	O
`	O
s	O
prenatal	B-Sign_symptom
course	I-Sign_symptom
was	O
uneventful	B-Lab_value
.	O

She	O
gained	B-Sign_symptom
13	B-Lab_value
kg	I-Lab_value
during	B-Detailed_description
pregnancy	I-Detailed_description
,	O
with	O
a	O
prepregnancy	B-Detailed_description
weight	O
of	O
72	B-Weight
kg	I-Weight
.	O

A	O
healthy	B-Detailed_description
male	B-Detailed_description
neonate	O
was	O
delivered	O
by	O
caesarean	B-Therapeutic_procedure
section	I-Therapeutic_procedure
at	B-Lab_value
38	I-Lab_value
weeks	I-Lab_value
`	I-Lab_value
gestation	I-Lab_value
without	O
complication	B-Sign_symptom
.	O

The	O
patient	O
`	O
s	O
medical	O
history	O
was	O
unremarkable	O
.	O

She	O
was	O
currently	O
not	O
taking	O
any	O
medications	B-Medication
,	O
and	O
she	O
reported	O
no	O
known	O
drug	B-Sign_symptom
allergies	I-Sign_symptom
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
the	O
patient	O
was	O
afebrile	B-Sign_symptom
and	O
her	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

Examination	B-Diagnostic_procedure
of	I-Diagnostic_procedure
the	I-Diagnostic_procedure
skin	I-Diagnostic_procedure
revealed	O
erythematous	B-Detailed_description
papules	B-Sign_symptom
and	O
urticarial	B-Detailed_description
plaques	B-Sign_symptom
involving	O
the	O
abdominal	B-Biological_structure
striae	I-Biological_structure
with	O
periumbilical	B-Biological_structure
sparing	I-Biological_structure
.	O

Similar	O
lesions	B-Sign_symptom
were	O
noted	O
on	O
the	O
legs	B-Biological_structure
and	O
buttocks	B-Biological_structure
(	O
Fig	O
.	O
1a	O
)	O
.	O

The	O
face	B-Biological_structure
,	O
palms	B-Biological_structure
,	O
and	O
soles	B-Biological_structure
were	O
uninvolved	B-Sign_symptom
.	O

No	O
vesicles	B-Sign_symptom
or	O
pustules	B-Sign_symptom
were	O
noted	O
.	O

Based	O
on	O
the	O
characteristic	O
clinical	O
presentation	O
and	O
disease	O
course	O
,	O
she	O
was	O
diagnosed	O
with	O
PUPPP	B-Disease_disorder
.	O

She	O
was	O
informed	O
of	O
the	O
safety	O
profile	O
and	O
potential	O
benefits	O
of	O
medications	O
but	O
remained	O
reluctant	O
to	O
use	O
medications	B-Medication
during	O
lactation	O
,	O
despite	O
her	O
severe	O
symptoms	O
.	O

AWB	B-Therapeutic_procedure
injection	I-Therapeutic_procedure
was	O
then	O
considered	O
for	O
her	O
treatment	O
.	O

Venous	B-Biological_structure
blood	I-Biological_structure
of	O
10	B-Volume
mL	I-Volume
was	O
drawn	B-Therapeutic_procedure
from	O
the	O
patient	O
,	O
followed	O
by	O
intramuscular	O
injection	B-Therapeutic_procedure
of	O
5	B-Volume
mL	I-Volume
of	O
the	O
blood	B-Biological_structure
on	O
each	B-Biological_structure
side	I-Biological_structure
of	I-Biological_structure
her	I-Biological_structure
buttock	I-Biological_structure
.	O

Seven	O
days	O
later	O
,	O
both	O
subjective	O
and	O
objective	O
improvements	B-Lab_value
of	O
symptoms	B-Sign_symptom
were	O
noticed	O
and	O
she	O
received	O
1	B-Lab_value
more	I-Lab_value
session	I-Lab_value
of	O
AWB	B-Therapeutic_procedure
injection	I-Therapeutic_procedure
(	O
Fig	O
.	O
1b	O
)	O
.	O

On	O
follow	O
-	O
up	O
after	O
12	O
days	O
,	O
all	O
subjective	O
symptoms	B-Sign_symptom
had	O
improved	B-Lab_value
,	O
leaving	O
only	O
postinflammatory	B-Detailed_description
hyperpigmentation	B-Sign_symptom
(	O
Fig	O
.	O
1c	O
)	O
.	O

No	O
complications	O
such	O
as	O
infection	B-Sign_symptom
,	O
abscess	B-Sign_symptom
formation	O
,	O
or	O
hematoma	B-Sign_symptom
were	O
observed	O
at	O
the	B-Biological_structure
injection	I-Biological_structure
site	I-Biological_structure
.	O

-DOCSTART- -X- -X- -X- O

A	O
78	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
previously	O
healthy	O
male	O
heavy	O
smoker	O
presented	O
at	O
the	O
Emergency	B-Nonbiological_location
Department	I-Nonbiological_location
with	O
generalized	B-Detailed_description
jaundice	B-Sign_symptom
(	O
sclera	B-Biological_structure
and	O
skin	B-Biological_structure
)	O
,	O
ascites	B-Sign_symptom
,	O
and	O
hepatic	B-Disease_disorder
coma	I-Disease_disorder
.	O

The	O
relatives	O
declared	O
that	O
he	O
was	O
known	O
to	O
have	O
a	O
urinary	O
bladder	O
carcinoma	O
that	O
was	O
diagnosed	O
at	O
a	O
routine	O
control	O
performed	O
3	O
months	O
before	O
but	O
no	O
medical	O
papers	O
to	O
prove	O
this	O
diagnosis	O
were	O
shown	O
.	O

They	O
also	O
mentioned	O
a	O
2	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
progressive	B-Detailed_description
jaundice	B-Sign_symptom
,	O
somnolence	O
,	O
and	O
temporary	B-Detailed_description
loss	B-Sign_symptom
of	I-Sign_symptom
consciousness	I-Sign_symptom
.	O

No	O
weight	B-Sign_symptom
loss	I-Sign_symptom
or	O
other	O
clinical	O
signs	O
were	O
mentioned	O
.	O

No	O
previously	O
viral	B-Disease_disorder
hepatitis	I-Disease_disorder
or	O
drug	O
excess	O
was	O
reported	O
.	O

No	O
family	O
history	O
of	O
cancer	O
was	O
declared	O
.	O

At	O
the	O
present	O
admission	O
,	O
the	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
showed	O
marked	O
hepatomegaly	B-Sign_symptom
with	O
multiple	B-Detailed_description
small	B-Detailed_description
nodules	B-Sign_symptom
(	O
2	B-Distance
-	I-Distance
10	I-Distance
mm	I-Distance
in	O
diameter	O
)	O
that	O
was	O
supposed	O
to	O
be	O
hepatic	B-Biological_structure
metastases	B-Sign_symptom
from	O
the	O
bladder	B-Disease_disorder
carcinoma	I-Disease_disorder
.	O

The	O
thoracic	B-Biological_structure
x	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
a	O
bilateral	B-Detailed_description
bronchopneumonia	B-Sign_symptom
without	O
abnormal	B-Lab_value
opacities	B-Sign_symptom
.	O

The	O
patient	O
died	O
with	O
hepatic	B-Disease_disorder
encephalopathy	I-Disease_disorder
at	O
7	B-Time
hours	I-Time
after	I-Time
admission	O
.	O

Prior	O
to	O
the	O
autopsy	B-Diagnostic_procedure
,	O
signed	O
informed	O
consent	O
of	O
the	O
relatives	O
was	O
obtained	O
for	O
the	O
case	O
publication	O
.	O

Being	O
about	O
a	O
case	O
report	O
,	O
no	O
Ethical	O
Committee	O
approval	O
was	O
necessary	O
.	O

At	O
autopsy	O
,	O
the	O
macroscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
a	O
huge	B-Lab_value
liver	B-Diagnostic_procedure
(	O
6	O
.	O
5	O
kg	O
)	O
with	O
widely	B-Detailed_description
distributed	I-Detailed_description
white	B-Color
nodules	B-Sign_symptom
of	O
varying	B-Detailed_description
sizes	I-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
urinary	B-Diagnostic_procedure
bladder	I-Diagnostic_procedure
was	O
not	B-Lab_value
modified	I-Lab_value
,	O
but	O
a	O
30	B-Volume
×	I-Volume
30	I-Volume
×	I-Volume
50	I-Volume
mm	I-Volume
prostate	B-Biological_structure
nodule	B-Sign_symptom
with	O
infiltrative	B-Detailed_description
aspect	I-Detailed_description
was	O
observed	O
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
bilateral	B-Detailed_description
bronchopneumonia	B-Sign_symptom
was	O
confirmed	O
,	O
without	O
any	O
central	B-Detailed_description
tumor	B-Sign_symptom
mass	I-Sign_symptom
.	O

A	O
10	B-Distance
-	I-Distance
mm	I-Distance
white	B-Color
nodule	B-Sign_symptom
was	O
identified	O
encasing	O
a	O
small	B-Biological_structure
bronchus	I-Biological_structure
from	O
the	O
middle	B-Biological_structure
lobe	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
lung	I-Biological_structure
,	O
without	O
peripheral	B-Sign_symptom
nodules	I-Sign_symptom
(	O
Fig	O
.	O
3	O
)	O
.	O

Except	O
for	O
moderate	B-Severity
edema	B-Sign_symptom
,	O
no	O
other	O
brain	B-Biological_structure
lesions	B-Sign_symptom
were	O
identified	O
.	O

The	O
other	B-Biological_structure
organs	I-Biological_structure
did	O
not	O
show	O
modifications	B-Sign_symptom
.	O

The	O
tissues	O
were	O
fixed	O
in	O
10	O
%	O
neutral	O
formalin	O
and	O
embedded	O
in	O
paraffin	O
together	O
with	O
iliac	O
crest	O
bone	O
grafting	O
.	O

Microscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
prostate	B-Biological_structure
showed	O
a	O
3	B-Diagnostic_procedure
+3	I-Diagnostic_procedure
Gleason	I-Diagnostic_procedure
`	I-Diagnostic_procedure
s	I-Diagnostic_procedure
grade	I-Diagnostic_procedure
2	B-Lab_value
occult	B-Detailed_description
adenocarcinoma	B-Disease_disorder
(	O
Fig	O
.	O
2	O
)	O
.	O

Clusters	O
and	O
sheets	O
of	O
small	O
round	O
cells	O
were	O
seen	O
in	O
the	O
liver	O
parenchyma	O
(	O
Fig	O
.	O
1	O
)	O
and	O
the	O
lymph	O
nodes	O
from	O
the	O
hepatic	O
hilum	O
.	O

Examination	O
of	O
the	O
lung	O
parenchyma	O
showed	O
a	O
peribronchial	B-Biological_structure
SCLC	B-Disease_disorder
with	O
multiple	B-Detailed_description
tumor	B-Sign_symptom
emboli	I-Sign_symptom
in	O
both	O
veins	B-Biological_structure
and	O
lymphatic	B-Biological_structure
vessels	I-Biological_structure
and	O
multiple	O
`	O
coin	B-Shape
-	I-Shape
shaped	I-Shape
`	O
tumor	B-Sign_symptom
nodules	O
of	O
1	B-Distance
to	I-Distance
2	I-Distance
mm	I-Distance
in	O
diameter	O
below	B-Biological_structure
the	I-Biological_structure
pleura	I-Biological_structure
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
small	O
round	O
tumor	O
cells	O
were	O
also	O
seen	O
in	O
bone	O
marrow	O
from	O
the	O
iliac	O
crest	O
bone	O
(	O
Fig	O
.	O
3	O
)	O
.	O

No	O
brain	B-Biological_structure
metastases	B-Sign_symptom
have	O
been	O
detected	O
.	O

Based	O
on	O
the	O
macro	O
-	O
and	O
microscopic	O
features	O
and	O
clinical	O
picture	O
,	O
the	O
final	O
diagnosis	O
was	O
`	O
peribronchial	B-Biological_structure
and	O
coin	B-Shape
-	I-Shape
like	I-Shape
peripheral	B-Detailed_description
SCLC	B-Disease_disorder
with	O
massive	B-Severity
angiolymphatic	B-Biological_structure
invasion	B-Disease_disorder
and	O
metastases	B-Sign_symptom
in	O
the	O
lymph	B-Biological_structure
nodes	I-Biological_structure
,	O
liver	B-Biological_structure
and	O
bone	B-Biological_structure
,	O
associated	O
with	O
encephalopathy	B-Disease_disorder
and	O
synchronous	B-Detailed_description
occult	B-Detailed_description
adenocarcinoma	B-Disease_disorder
of	O
the	O
prostate	B-Biological_structure
.	O
`	O

-DOCSTART- -X- -X- -X- O

This	O
16	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
boy	O
was	O
the	O
first	O
child	O
to	O
non	O
-	O
consanguineous	O
parents	O
.	O

His	O
parents	O
and	O
two	O
younger	O
siblings	O
were	O
healthy	O
.	O

He	O
was	O
well	O
until	O
starting	O
school	O
at	O
7	O
years	O
of	O
age	O
when	O
he	O
was	O
found	O
to	O
be	O
short	B-Sign_symptom
in	I-Sign_symptom
height	I-Sign_symptom
,	O
slightly	B-Sign_symptom
myopic	I-Sign_symptom
,	O
astigmatic	B-Sign_symptom
and	O
to	O
have	O
subnormal	B-Sign_symptom
visual	I-Sign_symptom
acuity	I-Sign_symptom
.	O

Endocrinological	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
were	O
performed	O
that	O
initially	O
revealed	O
borderline	B-Lab_value
values	I-Lab_value
for	O
growth	B-Sign_symptom
hormone	I-Sign_symptom
(	I-Sign_symptom
GH	I-Sign_symptom
)	I-Sign_symptom
deficiency	I-Sign_symptom
and	O
he	O
was	O
therefore	O
treated	O
for	O
a	O
period	O
with	O
GH	B-Medication
without	O
any	O
beneficiary	B-Sign_symptom
effect	I-Sign_symptom
on	I-Sign_symptom
his	I-Sign_symptom
growth	I-Sign_symptom
.	O

At	O
age	O
16	O
years	O
,	O
height	B-Sign_symptom
and	I-Sign_symptom
weight	I-Sign_symptom
was	I-Sign_symptom
−	I-Sign_symptom
3	I-Sign_symptom
SD	I-Sign_symptom
below	I-Sign_symptom
the	I-Sign_symptom
mean	I-Sign_symptom
compared	O
with	O
a	O
standardized	O
Swedish	O
growth	O
chart	O
.	O

Ophthalmological	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
at	O
10	O
years	O
of	O
age	O
showed	O
pigmentary	B-Sign_symptom
retinopathy	I-Sign_symptom
and	O
optic	B-Sign_symptom
atrophy	I-Sign_symptom
.	O

An	O
electroretinogram	B-Diagnostic_procedure
was	O
performed	O
and	O
showed	O
a	O
severe	B-Severity
rod	B-Sign_symptom
cone	I-Sign_symptom
dystrophy	I-Sign_symptom
.	O

He	O
had	O
decreased	B-Lab_value
visual	B-Sign_symptom
acuity	I-Sign_symptom
,	O
visual	B-Sign_symptom
fields	I-Sign_symptom
,	O
color	B-Sign_symptom
vision	I-Sign_symptom
,	O
and	O
dark	B-Sign_symptom
adaption	I-Sign_symptom
.	O

Nystagmus	B-Sign_symptom
has	O
been	O
noted	O
since	O
14	O
years	O
of	O
age	O
.	O

A	O
year	O
later	O
,	O
photophobia	B-Sign_symptom
and	O
bilateral	B-Sign_symptom
cataracts	I-Sign_symptom
were	O
developed	O
.	O

The	O
cataracts	B-Therapeutic_procedure
were	I-Therapeutic_procedure
operated	I-Therapeutic_procedure
on	I-Therapeutic_procedure
at	O
16	O
years	O
of	O
age	O
.	O

He	O
is	O
now	O
blind	B-Sign_symptom
.	O

At	O
14	O
years	O
of	O
age	O
,	O
he	O
was	O
referred	O
for	O
neurological	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
.	O

A	O
clinical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
mild	B-Severity
ataxia	B-Sign_symptom
with	I-Sign_symptom
tremor	I-Sign_symptom
,	O
dysmetria	B-Sign_symptom
and	O
gait	B-Sign_symptom
instability	I-Sign_symptom
together	O
with	O
mild	B-Severity
to	I-Severity
moderate	I-Severity
muscle	B-Sign_symptom
weakness	I-Sign_symptom
,	O
weak	B-Severity
to	I-Severity
absent	I-Severity
tendon	B-Sign_symptom
reflexes	I-Sign_symptom
in	O
the	O
lower	B-Biological_structure
extremities	I-Biological_structure
,	O
and	O
exercise	B-Sign_symptom
intolerance	I-Sign_symptom
.	O

Audiometric	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
revealed	O
a	O
mild	B-Severity
bilateral	B-Detailed_description
sensorineural	B-Sign_symptom
hearing	I-Sign_symptom
impairment	I-Sign_symptom
.	O

At	O
15	O
years	O
of	O
age	O
,	O
he	O
had	O
an	O
unprovoked	B-Detailed_description
epileptic	B-Sign_symptom
seizure	I-Sign_symptom
and	O
he	O
has	O
since	O
then	O
been	O
treated	O
with	O
levetiracetam	B-Medication
.	O

Decreased	B-Sign_symptom
renal	I-Sign_symptom
function	I-Sign_symptom
was	O
identified	O
at	O
15	O
years	O
of	O
age	O
,	O
with	O
increased	B-Lab_value
serum	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
to	O
145	B-Lab_value
μmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
(	O
reference	O
interval	O
30	O
-	O
90	O
μmol	O
/	O
l	O
)	O
,	O
proteinuria	B-Sign_symptom
with	O
urine	B-Diagnostic_procedure
albumine	I-Diagnostic_procedure
at	O
244	B-Lab_value
-	I-Lab_value
538	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
l	I-Lab_value
(	O
reference	O
interval	O
<	O
20	O
mg	O
/	O
l	O
)	O
,	O
and	O
urine	B-Diagnostic_procedure
albumine	I-Diagnostic_procedure
/	I-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
ratio	O
at	O
44	B-Lab_value
-	I-Lab_value
59	I-Lab_value
g	I-Lab_value
/	I-Lab_value
mol	I-Lab_value
(	O
reference	O
interval	O
<	O
3	O
g	O
/	O
mol	O
)	O
.	O

A	O
renal	B-Biological_structure
scintigraphy	B-Diagnostic_procedure
demonstrated	O
reduced	B-Sign_symptom
kidney	I-Sign_symptom
size	I-Sign_symptom
.	O

Cr51	B-Diagnostic_procedure
-	I-Diagnostic_procedure
EDTA	I-Diagnostic_procedure
clearance	I-Diagnostic_procedure
showed	O
a	O
decreased	B-Lab_value
glomerular	B-Diagnostic_procedure
filtration	I-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
42	B-Lab_value
%	I-Lab_value
of	I-Lab_value
normal	I-Lab_value
.	I-Lab_value

The	O
filtration	O
rate	O
decreased	B-Lab_value
over	O
time	O
to	O
29	B-Lab_value
%	I-Lab_value
of	I-Lab_value
normal	I-Lab_value
at	O
16	O
years	O
of	O
age	O
.	O

Since	O
14	O
years	O
of	O
age	O
,	O
cardiac	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
have	O
demonstrated	O
hypertrophy	B-Sign_symptom
of	O
the	O
walls	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
ventricle	I-Biological_structure
(	O
+3	O
SD	O
compared	O
with	O
normal	O
)	O
with	O
normal	B-Severity
systolic	B-Sign_symptom
and	I-Sign_symptom
diastolic	I-Sign_symptom
function	I-Sign_symptom
and	O
without	O
obstruction	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
outflow	I-Sign_symptom
.	O

Mitochondrial	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
were	O
performed	O
at	O
14	O
years	O
of	O
age	O
.	O

Blood	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	O
lactate	B-Diagnostic_procedure
and	O
pyruvate	B-Diagnostic_procedure
were	O
1	B-Lab_value
.	I-Lab_value
6	I-Lab_value
and	O
0	B-Lab_value
.	I-Lab_value
096	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
,	O
respectively	O
,	O
leading	O
to	O
a	O
ratio	B-Diagnostic_procedure
of	O
33	B-Lab_value
(	O
reference	O
interval	O
<	O
20	O
)	O
,	O
while	O
cerebrospinal	B-Diagnostic_procedure
fluid	I-Diagnostic_procedure
(	O
CSF	B-Diagnostic_procedure
)	O
levels	O
of	O
lactate	B-Diagnostic_procedure
and	O
pyruvate	B-Diagnostic_procedure
were	O
3	B-Lab_value
.	I-Lab_value
6	I-Lab_value
and	O
0	B-Lab_value
.	I-Lab_value
137	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
,	I-Lab_value
respectively	O
,	O
leading	O
to	O
a	O
lactate	B-Diagnostic_procedure
to	I-Diagnostic_procedure
pyruvate	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
of	O
26	B-Lab_value
.	O

The	O
urinary	B-Diagnostic_procedure
lactate	I-Diagnostic_procedure
excretion	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

The	O
CSF	B-Diagnostic_procedure
albumin	I-Diagnostic_procedure
was	O
increased	B-Lab_value
to	O
258	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
l	I-Lab_value
(	O
reference	O
level	O
<	O
225	O
mg	O
/	O
l	O
)	O
and	O
he	O
also	O
had	O
an	O
increased	B-Lab_value
CSF	B-Diagnostic_procedure
/	I-Diagnostic_procedure
plasma	I-Diagnostic_procedure
albumin	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
of	O
7	B-Lab_value
.	I-Lab_value
4	I-Lab_value
(	O
reference	O
level	O
<	O
5	O
)	O
.	O

The	O
serum	B-Diagnostic_procedure
acyl	I-Diagnostic_procedure
carnitine	I-Diagnostic_procedure
profile	I-Diagnostic_procedure
and	O
muscle	B-Diagnostic_procedure
carnitine	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

The	O
serum	B-Diagnostic_procedure
creatine	I-Diagnostic_procedure
kinase	I-Diagnostic_procedure
activity	I-Diagnostic_procedure
was	O
mildly	B-Lab_value
increased	I-Lab_value
to	O
5	B-Lab_value
.	I-Lab_value
4	I-Lab_value
μkat	I-Lab_value
/	I-Lab_value
l	I-Lab_value
(	O
reference	O
interval	O
<	O
3	O
.	O
5	O
μkat	O
/	O
l	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
61	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
was	O
referred	O
to	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
by	O
his	O
general	O
practitioner	O
in	O
April	O
2010	O
for	O
investigation	O
of	O
loose	B-Sign_symptom
bowel	I-Sign_symptom
motions	I-Sign_symptom
and	O
an	O
episode	O
of	O
black	B-Sign_symptom
stool	I-Sign_symptom
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
insulin	O
-	O
dependent	O
type	O
II	O
diabetes	O
mellitus	O
,	O
hypertension	O
,	O
ischaemic	O
heart	O
disease	O
with	O
two	O
previous	O
ischaemic	O
events	O
,	O
obstructive	O
sleep	O
apnoea	O
,	O
depression	O
,	O
schizophrenia	O
and	O
a	O
previous	O
incisional	O
hernia	O
repair	O
.	O

On	O
examination	O
,	O
he	O
was	O
morbidly	B-Disease_disorder
obese	I-Disease_disorder
(	O
BMI	B-Diagnostic_procedure
45	B-Lab_value
)	O
and	O
was	O
noted	O
to	O
have	O
marked	O
hepatomegaly	B-Disease_disorder
.	O

This	O
was	O
not	O
associated	O
with	O
any	O
recent	O
weight	B-Sign_symptom
loss	I-Sign_symptom
,	O
haematemesis	B-Sign_symptom
,	O
jaundice	B-Sign_symptom
or	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
.	O

The	O
patient	O
denied	O
previous	O
blood	O
transfusions	O
,	O
usage	O
of	O
intravenous	O
drugs	O
and	O
did	O
not	O
drink	O
alcohol	O
.	O

A	O
faecal	B-Diagnostic_procedure
occult	I-Diagnostic_procedure
blood	I-Diagnostic_procedure
test	I-Diagnostic_procedure
was	O
negative	B-Lab_value
,	O
and	O
the	O
patient	O
`	O
s	O
last	O
colonoscopy	B-Diagnostic_procedure
2	O
years	O
prior	O
was	O
unremarkable	B-Lab_value
.	O

He	O
was	O
referred	O
to	O
our	O
tertiary	B-Nonbiological_location
centre	I-Nonbiological_location
for	O
further	O
management	O
after	O
an	O
ultrasound	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
(	O
USS	B-Diagnostic_procedure
)	O
displayed	O
an	O
ovoid	B-Shape
mass	B-Sign_symptom
of	O
mixed	B-Detailed_description
echogenicity	I-Detailed_description
arising	O
from	O
the	O
liver	B-Biological_structure
,	O
measuring	O
12	B-Area
×	I-Area
9	I-Area
cm	I-Area
.	O

A	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
confirmed	O
a	O
malignant	B-Detailed_description
appearing	I-Detailed_description
,	O
pedunculated	B-Detailed_description
lesion	B-Sign_symptom
attached	O
to	O
segment	B-Biological_structure
IV	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
subsequent	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
confirmed	O
that	O
on	O
T2	B-Detailed_description
weighted	B-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
WI	B-Diagnostic_procedure
)	O
,	O
the	O
lesion	B-Sign_symptom
was	O
isointense	B-Detailed_description
to	O
the	O
liver	B-Biological_structure
peripherally	O
with	O
central	B-Detailed_description
branching	I-Detailed_description
hyperintensities	I-Detailed_description
(	O
Fig	O
.	O
2a	O
)	O
which	O
corresponded	O
to	O
the	O
hypointensities	B-Sign_symptom
seen	O
on	O
T1WI	B-Diagnostic_procedure
(	O
Fig	O
.	O
2b	O
)	O
.	O

Enhancement	B-Detailed_description
of	O
the	O
lesion	B-Sign_symptom
was	O
noted	O
in	O
arterial	B-Detailed_description
phase	I-Detailed_description
(	O
Fig	O
.	O
3a	O
)	O
,	O
during	O
portal	B-Detailed_description
venous	I-Detailed_description
phase	I-Detailed_description
(	O
Fig	O
.	O
3b	O
)	O
and	O
at	B-Detailed_description
2	I-Detailed_description
min	I-Detailed_description
(	O
Fig	O
.	O
3c	O
)	O
,	O
with	O
some	O
central	B-Detailed_description
areas	I-Detailed_description
of	I-Detailed_description
non	I-Detailed_description
-	I-Detailed_description
enhancement	I-Detailed_description
.	O

The	O
lesion	B-Sign_symptom
becomes	O
slightly	B-Detailed_description
hypointense	I-Detailed_description
on	O
delayed	B-Detailed_description
images	I-Detailed_description
at	O
10	B-Detailed_description
(	O
Fig	O
.	O
3d	O
)	O
and	O
20	B-Detailed_description
min	I-Detailed_description
compared	O
to	O
the	O
surrounding	O
liver	B-Biological_structure
.	O

Laboratory	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
revealed	O
a	O
mildly	B-Lab_value
elevated	I-Lab_value
gamma	B-Diagnostic_procedure
-	I-Diagnostic_procedure
glutamyl	I-Diagnostic_procedure
transpeptidase	I-Diagnostic_procedure
of	O
137	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
5	O
-	O
50	O
IU	O
/	O
L	O
)	O
.	O

Hepatitis	B-Diagnostic_procedure
screen	I-Diagnostic_procedure
,	O
alpha	B-Diagnostic_procedure
-	I-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
,	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
and	O
cancer	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
were	O
all	O
unremarkable	B-Lab_value
.	O

The	O
patient	O
underwent	O
a	O
subsegmental	B-Detailed_description
resection	B-Therapeutic_procedure
of	O
the	O
15	B-Distance
cm	I-Distance
segment	B-Biological_structure
IVb	I-Biological_structure
mass	B-Sign_symptom
in	O
June	O
2010	O
.	O

There	O
was	O
severe	B-Severity
hepatic	B-Disease_disorder
steatosis	I-Disease_disorder
,	O
but	O
no	O
cirrhosis	B-Disease_disorder
.	O

The	O
patient	O
was	O
discharged	O
postoperative	O
day	O
seven	O
without	O
complications	B-Sign_symptom
.	O

Pathology	B-Diagnostic_procedure
of	O
the	O
resection	B-Biological_structure
specimen	I-Biological_structure
confirmed	O
SFTL	B-Disease_disorder
.	O

The	O
specimen	O
displayed	O
a	O
pale	B-Color
tan	I-Color
nodular	B-Shape
appearance	I-Shape
with	O
a	O
firm	B-Texture
and	I-Texture
rubbery	I-Texture
cut	I-Texture
surface	I-Texture
.	O

Histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
fascicles	B-Lab_value
of	I-Lab_value
spindle	I-Lab_value
cells	I-Lab_value
in	O
storiform	B-Detailed_description
arrangement	I-Detailed_description
with	O
a	O
pushing	B-Detailed_description
margin	I-Detailed_description
.	O

There	O
was	O
evidence	B-Lab_value
of	I-Lab_value
extracellular	I-Lab_value
collagen	I-Lab_value
deposition	I-Lab_value
,	O
areas	B-Lab_value
of	I-Lab_value
myxoid	I-Lab_value
stroma	I-Lab_value
and	O
branching	B-Lab_value
vessels	I-Lab_value
with	I-Lab_value
hyalinisation	I-Lab_value
.	O

The	O
specimen	B-Biological_structure
displayed	O
a	O
high	B-Lab_value
mitotic	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
up	O
to	O
9	B-Lab_value
per	I-Lab_value
10	I-Lab_value
high	I-Lab_value
-	I-Lab_value
power	I-Lab_value
fields	I-Lab_value
(	O
HPF	O
)	O
with	O
no	B-Lab_value
necrotic	I-Lab_value
or	I-Lab_value
haemorrhagic	I-Lab_value
features	I-Lab_value
.	O

Immunohistochemistry	B-Diagnostic_procedure
showed	O
positive	B-Lab_value
staining	O
for	O
CD34	B-Diagnostic_procedure
,	O
CD99	B-Diagnostic_procedure
and	O
BCL	B-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
.	O

The	O
tumour	O
was	O
negative	B-Lab_value
for	O
c	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Kit	I-Diagnostic_procedure
,	O
CD31	B-Diagnostic_procedure
,	O
SMA	B-Diagnostic_procedure
,	O
desmin	B-Diagnostic_procedure
,	O
cytokeratins	B-Diagnostic_procedure
(	O
AE1	B-Detailed_description
/	I-Detailed_description
AE3	I-Detailed_description
,	I-Detailed_description
MNF116	I-Detailed_description
and	I-Detailed_description
Cam	I-Detailed_description
5	I-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
)	O
,	O
EMA	B-Diagnostic_procedure
and	O
S100	B-Diagnostic_procedure
.	O

The	O
margins	B-Diagnostic_procedure
were	O
clear	B-Lab_value
.	O

The	O
non	O
-	O
neoplastic	O
remainder	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
liver	I-Biological_structure
displayed	O
pericellular	B-Detailed_description
fibrosis	B-Sign_symptom
indicative	O
of	O
steatohepatitis	B-Disease_disorder
.	O

The	O
patient	O
was	O
followed	O
-	O
up	O
regularly	O
every	B-Frequency
4	I-Frequency
to	I-Frequency
6	I-Frequency
months	I-Frequency
with	O
CT	B-Diagnostic_procedure
scans	O
by	O
the	O
local	B-Nonbiological_location
general	I-Nonbiological_location
practitioner	I-Nonbiological_location
who	O
liaised	O
with	O
the	O
consultant	B-Nonbiological_location
surgeon	I-Nonbiological_location
.	O

There	O
were	O
two	B-Lab_value
episodes	O
of	O
re	O
-	O
admissions	O
for	O
further	O
investigation	O
of	O
recurrent	B-Detailed_description
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
pain	B-Sign_symptom
between	O
2011	O
and	O
2013	O
.	O

Multiple	B-Detailed_description
MRI	B-Diagnostic_procedure
scans	O
performed	O
during	O
this	O
period	O
revealed	O
expected	B-Sign_symptom
postsurgical	I-Sign_symptom
changes	I-Sign_symptom
with	O
no	O
tumour	B-Sign_symptom
recurrence	I-Sign_symptom
.	O

However	O
,	O
in	O
May	O
2016	O
,	O
the	O
patient	O
presented	O
to	O
his	O
local	B-Nonbiological_location
emergency	I-Nonbiological_location
department	I-Nonbiological_location
with	O
progressively	O
worsening	O
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
pain	B-Sign_symptom
and	O
increasing	O
dyspnoea	B-Sign_symptom
with	O
an	O
oxygen	B-Therapeutic_procedure
demand	I-Therapeutic_procedure
.	O

CT	B-Diagnostic_procedure
of	O
his	O
chest	B-Biological_structure
,	O
abdomen	B-Biological_structure
and	O
pelvis	B-Biological_structure
revealed	O
extensive	B-Detailed_description
tumour	B-Sign_symptom
recurrence	I-Sign_symptom
adjacent	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
previous	I-Biological_structure
resection	I-Biological_structure
site	I-Biological_structure
(	O
Fig	O
.	O
4	O
)	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
clinically	O
significant	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
and	O
a	O
pleural	B-Biological_structure
mass	B-Sign_symptom
at	O
the	O
right	B-Biological_structure
lung	I-Biological_structure
base	I-Biological_structure
measuring	O
3	O
.	O
8	O
cm	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Pleurocentesis	B-Therapeutic_procedure
was	O
performed	O
,	O
draining	O
1400	B-Volume
ml	I-Volume
of	O
serosanguineous	B-Biological_structure
fluid	I-Biological_structure
.	O

Cytology	B-Diagnostic_procedure
was	O
negative	B-Lab_value
for	O
malignant	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
.	O

The	O
case	O
was	O
discussed	O
extensively	O
in	O
a	O
multi	B-Nonbiological_location
-	I-Nonbiological_location
disciplinary	I-Nonbiological_location
setting	I-Nonbiological_location
,	O
and	O
it	O
was	O
decided	O
given	O
the	O
patient	O
`	O
s	O
two	O
sites	O
of	O
disease	O
and	O
significant	O
perioperative	O
risk	O
that	O
he	O
was	O
not	O
a	O
candidate	O
for	O
radical	O
reoperation	B-Therapeutic_procedure
.	O

There	O
were	O
also	O
no	O
suitable	O
chemo	B-Medication
-	O
or	O
radiotherapeutic	B-Therapeutic_procedure
therapies	I-Therapeutic_procedure
available	O
.	O

The	O
patient	O
was	O
subsequently	O
referred	O
to	O
the	O
palliative	B-Nonbiological_location
team	I-Nonbiological_location
for	O
management	O
of	O
his	O
symptoms	O
and	O
discharged	O
back	O
to	O
the	O
community	B-Nonbiological_location
.	O

He	O
was	O
still	O
alive	B-Sign_symptom
1	O
month	O
after	O
discharge	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
51	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
referred	O
to	O
our	O
hospital	B-Biological_structure
due	O
to	O
severe	B-Severity
congestive	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
and	O
ventricular	B-Biological_structure
arrhythmias	B-Disease_disorder
in	O
March	O
2008	O
.	O

He	O
had	O
been	O
suffering	O
from	O
heart	B-Disease_disorder
failure	I-Disease_disorder
and	O
ventricular	B-Biological_structure
tachycardia	B-Sign_symptom
for	B-Duration
years	I-Duration
despite	O
receiving	O
the	O
conventional	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
(	O
ie	O
,	O
furosemide	B-Medication
,	O
lisinopril	B-Medication
hydrate	I-Medication
,	O
pimobendan	B-Medication
,	O
warfarin	B-Medication
potassium	I-Medication
,	O
carvedilol	B-Medication
,	O
metildigoxin	B-Medication
and	O
amiodarone	B-Medication
hydrochloride	I-Medication
)	O
.	O

His	O
height	O
was	O
161	B-Height
cm	I-Height
and	O
body	O
weight	O
was	O
83	B-Weight
kg	I-Weight
.	O

Blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
110	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

The	O
fasting	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
glucose	I-Diagnostic_procedure
was	O
107	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
and	O
HbA1c	B-Diagnostic_procedure
was	O
6	B-Lab_value
.	I-Lab_value
3	I-Lab_value
%	I-Lab_value
.	O

The	O
chest	B-Biological_structure
x	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
cardiomegaly	B-Sign_symptom
with	O
a	O
cardiothoracic	B-Diagnostic_procedure
ratio	I-Diagnostic_procedure
of	O
0	B-Lab_value
.	I-Lab_value
67	I-Lab_value
(	O
figure	O
1A	O
)	O
.	O

ECG	B-Diagnostic_procedure
,	O
as	O
shown	O
in	O
video	O
1	O
,	O
revealed	O
a	O
diffused	B-Detailed_description
hypokinetic	B-Sign_symptom
left	I-Sign_symptom
ventricle	I-Sign_symptom
with	O
markedly	B-Lab_value
dilated	I-Lab_value
left	B-Diagnostic_procedure
ventricle	I-Diagnostic_procedure
dimension	I-Diagnostic_procedure
(	O
end	B-Diagnostic_procedure
-	I-Diagnostic_procedure
diastole	I-Diagnostic_procedure
:	O
95	B-Lab_value
mm	I-Lab_value
)	O
and	O
reduced	B-Lab_value
EF	B-Diagnostic_procedure
(	O
0	B-Lab_value
.	I-Lab_value
11	I-Lab_value
)	O
.	O

The	O
coronary	B-Biological_structure
angiogram	B-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

A	O
myocardial	B-Biological_structure
biopsy	B-Diagnostic_procedure
revealed	O
that	O
over	B-Lab_value
50	I-Lab_value
%	I-Lab_value
of	I-Lab_value
cardiomyocytes	I-Lab_value
were	O
replaced	O
by	O
fibrosis	B-Sign_symptom
(	O
figure	O
2	O
)	O
.	O

An	O
implantable	B-Detailed_description
cardioverter	B-Therapeutic_procedure
-	I-Therapeutic_procedure
defibrillator	I-Therapeutic_procedure
was	O
implanted	O
.	O

Due	O
to	O
the	O
typical	B-Lab_value
facial	B-Diagnostic_procedure
appearance	I-Diagnostic_procedure
and	O
thickening	B-Sign_symptom
of	I-Sign_symptom
hands	I-Sign_symptom
,	O
he	O
was	O
referred	O
to	O
the	O
endocrinology	B-Nonbiological_location
department	I-Nonbiological_location
.	O

The	O
plasma	B-Diagnostic_procedure
level	I-Diagnostic_procedure
of	I-Diagnostic_procedure
GH	I-Diagnostic_procedure
was	O
8	B-Lab_value
.	I-Lab_value
2	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
and	O
IGF	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
was	O
504	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
.	O

MRI	B-Diagnostic_procedure
demonstrated	O
a	O
macroadenoma	B-Disease_disorder
in	O
the	O
pituitary	B-Biological_structure
.	O

Thus	O
,	O
he	O
was	O
diagnosed	O
as	O
acromegaly	B-Disease_disorder
.	O

He	O
was	O
treated	O
with	O
octreotide	B-Medication
long	B-Detailed_description
-	I-Detailed_description
acting	I-Detailed_description
-	I-Detailed_description
release	I-Detailed_description
(	O
LAR	B-Detailed_description
)	O
for	O
8	B-Duration
months	I-Duration
.	O

Thereafter	O
,	O
he	O
underwent	O
trans	B-Therapeutic_procedure
-	I-Therapeutic_procedure
sphenoidal	I-Therapeutic_procedure
surgery	I-Therapeutic_procedure
in	O
January	O
2009	O
(	O
figure	O
3	O
)	O
.	O

The	O
plasma	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	I-Diagnostic_procedure
GH	I-Diagnostic_procedure
and	O
IGF	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
were	O
decreased	B-Lab_value
with	O
octreotide	B-Medication
LAR	B-Detailed_description
,	O
but	O
basal	B-Diagnostic_procedure
plasma	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	I-Diagnostic_procedure
GH	I-Diagnostic_procedure
were	O
always	O
more	B-Lab_value
than	I-Lab_value
4	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
and	O
plasma	B-Diagnostic_procedure
IGF	I-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
above	B-Lab_value
the	I-Lab_value
appropriate	I-Lab_value
age	I-Lab_value
range	I-Lab_value
(	O
figure	O
3	O
)	O
.	O

After	O
surgery	O
,	O
both	O
plasma	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	I-Diagnostic_procedure
GH	I-Diagnostic_procedure
and	O
IGF	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
further	B-Lab_value
decreased	I-Lab_value
.	O

Basal	B-Diagnostic_procedure
plasma	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	I-Diagnostic_procedure
GH	I-Diagnostic_procedure
were	O
mostly	B-Lab_value
less	I-Lab_value
than	I-Lab_value
0	I-Lab_value
.	I-Lab_value
5	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
and	O
IGF	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
levels	O
were	O
within	B-Lab_value
normal	I-Lab_value
ranges	I-Lab_value
(	O
figure	O
3	O
)	O
.	O

With	O
the	O
treatment	O
of	O
LAR	O
,	O
the	O
cardiac	B-Diagnostic_procedure
function	I-Diagnostic_procedure
improved	B-Lab_value
partially	I-Lab_value
(	O
cardiothoracic	B-Diagnostic_procedure
ratio	I-Diagnostic_procedure
=	O
0	B-Lab_value
.	I-Lab_value
58	I-Lab_value
;	O
EF	B-Diagnostic_procedure
=	O
0	B-Lab_value
.	I-Lab_value
20	I-Lab_value
in	O
September	O
2008	O
)	O
.	O

After	O
surgery	O
,	O
the	O
cardiac	B-Diagnostic_procedure
function	I-Diagnostic_procedure
improved	B-Lab_value
drastically	I-Lab_value
(	O
cardiothoracic	B-Diagnostic_procedure
ratio	I-Diagnostic_procedure
=	O
0	B-Lab_value
.	I-Lab_value
47	I-Lab_value
;	O
EF	B-Diagnostic_procedure
=	O
0	B-Lab_value
.	I-Lab_value
55	I-Lab_value
in	O
April	O
2009	O
;	O
figures	O
1B	O
and	O
and2B	O
)	O
.	O
2B	O
)	O
.	O

Frequency	B-Lab_value
of	I-Lab_value
ventricular	B-Biological_structure
arrhythmias	B-Disease_disorder
decreased	I-Lab_value
and	O
pimobendan	B-Medication
was	O
tapered	O
off	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
69	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
diabetic	O
patient	O
was	O
admitted	O
with	O
acute	B-Detailed_description
left	B-Disease_disorder
ventricular	I-Disease_disorder
(	I-Disease_disorder
LV	I-Disease_disorder
)	I-Disease_disorder
failure	I-Disease_disorder
and	O
was	O
treated	O
with	O
intensive	B-Detailed_description
decongestive	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

He	O
had	O
severe	B-Severity
peripheral	B-Biological_structure
edema	B-Sign_symptom
and	O
bilateral	B-Detailed_description
basal	B-Detailed_description
crepitations	B-Sign_symptom
.	O

Initial	O
workup	B-Diagnostic_procedure
revealed	O
normal	B-Lab_value
levels	O
of	O
troponine	B-Diagnostic_procedure
(	O
<	B-Lab_value
0	I-Lab_value
.	I-Lab_value
01	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
)	O
and	O
CPK	B-Diagnostic_procedure
-	I-Diagnostic_procedure
MB	I-Diagnostic_procedure
(	O
4	B-Lab_value
.	I-Lab_value
6	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
)	O
,	O
thereby	O
ruling	O
out	O
acute	B-Disease_disorder
coronary	I-Disease_disorder
syndrome	I-Disease_disorder
.	O

The	O
level	O
of	O
BNP	B-Diagnostic_procedure
was	O
1230	B-Lab_value
pg	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
confirming	O
the	O
diagnosis	O
of	O
heart	B-Disease_disorder
failure	I-Disease_disorder
.	O

Echocardiographic	B-Diagnostic_procedure
assessment	I-Diagnostic_procedure
revealed	O
LVEF	B-Diagnostic_procedure
of	O
10	B-Lab_value
%	I-Lab_value
with	O
dilated	B-Sign_symptom
cardiac	I-Sign_symptom
chambers	I-Sign_symptom
,	O
and	O
estimated	O
pulmonary	B-Diagnostic_procedure
artery	I-Diagnostic_procedure
systolic	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
(	O
PASP	B-Diagnostic_procedure
)	O
was	O
70	B-Lab_value
mm	I-Lab_value
of	I-Lab_value
Hg	I-Lab_value
with	O
features	B-Lab_value
of	I-Lab_value
raised	I-Lab_value
LV	I-Lab_value
diastolic	I-Lab_value
pressure	I-Lab_value
.	O

Angiography	B-Diagnostic_procedure
was	O
performed	O
after	B-Duration
3	I-Duration
days	I-Duration
of	O
decongestive	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
which	O
revealed	O
critical	B-Severity
triple	B-Disease_disorder
vessel	I-Disease_disorder
disease	I-Disease_disorder
with	O
left	B-Biological_structure
main	I-Biological_structure
coronary	B-Disease_disorder
artery	I-Disease_disorder
disease	I-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

He	O
was	O
referred	O
for	O
CABG	B-Therapeutic_procedure
.	O

The	O
patient	O
was	O
put	O
on	O
frusemide	B-Medication
infusion	O
with	O
oral	O
ramipril	B-Medication
and	O
aldactone	B-Medication
.	O

He	O
was	O
taken	O
up	O
for	O
elective	O
OPCAB	B-Therapeutic_procedure
1	O
week	O
after	O
angiography	O
.	O

Renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
was	O
monitored	O
regularly	O
to	B-Detailed_description
adjust	I-Detailed_description
diuretic	I-Detailed_description
dose	I-Detailed_description
.	O

There	O
was	O
no	O
feature	O
of	O
end	B-Disease_disorder
organ	I-Disease_disorder
dysfunction	I-Disease_disorder
.	O

STS	B-Diagnostic_procedure
risk	I-Diagnostic_procedure
of	I-Diagnostic_procedure
mortality	I-Diagnostic_procedure
was	O
2	B-Lab_value
.	I-Lab_value
4	I-Lab_value
%	I-Lab_value
.	O

Repeat	O
echocardiographic	B-Diagnostic_procedure
assessment	I-Diagnostic_procedure
revealed	O
improvement	B-Lab_value
of	O
LVEF	B-Diagnostic_procedure
to	O
15	B-Lab_value
%	I-Lab_value
and	O
decrease	B-Lab_value
in	O
PASP	B-Diagnostic_procedure
to	O
30	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
and	O
decrease	B-Lab_value
in	O
LV	B-Diagnostic_procedure
filling	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
.	O

OPCAB	B-Therapeutic_procedure
was	O
performed	O
through	O
median	B-Therapeutic_procedure
sternotomy	I-Therapeutic_procedure
.	O

Left	B-Biological_structure
ITA	I-Biological_structure
was	O
used	O
for	O
grafting	B-Therapeutic_procedure
left	B-Biological_structure
anterior	I-Biological_structure
descending	I-Biological_structure
artery	I-Biological_structure
(	O
LAD	B-Biological_structure
)	O
.	O

After	O
revascularizing	B-Therapeutic_procedure
LAD	B-Biological_structure
,	O
right	B-Biological_structure
ITA	I-Biological_structure
(	O
RITA	B-Biological_structure
)	O
and	O
RA	B-Biological_structure
composite	O
,	O
graft	B-Therapeutic_procedure
was	O
prepared	O
.	O

The	O
distal	B-Biological_structure
end	I-Biological_structure
of	I-Biological_structure
RITA	I-Biological_structure
was	O
used	O
for	O
revascularizing	B-Therapeutic_procedure
the	O
diagonal	B-Biological_structure
artery	I-Biological_structure
.	O

There	O
was	O
significant	B-Detailed_description
improvement	B-Lab_value
in	O
systolic	B-Detailed_description
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
after	O
this	O
distal	B-Detailed_description
anastomosis	B-Therapeutic_procedure
.	O

After	O
these	O
two	O
grafts	O
,	O
heart	B-Biological_structure
was	O
lifted	B-Therapeutic_procedure
for	I-Therapeutic_procedure
lateral	I-Therapeutic_procedure
and	I-Therapeutic_procedure
posterior	I-Therapeutic_procedure
wall	I-Therapeutic_procedure
vessels	I-Therapeutic_procedure
.	O

We	O
make	O
a	O
longer	O
skin	B-Therapeutic_procedure
incision	I-Therapeutic_procedure
,	O
open	B-Therapeutic_procedure
the	I-Therapeutic_procedure
sternum	I-Therapeutic_procedure
widely	O
,	O
and	O
release	B-Therapeutic_procedure
pericardium	I-Therapeutic_procedure
on	O
the	O
right	O
side	O
to	O
displace	O
the	O
heart	O
gradually	O
.	O

This	O
was	O
supplemented	O
with	O
headlow	B-Detailed_description
and	O
lateral	B-Detailed_description
tilt	I-Detailed_description
position	B-Therapeutic_procedure
.	O

Liberal	B-Dosage
doses	I-Dosage
of	O
inotropic	B-Medication
support	I-Medication
were	O
used	O
.	O

RA	B-Biological_structure
was	O
used	O
for	O
sequential	B-Detailed_description
grafting	B-Therapeutic_procedure
of	O
obtuse	B-Biological_structure
marginal	I-Biological_structure
,	O
posterior	B-Biological_structure
LV	I-Biological_structure
branch	I-Biological_structure
,	O
and	O
posterior	B-Biological_structure
descending	I-Biological_structure
artery	I-Biological_structure
.	O

All	O
these	O
five	B-Lab_value
distal	B-Detailed_description
anastamoses	B-Therapeutic_procedure
were	O
performed	O
uneventfully	O
.	O

The	O
patient	O
was	O
electively	O
ventilated	B-Therapeutic_procedure
for	O
2	B-Duration
days	I-Duration
.	O

Echocardiography	B-Diagnostic_procedure
on	O
1st	O
POD	O
revealed	O
improvement	B-Lab_value
in	O
LVEF	B-Diagnostic_procedure
to	O
20	B-Lab_value
%	I-Lab_value
.	O

He	O
was	O
started	O
on	O
low	B-Dosage
dose	I-Dosage
beta	B-Medication
blockers	I-Medication
after	O
inotropic	B-Medication
supports	I-Medication
were	O
weaned	O
off	O
.	O

He	O
had	O
slow	B-Lab_value
and	O
uneventful	B-Lab_value
recovery	O
.	O

Echocardiography	B-Diagnostic_procedure
on	O
4th	O
POD	O
revealed	O
improvement	B-Lab_value
in	O
LVEF	B-Diagnostic_procedure
to	O
30	B-Lab_value
%	I-Lab_value
(	O
Table	O
1	O
)	O
.	O

He	O
had	O
persistent	B-Detailed_description
pleural	B-Sign_symptom
drainage	I-Sign_symptom
requiring	O
prolonged	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
stay	O
.	O

After	O
pleural	B-Sign_symptom
drainage	I-Sign_symptom
subsided	O
and	O
drains	O
were	O
removed	O
,	O
he	O
was	O
discharged	O
on	O
diuretics	B-Medication
,	O
low	B-Dosage
dose	I-Dosage
beta	B-Medication
blocker	I-Medication
,	O
and	O
ramipril	B-Medication
.	O

-DOCSTART- -X- -X- -X- O

An	O
8	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
boy	O
with	O
S549R	O
/	O
1717	O
-	O
1G	O
>	O
A	O
genotype	O
was	O
started	O
on	O
ivacaftor	B-Medication
(	O
150	B-Dosage
mg	I-Dosage
b	I-Dosage
.	I-Dosage
i	I-Dosage
.	I-Dosage
d	I-Dosage
.	I-Dosage
)	O
on	O
compassionate	O
use	O
.	O

At	O
the	O
age	O
of	O
9	O
months	O
he	O
was	O
diagnosed	O
with	O
CF	B-Disease_disorder
due	O
to	O
failure	B-Disease_disorder
to	I-Disease_disorder
thrive	I-Disease_disorder
.	O

His	O
previous	O
history	O
was	O
remarkable	O
for	O
recurring	O
nasal	O
polyposis	O
requiring	O
endoscopic	O
surgery	O
and	O
exocrine	O
pancreatic	O
insufficiency	O
necessitating	O
enzyme	O
replacement	O
therapy	O
.	O

He	O
grew	O
with	O
body	O
weight	O
and	O
height	O
along	O
the	O
10th	O
percentile	O
.	O

He	O
suffered	O
from	O
rather	O
mild	B-Severity
respiratory	B-Sign_symptom
symptoms	I-Sign_symptom
,	O
primarily	O
intermittent	B-Detailed_description
productive	B-Detailed_description
cough	B-Sign_symptom
,	O
and	O
had	O
close	B-Lab_value
to	I-Lab_value
normal	I-Lab_value
lung	B-Diagnostic_procedure
function	I-Diagnostic_procedure
parameters	O
in	O
previous	O
years	O
as	O
measured	O
by	O
body	B-Diagnostic_procedure
plethysmography	I-Diagnostic_procedure
and	O
spirometry	B-Diagnostic_procedure
(	O
minimal	B-Lab_value
z	I-Lab_value
-	I-Lab_value
score	I-Lab_value
of	I-Lab_value
FEV1	I-Lab_value
:	I-Lab_value
−	I-Lab_value
1	I-Lab_value
.	I-Lab_value
2	I-Lab_value
)	O
.	O

Sputum	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
grew	O
Haemophilus	B-Lab_value
influenzae	I-Lab_value
and	O
Staphylococcus	B-Lab_value
aureus	I-Lab_value
on	O
several	B-Detailed_description
occasions	I-Detailed_description
.	O

After	O
6	B-Duration
weeks	I-Duration
of	O
ivacaftor	B-Medication
treatment	O
,	O
the	O
patient	O
reported	O
clinical	B-Lab_value
improvements	I-Lab_value
in	O
cough	B-Sign_symptom
frequency	O
,	O
sputum	B-Sign_symptom
production	I-Sign_symptom
,	O
physical	B-Diagnostic_procedure
performance	I-Diagnostic_procedure
,	O
and	O
less	O
salt	B-Sign_symptom
cravings	I-Sign_symptom
.	O

He	O
gained	B-Lab_value
1	I-Lab_value
.	I-Lab_value
4	I-Lab_value
kg	I-Lab_value
in	O
body	B-Diagnostic_procedure
weight	I-Diagnostic_procedure
without	O
changing	O
the	O
dose	O
of	O
his	O
pancreatic	B-Medication
enzyme	I-Medication
replacement	I-Medication
therapy	O
.	O

His	O
sweat	B-Diagnostic_procedure
chloride	I-Diagnostic_procedure
level	I-Diagnostic_procedure
(	O
Macroduct	O
®	O
)	O
decreased	O
from	O
115	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
before	B-Detailed_description
ivacaftor	I-Detailed_description
to	O
40	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
after	O
6	O
weeks	O
and	O
52	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
l	I-Lab_value
after	O
41	O
weeks	O
(	O
normal	O
<	O
30	O
mmol	O
/	O
l	O
[	O
11	O
]	O
)	O
of	O
treatment	O
.	O

His	O
FEV1	B-Diagnostic_procedure
increased	O
from	O
1	B-Lab_value
.	I-Lab_value
25	I-Lab_value
L	I-Lab_value
(	O
−	B-Lab_value
1	I-Lab_value
.	I-Lab_value
2	I-Lab_value
z	I-Lab_value
-	I-Lab_value
score	I-Lab_value
)	O
to	O
1	B-Lab_value
.	I-Lab_value
65	I-Lab_value
L	I-Lab_value
(	O
+0	B-Lab_value
.	I-Lab_value
5	I-Lab_value
z	I-Lab_value
-	I-Lab_value
score	I-Lab_value
)	O
after	O
41	O
weeks	O
of	O
ivacaftor	B-Medication
therapy	O
.	O

The	O
LCI	B-Diagnostic_procedure
(	O
normal	O
<	O
8	O
)	O
measured	B-Detailed_description
by	I-Detailed_description
N2	I-Detailed_description
-	I-Detailed_description
MBW	I-Detailed_description
decreased	O
from	O
14	B-Lab_value
.	I-Lab_value
5	I-Lab_value
to	O
8	B-Lab_value
.	I-Lab_value
3	I-Lab_value
after	O
6	O
weeks	O
and	O
7	B-Lab_value
.	I-Lab_value
8	I-Lab_value
after	O
41	O
weeks	O
of	O
ivacaftor	B-Medication
treatment	O
(	O
Table	O
1	O
and	O
Fig	O
.	O
1	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

This	O
73	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
,	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
disease	O
and	O
situs	O
inversus	O
,	O
had	O
recently	O
noticed	O
left	B-Biological_structure
arm	I-Biological_structure
exercise	B-Detailed_description
weakness	B-Sign_symptom
.	O

The	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
angiogram	I-Diagnostic_procedure
and	O
computer	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
of	O
the	O
upper	B-Biological_structure
limb	I-Biological_structure
vessels	I-Biological_structure
showed	O
critical	B-Severity
stenosis	B-Sign_symptom
of	O
the	O
left	B-Biological_structure
-	I-Biological_structure
side	I-Biological_structure
SCA	I-Biological_structure
with	O
calcification	B-Sign_symptom
near	O
the	O
orifice	B-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Percutaneous	B-Detailed_description
revascularization	B-Therapeutic_procedure
was	O
done	O
via	O
right	B-Detailed_description
femoral	I-Detailed_description
artery	I-Detailed_description
approach	I-Detailed_description
,	O
and	O
severe	B-Severity
left	B-Biological_structure
SCA	I-Biological_structure
stenosis	B-Sign_symptom
was	O
confirmed	O
(	O
Fig	O
.	O
2A	O
)	O
(	O
Supplementary	O
Video	O
1	O
,	O
only	O
online	O
)	O
.	O

Direct	B-Detailed_description
stenting	B-Therapeutic_procedure
in	O
the	O
left	B-Biological_structure
SCA	I-Biological_structure
was	O
carried	O
out	O
with	O
a	O
balloon	B-Detailed_description
-	I-Detailed_description
expansible	I-Detailed_description
Express	I-Detailed_description
LD	I-Detailed_description
10	I-Detailed_description
×	I-Detailed_description
25	I-Detailed_description
mm	I-Detailed_description
stent	I-Detailed_description
(	O
Boston	B-Detailed_description
Scientific	I-Detailed_description
Corporation	I-Detailed_description
,	I-Detailed_description
Natick	I-Detailed_description
,	I-Detailed_description
MA	I-Detailed_description
,	I-Detailed_description
USA	I-Detailed_description
)	O
(	O
Fig	O
.	O
2B	O
)	O
up	O
to	O
8	B-Lab_value
atmospheres	I-Lab_value
for	I-Lab_value
13	I-Lab_value
seconds	I-Lab_value
.	O

However	O
,	O
severe	B-Severity
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
and	O
hypotension	B-Sign_symptom
developed	O
after	O
stenting	O
.	O

The	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
down	O
to	O
88	B-Lab_value
/	I-Lab_value
56	I-Lab_value
,	O
and	O
the	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
up	O
to	O
90	B-Lab_value
.	O

The	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
was	O
down	O
to	O
74	B-Lab_value
%	I-Lab_value
.	O

Emergent	B-Detailed_description
intubation	B-Therapeutic_procedure
,	O
fluid	B-Therapeutic_procedure
infusion	I-Therapeutic_procedure
,	O
inotropic	B-Medication
agent	I-Medication
with	O
norepinephrine	B-Medication
were	O
given	O
.	O

The	O
immediate	B-Detailed_description
angiography	B-Diagnostic_procedure
showed	O
vascular	B-Sign_symptom
perforation	I-Sign_symptom
in	O
the	O
stented	B-Biological_structure
segment	I-Biological_structure
of	I-Biological_structure
left	I-Biological_structure
SCA	I-Biological_structure
(	O
Fig	O
.	O
2C	O
)	O
(	O
Supplementary	O
Video	O
2	O
,	O
only	O
online	O
)	O
.	O

Emergency	O
balloon	B-Therapeutic_procedure
inflation	I-Therapeutic_procedure
within	B-Biological_structure
the	I-Biological_structure
stent	I-Biological_structure
was	O
done	O
with	O
an	O
8	B-Detailed_description
×	I-Detailed_description
40	I-Detailed_description
mm	I-Detailed_description
balloon	I-Detailed_description
.	O

The	O
cardiovascular	B-Nonbiological_location
surgeon	I-Nonbiological_location
was	O
also	O
consulted	O
.	O

However	O
,	O
due	O
to	O
the	O
high	O
surgical	O
risk	O
of	O
bypass	O
,	O
endovascular	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
was	O
suggested	O
.	O

We	O
decided	O
to	O
do	O
a	O
retrograde	B-Therapeutic_procedure
approach	I-Therapeutic_procedure
through	O
the	O
left	B-Biological_structure
brachial	I-Biological_structure
artery	I-Biological_structure
by	B-Detailed_description
surgical	I-Detailed_description
cut	I-Detailed_description
-	I-Detailed_description
down	I-Detailed_description
.	O

Since	O
there	O
was	O
no	O
suitable	O
graft	O
stent	O
in	O
our	O
cath	O
lab	O
,	O
we	O
modified	B-Detailed_description
and	I-Detailed_description
cut	I-Detailed_description
the	I-Detailed_description
iliac	I-Detailed_description
extension	I-Detailed_description
of	O
self	B-Detailed_description
-	I-Detailed_description
expanding	I-Detailed_description
Endurant	B-Detailed_description
II	I-Detailed_description
graft	I-Detailed_description
stent	I-Detailed_description
10	B-Area
×	I-Area
82	I-Area
mm	I-Area
(	O
Medtronic	B-Detailed_description
,	I-Detailed_description
Inc	I-Detailed_description
.	I-Detailed_description
,	I-Detailed_description
Minneapolis	I-Detailed_description
,	I-Detailed_description
MN	I-Detailed_description
,	I-Detailed_description
USA	I-Detailed_description
)	O
,	O
which	O
was	O
originally	O
designed	O
to	O
treat	O
abdominal	O
aortic	O
aneurysms	O
(	O
AAA	O
)	O
,	O
to	O
a	O
suitable	O
length	O
(	O
around	B-Detailed_description
30	I-Detailed_description
mm	I-Detailed_description
)	O
(	O
Fig	O
.	O
3	O
)	O
.	O

After	O
retrograde	O
wiring	O
,	O
an	O
operator	O
-	O
modified	O
Endurant	O
II	O
graft	B-Therapeutic_procedure
stent	I-Therapeutic_procedure
was	O
deployed	O
in	O
the	O
stent	O
segment	O
(	O
Fig	O
.	O
2D	O
)	O
and	O
the	O
perforation	B-Therapeutic_procedure
was	I-Therapeutic_procedure
sealed	I-Therapeutic_procedure
successfully	O
.	O

After	O
stenting	O
of	O
the	O
graft	O
stent	O
,	O
however	O
,	O
slow	B-Lab_value
flow	B-Diagnostic_procedure
of	O
left	B-Biological_structure
common	I-Biological_structure
carotid	I-Biological_structure
artery	I-Biological_structure
(	O
LCCA	B-Biological_structure
)	O
was	O
noted	O
,	O
and	O
angiography	B-Diagnostic_procedure
confirmed	O
the	O
near	B-Severity
total	I-Severity
occlusion	B-Sign_symptom
of	O
the	O
LCCA	B-Biological_structure
,	O
occluded	B-Detailed_description
by	I-Detailed_description
the	I-Detailed_description
SCA	I-Detailed_description
graft	I-Detailed_description
stent	I-Detailed_description
(	O
Fig	O
.	O
2E	O
)	O
(	O
Supplementary	O
Video	O
3	O
,	O
only	O
online	O
)	O
.	O

A	O
firm	B-Therapeutic_procedure
wire	I-Therapeutic_procedure
(	O
Conquest	O
pro	O
,	O
Asahi	O
Inc	O
,	O
Seto	O
,	O
Japan	O
)	O
was	O
successfully	O
advanced	B-Detailed_description
outside	B-Biological_structure
the	I-Biological_structure
graft	I-Biological_structure
stent	I-Biological_structure
and	O
into	O
the	O
LCCA	B-Biological_structure
.	O

Despite	O
sequent	O
balloon	B-Therapeutic_procedure
dilations	I-Therapeutic_procedure
at	O
the	O
bifurcation	B-Biological_structure
site	I-Biological_structure
,	O
the	O
flow	B-Diagnostic_procedure
to	O
the	O
LCCA	B-Biological_structure
was	O
still	O
poor	B-Lab_value
.	O

Intravascular	B-Detailed_description
ultrasound	B-Diagnostic_procedure
also	O
confirmed	O
the	O
severe	B-Severity
compromise	B-Sign_symptom
of	O
the	O
LCCA	B-Biological_structure
ostium	I-Biological_structure
which	O
was	O
caused	B-Detailed_description
by	I-Detailed_description
the	I-Detailed_description
graft	I-Detailed_description
stent	I-Detailed_description
(	O
Fig	O
.	O
2F	O
)	O
.	O

Therefore	O
,	O
we	O
put	O
a	O
balloon	B-Detailed_description
-	I-Detailed_description
expansible	I-Detailed_description
carotid	B-Therapeutic_procedure
stent	I-Therapeutic_procedure
,	O
Express	B-Detailed_description
7	I-Detailed_description
×	I-Detailed_description
37	I-Detailed_description
mm	I-Detailed_description
(	O
Boston	B-Detailed_description
Scientific	I-Detailed_description
Corporation	I-Detailed_description
)	O
,	O
from	B-Biological_structure
the	I-Biological_structure
LCCA	I-Biological_structure
to	O
the	O
left	B-Biological_structure
brachiocephalic	I-Biological_structure
artery	I-Biological_structure
(	O
Fig	O
.	O
4A	O
)	O
.	O

TIMI	B-Diagnostic_procedure
III	I-Diagnostic_procedure
flow	I-Diagnostic_procedure
of	O
the	O
LCCA	B-Biological_structure
was	O
restored	B-Lab_value
after	O
stenting	O
(	O
Fig	O
.	O
4B	O
-	O
E	O
)	O
(	O
Supplementary	O
Video	O
4	O
,	O
only	O
online	O
)	O
.	O

Intravascular	B-Detailed_description
ultrasound	B-Diagnostic_procedure
also	O
confirmed	O
proper	B-Lab_value
expansion	B-Sign_symptom
of	O
the	O
LCCA	B-Biological_structure
stent	I-Biological_structure
(	O
Fig	O
.	O
4F	O
)	O
.	O

The	O
follow	O
-	O
up	O
chest	B-Biological_structure
radiography	B-Diagnostic_procedure
revealed	O
left	B-Detailed_description
-	I-Detailed_description
side	I-Detailed_description
hemothorax	B-Sign_symptom
.	O

After	O
thoracocentesis	B-Therapeutic_procedure
with	O
drainage	B-Detailed_description
and	O
proper	B-Therapeutic_procedure
care	I-Therapeutic_procedure
,	O
the	O
patient	O
was	O
discharged	O
.	O

Till	O
now	O
,	O
the	O
patient	O
has	O
been	O
free	O
from	O
symptoms	B-Sign_symptom
for	O
six	B-Duration
months	I-Duration
.	O

-DOCSTART- -X- -X- -X- O

A	O
20	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
previously	O
healthy	O
Bengali	O
man	O
presented	O
to	O
our	O
hospital	B-Nonbiological_location
with	O
anuria	B-Sign_symptom
and	O
features	O
of	O
uremic	B-Detailed_description
encephalopathy	B-Disease_disorder
.	O

Ten	O
days	O
prior	O
to	O
this	O
presentation	O
,	O
he	O
had	O
experienced	O
severe	B-Severity
upper	B-Biological_structure
abdominal	I-Biological_structure
pain	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
,	O
and	O
he	O
had	O
been	O
treated	B-Therapeutic_procedure
in	O
a	O
primary	B-Nonbiological_location
care	I-Nonbiological_location
facility	I-Nonbiological_location
for	O
having	O
a	O
case	O
of	O
acute	B-Detailed_description
pancreatitis	B-Disease_disorder
.	O

His	O
initial	B-Sign_symptom
symptoms	I-Sign_symptom
improved	O
;	O
however	O
,	O
he	O
gradually	O
became	O
anuric	B-Sign_symptom
and	O
disoriented	B-Sign_symptom
.	O

Then	O
he	O
was	O
transferred	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
further	O
management	O
.	O

At	O
presentation	O
to	O
our	O
hospital	O
,	O
he	O
was	O
severely	B-Severity
agitated	B-Sign_symptom
,	O
restless	B-Sign_symptom
,	O
and	O
disoriented	B-Sign_symptom
.	O

He	O
was	O
tachypneic	B-Sign_symptom
with	O
acidotic	B-Sign_symptom
breath	I-Sign_symptom
.	O

Mild	B-Severity
pedal	B-Biological_structure
edema	B-Sign_symptom
was	O
present	O
;	O
however	O
,	O
his	O
jugular	B-Diagnostic_procedure
venous	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
not	B-Lab_value
raised	I-Lab_value
.	O

His	O
pulse	B-Diagnostic_procedure
was	O
112	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
minute	I-Lab_value
,	O
his	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
140	B-Lab_value
/	I-Lab_value
90	I-Lab_value
mmHg	I-Lab_value
,	O
and	O
his	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
was	O
98	B-Lab_value
°F	I-Lab_value
.	O

Signs	O
of	O
meningeal	B-Biological_structure
irritation	B-Sign_symptom
were	O
absent	O
,	O
and	O
his	O
plantar	B-Diagnostic_procedure
response	I-Diagnostic_procedure
was	O
bilaterally	B-Lab_value
extensor	I-Lab_value
.	O

His	O
fundus	B-Diagnostic_procedure
could	B-Lab_value
not	I-Lab_value
be	I-Lab_value
evaluated	I-Lab_value
,	O
and	O
examination	B-Diagnostic_procedure
of	O
his	O
other	B-Biological_structure
systems	I-Biological_structure
was	O
unremarkable	B-Lab_value
.	O

His	O
laboratory	B-Diagnostic_procedure
parameters	I-Diagnostic_procedure
showed	O
features	O
of	O
renal	B-Disease_disorder
dysfunction	I-Disease_disorder
(	O
serum	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
13	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
serum	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
293	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
)	O
,	O
raised	B-Lab_value
pancreatic	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
(	O
serum	B-Diagnostic_procedure
amylase	I-Diagnostic_procedure
249	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
[	O
reference	O
up	O
to	O
100	O
U	O
/	O
L	O
]	O
,	O
serum	B-Diagnostic_procedure
lipase	I-Diagnostic_procedure
227	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
[	O
reference	O
13	O
-	O
60	O
U	O
/	O
L	O
)	O
,	O
normal	B-Lab_value
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	O
(	O
serum	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
0	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
alanine	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
38	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
aspartate	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
35	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
alkaline	B-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
122	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
serum	B-Diagnostic_procedure
albumin	I-Diagnostic_procedure
37	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
normal	B-Lab_value
potassium	B-Diagnostic_procedure
(	O
5	B-Lab_value
.	I-Lab_value
1	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
normal	B-Lab_value
bicarbonate	B-Diagnostic_procedure
(	O
19	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
and	O
normal	B-Lab_value
triglycerides	B-Diagnostic_procedure
(	O
173	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
)	O
.	O

His	O
serological	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
,	O
including	O
antinuclear	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
,	O
cytoplasmic	B-Diagnostic_procedure
antineutrophil	I-Diagnostic_procedure
cytoplasmic	I-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
,	O
perinuclear	B-Diagnostic_procedure
antineutrophil	I-Diagnostic_procedure
cytoplasmic	I-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
,	O
C3	B-Diagnostic_procedure
,	O
and	O
C4	B-Diagnostic_procedure
,	O
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

An	O
ultrasonogram	B-Diagnostic_procedure
of	O
his	O
whole	O
abdomen	B-Biological_structure
was	O
unremarkable	B-Lab_value
,	O
but	O
non	B-Detailed_description
-	I-Detailed_description
contrast	I-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
findings	O
were	O
suggestive	O
of	O
acute	B-Detailed_description
pancreatitis	B-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

His	O
kidneys	B-Diagnostic_procedure
were	O
unremarkable	B-Lab_value
,	O
however	O
.	O

The	O
patient	O
was	O
managed	O
as	O
having	O
a	O
case	O
of	O
AKI	B-Disease_disorder
and	O
acute	B-Detailed_description
pancreatitis	B-Disease_disorder
.	O

Urgent	B-Detailed_description
hemodialysis	B-Therapeutic_procedure
was	O
initiated	O
.	O

After	O
he	O
had	O
received	O
two	B-Detailed_description
sessions	I-Detailed_description
of	O
hemodialysis	B-Therapeutic_procedure
,	O
his	O
level	B-Diagnostic_procedure
of	I-Diagnostic_procedure
consciousness	I-Diagnostic_procedure
improved	B-Lab_value
,	O
but	O
he	O
complained	O
of	O
profound	B-Severity
visual	B-Disease_disorder
loss	I-Disease_disorder
.	O

An	O
assessment	O
revealed	O
only	O
perception	B-Sign_symptom
of	I-Sign_symptom
light	I-Sign_symptom
.	O

A	O
funduscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
retinal	B-Sign_symptom
whitening	I-Sign_symptom
and	O
extensive	B-Severity
cotton	B-Sign_symptom
wool	I-Sign_symptom
exudates	I-Sign_symptom
as	O
well	O
as	O
Purtscher	B-Sign_symptom
`	I-Sign_symptom
s	I-Sign_symptom
flecken	I-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
compatible	O
with	O
Purtscher	B-Disease_disorder
`	I-Disease_disorder
s	I-Disease_disorder
retinopathy	I-Disease_disorder
.	O

High	B-Dosage
-	I-Dosage
dose	I-Dosage
parenteral	O
methylprednisolone	B-Medication
(	O
1	B-Dosage
g	I-Dosage
intravenously	O
once	B-Dosage
daily	I-Dosage
for	O
3	B-Duration
days	I-Duration
)	O
was	O
administered	O
.	O

For	O
evaluation	B-Diagnostic_procedure
of	I-Diagnostic_procedure
renal	I-Diagnostic_procedure
dysfunction	I-Diagnostic_procedure
,	O
a	O
renal	B-Biological_structure
biopsy	B-Diagnostic_procedure
was	O
done	O
;	O
the	O
histopathological	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
compatible	O
with	O
renal	B-Disease_disorder
cortical	I-Disease_disorder
necrosis	I-Disease_disorder
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
patient	O
denied	O
substance	O
abuse	O
or	O
alcohol	O
ingestion	O
.	O

He	O
did	O
not	O
consume	O
any	O
nephrotoxic	O
drugs	O
or	O
herbal	O
products	O
in	O
the	O
recent	O
past	O
.	O

No	O
history	O
suggesting	O
connective	O
tissue	O
diseases	O
was	O
available	O
,	O
nor	O
did	O
he	O
have	O
a	O
history	O
of	O
hypotension	B-Sign_symptom
throughout	O
the	O
course	O
of	O
his	O
current	O
illness	O
.	O

The	O
patient	O
was	O
finally	O
diagnosed	O
with	O
acute	B-Detailed_description
pancreatitis	B-Disease_disorder
complicated	O
with	O
renal	B-Disease_disorder
cortical	I-Disease_disorder
necrosis	I-Disease_disorder
leading	O
to	O
AKI	B-Disease_disorder
and	O
Purtscher	B-Disease_disorder
`	I-Disease_disorder
s	I-Disease_disorder
retinopathy	I-Disease_disorder
leading	O
to	O
complete	B-Severity
bilateral	B-Detailed_description
blindness	B-Disease_disorder
.	O

He	O
died	O
16	O
months	O
after	O
his	O
initial	O
presentation	O
as	O
a	O
result	O
of	O
a	O
recurrent	B-Detailed_description
attack	O
of	O
acute	B-Detailed_description
pancreatitis	B-Disease_disorder
.	O

Before	O
that	O
,	O
he	O
had	O
been	O
undergoing	O
maintenance	B-Detailed_description
hemodialysis	B-Therapeutic_procedure
;	O
however	O
,	O
his	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
did	B-Lab_value
not	I-Lab_value
recover	I-Lab_value
,	O
though	O
his	O
vision	B-Diagnostic_procedure
was	O
improved	B-Lab_value
to	O
finger	B-Diagnostic_procedure
-	I-Diagnostic_procedure
counting	I-Diagnostic_procedure
at	O
2	B-Lab_value
feet	I-Lab_value
.	O

-DOCSTART- -X- -X- -X- O

Here	O
,	O
we	O
describe	O
another	O
case	O
in	O
a	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
from	O
San	O
Francisco	O
who	O
had	O
consumed	B-Activity
raw	I-Activity
pork	I-Activity
while	O
traveling	B-Activity
in	O
the	O
Philippines	B-Nonbiological_location
.	O

In	O
June	O
2003	O
,	O
this	O
man	O
became	O
ill	B-Sign_symptom
with	O
fever	B-Sign_symptom
,	O
diaphoresis	B-Sign_symptom
,	O
headache	B-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
and	O
anorexia	B-Sign_symptom
.	O

He	O
had	O
just	O
returned	B-Activity
from	O
a	O
7	B-Duration
-	I-Duration
month	I-Duration
vacation	B-Activity
in	O
the	O
Philippines	B-Nonbiological_location
.	O

Three	O
days	O
after	O
symptoms	O
onset	O
,	O
his	O
physician	O
prescribed	O
doxycycline	B-Medication
.	O

Symptoms	B-Sign_symptom
continued	I-Sign_symptom
and	O
he	O
was	O
admitted	O
to	O
a	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
5	O
days	O
later	O
with	O
a	O
fever	B-Sign_symptom
of	O
38	B-Lab_value
.	I-Lab_value
9	I-Lab_value
°C	I-Lab_value
,	O
nuchal	B-Sign_symptom
rigidity	I-Sign_symptom
,	O
headache	B-Sign_symptom
,	O
and	O
general	O
malaise	B-Sign_symptom
.	O

The	O
patient	O
described	O
no	O
recent	O
contact	O
with	O
sick	O
persons	O
;	O
past	O
medical	O
history	O
was	O
unremarkable	O
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
he	O
was	O
somnolent	B-Sign_symptom
but	O
fully	B-Sign_symptom
oriented	I-Sign_symptom
,	O
with	O
no	O
focal	B-Sign_symptom
findings	I-Sign_symptom
on	O
neurologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
and	O
only	O
slight	B-Severity
nuchal	B-Sign_symptom
rigidity	I-Sign_symptom
.	O

He	O
had	O
a	O
leukocyte	B-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
21,000	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
,	O
including	O
16,400	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
neutrophils	B-Diagnostic_procedure
.	O

Cerebrospinal	B-Biological_structure
fluid	I-Biological_structure
(	O
CSF	B-Biological_structure
)	O
showed	O
leukocyte	B-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
487	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
with	O
80	B-Lab_value
%	I-Lab_value
polymorphonuclear	I-Lab_value
cells	I-Lab_value
and	O
18	B-Lab_value
%	I-Lab_value
lymphocytes	I-Lab_value
,	O
and	O
glucose	B-Diagnostic_procedure
and	O
protein	B-Diagnostic_procedure
levels	O
<	B-Lab_value
20	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
and	O
<	B-Lab_value
167	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
respectively	O
.	O

Gram	B-Diagnostic_procedure
stain	I-Diagnostic_procedure
of	O
CSF	B-Biological_structure
showed	O
gram	B-Sign_symptom
-	I-Sign_symptom
positive	I-Sign_symptom
cocci	I-Sign_symptom
in	I-Sign_symptom
pairs	I-Sign_symptom
(	O
Figure	O
)	O
.	O

Empiric	O
therapy	O
(	O
ceftriaxone	B-Medication
,	O
vancomycin	B-Medication
,	O
and	O
ampicillin	B-Medication
)	O
for	O
bacterial	B-Disease_disorder
meningitis	I-Disease_disorder
was	O
begun	O
.	O

Computed	B-Diagnostic_procedure
tomographic	I-Diagnostic_procedure
scan	I-Diagnostic_procedure
of	O
the	O
head	B-Biological_structure
showed	O
only	O
sinusitis	B-Sign_symptom
;	O
findings	O
of	O
chest	B-Biological_structure
radiograph	B-Diagnostic_procedure
and	O
transesophageal	B-Diagnostic_procedure
echocardiogram	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

On	O
hospital	O
day	O
2	O
,	O
blood	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
grew	O
gram	B-Sign_symptom
-	I-Sign_symptom
positive	I-Sign_symptom
cocci	I-Sign_symptom
in	O
pairs	B-Detailed_description
and	O
chains	B-Detailed_description
.	O

The	O
organism	B-Sign_symptom
was	O
catalase	B-Diagnostic_procedure
-	O
negative	B-Lab_value
,	O
bile	B-Diagnostic_procedure
esculin	I-Diagnostic_procedure
-	O
negative	B-Lab_value
,	O
and	O
pyrrolidonyl	B-Diagnostic_procedure
aminopeptidase	I-Diagnostic_procedure
-	O
negative	B-Lab_value
,	O
consistent	O
with	O
Streptococcus	B-Sign_symptom
spp	I-Sign_symptom
.	O

A	O
latex	B-Diagnostic_procedure
agglutination	I-Diagnostic_procedure
test	I-Diagnostic_procedure
did	O
not	O
detect	O
Streptococcus	B-Sign_symptom
pneumoniae	I-Sign_symptom
antigen	I-Sign_symptom
.	O

Antimicrobial	B-Diagnostic_procedure
susceptibility	I-Diagnostic_procedure
testing	I-Diagnostic_procedure
showed	O
that	O
the	O
isolate	O
was	O
sensitive	B-Sign_symptom
to	I-Sign_symptom
penicillin	I-Sign_symptom
(	I-Sign_symptom
MIC	I-Sign_symptom
=	I-Sign_symptom
0	I-Sign_symptom
.	I-Sign_symptom
03	I-Sign_symptom
)	I-Sign_symptom
,	I-Sign_symptom
ceftriaxone	I-Sign_symptom
,	I-Sign_symptom
and	I-Sign_symptom
vancomycin	I-Sign_symptom
but	O
resistant	B-Sign_symptom
to	I-Sign_symptom
tetracycline	I-Sign_symptom
and	I-Sign_symptom
clindamycin	I-Sign_symptom
.	O

Antimicrobial	B-Medication
therapy	I-Medication
was	O
changed	O
to	O
penicillin	B-Medication
G	I-Medication
,	O
24	B-Dosage
million	I-Dosage
units	I-Dosage
intravenously	O
per	B-Frequency
day	I-Frequency
.	O

On	O
hospital	O
day	O
5	O
,	O
the	O
patient	O
complained	O
of	O
hearing	B-Sign_symptom
loss	I-Sign_symptom
in	O
his	O
left	B-Biological_structure
ear	I-Biological_structure
.	O

Results	O
of	O
nasopharyngeal	B-Diagnostic_procedure
endoscopy	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

By	O
hospital	O
day	O
7	O
,	O
the	O
organism	O
was	O
identified	O
by	O
the	O
API	B-Diagnostic_procedure
20	I-Diagnostic_procedure
Strep	I-Diagnostic_procedure
System	I-Diagnostic_procedure
(	O
bioMerieux	O
,	O
Marcy	O
l`Etoile	O
,	O
France	O
)	O
,	O
as	O
S	B-Sign_symptom
.	I-Sign_symptom
suis	I-Sign_symptom
serotype	I-Sign_symptom
2	I-Sign_symptom
.	O

The	O
patient	O
subsequently	O
stated	O
that	O
he	O
was	O
a	O
butcher	B-Occupation
with	O
a	O
culinary	B-Detailed_description
preference	I-Detailed_description
for	I-Detailed_description
partially	B-Other_entity
cooked	I-Other_entity
pork	I-Other_entity
,	I-Detailed_description
which	O
he	O
had	O
eaten	B-Activity
in	O
the	O
Philippines	B-Nonbiological_location
until	O
the	O
week	O
prior	O
to	O
onset	O
of	O
symptoms	O
.	O

On	O
hospital	O
day	O
9	O
,	O
a	O
formal	B-Diagnostic_procedure
audiology	I-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
showed	O
severe	B-Severity
bilateral	B-Sign_symptom
sensorineural	I-Sign_symptom
high	I-Sign_symptom
-	I-Sign_symptom
frequency	I-Sign_symptom
hearing	I-Sign_symptom
loss	I-Sign_symptom
(	O
-	B-Lab_value
70	I-Lab_value
dB	I-Lab_value
)	O
.	O

The	O
patient	O
completed	O
a	O
10	B-Duration
-	I-Duration
day	I-Duration
course	I-Duration
of	O
parenteral	B-Medication
antimicrobial	I-Medication
drugs	I-Medication
and	O
was	O
discharged	O
on	O
continued	B-Detailed_description
oral	B-Medication
therapy	I-Medication
with	O
close	O
followup	O
.	O

Two	O
months	O
after	O
discharge	O
,	O
the	O
patient	O
reported	O
much	B-Sign_symptom
improved	I-Sign_symptom
hearing	I-Sign_symptom
without	O
other	O
sequelae	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
76	B-Age
-	I-Age
year	I-Age
old	I-Age
woman	O
presented	O
with	O
a	O
24	B-Duration
-	I-Duration
month	I-Duration
history	I-Duration
of	O
enlarging	B-Lab_value
mass	B-Sign_symptom
involving	O
the	O
back	B-Biological_structure
history	O
of	O
trauma	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
a	O
mass	B-Sign_symptom
of	O
an	O
3x4	B-Area
cm	I-Area
in	O
diameter	O
,	O
localized	O
in	O
the	O
right	B-Biological_structure
inter	I-Biological_structure
-	I-Biological_structure
scapular	I-Biological_structure
region	I-Biological_structure
.	O

The	O
mass	O
was	O
ulcerative	B-Detailed_description
helophytic	B-Detailed_description
,	O
grayish	B-Color
in	O
colour	O
,	O
hard	B-Texture
in	O
consistency	O
and	O
easily	O
bleeding	B-Detailed_description
on	I-Detailed_description
manipulation	I-Detailed_description
.	O

The	O
remainder	O
of	O
the	O
examination	O
was	O
unremarkable	O
;	O
no	O
lymphadenopathy	B-Sign_symptom
and	O
no	O
abdominal	B-Biological_structure
masses	B-Sign_symptom
were	O
felt	O
.	O

After	O
resection	B-Therapeutic_procedure
,	O
the	O
histological	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
of	O
the	O
specimens	O
have	O
concluded	O
for	O
basal	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
.	O

A	O
local	B-Detailed_description
recurrence	B-Sign_symptom
was	O
observed	O
18	O
months	O
later	O
;	O
the	O
patient	O
was	O
admitted	O
to	O
our	O
institution	B-Nonbiological_location
for	O
Lumpectomy	B-Therapeutic_procedure
(	O
Figure	O
1	O
)	O
.	O

Histopathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
syringomatous	B-Sign_symptom
pattern	I-Sign_symptom
infiltrating	O
the	O
dermis	B-Biological_structure
(	O
Figure	O
2	O
,	O
Figure	O
3	O
)	O
,	O
subcutis	B-Biological_structure
and	O
skeletal	B-Biological_structure
muscle	I-Biological_structure
.	O

The	O
neoplastic	O
epithelial	O
cells	O
were	O
arranged	B-Detailed_description
in	I-Detailed_description
interconnecting	I-Detailed_description
cords	I-Detailed_description
with	O
microcystic	B-Detailed_description
areas	I-Detailed_description
.	O

Nests	O
,	O
cords	O
,	O
and	O
tubules	O
of	O
the	O
tumour	B-Sign_symptom
extended	O
into	O
the	O
dermis	B-Biological_structure
and	O
into	O
the	O
adjacent	B-Biological_structure
muscle	I-Biological_structure
.	O

Many	O
lobules	B-Sign_symptom
showed	O
squamous	B-Detailed_description
differentiation	I-Detailed_description
.	O

Sclerosis	B-Sign_symptom
of	O
stroma	B-Biological_structure
around	I-Biological_structure
the	I-Biological_structure
cords	I-Biological_structure
was	O
present	O
.	O

Tumour	B-Sign_symptom
cells	I-Sign_symptom
were	O
not	O
connected	O
to	O
the	O
epidermis	B-Biological_structure
.	O

The	O
immunohistochemical	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
positivity	B-Lab_value
for	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
CK7	I-Diagnostic_procedure
(	O
Figure	O
4	O
)	O
,	O
AE1	B-Diagnostic_procedure
/	I-Diagnostic_procedure
AE3	I-Diagnostic_procedure
and	O
negativity	B-Lab_value
for	O
anti	B-Diagnostic_procedure
CEA	I-Diagnostic_procedure
and	O
anti	B-Diagnostic_procedure
CK20	I-Diagnostic_procedure
.	O

Based	O
upon	O
her	O
histological	O
and	O
immunohistochemical	O
presentation	O
,	O
the	O
diagnosis	O
of	O
syringomatous	B-Disease_disorder
eccrine	I-Disease_disorder
carcinoma	I-Disease_disorder
was	O
established	O
.	O

Radiotherapy	B-Therapeutic_procedure
of	O
the	O
involved	O
area	O
was	O
performed	O
(	O
70	B-Dosage
Gy	I-Dosage
,	I-Dosage
35	I-Dosage
sessions	I-Dosage
)	O

-DOCSTART- -X- -X- -X- O

This	O
case	O
report	O
was	O
approved	O
by	O
the	O
Review	O
Board	O
of	O
Shandong	O
Power	O
Central	O
Hospital	O
and	O
the	O
patient	O
`	O
s	O
parents	O
signed	O
informed	O
consent	O
for	O
publication	O
of	O
the	O
case	O
report	O
and	O
any	O
accompanying	O
images	O
.	O

A	O
4	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
child	O
presented	O
at	O
the	O
outpatients	B-Nonbiological_location
department	I-Nonbiological_location
with	O
slowly	B-Detailed_description
enlarging	I-Detailed_description
,	O
painless	B-Detailed_description
,	O
symmetrical	B-Detailed_description
swelling	B-Sign_symptom
of	O
both	B-Biological_structure
cheeks	I-Biological_structure
.	O

When	O
the	O
girl	O
was	O
approximately	O
2	O
years	O
old	O
,	O
the	O
parents	O
noticed	O
a	O
change	B-Sign_symptom
in	I-Sign_symptom
her	I-Sign_symptom
facial	I-Sign_symptom
symmetry	I-Sign_symptom
,	O
which	O
later	O
became	O
more	O
obvious	O
.	O

On	O
palpation	B-Diagnostic_procedure
,	O
the	O
swellings	B-Sign_symptom
were	O
bony	B-Detailed_description
and	O
hard	B-Detailed_description
in	O
consistency	O
.	O

The	O
skin	B-Biological_structure
over	O
the	O
swelling	B-Sign_symptom
was	O
smooth	B-Texture
and	O
freely	B-Detailed_description
movable	I-Detailed_description
,	O
with	O
no	B-Lab_value
increase	I-Lab_value
in	O
temperature	B-Diagnostic_procedure
(	O
Fig	O
.	O
1	O
)	O
.	O

There	O
was	O
no	O
history	O
of	O
any	O
trauma	O
,	O
pain	O
,	O
pus	O
discharge	O
,	O
blood	O
discharge	O
,	O
fever	O
,	O
paresthesia	O
,	O
anorexia	O
,	O
or	O
weight	O
loss	O
.	O

No	O
significant	O
family	O
history	O
was	O
reported	O
.	O

Panoramic	B-Detailed_description
radiography	B-Diagnostic_procedure
revealed	O
involvement	B-Sign_symptom
of	O
both	O
the	O
mandible	B-Biological_structure
and	O
the	O
maxilla	B-Biological_structure
,	O
and	O
showed	O
a	O
soap	B-Shape
bubble	I-Shape
-	I-Shape
like	I-Shape
multilocular	B-Detailed_description
radiolucency	B-Sign_symptom
with	O
thin	B-Detailed_description
and	I-Detailed_description
expanded	I-Detailed_description
cortices	I-Detailed_description
.	O

Unerupted	B-Sign_symptom
teeth	I-Sign_symptom
included	O
:	O
15	B-Biological_structure
,	I-Biological_structure
25	I-Biological_structure
,	I-Biological_structure
35	I-Biological_structure
,	I-Biological_structure
37	I-Biological_structure
,	I-Biological_structure
45	I-Biological_structure
,	O
and	O
47	B-Biological_structure
was	O
impacted	B-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

Multislice	B-Detailed_description
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
showed	O
the	O
presence	O
of	O
multilocular	B-Detailed_description
cystic	B-Detailed_description
lesions	B-Sign_symptom
filled	O
with	O
soft	B-Detailed_description
-	I-Detailed_description
tissue	I-Detailed_description
density	I-Detailed_description
material	I-Detailed_description
and	O
dental	B-Biological_structure
anomalies	B-Sign_symptom
affecting	O
the	O
body	B-Biological_structure
and	I-Biological_structure
the	I-Biological_structure
sides	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
mandible	I-Biological_structure
.	O

Similar	O
lesions	B-Sign_symptom
were	O
also	O
observed	O
in	O
the	O
maxilla	B-Biological_structure
(	O
Fig	O
.	O
3	O
)	O
.	O

A	O
biopsy	B-Diagnostic_procedure
was	O
obtained	O
from	O
the	O
central	B-Biological_structure
area	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
rami	I-Biological_structure
.	O

Histologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
many	B-Detailed_description
large	B-Detailed_description
multinucleated	B-Detailed_description
giant	B-Sign_symptom
cells	I-Sign_symptom
in	O
a	O
loose	B-Detailed_description
,	O
delicate	B-Detailed_description
fibrillar	B-Detailed_description
connective	B-Biological_structure
tissue	I-Biological_structure
stroma	I-Biological_structure
containing	O
large	B-Biological_structure
numbers	I-Biological_structure
of	I-Biological_structure
fibroblasts	I-Biological_structure
and	O
many	B-Biological_structure
small	I-Biological_structure
blood	I-Biological_structure
vessels	I-Biological_structure
(	O
Fig	O
.	O
4	O
)	O
.	O

As	O
the	O
child	O
grows	O
older	O
,	O
the	O
lesions	O
often	O
become	O
static	O
and	O
may	O
show	O
regression	O
at	O
puberty	O
.	O

In	O
the	O
current	O
case	O
,	O
no	O
surgical	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
was	O
under	O
taken	O
and	O
the	O
patient	O
was	O
followed	O
up	O
at	O
regular	B-Detailed_description
intervals	I-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

A	O
28	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
referred	O
with	O
a	O
4	B-Duration
-	I-Duration
week	I-Duration
history	O
of	O
continuous	B-Detailed_description
,	O
moderate	B-Severity
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
pain	B-Sign_symptom
associated	O
with	O
jaundice	B-Sign_symptom
,	O
as	O
well	O
as	O
weight	B-Sign_symptom
loss	I-Sign_symptom
(	O
10	B-Lab_value
kg	I-Lab_value
over	O
3	B-Duration
months	I-Duration
)	O
and	O
a	O
liver	B-Biological_structure
mass	B-Sign_symptom
identified	O
by	O
ultrasonography	B-Diagnostic_procedure
.	O

The	O
pain	O
sensation	O
seemed	O
different	B-Lab_value
from	O
previous	O
colicky	B-Sign_symptom
attacks	I-Sign_symptom
the	O
patient	O
had	O
experienced	O
before	O
she	O
underwent	O
laparoscopic	B-Detailed_description
cholecystectomy	B-Therapeutic_procedure
7	O
years	O
previously	O
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
she	O
was	O
obese	B-Sign_symptom
(	O
body	B-Diagnostic_procedure
mass	I-Diagnostic_procedure
index	I-Diagnostic_procedure
37	B-Lab_value
.	I-Lab_value
8	I-Lab_value
)	O
,	O
with	O
icterus	B-Sign_symptom
noted	O
over	O
the	O
conjunctivae	B-Biological_structure
,	O
oral	B-Biological_structure
mucosa	I-Biological_structure
and	O
skin	B-Biological_structure
.	O

Imaging	O
modalities	O
included	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
,	O
positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
PET	B-Diagnostic_procedure
)	O
and	O
endoscopic	B-Diagnostic_procedure
cholangiopancreatography	I-Diagnostic_procedure
(	O
ERCP	B-Diagnostic_procedure
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
patient	O
underwent	O
exploratory	B-Detailed_description
laparotomy	B-Diagnostic_procedure
.	O

Intraoperative	B-Detailed_description
ultrasonography	B-Diagnostic_procedure
revealed	O
a	O
cystic	B-Detailed_description
lesion	B-Sign_symptom
measuring	O
3	B-Area
.	I-Area
5	I-Area
2	I-Area
.	I-Area
5	I-Area
cm	I-Area
within	O
the	O
central	B-Biological_structure
portion	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
liver	I-Biological_structure
,	O
anterior	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
porta	I-Biological_structure
hepatis	I-Biological_structure
.	O

Intraoperative	B-Detailed_description
cholangiography	B-Diagnostic_procedure
demonstrated	O
an	O
extensive	B-Severity
stricture	B-Sign_symptom
obliterating	O
the	O
left	B-Biological_structure
hepatic	I-Biological_structure
duct	I-Biological_structure
,	O
with	O
partial	B-Severity
occlusion	B-Sign_symptom
of	O
the	O
right	B-Biological_structure
hepatic	I-Biological_structure
duct	I-Biological_structure
.	O

An	O
extended	B-Detailed_description
left	B-Detailed_description
lobectomy	B-Therapeutic_procedure
was	O
done	O
en	B-Detailed_description
bloc	I-Detailed_description
with	I-Detailed_description
the	I-Detailed_description
biliary	I-Detailed_description
confluence	I-Detailed_description
.	O

On	O
frozen	B-Diagnostic_procedure
-	I-Diagnostic_procedure
section	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
all	O
margins	B-Diagnostic_procedure
of	I-Diagnostic_procedure
the	I-Diagnostic_procedure
excised	I-Diagnostic_procedure
specimen	I-Diagnostic_procedure
were	O
free	B-Lab_value
of	I-Lab_value
malignant	I-Lab_value
cells	I-Lab_value
.	O

Reconstruction	B-Therapeutic_procedure
was	O
performed	O
with	O
a	O
Roux	B-Detailed_description
-	I-Detailed_description
en	I-Detailed_description
-	I-Detailed_description
Y	I-Detailed_description
cholangiojejunostomy	B-Therapeutic_procedure
to	O
3	B-Biological_structure
second	I-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
radicals	I-Biological_structure
in	O
the	O
right	B-Detailed_description
side	I-Detailed_description
.	O

Intraoperatively	O
,	O
radiotherapy	B-Therapeutic_procedure
was	O
applied	O
to	O
the	O
surgical	B-Biological_structure
margins	I-Biological_structure
.	O

After	O
this	O
,	O
the	O
patient	O
underwent	O
6	B-Duration
weeks	I-Duration
of	O
image	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
external	B-Detailed_description
beam	I-Detailed_description
radiation	B-Therapeutic_procedure
centred	O
on	O
the	O
resection	B-Biological_structure
field	I-Biological_structure
labelled	O
at	O
surgery	O
.	O

The	O
final	O
pathology	O
described	O
this	O
tumour	O
as	O
an	O
infiltrating	B-Detailed_description
,	O
moderately	B-Lab_value
differentiated	B-Detailed_description
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
associated	O
with	O
severe	B-Severity
dysplasia	B-Disease_disorder
of	O
the	O
bile	B-Biological_structure
-	I-Biological_structure
duct	I-Biological_structure
epithelium	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
patient	O
recovered	B-Sign_symptom
without	O
complications	B-Sign_symptom
and	O
was	O
doing	B-Sign_symptom
well	I-Sign_symptom
18	O
months	O
after	O
the	O
initial	O
surgical	O
procedure	O
,	O
with	O
an	O
unremarkable	B-Lab_value
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

A	O
28	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
African	O
American	O
woman	O
presented	O
to	O
the	O
R	B-Nonbiological_location
Adams	I-Nonbiological_location
Cowley	I-Nonbiological_location
Shock	I-Nonbiological_location
Trauma	I-Nonbiological_location
Center	I-Nonbiological_location
in	O
Baltimore	B-Nonbiological_location
,	I-Nonbiological_location
Maryland	I-Nonbiological_location
,	O
for	O
evaluation	B-Diagnostic_procedure
of	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
paralysis	B-Disease_disorder
and	O
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
paresthesias	B-Sign_symptom
after	O
being	O
found	O
down	B-Detailed_description
in	O
her	O
home	B-Nonbiological_location
between	B-Detailed_description
her	I-Detailed_description
nightstand	I-Detailed_description
and	I-Detailed_description
her	I-Detailed_description
bed	I-Detailed_description
.	O

The	O
symptoms	O
began	O
after	O
eating	B-Activity
at	O
a	O
local	B-Nonbiological_location
restaurant	I-Nonbiological_location
chain	I-Nonbiological_location
,	O
consuming	B-Activity
alcohol	I-Activity
,	O
and	O
smoking	B-Activity
one	O
cigarette	B-Detailed_description
dipped	O
in	O
liquid	B-Detailed_description
phencyclidine	B-Detailed_description
(	O
PCP	B-Detailed_description
)	O
.	O

She	O
was	O
asymptomatic	B-Sign_symptom
that	B-Time
night	I-Time
and	O
went	B-Activity
to	I-Activity
bed	I-Activity
without	O
complications	B-Sign_symptom
.	O

She	O
was	O
found	O
down	B-Detailed_description
next	B-Nonbiological_location
to	I-Nonbiological_location
the	I-Nonbiological_location
bed	I-Nonbiological_location
the	B-Time
following	I-Time
morning	I-Time
unable	B-Sign_symptom
to	I-Sign_symptom
move	I-Sign_symptom
.	O

The	O
patient	O
denied	O
any	O
physical	B-Disease_disorder
trauma	I-Disease_disorder
other	O
than	O
falling	B-Sign_symptom
from	O
the	O
bed	O
.	O

She	O
had	O
no	O
history	O
of	O
seizures	O
,	O
sickle	O
cell	O
anemia	O
,	O
fever	O
,	O
urinary	O
or	O
bowel	O
incontinence	O
,	O
or	O
pain	O
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
viral	B-Disease_disorder
meningitis	I-Disease_disorder
without	B-Detailed_description
residual	I-Detailed_description
deficits	I-Detailed_description
eight	O
years	O
prior	O
,	O
gastric	O
bypass	O
surgery	O
,	O
and	O
cholecystectomy	O
,	O
and	O
she	O
was	O
treated	B-Therapeutic_procedure
for	O
a	O
presumed	O
urinary	B-Disease_disorder
tract	I-Disease_disorder
infection	I-Disease_disorder
five	O
days	O
prior	O
to	O
admission	O
at	O
an	O
outside	B-Nonbiological_location
institution	I-Nonbiological_location
.	O

Her	O
triage	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
temperature	B-Diagnostic_procedure
36	B-Lab_value
.	I-Lab_value
8	I-Lab_value
°C	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
155	B-Lab_value
/	I-Lab_value
100	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
90	B-Lab_value
beats	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
16	B-Lab_value
breaths	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
,	O
and	O
an	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
of	O
95	B-Lab_value
%	I-Lab_value
on	O
room	B-Detailed_description
air	I-Detailed_description
.	O

On	O
physical	B-Diagnostic_procedure
exam	I-Diagnostic_procedure
,	O
the	O
patient	O
was	O
alert	B-Sign_symptom
and	O
oriented	B-Sign_symptom
to	O
person	B-Detailed_description
,	O
place	B-Detailed_description
,	O
and	O
time	B-Detailed_description
.	O

Her	O
cranial	B-Diagnostic_procedure
nerves	I-Diagnostic_procedure
II	I-Diagnostic_procedure
-	I-Diagnostic_procedure
XII	I-Diagnostic_procedure
were	O
grossly	B-Lab_value
intact	I-Lab_value
.	O

She	O
had	O
2	B-Lab_value
/	I-Lab_value
5	I-Lab_value
strength	B-Diagnostic_procedure
in	O
her	O
right	B-Biological_structure
lower	I-Biological_structure
extremity	I-Biological_structure
,	O
3	B-Lab_value
/	I-Lab_value
5	I-Lab_value
in	O
her	O
left	B-Biological_structure
lower	I-Biological_structure
extremity	I-Biological_structure
,	O
and	O
4	B-Lab_value
/	I-Lab_value
5	I-Lab_value
bilaterally	B-Biological_structure
in	I-Biological_structure
her	I-Biological_structure
upper	I-Biological_structure
extremities	I-Biological_structure
.	O

Her	O
sensation	B-Diagnostic_procedure
was	O
intact	B-Lab_value
.	O

She	O
opened	B-Lab_value
her	O
eyes	B-Diagnostic_procedure
spontaneously	B-Detailed_description
,	O
her	O
verbal	B-Diagnostic_procedure
response	I-Diagnostic_procedure
was	O
oriented	B-Lab_value
and	O
appropriate	B-Lab_value
,	O
and	O
she	O
obeyed	B-Lab_value
commands	B-Diagnostic_procedure
,	O
resulting	O
in	O
a	O
Glasgow	B-Diagnostic_procedure
Coma	I-Diagnostic_procedure
Scale	I-Diagnostic_procedure
score	O
of	O
15	B-Lab_value
.	O

Pupils	B-Diagnostic_procedure
were	O
equal	B-Detailed_description
,	O
round	B-Shape
,	O
and	O
reactive	B-Lab_value
to	I-Lab_value
light	I-Lab_value
.	O

She	O
had	O
tenderness	B-Sign_symptom
to	O
palpation	B-Detailed_description
over	O
the	O
cervical	B-Biological_structure
,	O
thoracic	B-Biological_structure
,	O
and	O
lumbar	B-Biological_structure
spine	B-Biological_structure
without	O
obvious	O
external	O
signs	B-Sign_symptom
of	I-Sign_symptom
trauma	I-Sign_symptom
.	O

Her	O
anal	B-Diagnostic_procedure
sphincter	I-Diagnostic_procedure
tone	I-Diagnostic_procedure
was	O
intact	B-Lab_value
.	O

Multiple	O
laboratory	B-Diagnostic_procedure
abnormalities	B-Lab_value
were	O
noted	O
on	O
admission	O
,	O
including	O
hyperlactemia	B-Sign_symptom
,	O
elevated	B-Lab_value
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	O
,	O
and	O
electrolyte	B-Sign_symptom
derangements	I-Sign_symptom
.	O

Her	O
complete	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
and	O
remainder	O
of	O
her	O
complete	B-Diagnostic_procedure
metabolic	I-Diagnostic_procedure
panel	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

These	B-Other_entity
values	I-Other_entity
are	I-Other_entity
summarized	I-Other_entity
along	I-Other_entity
with	I-Other_entity
reference	I-Other_entity
ranges	I-Other_entity
in	I-Other_entity
Table	I-Other_entity
1	I-Other_entity
.	O

Her	O
toxicology	B-Diagnostic_procedure
screen	I-Diagnostic_procedure
was	O
positive	B-Lab_value
for	O
PCP	B-Diagnostic_procedure
.	O

Blood	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
drawn	O
on	O
admission	O
grew	O
the	O
aerobic	B-Detailed_description
bacteria	I-Detailed_description
Salmonella	B-Disease_disorder
enterica	I-Disease_disorder
serotype	B-Detailed_description
4,12	I-Detailed_description
:	I-Detailed_description
i	I-Detailed_description
,	O
and	O
then	O
repeat	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
drawn	O
two	O
days	O
later	O
grew	O
group	B-Detailed_description
B	I-Detailed_description
streptococcus	B-Disease_disorder
(	O
aerobic	B-Detailed_description
and	O
non	B-Detailed_description
-	I-Detailed_description
aerobic	I-Detailed_description
)	O
.	O

Subsequent	O
blood	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
were	O
negative	B-Lab_value
,	O
as	O
were	O
stool	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
.	O

Metronidazole	B-Medication
and	O
vancomycin	B-Medication
therapy	O
was	O
initiated	O
empirically	O
,	O
with	O
transition	O
to	O
ceftriaxone	B-Medication
upon	O
learning	O
of	O
the	O
culture	O
results	O
.	O

In	O
addition	O
,	O
she	O
had	O
a	O
detailed	O
autoimmunity	B-Diagnostic_procedure
workup	I-Diagnostic_procedure
including	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
nuclear	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
(	O
ANA	B-Diagnostic_procedure
)	O
and	O
HLA	B-Diagnostic_procedure
-	I-Diagnostic_procedure
B27	I-Diagnostic_procedure
,	O
all	O
of	O
which	O
returned	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

Admission	O
computerized	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
scan	O
of	O
her	O
cervical	B-Biological_structure
,	O
thoracic	B-Biological_structure
,	O
and	O
lumbar	B-Biological_structure
spine	B-Biological_structure
revealed	O
no	O
spinal	B-Biological_structure
fractures	B-Disease_disorder
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
revealed	O
no	O
acute	O
intracranial	B-Biological_structure
abnormalities	B-Sign_symptom
,	O
but	O
enhancement	B-Diagnostic_procedure
within	I-Diagnostic_procedure
the	I-Diagnostic_procedure
central	I-Diagnostic_procedure
aspect	I-Diagnostic_procedure
of	I-Diagnostic_procedure
C3	I-Diagnostic_procedure
-	I-Diagnostic_procedure
T2	I-Diagnostic_procedure
suggested	O
spinal	B-Biological_structure
cord	I-Biological_structure
edema	B-Sign_symptom
,	O
disc	B-Sign_symptom
protrusions	I-Sign_symptom
at	O
C3	B-Biological_structure
-	I-Biological_structure
4	I-Biological_structure
,	O
C4	B-Biological_structure
-	I-Biological_structure
5	I-Biological_structure
,	O
and	O
C5	B-Biological_structure
-	I-Biological_structure
6	I-Biological_structure
,	O
and	O
bilateral	B-Biological_structure
posterior	I-Biological_structure
neck	I-Biological_structure
muscle	I-Biological_structure
edema	B-Sign_symptom
.	O

A	O
lumbar	B-Therapeutic_procedure
puncture	I-Therapeutic_procedure
was	O
not	O
initially	O
performed	O
upon	O
patient	O
admission	O
due	O
to	O
concerns	O
about	O
raised	O
intracranial	O
pressure	O
from	O
suspected	O
trauma	O
.	O

Four	B-Time
hours	I-Time
after	I-Time
presentation	O
,	O
her	O
strength	B-Diagnostic_procedure
had	O
progressively	O
deteriorated	B-Lab_value
to	O
1	B-Lab_value
/	I-Lab_value
5	I-Lab_value
in	O
all	B-Biological_structure
extremities	I-Biological_structure
.	O

She	O
lost	B-Lab_value
proprioception	B-Diagnostic_procedure
in	O
her	O
toes	B-Biological_structure
bilaterally	B-Detailed_description
and	O
developed	O
absent	B-Lab_value
anal	B-Diagnostic_procedure
sphincter	I-Diagnostic_procedure
tone	I-Diagnostic_procedure
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
neurotrauma	B-Nonbiological_location
intensive	I-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
with	O
further	O
deterioration	O
ultimately	O
requiring	O
endotracheal	B-Detailed_description
intubation	B-Therapeutic_procedure
due	O
to	O
respiratory	B-Disease_disorder
failure	I-Disease_disorder
.	O

Upon	O
her	O
positive	O
blood	O
culture	O
results	O
,	O
lumbar	B-Therapeutic_procedure
puncture	I-Therapeutic_procedure
was	O
performed	O
,	O
which	O
demonstrated	O
a	O
pattern	O
consistent	O
with	O
ATM	B-Disease_disorder
,	O
the	O
results	O
of	O
which	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

An	O
extensive	O
workup	B-Diagnostic_procedure
for	I-Diagnostic_procedure
infectious	I-Diagnostic_procedure
etiologies	I-Diagnostic_procedure
was	O
also	O
completed	O
,	O
with	O
the	O
results	O
summarized	O
in	O
Table	O
3	O
.	O

Plasma	B-Therapeutic_procedure
exchange	I-Therapeutic_procedure
therapy	I-Therapeutic_procedure
was	O
initiated	O
with	O
a	O
suspected	O
diagnosis	O
of	O
ATM	B-Disease_disorder
.	O

Despite	O
maximal	B-Detailed_description
medical	O
therapy	B-Therapeutic_procedure
,	O
the	O
patient	O
remains	O
quadriplegic	B-Disease_disorder
,	O
is	O
experiencing	O
neurologic	B-Biological_structure
pain	B-Sign_symptom
,	O
received	O
a	O
tracheostomy	B-Therapeutic_procedure
due	O
to	O
prolonged	B-Detailed_description
respiratory	B-Disease_disorder
failure	I-Disease_disorder
,	O
and	O
required	O
a	O
feeding	O
jejunostomy	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
placement	O
at	O
the	O
time	O
of	O
this	O
report	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
46	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
a	O
history	O
of	O
Graves	O
`	O
disease	O
(	O
GD	O
)	O
was	O
transferred	O
to	O
our	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
on	O
suspicion	O
of	O
DKA	B-Disease_disorder
.	O

She	O
had	O
noticed	O
polydipsia	B-Sign_symptom
,	O
polyuria	B-Sign_symptom
,	O
and	O
fatigue	B-Sign_symptom
approximately	O
four	B-Duration
months	I-Duration
prior	I-Duration
to	I-Duration
admission	I-Duration
.	O

She	O
had	O
also	O
been	O
suffering	O
from	O
a	O
1	B-Duration
-	I-Duration
month	I-Duration
complaint	O
of	O
appetite	B-Sign_symptom
loss	I-Sign_symptom
,	O
approximately	O
7	B-Lab_value
kg	I-Lab_value
weight	B-Sign_symptom
loss	I-Sign_symptom
,	O
fatigue	B-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
and	O
sweating	B-Sign_symptom
.	O

Her	O
medical	O
history	O
included	O
GD	B-Disease_disorder
,	O
diagnosed	O
at	O
42	O
years	O
of	O
age	O
and	O
managed	O
with	O
methimazole	B-Medication
.	O

However	O
,	O
she	O
had	O
poor	B-Lab_value
compliance	I-Lab_value
with	O
anti	B-Medication
-	I-Medication
thyroid	I-Medication
drugs	I-Medication
.	O

She	O
denied	O
a	O
family	O
history	O
of	O
thyroid	O
diseases	O
or	O
diabetes	O
.	O

Three	O
days	O
before	O
admission	O
,	O
she	O
was	O
also	O
diagnosed	O
with	O
influenza	B-Disease_disorder
A	I-Disease_disorder
at	O
a	O
nearby	B-Nonbiological_location
hospital	I-Nonbiological_location
,	O
and	O
oseltamivir	B-Medication
phosphate	I-Medication
was	O
prescribed	O
.	O

At	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
,	O
she	O
presented	O
with	O
drowsiness	B-Sign_symptom
and	O
a	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
of	O
37	B-Lab_value
.	I-Lab_value
0	I-Lab_value
℃	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
90	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mmHg	I-Lab_value
,	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
200	B-Lab_value
bpm	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
32	B-Lab_value
breaths	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
of	O
99	B-Lab_value
%	I-Lab_value
in	O
5	B-Lab_value
L	I-Lab_value
nasal	I-Lab_value
air	I-Lab_value
,	O
and	O
a	O
Glasgow	B-Diagnostic_procedure
coma	I-Diagnostic_procedure
scale	I-Diagnostic_procedure
(	O
GCS	B-Diagnostic_procedure
)	O
score	O
of	O
14	B-Lab_value
.	O

Her	O
clinical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
diffuse	B-Detailed_description
goiter	B-Sign_symptom
with	O
bilateral	B-Detailed_description
exophthalmoses	I-Detailed_description
.	O

Her	O
lungs	B-Biological_structure
were	O
clear	B-Lab_value
when	O
auscultated	B-Diagnostic_procedure
.	O

Her	O
abdomen	B-Biological_structure
was	O
soft	B-Lab_value
and	O
non	O
-	O
tender	B-Sign_symptom
.	O

Her	O
skin	B-Biological_structure
was	O
warm	B-Lab_value
and	O
wet	B-Lab_value
.	O

She	O
had	O
no	O
lower	B-Biological_structure
extremity	I-Biological_structure
edema	B-Sign_symptom
.	O

The	O
electrocardiogram	B-Diagnostic_procedure
showed	O
marked	B-Detailed_description
tachycardia	B-Sign_symptom
with	O
atrial	B-Disease_disorder
fibrillation	I-Disease_disorder
,	O
and	O
a	O
chest	B-Biological_structure
radiograph	B-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

The	O
laboratory	B-Diagnostic_procedure
data	I-Diagnostic_procedure
are	O
shown	O
in	O
Table	O
1	O
.	O

Her	O
initial	O
laboratory	B-Diagnostic_procedure
data	I-Diagnostic_procedure
demonstrated	O
marked	O
metabolic	B-Sign_symptom
acidosis	I-Sign_symptom
,	O
an	O
increased	B-Lab_value
plasma	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
level	O
of	O
472	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
an	O
increased	B-Lab_value
HbA1c	B-Diagnostic_procedure
level	O
of	O
13	B-Lab_value
.	I-Lab_value
7	I-Lab_value
%	I-Lab_value
,	O
an	O
increased	B-Lab_value
free	B-Diagnostic_procedure
triiodothyronine	I-Diagnostic_procedure
level	O
of	O
6	B-Lab_value
.	I-Lab_value
440	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
and	O
a	O
free	B-Diagnostic_procedure
thyroxine	I-Diagnostic_procedure
level	O
of	O
2	B-Lab_value
.	I-Lab_value
830	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
with	O
a	O
suppressed	B-Diagnostic_procedure
thyrotropin	I-Diagnostic_procedure
(	O
TSH	O
)	O
level	O
of	O
0	B-Lab_value
.	I-Lab_value
005	I-Lab_value
μIU	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

She	O
scored	O
55	B-Lab_value
on	O
the	O
diagnostic	B-Diagnostic_procedure
criteria	I-Diagnostic_procedure
of	I-Diagnostic_procedure
Burch	I-Diagnostic_procedure
&	I-Diagnostic_procedure
Wartofsky	I-Diagnostic_procedure
for	I-Diagnostic_procedure
thyroid	I-Diagnostic_procedure
storm	I-Diagnostic_procedure
,	O
and	O
the	O
diagnostic	B-Diagnostic_procedure
criteria	I-Diagnostic_procedure
of	I-Diagnostic_procedure
the	I-Diagnostic_procedure
Japan	I-Diagnostic_procedure
Thyroid	I-Diagnostic_procedure
Association	I-Diagnostic_procedure
for	I-Diagnostic_procedure
thyroid	I-Diagnostic_procedure
storm	I-Diagnostic_procedure
were	O
also	O
satisfied	B-Lab_value
,	O
since	O
she	O
had	O
thyrotoxicosis	B-Disease_disorder
,	O
symptoms	B-Sign_symptom
involving	I-Sign_symptom
the	I-Sign_symptom
central	I-Sign_symptom
nervous	I-Sign_symptom
system	I-Sign_symptom
,	O
tachycardia	B-Sign_symptom
,	O
and	O
gastrointestinal	B-Sign_symptom
symptoms	I-Sign_symptom
(	O
4	O
)	O
.	O

Accordingly	O
,	O
she	O
was	O
diagnosed	O
with	O
DKA	B-Disease_disorder
and	O
thyroid	B-Disease_disorder
storm	I-Disease_disorder
and	O
admitted	O
to	O
the	O
medical	B-Nonbiological_location
intensive	I-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
for	O
further	O
monitoring	B-Diagnostic_procedure
and	O
treatment	B-Therapeutic_procedure
.	O

The	O
clinical	O
course	O
is	O
shown	O
in	O
Figure	O
.	O

She	O
was	O
treated	O
with	O
an	O
intravenous	O
insulin	B-Medication
drip	O
and	O
aggressive	B-Detailed_description
intravenous	O
fluid	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

The	O
thyroid	B-Disease_disorder
storm	I-Disease_disorder
with	O
GD	B-Disease_disorder
was	O
treated	O
with	O
intravenous	O
hydrocortisone	B-Medication
100	B-Dosage
mg	I-Dosage
every	I-Dosage
8	I-Dosage
hours	I-Dosage
,	O
oral	O
potassium	B-Medication
iodine	I-Medication
50	B-Dosage
mg	I-Dosage
every	I-Dosage
6	I-Dosage
hours	I-Dosage
,	O
and	O
oral	O
methimazole	B-Medication
20	B-Dosage
mg	I-Dosage
every	I-Dosage
6	I-Dosage
hours	I-Dosage
.	O

Since	O
she	O
had	O
a	O
history	O
of	O
asthma	O
,	O
landiolol	B-Medication
hydrochloride	I-Medication
,	O
a	O
short	O
-	O
acting	O
beta	O
-	O
adrenoceptor	O
blocker	O
,	O
was	O
used	O
at	O
4	B-Dosage
-	I-Dosage
12	I-Dosage
μg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
min	I-Dosage
to	O
control	O
her	O
heart	O
rate	O
.	O

By	O
Day	O
3	O
,	O
her	O
tachycardia	B-Sign_symptom
had	O
resolved	O
,	O
and	O
landiolol	B-Medication
hydrochloride	I-Medication
was	O
discontinued	O
.	O

On	O
Day	O
6	O
,	O
the	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
had	O
decreased	O
to	O
2,800	B-Lab_value
cells	I-Lab_value
/	I-Lab_value
mm3	I-Lab_value
[	O
neutrophils	B-Lab_value
,	I-Lab_value
44	I-Lab_value
.	I-Lab_value
2	I-Lab_value
%	I-Lab_value
(	I-Lab_value
1,238	I-Lab_value
cells	I-Lab_value
/	I-Lab_value
mm3	I-Lab_value
)	I-Lab_value
]	O
.	O

Methimazole	B-Medication
was	O
discontinued	O
because	O
methimazole	B-Detailed_description
-	I-Detailed_description
induced	I-Detailed_description
neutropenia	B-Sign_symptom
was	O
suspected	O
.	O

The	O
patient	O
was	O
referred	O
to	O
an	O
endocrine	B-Nonbiological_location
surgeon	I-Nonbiological_location
,	O
and	O
thyroidectomy	B-Therapeutic_procedure
was	O
performed	O
on	O
Day	O
32	O
.	O

She	O
was	O
discharged	O
from	O
the	O
hospital	B-Nonbiological_location
on	O
Day	O
37	O
and	O
maintained	O
on	O
multiple	B-Dosage
daily	I-Dosage
insulin	B-Medication
infusion	O
and	O
levothyroxine	B-Medication
sodium	I-Medication
hydrate	I-Medication
.	O

Further	O
immunological	B-Diagnostic_procedure
investigation	I-Diagnostic_procedure
revealed	O
elevated	B-Lab_value
levels	I-Lab_value
of	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
glutamic	I-Diagnostic_procedure
acid	I-Diagnostic_procedure
decarboxylase	I-Diagnostic_procedure
(	I-Diagnostic_procedure
GAD	I-Diagnostic_procedure
)	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
insulinoma	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
2	I-Diagnostic_procedure
(	I-Diagnostic_procedure
IA	I-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
)	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
,	O
and	O
insulin	B-Diagnostic_procedure
autoantibody	I-Diagnostic_procedure
,	O
consistent	O
with	O
T1D	B-Disease_disorder
.	O

The	O
intravenous	B-Diagnostic_procedure
glucagon	I-Diagnostic_procedure
stimulation	I-Diagnostic_procedure
test	I-Diagnostic_procedure
was	O
performed	O
with	O
blood	B-Biological_structure
samples	I-Biological_structure
for	B-Detailed_description
glucose	I-Detailed_description
and	I-Detailed_description
C	I-Detailed_description
-	I-Detailed_description
peptide	I-Detailed_description
taken	I-Detailed_description
at	I-Detailed_description
baseline	I-Detailed_description
and	I-Detailed_description
6	I-Detailed_description
minutes	I-Detailed_description
.	O

Her	O
plasma	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
levels	O
were	O
139	B-Lab_value
and	O
152	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
at	O
baseline	B-Detailed_description
and	O
6	B-Detailed_description
minutes	I-Detailed_description
,	O
respectively	O
.	O

The	O
corresponding	O
serum	B-Diagnostic_procedure
C	I-Diagnostic_procedure
-	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
levels	O
were	O
0	B-Lab_value
.	I-Lab_value
8	I-Lab_value
and	O
1	B-Lab_value
.	I-Lab_value
3	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
at	O
baseline	B-Detailed_description
and	O
6	B-Detailed_description
minutes	I-Detailed_description
,	O
respectively	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
with	O
a	O
retroperitoneal	B-Biological_structure
metastatic	B-Sign_symptom
lymph	B-Biological_structure
node	I-Biological_structure
in	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
(	O
MR	B-Diagnostic_procedure
)	O
imaging	O
with	O
a	O
history	O
of	O
right	B-Biological_structure
liver	I-Biological_structure
resection	B-Therapeutic_procedure
in	O
2010	O
,	O
pulmonary	B-Biological_structure
wedge	I-Biological_structure
resection	B-Therapeutic_procedure
in	O
2012	O
,	O
and	O
transarterial	B-Therapeutic_procedure
chemoembolization	I-Therapeutic_procedure
twice	B-Detailed_description
in	O
2014	O
,	O
in	O
which	O
the	O
postoperative	O
pathology	B-Diagnostic_procedure
suggested	O
the	O
mixed	B-Detailed_description
liver	B-Disease_disorder
cancer	I-Disease_disorder
,	O
and	O
poorly	B-Detailed_description
differentiated	I-Detailed_description
lung	B-Disease_disorder
cancer	I-Disease_disorder
from	O
liver	B-Biological_structure
metastasis	B-Sign_symptom
.	O

At	O
examination	B-Diagnostic_procedure
,	O
the	O
tumor	O
was	O
very	O
close	O
to	O
the	O
duodenum	B-Biological_structure
,	O
pancreas	B-Biological_structure
,	O
stomach	B-Biological_structure
,	O
and	O
hepatic	B-Biological_structure
portal	I-Biological_structure
vein	I-Biological_structure
.	O

The	O
patient	O
with	O
unresectable	B-Detailed_description
masses	B-Sign_symptom
had	O
hypertension	B-Sign_symptom
over	O
10	B-Duration
years	I-Duration
and	O
chronic	B-Detailed_description
HBV	B-Disease_disorder
-	I-Disease_disorder
related	I-Disease_disorder
cirrhosis	I-Disease_disorder
for	O
30	B-Duration
years	I-Duration
when	O
he	O
was	O
treated	O
with	O
lamivudine	B-Medication
100	B-Dosage
mg	I-Dosage
qd	I-Dosage
,	O
and	O
adefovir	B-Medication
dipivoxil	I-Medication
10	B-Dosage
mg	I-Dosage
qd	I-Dosage
for	O
6	B-Duration
years	I-Duration
.	O

He	O
kept	O
a	O
constant	B-Lab_value
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
of	O
37	B-Lab_value
°C	I-Lab_value
,	O
the	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
148	B-Lab_value
/	I-Lab_value
96	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
and	O
the	O
pulse	B-Diagnostic_procedure
of	O
77	B-Lab_value
beats	I-Lab_value
every	I-Lab_value
minute	I-Lab_value
.	O

The	O
patient	O
had	O
no	O
obvious	O
sense	O
of	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
abdominal	B-Biological_structure
distention	B-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
and	O
vomiting	B-Sign_symptom
.	O

On	O
a	O
test	O
of	O
tumor	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
levels	O
,	O
the	O
results	O
were	O
normal	B-Lab_value
,	O
which	O
showed	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
3	B-Lab_value
.	I-Lab_value
7	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
alpha	B-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
17	B-Lab_value
.	I-Lab_value
3	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
and	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
levels	O
6	B-Lab_value
.	I-Lab_value
1	I-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

In	O
this	O
study	O
,	O
the	O
procedure	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Zhejiang	O
University	O
.	O

The	O
efficacy	O
of	O
local	B-Detailed_description
ablation	B-Therapeutic_procedure
was	O
estimated	O
with	O
Choi	B-Diagnostic_procedure
criteria	I-Diagnostic_procedure
,	O
which	O
appraised	O
the	O
variations	O
both	O
in	O
tumor	O
size	O
and	O
lesion	O
density	O
on	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
imaging	O
:	O
complete	B-Other_entity
response	I-Other_entity
,	I-Other_entity
disappearance	I-Other_entity
of	I-Other_entity
all	I-Other_entity
lesions	I-Other_entity
and	I-Other_entity
no	I-Other_entity
new	I-Other_entity
lesions	I-Other_entity
;	I-Other_entity
partial	I-Other_entity
response	I-Other_entity
(	I-Other_entity
PR	I-Other_entity
)	I-Other_entity
,	I-Other_entity
a	I-Other_entity
decrease	I-Other_entity
in	I-Other_entity
size	I-Other_entity
of	I-Other_entity
10	I-Other_entity
%	I-Other_entity
or	I-Other_entity
a	I-Other_entity
decrease	I-Other_entity
in	I-Other_entity
tumor	I-Other_entity
density	I-Other_entity
over	I-Other_entity
15	I-Other_entity
%	I-Other_entity
on	I-Other_entity
CT	I-Other_entity
and	I-Other_entity
no	I-Other_entity
new	I-Other_entity
lesions	I-Other_entity
;	I-Other_entity
stable	I-Other_entity
disease	I-Other_entity
,	I-Other_entity
not	I-Other_entity
fit	I-Other_entity
for	I-Other_entity
complete	I-Other_entity
response	I-Other_entity
,	I-Other_entity
PR	I-Other_entity
,	I-Other_entity
or	I-Other_entity
progressive	I-Other_entity
disease	I-Other_entity
;	I-Other_entity
and	I-Other_entity
progressive	I-Other_entity
disease	I-Other_entity
,	I-Other_entity
an	I-Other_entity
increase	I-Other_entity
in	I-Other_entity
tumor	I-Other_entity
size	I-Other_entity
over	I-Other_entity
10	I-Other_entity
%	I-Other_entity
and	I-Other_entity
not	I-Other_entity
fit	I-Other_entity
for	I-Other_entity
PR	I-Other_entity
by	I-Other_entity
tumor	I-Other_entity
density	I-Other_entity
on	I-Other_entity
CT	I-Other_entity
or	I-Other_entity
new	I-Other_entity
lesions	I-Other_entity
.	O
[	O
19	O
]	O

Preoperative	O
MR	B-Diagnostic_procedure
imaging	O
scan	O
showed	O
a	O
mass	B-Sign_symptom
of	O
2	B-Area
.	I-Area
8	I-Area
×	I-Area
3	I-Area
.	I-Area
5	I-Area
cm	I-Area
in	O
size	O
close	O
to	O
the	O
duodenum	B-Biological_structure
,	O
pancreas	B-Biological_structure
,	O
and	O
blood	B-Biological_structure
vessels	I-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
.	O

During	O
substance	B-Detailed_description
phase	I-Detailed_description
,	O
MR	B-Diagnostic_procedure
images	O
indicated	O
mildly	B-Severity
high	I-Severity
signal	B-Sign_symptom
intensity	I-Sign_symptom
around	O
the	O
tumor	O
and	O
intermediate	B-Severity
low	I-Severity
signal	B-Sign_symptom
intensity	I-Sign_symptom
in	O
the	O
solid	B-Biological_structure
component	I-Biological_structure
and	O
in	O
the	O
walls	B-Biological_structure
(	O
Fig	O
.	O
1B	O
)	O
.	O

Before	O
the	O
initial	O
ablation	B-Therapeutic_procedure
,	O
there	O
was	O
a	O
retroperitoneal	B-Biological_structure
mild	B-Severity
hyperechoic	B-Sign_symptom
area	I-Sign_symptom
on	O
axial	B-Detailed_description
US	B-Diagnostic_procedure
image	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
inpatient	O
underwent	O
percutaneous	B-Detailed_description
transhepatic	B-Biological_structure
biopsies	B-Diagnostic_procedure
and	O
ablations	B-Therapeutic_procedure
to	O
avoid	O
the	O
nearby	O
blood	O
vessels	O
,	O
the	O
procedure	O
of	O
which	O
was	O
performed	O
about	B-Duration
40	I-Duration
minutes	I-Duration
under	O
local	B-Medication
anesthesia	I-Medication
and	O
mild	O
sedation	B-Medication
.	O

We	O
used	O
ultrasonography	B-Diagnostic_procedure
to	O
real	B-Detailed_description
-	I-Detailed_description
timely	I-Detailed_description
guide	O
the	O
inserting	O
of	O
2	B-Detailed_description
Nd	I-Detailed_description
:	I-Detailed_description
YAG	I-Detailed_description
laser	B-Therapeutic_procedure
fibers	I-Therapeutic_procedure
(	O
Echolaser	B-Detailed_description
X4	I-Detailed_description
,	I-Detailed_description
ESAOTE	I-Detailed_description
,	I-Detailed_description
Italy	I-Detailed_description
)	O
in	O
0	B-Detailed_description
.	I-Detailed_description
3	I-Detailed_description
mm	I-Detailed_description
diameter	I-Detailed_description
through	B-Detailed_description
a	I-Detailed_description
21	I-Detailed_description
-	I-Detailed_description
gauge	I-Detailed_description
Chiba	I-Detailed_description
needle	I-Detailed_description
into	O
the	O
lesions	B-Sign_symptom
(	O
Fig	O
.	O
1D	O
)	O
.	O

Although	O
part	O
of	O
the	O
heat	O
ran	O
off	O
by	O
blood	O
flow	O
,	O
[	O
20	O
]	O
ablation	B-Therapeutic_procedure
could	O
keep	O
valid	O
area	B-Detailed_description
from	I-Detailed_description
12	I-Detailed_description
to	I-Detailed_description
15	I-Detailed_description
mm	I-Detailed_description
with	O
the	O
power	B-Detailed_description
of	I-Detailed_description
5	I-Detailed_description
W	I-Detailed_description
in	O
5	B-Detailed_description
to	I-Detailed_description
6	I-Detailed_description
minutes	I-Detailed_description
.	O

Subsequently	O
,	O
immediate	O
ultrasonography	B-Diagnostic_procedure
showed	O
that	O
the	O
whole	O
lesion	B-Sign_symptom
was	O
covered	O
with	O
hyperechoic	B-Sign_symptom
zone	I-Sign_symptom
(	O
Fig	O
.	O
(	O
Fig	O
.	O
1E	O
and	O
F	O
)	O
.	O

However	O
,	O
the	O
next	O
day	O
contrast	B-Diagnostic_procedure
-	I-Diagnostic_procedure
enhanced	I-Diagnostic_procedure
ultrasound	I-Diagnostic_procedure
(	O
CEUS	B-Diagnostic_procedure
)	O
revealed	O
an	O
abnormal	B-Sign_symptom
residual	I-Sign_symptom
of	O
proximal	B-Biological_structure
part	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
pancreatic	I-Biological_structure
head	I-Biological_structure
(	O
Fig	O
.	O
2A	O
)	O
.	O

At	O
5	O
-	O
day	O
follow	O
-	O
up	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
images	I-Diagnostic_procedure
,	O
the	O
lower	B-Detailed_description
mass	B-Sign_symptom
had	O
low	B-Severity
signal	B-Sign_symptom
intensity	I-Sign_symptom
and	O
upper	B-Detailed_description
tumor	B-Sign_symptom
revealed	O
intermediate	B-Severity
high	I-Severity
signal	B-Sign_symptom
intensity	I-Sign_symptom
of	O
residual	B-Detailed_description
in	I-Detailed_description
substance	I-Detailed_description
phase	I-Detailed_description
(	O
Fig	O
.	O
2B	O
and	O
C	O
)	O
.	O

Surprizingly	O
,	O
1	O
-	O
week	O
follow	O
-	O
up	O
CEUS	B-Diagnostic_procedure
image	O
showed	O
an	O
enlarged	B-Sign_symptom
retroperitoneal	B-Biological_structure
lymph	B-Biological_structure
node	I-Biological_structure
located	O
near	B-Biological_structure
the	I-Biological_structure
pancreatic	I-Biological_structure
head	I-Biological_structure
,	O
which	O
could	O
be	O
fusion	O
of	O
these	O
residuary	O
small	O
nodules	O
(	O
Fig	O
.	O
2D	O
)	O
.	O

Then	O
the	O
patient	O
undergoing	O
the	O
2nd	B-Detailed_description
ablation	B-Therapeutic_procedure
with	O
2	B-Detailed_description
laser	B-Therapeutic_procedure
fibers	I-Therapeutic_procedure
showed	O
the	O
lesions	B-Sign_symptom
well	O
-	O
defined	O
hyperechoic	B-Sign_symptom
zone	I-Sign_symptom
(	O
Fig	O
.	O
2E	O
and	O
F	O
)	O
.	O

On	O
the	O
2nd	O
day	O
,	O
postoperative	O
CEUS	B-Diagnostic_procedure
images	O
showed	O
they	O
were	O
still	O
remanent	O
(	O
Fig	O
.	O
2G	O
and	O
I	O
)	O
.	O

At	O
the	O
corresponding	O
MR	B-Diagnostic_procedure
imaging	O
,	O
it	O
also	O
showed	O
this	O
in	O
left	O
of	O
tumor	B-Sign_symptom
(	O
Fig	O
.	O
2H	O
)	O
.	O

Thus	O
,	O
the	O
3rd	B-Detailed_description
laser	B-Detailed_description
ablation	B-Therapeutic_procedure
was	O
performed	O
(	O
Fig	O
.	O
2J	O
)	O
2J	O
)	O
and	O
3	O
days	O
later	O
CEUS	B-Diagnostic_procedure
found	O
that	O
there	O
was	O
still	O
a	O
minor	B-Severity
lesion	B-Sign_symptom
located	O
in	O
the	O
separation	O
gap	O
of	O
last	O
2	O
needles	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

Subsequently	O
the	O
patient	O
had	O
the	O
4th	B-Detailed_description
ablation	B-Therapeutic_procedure
along	O
this	O
separation	O
gap	O
until	O
hyperechoic	O
overlay	O
(	O
Fig	O
.	O
3B	O
-	O
D	O
)	O
,	O
then	O
3	O
days	O
later	O
,	O
based	O
on	O
these	O
4	O
treatments	O
,	O
enhanced	O
CT	B-Diagnostic_procedure
image	O
of	O
the	O
retroperitoneal	B-Biological_structure
mass	B-Sign_symptom
suggested	O
complete	O
necrosis	B-Sign_symptom
(	O
Fig	O
.	O
3E	O
-	O
G	O
)	O
.	O
3E	O
-	O
G	O
)	O
.	O

After	O
the	O
following	O
1	O
month	O
,	O
substance	O
phase	O
MR	B-Diagnostic_procedure
revealed	O
low	O
-	O
intensity	O
signal	B-Sign_symptom
of	I-Sign_symptom
tumor	I-Sign_symptom
necrosis	I-Sign_symptom
with	O
resolution	O
of	O
his	O
problems	B-Sign_symptom
(	O
Fig	O
.	O
3H	O
)	O
.	O

Until	O
5	O
months	O
after	O
4	O
ablations	O
,	O
CT	B-Diagnostic_procedure
showed	O
the	O
tumor	B-Sign_symptom
PR	O
with	O
little	O
enhanced	O
recurrence	B-Sign_symptom
(	O
yellow	O
arrows	O
)	O
,	O
which	O
located	O
in	O
the	O
left	O
lower	O
edge	O
of	O
original	O
lesions	O
(	O
Fig	O
.	O
4A	O
and	O
B	O
)	O
.	O

On	O
laboratory	O
test	O
of	O
tumor	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
,	O
the	O
levels	O
of	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
,	O
alpha	B-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
,	O
and	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
indicated	O
3	B-Lab_value
.	I-Lab_value
6	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
26	B-Lab_value
.	I-Lab_value
7	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
and	O
8	B-Lab_value
.	I-Lab_value
1	I-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
respectively	O
.	O

No	O
obvious	O
side	B-Sign_symptom
effects	I-Sign_symptom
were	O
discovered	O
in	O
this	O
case	O
during	O
these	O
procedures	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
65	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
admitted	O
to	O
the	O
China	B-Nonbiological_location
-	I-Nonbiological_location
Japan	I-Nonbiological_location
Friendship	I-Nonbiological_location
hospital	I-Nonbiological_location
with	O
a	O
chief	O
complaint	O
of	O
progressive	B-Detailed_description
dysphagia	B-Sign_symptom
for	O
3	B-Duration
mo	I-Duration
.	O

He	O
also	O
complained	O
of	O
a	O
drastic	B-Severity
weight	B-Sign_symptom
loss	I-Sign_symptom
of	O
8	B-Lab_value
kg	I-Lab_value
in	O
the	O
past	B-Duration
2	I-Duration
mo	I-Duration
.	O

He	O
denied	O
a	O
history	O
of	O
smoking	O
,	O
alcohol	O
intake	O
and	O
substance	O
abuse	O
,	O
but	O
had	O
a	O
chronic	B-Detailed_description
atrophic	B-Detailed_description
gastritis	B-Disease_disorder
for	O
nearly	B-Duration
10	I-Duration
years	I-Duration
.	O

Also	O
,	O
there	O
was	O
no	O
family	O
history	O
of	O
genetic	O
defect	O
or	O
malignancy	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
no	B-Lab_value
palpable	I-Lab_value
findings	I-Lab_value
.	O

Admission	O
blood	B-Diagnostic_procedure
test	I-Diagnostic_procedure
showed	O
a	O
slight	B-Lab_value
decrease	I-Lab_value
in	O
hemoglobin	B-Diagnostic_procedure
(	O
106	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
.	O

Upper	B-Biological_structure
gastrointestinal	I-Biological_structure
(	O
GI	B-Biological_structure
)	O
examination	B-Diagnostic_procedure
using	O
barium	B-Detailed_description
contrasts	I-Detailed_description
showed	O
a	O
large	B-Severity
tumor	B-Sign_symptom
blocking	B-Sign_symptom
the	O
esophago	B-Biological_structure
-	I-Biological_structure
gastric	I-Biological_structure
junction	I-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
revealed	O
a	O
soft	B-Texture
mass	B-Sign_symptom
in	O
the	O
esophago	B-Biological_structure
-	I-Biological_structure
gastric	I-Biological_structure
junction	I-Biological_structure
with	O
lymph	B-Biological_structure
node	I-Biological_structure
metastasis	B-Sign_symptom
in	O
the	O
lesser	B-Biological_structure
curvature	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
stomach	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

Endoscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
a	O
black	B-Color
spot	B-Sign_symptom
in	O
the	O
lower	B-Biological_structure
esophagus	I-Biological_structure
and	O
a	O
bulky	B-Detailed_description
black	B-Color
mass	B-Sign_symptom
blocking	B-Sign_symptom
the	O
esophago	B-Biological_structure
-	I-Biological_structure
gastric	I-Biological_structure
junction	I-Biological_structure
,	O
as	O
well	O
as	O
two	B-Detailed_description
black	B-Color
crater	B-Shape
-	I-Shape
like	I-Shape
ulcers	B-Sign_symptom
in	O
the	O
fundus	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
stomach	I-Biological_structure
(	O
Figure	O
3	O
)	O
.	O

Biopsy	B-Diagnostic_procedure
specimens	O
taken	O
from	O
the	O
tumor	B-Sign_symptom
were	O
identified	O
as	O
poorly	B-Detailed_description
differentiated	I-Detailed_description
adenocarcinoma	B-Disease_disorder
.	O

Preoperative	O
nutrition	B-Diagnostic_procedure
status	I-Diagnostic_procedure
of	O
this	O
case	O
was	O
scored	O
2	B-Lab_value
based	O
on	O
the	O
Nutrition	B-Detailed_description
Risk	I-Detailed_description
Screening	I-Detailed_description
2002	I-Detailed_description
(	O
NRS	O
2002	O
)	O
[	O
6	O
]	O
.	O

Because	O
of	O
the	O
obstructive	O
symptom	O
caused	O
by	O
the	O
tumor	O
,	O
a	O
debulking	B-Therapeutic_procedure
surgery	I-Therapeutic_procedure
of	O
distal	B-Detailed_description
esophagectomy	B-Therapeutic_procedure
and	O
proximal	B-Detailed_description
gastrectomy	B-Therapeutic_procedure
was	O
performed	O
.	O

Esophagogastric	B-Biological_structure
anastomosis	B-Therapeutic_procedure
and	O
reconstruction	B-Therapeutic_procedure
was	O
then	O
completed	O
with	O
stapling	B-Therapeutic_procedure
device	I-Therapeutic_procedure
.	O

Intraoperatively	O
,	O
the	O
tumor	B-Sign_symptom
was	O
found	O
located	O
at	O
the	O
esophago	B-Biological_structure
-	I-Biological_structure
gastric	I-Biological_structure
junction	I-Biological_structure
and	O
the	O
tumor	O
infiltrated	B-Sign_symptom
the	O
whole	B-Biological_structure
layer	I-Biological_structure
with	O
lymph	B-Biological_structure
node	I-Biological_structure
metastasis	B-Sign_symptom
at	O
station	B-Biological_structure
four	I-Biological_structure
.	O

No	O
ascites	B-Sign_symptom
or	O
dissemination	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
tumor	I-Sign_symptom
was	O
observed	O
in	O
the	O
peritoneal	B-Biological_structure
cavity	I-Biological_structure
.	O

The	O
tumor	B-Sign_symptom
measured	O
3	B-Area
cm	I-Area
×	I-Area
6	I-Area
cm	I-Area
in	O
size	O
with	O
black	B-Color
pigmentation	I-Color
(	O
Figure	O
4	O
)	O
.	O

There	O
were	O
several	B-Detailed_description
pigmented	B-Color
satellite	B-Detailed_description
nodules	B-Sign_symptom
beside	O
the	O
main	O
tumor	O
lesion	O
,	O
the	O
largest	O
one	O
being	O
1	B-Area
cm	I-Area
×	I-Area
1	I-Area
cm	I-Area
in	O
diameter	O
.	O

Moreover	O
,	O
two	O
ulceration	B-Detailed_description
lesions	B-Sign_symptom
were	O
found	O
at	O
the	O
fundus	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
stomach	I-Biological_structure
.	O

Microscopically	B-Diagnostic_procedure
,	O
the	O
excised	O
tumor	B-Biological_structure
tissue	I-Biological_structure
was	O
composed	O
of	O
non	B-Lab_value
-	I-Lab_value
organized	I-Lab_value
and	O
pleomorphic	B-Lab_value
cells	B-Diagnostic_procedure
exhibiting	O
atypical	B-Lab_value
nuclei	B-Diagnostic_procedure
,	O
and	O
abundant	B-Lab_value
melanin	B-Diagnostic_procedure
granules	I-Diagnostic_procedure
(	O
Figure	O
5	O
)	O
.	O

Pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
identified	O
this	O
case	O
at	O
a	O
stage	B-Diagnostic_procedure
of	O
IVA	B-Lab_value
(	O
T4aN1M0	B-Lab_value
)	O
.	O

Immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
showed	O
that	O
the	O
tumor	O
was	O
positive	B-Lab_value
for	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
,	O
HMB	B-Diagnostic_procedure
-	I-Diagnostic_procedure
45	I-Diagnostic_procedure
,	O
mclean	B-Diagnostic_procedure
-	I-Diagnostic_procedure
A	I-Diagnostic_procedure
and	O
Vimentin	B-Diagnostic_procedure
,	O
but	O
negative	B-Lab_value
for	O
cytokeratin	B-Diagnostic_procedure
7	I-Diagnostic_procedure
and	O
cytokeratin	B-Diagnostic_procedure
20	I-Diagnostic_procedure
(	O
Figure	O
6	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
a	O
diagnosis	O
of	O
primary	B-Detailed_description
advanced	B-Severity
esophago	B-Detailed_description
-	I-Detailed_description
gastric	I-Detailed_description
melanoma	B-Disease_disorder
was	O
established	O
.	O

The	O
postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
smooth	B-Lab_value
and	O
without	O
complications	B-Sign_symptom
.	O

The	O
patient	O
gradually	O
recovered	B-Sign_symptom
and	O
was	O
discharged	O
14	O
d	O
after	O
surgery	O
.	O

As	O
the	O
patient	O
denied	O
a	O
postoperative	O
adjuvant	B-Medication
therapy	I-Medication
,	O
abdominal	B-Biological_structure
recurrence	B-Sign_symptom
and	O
hepatic	B-Biological_structure
metastases	B-Sign_symptom
were	O
found	O
within	O
one	O
month	O
by	O
a	O
postoperative	O
follow	O
-	O
up	O
CT	B-Diagnostic_procedure
.	O

No	O
other	B-Therapeutic_procedure
effective	I-Therapeutic_procedure
treatment	I-Therapeutic_procedure
was	O
administered	O
afterwards	O
.	O

The	O
patient	O
died	O
of	O
diffuse	B-Detailed_description
metastatic	B-Disease_disorder
disease	I-Disease_disorder
2	O
mo	O
later	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
patient	O
was	O
a	O
3	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
girl	O
with	O
the	O
following	O
features	O
of	O
VACTERL	B-Diagnostic_procedure
association	I-Diagnostic_procedure
:	O
absent	B-Detailed_description
C1	B-Biological_structure
vertebra	I-Biological_structure
,	O
supernumerary	B-Detailed_description
lumbar	B-Biological_structure
vertebrae	I-Biological_structure
,	O
hypoplastic	B-Detailed_description
sacrum	B-Biological_structure
/	O
coccyx	B-Biological_structure
,	O
fatty	B-Detailed_description
filum	B-Biological_structure
terminale	I-Biological_structure
with	O
tethered	B-Detailed_description
spinal	B-Biological_structure
cord	I-Biological_structure
,	O
and	O
three	B-Lab_value
fused	B-Detailed_description
ribs	B-Biological_structure
;	O
an	O
anorectal	B-Disease_disorder
malformation	I-Disease_disorder
including	O
a	O
cloaca	B-Biological_structure
consisting	O
of	O
a	O
common	B-Detailed_description
urogenital	B-Biological_structure
sinus	I-Biological_structure
and	O
a	O
duplex	B-Detailed_description
vagina	B-Biological_structure
with	O
midline	B-Detailed_description
septum	I-Detailed_description
;	O
type	B-Detailed_description
C	I-Detailed_description
TE	B-Disease_disorder
fistula	I-Disease_disorder
;	O
right	B-Biological_structure
renal	I-Biological_structure
agenesis	B-Disease_disorder
with	O
moderate	B-Severity
left	B-Detailed_description
hydronephrosis	B-Disease_disorder
and	O
vesicoureteral	B-Disease_disorder
reflux	I-Disease_disorder
.	O

She	O
had	O
no	O
cardiac	B-Disease_disorder
or	I-Disease_disorder
limb	B-Disease_disorder
malformations	I-Disease_disorder
,	O
and	O
no	O
other	B-Disease_disorder
major	I-Disease_disorder
organ	I-Disease_disorder
anomalies	I-Disease_disorder
.	O

Both	O
she	B-Other_entity
and	O
her	O
father	O
were	O
additionally	O
clinically	O
diagnosed	O
with	O
hypermobile	B-Detailed_description
type	I-Detailed_description
Ehlers	O
-	O
Danlos	O
syndrome	O
,	O
but	O
family	O
history	O
was	O
otherwise	O
noncontributory	O
.	O

The	O
diagnosis	O
of	O
hypermobile	B-Detailed_description
type	I-Detailed_description
Ehlers	B-Disease_disorder
-	I-Disease_disorder
Danlos	I-Disease_disorder
was	O
based	O
on	O
the	O
patient	O
`	O
s	O
hypermobility	B-Disease_disorder
(	O
9	B-Lab_value
/	I-Lab_value
9	I-Lab_value
on	O
the	O
Beighton	B-Diagnostic_procedure
hypermobility	I-Diagnostic_procedure
scale	I-Diagnostic_procedure
)	O
,	O
very	B-Lab_value
soft	B-Texture
,	O
fragile	B-Texture
skin	B-Biological_structure
with	O
unusual	B-Detailed_description
scarring	I-Detailed_description
,	O
and	O
poor	B-Lab_value
skin	B-Detailed_description
healing	I-Detailed_description
.	O

Skin	B-Biological_structure
biopsy	B-Diagnostic_procedure
was	O
not	O
performed	O
,	O
but	O
testing	B-Diagnostic_procedure
on	O
peripheral	B-Biological_structure
blood	I-Biological_structure
did	O
not	O
reveal	O
mutations	B-Diagnostic_procedure
associated	O
with	O
other	B-Detailed_description
forms	I-Detailed_description
of	O
Ehlers	B-Disease_disorder
-	I-Disease_disorder
Danlos	I-Disease_disorder
syndrome	I-Disease_disorder
.	O

Microarray	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
initially	O
showed	O
a	O
maternally	B-Detailed_description
-	I-Detailed_description
inherited	I-Detailed_description
deletion	B-Diagnostic_procedure
at	O
4q35	B-Biological_structure
.	I-Biological_structure
1	I-Biological_structure
detected	O
with	O
one	B-Diagnostic_procedure
clone	I-Diagnostic_procedure
and	O
confirmed	O
by	O
FISH	B-Diagnostic_procedure
(	B-Diagnostic_procedure
RP11	I-Diagnostic_procedure
-	I-Diagnostic_procedure
173M11	I-Diagnostic_procedure
)	I-Diagnostic_procedure
.	O

Subsequent	O
performance	O
of	O
an	O
180K	B-Diagnostic_procedure
custom	I-Diagnostic_procedure
oligonucleotide	I-Diagnostic_procedure
microarray	I-Diagnostic_procedure
(	O
Baylor	B-Nonbiological_location
College	I-Nonbiological_location
of	I-Nonbiological_location
Medicine	I-Nonbiological_location
Medical	I-Nonbiological_location
Genetics	I-Nonbiological_location
Laboratories	I-Nonbiological_location
)	O
refined	O
the	O
deleted	B-Diagnostic_procedure
region	I-Diagnostic_procedure
deletion	I-Diagnostic_procedure
to	O
a	O
maximum	B-Lab_value
size	I-Lab_value
of	I-Lab_value
1	I-Lab_value
.	I-Lab_value
37	I-Lab_value
Mb	I-Lab_value
,	O
with	O
karyotype	B-Diagnostic_procedure
revised	O
to	O
46	B-Detailed_description
,	I-Detailed_description
XX	I-Detailed_description
,	I-Detailed_description
arr	I-Detailed_description
cgh	I-Detailed_description
4q35	I-Detailed_description
.	I-Detailed_description
1q35	I-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
(	I-Detailed_description
187,321	I-Detailed_description
-	I-Detailed_description
768	I-Detailed_description
-	I-Detailed_description
188,694	I-Detailed_description
-	I-Detailed_description
589	I-Detailed_description
)	I-Detailed_description
3	I-Detailed_description
1	I-Detailed_description
.	O

Genes	B-Diagnostic_procedure
in	O
the	O
deleted	B-Detailed_description
region	I-Detailed_description
,	O
which	O
contains	O
a	O
number	O
of	O
much	O
smaller	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
identified	O
in	O
normal	O
controls	O
,	O
include	O
CYP4V2	B-Diagnostic_procedure
,	O
KLKB2	B-Diagnostic_procedure
,	O
F11	B-Diagnostic_procedure
,	O
MTRNR1A	B-Diagnostic_procedure
,	O
and	O
FAT1	B-Diagnostic_procedure
,	O
none	O
of	O
which	O
can	O
be	O
clearly	O
related	O
to	O
her	O
phenotype	O
,	O
especially	O
as	O
her	O
mother	O
,	O
from	B-Detailed_description
whom	I-Detailed_description
the	I-Detailed_description
deletion	I-Detailed_description
was	I-Detailed_description
inherited	I-Detailed_description
,	O
is	O
unaffected	O
.	O

Evidence	O
for	O
mitochondrial	B-Disease_disorder
dysfunction	I-Disease_disorder
began	O
at	O
13	B-Age
months	I-Age
of	I-Age
age	I-Age
with	O
progressive	B-Detailed_description
muscle	B-Sign_symptom
weakness	I-Sign_symptom
,	O
autonomic	B-Disease_disorder
dysregulation	I-Disease_disorder
,	O
hypoglycemic	B-Disease_disorder
episodes	I-Disease_disorder
,	O
exocrine	B-Disease_disorder
pancreatic	I-Disease_disorder
dysfunction	I-Disease_disorder
,	O
and	O
decline	B-Detailed_description
of	O
gastrointestinal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
,	O
eventually	O
leading	O
to	O
total	B-Severity
parenteral	B-Detailed_description
nutrition	B-Disease_disorder
dependency	I-Disease_disorder
due	O
to	O
visceral	B-Biological_structure
hyperalgesia	B-Disease_disorder
,	O
dysmotility	B-Disease_disorder
,	O
and	O
malabsorption	B-Disease_disorder
.	O

Muscle	B-Biological_structure
biopsy	B-Diagnostic_procedure
showed	O
a	O
mild	B-Severity
increase	B-Lab_value
in	O
fiber	B-Diagnostic_procedure
size	I-Diagnostic_procedure
variability	I-Diagnostic_procedure
but	O
no	O
other	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
consistent	B-Detailed_description
with	I-Detailed_description
mitochondrial	I-Detailed_description
disease	I-Detailed_description
,	O
including	O
via	O
electron	B-Diagnostic_procedure
microscopy	I-Diagnostic_procedure
.	O

However	O
,	O
analysis	O
of	O
electron	B-Diagnostic_procedure
transport	I-Diagnostic_procedure
chain	I-Diagnostic_procedure
(	B-Diagnostic_procedure
ETC	I-Diagnostic_procedure
)	I-Diagnostic_procedure
activity	I-Diagnostic_procedure
showed	O
normal	B-Lab_value
activity	O
of	O
complexes	B-Diagnostic_procedure
I	I-Diagnostic_procedure
,	I-Diagnostic_procedure
II	I-Diagnostic_procedure
,	I-Diagnostic_procedure
and	I-Diagnostic_procedure
III	I-Diagnostic_procedure
,	O
but	O
complex	B-Diagnostic_procedure
IV	I-Diagnostic_procedure
,	O
or	O
cytochrome	B-Diagnostic_procedure
c	I-Diagnostic_procedure
oxidase	I-Diagnostic_procedure
,	O
activity	O
was	O
45	B-Lab_value
.	I-Lab_value
4	I-Lab_value
lmol	I-Lab_value
/	I-Lab_value
min	I-Lab_value
/	I-Lab_value
g	I-Lab_value
weight	I-Lab_value
,	O
well	B-Detailed_description
below	I-Detailed_description
the	I-Detailed_description
control	I-Detailed_description
range	I-Detailed_description
(	O
148	O
.	O
9	O
+	O
/	O
−	O
67	O
.	O
2	O
lmol	O
/	O
min	O
/	O
g	O
weight	O
)	O
.	O

Repeat	B-Detailed_description
ETC	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
in	O
isolated	B-Detailed_description
mitochondria	B-Biological_structure
confirmed	O
a	O
profound	B-Severity
and	O
reproducible	B-Detailed_description
complex	B-Disease_disorder
IV	I-Disease_disorder
deficiency	I-Disease_disorder
.	O

Citrate	B-Diagnostic_procedure
synthase	I-Diagnostic_procedure
activity	I-Diagnostic_procedure
and	I-Diagnostic_procedure
content	I-Diagnostic_procedure
in	O
both	O
ETC	O
analyses	O
were	O
normal	B-Lab_value
,	O
confirming	O
good	B-Lab_value
sample	B-Diagnostic_procedure
quality	I-Diagnostic_procedure
and	O
normal	B-Lab_value
mitochondrial	B-Diagnostic_procedure
content	I-Diagnostic_procedure
.	O

Whole	B-Detailed_description
mitochondrial	B-Biological_structure
genome	B-Diagnostic_procedure
sequencing	I-Diagnostic_procedure
,	O
and	O
sequencing	B-Diagnostic_procedure
of	O
DNA	B-Diagnostic_procedure
Polymerase	I-Diagnostic_procedure
Gamma	I-Diagnostic_procedure
1	I-Diagnostic_procedure
and	I-Diagnostic_procedure
2	I-Diagnostic_procedure
(	O
POLG1	B-Diagnostic_procedure
and	O
POLG2	B-Diagnostic_procedure
)	O
and	O
Thymidine	B-Diagnostic_procedure
Phosphorylase	I-Diagnostic_procedure
did	O
not	O
reveal	O
abnormalities	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
newborn	B-Age
boy	O
of	O
healthy	O
nonconsanguineous	O
parents	O
was	O
delivered	O
at	O
37	O
weeks	O
`	O
gestation	O
by	O
cesarean	B-Therapeutic_procedure
section	I-Therapeutic_procedure
.	O

His	O
mother	O
(	O
primipara	O
,	O
32	O
years	O
old	O
)	O
had	O
been	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
2	O
weeks	O
previously	O
because	O
of	O
reduced	B-Lab_value
fetal	B-Sign_symptom
intrauterine	I-Sign_symptom
movements	I-Sign_symptom
and	O
polyhydramnios	B-Sign_symptom
.	O

The	O
child	O
`	O
s	O
birthweight	B-Diagnostic_procedure
was	O
2,330	B-Lab_value
g	I-Lab_value
(	O
<	B-Lab_value
10th	I-Lab_value
percentile	I-Lab_value
)	O
,	O
length	B-Diagnostic_procedure
47	B-Lab_value
cm	I-Lab_value
,	O
and	O
head	B-Diagnostic_procedure
circumference	I-Diagnostic_procedure
33	B-Lab_value
.	I-Lab_value
2	I-Lab_value
cm	I-Lab_value
(	O
25th	O
percentile	O
)	O
.	O

He	O
had	O
low	B-Sign_symptom
-	I-Sign_symptom
set	I-Sign_symptom
ears	I-Sign_symptom
and	O
bilateral	B-Sign_symptom
clubfoot	I-Sign_symptom
.	O

Apgar	B-Diagnostic_procedure
scores	I-Diagnostic_procedure
were	O
2	B-Lab_value
,	O
6	B-Lab_value
,	O
and	O
7	B-Lab_value
at	O
1	B-Time
,	I-Time
5	B-Time
,	I-Time
and	I-Time
10	B-Time
minutes	I-Time
.	O

The	O
child	O
presented	O
with	O
severe	B-Severity
hypotonia	B-Sign_symptom
and	O
generalized	B-Sign_symptom
muscle	I-Sign_symptom
weakness	I-Sign_symptom
,	O
requiring	O
ventilatory	B-Therapeutic_procedure
assistance	I-Therapeutic_procedure
and	O
total	B-Therapeutic_procedure
parenteral	I-Therapeutic_procedure
nutrition	I-Therapeutic_procedure
.	O

Weaning	O
failed	O
because	O
of	O
inadequate	O
pulmonary	O
ventilation	O
and	O
respiratory	B-Disease_disorder
acidosis	I-Disease_disorder
.	O

Hearing	B-Sign_symptom
loss	I-Sign_symptom
was	O
detected	O
by	O
auditory	B-Diagnostic_procedure
evoked	I-Diagnostic_procedure
potentials	I-Diagnostic_procedure
,	O
while	O
cranial	B-Biological_structure
MRI	B-Diagnostic_procedure
showed	O
mildly	B-Lab_value
enlarged	I-Lab_value
ventricles	B-Biological_structure
and	O
liquor	B-Biological_structure
spaces	I-Biological_structure
.	O

Two	O
days	O
after	O
birth	O
,	O
the	O
infant	O
presented	O
with	O
severe	B-Severity
abdominal	B-Sign_symptom
distension	I-Sign_symptom
with	O
a	O
hypoactive	B-Sign_symptom
bowel	I-Sign_symptom
.	O

MRI	B-Diagnostic_procedure
revealed	O
marked	B-Severity
intestinal	B-Sign_symptom
dilation	I-Sign_symptom
without	O
mechanical	B-Sign_symptom
obstruction	I-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
investigations	I-Diagnostic_procedure
showed	O
hypoglycemia	B-Sign_symptom
(	O
27	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
,	O
hypomagnesemia	B-Sign_symptom
(	O
0	B-Lab_value
.	I-Lab_value
58	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
and	O
hypokalemia	B-Sign_symptom
(	O
2	B-Lab_value
.	I-Lab_value
4	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
.	O

Blood	B-Diagnostic_procedure
lactate	I-Diagnostic_procedure
was	O
normal	B-Lab_value
(	O
1	B-Lab_value
.	I-Lab_value
3	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
normal	B-Detailed_description
range	I-Detailed_description
0	I-Detailed_description
.	I-Detailed_description
5	I-Detailed_description
-	I-Detailed_description
2	I-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
mmol	I-Detailed_description
/	I-Detailed_description
L	I-Detailed_description
)	O
and	O
liver	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
were	O
unremarkable	B-Lab_value
.	O

A	O
skeletal	B-Biological_structure
muscle	I-Biological_structure
biopsy	B-Diagnostic_procedure
was	O
performed	O
and	O
showed	O
scattered	B-Detailed_description
,	O
hypertrophic	B-Detailed_description
cytochrome	B-Diagnostic_procedure
c	I-Diagnostic_procedure
oxidase	I-Diagnostic_procedure
(	O
COX	B-Diagnostic_procedure
)	O
-	O
deficient	B-Lab_value
and	O
succinate	B-Diagnostic_procedure
dehydrogenase	I-Diagnostic_procedure
-	O
positive	B-Lab_value
muscle	B-Biological_structure
fibers	I-Biological_structure
(	O
figure	O
)	O
,	O
suggesting	O
a	O
mitochondrial	B-Disease_disorder
disorder	I-Disease_disorder
.	O

Molecular	B-Diagnostic_procedure
genetic	I-Diagnostic_procedure
studies	I-Diagnostic_procedure
revealed	O
marked	B-Severity
mtDNA	B-Sign_symptom
depletion	I-Sign_symptom
in	O
muscle	O
(	O
93	B-Lab_value
%	I-Lab_value
decrease	I-Lab_value
as	O
compared	B-Detailed_description
to	I-Detailed_description
age	I-Detailed_description
-	I-Detailed_description
matched	I-Detailed_description
controls	I-Detailed_description
)	O
,	O
while	O
a	O
screen	B-Diagnostic_procedure
for	I-Diagnostic_procedure
mtDNA	I-Diagnostic_procedure
rearrangements	I-Diagnostic_procedure
within	O
individual	B-Biological_structure
COX	I-Biological_structure
-	I-Biological_structure
positive	I-Biological_structure
and	I-Biological_structure
COX	B-Biological_structure
-	I-Biological_structure
deficient	I-Biological_structure
fibers4	I-Biological_structure
was	O
negative	B-Lab_value
.	O

We	O
sequenced	B-Diagnostic_procedure
the	O
entire	B-Detailed_description
coding	I-Detailed_description
region	I-Detailed_description
and	I-Detailed_description
intron	I-Detailed_description
-	I-Detailed_description
exon	I-Detailed_description
boundaries	I-Detailed_description
of	O
the	O
POLG1	B-Biological_structure
gene	I-Biological_structure
,	O
identifying	O
two	B-Lab_value
reported	O
heterozygous	B-Sign_symptom
missense	I-Sign_symptom
mutations	I-Sign_symptom
in	O
compound	O
c	B-Sign_symptom
.	I-Sign_symptom
679C	I-Sign_symptom
>	I-Sign_symptom
T	I-Sign_symptom
predicting	I-Sign_symptom
p	I-Sign_symptom
.	I-Sign_symptom
R227W	I-Sign_symptom
and	O
c	B-Sign_symptom
.	I-Sign_symptom
2542G	I-Sign_symptom
>	I-Sign_symptom
A	I-Sign_symptom
predicting	I-Sign_symptom
p	I-Sign_symptom
.	I-Sign_symptom
G848S	I-Sign_symptom
.	O

Sequencing	B-Diagnostic_procedure
of	I-Diagnostic_procedure
parental	I-Diagnostic_procedure
samples	I-Diagnostic_procedure
confirmed	O
recessive	B-Sign_symptom
inheritance	I-Sign_symptom
.	O

The	O
infant	O
died	O
at	O
20	O
days	O
of	O
respiratory	B-Disease_disorder
failure	I-Disease_disorder
.	O

At	O
autopsy	B-Diagnostic_procedure
,	O
the	O
brain	B-Biological_structure
did	O
not	O
show	O
remarkable	B-Sign_symptom
changes	I-Sign_symptom
on	O
gross	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
.	O

Histology	B-Diagnostic_procedure
was	O
not	O
informative	O
due	O
to	O
poor	O
preservation	O
of	O
tissue	O
;	O
there	O
was	O
no	O
evidence	O
of	O
neuronal	B-Sign_symptom
damage	I-Sign_symptom
in	O
the	O
spinal	B-Biological_structure
cord	I-Biological_structure
.	O

The	O
liver	B-Biological_structure
showed	O
diffuse	B-Detailed_description
cholestasis	B-Sign_symptom
,	O
consistent	O
with	O
total	O
parenteral	O
nutrition	O
;	O
hepatocyte	B-Biological_structure
steatosis	B-Sign_symptom
,	O
necrosis	B-Sign_symptom
,	O
or	O
liver	B-Biological_structure
fibrosis	B-Sign_symptom
were	O
not	O
observed	O
.	O

The	O
testicles	O
were	O
undescended	O
,	O
while	O
remaining	O
visceral	O
organs	O
were	O
normal	O
except	O
for	O
a	O
marked	O
dilation	B-Sign_symptom
and	O
thinning	B-Sign_symptom
of	O
the	O
bowel	B-Biological_structure
wall	I-Biological_structure
.	O

Despite	O
normal	O
histology	O
,	O
analysis	O
of	O
stomach	B-Biological_structure
,	I-Biological_structure
ileum	B-Biological_structure
,	I-Biological_structure
and	I-Biological_structure
colon	B-Biological_structure
homogenates	I-Biological_structure
revealed	O
severe	B-Severity
mtDNA	B-Sign_symptom
depletion	I-Sign_symptom
(	O
up	B-Lab_value
to	I-Lab_value
94	I-Lab_value
%	I-Lab_value
decrease	I-Lab_value
;	O
table	O
e	O
-	O
1	O
on	O
the	O
Neurology	O
®	O
Web	O
site	O
at	O
www	O
.	O
neurology	O
.	O
org	O
)	O
.	O

Laser	B-Diagnostic_procedure
capture	I-Diagnostic_procedure
microdissection	I-Diagnostic_procedure
analysis5	I-Diagnostic_procedure
revealed	O
that	O
the	O
mtDNA	O
depletion	O
was	O
confined	O
to	O
the	O
muscularis	B-Biological_structure
propria	I-Biological_structure
,	O
being	O
most	O
prominent	O
in	O
its	O
external	B-Detailed_description
layer	I-Detailed_description
(	O
figure	O
)	O
.	O

Ganglion	B-Biological_structure
cells	I-Biological_structure
from	O
the	O
myenteric	B-Biological_structure
plexus	I-Biological_structure
showed	O
milder	B-Severity
mtDNA	O
depletion	O
,	O
restricted	O
to	O
the	O
small	B-Biological_structure
intestine	I-Biological_structure
(	O
figure	O
)	O
.	O

There	O
was	O
no	O
mtDNA	B-Sign_symptom
depletion	I-Sign_symptom
in	O
liver	B-Biological_structure
(	O
not	O
shown	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
patient	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
on	O
Feb	O
.	O
18	O
,	O
2016	O
because	O
of	O
frequent	B-Frequency
episodes	O
of	O
hemoptysis	B-Sign_symptom
for	O
2	B-Duration
weeks	I-Duration
.	O

In	O
the	O
previous	O
decade	O
,	O
the	O
patient	O
had	O
frequent	B-Frequency
but	O
less	B-Severity
severe	I-Severity
episodes	O
of	O
hemoptysis	B-Sign_symptom
,	O
which	O
typically	O
ensued	O
following	O
an	O
upper	B-Biological_structure
respiratory	I-Biological_structure
tract	I-Biological_structure
infection	B-Disease_disorder
.	O

Ear	B-Diagnostic_procedure
,	I-Diagnostic_procedure
nose	I-Diagnostic_procedure
,	I-Diagnostic_procedure
and	I-Diagnostic_procedure
throat	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
and	O
laryngoscope	B-Diagnostic_procedure
failed	O
to	O
identify	O
an	O
apparent	O
source	B-Sign_symptom
of	I-Sign_symptom
bleeding	I-Sign_symptom
.	O

CT	B-Diagnostic_procedure
chest	B-Biological_structure
scan	O
revealed	O
no	O
abnormality	B-Sign_symptom
.	O

The	O
most	O
recent	O
episode	O
occurred	O
after	O
an	O
upper	B-Biological_structure
respiratory	I-Biological_structure
tract	I-Biological_structure
infection	B-Disease_disorder
2	O
weeks	O
ago	O
.	O

The	O
patient	O
coughed	B-Sign_symptom
up	O
as	O
much	O
as	O
about	O
500	B-Volume
mL	I-Volume
of	O
fresh	B-Sign_symptom
blood	I-Sign_symptom
in	O
an	O
episode	O
of	O
hemoptysis	B-Sign_symptom
,	O
which	O
was	O
alleviated	O
by	O
anti	B-Medication
-	I-Medication
tussive	I-Medication
therapy	I-Medication
.	O

The	O
patient	O
denied	O
a	O
history	O
of	O
smoking	O
and	O
illicit	O
drug	O
use	O
.	O

Diagnostic	B-Diagnostic_procedure
workup	I-Diagnostic_procedure
revealed	O
no	O
evidence	O
of	O
coagulopathy	B-Disease_disorder
.	O

Upon	O
admission	O
,	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
signs	O
of	O
rhonchi	B-Sign_symptom
and	O
reduced	B-Lab_value
breath	B-Diagnostic_procedure
sounds	I-Diagnostic_procedure
.	O

Bronchoscopy	B-Diagnostic_procedure
showed	O
a	O
1	B-Distance
-	I-Distance
cm	I-Distance
lesion	B-Sign_symptom
at	O
the	O
membranous	B-Biological_structure
trachea	I-Biological_structure
2	B-Distance
cm	I-Distance
to	O
the	O
carina	B-Biological_structure
.	O

Tortuous	B-Sign_symptom
blood	I-Sign_symptom
vessels	I-Sign_symptom
were	O
observed	O
running	O
in	O
the	O
submucosa	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
trachea	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

CT	B-Diagnostic_procedure
angiography	I-Diagnostic_procedure
was	O
performed	O
,	O
demonstrating	O
an	O
artery	B-Sign_symptom
extending	I-Sign_symptom
into	O
the	O
submucosa	B-Biological_structure
from	O
the	O
descending	B-Biological_structure
aorta	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

A	O
diagnosis	O
of	O
Dieulafoy	B-Therapeutic_procedure
disease	I-Therapeutic_procedure
of	O
the	O
trachea	B-Biological_structure
was	O
entertained	O
.	O

Since	O
the	O
blood	O
vessel	O
was	O
considered	O
to	O
be	O
the	O
culprit	O
of	O
hemoptysis	B-Sign_symptom
,	O
selective	B-Detailed_description
arterial	B-Therapeutic_procedure
embolization	I-Therapeutic_procedure
was	O
performed	O
1	O
week	O
later	O
.	O

No	O
fresh	O
episode	O
of	O
acute	B-Detailed_description
hemoptysis	B-Sign_symptom
was	O
observed	O
and	O
the	O
patient	O
was	O
still	O
being	O
followed	O
up	O
at	O
the	O
time	O
of	O
writing	O
this	O
report	O
.	O

This	O
study	O
was	O
approved	O
by	O
Ethics	O
Committee	O
of	O
Shanghai	O
Jiao	O
Tong	O
University	O
Affiliated	O
Sixth	O
People	O
`	O
s	O
Hospital	O
,	O
and	O
also	O
got	O
an	O
informed	O
written	O
consent	O
from	O
the	O
patient	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
16	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
suffered	O
from	O
an	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
at	O
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
,	O
lasting	O
for	O
more	B-Duration
than	I-Duration
10	I-Duration
days	I-Duration
.	O

Shortly	O
ahead	O
of	O
her	O
medical	O
consultation	O
,	O
4	B-Lab_value
ascaris	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
worms	I-Detailed_description
were	O
vomited	B-Sign_symptom
out	O
,	O
individually	O
with	O
a	O
length	O
of	O
about	O
10	B-Distance
cm	I-Distance
.	O

She	O
had	O
a	O
previous	B-Detailed_description
onset	I-Detailed_description
of	O
ascariasis	B-Disease_disorder
,	O
during	O
which	O
low	B-Lab_value
-	I-Lab_value
grade	I-Lab_value
fever	B-Sign_symptom
(	O
38	B-Lab_value
.	I-Lab_value
4	I-Lab_value
°C	I-Lab_value
)	O
occurred	O
without	O
apparent	O
jaundice	B-Sign_symptom
,	O
diarrhea	B-Sign_symptom
,	O
or	O
anemia	B-Sign_symptom
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
tenderness	B-Sign_symptom
at	O
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
.	O

Her	O
total	B-Diagnostic_procedure
leukocyte	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
11	B-Lab_value
.	I-Lab_value
2	I-Lab_value
G	I-Lab_value
/	I-Lab_value
L	I-Lab_value
consisting	O
of	O
5	B-Lab_value
.	I-Lab_value
2	I-Lab_value
%	I-Lab_value
eosinophils	I-Lab_value
.	O

Serum	B-Biological_structure
and	O
urine	B-Biological_structure
amylase	B-Diagnostic_procedure
were	O
386	B-Lab_value
and	I-Lab_value
928	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
respectively	O
.	O

In	O
terms	O
of	O
liver	B-Diagnostic_procedure
functionality	I-Diagnostic_procedure
,	O
the	O
level	O
of	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
rose	B-Lab_value
up	I-Lab_value
to	O
23	B-Lab_value
.	I-Lab_value
2	I-Lab_value
μm	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
meanwhile	O
the	O
hepatic	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
were	O
similarly	O
elevated	B-Lab_value
(	O
alanine	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
163	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
aspartate	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
96	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
.	O

Abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
described	O
the	O
enlargement	B-Sign_symptom
of	O
the	O
gallbladder	B-Biological_structure
,	O
upper	B-Biological_structure
segment	I-Biological_structure
of	I-Biological_structure
common	I-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
(	O
1	B-Distance
.	I-Distance
5	I-Distance
cm	I-Distance
in	I-Distance
diameter	I-Distance
)	O
and	O
intrahepatic	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
(	O
1	B-Distance
.	I-Distance
3	I-Distance
cm	I-Distance
in	I-Distance
diameter	I-Distance
)	O
.	O

Furthermore	O
,	O
the	O
intrahepatic	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
was	O
also	O
discovered	O
to	O
be	O
filled	O
with	O
echogenic	B-Sign_symptom
and	O
banded	B-Sign_symptom
substances	I-Sign_symptom
.	O

Based	O
on	O
such	O
evidences	O
,	O
she	O
was	O
clinically	O
diagnosed	O
as	O
biliary	B-Biological_structure
ascariasis	B-Disease_disorder
with	O
a	O
concomitant	O
manifestation	O
of	O
biliary	B-Biological_structure
duct	I-Biological_structure
infection	B-Disease_disorder
.	O

Through	O
a	O
laparoscopic	B-Diagnostic_procedure
exploration	I-Diagnostic_procedure
,	O
the	O
enlarged	B-Sign_symptom
gallbladder	B-Biological_structure
and	O
common	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
were	O
visually	O
confirmed	O
,	O
as	O
well	O
as	O
the	O
massive	B-Severity
storage	I-Severity
of	O
worms	B-Sign_symptom
within	O
the	O
biliary	B-Biological_structure
tract	I-Biological_structure
.	O

Subsequently	O
,	O
a	O
1	B-Distance
cm	I-Distance
incision	B-Therapeutic_procedure
was	O
made	O
on	O
the	O
common	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
in	O
order	O
to	O
facilitate	O
the	O
extraction	B-Therapeutic_procedure
of	O
the	O
pathogenic	O
worms	B-Sign_symptom
,	O
which	O
were	O
then	O
placed	B-Therapeutic_procedure
into	I-Therapeutic_procedure
a	I-Therapeutic_procedure
specimen	I-Therapeutic_procedure
bag	I-Therapeutic_procedure
laparoscopically	B-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
.	O

Once	O
the	O
contained	O
worms	B-Sign_symptom
were	O
virtually	O
cleared	O
out	O
under	O
laparoscope	B-Diagnostic_procedure
,	O
chodedochoscopy	B-Diagnostic_procedure
was	O
employed	O
to	O
seek	O
for	O
more	O
hidden	B-Detailed_description
worms	B-Sign_symptom
inside	O
the	O
biliary	B-Biological_structure
system	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

After	O
finishing	O
the	O
removal	B-Therapeutic_procedure
of	O
ascarides	O
,	O
the	O
biliary	B-Biological_structure
duct	I-Biological_structure
incision	B-Therapeutic_procedure
was	I-Therapeutic_procedure
well	I-Therapeutic_procedure
sutured	I-Therapeutic_procedure
,	O
with	O
a	O
T	B-Therapeutic_procedure
-	I-Therapeutic_procedure
tube	I-Therapeutic_procedure
placed	I-Therapeutic_procedure
in	O
situ	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Eventually	O
,	O
a	O
standard	O
laparoscopic	B-Detailed_description
cholecystectomy	B-Therapeutic_procedure
was	O
performed	O
,	O
followed	O
by	O
the	O
removal	B-Therapeutic_procedure
of	I-Therapeutic_procedure
specimen	I-Therapeutic_procedure
bags	I-Therapeutic_procedure
and	O
drainage	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
placement	I-Therapeutic_procedure
(	O
Fig	O
.	O
4	O
)	O
.	O

The	O
total	O
amount	O
of	O
worms	B-Sign_symptom
inside	O
the	O
common	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
summed	O
up	O
to	O
more	B-Lab_value
than	I-Lab_value
100	I-Lab_value
(	O
Fig	O
.	O
5	O
)	O
.	O

Postoperatively	O
,	O
she	O
was	O
treated	O
with	O
oral	O
antihelminthic	B-Medication
drugs	I-Medication
for	O
3	B-Duration
days	I-Duration
.	O

The	O
T	B-Therapeutic_procedure
-	I-Therapeutic_procedure
tube	I-Therapeutic_procedure
was	I-Therapeutic_procedure
rinsed	I-Therapeutic_procedure
with	I-Therapeutic_procedure
saline	I-Therapeutic_procedure
every	O
day	O
,	O
and	O
during	B-Duration
the	I-Duration
first	I-Duration
3	I-Duration
days	I-Duration
,	O
6	B-Lab_value
more	O
worms	B-Sign_symptom
were	O
additionally	O
washed	O
out	O
.	O

The	O
patient	O
experienced	O
a	O
smooth	B-Lab_value
postoperative	B-Therapeutic_procedure
recovery	I-Therapeutic_procedure
and	O
was	O
finally	O
discharged	O
from	B-Nonbiological_location
hospital	I-Nonbiological_location
without	O
any	O
complications	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

An	O
18	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
lady	O
presented	O
with	O
history	O
of	O
progressive	O
swaying	B-Sign_symptom
while	O
walking	O
,	O
worse	B-Lab_value
in	O
night	B-Time
since	O
5	B-Duration
years	I-Duration
.	O

Speech	B-Diagnostic_procedure
was	O
normal	B-Lab_value
and	O
there	O
was	O
not	O
any	O
tremulousness	B-Sign_symptom
of	O
upper	B-Biological_structure
limbs	I-Biological_structure
.	O

Also	O
,	O
there	O
was	O
no	O
history	O
of	O
weakness	B-Sign_symptom
or	O
numbness	B-Sign_symptom
.	O

The	O
family	O
history	O
was	O
significant	O
as	O
her	O
elder	O
sister	O
had	O
similar	O
difficulty	B-Sign_symptom
in	I-Sign_symptom
walking	I-Sign_symptom
of	O
7	B-Duration
-	I-Duration
year	I-Duration
duration	O
and	O
died	O
because	O
of	O
poorly	B-Lab_value
controlled	I-Lab_value
diabetes	B-Disease_disorder
mellitus	I-Disease_disorder
at	O
an	O
age	O
of	O
20	B-Age
years	I-Age
.	O

No	O
other	O
members	O
of	O
the	O
kin	O
were	O
affected	O
and	O
there	O
was	O
no	O
history	O
of	O
consanguinity	O
in	O
the	O
parents	O
.	O

The	O
cognitive	B-Diagnostic_procedure
function	I-Diagnostic_procedure
was	O
normal	B-Lab_value
and	O
her	O
Mini	B-Diagnostic_procedure
Mental	I-Diagnostic_procedure
Status	I-Diagnostic_procedure
Score	I-Diagnostic_procedure
was	O
30	B-Lab_value
/	I-Lab_value
30	I-Lab_value
.	O

Visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
and	O
fundus	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

The	O
extraocular	B-Diagnostic_procedure
movements	I-Diagnostic_procedure
including	O
saccades	B-Diagnostic_procedure
,	O
pursuits	B-Diagnostic_procedure
were	O
normal	B-Lab_value
,	O
and	O
no	O
saccadic	B-Disease_disorder
intrusions	I-Disease_disorder
or	O
nystagmus	B-Disease_disorder
were	O
noticed	O
.	O

The	O
tone	B-Diagnostic_procedure
and	O
power	B-Diagnostic_procedure
were	O
normal	B-Lab_value
in	O
all	B-Biological_structure
four	I-Biological_structure
limbs	I-Biological_structure
;	O
however	O
,	O
there	O
was	O
generalised	O
exaggeration	B-Lab_value
of	O
myotatic	B-Diagnostic_procedure
reflexes	I-Diagnostic_procedure
along	O
with	O
bilateral	B-Sign_symptom
extensor	I-Sign_symptom
plantar	I-Sign_symptom
response	I-Sign_symptom
.	O

Vibration	B-Diagnostic_procedure
and	O
joint	B-Diagnostic_procedure
position	I-Diagnostic_procedure
sense	I-Diagnostic_procedure
were	O
intact	B-Lab_value
but	O
Romberg	B-Diagnostic_procedure
`	I-Diagnostic_procedure
s	I-Diagnostic_procedure
was	O
positive	B-Lab_value
.	O

Patient	O
swayed	B-Sign_symptom
to	B-Detailed_description
either	I-Detailed_description
side	I-Detailed_description
while	O
performing	B-Activity
tandem	I-Activity
walk	I-Activity
.	O

Fasting	B-Detailed_description
and	O
postprandial	B-Detailed_description
blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
levels	O
were	O
normal	B-Lab_value
.	O

Haemogram	B-Diagnostic_procedure
,	O
renal	B-Diagnostic_procedure
,	O
liver	B-Diagnostic_procedure
and	O
thyroid	B-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Serum	B-Diagnostic_procedure
vitamin	I-Diagnostic_procedure
B12	I-Diagnostic_procedure
and	O
folic	B-Diagnostic_procedure
acid	I-Diagnostic_procedure
levels	O
were	O
within	O
normal	B-Lab_value
limits	O
.	O

Nerve	B-Diagnostic_procedure
conduction	I-Diagnostic_procedure
study	I-Diagnostic_procedure
showed	O
absent	B-Lab_value
sensory	B-Diagnostic_procedure
nerve	I-Diagnostic_procedure
action	I-Diagnostic_procedure
potential	I-Diagnostic_procedure
with	O
normal	B-Lab_value
distal	B-Diagnostic_procedure
latency	I-Diagnostic_procedure
,	O
conduction	B-Diagnostic_procedure
velocity	I-Diagnostic_procedure
and	O
amplitude	B-Diagnostic_procedure
of	I-Diagnostic_procedure
compound	I-Diagnostic_procedure
muscle	I-Diagnostic_procedure
action	I-Diagnostic_procedure
potential	I-Diagnostic_procedure
(	O
CMAP	B-Diagnostic_procedure
)	O
in	O
all	O
nerves	B-Biological_structure
trunks	I-Biological_structure
.	O

MRI	B-Diagnostic_procedure
showed	O
marked	B-Severity
atrophy	B-Sign_symptom
of	O
the	O
cervical	B-Biological_structure
cord	I-Biological_structure
as	O
compared	O
to	O
cerebellum	B-Biological_structure
which	O
was	O
normal	B-Lab_value
(	O
figure	O
1	O
)	O
.	O

The	O
genetic	B-Diagnostic_procedure
testing	I-Diagnostic_procedure
using	O
PCR	B-Diagnostic_procedure
disclosed	O
expansion	B-Sign_symptom
of	I-Sign_symptom
GAA	I-Sign_symptom
repeat	I-Sign_symptom
in	O
both	B-Detailed_description
alleles	I-Detailed_description
(	I-Detailed_description
254	I-Detailed_description
and	I-Detailed_description
298	I-Detailed_description
)	I-Detailed_description
of	I-Detailed_description
FXN	I-Detailed_description
gene	I-Detailed_description
.	O

A	O
variety	O
of	O
causes	O
of	O
autosomal	B-Disease_disorder
recessive	I-Disease_disorder
ataxias	I-Disease_disorder
need	O
to	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
FRDA	B-Disease_disorder
.	O

These	O
were	O
systemically	O
excluded	O
here	O
.	O

Ataxia	B-Disease_disorder
with	I-Disease_disorder
vitamin	I-Disease_disorder
E	I-Disease_disorder
deficiency	I-Disease_disorder
(	O
AVED	B-Disease_disorder
)	O
has	O
a	O
phenotype	O
quite	O
similar	O
to	O
FRDA	O
,	O
though	O
titubation	B-Sign_symptom
and	O
hyperkinesia	B-Sign_symptom
are	O
more	O
common	O
in	O
AVED	O
.	O
4	O
A	O
strong	O
family	O
history	O
of	O
ataxia	O
and	O
diabetes	O
mellitus	O
in	O
elder	O
sister	O
favoured	O
FRDA	O
.	O

Ataxia	B-Disease_disorder
with	I-Disease_disorder
oculomotor	I-Disease_disorder
apraxia	I-Disease_disorder
(	O
AOA	B-Disease_disorder
)	O
types	B-Detailed_description
1	I-Detailed_description
and	I-Detailed_description
2	I-Detailed_description
were	O
not	O
considered	O
owing	O
to	O
lack	O
of	O
apraxia	B-Sign_symptom
of	I-Sign_symptom
ocular	I-Sign_symptom
movements	I-Sign_symptom
,	O
distal	B-Sign_symptom
amyotrophy	I-Sign_symptom
(	O
severe	B-Severity
axonal	B-Sign_symptom
sensorimotor	I-Sign_symptom
polyneuropathy	I-Sign_symptom
)	O
,	O
atrophy	B-Sign_symptom
of	O
cerebellum	B-Biological_structure
and	O
involuntary	B-Sign_symptom
movements	I-Sign_symptom
.	O
5	O
Ataxia	B-Disease_disorder
telengiectesia	I-Disease_disorder
has	O
presentation	O
very	O
similar	O
to	O
AOA	O
types	O
1	O
and	O
2	O
.	O

Muco	B-Sign_symptom
-	I-Sign_symptom
cutaneous	I-Sign_symptom
markers	I-Sign_symptom
,	O
sino	B-Biological_structure
-	I-Biological_structure
pulmonary	I-Biological_structure
infections	B-Sign_symptom
,	O
hypogammaglobulinaemia	B-Sign_symptom
and	O
radiosensitivity	B-Sign_symptom
along	O
with	O
predisposition	O
to	O
development	O
of	O
a	O
variety	O
of	O
neoplasms	B-Sign_symptom
are	O
features	O
of	O
ataxia	O
telengiectasia	O
not	O
seen	O
in	O
AOAs	O
and	O
FRDA	O
.	O

The	O
other	O
important	O
causes	O
of	O
autosomal	B-Disease_disorder
recessive	I-Disease_disorder
spastic	I-Disease_disorder
ataxia	I-Disease_disorder
apart	O
from	O
FRDA	O
would	O
be	O
autosomal	B-Disease_disorder
recessive	I-Disease_disorder
spastic	I-Disease_disorder
ataxia	I-Disease_disorder
of	I-Disease_disorder
Charlevoix	I-Disease_disorder
-	I-Disease_disorder
Saguenay	I-Disease_disorder
and	O
Marinesco	B-Disease_disorder
-	I-Disease_disorder
Sjögren	I-Disease_disorder
syndrome	I-Disease_disorder
.	O

Charcot	B-Disease_disorder
-	I-Disease_disorder
Marie	I-Disease_disorder
-	I-Disease_disorder
Tooth	I-Disease_disorder
disease	I-Disease_disorder
,	O
an	O
inherited	B-Detailed_description
polyneuropathy	B-Disease_disorder
has	O
gait	B-Sign_symptom
ataxia	I-Sign_symptom
in	O
common	O
with	O
FRDA	O
;	O
however	O
,	O
in	O
this	O
case	O
,	O
CMT	B-Disease_disorder
was	O
improbable	O
due	O
to	O
following	O
features	O
in	O
this	O
case	O
:	O
lack	O
of	O
motor	B-Sign_symptom
weakness	I-Sign_symptom
,	O
retained	B-Sign_symptom
reflexes	I-Sign_symptom
,	O
bilaterally	B-Sign_symptom
extensor	I-Sign_symptom
plantar	I-Sign_symptom
and	O
pure	B-Sign_symptom
sensory	I-Sign_symptom
neuropathy	I-Sign_symptom
on	O
nerve	B-Diagnostic_procedure
conduction	I-Diagnostic_procedure
study	I-Diagnostic_procedure
.	O

Idebenone	B-Medication
was	O
started	O
at	O
a	O
dose	O
of	O
450	B-Dosage
mg	I-Dosage
twice	I-Dosage
a	I-Dosage
day	I-Dosage
for	O
its	O
antioxidant	B-Detailed_description
properties	I-Detailed_description
.	O

For	O
gait	O
ataxia	O
,	O
physiotherapy	B-Therapeutic_procedure
-	O
Frenkel	B-Therapeutic_procedure
`	I-Therapeutic_procedure
s	I-Therapeutic_procedure
exercise	I-Therapeutic_procedure
-	O
was	O
initiated	O
.	O

Blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
is	O
monitored	O
regularly	B-Frequency
.	O

At	O
4	O
months	O
,	O
there	O
was	O
no	B-Severity
significant	I-Severity
change	I-Severity
in	O
the	O
gait	B-Diagnostic_procedure
difficulty	I-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

A	O
69	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
became	O
aware	O
of	O
the	O
onset	O
of	O
exertional	B-Detailed_description
dyspnea	B-Sign_symptom
in	O
July	O
2010	O
.	O

He	O
had	O
a	O
history	O
of	O
smoking	O
for	O
more	O
than	O
40	O
years	O
,	O
20	O
cigarettes	O
per	O
day	O
.	O

His	O
parents	O
and	O
1	O
brother	O
had	O
lung	O
cancer	O
.	O

His	O
past	O
medical	O
history	O
was	O
unremarkable	O
.	O

He	O
had	O
no	O
occupational	O
exposure	O
.	O

Due	O
to	O
the	O
exertional	B-Detailed_description
dyspnea	B-Sign_symptom
,	O
he	O
was	O
admitted	O
to	O
the	O
People	B-Nonbiological_location
`	I-Nonbiological_location
s	I-Nonbiological_location
Hospital	I-Nonbiological_location
of	I-Nonbiological_location
Shunde	I-Nonbiological_location
District	I-Nonbiological_location
for	O
echocardiography	B-Diagnostic_procedure
and	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
pulmonary	I-Diagnostic_procedure
angiography	I-Diagnostic_procedure
(	O
CTPA	B-Diagnostic_procedure
)	O
.	O

Echocardiography	B-Diagnostic_procedure
indicated	O
that	O
he	O
had	O
severe	B-Severity
PAH	B-Disease_disorder
,	O
because	O
his	O
pulmonary	B-Diagnostic_procedure
arterial	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
(	O
PAP	B-Diagnostic_procedure
)	O
was	O
104	B-Lab_value
mmHg	I-Lab_value
,	O
and	O
his	O
right	B-Biological_structure
heart	I-Biological_structure
was	O
enlarged	B-Sign_symptom
(	O
the	O
right	B-Diagnostic_procedure
ventricle	I-Diagnostic_procedure
diameter	I-Diagnostic_procedure
:	O
57	B-Lab_value
mm	I-Lab_value
)	O
.	O

CTPA	B-Diagnostic_procedure
showed	O
that	O
he	O
had	O
not	O
only	O
PAH	B-Disease_disorder
,	O
but	O
also	O
a	O
thrombus	B-Disease_disorder
in	O
the	O
upper	B-Biological_structure
lobe	I-Biological_structure
artery	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
lung	I-Biological_structure
.	O

However	O
,	O
the	O
region	B-Biological_structure
in	I-Biological_structure
the	I-Biological_structure
lung	I-Biological_structure
affected	O
by	O
this	O
PE	O
was	O
considered	O
too	O
small	O
to	O
induce	O
such	O
a	O
severe	O
PAH	O
.	O

In	O
addition	O
,	O
he	O
did	O
not	O
have	O
connective	O
tissue	O
disease	O
,	O
drug	O
use	O
,	O
history	O
of	O
chemotherapy	O
,	O
or	O
HIV	O
test	O
(	O
+	O
)	O
,	O
so	O
he	O
was	O
diagnosed	O
as	O
IPAH	B-Disease_disorder
combined	O
with	O
PE	B-Disease_disorder
.	O

He	O
was	O
treated	O
with	O
warfarin	B-Medication
(	O
2	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
per	I-Dosage
day	I-Dosage
with	O
a	O
target	O
of	O
the	O
international	B-Diagnostic_procedure
normalized	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
[	O
INR	B-Diagnostic_procedure
]	O
between	O
1	B-Lab_value
.	I-Lab_value
5	I-Lab_value
and	I-Lab_value
2	I-Lab_value
.	I-Lab_value
5	I-Lab_value
)	O
and	O
slidenafil	B-Medication
targeted	O
PAH	O
therapy	O
(	O
20	B-Dosage
mg	I-Dosage
twice	I-Dosage
per	I-Dosage
day	I-Dosage
)	O
.	O

The	O
patient	O
`	O
s	O
dyspnea	B-Sign_symptom
was	O
relieved	O
slightly	O
after	O
the	O
use	O
of	O
these	O
medications	B-Medication
for	O
1	B-Duration
month	I-Duration
and	O
the	O
retested	O
PAP	B-Diagnostic_procedure
by	O
echocardiography	B-Detailed_description
was	O
decreased	B-Lab_value
to	O
72	B-Lab_value
mmHg	I-Lab_value
,	O
but	O
all	O
the	O
other	B-Sign_symptom
symptoms	I-Sign_symptom
and	I-Sign_symptom
signs	I-Sign_symptom
failed	B-Lab_value
to	I-Lab_value
further	I-Lab_value
improve	I-Lab_value
after	O
taking	O
these	O
medications	B-Medication
for	O
6	B-Duration
months	I-Duration
.	O

In	O
March	O
2011	O
,	O
he	O
went	O
to	O
the	O
Kyorin	B-Nonbiological_location
University	I-Nonbiological_location
affiliated	I-Nonbiological_location
hospital	I-Nonbiological_location
in	O
Japan	B-Nonbiological_location
for	O
further	O
treatment	O
.	O

Right	B-Biological_structure
heart	I-Biological_structure
catheterization	B-Diagnostic_procedure
revealed	O
PAP	B-Diagnostic_procedure
72	B-Lab_value
/	I-Lab_value
34	I-Lab_value
/	I-Lab_value
47	I-Lab_value
mmHg	I-Lab_value
,	O
pulmonary	B-Diagnostic_procedure
capillary	I-Diagnostic_procedure
wedge	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
(	O
PCWP	B-Diagnostic_procedure
)	O
17	B-Lab_value
/	I-Lab_value
5	I-Lab_value
/	I-Lab_value
10	I-Lab_value
mmHg	I-Lab_value
,	O
cardiac	B-Diagnostic_procedure
output	I-Diagnostic_procedure
4	B-Lab_value
.	I-Lab_value
3	I-Lab_value
L	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
cardiac	B-Diagnostic_procedure
ejection	I-Diagnostic_procedure
index	I-Diagnostic_procedure
2	B-Lab_value
.	I-Lab_value
36	I-Lab_value
L	I-Lab_value
/	I-Lab_value
min	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
,	O
and	O
pulmonary	B-Diagnostic_procedure
vascular	I-Diagnostic_procedure
resistance	I-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
3	I-Lab_value
Wood	I-Lab_value
units	I-Lab_value
.	O

He	O
was	O
retested	O
for	O
CTPA	B-Diagnostic_procedure
that	O
showed	O
that	O
the	O
thrombus	B-Disease_disorder
in	O
the	O
upper	B-Biological_structure
lobe	I-Biological_structure
artery	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
lung	I-Biological_structure
disappeared	O
.	O

He	O
was	O
still	O
diagnosed	O
as	O
having	O
IPAH	B-Disease_disorder
,	O
so	O
treated	O
with	O
sildenafil	B-Medication
(	O
20	B-Dosage
mg	I-Dosage
3	I-Dosage
times	I-Dosage
a	I-Dosage
day	I-Dosage
)	O
and	O
sorafenib	B-Medication
(	O
400	B-Dosage
mg	I-Dosage
once	I-Dosage
a	I-Dosage
day	I-Dosage
)	O
targeted	O
PAH	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
and	O
oral	O
warfarin	B-Medication
anticoagulation	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
(	O
2	B-Dosage
.	I-Dosage
5	I-Dosage
-	I-Dosage
3	I-Dosage
.	I-Dosage
75	I-Dosage
mg	I-Dosage
per	I-Dosage
day	I-Dosage
,	O
but	O
the	O
daily	O
dose	O
was	O
adjusted	O
by	O
INR	B-Diagnostic_procedure
that	O
was	O
between	O
2	B-Lab_value
and	I-Lab_value
3	I-Lab_value
)	O
.	O

Disappointingly	O
,	O
his	O
dyspnea	B-Sign_symptom
was	O
not	O
relieved	O
and	O
the	O
PAP	B-Diagnostic_procedure
tested	O
by	O
the	O
echocardiography	B-Detailed_description
was	O
around	B-Lab_value
95	I-Lab_value
mmHg	I-Lab_value
.	O

In	O
September	O
2011	O
,	O
he	O
visited	O
the	O
Shanghai	B-Nonbiological_location
Pulmonary	I-Nonbiological_location
hospital	I-Nonbiological_location
in	O
China	B-Nonbiological_location
because	O
of	O
no	O
relief	O
of	O
dyspnea	B-Sign_symptom
.	O

Arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gas	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
that	O
PaO2	B-Diagnostic_procedure
was	O
63	B-Lab_value
mmHg	I-Lab_value
with	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
93	B-Lab_value
%	I-Lab_value
;	O
lung	B-Diagnostic_procedure
function	I-Diagnostic_procedure
test	I-Diagnostic_procedure
revealed	O
a	O
mild	B-Severity
obstructive	B-Disease_disorder
dysfunction	I-Disease_disorder
of	O
the	O
pulmonary	B-Detailed_description
ventilation	I-Detailed_description
(	O
FEV1	B-Diagnostic_procedure
/	I-Diagnostic_procedure
FVC	I-Diagnostic_procedure
62	B-Lab_value
.	I-Lab_value
06	I-Lab_value
%	I-Lab_value
,	O
FEV1	B-Diagnostic_procedure
%	I-Diagnostic_procedure
Prediction	B-Detailed_description
80	B-Lab_value
.	I-Lab_value
9	I-Lab_value
%	I-Lab_value
)	O
and	O
a	O
severe	O
reduction	B-Lab_value
in	O
the	O
diffusing	B-Diagnostic_procedure
capacity	I-Diagnostic_procedure
of	I-Diagnostic_procedure
the	I-Diagnostic_procedure
lungs	I-Diagnostic_procedure
for	I-Diagnostic_procedure
carbon	I-Diagnostic_procedure
monoxide	I-Diagnostic_procedure
(	O
DLCO	B-Diagnostic_procedure
42	B-Lab_value
%	I-Lab_value
)	O
;	O
6	B-Detailed_description
-	I-Detailed_description
minute	I-Detailed_description
walk	B-Diagnostic_procedure
test	I-Diagnostic_procedure
was	O
385	B-Lab_value
m	I-Lab_value
.	O

Chest	B-Biological_structure
high	B-Diagnostic_procedure
-	I-Diagnostic_procedure
resolution	I-Diagnostic_procedure
computed	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
HRCT	B-Diagnostic_procedure
)	O
(	O
Fig	O
.	O
1A	O
and	O
B	O
)	O
showed	O
smooth	B-Texture
thickening	B-Sign_symptom
of	O
interlobular	B-Biological_structure
septa	I-Biological_structure
,	O
diffuse	B-Detailed_description
centrilobular	B-Biological_structure
nodules	B-Sign_symptom
,	O
and	O
the	O
enlargement	B-Sign_symptom
of	O
mediastinal	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
.	O

The	O
right	B-Biological_structure
heart	I-Biological_structure
catheterization	B-Diagnostic_procedure
revealed	O
that	O
PAP	B-Diagnostic_procedure
was	O
83	B-Lab_value
/	I-Lab_value
34	I-Lab_value
/	I-Lab_value
53	I-Lab_value
mmHg	I-Lab_value
and	O
PCWP	B-Diagnostic_procedure
was	O
14	B-Lab_value
/	I-Lab_value
6	I-Lab_value
/	I-Lab_value
11	I-Lab_value
mmHg	I-Lab_value
.	O

Acute	B-Diagnostic_procedure
vasodilator	I-Diagnostic_procedure
testing	I-Diagnostic_procedure
was	O
negative	B-Lab_value
.	O

Coronary	B-Diagnostic_procedure
angiography	I-Diagnostic_procedure
and	O
CTPA	B-Diagnostic_procedure
were	O
both	O
normal	B-Lab_value
;	O
pulmonary	B-Biological_structure
ventilation	B-Diagnostic_procedure
/	I-Diagnostic_procedure
perfusion	I-Diagnostic_procedure
(	O
V	B-Diagnostic_procedure
`	I-Diagnostic_procedure
/	I-Diagnostic_procedure
Q	I-Diagnostic_procedure
`	I-Diagnostic_procedure
)	O
lung	B-Biological_structure
scan	O
showed	O
a	O
matched	B-Sign_symptom
ventilation	I-Sign_symptom
and	I-Sign_symptom
perfusion	I-Sign_symptom
defects	I-Sign_symptom
.	O

Bronchoalveolar	B-Diagnostic_procedure
lavage	I-Diagnostic_procedure
showed	O
an	O
elevated	B-Lab_value
percentage	O
(	O
65	B-Lab_value
%	I-Lab_value
)	O
of	O
hemosiderin	B-Biological_structure
-	I-Biological_structure
laden	I-Biological_structure
macrophages	I-Biological_structure
with	O
the	O
Golde	B-Diagnostic_procedure
score	I-Diagnostic_procedure
80	B-Lab_value
(	O
the	O
normal	O
range	O
:	O
0	O
-	O
20	O
)	O
.	O

He	O
was	O
still	O
diagnosed	O
as	O
having	O
IPAH	B-Disease_disorder
,	O
but	O
he	O
was	O
suspected	O
as	O
actually	O
having	O
PVOD	B-Disease_disorder
.	O

He	O
was	O
continuously	O
treated	O
with	O
the	O
targeted	O
PAH	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
,	O
and	O
he	O
was	O
asked	O
to	O
continue	O
his	O
anticoagulation	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
,	O
but	O
he	O
stopped	O
warfarin	B-Medication
anticoagulation	O
treatment	O
by	B-Detailed_description
himself	I-Detailed_description
sometime	O
in	O
2014	O
(	O
he	O
failed	O
to	O
recall	O
the	O
exact	O
date	O
.	O
)	O
because	O
he	O
felt	O
that	O
it	O
was	O
too	O
cumbersome	O
to	O
frequently	O
test	O
the	O
INR	O
for	O
blood	O
coagulation	O
monitoring	O
.	O

Furthermore	O
,	O
after	O
he	O
discontinued	O
his	O
warfarin	O
therapy	O
,	O
he	O
also	O
failed	O
to	O
monitor	B-Diagnostic_procedure
D	I-Diagnostic_procedure
-	I-Diagnostic_procedure
Dimer	I-Diagnostic_procedure
to	O
prevent	O
PE	O
recurrence	O
.	O

His	O
dyspnea	B-Sign_symptom
was	O
relatively	O
stable	B-Lab_value
,	O
but	O
he	O
developed	O
many	B-Detailed_description
,	O
but	O
not	B-Severity
fatal	I-Severity
,	O
episodes	O
of	O
pulmonary	B-Disease_disorder
edema	I-Disease_disorder
during	O
the	O
therapy	O
.	O

In	O
January	O
2015	O
,	O
he	O
was	O
rushed	O
to	O
hospital	B-Nonbiological_location
because	O
his	O
dyspnea	B-Sign_symptom
was	O
suddenly	O
exacerbated	B-Detailed_description
.	O

CTPA	B-Diagnostic_procedure
showed	O
a	O
thrombus	B-Disease_disorder
in	O
the	O
right	B-Biological_structure
main	I-Biological_structure
pulmonary	I-Biological_structure
artery	I-Biological_structure
(	O
Fig	O
.	O
1C	O
)	O
.	O

Rivaroxaban	B-Medication
was	O
administered	O
for	O
anticoagulation	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
,	O
but	O
this	O
medication	O
did	O
not	O
relieve	O
his	O
dyspnea	B-Sign_symptom
,	O
therefore	O
,	O
he	O
was	O
too	B-Sign_symptom
ill	I-Sign_symptom
to	I-Sign_symptom
walk	I-Sign_symptom
.	O

Instead	O
,	O
he	O
was	O
bound	B-Activity
to	I-Activity
his	I-Activity
wheelchair	I-Activity
for	O
half	B-Duration
a	I-Duration
year	I-Duration
.	O

The	O
severe	O
PAH	B-Disease_disorder
(	O
suspected	O
as	O
PVOD	B-Disease_disorder
)	O
combined	O
with	O
a	O
life	B-Severity
-	I-Severity
threatening	I-Severity
PE	B-Disease_disorder
mandates	O
a	O
lung	B-Therapeutic_procedure
transplantation	I-Therapeutic_procedure
for	O
his	O
survival	O
.	O

Six	O
months	O
later	O
,	O
he	O
was	O
undergone	O
a	O
bilateral	B-Detailed_description
sequential	B-Detailed_description
allogenic	B-Detailed_description
lung	B-Therapeutic_procedure
transplantation	I-Therapeutic_procedure
assisted	O
by	O
veno	B-Therapeutic_procedure
-	I-Therapeutic_procedure
arterial	I-Therapeutic_procedure
extra	I-Therapeutic_procedure
-	I-Therapeutic_procedure
corporeal	I-Therapeutic_procedure
membrane	I-Therapeutic_procedure
oxygenation	I-Therapeutic_procedure
(	O
VA	B-Therapeutic_procedure
-	I-Therapeutic_procedure
ECMO	I-Therapeutic_procedure
)	O
after	O
he	O
signed	O
the	O
written	O
consent	O
on	O
July	O
29	O
,	O
2015	O
.	O

Histology	B-Diagnostic_procedure
of	O
the	O
explanted	B-Biological_structure
lung	I-Biological_structure
specimen	I-Biological_structure
showed	O
pulmonary	B-Biological_structure
vein	I-Biological_structure
occlusion	B-Lab_value
(	O
Fig	O
.	O
1D	O
-	O
F	O
)	O
and	O
the	O
pulmonary	B-Biological_structure
embolism	B-Lab_value
in	O
the	O
right	B-Biological_structure
pulmonary	I-Biological_structure
artery	I-Biological_structure
.	O

Until	O
then	O
,	O
he	O
was	O
confirmed	O
as	O
having	O
PVOD	B-Disease_disorder
combined	O
with	O
PE	B-Disease_disorder
,	O
instead	O
of	O
IPAH	B-Disease_disorder
.	O

He	O
has	O
been	O
living	O
well	B-Sign_symptom
without	O
dyspnea	B-Sign_symptom
for	O
more	B-Duration
than	I-Duration
1	I-Duration
year	I-Duration
after	O
the	O
lung	O
transplantation	O
and	O
the	O
echocardiography	B-Diagnostic_procedure
showed	O
the	O
normalizations	B-Lab_value
of	O
PAP	B-Diagnostic_procedure
and	O
the	O
once	O
enlarged	B-Sign_symptom
right	B-Biological_structure
ventricle	I-Biological_structure
of	I-Biological_structure
his	I-Biological_structure
heart	I-Biological_structure
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
The	O
People	O
`	O
s	O
Hospital	O
of	O
Zhongshan	O
City	O
.	O

The	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
52	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
with	O
a	O
30	O
-	O
year	O
history	O
of	O
smoking	O
presented	O
with	O
an	O
abnormal	B-Detailed_description
nodule	B-Sign_symptom
measuring	O
0	B-Area
.	I-Area
8	I-Area
×	I-Area
1	I-Area
.	I-Area
5	I-Area
cm	I-Area
in	O
the	O
left	B-Biological_structure
upper	I-Biological_structure
lung	I-Biological_structure
lobe	I-Biological_structure
imaged	O
through	O
chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scanning	O
in	O
March	O
2012	O
in	O
a	O
community	B-Nonbiological_location
hospital	I-Nonbiological_location
.	O

He	O
had	O
previously	O
been	O
well	O
without	O
any	O
additional	O
relevant	O
or	O
abnormal	O
symptoms	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
suggested	O
no	O
significant	O
abnormalities	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
range	I-Lab_value
,	O
except	O
for	O
a	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
CEA	B-Diagnostic_procedure
)	O
level	O
of	O
30	B-Lab_value
.	I-Lab_value
25	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
range	O
,	O
0	O
-	O
5	O
ng	O
/	O
mL	O
)	O
found	O
in	O
the	O
serum	B-Biological_structure
.	O

Subsequently	O
,	O
a	O
positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
PET	B-Diagnostic_procedure
)	O
/	O
CT	B-Diagnostic_procedure
scan	O
showed	O
a	O
lung	B-Biological_structure
lesion	B-Sign_symptom
with	O
a	O
standardized	B-Diagnostic_procedure
uptake	I-Diagnostic_procedure
value	I-Diagnostic_procedure
of	O
7	B-Lab_value
.	I-Lab_value
94	I-Lab_value
,	O
which	O
was	O
highly	O
suspected	O
to	O
be	O
a	O
malignant	B-Disease_disorder
tumor	I-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

Subsequently	O
,	O
he	O
underwent	O
left	B-Biological_structure
upper	I-Biological_structure
lung	I-Biological_structure
lobectomy	B-Therapeutic_procedure
and	O
lymph	B-Therapeutic_procedure
node	I-Therapeutic_procedure
dissection	I-Therapeutic_procedure
.	O

Postoperative	O
pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
an	O
adenocarcinoma	B-Disease_disorder
(	O
ADC	B-Disease_disorder
)	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Immunohistochemistry	B-Diagnostic_procedure
(	O
IHC	B-Diagnostic_procedure
)	O
staining	O
results	O
were	O
positive	B-Lab_value
for	O
CK7	B-Diagnostic_procedure
,	O
TTF	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
,	O
p63	B-Diagnostic_procedure
,	O
and	O
NapsinA	B-Diagnostic_procedure
and	O
negative	B-Lab_value
for	O
CK	B-Diagnostic_procedure
5	I-Diagnostic_procedure
/	I-Diagnostic_procedure
6	I-Diagnostic_procedure
,	O
Syn	B-Diagnostic_procedure
,	O
cgA	B-Diagnostic_procedure
,	O
and	O
Ki	B-Diagnostic_procedure
-	I-Diagnostic_procedure
67	I-Diagnostic_procedure
(	O
20	O
%	O
-	O
30	O
%	O
)	O
.	O

The	O
clinical	B-Diagnostic_procedure
stage	I-Diagnostic_procedure
was	O
classified	O
as	O
IA2	B-Lab_value
(	O
pT1bN0M0	B-Lab_value
)	O
.	O

Because	O
the	O
tumor	O
was	O
still	O
in	O
an	O
early	B-Detailed_description
stage	I-Detailed_description
,	O
the	O
patient	O
did	O
not	O
receive	O
adjuvant	B-Medication
treatment	I-Medication
but	O
continued	O
to	O
be	O
monitored	B-Therapeutic_procedure
through	O
regular	O
hospital	B-Nonbiological_location
visits	O
every	B-Frequency
3	I-Frequency
months	I-Frequency
.	O

The	O
patient	O
`	O
s	O
condition	B-Diagnostic_procedure
had	O
been	O
stable	B-Lab_value
until	O
the	O
onset	O
of	O
left	B-Biological_structure
chest	I-Biological_structure
pain	B-Sign_symptom
in	O
April	O
2015	O
.	O

The	O
patient	O
was	O
transferred	O
to	O
our	O
hospital	B-Nonbiological_location
(	O
a	O
tertiary	B-Nonbiological_location
care	I-Nonbiological_location
hospital	I-Nonbiological_location
)	O
for	O
further	O
treatment	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
suggested	O
a	O
significant	B-Severity
tender	B-Sign_symptom
point	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
chest	I-Biological_structure
wall	I-Biological_structure
.	O

Laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
showed	O
only	O
a	O
single	O
parameter	O
outside	O
the	O
normal	O
range	O
:	O
the	O
cytokeratin19	B-Diagnostic_procedure
fragment	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
21	I-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
(	O
CYFRA21	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
)	O
level	O
was	O
17	B-Lab_value
.	I-Lab_value
45	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
in	O
the	O
serum	B-Biological_structure
(	O
normal	O
range	O
=	O
0	O
-	O
3	O
.	O
3	O
ng	O
/	O
mL	O
)	O
.	O

CT	B-Diagnostic_procedure
and	O
PET	B-Diagnostic_procedure
/	O
CT	B-Diagnostic_procedure
scans	O
highlighted	O
the	O
serious	B-Severity
involvement	B-Sign_symptom
of	O
left	B-Biological_structure
pleura	I-Biological_structure
,	O
showing	O
bilateral	B-Detailed_description
lung	B-Biological_structure
lesions	B-Sign_symptom
(	O
Fig	O
.	O
3A	O
and	O
E	O
)	O
.	O

At	O
that	O
point	O
,	O
the	O
clinical	B-Diagnostic_procedure
stage	I-Diagnostic_procedure
was	O
upgraded	B-Lab_value
to	O
IVB	B-Lab_value
.	O

After	O
the	O
CT	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
left	B-Biological_structure
pleura	I-Biological_structure
puncture	B-Therapeutic_procedure
,	O
pathological	O
IHC	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
showed	O
positive	B-Lab_value
staining	O
for	O
p63	B-Diagnostic_procedure
,	O
p40	B-Diagnostic_procedure
,	O
CK	B-Diagnostic_procedure
7	I-Diagnostic_procedure
,	O
and	O
CK	B-Diagnostic_procedure
5	I-Diagnostic_procedure
/	I-Diagnostic_procedure
6	I-Diagnostic_procedure
,	O
while	O
TTF	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
and	O
NapsinA	B-Diagnostic_procedure
staining	O
were	O
absent	B-Lab_value
,	O
supporting	O
a	O
diagnosis	O
of	O
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
(	O
SCC	B-Disease_disorder
)	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Meanwhile	O
,	O
molecular	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
confirmed	O
an	O
L858R	B-Sign_symptom
mutation	I-Sign_symptom
in	O
exon	B-Detailed_description
21	I-Detailed_description
and	O
a	O
T790M	B-Sign_symptom
mutation	I-Sign_symptom
in	O
exon	B-Detailed_description
20	I-Detailed_description
(	O
Fig	O
.	O
4B	O
and	O
C	O
)	O
.	O

Considering	B-Other_entity
the	I-Other_entity
pathology	I-Other_entity
of	I-Other_entity
the	I-Other_entity
SCC	I-Other_entity
was	I-Other_entity
quite	I-Other_entity
distinct	I-Other_entity
compared	I-Other_entity
with	I-Other_entity
that	I-Other_entity
of	I-Other_entity
the	I-Other_entity
originally	I-Other_entity
resected	I-Other_entity
NSCLC	I-Other_entity
specimen	I-Other_entity
,	I-Other_entity
we	I-Other_entity
retrospectively	I-Other_entity
reassessed	I-Other_entity
the	I-Other_entity
surgery	I-Other_entity
specimen	I-Other_entity
to	I-Other_entity
verify	I-Other_entity
our	I-Other_entity
primary	I-Other_entity
diagnosis	I-Other_entity
.	O

The	B-Other_entity
morphologic	I-Other_entity
and	I-Other_entity
IHC	I-Other_entity
results	I-Other_entity
were	I-Other_entity
in	I-Other_entity
complete	I-Other_entity
agreement	I-Other_entity
with	I-Other_entity
the	I-Other_entity
initial	I-Other_entity
diagnoses	I-Other_entity
,	I-Other_entity
but	I-Other_entity
an	I-Other_entity
L858R	I-Other_entity
mutation	I-Other_entity
was	I-Other_entity
identified	I-Other_entity
using	I-Other_entity
the	I-Other_entity
newly	I-Other_entity
added	I-Other_entity
molecular	I-Other_entity
evaluation	I-Other_entity
(	O
Fig	O
.	O
4A	O
)	O
.	O

To	O
relieve	O
the	O
acute	O
pain	O
in	O
the	O
left	O
pleura	O
as	O
quickly	O
as	O
possible	O
,	O
palliative	B-Detailed_description
three	B-Therapeutic_procedure
-	I-Therapeutic_procedure
dimensional	I-Therapeutic_procedure
conformal	I-Therapeutic_procedure
radiotherapy	I-Therapeutic_procedure
(	O
3D	B-Therapeutic_procedure
-	I-Therapeutic_procedure
CRT	I-Therapeutic_procedure
)	O
for	O
the	O
chest	B-Biological_structure
lesion	B-Sign_symptom
was	O
delivered	O
at	O
a	O
total	O
dose	O
of	O
42	B-Dosage
Gy	I-Dosage
/	I-Dosage
14	I-Dosage
fractions	I-Dosage
(	O
f	O
)	O
,	O
once	B-Frequency
daily	I-Frequency
and	O
5f	B-Dosage
/	I-Dosage
week	I-Dosage
(	O
Fig	O
.	O
5	O
)	O
.	O

The	O
volume	B-Diagnostic_procedure
over	I-Diagnostic_procedure
radiation	I-Diagnostic_procedure
dose	I-Diagnostic_procedure
5	I-Diagnostic_procedure
Gy	I-Diagnostic_procedure
(	O
V5	O
)	O
values	O
of	O
the	O
left	B-Biological_structure
,	O
right	B-Biological_structure
,	O
and	O
total	B-Biological_structure
lungs	I-Biological_structure
were	O
20	B-Lab_value
%	I-Lab_value
,	O
0	B-Lab_value
%	I-Lab_value
,	O
and	O
7	B-Lab_value
.	I-Lab_value
8	I-Lab_value
%	I-Lab_value
,	O
respectively	O
;	O
the	O
volume	B-Diagnostic_procedure
over	I-Diagnostic_procedure
radiation	I-Diagnostic_procedure
dose	I-Diagnostic_procedure
20	I-Diagnostic_procedure
Gy	I-Diagnostic_procedure
(	O
V20	O
)	O
values	O
were	O
10	B-Lab_value
%	I-Lab_value
,	O
0	B-Lab_value
%	I-Lab_value
,	O
and	O
5	B-Lab_value
%	I-Lab_value
,	O
respectively	O
;	O
the	O
mean	B-Diagnostic_procedure
lung	I-Diagnostic_procedure
dose	I-Diagnostic_procedure
(	O
MLD	B-Diagnostic_procedure
)	O
was	O
5	B-Lab_value
Gy	I-Lab_value
.	O

Meanwhile	O
,	O
considering	O
the	O
MST	O
pathology	O
was	O
that	O
of	O
SCC	O
,	O
the	O
patient	O
received	O
GP	B-Medication
chemotherapy	I-Medication
(	O
cisplatin	B-Medication
75	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
d1	I-Dosage
,	O
gemcitabine	B-Medication
1250	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
d1	I-Dosage
,	I-Dosage
d8	I-Dosage
,	O
for	O
21	B-Detailed_description
days	I-Detailed_description
as	I-Detailed_description
a	I-Detailed_description
cycle	I-Detailed_description
)	O
for	O
4	B-Lab_value
cycles	I-Lab_value
,	O
and	O
the	O
patient	O
achieved	O
partial	B-Detailed_description
remission	B-Sign_symptom
(	O
PR	O
)	O
after	O
2	O
cycles	O
,	O
followed	O
by	O
stable	B-Disease_disorder
disease	I-Disease_disorder
(	O
SD	B-Disease_disorder
)	O
after	O
4	O
cycles	O
(	O
Fig	O
.	O
3	O
[	O
B3	O
[	O
B	O
and	O
F	O
]	O
and	O
[	O
C	O
and	O
G	O
]	O
)	O
according	O
to	O
response	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
criteria	I-Diagnostic_procedure
in	I-Diagnostic_procedure
solid	I-Diagnostic_procedure
tumors	I-Diagnostic_procedure
(	O
RECIST	B-Diagnostic_procedure
)	O
1	B-Detailed_description
.	I-Detailed_description
1	I-Detailed_description
.	O

Then	O
,	O
gefitinib	B-Medication
(	O
150	B-Dosage
mg	I-Dosage
qd	I-Dosage
)	O
was	O
used	O
as	O
maintenance	O
treatment	O
from	O
November	O
2015	O
onward	O
.	O

During	O
the	O
treatment	O
,	O
Ibandronate	B-Medication
sodium	I-Medication
was	O
given	O
monthly	B-Frequency
for	O
skeletal	B-Sign_symptom
-	I-Sign_symptom
related	I-Sign_symptom
events	I-Sign_symptom
.	O

The	O
patient	O
is	O
currently	O
under	O
surveillance	O
with	O
SD	B-Diagnostic_procedure
(	O
Fig	O
.	O
3D	O
and	O
H	O
)	O
and	O
with	O
PS	B-Diagnostic_procedure
scores	O
of	O
0	B-Lab_value
.	O

-DOCSTART- -X- -X- -X- O

A	O
65	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
with	O
a	O
45	B-Duration
-	I-Duration
year	I-Duration
history	O
of	O
cigarette	B-Activity
smoking	I-Activity
visited	O
our	O
hospital	B-Nonbiological_location
for	O
the	O
diagnosis	O
of	O
an	O
abnormal	B-Detailed_description
chest	B-Biological_structure
shadow	B-Sign_symptom
on	O
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
.	O

He	O
did	O
not	O
have	O
any	O
remarkable	O
medical	O
history	O
and	O
had	O
not	O
been	O
prescribed	O
anticoagulants	B-Medication
or	O
antiplatelet	B-Medication
agents	I-Medication
.	O

A	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
revealed	O
a	O
huge	B-Detailed_description
mass	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
upper	I-Biological_structure
lobe	I-Biological_structure
(	O
maximum	O
size	O
:	O
11	B-Distance
.	I-Distance
0	I-Distance
cm	I-Distance
in	O
diameter	O
)	O
that	O
subsequently	O
expanded	O
to	O
the	O
left	B-Biological_structure
hilum	I-Biological_structure
and	O
mediastinum	B-Biological_structure
,	O
as	O
well	O
as	O
an	O
intrapulmonary	B-Biological_structure
metastasis	B-Sign_symptom
located	O
in	O
the	O
left	B-Biological_structure
lower	I-Biological_structure
lobe	I-Biological_structure
,	O
pleural	B-Disease_disorder
effusion	I-Disease_disorder
on	O
the	O
left	B-Detailed_description
side	I-Detailed_description
,	O
and	O
multiple	B-Detailed_description
liver	B-Biological_structure
tumors	B-Sign_symptom
ranging	O
from	O
0	B-Distance
.	I-Distance
5	I-Distance
to	I-Distance
4	I-Distance
.	I-Distance
7	I-Distance
cm	I-Distance
in	O
diameter	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Of	O
note	O
,	O
some	B-Detailed_description
of	O
the	O
liver	B-Biological_structure
metastases	O
were	O
located	B-Detailed_description
subcapsularly	I-Detailed_description
,	O
and	O
the	O
liver	B-Biological_structure
surface	I-Biological_structure
was	O
irregularly	B-Detailed_description
distorted	B-Sign_symptom
.	O

The	O
laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
11,900	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
,	O
hemoglobin	B-Diagnostic_procedure
14	B-Lab_value
.	I-Lab_value
8	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
214,000	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
,	O
aspartate	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
31	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
alanine	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
19	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
lactate	B-Diagnostic_procedure
dehydrogenase	I-Diagnostic_procedure
(	O
LDH	B-Diagnostic_procedure
)	O
749	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

No	O
coagulation	B-Sign_symptom
abnormalities	I-Sign_symptom
were	O
found	O
.	O

A	O
subsequent	O
histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
a	O
tumor	B-Sign_symptom
specimen	O
obtained	O
by	O
bronchoscopy	B-Diagnostic_procedure
confirmed	O
the	O
diagnosis	O
of	O
small	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
.	O

On	O
considering	O
the	O
clinical	O
diagnosis	O
,	O
performance	O
status	O
,	O
and	O
age	O
of	O
the	O
patient	O
,	O
we	O
decided	O
on	O
a	O
regimen	O
of	O
antitumor	B-Detailed_description
chemotherapy	B-Medication
consisting	O
of	O
cisplatin	B-Medication
(	O
60	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
body	I-Dosage
surface	I-Dosage
area	I-Dosage
on	O
Day	O
1	O
)	O
and	O
etoposide	B-Medication
(	O
100	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
body	I-Dosage
surface	I-Dosage
area	I-Dosage
on	O
Days	O
1	O
-	O
3	O
)	O
.	O

On	O
a	O
day	O
after	O
2	O
weeks	O
from	O
the	O
initial	O
CT	B-Diagnostic_procedure
scan	O
,	O
he	O
started	O
his	O
first	O
chemotherapy	B-Medication
session	O
.	O

On	O
Day	O
3	O
after	O
initiating	O
chemotherapy	O
,	O
he	O
complained	O
of	O
abdominal	B-Biological_structure
discomfort	B-Sign_symptom
,	O
and	O
his	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
showed	O
tachycardia	B-Sign_symptom
(	O
120	B-Lab_value
beats	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
)	O
and	O
hypotension	B-Sign_symptom
(	O
85	B-Lab_value
/	I-Lab_value
55	I-Lab_value
mmHg	I-Lab_value
)	O
.	O

A	O
hematological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
severe	B-Severity
anemia	B-Sign_symptom
(	O
hemoglobin	B-Diagnostic_procedure
6	B-Lab_value
.	I-Lab_value
7	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
that	O
had	O
dramatically	O
dropped	B-Lab_value
from	O
14	B-Lab_value
.	I-Lab_value
8	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
over	B-Duration
10	I-Duration
days	I-Duration
.	O

We	O
attempted	O
to	O
identify	O
the	O
bleeding	O
site	O
on	O
gastrointestinal	B-Biological_structure
endoscopy	B-Diagnostic_procedure
,	O
to	O
no	O
avail	O
,	O
but	O
a	O
CT	B-Diagnostic_procedure
scan	O
revealed	O
the	O
rapid	B-Detailed_description
enlargement	B-Sign_symptom
of	O
a	O
liver	B-Biological_structure
tumor	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
lobe	I-Biological_structure
,	O
which	O
contained	O
partial	B-Detailed_description
high	B-Sign_symptom
-	I-Sign_symptom
density	I-Sign_symptom
areas	I-Sign_symptom
on	O
the	O
plain	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
,	O
and	O
also	O
a	O
novel	O
finding	O
of	O
ascites	B-Sign_symptom
showing	O
higher	B-Detailed_description
density	I-Detailed_description
than	I-Detailed_description
usual	I-Detailed_description
,	O
all	O
suggesting	O
a	O
ruptured	B-Detailed_description
liver	B-Biological_structure
metastasis	B-Sign_symptom
and	O
associated	O
hemorrhagic	B-Detailed_description
ascites	B-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

A	O
subsequent	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
image	O
was	O
negative	O
for	O
extravasation	B-Sign_symptom
.	O

He	O
underwent	O
angiography	B-Diagnostic_procedure
for	O
the	O
left	B-Biological_structure
and	I-Biological_structure
right	I-Biological_structure
hepatic	I-Biological_structure
arteries	I-Biological_structure
,	O
but	O
we	O
only	O
observed	O
obscure	B-Detailed_description
tumor	B-Sign_symptom
vessels	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
hepatic	I-Biological_structure
lobe	I-Biological_structure
without	O
extravasation	B-Sign_symptom
(	O
Fig	O
.	O
3A	O
)	O
.	O

We	O
suspected	O
this	O
might	O
be	O
due	O
to	O
the	O
hypovascularity	O
of	O
the	O
metastatic	O
tumors	O
and	O
inactive	O
bleeding	O
at	O
the	O
time	O
.	O

Although	O
the	O
benefit	O
of	O
therapeutic	O
embolization	O
of	O
the	O
hepatic	O
artery	O
was	O
uncertain	O
based	O
on	O
the	O
findings	O
on	O
angiography	O
,	O
we	O
performed	O
transcatheter	B-Therapeutic_procedure
arterial	I-Therapeutic_procedure
embolization	I-Therapeutic_procedure
(	O
TAE	B-Therapeutic_procedure
)	O
of	O
the	O
left	B-Biological_structure
main	I-Biological_structure
hepatic	I-Biological_structure
artery	I-Biological_structure
using	O
gelform	B-Therapeutic_procedure
particles	I-Therapeutic_procedure
to	O
prevent	O
future	O
re	O
-	O
bleeding	O
.	O

Post	O
-	O
embolization	O
angiography	B-Diagnostic_procedure
revealed	O
a	O
slowed	B-Lab_value
blood	B-Diagnostic_procedure
flow	I-Diagnostic_procedure
in	O
the	O
left	B-Biological_structure
hepatic	I-Biological_structure
artery	I-Biological_structure
,	O
and	O
the	O
peripheral	O
vessels	O
were	O
weakly	O
visualized	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

After	O
the	O
embolization	O
concomitant	O
with	O
supportive	B-Therapeutic_procedure
therapies	I-Therapeutic_procedure
,	O
including	O
RBC	B-Medication
transfusions	O
of	O
6	B-Dosage
U	I-Dosage
in	O
total	O
,	O
the	O
clinical	B-Diagnostic_procedure
course	I-Diagnostic_procedure
of	O
the	O
patient	O
stabilized	B-Lab_value
.	O

His	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
remained	O
around	O
120	B-Lab_value
/	I-Lab_value
70	I-Lab_value
mmHg	I-Lab_value
,	O
tachycardia	B-Sign_symptom
disappeared	O
,	O
and	O
the	O
anemia	B-Sign_symptom
was	O
improved	O
after	O
transfusion	O
and	O
did	O
not	O
progress	O
again	O
.	O

Liver	B-Biological_structure
dysfunction	B-Sign_symptom
did	O
not	O
appear	O
.	O

A	O
month	O
after	O
the	O
embolization	O
,	O
he	O
was	O
in	O
relatively	B-Lab_value
good	I-Lab_value
health	B-Diagnostic_procedure
and	O
re	O
-	O
started	O
his	O
antitumor	B-Detailed_description
chemotherapy	B-Medication
,	O
which	O
he	O
continued	O
(	O
first	O
-	O
line	O
regimen	O
)	O
for	O
six	B-Dosage
courses	I-Dosage
.	O

A	O
good	B-Lab_value
partial	B-Lab_value
response	B-Diagnostic_procedure
was	O
gained	O
after	O
chemotherapy	B-Medication
for	O
both	O
the	O
lung	B-Biological_structure
and	O
liver	B-Biological_structure
lesions	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

An	O
82	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
transferred	O
to	O
our	O
hospital	B-Nonbiological_location
because	O
of	O
dyspnea	B-Sign_symptom
and	O
massive	B-Severity
hemoptysis	B-Sign_symptom
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
that	O
was	O
well	O
-	O
controlled	O
with	O
bronchodilator	O
medications	O
.	O

She	O
had	O
no	O
history	O
of	O
tuberculosis	O
,	O
nontuberculous	O
mycobacterial	O
infection	O
,	O
or	O
smoking	O
.	O

The	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
diffuse	B-Detailed_description
bilateral	B-Detailed_description
crackles	B-Sign_symptom
.	O

She	O
suffered	O
from	O
severe	B-Severity
hypoxemia	B-Sign_symptom
(	O
pH	B-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
362	I-Lab_value
,	O
PCO2	B-Diagnostic_procedure
35	B-Lab_value
.	I-Lab_value
1	I-Lab_value
mmHg	I-Lab_value
,	O
PO2	B-Diagnostic_procedure
61	B-Lab_value
.	I-Lab_value
0	I-Lab_value
mmHg	I-Lab_value
,	O
HCO3	B-Diagnostic_procedure
-	I-Diagnostic_procedure
20	B-Lab_value
.	I-Lab_value
1	I-Lab_value
mmHg	I-Lab_value
,	O
BE	B-Diagnostic_procedure
-	B-Lab_value
5	I-Lab_value
.	I-Lab_value
5	I-Lab_value
mmHg	I-Lab_value
,	O
SpO2	B-Diagnostic_procedure
90	B-Lab_value
.	I-Lab_value
5	I-Lab_value
%	I-Lab_value
,	O
under	B-Lab_value
10	I-Lab_value
L	I-Lab_value
O2	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
reservoir	B-Detailed_description
mask	I-Detailed_description
)	O
.	O

After	O
the	O
tracheal	B-Biological_structure
intubation	B-Therapeutic_procedure
,	O
100	B-Volume
mL	I-Volume
of	O
bright	B-Color
-	I-Color
red	I-Color
blood	B-Biological_structure
was	O
aspirated	B-Sign_symptom
.	O

A	O
chest	B-Biological_structure
radiograph	B-Diagnostic_procedure
showed	O
bilateral	B-Detailed_description
infiltrates	B-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
chest	B-Biological_structure
CT	B-Diagnostic_procedure
further	O
demonstrated	O
multiple	B-Detailed_description
consolidations	B-Sign_symptom
and	O
ground	B-Texture
glass	I-Texture
opacity	B-Sign_symptom
and	O
focal	B-Detailed_description
bronchiectasis	B-Disease_disorder
in	O
right	B-Biological_structure
segment	I-Biological_structure
4	I-Biological_structure
(	O
S4	B-Biological_structure
)	O
(	O
Fig	O
.	O
2	O
)	O
.	O

There	O
were	O
no	O
space	B-Detailed_description
-	I-Detailed_description
occupying	I-Detailed_description
lesions	B-Sign_symptom
.	O

Four	O
days	O
after	O
admission	O
,	O
her	O
respiratory	B-Diagnostic_procedure
condition	I-Diagnostic_procedure
was	O
improved	B-Lab_value
.	O

Since	O
there	O
was	O
no	O
active	B-Detailed_description
hemorrhaging	B-Sign_symptom
from	O
the	O
tracheal	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
,	O
she	O
was	O
then	O
extubated	B-Therapeutic_procedure
.	O

After	O
that	O
,	O
only	O
a	O
small	B-Severity
amount	I-Severity
of	O
bloody	B-Detailed_description
sputum	B-Sign_symptom
was	O
coughed	O
up	O
.	O

To	O
determine	O
the	O
origin	O
of	O
bleeding	O
,	O
she	O
underwent	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
,	O
which	O
showed	O
bronchiectasis	B-Disease_disorder
in	O
right	B-Biological_structure
S4	I-Biological_structure
and	O
regression	O
of	O
the	O
infiltration	B-Sign_symptom
.	O

CTA	B-Diagnostic_procedure
revealed	O
an	O
abnormal	B-Detailed_description
vascular	B-Biological_structure
anastomosis	B-Disease_disorder
between	O
the	O
right	B-Biological_structure
inferior	I-Biological_structure
phrenic	I-Biological_structure
artery	I-Biological_structure
and	O
right	B-Biological_structure
pulmonary	I-Biological_structure
artery	I-Biological_structure
beside	O
the	O
focal	B-Detailed_description
bronchiectasis	B-Disease_disorder
at	O
the	O
right	B-Biological_structure
middle	I-Biological_structure
lobe	I-Biological_structure
(	O
Fig	O
.	O
3	O
)	O
,	O
which	O
led	O
us	O
to	O
suspect	O
it	O
as	O
the	O
possible	O
source	O
of	O
the	O
massive	B-Severity
hemoptysis	B-Sign_symptom
.	O

We	O
therefore	O
performed	O
embolization	B-Therapeutic_procedure
by	O
superselecting	B-Therapeutic_procedure
the	O
right	B-Biological_structure
inferior	I-Biological_structure
phrenic	I-Biological_structure
artery	I-Biological_structure
with	O
a	O
2	B-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
-	I-Detailed_description
Fr	I-Detailed_description
.	I-Detailed_description
microcatheter	I-Detailed_description
(	O
Fig	O
.	O
4	O
)	O
.	O

An	O
angiogram	B-Diagnostic_procedure
of	O
the	O
right	B-Biological_structure
bronchial	I-Biological_structure
artery	I-Biological_structure
showed	O
no	O
obvious	O
active	B-Detailed_description
bleeding	B-Sign_symptom
.	O

Three	O
weeks	O
after	O
the	O
embolization	O
,	O
she	O
was	O
successfully	O
discharged	O
and	O
has	O
been	O
free	O
from	O
recurrent	B-Detailed_description
hemoptysis	B-Sign_symptom
for	O
three	B-Duration
years	I-Duration
.	O

-DOCSTART- -X- -X- -X- O

A	O
65	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
reported	O
persistent	B-Detailed_description
back	B-Biological_structure
pain	B-Sign_symptom
for	O
almost	B-Duration
3	I-Duration
months	I-Duration
.	O

The	O
symptoms	O
would	O
be	O
severe	B-Severity
after	O
walking	B-Activity
or	O
changing	B-Activity
positions	I-Activity
and	O
would	O
be	O
slightly	O
relieve	B-Sign_symptom
after	O
taking	O
painkillers	B-Medication
.	O

The	O
patient	O
described	O
no	O
pain	B-Sign_symptom
or	O
numbness	B-Sign_symptom
in	O
her	O
legs	B-Biological_structure
.	O

She	O
also	O
described	O
no	O
bowel	B-Biological_structure
or	O
bladder	B-Biological_structure
voiding	B-Sign_symptom
difficulties	I-Sign_symptom
.	O

The	O
patient	O
reported	O
past	O
medical	O
history	O
of	O
hypertension	O
,	O
coronary	O
heart	O
disease	O
,	O
cerebral	O
infarction	O
,	O
and	O
asthma	O
,	O
all	O
of	O
which	O
were	O
well	O
controlled	O
.	O

Physical	B-Diagnostic_procedure
exam	I-Diagnostic_procedure
demonstrated	O
kyphosis	B-Disease_disorder
of	O
the	O
thoracic	B-Biological_structure
spine	I-Biological_structure
in	B-Detailed_description
standing	I-Detailed_description
position	I-Detailed_description
and	O
lumbar	B-Detailed_description
vertebra	I-Detailed_description
bend	I-Detailed_description
forward	I-Detailed_description
and	I-Detailed_description
backward	I-Detailed_description
straight	O
activities	O
were	O
limited	O
.	O

There	O
is	O
obvious	O
rap	B-Detailed_description
pain	B-Sign_symptom
in	O
back	B-Biological_structure
about	O
T12	B-Biological_structure
level	O
.	O

The	O
patient	O
`	O
s	O
general	B-Diagnostic_procedure
medical	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
in	O
upper	B-Biological_structure
and	I-Biological_structure
lower	I-Biological_structure
extremity	I-Biological_structure
motor	I-Biological_structure
,	O
stretch	B-Detailed_description
reflex	I-Detailed_description
,	O
and	O
sensory	B-Biological_structure
examinations	B-Diagnostic_procedure
.	O

X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
,	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
,	O
and	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
exams	O
were	O
performed	O
after	O
the	O
patient	O
in	O
hospital	B-Nonbiological_location
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
lateral	B-Detailed_description
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
T12	B-Biological_structure
fracture	B-Disease_disorder
with	O
40	B-Lab_value
°	I-Lab_value
kyphotic	I-Lab_value
cobb	B-Diagnostic_procedure
angle	I-Diagnostic_procedure
.	O

CT	B-Diagnostic_procedure
showed	O
an	O
intravertebral	B-Sign_symptom
vacuum	I-Sign_symptom
sign	I-Sign_symptom
.	O

Sagittal	B-Detailed_description
T1	I-Detailed_description
-	I-Detailed_description
weighted	I-Detailed_description
MRI	B-Diagnostic_procedure
showed	O
a	O
decreased	B-Detailed_description
signal	I-Detailed_description
intravertebral	B-Sign_symptom
vacuum	I-Sign_symptom
cleft	I-Sign_symptom
and	O
posterior	B-Biological_structure
cortex	I-Biological_structure
breakage	B-Disease_disorder
with	O
cord	B-Sign_symptom
compression	I-Sign_symptom
in	O
T12	B-Biological_structure
.	O

Sagittal	B-Detailed_description
T2	I-Detailed_description
-	I-Detailed_description
weighted	I-Detailed_description
MRI	B-Diagnostic_procedure
showed	O
an	O
increased	B-Detailed_description
signal	I-Detailed_description
in	O
the	O
intravertebral	B-Sign_symptom
vacuum	I-Sign_symptom
cleft	I-Sign_symptom
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
Kümmell	B-Disease_disorder
disease	I-Disease_disorder
(	O
Stage	B-Lab_value
III	I-Lab_value
)	O
.	O
[	O
9	O
]	O

The	O
operation	B-Therapeutic_procedure
was	O
performed	O
under	O
general	B-Medication
anesthesia	I-Medication
and	O
prone	B-Detailed_description
position	I-Detailed_description
.	O

A	O
standard	B-Detailed_description
posterior	B-Therapeutic_procedure
exposure	I-Therapeutic_procedure
of	O
the	O
spine	B-Biological_structure
was	O
given	O
,	O
pedicle	B-Therapeutic_procedure
screws	I-Therapeutic_procedure
were	O
inserted	O
in	O
target	O
vertebrae	B-Biological_structure
T10	B-Biological_structure
,	O
T11	B-Biological_structure
,	O
L1	B-Biological_structure
,	O
and	O
L2	B-Biological_structure
under	O
C	B-Detailed_description
-	I-Detailed_description
arm	I-Detailed_description
guidance	I-Detailed_description
.	O
[	O
10	O
]	O
The	O
screws	O
were	O
connected	B-Detailed_description
on	I-Detailed_description
the	I-Detailed_description
left	I-Detailed_description
side	I-Detailed_description
with	I-Detailed_description
a	I-Detailed_description
temporary	I-Detailed_description
stabilizing	I-Detailed_description
rod	I-Detailed_description
.	O

Laminectomy	B-Therapeutic_procedure
was	O
performed	O
to	O
decompress	O
and	O
fully	O
visualize	O
the	O
spinal	O
cord	O
.	O
[	O
10	O
]	O
Careful	O
subperiosteal	B-Therapeutic_procedure
dissection	I-Therapeutic_procedure
was	O
carried	O
out	O
on	O
the	O
right	B-Detailed_description
side	I-Detailed_description
to	O
exposure	O
the	O
lateral	B-Biological_structure
wall	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
T12	I-Biological_structure
vertebral	I-Biological_structure
body	I-Biological_structure
until	O
the	O
anterior	O
aspect	O
was	O
reached	O
.	O

The	O
right	B-Biological_structure
side	I-Biological_structure
pedicle	I-Biological_structure
and	O
articular	B-Biological_structure
process	I-Biological_structure
of	O
the	O
T12	B-Biological_structure
vertebral	I-Biological_structure
body	I-Biological_structure
were	O
removed	B-Therapeutic_procedure
.	O

T11	B-Biological_structure
/	I-Biological_structure
T12	I-Biological_structure
and	O
T12	B-Biological_structure
/	I-Biological_structure
L1	I-Biological_structure
intervertebral	B-Biological_structure
disks	I-Biological_structure
were	O
also	O
removed	B-Therapeutic_procedure
.	O

Then	O
,	O
the	O
temporary	B-Detailed_description
stabilizing	I-Detailed_description
rod	B-Therapeutic_procedure
was	O
replaced	O
by	O
rod	B-Therapeutic_procedure
bended	B-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
desired	I-Detailed_description
contour	I-Detailed_description
.	O

Autologous	B-Detailed_description
bone	B-Therapeutic_procedure
graft	I-Therapeutic_procedure
and	O
titanium	B-Therapeutic_procedure
mesh	I-Therapeutic_procedure
were	O
placed	O
in	O
the	O
intervertebral	B-Biological_structure
space	I-Biological_structure
.	O

Another	B-Detailed_description
rod	B-Therapeutic_procedure
with	B-Detailed_description
the	I-Detailed_description
desired	I-Detailed_description
contour	I-Detailed_description
was	O
connected	O
on	O
the	O
right	B-Detailed_description
side	I-Detailed_description
.	O

Adequate	O
hemostasis	B-Therapeutic_procedure
was	O
ensured	O
and	O
wound	B-Biological_structure
was	O
thoroughly	O
irrigated	B-Therapeutic_procedure
with	I-Therapeutic_procedure
saline	I-Therapeutic_procedure
.	O

Drainage	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
was	O
inserted	O
and	O
the	O
surgical	B-Biological_structure
wound	I-Biological_structure
was	O
closed	B-Therapeutic_procedure
layer	B-Detailed_description
-	I-Detailed_description
by	I-Detailed_description
-	I-Detailed_description
layer	I-Detailed_description
.	O
[	O
10	O
]	O
Time	O
from	O
skin	O
incision	O
to	O
completion	O
of	O
wound	O
closure	O
lasted	O
150	B-Duration
minutes	I-Duration
,	O
and	O
estimated	O
blood	B-Disease_disorder
loss	I-Disease_disorder
totaled	O
600	B-Volume
mL	I-Volume
.	O

Postoperatively	O
,	O
the	O
patient	O
was	O
given	O
preventive	O
antibiotic	B-Medication
treatment	O
for	O
1	B-Duration
day	I-Duration
,	O
pain	B-Medication
treatment	I-Medication
for	O
3	B-Duration
days	I-Duration
,	O
and	O
anticoagulant	B-Medication
therapy	O
for	O
1	B-Duration
week	I-Duration
.	O

The	O
drainage	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
was	O
removed	O
at	O
3	O
days	O
postoperative	O
when	O
volume	B-Diagnostic_procedure
of	I-Diagnostic_procedure
drainage	I-Diagnostic_procedure
was	O
less	B-Lab_value
than	I-Lab_value
50	I-Lab_value
mL	I-Lab_value
per	I-Lab_value
24	I-Lab_value
hours	I-Lab_value
.	O

Patient	O
was	O
allowed	O
out	O
of	O
bed	B-Nonbiological_location
with	O
a	O
custom	B-Detailed_description
-	I-Detailed_description
made	I-Detailed_description
plastic	B-Detailed_description
orthosis	B-Therapeutic_procedure
at	O
1	O
week	O
after	O
operation	O
.	O

The	O
plastic	O
orthosis	O
was	O
kept	O
for	O
at	B-Duration
least	I-Duration
3	I-Duration
months	I-Duration
.	O

The	O
patient	O
was	O
allowed	O
out	O
of	O
hospital	B-Nonbiological_location
at	O
12	O
days	O
after	O
operation	O
when	O
surgical	B-Therapeutic_procedure
suture	I-Therapeutic_procedure
had	O
been	O
removed	O
.	O

Pain	B-Diagnostic_procedure
assessments	I-Diagnostic_procedure
were	O
conducted	O
using	O
the	O
visual	B-Diagnostic_procedure
analogue	I-Diagnostic_procedure
scale	I-Diagnostic_procedure
(	O
VAS	B-Diagnostic_procedure
)	O
.	O

VAS	O
for	O
preoperative	O
,	O
1	O
week	O
after	O
operation	O
,	O
and	O
1	O
year	O
after	O
operation	O
were	O
9	B-Lab_value
score	I-Lab_value
,	O
3	B-Lab_value
score	I-Lab_value
,	O
and	O
2	B-Lab_value
score	I-Lab_value
,	O
respectively	O
,	O
which	O
demonstrated	O
significant	O
improvement	B-Lab_value
.	O

The	O
patient	O
resumed	O
normal	B-Activity
activities	I-Activity
and	O
returned	B-Activity
to	I-Activity
work	I-Activity
at	O
3	O
months	O
after	O
operation	O
.	O

Kyphotic	B-Lab_value
Cobb	B-Diagnostic_procedure
angle	I-Diagnostic_procedure
for	O
preoperative	O
,	O
1	O
week	O
after	O
operation	O
,	O
and	O
1	O
year	O
after	O
operation	O
were	O
40	B-Lab_value
°	I-Lab_value
,	O
8	B-Lab_value
°	I-Lab_value
,	O
and	O
17	B-Lab_value
°	I-Lab_value
,	O
respectively	O
,	O
which	O
demonstrated	O
significant	O
improvement	B-Lab_value
(	O
Fig	O
.	O
2	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
57	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
with	O
5	B-Duration
months	I-Duration
`	O
history	O
of	O
massive	B-Severity
rectal	B-Biological_structure
bleeding	B-Sign_symptom
(	O
rectorrhagia	O
)	O
.	O

He	O
had	O
past	O
history	O
of	O
passage	B-Sign_symptom
of	I-Sign_symptom
fresh	I-Sign_symptom
blood	I-Sign_symptom
mixed	I-Sign_symptom
stool	I-Sign_symptom
since	O
last	B-Duration
55	I-Duration
years	I-Duration
.	O

He	O
first	O
complained	O
of	O
rectal	B-Biological_structure
bleeding	B-Sign_symptom
at	O
the	O
age	O
of	O
2	O
.	O

He	O
went	O
hospital	B-Nonbiological_location
numerous	O
times	O
for	O
this	O
symptom	O
;	O
multiple	O
interventions	B-Therapeutic_procedure
were	O
done	O
but	O
disease	O
was	O
not	O
cured	O
completely	O
.	O

During	O
one	O
of	O
his	O
hospital	O
visit	O
in	O
the	O
past	O
(	O
patient	O
forgot	O
the	O
date	O
)	O
,	O
he	O
was	O
diagnosed	O
and	O
treated	O
as	O
hemorrhoids	O
.	O

The	O
symptom	B-Sign_symptom
was	O
relieved	O
for	O
a	B-Duration
while	I-Duration
and	O
then	O
recurred	B-Sign_symptom
again	O
.	O

Thirty	O
years	O
ago	O
,	O
he	O
was	O
diagnosed	O
as	O
rectal	B-Biological_structure
hemangioma	B-Disease_disorder
and	O
managed	O
with	O
cryotherapy	B-Therapeutic_procedure
in	O
our	O
hospital	B-Nonbiological_location
.	O

That	O
could	O
also	O
just	O
relieve	O
the	O
symptom	B-Sign_symptom
for	O
few	B-Duration
years	I-Duration
and	O
it	O
recurred	B-Sign_symptom
again	O
.	O

Then	O
,	O
he	O
consulted	O
many	B-Nonbiological_location
other	I-Nonbiological_location
hospitals	I-Nonbiological_location
,	O
but	O
could	O
only	O
get	O
short	B-Detailed_description
-	I-Detailed_description
term	I-Detailed_description
symptomatic	B-Sign_symptom
relief	I-Sign_symptom
without	O
proper	O
treatment	O
of	O
the	O
cause	O
.	O

Since	B-Duration
5	I-Duration
months	I-Duration
,	O
the	O
severity	O
of	O
rectal	B-Biological_structure
bleeding	B-Sign_symptom
increased	O
.	O

He	O
then	O
went	O
to	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
where	O
intervention	B-Therapeutic_procedure
was	O
done	O
to	O
control	O
bleeding	B-Sign_symptom
and	O
symptomatic	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
was	O
done	O
with	O
intravenous	O
fluid	B-Medication
and	O
blood	B-Therapeutic_procedure
transfusion	I-Therapeutic_procedure
.	O

He	O
finally	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
further	O
evaluation	O
.	O

Intermediate	B-Severity
rectal	B-Biological_structure
bleeding	B-Sign_symptom
of	O
fresh	B-Detailed_description
blood	I-Detailed_description
was	O
presented	O
on	O
admission	O
.	O

Patient	O
complained	O
of	O
dizziness	B-Sign_symptom
on	O
standing	B-Detailed_description
,	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
,	O
and	O
palpitation	B-Sign_symptom
on	O
walking	B-Detailed_description
a	I-Detailed_description
short	I-Detailed_description
distance	I-Detailed_description
.	O

There	O
was	O
no	O
history	O
of	O
similar	O
illness	O
in	O
family	O
.	O

On	O
general	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
patient	O
appeared	O
pale	B-Sign_symptom
,	O
but	O
his	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
and	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limit	I-Lab_value
during	O
rest	O
.	O

He	O
lost	B-Lab_value
5	I-Lab_value
kg	I-Lab_value
of	O
his	O
body	B-Diagnostic_procedure
weight	I-Diagnostic_procedure
during	B-Duration
last	I-Duration
5	I-Duration
months	I-Duration
.	O

On	O
rectal	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
fresh	B-Sign_symptom
blood	I-Sign_symptom
was	O
seen	O
around	B-Biological_structure
anal	I-Biological_structure
region	I-Biological_structure
and	O
soft	B-Texture
mass	B-Sign_symptom
was	O
felt	O
on	O
digital	B-Diagnostic_procedure
rectal	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
.	O

On	O
proctoscopy	B-Diagnostic_procedure
,	O
anal	B-Biological_structure
cavity	I-Biological_structure
and	O
rectum	B-Biological_structure
were	O
seen	O
filled	O
with	O
fresh	B-Sign_symptom
blood	I-Sign_symptom
,	O
but	O
active	B-Sign_symptom
site	I-Sign_symptom
of	I-Sign_symptom
bleeding	I-Sign_symptom
,	O
polyp	B-Sign_symptom
,	O
or	O
ulcer	B-Sign_symptom
was	O
not	O
detected	O
.	O

On	O
laboratory	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
red	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
3	B-Lab_value
.	I-Lab_value
09	I-Lab_value
×	I-Lab_value
1012	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
Normal	O
:	O
4	O
.	O
32	O
-	O
5	O
.	O
72	O
×	O
1012	O
/	O
L	O
)	O
and	O
hemoglobin	B-Diagnostic_procedure
was	O
86	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
Normal	O
:	O
135	O
-	O
175	O
g	O
/	O
L	O
)	O
.	O

All	B-Diagnostic_procedure
other	I-Diagnostic_procedure
parameters	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limit	I-Lab_value
.	O

None	B-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
showed	O
isodense	B-Detailed_description
(	O
35	B-Lab_value
HU	I-Lab_value
)	O
homogenous	B-Detailed_description
bowel	B-Biological_structure
wall	I-Biological_structure
thickening	B-Sign_symptom
that	O
on	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
venous	B-Detailed_description
phase	I-Detailed_description
enhances	B-Sign_symptom
heterogeneously	B-Detailed_description
.	O

Multiple	B-Detailed_description
calcifications	B-Sign_symptom
were	O
seen	O
in	O
the	O
thickened	B-Biological_structure
bowel	I-Biological_structure
wall	I-Biological_structure
and	O
around	O
the	O
peri	B-Biological_structure
-	I-Biological_structure
rectal	I-Biological_structure
area	I-Biological_structure
.	O

Lesion	B-Sign_symptom
was	O
seen	O
extending	O
from	O
distal	B-Biological_structure
sigmoid	I-Biological_structure
to	O
whole	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
rectum	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Multiple	B-Detailed_description
hypodense	B-Detailed_description
lesions	B-Sign_symptom
were	O
also	O
seen	O
in	O
spleen	B-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

After	O
initial	O
management	B-Therapeutic_procedure
of	O
anemia	B-Sign_symptom
,	O
the	O
patient	O
underwent	O
abdominal	B-Biological_structure
laparotomy	B-Therapeutic_procedure
followed	O
by	O
surgical	B-Therapeutic_procedure
excision	I-Therapeutic_procedure
.	O

During	O
surgery	O
,	O
25	B-Distance
cm	I-Distance
long	O
lesion	B-Sign_symptom
was	O
found	O
extending	O
from	O
distal	B-Biological_structure
sigmoid	I-Biological_structure
to	O
whole	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
rectum	I-Biological_structure
.	O

Whole	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
rectum	I-Biological_structure
and	O
part	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
sigmoid	I-Biological_structure
colon	I-Biological_structure
were	O
excised	B-Therapeutic_procedure
and	O
sigmoid	B-Detailed_description
-	I-Detailed_description
anus	I-Detailed_description
anastomosis	B-Therapeutic_procedure
was	O
done	O
.	O

Postsurgical	O
histopathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
excised	B-Detailed_description
specimen	I-Detailed_description
showed	O
submucosal	B-Detailed_description
multiple	I-Detailed_description
thin	I-Detailed_description
-	I-Detailed_description
walled	I-Detailed_description
vessel	I-Detailed_description
of	O
varying	B-Lab_value
size	I-Lab_value
with	O
interposed	B-Lab_value
stroma	I-Lab_value
.	O

Some	B-Lab_value
vessels	I-Lab_value
lumen	I-Lab_value
consisted	I-Lab_value
of	I-Lab_value
blood	I-Lab_value
cells	I-Lab_value
(	O
consistent	O
with	O
blood	O
vessel	O
)	O
,	O
whereas	O
other	B-Lab_value
consisted	I-Lab_value
of	I-Lab_value
clear	I-Lab_value
fluid	I-Lab_value
(	O
consistent	O
with	O
lymph	O
vessel	O
)	O
.	O

Immunohistochemistry	B-Diagnostic_procedure
of	O
specimen	O
showed	O
endothelial	B-Biological_structure
cells	I-Biological_structure
positive	B-Lab_value
for	O
CD	B-Diagnostic_procedure
31	I-Diagnostic_procedure
and	O
CD	B-Diagnostic_procedure
34	I-Diagnostic_procedure
.	O

Some	B-Biological_structure
cells	I-Biological_structure
were	O
positive	B-Lab_value
for	O
D2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
40	I-Diagnostic_procedure
,	O
while	O
others	B-Biological_structure
were	O
negative	B-Lab_value
for	O
D2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
40	I-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

On	O
the	O
basis	O
of	O
histopathological	O
report	O
and	O
immunohistochemistry	O
,	O
hemolymphangioma	B-Disease_disorder
was	O
diagnosed	O
.	O

The	O
surgery	O
,	O
which	O
followed	O
by	O
complication	O
(	O
intestinal	B-Biological_structure
infection	B-Disease_disorder
)	O
,	O
was	O
well	O
managed	B-Therapeutic_procedure
and	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	B-Nonbiological_location
on	O
the	O
23rd	O
day	O
of	O
surgery	O
.	O

Then	O
after	O
,	O
no	O
further	O
complication	B-Sign_symptom
or	O
recurrence	B-Sign_symptom
was	O
noticed	O
during	O
6	B-Duration
months	I-Duration
`	I-Duration
follow	O
-	O
up	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Sun	O
Yat	O
-	O
Sen	O
University	O
Institutional	O
Review	O
Board	O
.	O

Written	O
consent	O
for	O
this	O
case	O
report	O
was	O
obtained	O
from	O
the	O
patient	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
21	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
patient	O
presented	O
to	O
the	O
closest	B-Nonbiological_location
emergency	I-Nonbiological_location
department	I-Nonbiological_location
at	O
8	B-Time
PM	I-Time
for	O
nausea	B-Sign_symptom
,	O
numbness	B-Sign_symptom
of	O
the	O
left	B-Biological_structure
limbs	I-Biological_structure
,	O
incoordination	B-Sign_symptom
of	I-Sign_symptom
walking	I-Sign_symptom
and	O
dysarthria	B-Sign_symptom
,	O
with	O
the	O
symptomatology	B-Sign_symptom
installed	O
in	O
a	O
progressive	B-Detailed_description
mode	O
4	B-Time
hours	I-Time
before	I-Time
presentation	O
.	O

The	O
nausea	B-Sign_symptom
was	O
the	O
initial	O
symptom	O
,	O
starting	O
at	O
4	B-Time
PM	I-Time
(	O
without	O
headache	B-Sign_symptom
,	O
nuchal	B-Biological_structure
pain	B-Sign_symptom
,	O
or	O
vomit	B-Sign_symptom
)	O
and	O
then	O
,	O
after	B-Time
5	I-Time
.	I-Time
30	I-Time
PM	I-Time
,	O
the	O
numbness	B-Sign_symptom
of	O
the	O
left	B-Biological_structure
limbs	I-Biological_structure
and	O
the	O
incoordination	B-Sign_symptom
of	I-Sign_symptom
walking	I-Sign_symptom
and	O
by	O
7	B-Time
PM	I-Time
dysarthria	B-Sign_symptom
was	O
added	O
to	O
the	O
entire	O
clinical	O
constellation	O
.	O

The	O
patient	O
did	O
not	O
have	O
a	O
medical	O
history	O
or	O
a	O
current	O
medication	O
.	O

He	O
was	O
a	O
student	B-Occupation
.	O

He	O
did	O
not	O
smoke	O
and	O
did	O
not	O
use	O
recreational	O
drugs	O
.	O

He	O
only	O
drank	O
alcohol	O
occasionally	O
.	O

There	O
was	O
no	O
family	O
history	O
of	O
thromboembolism	O
,	O
cardiovascular	O
problems	O
,	O
or	O
hematologic	O
diseases	O
.	O

He	O
was	O
first	O
evaluated	B-Diagnostic_procedure
by	O
a	O
neurosurgeon	B-Nonbiological_location
in	O
the	O
emergency	B-Nonbiological_location
unit	I-Nonbiological_location
and	O
had	O
a	O
brain	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
that	O
highlighted	O
infracentimetric	B-Detailed_description
hypodensity	B-Sign_symptom
in	O
the	O
thalamic	B-Biological_structure
nucleus	I-Biological_structure
,	O
on	O
the	O
left	B-Detailed_description
side	I-Detailed_description
and	O
at	O
the	O
level	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
cerebellar	I-Biological_structure
hemisphere	I-Biological_structure
in	O
the	O
PICA	B-Biological_structure
territory	I-Biological_structure
,	O
and	O
also	O
a	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
that	O
revealed	O
a	O
widened	B-Sign_symptom
projection	I-Sign_symptom
area	I-Sign_symptom
of	O
the	O
right	B-Biological_structure
side	I-Biological_structure
hilum	I-Biological_structure
,	O
without	O
any	O
other	B-Sign_symptom
pathological	I-Sign_symptom
findings	I-Sign_symptom
.	O

Following	O
this	O
evaluation	O
,	O
he	O
was	O
sent	O
to	O
the	O
National	B-Nonbiological_location
Institute	I-Nonbiological_location
of	I-Nonbiological_location
Neurology	I-Nonbiological_location
and	I-Nonbiological_location
Cerebrovascular	I-Nonbiological_location
Diseases	I-Nonbiological_location
for	O
consultation	O
and	O
special	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
.	O

During	O
the	O
ambulance	B-Detailed_description
transportation	O
,	O
he	O
had	O
repeated	B-Detailed_description
episodes	O
of	O
vomiting	B-Sign_symptom
.	O

The	O
initial	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
(	O
at	O
10	B-Time
P	I-Time
.	I-Time
M	I-Time
)	O
showed	O
normal	B-Lab_value
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
:	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
130	B-Lab_value
/	I-Lab_value
80mmHg	I-Lab_value
,	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
100	B-Lab_value
beats	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
and	O
normal	B-Lab_value
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
36,8	B-Lab_value
°C	I-Lab_value
.	O

The	O
cardiopulmonary	B-Diagnostic_procedure
exam	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

No	O
carotid	B-Sign_symptom
bruits	I-Sign_symptom
were	O
registered	O
.	O

The	O
neurological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
notable	O
for	O
normal	B-Lab_value
orientation	I-Lab_value
.	O

The	O
patient	O
had	O
equal	B-Lab_value
,	O
reactive	B-Lab_value
pupils	B-Diagnostic_procedure
,	O
divergent	B-Detailed_description
strabismus	B-Sign_symptom
to	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
,	O
horizontal	B-Detailed_description
nystagmus	B-Sign_symptom
,	O
normal	B-Lab_value
deglutition	B-Diagnostic_procedure
,	O
mild	B-Severity
paresis	B-Disease_disorder
of	O
the	O
left	B-Biological_structure
arm	I-Biological_structure
,	O
ataxia	B-Disease_disorder
of	O
all	B-Biological_structure
limbs	I-Biological_structure
,	O
with	O
an	O
accent	B-Biological_structure
on	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
extremities	I-Biological_structure
,	O
numbness	B-Sign_symptom
of	O
the	O
left	B-Biological_structure
limbs	I-Biological_structure
,	O
bilateral	B-Lab_value
response	I-Lab_value
present	O
at	O
all	B-Biological_structure
deep	I-Biological_structure
tendons	I-Biological_structure
reflex	B-Diagnostic_procedure
,	O
Babinski	B-Sign_symptom
sign	I-Sign_symptom
on	O
the	O
left	B-Detailed_description
side	I-Detailed_description
,	O
stereotypical	B-Lab_value
language	B-Diagnostic_procedure
.	O

The	O
patient	O
was	O
able	B-Detailed_description
to	I-Detailed_description
repeat	I-Detailed_description
a	I-Detailed_description
few	I-Detailed_description
words	I-Detailed_description
and	I-Detailed_description
fragment	I-Detailed_description
of	I-Detailed_description
phrases	I-Detailed_description
and	O
to	O
perform	B-Detailed_description
simple	I-Detailed_description
commands	I-Detailed_description
of	I-Detailed_description
medium	I-Detailed_description
complexity	I-Detailed_description
.	O

The	O
laboratory	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
highlighted	O
a	O
normal	B-Lab_value
hemoleucogram	B-Diagnostic_procedure
,	O
normal	B-Lab_value
blood	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
level	O
9,11	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
3,9	O
-	O
5,8	O
mmol	O
/	O
L	O
)	O
,	O
serum	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
0,69	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
range	O
0,5	O
-	O
0,9	O
mmol	O
/	O
L	O
)	O
,	O
total	B-Diagnostic_procedure
serum	I-Diagnostic_procedure
cholesterol	I-Diagnostic_procedure
5,2	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
<	O
5,2	O
mmol	O
/	O
L	O
)	O
.	O

The	O
tests	O
for	O
thrombophilia	B-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

He	O
also	O
presented	O
a	O
normal	B-Lab_value
sinus	B-Diagnostic_procedure
rhythm	I-Diagnostic_procedure
on	O
the	O
ECG	B-Detailed_description
.	O

The	O
brain	B-Biological_structure
CT	B-Diagnostic_procedure
performed	O
at	O
the	O
first	O
emergency	O
unit	O
,	O
as	O
mentioned	O
above	O
,	O
revealed	O
a	O
infracentimetric	B-Detailed_description
hypodensity	B-Sign_symptom
at	O
the	O
level	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
thalamic	I-Biological_structure
nucleus	I-Biological_structure
and	O
at	O
the	O
level	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
cerebellar	I-Biological_structure
hemisphere	I-Biological_structure
in	O
the	O
PICA	B-Biological_structure
territory	I-Biological_structure
.	O

Doppler	B-Detailed_description
ultrasound	B-Diagnostic_procedure
for	O
cerebral	B-Biological_structure
and	I-Biological_structure
cervical	I-Biological_structure
blood	I-Biological_structure
vessels	I-Biological_structure
highlighted	O
the	O
marked	O
frena	B-Lab_value
in	O
the	O
flow	B-Diagnostic_procedure
velocities	I-Diagnostic_procedure
of	O
the	O
V2	B-Biological_structure
segment	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
,	O
an	O
accentuated	B-Sign_symptom
aspect	I-Sign_symptom
in	O
the	O
high	B-Biological_structure
V2	I-Biological_structure
segments	I-Biological_structure
with	O
the	O
complete	B-Lab_value
disappearance	I-Lab_value
of	O
the	O
flow	B-Diagnostic_procedure
in	O
the	O
V3	B-Biological_structure
segment	I-Biological_structure
,	O
without	O
carotid	B-Biological_structure
atheromatous	B-Detailed_description
lesions	B-Sign_symptom
or	O
modifications	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
trajectories	I-Sign_symptom
or	I-Sign_symptom
the	I-Sign_symptom
arterial	I-Sign_symptom
caliber	I-Sign_symptom
.	O

Overall	O
,	O
there	O
was	O
a	O
possibility	O
of	O
a	O
dissection	B-Disease_disorder
of	O
the	O
right	B-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
in	O
the	O
higher	B-Detailed_description
segments	I-Detailed_description
with	O
indication	O
of	O
cerebral	B-Biological_structure
and	O
angio	B-Biological_structure
MRI	B-Diagnostic_procedure
.	O

Cerebral	O
and	O
angio	O
MRI	O
showed	O
:	O
areas	O
with	O
T2	B-Detailed_description
,	O
FLAIR	B-Diagnostic_procedure
hypersignal	B-Lab_value
,	O
with	O
an	O
important	O
restriction	B-Sign_symptom
of	I-Sign_symptom
diffusion	I-Sign_symptom
and	O
low	B-Lab_value
ADC	B-Diagnostic_procedure
,	O
situated	O
in	O
the	O
right	B-Biological_structure
cerebellar	I-Biological_structure
area	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
postero	I-Biological_structure
-	I-Biological_structure
inferior	I-Biological_structure
territory	I-Biological_structure
,	O
anterior	B-Biological_structure
bilateral	I-Biological_structure
cerebellar	I-Biological_structure
territory	I-Biological_structure
,	O
left	B-Biological_structure
cerebellar	I-Biological_structure
peduncle	I-Biological_structure
,	O
both	B-Biological_structure
right	I-Biological_structure
>	I-Biological_structure
left	I-Biological_structure
thalamic	I-Biological_structure
nuclei	I-Biological_structure
,	O
as	O
well	O
as	O
subcortical	B-Biological_structure
occipital	I-Biological_structure
bilateral	I-Biological_structure
,	O
with	O
an	O
ischemic	B-Sign_symptom
aspect	I-Sign_symptom
that	O
was	O
recently	O
constituted	O
in	B-Biological_structure
the	I-Biological_structure
vertebrobasilar	I-Biological_structure
territory	I-Biological_structure
.	O

T1	B-Diagnostic_procedure
FS	I-Diagnostic_procedure
hypersignal	B-Lab_value
was	O
present	O
on	O
the	O
entire	B-Biological_structure
intracranial	I-Biological_structure
segment	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
and	O
the	O
cranio	B-Biological_structure
-	I-Biological_structure
spinal	I-Biological_structure
junction	I-Biological_structure
.	O

On	O
the	O
angiographic	B-Diagnostic_procedure
arterial	B-Detailed_description
3D	B-Detailed_description
TOF	B-Detailed_description
sequence	O
,	O
the	O
presence	O
of	O
the	O
rapid	B-Lab_value
flow	B-Diagnostic_procedure
of	O
the	O
right	B-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
could	O
be	O
viewed	O
,	O
up	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
C2	I-Biological_structure
segment	I-Biological_structure
,	O
where	O
there	O
was	O
a	O
progressive	B-Detailed_description
pinch	B-Sign_symptom
out	I-Sign_symptom
with	O
an	O
aspect	O
of	O
flute	B-Shape
beak	I-Shape
shape	I-Shape
.	O

Distal	B-Biological_structure
of	I-Biological_structure
this	I-Biological_structure
level	I-Biological_structure
,	O
there	O
was	O
an	O
absence	B-Lab_value
of	O
the	O
rapid	B-Diagnostic_procedure
flow	I-Diagnostic_procedure
signal	O
and	O
also	O
a	O
lack	B-Lab_value
of	O
right	B-Biological_structure
PICA	I-Biological_structure
visualization	B-Diagnostic_procedure
.	O

The	O
MRI	B-Diagnostic_procedure
aspect	O
suggested	O
a	O
subacute	B-Detailed_description
dissection	B-Disease_disorder
of	O
the	O
right	B-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
.	O

The	O
cerebral	B-Biological_structure
ventricular	I-Biological_structure
system	I-Biological_structure
had	O
normal	B-Lab_value
dimensions	B-Diagnostic_procedure
,	O
shape	B-Diagnostic_procedure
,	O
and	O
topography	B-Diagnostic_procedure
.	O

The	O
pericerebral	B-Diagnostic_procedure
fluid	I-Diagnostic_procedure
spaces	I-Diagnostic_procedure
and	O
the	O
basal	B-Diagnostic_procedure
cisterns	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Conclusions	O
:	O
there	O
were	O
some	O
ischemic	B-Detailed_description
lesions	B-Sign_symptom
recently	O
constituted	O
in	O
the	O
vertebrobasilar	B-Biological_structure
territory	I-Biological_structure
and	O
also	O
a	O
subacute	B-Detailed_description
dissection	B-Disease_disorder
of	O
the	O
right	B-Biological_structure
vertebral	I-Biological_structure
artery	I-Biological_structure
.	O

Heparin	B-Medication
administration	O
was	O
started	O
immediately	O
in	O
the	O
process	O
of	O
hospitalization	O
because	O
of	O
the	O
dissection	O
.	O

The	O
APTT	B-Diagnostic_procedure
value	I-Diagnostic_procedure
was	O
kept	O
in	O
the	O
range	B-Lab_value
of	I-Lab_value
50	I-Lab_value
-	I-Lab_value
70	I-Lab_value
seconds	I-Lab_value
.	O

Also	O
,	O
the	O
prophylactic	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
for	O
stress	B-Detailed_description
ulcer	I-Detailed_description
was	O
performed	O
.	O

After	O
7	O
days	O
from	O
the	O
debut	O
,	O
the	O
patient	O
was	O
transitioned	O
to	O
acenocumarol	B-Medication
for	O
long	O
-	O
term	O
anticoagulation	O
.	O

The	O
treatment	O
with	O
acenocumarol	B-Medication
was	O
instituted	O
with	O
the	O
heparin	B-Medication
overlap	O
until	O
getting	O
the	O
INR	B-Diagnostic_procedure
therapeutic	B-Lab_value
in	O
the	O
2	B-Detailed_description
-	I-Detailed_description
3	I-Detailed_description
intervals	I-Detailed_description
.	O

The	O
evolution	B-Diagnostic_procedure
was	O
favorable	B-Lab_value
,	O
the	O
patient	O
regaining	B-Lab_value
the	O
verbal	B-Diagnostic_procedure
fluency	I-Diagnostic_procedure
and	O
the	O
capacity	O
for	O
autonomy	B-Sign_symptom
in	I-Sign_symptom
movement	I-Sign_symptom
.	O

The	O
ataxia	B-Disease_disorder
was	O
remitted	B-Detailed_description
at	I-Detailed_description
the	I-Detailed_description
right	I-Detailed_description
limbs	I-Detailed_description
and	O
persisted	B-Detailed_description
at	I-Detailed_description
the	I-Detailed_description
left	I-Detailed_description
extremities	I-Detailed_description
,	O
but	O
registered	O
a	O
lot	O
of	O
improvement	B-Lab_value
.	O

The	O
patient	O
was	O
discharged	O
home	B-Nonbiological_location
with	O
the	O
recommendation	B-Other_entity
to	I-Other_entity
continue	I-Other_entity
the	I-Other_entity
treatment	I-Other_entity
with	I-Other_entity
Acenocumarol	I-Other_entity
for	I-Other_entity
6	I-Other_entity
months	I-Other_entity
with	I-Other_entity
clinical	I-Other_entity
,	I-Other_entity
paraclinical	I-Other_entity
and	I-Other_entity
treatment	I-Other_entity
reevaluation	I-Other_entity
at	I-Other_entity
6	I-Other_entity
months	I-Other_entity
.	O

The	O
follow	O
up	O
was	O
not	O
possible	O
because	O
the	O
patient	O
did	O
not	O
return	O
to	O
the	O
hospital	B-Nonbiological_location
after	O
6	O
months	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
33	B-Age
-	I-Age
year	I-Age
old	I-Age
woman	O
presented	O
to	O
our	O
cardiology	O
service	O
with	O
signs	O
and	O
symptoms	O
of	O
congestive	B-Sign_symptom
heart	I-Sign_symptom
failure	I-Sign_symptom
.	O

Her	O
medical	O
history	O
was	O
unremarkable	B-Detailed_description
,	O
however	O
a	O
year	O
ago	O
and	O
soon	O
after	O
her	O
third	O
child	B-Other_event
delivery	I-Other_event
,	O
she	O
had	O
been	O
admitted	O
in	O
another	O
hospital	B-Nonbiological_location
for	O
acute	B-Disease_disorder
pulmonary	I-Disease_disorder
oedema	I-Disease_disorder
after	O
labor	O
.	O

Cor	B-Disease_disorder
triatriatum	I-Disease_disorder
with	O
obstructive	O
behavior	O
causing	O
pulmonary	B-Sign_symptom
hypertension	I-Sign_symptom
had	O
bee	O
diagnosed	O
,	O
while	O
the	O
left	B-Biological_structure
ventricle	I-Biological_structure
was	O
structurally	B-Detailed_description
and	I-Detailed_description
functionally	I-Detailed_description
intact	I-Detailed_description
.	O

The	O
patient	O
at	O
that	O
time	O
denied	O
surgey	O
and	O
had	O
been	O
discharged	O
on	O
medical	B-Detailed_description
therapy	B-Therapeutic_procedure
.	O

At	O
present	O
admission	O
the	O
patient	O
presented	O
with	O
NYHA	B-Disease_disorder
functional	I-Disease_disorder
class	I-Disease_disorder
III	I-Disease_disorder
,	O
symptoms	O
of	O
heart	B-Sign_symptom
failure	I-Sign_symptom
and	I-Sign_symptom
palpittions	I-Sign_symptom
as	O
a	O
result	O
of	O
persistent	B-Sign_symptom
atrial	I-Sign_symptom
flutter	I-Sign_symptom
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
a	O
loud	O
pulmonary	O
component	O
of	O
the	O
2nd	O
heart	O
sound	O
and	O
a	O
diastolic	O
murmur	O
was	O
heard	O
in	O
the	O
mitral	B-Biological_structure
area	I-Biological_structure
.	O

Signs	O
of	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
were	O
absent	O
.	O

A	O
transthoracic	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
revealed	O
a	O
moderately	B-Detailed_description
dilated	I-Detailed_description
left	B-Biological_structure
ventricle	I-Biological_structure
(	O
LV	B-Biological_structure
)	O
,	O
globally	B-Detailed_description
hypokinetic	B-Disease_disorder
,	O
with	O
severely	B-Detailed_description
impaired	I-Detailed_description
systolic	B-Disease_disorder
function	I-Disease_disorder
(	O
EF	O
estimated	O
≥	O
30	B-Lab_value
%	I-Lab_value
)	O
.	O

Left	B-Biological_structure
atrium	I-Biological_structure
(	O
LA	B-Biological_structure
)	O
was	O
dilated	B-Shape
,	O
with	O
a	O
mobile	B-Detailed_description
,	I-Detailed_description
membrane	I-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
echogenic	B-Biological_structure
structure	I-Biological_structure
into	O
it	O
.	O

Transesophageal	B-Diagnostic_procedure
echocardiogram	I-Diagnostic_procedure
(	O
TEE	B-Diagnostic_procedure
)	O
documented	O
a	O
fibromuscular	B-Biological_structure
membrane	I-Biological_structure
across	O
the	O
LA	B-Biological_structure
,	O
dividing	O
it	O
into	O
two	O
compartments	O
,	O
a	O
proximal	O
one	O
receiving	O
the	O
pulmonary	O
venous	O
flow	O
and	O
a	O
distal	O
one	O
containing	O
the	O
left	B-Biological_structure
atrial	I-Biological_structure
appendage	I-Biological_structure
(	O
LAA	B-Biological_structure
)	O
.	O

The	O
two	O
chambers	B-Biological_structure
communicated	O
via	O
a	O
non	B-Detailed_description
-	I-Detailed_description
restrictive	I-Detailed_description
orifice	B-Biological_structure
,	O
but	O
the	O
membrane	B-Biological_structure
prolapsed	O
towards	O
the	O
mitral	B-Biological_structure
valve	I-Biological_structure
inflow	O
causing	O
severe	O
obstruction	O
.	O

Mitral	B-Biological_structure
valve	I-Biological_structure
appeared	O
normal	O
,	O
with	O
mild	O
regurgitation	O
.	O

Patent	B-Disease_disorder
foramen	I-Disease_disorder
ovale	I-Disease_disorder
(	O
PFO	B-Disease_disorder
)	O
,	O
atrial	B-Disease_disorder
septal	I-Disease_disorder
defect	I-Disease_disorder
(	O
ASD	B-Disease_disorder
)	O
and	O
anomalous	O
venous	O
connections	O
were	O
ruled	O
out	O
and	O
the	O
diagnosis	O
of	O
cor	B-Disease_disorder
triatriatum	I-Disease_disorder
was	O
reconfirmed	O
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
of	O
the	O
heart	O
also	O
revealed	O
the	O
fibromuscular	B-Biological_structure
septum	I-Biological_structure
into	O
the	O
left	B-Biological_structure
atrium	I-Biological_structure
and	O
the	O
low	O
left	O
ventricular	B-Lab_value
ejection	I-Lab_value
fraction	I-Lab_value
[	O
(	O
LVEF	B-Lab_value
)	O
30	B-Lab_value
%	I-Lab_value
,	O
cardiac	B-Lab_value
index	I-Lab_value
1,6	B-Lab_value
L	I-Lab_value
/	I-Lab_value
min	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
,	O
cardiac	B-Lab_value
output	I-Lab_value
2,7	B-Lab_value
L	I-Lab_value
/	I-Lab_value
min	I-Lab_value
]	O
(	O
figure	O
1	O
)	O
.	O

Coronary	B-Diagnostic_procedure
angiography	I-Diagnostic_procedure
showed	O
normal	O
coronary	B-Biological_structure
arteries	I-Biological_structure
.	O

With	O
these	O
findings	O
the	O
patient	O
was	O
scheduled	O
for	O
surgery	O
.	O

Anesthetic	O
induction	O
was	O
achieved	O
with	O
standard	O
technique	O
including	O
administration	O
of	O
sodium	B-Medication
pentothal	I-Medication
,	O
sevofluorane	B-Medication
,	O
fentanyl	B-Medication
and	O
muscle	B-Medication
relaxant	I-Medication
.	O

Invasive	O
monitoring	O
included	O
the	O
use	O
of	O
right	B-Other_entity
radial	I-Other_entity
arterial	I-Other_entity
lines	I-Other_entity
,	O
a	O
pulmonary	B-Other_entity
artery	I-Other_entity
catheter	I-Other_entity
and	O
a	O
foley	B-Other_entity
catheter	I-Other_entity
with	O
temperature	B-Other_entity
probe	I-Other_entity
to	O
measure	O
bladder	O
temperature	O
as	O
an	O
indicator	O
of	O
core	O
body	O
temperature	O
.	O

Transesophageal	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
TEE	B-Diagnostic_procedure
)	O
was	O
also	O
instituted	O
.	O

Surgery	O
was	O
performed	O
through	O
a	O
median	B-Therapeutic_procedure
sternotomy	I-Therapeutic_procedure
.	O

Connection	O
to	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
was	O
achieved	O
by	O
standard	O
ascending	O
aorta	O
and	O
bicaval	O
cannulation	O
.	O

Mildly	O
hypothermic	B-Sign_symptom
(	O
32	B-Lab_value
°C	I-Lab_value
)	O
CPB	O
was	O
established	O
.	O

Cold	O
blood	O
cardioplegia	O
was	O
administered	O
in	O
an	O
antegrade	O
fashion	O
through	O
the	O
aortic	O
root	O
after	O
clamping	O
the	O
aorta	O
.	O

The	O
interatrial	O
groove	O
was	O
developed	O
and	O
the	O
common	O
pulmonary	O
venous	O
chamber	O
of	O
the	O
left	O
atrium	O
was	O
opened	O
through	O
a	O
vertical	O
incision	O
anterior	O
to	O
the	O
right	O
pulmonary	O
veins	O
,	O
exactly	O
as	O
for	O
mitral	B-Therapeutic_procedure
valve	I-Therapeutic_procedure
surgery	I-Therapeutic_procedure
.	O

After	O
insertion	O
of	O
a	O
self	O
-	O
retaining	O
retractor	O
to	O
facilitate	O
exposure	O
,	O
the	O
diaphragm	B-Biological_structure
was	O
exposed	O
and	O
the	O
central	O
hole	O
in	O
it	O
was	O
identified	O
.	O

A	O
preliminary	O
incision	O
out	O
from	O
the	O
hole	O
improved	O
exposure	O
for	O
the	O
definitive	O
excision	O
.	O

Orifices	O
of	O
the	O
pulmonary	B-Biological_structure
veins	I-Biological_structure
on	O
both	O
sides	O
were	O
located	O
.	O

Position	O
of	O
the	O
atrial	B-Disease_disorder
septum	I-Disease_disorder
was	O
also	O
identified	O
by	O
a	O
small	O
opening	O
in	O
the	O
right	B-Biological_structure
atrium	I-Biological_structure
and	O
by	O
inserting	O
a	O
curved	B-Other_entity
clamp	I-Other_entity
to	O
displace	O
the	O
septum	O
into	O
the	O
common	O
pulmonary	O
venous	O
chamber	O
of	O
the	O
left	B-Biological_structure
atrium	I-Biological_structure
.	O

There	O
was	O
no	O
atrial	B-Disease_disorder
septal	I-Disease_disorder
defect	I-Disease_disorder
or	O
patent	B-Disease_disorder
foramen	I-Disease_disorder
ovale	I-Disease_disorder
.	O

The	O
diaphragm	B-Biological_structure
was	O
then	O
easily	O
completely	O
excised	O
exposing	O
the	O
mitral	B-Biological_structure
valve	I-Biological_structure
(	O
figure	O
2	O
)	O
.	O

The	O
left	O
atrial	O
appendage	O
was	O
closed	O
from	O
inside	O
the	O
left	O
atrium	O
using	O
a	O
running	O
3	O
-	O
0	O
polypropylene	O
suture	O
to	O
prevent	O
future	O
thrombus	B-Sign_symptom
formation	I-Sign_symptom
.	O

The	O
atriotomy	B-Therapeutic_procedure
incisions	I-Therapeutic_procedure
were	O
closed	O
,	O
the	O
heart	O
having	O
been	O
filled	O
with	O
blood	O
before	O
the	O
last	O
few	O
sutures	O
were	O
placed	O
.	O

The	O
patient	O
was	O
rewarmed	O
,	O
the	O
aortic	B-Other_entity
cross	I-Other_entity
-	I-Other_entity
clamp	I-Other_entity
was	O
removed	O
and	O
additional	O
de	O
-	O
airing	O
was	O
carried	O
out	O
in	O
the	O
usual	O
manner	O
.	O

CPB	O
was	O
terminated	O
with	O
minimal	O
inotropic	O
support	O
,	O
involving	O
milrinone	O
and	O
levophed	O
with	O
good	O
hemodynamics	O
.	O

The	O
postoperative	O
course	O
was	O
uneventful	O
and	O
the	O
patient	O
was	O
extubated	O
after	O
12	O
hours	O
and	O
discharged	O
from	O
the	O
hospital	O
on	O
the	O
fifth	O
postoperative	O
day	O
.	O

At	O
3	O
months	O
follow	O
-	O
up	O
,	O
the	O
patient	O
was	O
asymptomatic	O
(	O
NYHA	O
class	O
I	O
)	O
,	O
in	O
sinus	O
rhythm	O
.	O

TTE	B-Diagnostic_procedure
and	O
MRI	B-Diagnostic_procedure
revealed	O
a	O
mildly	O
dilated	O
LV	O
with	O
great	O
improvement	O
in	O
systolic	O
function	O
and	O
an	O
estimated	O
LVEF	B-Lab_value
of	O
50	B-Lab_value
%	I-Lab_value
.	O

-DOCSTART- -X- -X- -X- O

A	O
42	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
with	O
a	O
right	B-Biological_structure
breast	I-Biological_structure
lump	B-Sign_symptom
,	O
lower	B-Biological_structure
back	I-Biological_structure
pain	B-Sign_symptom
,	O
loss	B-Sign_symptom
of	I-Sign_symptom
height	I-Sign_symptom
,	O
marked	O
kyphosis	B-Sign_symptom
and	O
hepatomegaly	B-Sign_symptom
.	O

Core	O
biopsies	B-Diagnostic_procedure
from	O
the	O
breast	B-Biological_structure
lump	I-Biological_structure
showed	O
ductal	B-Disease_disorder
carcinoma	I-Disease_disorder
in	O
situ	O
(	O
sample	O
labelled	O
P1	O
.	O
1	O
;	O
Supplementary	O
Fig	O
.	O
1	O
and	O
Supplementary	O
Table	O
1	O
)	O
.	O

An	O
additional	O
biopsy	B-Diagnostic_procedure
from	O
an	O
ipsilateral	B-Biological_structure
axillary	I-Biological_structure
lymph	I-Biological_structure
node	I-Biological_structure
(	O
P1	O
.	O
2	O
)	O
revealed	O
metastatic	B-Detailed_description
ductal	B-Disease_disorder
adenocarcinoma	I-Disease_disorder
(	O
ER	O
+	O
(	O
8	O
/	O
8	O
)	O
and	O
HER2	O
+	O
(	O
3	O
+	O
)	O
)	O
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
scan	O
revealed	O
widespread	B-Detailed_description
metastatic	B-Disease_disorder
disease	I-Disease_disorder
in	O
bones	B-Biological_structure
,	O
pleura	B-Biological_structure
and	O
liver	B-Biological_structure
(	O
Supplementary	O
Fig	O
.	O
2	O
and	O
Supplementary	O
Table	O
2	O
)	O
.	O

The	O
patient	O
was	O
started	O
on	O
treatment	O
with	O
trastuzumab	B-Medication
and	O
taxane	B-Medication
-	I-Medication
based	I-Medication
chemotherapy	I-Medication
,	O
with	O
a	O
significant	B-Detailed_description
partial	B-Detailed_description
response	B-Sign_symptom
(	O
Supplementary	O
Fig	O
.	O
3	O
)	O
.	O

After	O
induction	B-Detailed_description
chemotherapy	B-Medication
,	O
she	O
was	O
maintained	O
on	O
tamoxifen	B-Medication
and	O
trastuzumab	B-Medication
.	O

After	O
19	B-Duration
months	I-Duration
on	O
treatment	O
,	O
she	O
presented	O
with	O
seizures	B-Sign_symptom
and	O
head	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
revealed	O
a	O
large	O
metastasis	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
frontal	I-Biological_structure
lobe	I-Biological_structure
(	O
Supplementary	O
Fig	O
.	O
4	O
)	O
,	O
which	O
was	O
resected	B-Therapeutic_procedure
(	O
M2	O
.	O
1	O
)	O
.	O

Therapy	O
with	O
tamoxifen	B-Medication
and	O
trastuzumab	B-Medication
was	O
continued	O
and	O
collection	O
of	O
plasma	B-Diagnostic_procedure
samples	I-Diagnostic_procedure
was	O
initiated	O
(	O
samples	O
T1	O
-	O
T9	O
)	O
.	O

Four	O
months	O
after	O
surgery	O
,	O
she	O
had	O
enlarging	B-Detailed_description
liver	B-Biological_structure
lesions	B-Sign_symptom
and	O
a	O
new	O
metastatic	B-Sign_symptom
deposit	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
ovary	I-Biological_structure
(	O
Supplementary	O
Fig	O
.	O
5	O
)	O
.	O

Treatment	O
was	O
switched	O
to	O
a	O
combination	O
of	O
lapatinib	B-Medication
and	O
capecitabine	B-Medication
,	O
resulting	O
in	O
stable	B-Sign_symptom
disease	I-Sign_symptom
for	O
12	B-Duration
months	I-Duration
(	O
Supplementary	O
Fig	O
.	O
6	O
)	O
.	O

General	B-Sign_symptom
deterioration	I-Sign_symptom
then	O
occurred	O
,	O
with	O
disease	B-Sign_symptom
progression	I-Sign_symptom
in	O
the	O
chest	B-Biological_structure
(	O
new	O
pulmonary	B-Biological_structure
nodules	B-Sign_symptom
,	O
bilateral	B-Detailed_description
pleural	B-Disease_disorder
effusions	I-Disease_disorder
and	O
posterior	B-Biological_structure
chest	I-Biological_structure
wall	I-Biological_structure
mass	B-Sign_symptom
,	O
Supplementary	O
Fig	O
.	O
7	O
;	O
Eastern	B-Diagnostic_procedure
Cooperative	I-Diagnostic_procedure
Oncology	I-Diagnostic_procedure
Group	I-Diagnostic_procedure
performance	I-Diagnostic_procedure
status	I-Diagnostic_procedure
2	B-Lab_value
-	I-Lab_value
3	I-Lab_value
)	O
.	O

Treatment	B-Therapeutic_procedure
was	O
stopped	O
and	O
the	O
patient	O
died	O
∼	O
4	O
months	O
later	O
.	O

Tumour	O
samples	O
were	O
obtained	O
at	O
diagnosis	O
from	O
the	O
primary	O
breast	O
site	O
(	O
P1	O
.	O
1	O
)	O
and	O
an	O
axillary	O
lymph	O
node	O
(	O
P1	O
.	O
2	O
)	O
;	O
after	O
19	O
months	O
from	O
the	O
brain	O
metastasis	O
area	O
(	O
M2	O
.	O
1	O
)	O
;	O
and	O
at	O
autopsy	O
after	O
3	O
years	O
on	O
treatment	O
(	O
from	O
the	O
primary	O
breast	O
site	O
,	O
and	O
from	O
metastatic	O
deposits	O
in	O
the	O
chest	O
,	O
liver	O
,	O
ovary	O
and	O
vertebrae	O
,	O
labelled	O
P3	O
.	O
1	O
and	O
M3	O
.	O
1	O
-	O
M3	O
.	O
4	O
,	O
respectively	O
)	O
.	O

Serial	O
plasma	O
samples	O
were	O
obtained	O
over	O
the	O
last	O
500	O
days	O
of	O
clinical	O
follow	O
-	O
up	O
(	O
T1	O
-	O
T9	O
)	O
.	O

Tumour	O
and	O
plasma	O
samples	O
collected	O
and	O
the	O
clinical	O
course	O
are	O
summarized	O
in	O
Fig	O
.	O
1a	O
,	O
b	O
.	O

-DOCSTART- -X- -X- -X- O

Our	O
patient	O
was	O
a	O
68	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

She	O
had	O
no	O
history	O
of	O
gastroesophageal	O
reflux	O
disease	O
or	O
esophageal	O
disorders	O
but	O
was	O
found	O
to	O
have	O
a	O
progressive	B-Detailed_description
solitary	B-Detailed_description
pulmonary	B-Biological_structure
nodule	B-Sign_symptom
(	O
1	B-Area
×	I-Area
1	I-Area
.	I-Area
3	I-Area
cm	I-Area
)	O
.	O

A	O
right	B-Detailed_description
lower	I-Detailed_description
wedge	I-Detailed_description
resection	B-Therapeutic_procedure
was	O
performed	O
in	O
December	O
2011	O
and	O
the	O
University	B-Nonbiological_location
of	I-Nonbiological_location
Iowa	I-Nonbiological_location
pathology	I-Nonbiological_location
department	I-Nonbiological_location
identified	O
the	O
tumor	O
as	O
a	O
LCNEC	B-Disease_disorder
.	O

Approximately	O
six	O
months	O
after	O
her	O
operation	O
,	O
our	O
patient	O
started	O
having	O
slowly	B-Detailed_description
progressing	I-Detailed_description
dysphagia	B-Sign_symptom
for	B-Detailed_description
both	I-Detailed_description
solids	I-Detailed_description
and	I-Detailed_description
liquids	I-Detailed_description
.	O

A	O
positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
PET	B-Diagnostic_procedure
)	O
scan	O
performed	O
in	O
2012	O
,	O
one	O
year	O
post	O
surgery	O
,	O
was	O
unremarkable	B-Lab_value
for	O
recurrence	O
or	O
metastasis	O
.	O

Repeat	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
in	O
June	O
2013	O
(	O
18	O
months	O
post	O
surgery	O
)	O
did	O
not	O
show	O
any	O
recurrence	B-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

Our	O
patient	O
had	O
an	O
esophagogastroduodenoscopy	B-Diagnostic_procedure
(	O
EGD	B-Diagnostic_procedure
)	O
and	O
barium	B-Diagnostic_procedure
swallow	I-Diagnostic_procedure
that	O
revealed	O
no	O
stricture	B-Sign_symptom
of	O
her	O
esophagus	B-Biological_structure
but	O
failure	B-Sign_symptom
of	O
primary	B-Biological_structure
and	I-Biological_structure
secondary	I-Biological_structure
peristaltic	I-Biological_structure
waves	I-Biological_structure
and	O
reflux	B-Biological_structure
.	O

In	O
July	O
2013	O
,	O
esophageal	B-Diagnostic_procedure
manometry	I-Diagnostic_procedure
found	O
failure	B-Sign_symptom
of	O
the	O
lower	B-Detailed_description
esophageal	I-Detailed_description
sphincter	I-Detailed_description
to	I-Detailed_description
relax	I-Detailed_description
,	O
with	O
a	O
residual	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
32mmHg	B-Lab_value
.	O

Our	O
patient	O
was	O
treated	O
with	O
calcium	B-Medication
channel	I-Medication
blockers	I-Medication
with	O
partial	O
relief	B-Sign_symptom
.	O

Thus	O
far	O
,	O
up	B-Duration
to	I-Duration
18	I-Duration
months	I-Duration
post	I-Duration
resection	O
,	O
our	O
patient	O
had	O
been	O
able	O
to	O
maintain	B-Lab_value
her	O
weight	B-Diagnostic_procedure
and	O
her	O
basic	B-Diagnostic_procedure
laboratory	I-Diagnostic_procedure
parameters	I-Diagnostic_procedure
,	O
including	O
hemoglobin	B-Diagnostic_procedure
,	O
albumin	B-Diagnostic_procedure
and	O
cholesterol	B-Diagnostic_procedure
levels	O
.	O

However	O
,	O
in	O
January	O
2014	O
,	O
she	O
reported	O
worsening	O
dysphagia	B-Sign_symptom
and	O
weight	B-Sign_symptom
loss	I-Sign_symptom
of	O
10	B-Lab_value
lbs	I-Lab_value
over	B-Duration
a	I-Duration
period	I-Duration
of	I-Duration
one	I-Duration
month	I-Duration
.	O

She	O
was	O
referred	O
to	O
our	O
center	B-Nonbiological_location
for	O
further	O
treatment	B-Therapeutic_procedure
of	O
her	O
achalasia	B-Disease_disorder
.	O

A	O
repeat	O
esophageal	B-Diagnostic_procedure
manometry	I-Diagnostic_procedure
showed	O
an	O
elevated	B-Lab_value
lower	B-Diagnostic_procedure
esophageal	I-Diagnostic_procedure
sphincter	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
50mmHg	B-Lab_value
as	O
well	O
non	B-Detailed_description
-	I-Detailed_description
propagative	I-Detailed_description
,	O
non	B-Detailed_description
-	I-Detailed_description
peristaltic	I-Detailed_description
contractions	B-Sign_symptom
throughout	O
her	O
esophageal	B-Biological_structure
musculature	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

A	O
repeat	O
EGD	B-Diagnostic_procedure
with	O
an	O
intention	O
to	O
perform	O
therapeutic	O
pneumatic	B-Therapeutic_procedure
dilation	I-Therapeutic_procedure
showed	O
a	O
nearly	B-Detailed_description
circumferential	I-Detailed_description
ulcerated	B-Detailed_description
,	O
fungating	B-Detailed_description
mass	B-Sign_symptom
from	O
approximately	B-Distance
36	I-Distance
cm	I-Distance
that	O
extended	O
to	O
her	O
gastroesophageal	B-Biological_structure
junction	I-Biological_structure
at	B-Distance
39	I-Distance
cm	I-Distance
.	O

Biopsies	B-Diagnostic_procedure
revealed	O
a	O
LCNEC	B-Disease_disorder
with	O
similar	B-Detailed_description
features	I-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
primary	I-Detailed_description
tumor	I-Detailed_description
resected	I-Detailed_description
in	I-Detailed_description
2011	I-Detailed_description
,	O
and	O
was	O
concluded	O
to	O
be	O
a	O
metastasis	B-Sign_symptom
.	O

Subsequently	O
,	O
a	O
repeat	O
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
revealed	O
progressive	B-Detailed_description
diffuse	B-Detailed_description
metastatic	B-Disease_disorder
disease	I-Disease_disorder
.	O

Our	O
patient	O
underwent	O
two	B-Detailed_description
courses	I-Detailed_description
of	O
chemotherapy	B-Medication
but	O
died	O
from	O
the	O
disease	O
after	O
six	O
months	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
55	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
because	O
of	O
a	O
suspicion	O
of	O
mediastinal	B-Biological_structure
tumor	B-Sign_symptom
incidentally	O
found	O
through	O
a	O
medical	O
-	O
checkup	O
plain	O
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
photography	I-Diagnostic_procedure
(	O
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
P	I-Diagnostic_procedure
)	O
(	O
Figure	O
(	O
Figure1A	O
)	O
.	O
1A	O
)	O
.	O

Chest	B-Biological_structure
MRI	B-Diagnostic_procedure
revealed	O
a	O
3	B-Distance
cm	I-Distance
diameter	O
tumor	B-Sign_symptom
which	O
seemed	O
to	O
connect	O
to	O
the	O
right	B-Biological_structure
lobe	I-Biological_structure
of	I-Biological_structure
thyroid	I-Biological_structure
and	O
projected	O
into	O
the	O
mediastinum	B-Biological_structure
(	O
Figure	O
1B	O
)	O
.	O

By	O
123I	B-Diagnostic_procedure
-	I-Diagnostic_procedure
RI	I-Diagnostic_procedure
,	O
no	B-Lab_value
unusual	I-Lab_value
accumulation	I-Lab_value
was	O
detected	O
(	O
Figure	O
1C	O
)	O
.	O

A	O
fine	B-Detailed_description
needle	I-Detailed_description
aspiration	I-Detailed_description
biopsy	B-Diagnostic_procedure
,	O
which	O
is	O
viewed	O
as	O
the	O
`	O
gold	O
standard	O
`	O
for	O
diagnosis	O
in	O
most	O
cases	O
,	O
was	O
tried	O
but	O
could	B-Lab_value
not	I-Lab_value
reach	I-Lab_value
a	I-Lab_value
conclusive	I-Lab_value
diagnosis	I-Lab_value
.	O

Thereby	O
,	O
18F	B-Diagnostic_procedure
-	I-Diagnostic_procedure
FDG	I-Diagnostic_procedure
-	I-Diagnostic_procedure
PET	I-Diagnostic_procedure
was	O
performed	O
and	O
a	O
high	B-Lab_value
accumulation	I-Lab_value
was	O
revealed	O
with	O
standardized	B-Diagnostic_procedure
uptake	I-Diagnostic_procedure
value	I-Diagnostic_procedure
(	O
SUV	B-Diagnostic_procedure
)	O
of	O
3	B-Lab_value
.	I-Lab_value
8	I-Lab_value
(	O
Figure	O
1D	O
)	O
.	O

Thus	O
,	O
as	O
a	O
possibility	O
of	O
malignancy	B-Disease_disorder
could	O
not	O
be	O
excluded	O
,	O
the	O
right	B-Biological_structure
lobe	I-Biological_structure
excision	B-Therapeutic_procedure
procedure	O
for	O
thyroid	B-Biological_structure
gland	I-Biological_structure
was	O
enforced	O
.	O

The	O
obtained	O
tumor	B-Sign_symptom
was	O
continuous	O
to	O
the	O
right	B-Biological_structure
lobe	I-Biological_structure
as	O
expected	O
.	O

The	O
surface	O
was	O
flat	B-Texture
and	O
smooth	B-Texture
and	O
the	O
exfoliation	O
from	O
the	O
circumference	O
organization	O
was	O
easy	O
(	O
Figure	O
2A	O
)	O
.	O

Microscopically	B-Diagnostic_procedure
,	O
the	O
encapsulated	O
tumor	O
consisted	O
of	O
atypical	B-Sign_symptom
large	B-Detailed_description
-	I-Detailed_description
sized	I-Detailed_description
follicles	B-Biological_structure
without	O
malignant	B-Sign_symptom
characteristics	I-Sign_symptom
,	O
the	O
background	O
thyroid	B-Biological_structure
tissue	I-Biological_structure
showing	O
no	O
remarkable	O
change	B-Sign_symptom
(	O
Figure	O
2B	O
)	O
.	O

Thus	O
,	O
histological	B-Diagnostic_procedure
diagnosis	I-Diagnostic_procedure
was	O
follicular	B-Disease_disorder
thyroid	I-Disease_disorder
adenoma	I-Disease_disorder
.	O

Ethical	O
approval	O
was	O
not	O
thought	O
to	O
be	O
necessary	O
because	O
all	O
the	O
clinical	O
course	O
of	O
the	O
case	O
was	O
completely	O
within	O
usual	O
medical	O
cares	O
.	O

Informed	O
consent	O
was	O
given	O
from	O
the	O
case	O
on	O
each	O
occasion	O
of	O
diagnostic	O
examinations	O
and	O
therapeutic	O
procedures	O
.	O

-DOCSTART- -X- -X- -X- O

We	O
present	O
the	O
case	O
of	O
a	O
16	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
girl	O
,	O
admitted	O
to	O
our	O
clinic	B-Nonbiological_location
with	O
severe	B-Severity
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
loss	B-Sign_symptom
of	I-Sign_symptom
appetite	I-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
and	O
vomiting	B-Sign_symptom
.	O

The	O
anamnesis	B-Diagnostic_procedure
revealed	O
that	O
the	O
girl	O
comes	O
from	O
a	O
family	O
of	O
potters	O
,	O
and	O
that	O
she	O
also	O
participated	B-Occupation
in	I-Occupation
the	I-Occupation
process	I-Occupation
of	I-Occupation
pottery	I-Occupation
,	O
her	O
father	O
being	O
diagnosed	O
with	O
lead	O
poisoning	O
2	O
years	O
before	O
.	O

The	O
patient	O
`	O
s	O
personal	O
history	O
underlined	O
that	O
approximately	O
1	O
year	O
ago	O
she	O
presented	O
with	O
severe	B-Severity
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
being	O
diagnosed	O
with	O
acute	B-Detailed_description
appendicitis	B-Disease_disorder
and	O
she	O
underwent	O
appendectomy	B-Therapeutic_procedure
,	O
but	O
the	O
pain	B-Sign_symptom
persisted	B-Detailed_description
,	O
thus	O
due	O
to	O
family	O
history	O
of	O
lead	O
poisoning	O
,	O
the	O
suspicion	O
of	O
saturnine	B-Disease_disorder
colic	I-Disease_disorder
rose	O
,	O
and	O
she	O
was	O
diagnosed	O
with	O
lead	B-Disease_disorder
poisoning	I-Disease_disorder
(	O
urinary	B-Diagnostic_procedure
lead	I-Diagnostic_procedure
:	O
219	B-Lab_value
μg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
but	O
she	O
received	O
only	O
symptomatic	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
.	O

Approximately	O
3	O
weeks	O
before	O
admission	O
to	O
our	O
clinic	O
,	O
she	O
was	O
admitted	O
to	O
the	O
regional	B-Nonbiological_location
hospital	I-Nonbiological_location
with	O
another	O
episode	O
of	O
saturnine	B-Disease_disorder
colic	I-Disease_disorder
(	O
blood	B-Diagnostic_procedure
lead	I-Diagnostic_procedure
:	O
113	B-Lab_value
.	I-Lab_value
2	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
,	O
and	O
chelation	B-Medication
therapy	I-Medication
with	O
EDTA	B-Medication
(	O
4	O
days	O
before	O
the	O
admission	O
in	O
our	O
clinic	O
)	O
was	O
initiated	O
,	O
with	O
a	O
dose	O
of	O
2	B-Dosage
tablets	I-Dosage
daily	I-Dosage
,	O
one	B-Dosage
in	I-Dosage
the	I-Dosage
morning	I-Dosage
and	I-Dosage
one	I-Dosage
in	I-Dosage
the	I-Dosage
evening	I-Dosage
associated	O
with	O
calcium	B-Medication
supplements	I-Medication
.	O

The	O
clinical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
performed	O
at	O
the	O
time	O
of	O
admission	O
revealed	O
the	O
following	O
pathological	O
elements	O
:	O
influenced	B-Sign_symptom
general	I-Sign_symptom
status	I-Sign_symptom
,	O
ailing	B-Sign_symptom
face	I-Sign_symptom
,	O
jaundice	B-Sign_symptom
of	O
the	O
sclera	B-Biological_structure
,	O
blue	B-Color
pigmentation	B-Sign_symptom
of	O
the	O
nails	B-Biological_structure
,	O
painful	B-Sign_symptom
abdomen	B-Biological_structure
at	O
palpation	B-Detailed_description
,	O
and	O
weight	B-Diagnostic_procedure
:	O
45	B-Lab_value
kg	I-Lab_value
.	O

The	O
laboratory	B-Diagnostic_procedure
test	I-Diagnostic_procedure
performed	O
upon	O
admission	O
revealed	O
hypochromic	B-Detailed_description
anemia	B-Sign_symptom
(	O
hemoglobin	B-Diagnostic_procedure
(	O
Hb	B-Diagnostic_procedure
)	O
:	O
10	B-Lab_value
.	I-Lab_value
9	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
hematocrit	B-Diagnostic_procedure
(	O
Htc	B-Diagnostic_procedure
)	O
:	O
31	B-Lab_value
.	I-Lab_value
6	I-Lab_value
%	I-Lab_value
,	O
medium	B-Diagnostic_procedure
cellular	I-Diagnostic_procedure
volume	I-Diagnostic_procedure
(	O
MCV	B-Diagnostic_procedure
)	O
:	O
77	B-Lab_value
.	I-Lab_value
6	I-Lab_value
fL	I-Lab_value
)	O
,	O
increased	B-Lab_value
level	O
of	O
liver	B-Diagnostic_procedure
transaminases	I-Diagnostic_procedure
(	O
alanine	B-Diagnostic_procedure
-	I-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
(	O
ALAT	B-Diagnostic_procedure
)	O
:	O
158	B-Lab_value
.	I-Lab_value
9	I-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
aspartate	B-Diagnostic_procedure
-	I-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
(	O
ASAT	B-Diagnostic_procedure
)	O
:	O
63	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
gamma	B-Diagnostic_procedure
-	I-Diagnostic_procedure
glutamyl	I-Diagnostic_procedure
-	I-Diagnostic_procedure
transferase	I-Diagnostic_procedure
(	O
GGT	B-Diagnostic_procedure
)	O
:	O
128	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
conjugated	B-Sign_symptom
hyperbilirubinemia	I-Sign_symptom
(	O
direct	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
(	O
DBi	B-Diagnostic_procedure
)	O
:	O
1	B-Lab_value
.	I-Lab_value
432	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
,	O
hyponatremia	B-Sign_symptom
(	O
Na	B-Diagnostic_procedure
:	O
132	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
and	O
hypopotassemia	B-Sign_symptom
(	O
K	B-Diagnostic_procedure
:	O
2	B-Lab_value
.	I-Lab_value
85	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
.	O

The	O
systolic	B-Detailed_description
arterial	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
156	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
and	O
the	O
diastolic	B-Detailed_description
was	O
96	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

The	O
blood	B-Biological_structure
lead	B-Diagnostic_procedure
level	O
was	O
66	B-Lab_value
.	I-Lab_value
28	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
the	O
urinary	B-Biological_structure
one	O
was	O
419	B-Lab_value
.	I-Lab_value
7	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
<	O
50	O
μg	O
/	O
L	O
)	O
and	O
the	O
value	O
of	O
delta	B-Diagnostic_procedure
-	I-Diagnostic_procedure
aminolevulinic	I-Diagnostic_procedure
acid	I-Diagnostic_procedure
was	O
7	B-Lab_value
.	I-Lab_value
66	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
<	O
4	O
.	O
5	O
mg	O
/	O
L	O
)	O
.	O

We	O
also	O
performed	O
abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
which	O
revealed	O
a	O
disappearance	B-Sign_symptom
of	O
the	O
delimitation	B-Detailed_description
between	I-Detailed_description
the	I-Detailed_description
cortical	I-Detailed_description
and	I-Detailed_description
medullar	I-Detailed_description
parts	I-Detailed_description
in	O
both	B-Biological_structure
kidneys	I-Biological_structure
.	O

We	O
requested	O
consultation	O
from	O
an	O
occupational	B-Nonbiological_location
healthcare	I-Nonbiological_location
specialist	I-Nonbiological_location
,	O
who	O
recommended	O
the	O
continuation	O
of	O
chelation	B-Medication
therapy	I-Medication
with	O
EDTA	B-Medication
,	O
increasing	O
the	O
dose	O
at	O
4	B-Dosage
tablets	I-Dosage
/	I-Dosage
day	I-Dosage
.	O

We	O
also	O
required	O
a	O
neurological	B-Detailed_description
consultation	O
,	O
and	O
the	O
specialist	O
established	O
the	O
diagnosis	O
of	O
behavioral	B-Disease_disorder
disorders	I-Disease_disorder
with	O
depressive	B-Disease_disorder
elements	O
,	O
and	O
recommended	O
psychotherapy	B-Diagnostic_procedure
.	O

Based	O
on	O
all	O
these	O
clinical	O
and	O
laboratory	O
findings	O
,	O
we	O
established	O
the	O
diagnosis	O
of	O
lead	B-Disease_disorder
poisoning	I-Disease_disorder
.	O

We	O
initiated	O
an	O
intense	O
i	O
.	O
v	O
.	O
hydration	B-Medication
in	O
order	O
to	O
favor	O
lead	O
elimination	O
,	O
approximately	O
3	B-Dosage
liters	I-Dosage
per	I-Dosage
24	I-Dosage
hours	I-Dosage
initially	O
,	O
and	O
we	O
decreased	O
progressively	O
the	O
quantity	O
once	O
she	O
ceased	O
to	O
vomit	B-Sign_symptom
,	O
and	O
she	O
was	O
able	B-Sign_symptom
to	I-Sign_symptom
consume	I-Sign_symptom
liquids	I-Sign_symptom
.	O

We	O
associated	O
diuretics	B-Medication
,	O
initially	O
furosemide	B-Medication
by	O
vein	O
,	O
but	O
the	O
values	O
of	O
the	O
arterial	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
persisted	O
above	B-Lab_value
the	I-Lab_value
upper	I-Lab_value
limit	I-Lab_value
,	O
therefore	O
we	O
were	O
forced	O
to	O
introduce	O
also	O
an	O
angiotensin	B-Medication
-	I-Medication
converting	I-Medication
enzyme	I-Medication
inhibitor	I-Medication
,	O
with	O
the	O
remission	O
of	O
arterial	B-Sign_symptom
hypertension	I-Sign_symptom
.	O

Regarding	O
the	O
liver	O
function	O
,	O
we	O
administered	O
amino	B-Medication
acids	I-Medication
intravenously	O
,	O
associated	O
with	O
liver	B-Medication
protectors	I-Medication
by	O
mouth	O
.	O

We	O
also	O
administered	O
vitamins	B-Medication
of	I-Medication
the	I-Medication
B	I-Medication
complex	I-Medication
in	O
order	O
to	O
improve	O
the	O
neurological	O
impairment	O
.	O

The	O
evolution	B-Diagnostic_procedure
was	O
slightly	B-Lab_value
favorable	I-Lab_value
,	O
in	O
the	O
first	O
3	O
days	O
after	O
the	O
admission	O
,	O
the	O
patient	O
continued	O
to	O
present	O
severe	B-Severity
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
vomiting	B-Sign_symptom
,	O
and	O
she	O
also	O
complained	O
of	O
pain	B-Sign_symptom
in	O
the	O
lumbar	B-Biological_structure
area	I-Biological_structure
.	O

All	O
the	O
laboratory	B-Diagnostic_procedure
parameters	I-Diagnostic_procedure
presented	O
normalization	B-Lab_value
of	O
the	O
values	O
after	O
approximately	B-Duration
10	I-Duration
days	I-Duration
of	O
treatment	B-Therapeutic_procedure
.	O

On	O
the	O
6th	O
day	O
of	O
admission	O
,	O
we	O
ceased	O
the	O
chelation	B-Medication
therapy	I-Medication
with	O
EDTA	B-Medication
.	O

We	O
also	O
repeated	O
the	O
blood	B-Biological_structure
and	O
urinary	B-Biological_structure
lead	B-Diagnostic_procedure
levels	O
.	O

The	O
blood	B-Biological_structure
level	O
was	O
45	B-Lab_value
.	I-Lab_value
57	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
and	O
the	O
urinary	B-Biological_structure
one	O
was	O
836	B-Lab_value
.	I-Lab_value
4	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
before	O
discharging	O
the	O
patient	O
.	O

The	O
abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
reevaluation	O
revealed	O
no	O
pathological	B-Sign_symptom
modifications	I-Sign_symptom
.	O

After	O
14	O
days	O
of	O
admission	O
,	O
the	O
patient	O
was	O
discharged	O
without	O
any	O
complaints	B-Sign_symptom
,	O
and	O
we	O
recommended	O
no	O
further	O
exposure	O
to	O
lead	O
,	O
avoiding	O
the	O
contact	O
and	O
the	O
working	O
in	O
the	O
pottery	O
process	O
.	O

The	O
long	O
-	O
term	O
outcome	O
of	O
this	O
case	O
depends	O
on	O
further	O
exposure	O
to	O
this	O
heavy	O
metal	O
.	O

Nevertheless	B-Other_entity
,	I-Other_entity
we	I-Other_entity
intend	I-Other_entity
to	I-Other_entity
repeat	I-Other_entity
the	I-Other_entity
blood	I-Other_entity
lead	I-Other_entity
levels	I-Other_entity
after	I-Other_entity
12	I-Other_entity
and	I-Other_entity
24	I-Other_entity
months	I-Other_entity
,	I-Other_entity
assessing	I-Other_entity
also	I-Other_entity
the	I-Other_entity
renal	I-Other_entity
(	I-Other_entity
urea	I-Other_entity
,	I-Other_entity
creatinine	I-Other_entity
,	I-Other_entity
urinary	I-Other_entity
exam	I-Other_entity
)	I-Other_entity
and	I-Other_entity
hepatic	I-Other_entity
functions	I-Other_entity
(	I-Other_entity
ASAT	I-Other_entity
,	I-Other_entity
ALAT	I-Other_entity
,	I-Other_entity
GGT	I-Other_entity
,	I-Other_entity
bilirubin	I-Other_entity
)	I-Other_entity
.	O

-DOCSTART- -X- -X- -X- O

A	O
29	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
primipara	O
presented	O
with	O
complaints	O
of	O
persistent	B-Detailed_description
,	O
severe	B-Severity
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
upper	B-Biological_structure
abdominal	I-Biological_structure
pain	B-Sign_symptom
during	B-Detailed_description
deep	I-Detailed_description
inspiration	I-Detailed_description
,	O
physical	B-Activity
exercise	I-Activity
and	O
on	B-Detailed_description
local	I-Detailed_description
pressure	I-Detailed_description
.	O

These	O
complaints	O
had	O
developed	B-Detailed_description
gradually	I-Detailed_description
after	O
giving	O
birth	O
one	O
year	O
earlier	O
.	O

This	O
pregnancy	O
had	O
been	O
complicated	O
by	O
HELLP	B-Disease_disorder
syndrome	I-Disease_disorder
with	O
a	O
subcapsular	B-Detailed_description
liver	B-Biological_structure
hematoma	B-Sign_symptom
sized	O
20	B-Area
cm	I-Area
×	I-Area
5	I-Area
cm	I-Area
,	O
which	O
had	O
resolved	B-Detailed_description
spontaneously	I-Detailed_description
.	O

At	O
current	O
presentation	O
,	O
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

She	O
assured	O
having	O
never	O
experienced	O
signs	O
suggestive	O
of	O
sexually	B-Disease_disorder
transmitted	I-Disease_disorder
diseases	I-Disease_disorder
or	O
pelvic	B-Disease_disorder
inflammatory	I-Disease_disorder
disease	I-Disease_disorder
(	B-Disease_disorder
PID	I-Disease_disorder
)	I-Disease_disorder
.	O

She	O
had	O
never	O
undergone	O
intra	B-Biological_structure
-	I-Biological_structure
abdominal	I-Biological_structure
interventions	B-Therapeutic_procedure
.	O

An	O
upper	B-Biological_structure
-	I-Biological_structure
abdominal	I-Biological_structure
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
revealed	O
a	O
density	B-Sign_symptom
between	B-Biological_structure
liver	I-Biological_structure
and	I-Biological_structure
diaphragm	I-Biological_structure
at	O
the	O
site	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
former	I-Biological_structure
subcapsular	I-Biological_structure
hematoma	I-Biological_structure
,	O
suspect	O
of	O
perihepatic	B-Sign_symptom
adhesions	I-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

She	O
was	O
referred	O
to	O
the	O
hepatobiliary	B-Nonbiological_location
surgeon	I-Nonbiological_location
,	O
who	O
performed	O
a	O
laparoscopy	B-Diagnostic_procedure
and	O
confirmed	O
the	O
presence	O
of	O
a	O
thick	B-Detailed_description
adhesion	B-Sign_symptom
between	B-Biological_structure
liver	I-Biological_structure
segment	I-Biological_structure
V	I-Biological_structure
/	I-Biological_structure
VIII	I-Biological_structure
and	I-Biological_structure
the	I-Biological_structure
diaphragm	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

Adhesiolysis	B-Therapeutic_procedure
was	O
performed	O
in	O
the	O
same	O
session	O
by	O
monopolar	B-Therapeutic_procedure
diathermia	I-Therapeutic_procedure
and	O
sharp	B-Therapeutic_procedure
dissection	I-Therapeutic_procedure
,	O
followed	O
by	O
the	O
instillation	O
of	O
1	B-Dosage
.	I-Dosage
5	I-Dosage
L	I-Dosage
Adept	B-Medication
(	O
4	B-Medication
%	I-Medication
icodextrin	I-Medication
solution	I-Medication
)	O
into	O
the	O
peritoneal	B-Biological_structure
cavity	I-Biological_structure
to	O
prevent	O
the	O
formation	O
of	O
new	O
adhesions	O
.	O

On	O
follow	O
-	O
up	O
until	B-Duration
three	I-Duration
years	I-Duration
post	I-Duration
-	I-Duration
surgery	I-Duration
,	O
she	O
was	O
free	O
of	O
symptoms	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
68	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
smoker	O
with	O
a	O
history	O
of	O
pulmonary	O
embolism	O
and	O
diabetes	O
mellitus	O
was	O
diagnosed	O
with	O
Stage	B-Detailed_description
IIIB	I-Detailed_description
(	O
T4N2M0	B-Detailed_description
)	O
squamous	B-Detailed_description
NSCLC	B-Disease_disorder
.	O

She	O
was	O
treated	O
by	O
definitive	B-Detailed_description
chemoradiotherapy	B-Therapeutic_procedure
with	O
cisplatin	B-Medication
and	O
vinorelbine	B-Medication
until	O
September	O
2014	O
.	O

In	O
October	O
2014	O
,	O
positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
-	I-Diagnostic_procedure
computed	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	B-Diagnostic_procedure
PET	I-Diagnostic_procedure
-	I-Diagnostic_procedure
CT	I-Diagnostic_procedure
)	I-Diagnostic_procedure
scan	O
demonstrated	O
a	O
good	B-Lab_value
response	I-Lab_value
in	O
the	O
primary	B-Biological_structure
lesion	I-Biological_structure
;	O
however	O
,	O
new	O
metastases	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
adrenal	I-Biological_structure
gland	I-Biological_structure
and	O
right	B-Biological_structure
femur	I-Biological_structure
developed	O
and	O
were	O
irradiated	B-Therapeutic_procedure
in	O
November	O
2014	O
.	O

A	O
month	O
later	O
the	O
disease	O
progressed	O
with	O
development	O
of	O
multiple	B-Detailed_description
bone	B-Biological_structure
and	O
subcutaneous	B-Biological_structure
metastases	B-Sign_symptom
.	O

At	O
that	O
point	O
,	O
the	O
patient	O
suffered	O
from	O
severe	B-Severity
dyspnea	B-Sign_symptom
and	O
was	O
oxygen	B-Therapeutic_procedure
-	I-Therapeutic_procedure
dependent	I-Therapeutic_procedure
.	O

She	O
received	O
one	B-Dosage
cycle	I-Dosage
of	O
carboplatin	B-Medication
and	O
gemcitabine	B-Medication
followed	O
by	O
severe	B-Severity
pancytopenia	B-Sign_symptom
,	O
and	O
treatment	O
was	O
switched	O
to	O
nivolumab	B-Medication
3	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
q14	I-Dosage
days	I-Dosage
in	O
January	O
2015	O
.	O

One	O
week	O
after	O
the	O
first	O
cycle	O
of	O
nivolumab	B-Medication
,	O
a	O
subcutaneous	B-Biological_structure
lesion	B-Sign_symptom
in	O
her	O
upper	B-Biological_structure
back	I-Biological_structure
grew	B-Detailed_description
substantially	I-Detailed_description
,	O
accompanied	O
by	O
severe	B-Severity
pain	B-Sign_symptom
and	O
significant	B-Severity
inflammatory	B-Sign_symptom
reaction	I-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

Other	O
subcutaneous	B-Biological_structure
metastases	B-Sign_symptom
grew	B-Detailed_description
slightly	I-Detailed_description
as	O
well	O
.	O

After	O
the	O
second	O
cycle	O
of	O
treatment	O
marked	O
symptomatic	B-Sign_symptom
improvement	I-Sign_symptom
was	O
observed	O
,	O
including	O
improvement	B-Sign_symptom
in	I-Sign_symptom
general	I-Sign_symptom
appearance	I-Sign_symptom
and	O
dyspnea	B-Sign_symptom
and	O
reduction	O
of	O
the	O
bone	B-Biological_structure
pain	B-Sign_symptom
.	O

The	O
patient	O
no	O
longer	O
required	O
oxygen	B-Therapeutic_procedure
supplementation	I-Therapeutic_procedure
.	O

The	O
subcutaneous	B-Biological_structure
lesions	B-Sign_symptom
started	O
to	O
regress	O
too	O
,	O
with	O
complete	B-Lab_value
resolution	I-Lab_value
by	O
the	O
12th	O
week	O
as	O
well	O
as	O
improvement	O
in	O
all	O
bone	B-Biological_structure
lesions	B-Sign_symptom
(	O
Figs	O
.	O
1	O
and	O
2	O
)	O
.	O

The	O
patient	O
continued	O
on	O
nivolumab	B-Medication
until	O
June	O
2015	O
,	O
and	O
tolerated	O
the	O
treatment	O
well	O
.	O

Unfortunately	O
,	O
she	O
developed	O
bacterial	B-Detailed_description
aspiration	I-Detailed_description
pneumonia	B-Sign_symptom
and	O
passed	O
away	O
in	O
June	O
2015	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
white	O
Brazilian	O
man	O
,	O
with	O
controlled	O
hypertension	O
and	O
stage	O
2	O
obesity	O
presented	O
to	O
our	O
institution	B-Nonbiological_location
with	O
a	O
complaint	O
of	O
progressive	B-Detailed_description
fatigue	B-Sign_symptom
with	O
moderate	B-Detailed_description
to	I-Detailed_description
light	I-Detailed_description
exertion	I-Detailed_description
of	O
approximately	B-Duration
1	I-Duration
year	I-Duration
`	O
s	O
duration	O
.	O

During	O
that	O
period	O
,	O
he	O
had	O
undergone	O
myocardial	B-Detailed_description
perfusion	I-Detailed_description
scintigraphy	B-Diagnostic_procedure
without	O
evidence	O
of	O
obstructive	B-Disease_disorder
ischemic	I-Disease_disorder
disease	I-Disease_disorder
.	O

He	O
had	O
no	O
clinical	O
evidence	O
of	O
systolic	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
.	O

He	O
had	O
undergone	O
biological	B-Detailed_description
mitral	B-Therapeutic_procedure
valve	I-Therapeutic_procedure
replacement	I-Therapeutic_procedure
3	O
years	O
previously	O
for	O
mitral	B-Disease_disorder
valve	I-Disease_disorder
stenosis	I-Disease_disorder
and	O
had	O
undergone	O
ablation	B-Therapeutic_procedure
of	O
atrioventricular	B-Biological_structure
nodal	I-Biological_structure
reentry	I-Biological_structure
tachycardia	B-Sign_symptom
18	O
months	O
previously	O
.	O

At	O
the	O
time	O
of	O
valve	O
replacement	O
,	O
there	O
was	O
no	O
reported	O
evidence	O
of	O
pulmonary	B-Disease_disorder
arterial	I-Disease_disorder
hypertension	I-Disease_disorder
.	O

The	O
patient	O
`	O
s	O
medication	O
list	O
included	O
aspirin	B-Medication
100	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
,	O
carvedilol	B-Medication
50	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
,	O
atorvastatin	B-Medication
10	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
,	O
and	O
losartan	B-Medication
25	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
.	O

His	O
echocardiogram	B-Diagnostic_procedure
showed	O
normal	B-Lab_value
function	I-Lab_value
of	O
a	O
mitral	B-Biological_structure
prosthesis	I-Biological_structure
,	O
global	B-Diagnostic_procedure
left	I-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
systolic	I-Diagnostic_procedure
function	I-Diagnostic_procedure
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
(	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
ejection	I-Diagnostic_procedure
fraction	I-Diagnostic_procedure
62	B-Lab_value
%	I-Lab_value
measured	O
using	B-Detailed_description
the	I-Detailed_description
Teichholz	I-Detailed_description
method	I-Detailed_description
)	O
,	O
stage	B-Lab_value
I	I-Lab_value
diastolic	B-Disease_disorder
dysfunction	I-Disease_disorder
,	O
and	O
mean	B-Detailed_description
pulmonary	B-Biological_structure
arterial	I-Biological_structure
systolic	B-Detailed_description
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
50	B-Lab_value
mmHg	I-Lab_value
.	O

In	O
the	O
6	B-Detailed_description
-	I-Detailed_description
minute	I-Detailed_description
walk	B-Diagnostic_procedure
test	I-Diagnostic_procedure
,	O
the	O
patient	O
walked	O
104	B-Lab_value
meters	I-Lab_value
(	O
Table	O
1	O
)	O
.	O

Catheterization	B-Diagnostic_procedure
of	O
his	O
right	B-Biological_structure
heart	I-Biological_structure
chambers	I-Biological_structure
and	O
pulmonary	B-Biological_structure
arteries	I-Biological_structure
confirmed	O
the	O
diagnosis	O
of	O
pulmonary	B-Disease_disorder
hypertension	I-Disease_disorder
(	O
Table	O
2	O
)	O
.	O

During	O
the	O
follow	O
-	O
up	O
period	O
,	O
therapy	O
with	O
nifedipine	B-Medication
and	O
sildenafil	B-Medication
was	O
not	O
tolerated	O
secondary	O
to	O
orthostatic	B-Detailed_description
hypotension	B-Sign_symptom
.	O

The	O
patient	O
was	O
referred	O
for	O
radiofrequency	B-Detailed_description
ablation	B-Therapeutic_procedure
of	O
the	O
pulmonary	B-Biological_structure
artery	I-Biological_structure
trunk	I-Biological_structure
for	O
the	O
treatment	O
of	O
refractory	B-Detailed_description
pulmonary	B-Disease_disorder
hypertension	I-Disease_disorder
.	O

The	O
procedure	O
was	O
performed	O
in	O
the	O
catheterization	B-Nonbiological_location
laboratory	I-Nonbiological_location
with	O
direct	B-Detailed_description
visualization	I-Detailed_description
using	I-Detailed_description
fluoroscopy	I-Detailed_description
and	I-Detailed_description
radiopaque	I-Detailed_description
contrast	I-Detailed_description
dye	I-Detailed_description
.	O

The	O
patient	O
remained	O
under	O
unconscious	O
sedation	B-Therapeutic_procedure
.	O

Catheterization	B-Diagnostic_procedure
of	O
the	O
right	B-Biological_structure
femoral	I-Biological_structure
artery	I-Biological_structure
via	O
the	O
standard	B-Detailed_description
Seldinger	I-Detailed_description
technique	I-Detailed_description
was	O
performed	O
using	B-Detailed_description
an	I-Detailed_description
8	I-Detailed_description
-	I-Detailed_description
French	I-Detailed_description
valved	I-Detailed_description
short	I-Detailed_description
sheath	I-Detailed_description
after	O
subcutaneous	O
injection	O
of	O
a	O
local	B-Medication
anesthetic	I-Medication
.	O

Subsequently	O
,	O
this	O
sheath	B-Detailed_description
was	I-Detailed_description
replaced	I-Detailed_description
with	I-Detailed_description
a	I-Detailed_description
steerable	I-Detailed_description
long	I-Detailed_description
sheath	I-Detailed_description
(	O
Agilis	B-Detailed_description
®	I-Detailed_description
;	I-Detailed_description
St	I-Detailed_description
.	I-Detailed_description
Jude	I-Detailed_description
Medical	I-Detailed_description
,	I-Detailed_description
St	I-Detailed_description
.	I-Detailed_description
Paul	I-Detailed_description
,	I-Detailed_description
MN	I-Detailed_description
,	I-Detailed_description
USA	I-Detailed_description
)	O
using	B-Detailed_description
the	I-Detailed_description
standard	I-Detailed_description
over	I-Detailed_description
-	I-Detailed_description
the	I-Detailed_description
-	I-Detailed_description
wire	I-Detailed_description
technique	I-Detailed_description
.	O

Unfractionated	B-Medication
heparin	I-Medication
was	O
administered	O
intravenously	O
,	O
targeting	O
an	O
activated	B-Diagnostic_procedure
coagulation	I-Diagnostic_procedure
time	I-Diagnostic_procedure
between	B-Lab_value
250	I-Lab_value
and	I-Lab_value
350	I-Lab_value
seconds	I-Lab_value
.	O

Electroanatomic	B-Diagnostic_procedure
reconstruction	I-Diagnostic_procedure
of	O
both	O
the	O
right	B-Biological_structure
ventricular	I-Biological_structure
outflow	I-Biological_structure
tract	I-Biological_structure
and	O
pulmonary	B-Biological_structure
artery	I-Biological_structure
was	O
performed	O
using	O
the	O
EnSite	B-Detailed_description
Velocity	I-Detailed_description
Cardiac	I-Detailed_description
Mapping	I-Detailed_description
System	I-Detailed_description
(	O
St	B-Detailed_description
.	I-Detailed_description
Jude	I-Detailed_description
Medical	I-Detailed_description
)	O
under	O
direct	B-Detailed_description
fluoroscopic	I-Detailed_description
visualization	I-Detailed_description
,	O
and	O
a	O
merger	O
was	O
made	O
with	O
the	O
formatted	O
image	O
obtained	O
by	O
performing	O
cardiac	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
angiography	I-Diagnostic_procedure
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
Agilis	B-Detailed_description
®	I-Detailed_description
sheath	B-Diagnostic_procedure
was	I-Diagnostic_procedure
advanced	I-Diagnostic_procedure
into	O
the	O
right	B-Biological_structure
ventricular	I-Biological_structure
outflow	I-Biological_structure
tract	I-Biological_structure
just	O
before	B-Biological_structure
reaching	I-Biological_structure
the	I-Biological_structure
pulmonary	I-Biological_structure
valve	I-Biological_structure
.	O

Through	O
this	O
long	O
sheath	O
,	O
we	O
introduced	O
an	O
ablation	B-Therapeutic_procedure
catheter	I-Therapeutic_procedure
with	O
an	O
open	B-Detailed_description
irrigated	I-Detailed_description
tip	I-Detailed_description
(	O
St	B-Detailed_description
.	I-Detailed_description
Jude	I-Detailed_description
Medical	I-Detailed_description
)	O
.	O

The	O
parameters	O
used	O
for	O
each	O
application	O
according	O
to	O
our	O
protocol	O
were	O
as	O
follows	O
:	O
power	B-Lab_value
of	I-Lab_value
5	I-Lab_value
W	I-Lab_value
,	O
maximum	B-Lab_value
temperature	I-Lab_value
of	I-Lab_value
48	I-Lab_value
°C	I-Lab_value
,	O
60	B-Lab_value
-	I-Lab_value
second	I-Lab_value
duration	I-Lab_value
in	I-Lab_value
each	I-Lab_value
spot	I-Lab_value
,	O
maximum	B-Lab_value
impedance	I-Lab_value
variation	I-Lab_value
of	I-Lab_value
10	I-Lab_value
%	I-Lab_value
from	I-Lab_value
baseline	I-Lab_value
values	I-Lab_value
,	O
and	O
an	O
irrigation	B-Lab_value
flow	I-Lab_value
rate	I-Lab_value
of	I-Lab_value
17	I-Lab_value
ml	I-Lab_value
/	I-Lab_value
minute	I-Lab_value
,	O
which	O
created	B-Therapeutic_procedure
a	I-Therapeutic_procedure
circle	I-Therapeutic_procedure
in	O
the	O
pulmonary	B-Biological_structure
artery	I-Biological_structure
trunk	I-Biological_structure
.	O

The	O
patient	O
was	O
discharged	O
the	O
next	B-Time
morning	I-Time
.	O

No	O
noteworthy	O
changes	B-Sign_symptom
before	O
or	O
after	O
the	O
procedure	O
or	O
before	O
discharge	O
in	O
the	O
patient	O
`	O
s	O
radiographic	B-Detailed_description
or	I-Detailed_description
echocardiographic	I-Detailed_description
laboratory	I-Detailed_description
parameters	I-Detailed_description
were	O
seen	O
.	O

The	O
patient	O
`	O
s	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
in	O
both	B-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
heart	I-Biological_structure
chambers	I-Biological_structure
and	O
the	O
pulmonary	B-Biological_structure
artery	I-Biological_structure
were	O
determined	O
using	B-Detailed_description
catheterization	I-Detailed_description
before	O
and	O
at	O
3	O
and	O
6	O
months	O
after	O
the	O
procedure	O
.	O

The	O
results	O
are	O
shown	O
in	O
Table	O
2	O
.	O

At	O
the	O
patient	O
`	O
s	O
3	O
-	O
month	O
follow	O
-	O
up	O
examination	O
,	O
he	O
showed	O
an	O
improvement	B-Lab_value
in	O
functional	B-Diagnostic_procedure
class	I-Diagnostic_procedure
for	I-Diagnostic_procedure
fatigue	I-Diagnostic_procedure
with	I-Diagnostic_procedure
major	I-Diagnostic_procedure
exertion	I-Diagnostic_procedure
.	O

He	O
also	O
demonstrated	O
an	O
increased	B-Lab_value
distance	I-Lab_value
walked	O
in	O
the	O
6	B-Detailed_description
-	I-Detailed_description
minute	I-Detailed_description
walk	B-Diagnostic_procedure
test	I-Diagnostic_procedure
and	O
reduction	B-Lab_value
of	O
the	O
pressures	B-Diagnostic_procedure
in	O
both	O
the	O
right	B-Biological_structure
cavities	I-Biological_structure
and	O
the	O
pulmonary	B-Biological_structure
artery	I-Biological_structure
.	O

Currently	O
,	O
with	O
6	B-Duration
months	I-Duration
of	O
clinical	O
follow	O
-	O
up	O
,	O
he	O
has	O
maintained	O
his	O
improvement	B-Lab_value
in	O
functional	B-Diagnostic_procedure
classification	I-Diagnostic_procedure
and	O
is	O
pedaling	B-Activity
his	I-Activity
bicycle	I-Activity
.	O

-DOCSTART- -X- -X- -X- O

A	O
31	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
developed	O
diabetes	B-Disease_disorder
insipidus	I-Disease_disorder
with	O
urine	B-Diagnostic_procedure
volume	I-Diagnostic_procedure
up	O
to	O
10	B-Volume
to	I-Volume
20	I-Volume
L	I-Volume
every	B-Frequency
24	I-Frequency
hours	I-Frequency
in	O
2003	O
.	O

Four	O
years	O
later	O
,	O
he	O
complained	O
of	O
fatigue	B-Sign_symptom
,	O
anorexia	B-Sign_symptom
,	O
jaundice	B-Sign_symptom
and	O
pruritus	B-Sign_symptom
,	O
and	O
a	O
symptomatic	B-Detailed_description
occipital	B-Biological_structure
mass	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
an	O
abnormal	B-Lab_value
liver	B-Diagnostic_procedure
enzyme	I-Diagnostic_procedure
(	O
Table	O
1	O
)	O
,	O
the	O
patient	O
was	O
negative	B-Lab_value
for	O
hepatitis	B-Diagnostic_procedure
viruses	I-Diagnostic_procedure
.	O

As	O
shown	O
in	O
Fig	O
.	O
1	O
,	O
abdominal	B-Biological_structure
MRI	B-Diagnostic_procedure
showed	O
multiple	B-Detailed_description
low	B-Detailed_description
-	I-Detailed_description
density	I-Detailed_description
lesions	B-Sign_symptom
in	O
the	O
liver	B-Biological_structure
on	O
the	O
T1	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
image	I-Diagnostic_procedure
and	O
obvious	B-Severity
expansion	B-Sign_symptom
of	O
the	O
intrahepatic	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
on	O
the	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
image	I-Diagnostic_procedure
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
cholangiopancreatography	I-Diagnostic_procedure
revealed	O
multifocal	B-Detailed_description
intrahepatic	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
strictures	B-Sign_symptom
and	O
dilatation	B-Sign_symptom
,	O
but	O
the	O
common	B-Diagnostic_procedure
hepatic	I-Diagnostic_procedure
duct	I-Diagnostic_procedure
was	O
normal	B-Lab_value
,	O
it	O
was	O
highly	O
suggestive	O
of	O
SC	B-Disease_disorder
.	O

The	O
neurohypophyseal	B-Biological_structure
area	I-Biological_structure
MRI	B-Diagnostic_procedure
showed	O
the	O
thickened	B-Sign_symptom
hypothalamic	B-Biological_structure
nuclei	I-Biological_structure
and	O
a	O
low	B-Detailed_description
-	I-Detailed_description
density	I-Detailed_description
signal	B-Sign_symptom
of	O
4	B-Area
.	I-Area
9	I-Area
×	I-Area
5	I-Area
.	I-Area
6	I-Area
mm	I-Area
in	O
size	O
in	O
the	O
hypothalamic	B-Biological_structure
-	I-Biological_structure
pituitary	I-Biological_structure
area	I-Biological_structure
.	O

A	O
multisystem	B-Detailed_description
,	O
high	B-Severity
-	I-Severity
risk	I-Severity
organ	B-Detailed_description
LCH	B-Disease_disorder
was	O
confirmed	O
after	O
occipital	B-Biological_structure
mass	B-Sign_symptom
was	O
biopsied	B-Diagnostic_procedure
in	O
the	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
,	O
the	O
patient	O
was	O
given	O
ursodeoxycholic	B-Medication
acid	I-Medication
150	B-Dosage
mg	I-Dosage
3	I-Dosage
times	I-Dosage
a	I-Dosage
day	I-Dosage
.	O

Then	O
,	O
he	O
began	O
to	O
receive	O
a	O
course	O
of	O
COEP	B-Medication
chemotherapy	I-Medication
(	O
cyclophosphamide	B-Medication
,	O
1000	B-Dosage
mg	I-Dosage
;	O
vincristine	B-Medication
,	O
2	B-Dosage
mg	I-Dosage
;	O
epirubicin	B-Medication
,	O
90	B-Dosage
mg	I-Dosage
;	O
and	O
prednisone	B-Medication
,	O
90	B-Dosage
mg	I-Dosage
)	O
in	O
2009	O
.	O

However	O
,	O
on	O
the	O
5th	O
day	O
of	O
the	O
1st	O
COEP	B-Medication
chemotherapy	I-Medication
,	O
the	O
patient	O
appeared	O
to	O
severe	B-Severity
liver	B-Biological_structure
function	B-Disease_disorder
injury	I-Disease_disorder
with	O
an	O
obvious	B-Severity
increase	B-Lab_value
of	O
serum	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
(	O
Table	O
1	O
)	O
.	O

He	O
refused	O
further	O
chemotherapy	B-Medication
.	O

One	O
year	O
later	O
,	O
the	O
patient	O
developed	O
liver	B-Biological_structure
decompensation	B-Disease_disorder
with	O
bleeding	B-Detailed_description
esophageal	B-Biological_structure
varices	B-Sign_symptom
,	O
ascites	B-Sign_symptom
,	O
and	O
splenomegaly	B-Sign_symptom
,	O
and	O
he	O
was	O
referred	O
to	O
LT	B-Therapeutic_procedure
(	O
Model	B-Diagnostic_procedure
for	I-Diagnostic_procedure
End	I-Diagnostic_procedure
Stage	I-Diagnostic_procedure
Liver	I-Diagnostic_procedure
Disease	I-Diagnostic_procedure
score	O
17	B-Lab_value
)	O
.	O

He	O
underwent	O
successful	O
orthotopic	B-Detailed_description
LT	B-Therapeutic_procedure
in	O
November	O
2011	O
in	O
our	O
center	B-Nonbiological_location
,	O
and	O
the	O
donor	O
came	O
from	O
voluntary	B-Detailed_description
deceased	I-Detailed_description
citizen	I-Detailed_description
organ	O
donation	O
in	O
China	B-Nonbiological_location
.	O

Liver	B-Diagnostic_procedure
histopathology	I-Diagnostic_procedure
after	O
LT	B-Therapeutic_procedure
revealed	O
micronodular	B-Detailed_description
cirrhosis	B-Disease_disorder
with	O
SC	B-Disease_disorder
and	O
positive	B-Lab_value
immunostaining	B-Diagnostic_procedure
(	O
CD1a	B-Diagnostic_procedure
and	O
S100	B-Diagnostic_procedure
)	O
,	O
suggestive	O
of	O
LCH	B-Disease_disorder
involving	O
in	O
the	O
liver	B-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

Postoperatively	O
,	O
the	O
man	O
continued	O
to	O
be	O
immunosuppressed	B-Disease_disorder
with	O
tacrolimus	B-Medication
and	O
mycofenolate	B-Medication
mofetil	I-Medication
.	O

The	O
patient	O
is	O
currently	O
well	B-Sign_symptom
with	O
normal	B-Lab_value
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
and	O
no	O
evidence	O
of	O
recurrence	B-Sign_symptom
of	O
LCH	B-Disease_disorder
for	O
4	O
and	O
a	O
half	O
years	O
follow	O
-	O
up	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
13	B-Age
year	I-Age
-	I-Age
old	I-Age
boy	O
presented	O
with	O
a	O
1	B-Duration
month	I-Duration
history	O
of	O
intermittent	B-Biological_structure
episodes	O
of	O
small	B-Detailed_description
volume	I-Detailed_description
epistaxis	B-Sign_symptom
.	O

There	O
was	O
no	O
significant	O
past	O
medical	O
,	O
surgical	O
or	O
family	O
history	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
left	B-Biological_structure
palatal	I-Biological_structure
fleshy	B-Detailed_description
mass	B-Sign_symptom
centered	O
at	O
left	B-Biological_structure
posterior	I-Biological_structure
molars	I-Biological_structure
.	O

A	O
nasoendoscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
demonstrated	O
a	O
large	B-Severity
swelling	B-Sign_symptom
on	O
the	O
floor	B-Biological_structure
of	I-Biological_structure
left	I-Biological_structure
anterior	I-Biological_structure
nasal	I-Biological_structure
space	I-Biological_structure
,	O
involving	O
the	O
left	B-Biological_structure
inferior	I-Biological_structure
meatus	I-Biological_structure
and	O
abutting	O
the	O
inferior	B-Biological_structure
turbinate	I-Biological_structure
.	O

Computed	B-Diagnostic_procedure
Tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
of	O
the	O
paranasal	B-Biological_structure
sinuses	I-Biological_structure
showed	O
a	O
lobulated	B-Detailed_description
,	O
expansile	B-Detailed_description
lytic	B-Detailed_description
lesion	B-Sign_symptom
of	O
left	B-Biological_structure
maxilla	I-Biological_structure
[	O
Fig	O
1	O
]	O
with	O
a	O
lucent	B-Detailed_description
center	I-Detailed_description
and	O
peripheral	B-Detailed_description
calcifications	I-Detailed_description
.	O

The	O
lesion	O
was	O
associated	O
with	O
a	O
large	B-Detailed_description
soft	I-Detailed_description
tissue	I-Detailed_description
component	I-Detailed_description
that	O
demonstrated	O
mild	B-Severity
heterogeneous	B-Detailed_description
contrast	B-Sign_symptom
enhancement	I-Sign_symptom
.	O

The	O
lesion	O
was	O
centered	O
at	O
the	O
left	B-Biological_structure
maxillary	I-Biological_structure
alveolus	I-Biological_structure
,	O
involving	O
the	O
left	B-Biological_structure
hard	I-Biological_structure
palate	I-Biological_structure
,	O
inferior	B-Biological_structure
part	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
anterior	I-Biological_structure
left	I-Biological_structure
maxillary	I-Biological_structure
wall	I-Biological_structure
and	O
medial	B-Biological_structure
left	I-Biological_structure
maxillary	I-Biological_structure
wall	I-Biological_structure
.	O

The	O
lesion	O
also	O
involved	O
the	O
roots	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
maxillary	I-Biological_structure
molars	I-Biological_structure
and	I-Biological_structure
pre	I-Biological_structure
-	I-Biological_structure
molars	I-Biological_structure
and	O
was	O
abutting	O
the	O
left	B-Biological_structure
orbital	I-Biological_structure
floor	I-Biological_structure
,	O
with	O
no	O
gross	O
orbital	B-Biological_structure
invasion	B-Sign_symptom
.	O

The	O
patient	O
subsequently	O
underwent	O
18	B-Diagnostic_procedure
-	I-Diagnostic_procedure
FDG	I-Diagnostic_procedure
PET	I-Diagnostic_procedure
-	I-Diagnostic_procedure
CT	I-Diagnostic_procedure
study	I-Diagnostic_procedure
.	O

The	O
mass	O
centered	O
in	O
left	B-Biological_structure
maxilla	I-Biological_structure
was	O
hypermetabolic	B-Detailed_description
,	O
with	O
index	B-Lab_value
SUVmax	I-Lab_value
9	I-Lab_value
.	I-Lab_value
7	I-Lab_value
[	O
Fig	O
2	O
]	O
.	O

There	O
was	O
no	O
FDG	B-Detailed_description
-	I-Detailed_description
avid	I-Detailed_description
metastatic	B-Disease_disorder
disease	I-Disease_disorder
.	O

A	O
trans	B-Detailed_description
-	I-Detailed_description
oral	I-Detailed_description
incisional	B-Diagnostic_procedure
biopsy	I-Diagnostic_procedure
of	O
the	O
left	B-Biological_structure
palatal	I-Biological_structure
mass	B-Sign_symptom
was	O
performed	O
and	O
was	O
suggestive	O
of	O
a	O
preliminary	O
diagnosis	O
of	O
mesenchymal	B-Disease_disorder
chondrosarcoma	I-Disease_disorder
,	O
as	O
evidenced	O
by	O
a	O
biphasic	B-Detailed_description
pattern	I-Detailed_description
featuring	O
sheets	B-Detailed_description
of	I-Detailed_description
small	I-Detailed_description
round	I-Detailed_description
cells	I-Detailed_description
with	O
hemangiopericytoma	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
vascular	I-Detailed_description
pattern	I-Detailed_description
and	O
mature	B-Detailed_description
cartilaginous	I-Detailed_description
islands	I-Detailed_description
.	O

The	O
patient	O
underwent	O
left	B-Detailed_description
subtotal	I-Detailed_description
maxillectomy	B-Therapeutic_procedure
via	O
lateral	B-Detailed_description
rhinotomy	B-Therapeutic_procedure
and	O
translabial	B-Detailed_description
approach	I-Detailed_description
.	O

The	O
final	O
histology	B-Diagnostic_procedure
was	O
conclusive	O
of	O
a	O
5	B-Distance
cm	I-Distance
high	B-Lab_value
-	I-Lab_value
grade	I-Lab_value
(	O
Grade	B-Lab_value
3	I-Lab_value
)	O
mesenchymal	B-Disease_disorder
chondrosarcoma	I-Disease_disorder
.	O

One	O
of	O
the	O
resection	B-Biological_structure
margins	I-Biological_structure
was	O
positive	O
for	O
tumor	B-Sign_symptom
involvement	I-Sign_symptom
and	O
the	O
patient	O
was	O
planned	O
for	O
adjuvant	B-Detailed_description
chemotherapy	B-Medication
.	O

-DOCSTART- -X- -X- -X- O

A	O
woman	O
in	O
her	O
60s	B-Age
was	O
found	O
to	O
have	O
screen	B-Diagnostic_procedure
detected	O
invasive	B-Detailed_description
lobular	B-Detailed_description
breast	B-Disease_disorder
carcinoma	I-Disease_disorder
of	O
the	O
right	B-Biological_structure
breast	I-Biological_structure
and	O
invasive	B-Detailed_description
ductal	B-Disease_disorder
carcinoma	I-Disease_disorder
,	O
no	B-Detailed_description
special	I-Detailed_description
type	I-Detailed_description
,	O
of	O
the	O
left	B-Biological_structure
breast	I-Biological_structure
.	O

Staging	O
CT	B-Diagnostic_procedure
imaging	I-Diagnostic_procedure
prior	O
to	O
mastectomy	B-Therapeutic_procedure
showed	O
a	O
12	B-Distance
cm	I-Distance
pelvic	B-Biological_structure
mass	B-Sign_symptom
which	O
on	O
initial	O
impression	O
was	O
thought	O
to	O
be	O
a	O
fibroid	B-Sign_symptom
uterus	B-Biological_structure
.	O

Associated	O
postmenopausal	B-Detailed_description
bleeding	B-Sign_symptom
led	O
to	O
pelvic	B-Biological_structure
ultrasound	B-Diagnostic_procedure
,	O
hysteroscopy	B-Diagnostic_procedure
and	O
biopsy	B-Diagnostic_procedure
.	O

The	O
biopsy	B-Diagnostic_procedure
showed	O
undifferentiated	B-Detailed_description
sarcoma	B-Disease_disorder
,	O
unclassifiable	B-Lab_value
with	O
immunohistochemistry	B-Diagnostic_procedure
.	O

Following	O
discussion	O
at	O
a	O
multidisciplinary	O
team	O
meeting	O
it	O
was	O
felt	O
that	O
the	O
uterine	B-Biological_structure
tumour	B-Sign_symptom
was	O
a	O
separate	O
primary	B-Detailed_description
malignancy	I-Detailed_description
rather	O
than	O
metastasis	B-Disease_disorder
from	O
the	O
breast	B-Biological_structure
.	O

Hysterectomy	B-Therapeutic_procedure
and	O
bilateral	B-Detailed_description
salpingo	B-Therapeutic_procedure
-	I-Therapeutic_procedure
oophorectomy	I-Therapeutic_procedure
was	O
performed	O
for	O
both	O
treatment	O
purposes	O
and	O
to	O
fully	O
categorise	O
the	O
malignancy	O
to	O
guide	O
further	O
adjuvant	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

Histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
resection	O
specimen	O
showed	O
a	O
partially	B-Detailed_description
necrotic	I-Detailed_description
tumour	B-Sign_symptom
with	O
a	O
discrete	B-Detailed_description
outline	I-Detailed_description
located	O
within	O
and	O
extending	O
throughout	O
the	O
myometrium	B-Biological_structure
.	O

The	O
tumour	O
was	O
composed	O
of	O
malignant	B-Detailed_description
spindle	I-Detailed_description
cells	I-Detailed_description
(	O
figure	O
1A	O
)	O
,	O
with	O
an	O
intermittent	O
component	O
of	O
pleomorphic	B-Detailed_description
cells	I-Detailed_description
with	O
abundant	O
eosinophilic	B-Detailed_description
cytoplasm	I-Detailed_description
.	O

Plentiful	B-Detailed_description
osteoclast	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
giant	B-Sign_symptom
cells	I-Sign_symptom
were	O
present	O
(	O
figure	O
1B	O
)	O
.	O

Mitoses	B-Diagnostic_procedure
were	O
numerous	B-Lab_value
and	O
structurally	B-Sign_symptom
abnormal	I-Sign_symptom
forms	I-Sign_symptom
were	O
common	O
.	O

Neoplastic	O
cells	O
were	O
surrounded	O
by	O
hyaline	O
osteoid	O
matrix	O
and	O
foci	O
of	O
coarse	O
neoplastic	O
woven	O
bone	O
(	O
figure	O
1C	O
)	O
.	O

Generous	O
sampling	O
of	O
the	O
tumour	O
showed	O
no	O
admixed	O
neoplastic	B-Sign_symptom
epithelial	I-Sign_symptom
elements	I-Sign_symptom
,	O
thus	O
ruling	O
out	O
the	O
more	O
common	O
carcinosarcoma	O
(	O
malignant	B-Disease_disorder
mixed	I-Disease_disorder
Müllerian	I-Disease_disorder
tumour	I-Disease_disorder
)	O
.	O

Tumour	O
cells	O
showed	O
immunohistochemical	B-Diagnostic_procedure
expression	B-Lab_value
for	O
vimentin	B-Diagnostic_procedure
,	O
smooth	B-Diagnostic_procedure
muscle	I-Diagnostic_procedure
actin	I-Diagnostic_procedure
(	O
SMA	B-Diagnostic_procedure
)	O
,	O
desmin	B-Diagnostic_procedure
(	O
focally	B-Lab_value
)	O
and	O
CD99	B-Diagnostic_procedure
.	O

Epithelial	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
were	O
not	B-Lab_value
expressed	I-Lab_value
.	O

The	O
morphological	O
and	O
immunohistochemical	O
appearances	O
were	O
in	O
keeping	O
with	O
primary	B-Detailed_description
uterine	I-Detailed_description
osteoblastic	I-Detailed_description
variant	I-Detailed_description
of	O
osteosarcoma	B-Disease_disorder
.	O

Unfortunately	O
,	O
despite	O
treatment	O
,	O
further	O
CT	B-Diagnostic_procedure
imaging	I-Diagnostic_procedure
showed	O
the	O
development	O
of	O
multiple	B-Detailed_description
peritoneal	B-Biological_structure
and	O
pulmonary	B-Biological_structure
deposits	B-Sign_symptom
,	O
confirmed	O
on	O
biopsy	B-Diagnostic_procedure
to	O
be	O
metastatic	B-Detailed_description
osteosarcoma	B-Disease_disorder
.	O

The	O
patient	O
received	O
palliative	B-Detailed_description
chemotherapy	B-Therapeutic_procedure
and	O
died	O
several	O
months	O
later	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
68	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
nonsmoker	O
,	O
nondrinker	O
with	O
a	O
medical	O
history	O
of	O
hypertension	O
presented	O
with	O
new	B-Detailed_description
-	I-Detailed_description
onset	I-Detailed_description
painless	B-Detailed_description
jaundice	B-Sign_symptom
and	O
pruritus	B-Sign_symptom
,	O
a	O
three	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
9	B-Lab_value
.	I-Lab_value
9	I-Lab_value
kg	I-Lab_value
weight	B-Sign_symptom
loss	I-Sign_symptom
and	O
chronic	B-Detailed_description
diarrhea	B-Sign_symptom
with	O
four	B-Lab_value
to	I-Lab_value
five	I-Lab_value
loose	B-Lab_value
bowel	B-Diagnostic_procedure
movements	I-Diagnostic_procedure
per	B-Detailed_description
day	I-Detailed_description
.	O

Medications	B-Medication
included	O
vitamin	B-Medication
D	I-Medication
,	O
amlodipine	B-Medication
and	O
eprosartan	B-Medication
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
normal	B-Lab_value
except	O
for	O
jaundice	B-Sign_symptom
and	O
muscle	B-Disease_disorder
wasting	I-Disease_disorder
.	O

Recent	O
colonoscopy	B-Diagnostic_procedure
had	O
been	O
normal	B-Lab_value
.	O

Total	B-Detailed_description
and	O
direct	B-Detailed_description
bilirubin	B-Diagnostic_procedure
levels	O
were	O
6	B-Lab_value
.	I-Lab_value
84	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
116	B-Lab_value
.	I-Lab_value
96	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
and	O
9	B-Lab_value
.	I-Lab_value
18	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
156	B-Lab_value
.	I-Lab_value
98	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
respectively	O
.	O

Other	O
results	O
included	O
an	O
international	B-Diagnostic_procedure
normalized	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
of	O
1	B-Lab_value
.	I-Lab_value
0	I-Lab_value
,	O
alanine	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
level	O
247	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
<	O
33	O
U	O
/	O
L	O
)	O
,	O
aspartate	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
level	O
139	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
<	O
32	O
U	O
/	O
L	O
)	O
and	O
alkaline	B-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
level	O
524	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
35	O
to	O
104	O
U	O
/	O
L	O
)	O
.	O

Viral	B-Diagnostic_procedure
hepatitis	I-Diagnostic_procedure
serologies	I-Diagnostic_procedure
,	O
and	O
antimitochondrial	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
and	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
smooth	I-Diagnostic_procedure
muscle	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
tests	O
were	O
negative	B-Lab_value
.	O

Her	O
alpha	B-Diagnostic_procedure
-	I-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
level	O
was	O
2	B-Lab_value
.	I-Lab_value
4	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
<	O
5	O
ng	O
/	O
mL	O
)	O
,	O
total	B-Diagnostic_procedure
immunoglobulin	I-Diagnostic_procedure
(	I-Diagnostic_procedure
Ig	I-Diagnostic_procedure
)	I-Diagnostic_procedure
G	I-Diagnostic_procedure
was	O
1880	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
normal	O
<	O
640	O
mg	O
/	O
dL	O
)	O
,	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
was	O
856	B-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
<	O
33	O
U	O
/	O
mL	O
)	O
and	O
IgG4	B-Diagnostic_procedure
was	O
890	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
<	O
3	O
g	O
/	O
L	O
)	O
.	O

Doppler	B-Detailed_description
ultrasound	B-Diagnostic_procedure
,	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
cholangiopancreatography	I-Diagnostic_procedure
and	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
of	O
the	O
liver	B-Biological_structure
were	O
suspicious	O
for	O
a	O
subtly	B-Detailed_description
enhancing	I-Detailed_description
mass	B-Sign_symptom
(	O
2	B-Distance
.	I-Distance
8	I-Distance
cm	I-Distance
to	I-Distance
4	I-Distance
.	I-Distance
2	I-Distance
cm	I-Distance
in	O
diameter	O
)	O
in	O
the	O
region	O
of	O
the	O
hilum	B-Biological_structure
and	O
porta	B-Biological_structure
hepatis	I-Biological_structure
,	O
obstructing	B-Sign_symptom
both	O
the	O
right	B-Biological_structure
and	I-Biological_structure
left	I-Biological_structure
hepatic	I-Biological_structure
ducts	I-Biological_structure
.	O

Endoscopic	B-Detailed_description
retrograde	B-Detailed_description
cholangiopancreatography	B-Diagnostic_procedure
identified	O
strictures	B-Sign_symptom
in	O
the	O
central	B-Biological_structure
portions	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
and	I-Biological_structure
left	I-Biological_structure
hepatic	I-Biological_structure
duct	I-Biological_structure
,	O
which	O
was	O
concerning	O
for	O
cholangiocarcinoma	B-Disease_disorder
(	O
Figure	O
1	O
)	O
.	O

Biliary	B-Diagnostic_procedure
brushings	I-Diagnostic_procedure
were	O
negative	B-Lab_value
for	I-Lab_value
malignancy	I-Lab_value
.	O

Esophagogastroduodenoscopy	B-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

Biopsies	B-Diagnostic_procedure
of	O
the	O
ampulla	B-Biological_structure
of	I-Biological_structure
Vater	I-Biological_structure
revealed	O
chronic	B-Detailed_description
active	B-Detailed_description
duodenitis	B-Disease_disorder
(	O
Figures	O
2	O
and	O
and3	O
)	O
;	O
3	O
)	O
;	O
an	O
ancillary	B-Diagnostic_procedure
test	I-Diagnostic_procedure
confirmed	B-Lab_value
the	I-Lab_value
diagnosis	I-Lab_value
(	O
Figure	O
4	O
)	O
.	O

Treatment	O
with	O
corticosteroids	B-Medication
normalized	O
the	O
patient	O
`	O
s	O
biochemical	B-Detailed_description
and	O
radiological	B-Detailed_description
abnormalities	B-Disease_disorder
within	O
three	O
months	O
.	O

-DOCSTART- -X- -X- -X- O

This	O
is	O
the	O
case	O
of	O
a	O
58	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
white	O
Hispanic	O
woman	O
with	O
a	O
history	O
of	O
uveal	O
melanoma	O
in	O
her	O
right	O
eye	O
(	O
Fig	O
.	O
1	O
)	O
.	O

She	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
jaundice	B-Sign_symptom
and	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
for	O
10	B-Duration
days	I-Duration
.	O

On	O
admission	O
,	O
laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
were	O
obtained	O
(	O
a	O
complete	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
,	O
amylase	B-Diagnostic_procedure
:	O
136	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
:	O
6	B-Lab_value
.	I-Lab_value
37	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
with	O
a	O
direct	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
5	B-Lab_value
.	I-Lab_value
30	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
.	O

Cross	B-Detailed_description
-	I-Detailed_description
sectional	I-Detailed_description
,	O
abdominal	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
with	B-Detailed_description
contrast	I-Detailed_description
,	O
showed	O
a	O
low	B-Detailed_description
-	I-Detailed_description
attenuating	I-Detailed_description
lesion	B-Sign_symptom
localized	O
in	O
the	O
pancreatic	B-Biological_structure
head	I-Biological_structure
(	O
measuring	O
4	B-Area
×	I-Area
3	I-Area
cm	I-Area
)	O
and	O
a	O
thinner	B-Biological_structure
section	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
distal	I-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
suspicious	O
for	O
compression	O
)	O
.	O

After	O
a	O
multidisciplinary	O
meeting	O
,	O
our	O
patient	O
was	O
scheduled	O
for	O
EUS	B-Diagnostic_procedure
-	I-Diagnostic_procedure
FNA	I-Diagnostic_procedure
.	O

EUS	O
showed	O
a	O
solid	B-Detailed_description
,	O
heteroechoic	B-Detailed_description
with	O
predominantly	B-Detailed_description
hypoechoic	I-Detailed_description
areas	I-Detailed_description
,	O
well	B-Detailed_description
-	I-Detailed_description
defined	I-Detailed_description
lesion	B-Sign_symptom
with	O
regular	B-Texture
contours	I-Texture
(	O
measuring	O
3	B-Area
.	I-Area
1	I-Area
×	I-Area
2	I-Area
.	I-Area
6	I-Area
cm	I-Area
)	O
,	O
localized	O
between	B-Biological_structure
the	I-Biological_structure
head	I-Biological_structure
and	I-Biological_structure
neck	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
pancreas	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

There	O
was	O
no	O
vascular	B-Sign_symptom
or	I-Sign_symptom
lymph	I-Sign_symptom
node	I-Sign_symptom
invasion	I-Sign_symptom
identified	O
.	O

EUS	O
-	O
FNA	O
was	O
performed	O
with	B-Detailed_description
a	I-Detailed_description
22G	I-Detailed_description
needle	I-Detailed_description
using	B-Detailed_description
the	I-Detailed_description
fanning	I-Detailed_description
technique	I-Detailed_description
.	O

In	O
the	O
cytology	B-Diagnostic_procedure
specimens	I-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
,	O
the	O
cells	B-Biological_structure
presented	O
have	O
a	O
discohesive	B-Lab_value
dispersed	I-Lab_value
pattern	I-Lab_value
,	O
with	O
marked	O
variation	B-Lab_value
in	I-Lab_value
size	I-Lab_value
and	I-Lab_value
shape	I-Lab_value
including	O
epithelioid	B-Shape
and	O
spindle	B-Shape
-	I-Shape
shaped	I-Shape
cells	B-Biological_structure
with	O
plasmacytoid	B-Shape
and	O
round	B-Shape
nuclei	B-Biological_structure
.	O

The	O
nuclear	B-Diagnostic_procedure
chromatin	I-Diagnostic_procedure
is	O
clumping	B-Lab_value
and	O
irregular	B-Lab_value
with	O
excessive	B-Lab_value
parachromatin	I-Lab_value
clearing	I-Lab_value
,	O
there	O
are	O
single	B-Detailed_description
or	O
multiple	B-Detailed_description
macronucleoli	B-Biological_structure
,	O
and	O
abundant	B-Detailed_description
cytoplasm	B-Biological_structure
with	O
deep	B-Lab_value
brownish	I-Lab_value
-	I-Lab_value
black	I-Lab_value
granules	I-Lab_value
obscuring	O
the	O
cell	O
details	O
.	O

The	O
background	B-Diagnostic_procedure
shows	O
necrosis	B-Sign_symptom
and	O
hemorrhage	B-Sign_symptom
.	O

Our	O
patient	O
underwent	O
right	B-Biological_structure
orbital	I-Biological_structure
exenteration	B-Therapeutic_procedure
and	O
followed	O
by	O
duodenopancreatectomy	B-Therapeutic_procedure
(	O
the	O
Whipple	B-Detailed_description
procedure	I-Detailed_description
)	O
,	O
without	O
any	O
complications	B-Sign_symptom
(	O
Fig	O
.	O
4	O
)	O
.	O

The	O
surgical	B-Diagnostic_procedure
specimen	I-Diagnostic_procedure
showed	O
undifferentiated	B-Detailed_description
cells	B-Biological_structure
,	O
with	O
extended	B-Lab_value
disposition	I-Lab_value
of	I-Lab_value
brown	I-Lab_value
pigment	I-Lab_value
,	O
infiltrating	B-Sign_symptom
the	O
pancreas	B-Biological_structure
and	O
the	O
serosa	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
duodenal	I-Biological_structure
wall	I-Biological_structure
.	O

Immunohistochemistry	B-Diagnostic_procedure
was	O
positive	B-Lab_value
for	O
Melan	B-Diagnostic_procedure
-	I-Diagnostic_procedure
A	I-Diagnostic_procedure
,	O
HMB45	B-Diagnostic_procedure
,	O
vimentin	B-Diagnostic_procedure
,	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
and	O
negative	B-Lab_value
for	O
cytokeratin	B-Diagnostic_procedure
,	O
all	O
consistent	O
with	O
metastatic	B-Detailed_description
malignant	B-Detailed_description
melanoma	B-Disease_disorder
.	O

At	O
the	O
moment	O
,	O
our	O
patient	O
is	O
receiving	O
adjuvant	B-Detailed_description
chemotherapy	B-Medication
at	O
an	O
outside	B-Nonbiological_location
oncology	I-Nonbiological_location
clinic	I-Nonbiological_location
.	O

-DOCSTART- -X- -X- -X- O

A	O
4	B-Age
and	I-Age
a	I-Age
half	I-Age
years	I-Age
old	I-Age
male	O
child	O
presented	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
abdominal	B-Biological_structure
swelling	B-Sign_symptom
.	O

The	O
child	O
occasionally	B-Detailed_description
felt	O
stomach	B-Sign_symptom
ache	I-Sign_symptom
that	O
was	O
relieved	B-Detailed_description
for	I-Detailed_description
no	I-Detailed_description
reason	I-Detailed_description
.	O

The	O
child	O
showed	O
no	O
obvious	O
tenderness	B-Sign_symptom
and	O
rebound	B-Sign_symptom
.	O

He	O
was	O
born	O
as	O
a	O
premature	O
baby	O
in	O
the	O
32nd	O
week	O
of	O
his	O
mother	O
`	O
s	O
pregnancy	O
.	O

His	O
medical	O
history	O
included	O
inguinal	O
hernia	O
on	O
2	O
sides	O
,	O
but	O
he	O
had	O
only	O
received	O
an	O
operation	O
for	O
the	O
left	O
inguinal	O
hernia	O
.	O

No	O
family	O
or	O
genetic	O
history	O
was	O
found	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
this	O
child	O
showed	O
that	O
the	O
abdomen	B-Biological_structure
was	O
obviously	B-Detailed_description
bulging	B-Sign_symptom
.	O

The	O
mass	B-Sign_symptom
could	O
be	O
touched	O
below	B-Biological_structure
umbilicus	I-Biological_structure
about	B-Distance
3	I-Distance
fingers	I-Distance
.	O

There	O
were	O
no	O
other	O
positive	O
signs	O
.	O

The	O
results	O
of	O
laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
were	O
almost	B-Lab_value
normal	I-Lab_value
,	O
including	O
alpha	B-Diagnostic_procedure
-	I-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
(	O
AFP	B-Diagnostic_procedure
)	O
level	O
.	O

The	O
Child	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Pugh	I-Diagnostic_procedure
score	I-Diagnostic_procedure
was	O
less	B-Lab_value
than	I-Lab_value
5	I-Lab_value
.	O

Abdominal	B-Biological_structure
ultrasonography	B-Diagnostic_procedure
showed	O
an	O
uneven	B-Detailed_description
lesion	B-Sign_symptom
in	O
the	O
liver	B-Biological_structure
and	O
a	O
diagnosis	O
of	O
HB	B-Disease_disorder
was	O
considered	O
.	O

Enhancement	B-Detailed_description
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scanning	O
showed	O
a	O
large	B-Detailed_description
mass	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
upper	I-Biological_structure
abdomen	I-Biological_structure
and	O
left	B-Biological_structure
lobe	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
liver	I-Biological_structure
with	O
an	O
irregular	B-Shape
edge	I-Shape
.	O

The	O
size	O
of	O
the	O
mass	O
was	O
12	B-Volume
.	I-Volume
3	I-Volume
×	I-Volume
10	I-Volume
.	I-Volume
2	I-Volume
×	I-Volume
7	I-Volume
.	I-Volume
2	I-Volume
cm	I-Volume
(	O
Fig	O
.	O
1	O
)	O
.	O

There	O
was	O
an	O
uneven	B-Detailed_description
nodular	I-Detailed_description
shadow	I-Detailed_description
and	O
the	O
edge	B-Detailed_description
was	I-Detailed_description
obvious	I-Detailed_description
when	O
the	O
mass	O
was	O
enhanced	O
.	O

Calcification	B-Sign_symptom
and	O
an	O
expanded	B-Sign_symptom
bile	I-Sign_symptom
duct	I-Sign_symptom
were	O
not	O
observed	O
.	O

The	O
left	B-Biological_structure
branch	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
portal	I-Biological_structure
was	O
pressed	B-Detailed_description
and	O
the	O
distant	B-Detailed_description
part	I-Detailed_description
was	I-Detailed_description
shown	I-Detailed_description
to	I-Detailed_description
be	I-Detailed_description
unclear	I-Detailed_description
.	O

Abnormal	B-Sign_symptom
was	O
not	O
observed	O
in	O
the	O
right	B-Biological_structure
branch	I-Biological_structure
.	O

According	O
to	O
the	O
medical	O
history	O
,	O
the	O
diagnosis	O
of	O
HB	B-Disease_disorder
was	O
considered	O
.	O

We	O
did	O
not	O
recommend	O
a	O
biopsy	B-Diagnostic_procedure
to	O
the	O
patient	O
because	O
it	O
might	O
cause	O
bleeding	O
and	O
tumor	O
diffusion	O
.	O

An	O
operation	B-Therapeutic_procedure
was	O
necessary	O
.	O

The	O
patient	O
underwent	O
DVSS	B-Therapeutic_procedure
surgery	I-Therapeutic_procedure
with	B-Detailed_description
sufficient	I-Detailed_description
preparation	I-Detailed_description
.	O

Exploration	B-Diagnostic_procedure
showed	O
an	O
extrahepatic	B-Detailed_description
12	B-Area
×	I-Area
10	I-Area
cm	I-Area
mass	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
lobe	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
liver	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

After	O
the	O
operation	O
,	O
the	O
sample	O
was	O
split	B-Detailed_description
.	O

The	O
edge	B-Shape
of	I-Shape
the	I-Shape
tumor	I-Shape
was	I-Shape
clear	I-Shape
but	O
no	B-Detailed_description
envelope	I-Detailed_description
.	O

Tremelloid	B-Detailed_description
mesenchyme	B-Biological_structure
was	O
seen	O
on	O
the	O
section	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

The	O
pathological	O
examination	O
showed	O
that	O
the	O
sample	O
was	O
grey	B-Color
red	I-Color
and	O
14	B-Volume
×	I-Volume
13	I-Volume
×	I-Volume
7	I-Volume
cm	I-Volume
in	O
size	O
.	O

The	O
color	O
of	O
the	O
section	O
was	O
grey	B-Color
red	I-Color
and	O
grey	B-Color
white	I-Color
.	O

MHL	B-Disease_disorder
was	O
diagnosed	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Immunohistochemistry	B-Diagnostic_procedure
results	I-Diagnostic_procedure
(	O
Fig	O
.	O
4	O
)	O
were	O
the	O
following	O
:	O
mesenchymal	B-Diagnostic_procedure
CD34	I-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
D2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
40	I-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
,	O
SMA	B-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
CD7	B-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
,	O
epithelium	B-Diagnostic_procedure
CK19	I-Diagnostic_procedure
(	O
+	B-Lab_value
)	O
,	O
AFP	B-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
,	O
HCG	B-Diagnostic_procedure
(	O
-	B-Lab_value
)	O
.	O

After	O
9	B-Duration
days	I-Duration
of	O
recovery	B-Therapeutic_procedure
,	O
the	O
patient	O
returned	O
home	B-Nonbiological_location
without	O
complications	B-Sign_symptom
.	O

A	O
follow	O
-	O
up	O
examination	O
,	O
which	O
included	O
blood	B-Diagnostic_procedure
routine	I-Diagnostic_procedure
,	O
liver	B-Diagnostic_procedure
renal	I-Diagnostic_procedure
function	I-Diagnostic_procedure
,	O
coagulation	B-Diagnostic_procedure
routine	I-Diagnostic_procedure
,	O
and	O
ultrasound	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
at	O
30	O
days	O
,	O
did	O
not	O
show	O
any	O
abnormality	B-Sign_symptom
.	O

No	O
adverse	B-Sign_symptom
or	I-Sign_symptom
unanticipated	I-Sign_symptom
event	I-Sign_symptom
was	O
presented	O
.	O

-DOCSTART- -X- -X- -X- O

CASE	O
:	O
A	O
28	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
previously	O
healthy	B-Sign_symptom
man	O
presented	O
with	O
a	O
6	B-Duration
-	I-Duration
week	I-Duration
history	O
of	O
palpitations	B-Sign_symptom
.	O

The	O
symptoms	O
occurred	O
during	O
rest	O
,	O
2	B-Frequency
-	I-Frequency
3	I-Frequency
times	I-Frequency
per	I-Frequency
week	I-Frequency
,	O
lasted	O
up	B-Detailed_description
to	I-Detailed_description
30	I-Detailed_description
minutes	I-Detailed_description
at	I-Detailed_description
a	I-Detailed_description
time	I-Detailed_description
and	O
were	O
associated	O
with	O
dyspnea	B-Sign_symptom
.	O

Except	O
for	O
a	O
grade	B-Lab_value
2	I-Lab_value
/	I-Lab_value
6	I-Lab_value
holosystolic	B-Detailed_description
tricuspid	B-Biological_structure
regurgitation	B-Sign_symptom
murmur	I-Sign_symptom
(	O
best	O
heard	O
at	O
the	O
left	B-Biological_structure
sternal	I-Biological_structure
border	I-Biological_structure
with	O
inspiratory	B-Detailed_description
accentuation	I-Detailed_description
)	O
,	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
yielded	O
unremarkable	B-Lab_value
findings	O
.	O

An	O
electrocardiogram	B-Diagnostic_procedure
(	O
ECG	B-Diagnostic_procedure
)	O
revealed	O
normal	B-Lab_value
sinus	B-Diagnostic_procedure
rhythm	I-Diagnostic_procedure
and	O
a	O
Wolff	B-Sign_symptom
-	I-Sign_symptom
Parkinson	I-Sign_symptom
-	I-Sign_symptom
White	I-Sign_symptom
pre	I-Sign_symptom
-	I-Sign_symptom
excitation	I-Sign_symptom
pattern	I-Sign_symptom
(	O
Fig	O
.	O
1	O
:	O
Top	O
)	O
,	O
produced	O
by	O
a	O
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
accessory	B-Disease_disorder
pathway	I-Disease_disorder
.	O

Transthoracic	B-Biological_structure
echocardiography	B-Diagnostic_procedure
demonstrated	O
the	O
presence	O
of	O
Ebstein	B-Disease_disorder
`	I-Disease_disorder
s	I-Disease_disorder
anomaly	I-Disease_disorder
of	O
the	O
tricuspid	B-Biological_structure
valve	I-Biological_structure
,	O
with	O
apical	B-Sign_symptom
displacement	I-Sign_symptom
of	O
the	O
valve	O
and	O
formation	O
of	O
an	O
`	O
atrialized	B-Disease_disorder
`	O
right	B-Biological_structure
ventricle	I-Biological_structure
(	O
a	O
functional	O
unit	O
between	O
the	O
right	B-Biological_structure
atrium	I-Biological_structure
and	O
the	O
inlet	B-Biological_structure
[	O
inflow	O
]	O
portion	O
of	O
the	O
right	B-Biological_structure
ventricle	I-Biological_structure
)	O
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
anterior	B-Biological_structure
tricuspid	I-Biological_structure
valve	I-Biological_structure
leaflet	I-Biological_structure
was	O
elongated	B-Sign_symptom
(	O
Fig	O
.	O
2C	O
,	O
arrow	O
)	O
,	O
whereas	O
the	O
septal	B-Biological_structure
leaflet	I-Biological_structure
was	O
rudimentary	B-Sign_symptom
(	O
Fig	O
.	O
2C	O
,	O
arrowhead	O
)	O
.	O

Contrast	B-Detailed_description
echocardiography	B-Diagnostic_procedure
using	B-Detailed_description
saline	I-Detailed_description
revealed	O
a	O
patent	B-Disease_disorder
foramen	I-Disease_disorder
ovale	I-Disease_disorder
with	O
right	B-Sign_symptom
-	I-Sign_symptom
to	I-Sign_symptom
-	I-Sign_symptom
left	I-Sign_symptom
shunting	I-Sign_symptom
and	O
bubbles	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
atrium	I-Biological_structure
(	O
Fig	O
.	O
2D	O
)	O
.	O

The	O
patient	O
underwent	O
an	O
electrophysiologic	B-Diagnostic_procedure
study	I-Diagnostic_procedure
with	O
mapping	B-Diagnostic_procedure
of	O
the	O
accessory	B-Biological_structure
pathway	I-Biological_structure
,	O
followed	O
by	O
radiofrequency	B-Detailed_description
ablation	B-Therapeutic_procedure
(	O
interruption	O
of	O
the	O
pathway	O
using	O
the	O
heat	O
generated	O
by	O
electromagnetic	O
waves	O
at	O
the	O
tip	O
of	O
an	O
ablation	B-Therapeutic_procedure
catheter	I-Therapeutic_procedure
)	O
.	O

His	O
post	O
-	O
ablation	O
ECG	B-Diagnostic_procedure
showed	O
a	O
prolonged	B-Lab_value
PR	B-Diagnostic_procedure
interval	I-Diagnostic_procedure
and	O
an	O
odd	B-Lab_value
`	B-Lab_value
second	I-Lab_value
`	I-Lab_value
QRS	B-Diagnostic_procedure
complex	I-Diagnostic_procedure
in	O
leads	B-Detailed_description
III	I-Detailed_description
,	I-Detailed_description
aVF	I-Detailed_description
and	I-Detailed_description
V2	I-Detailed_description
-	I-Detailed_description
V4	I-Detailed_description
(	O
Fig	O
.	O
1Bottom	O
)	O
,	O
a	O
consequence	O
of	O
abnormal	B-Disease_disorder
impulse	I-Disease_disorder
conduction	I-Disease_disorder
in	O
the	O
`	O
atrialized	B-Disease_disorder
`	O
right	B-Biological_structure
ventricle	I-Biological_structure
.	O

The	O
patient	O
reported	O
no	O
recurrence	O
of	O
palpitations	B-Sign_symptom
at	O
follow	O
-	O
up	O
6	O
months	O
after	O
the	O
ablation	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
47	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
to	O
the	O
hospital	B-Nonbiological_location
with	O
a	O
1	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
abdominal	B-Biological_structure
distention	B-Sign_symptom
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
huge	B-Severity
mass	B-Sign_symptom
in	O
the	O
lower	B-Biological_structure
abdomen	I-Biological_structure
.	O

The	O
peripheral	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
test	I-Diagnostic_procedure
showed	O
elevated	B-Lab_value
levels	O
of	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
CEA	B-Diagnostic_procedure
,	O
335	B-Lab_value
.	I-Lab_value
2	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
[	O
normal	O
,	O
<	O
5	O
ng	O
/	O
mL	O
]	O
)	O
and	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
CA	B-Diagnostic_procedure
)	O
125	B-Detailed_description
(	O
219	B-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
[	O
normal	O
,	O
<	O
45	O
U	O
/	O
mL	O
]	O
)	O
but	O
a	O
normal	B-Lab_value
level	O
of	O
CA19	B-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
(	O
9	B-Lab_value
U	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
[	O
normal	O
,	O
<	O
37	O
U	O
/	O
mL	O
]	O
)	O
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
demonstrated	O
a	O
large	B-Severity
,	O
round	B-Shape
mass	B-Sign_symptom
with	O
a	O
maximum	O
diameter	O
of	O
15	B-Distance
cm	I-Distance
in	O
the	O
pelvic	B-Biological_structure
cavity	I-Biological_structure
without	O
the	O
presence	O
of	O
ascites	B-Sign_symptom
or	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
(	O
Fig	O
.	O
1a	O
,	O
b	O
)	O
.	O

Colonoscopy	B-Diagnostic_procedure
identified	O
an	O
elevated	B-Lab_value
lesion	B-Sign_symptom
with	O
severe	B-Severity
stenosis	B-Sign_symptom
in	O
the	O
sigmoid	B-Biological_structure
colon	I-Biological_structure
,	O
and	O
histopathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
biopsy	B-Diagnostic_procedure
specimens	I-Diagnostic_procedure
from	O
the	O
tumor	O
showed	O
moderately	B-Lab_value
differentiated	I-Lab_value
adenocarcinoma	B-Disease_disorder
.	O

Although	O
we	O
scheduled	O
an	O
early	O
operation	B-Therapeutic_procedure
,	O
the	O
patient	O
developed	O
acute	B-Lab_value
dyspnea	B-Sign_symptom
and	O
general	B-Lab_value
edema	B-Sign_symptom
2	O
weeks	O
after	O
the	O
first	O
CT	O
scan	O
.	O

The	O
second	O
CT	B-Diagnostic_procedure
scan	O
examination	O
demonstrated	O
massive	B-Severity
bilateral	B-Detailed_description
pleural	B-Sign_symptom
effusion	I-Sign_symptom
with	O
atelectasis	B-Sign_symptom
and	O
ascites	B-Sign_symptom
(	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
.	O

Thoracic	B-Therapeutic_procedure
drainage	I-Therapeutic_procedure
and	O
laparotomy	B-Therapeutic_procedure
were	O
emergently	O
performed	O
.	O

Macroscopically	B-Diagnostic_procedure
,	O
the	O
tumor	O
in	O
the	O
sigmoid	B-Biological_structure
colon	I-Biological_structure
had	O
invaded	B-Sign_symptom
the	O
serosa	B-Biological_structure
,	O
and	O
the	O
huge	B-Severity
pelvic	B-Biological_structure
mass	B-Sign_symptom
was	O
found	O
to	O
contain	O
a	O
right	B-Detailed_description
ovarian	B-Disease_disorder
tumor	I-Disease_disorder
.	O

Several	O
small	O
nodules	B-Sign_symptom
of	O
peritoneal	B-Biological_structure
dissemination	B-Sign_symptom
were	O
distributed	O
over	O
the	O
greater	B-Biological_structure
omentum	I-Biological_structure
.	O

Perioperatively	O
,	O
3800	B-Volume
mL	I-Volume
of	O
serous	B-Lab_value
ascitic	B-Sign_symptom
fluid	I-Sign_symptom
was	O
drained	B-Therapeutic_procedure
.	O

Cytodiagnosis	B-Diagnostic_procedure
of	O
the	O
fluid	B-Sign_symptom
drained	O
from	O
the	O
ascites	B-Sign_symptom
and	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
revealed	O
no	B-Lab_value
tumor	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
.	O

Bilateral	B-Detailed_description
oophorectomy	B-Therapeutic_procedure
,	O
total	B-Detailed_description
hysterectomy	B-Therapeutic_procedure
,	O
omentectomy	B-Therapeutic_procedure
,	O
and	O
sigmoidectomy	B-Therapeutic_procedure
with	O
regional	B-Detailed_description
node	B-Therapeutic_procedure
dissection	I-Therapeutic_procedure
were	O
performed	O
(	O
Fig	O
.	O
3a	O
)	O
.	O

Histopathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
resected	O
specimens	O
showed	O
moderately	B-Lab_value
differentiated	I-Lab_value
adenocarcinoma	B-Disease_disorder
in	O
the	O
tumors	B-Sign_symptom
of	O
both	O
the	O
ovaries	B-Biological_structure
and	O
the	O
sigmoid	B-Biological_structure
colon	I-Biological_structure
(	O
Fig	O
.	O
3b	O
)	O
.	O

The	O
dissected	O
paracolic	B-Biological_structure
nodes	I-Biological_structure
showed	O
malignant	B-Sign_symptom
cells	I-Sign_symptom
.	O

Immunohistochemically	B-Diagnostic_procedure
,	O
tumor	B-Sign_symptom
cells	I-Sign_symptom
from	O
the	O
ovaries	B-Biological_structure
and	O
the	O
colon	B-Biological_structure
both	O
showed	O
positive	B-Lab_value
expression	I-Lab_value
of	O
cytokeratin	B-Diagnostic_procedure
20	I-Diagnostic_procedure
(	O
CK20	B-Diagnostic_procedure
)	O
but	O
no	B-Lab_value
expression	I-Lab_value
of	O
cytokeratin	B-Diagnostic_procedure
7	I-Diagnostic_procedure
(	O
CK7	B-Diagnostic_procedure
)	O
,	O
confirming	O
that	O
the	O
ovarian	B-Disease_disorder
tumors	I-Disease_disorder
were	O
metastases	B-Sign_symptom
from	O
primary	B-Disease_disorder
colon	I-Disease_disorder
cancer	I-Disease_disorder
(	O
Fig	O
.	O
4a	O
,	O
b	O
)	O
.	O

The	O
postoperative	B-Diagnostic_procedure
course	I-Diagnostic_procedure
was	O
uneventful	B-Lab_value
,	O
and	O
both	O
pleural	B-Sign_symptom
effusion	I-Sign_symptom
and	O
ascites	B-Sign_symptom
rapidly	O
resolved	O
.	O

Postoperatively	O
,	O
a	O
regimen	O
of	O
5	B-Medication
-	I-Medication
fluorouracil	I-Medication
(	O
5	B-Medication
-	I-Medication
FU	I-Medication
)	O
,	O
leucovorin	B-Medication
,	O
and	O
oxaliplatin	B-Medication
(	O
FOLFOX	B-Medication
)	O
was	O
administered	O
every	B-Frequency
2	I-Frequency
weeks	I-Frequency
for	I-Frequency
5	I-Frequency
months	I-Frequency
.	O

At	O
29	O
months	O
after	O
the	O
first	O
operation	O
,	O
the	O
patient	O
required	O
curative	O
hepatic	B-Biological_structure
resection	B-Therapeutic_procedure
for	O
liver	B-Biological_structure
metastases	B-Sign_symptom
.	O

At	O
78	O
months	O
after	O
the	O
first	O
operation	O
,	O
the	O
patient	O
remains	O
alive	B-Sign_symptom
with	O
no	O
evidence	O
of	O
a	O
disease	B-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

We	O
present	O
the	O
case	O
of	O
a	O
66	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
patient	O
with	O
no	O
significant	O
past	O
medical	O
history	O
presenting	O
with	O
chest	B-Biological_structure
pain	B-Sign_symptom
that	O
was	O
treated	O
with	O
antacids	B-Medication
by	O
her	O
primary	B-Nonbiological_location
care	I-Nonbiological_location
physician	I-Nonbiological_location
.	O

The	O
next	O
day	O
she	O
presented	O
to	O
the	O
emergency	B-Nonbiological_location
room	I-Nonbiological_location
,	O
where	O
an	O
electrocardiogram	B-Diagnostic_procedure
revealed	O
posterolateral	B-Detailed_description
ST	B-Detailed_description
elevation	I-Detailed_description
myocardial	B-Disease_disorder
infarction	I-Disease_disorder
.	O

The	O
patient	O
was	O
immediately	O
taken	O
to	O
the	O
catheterization	B-Nonbiological_location
lab	I-Nonbiological_location
.	O

A	O
successful	O
percutaneous	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
was	O
performed	O
on	O
an	O
acutely	B-Severity
occluded	B-Sign_symptom
large	B-Biological_structure
ramus	I-Biological_structure
intermedius	I-Biological_structure
vessel	I-Biological_structure
that	O
was	O
supplying	B-Sign_symptom
a	O
large	O
portion	O
of	O
the	O
lateral	B-Biological_structure
wall	I-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

The	O
patient	O
did	B-Sign_symptom
well	I-Sign_symptom
initially	B-Detailed_description
,	O
but	O
several	B-Time
hours	I-Time
later	I-Time
she	O
suddenly	B-Lab_value
went	O
into	O
cardiogenic	B-Disease_disorder
shock	I-Disease_disorder
.	O

An	O
intra	B-Therapeutic_procedure
-	I-Therapeutic_procedure
aortic	I-Therapeutic_procedure
balloon	I-Therapeutic_procedure
pump	I-Therapeutic_procedure
was	O
placed	O
,	O
and	O
an	O
echocardiogram	B-Diagnostic_procedure
demonstrated	O
that	O
she	O
had	O
severe	B-Severity
mitral	B-Disease_disorder
regurgitation	I-Disease_disorder
from	O
a	O
ruptured	B-Disease_disorder
papillary	B-Biological_structure
muscle	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
,	O
on	O
maximal	B-Lab_value
support	B-Therapeutic_procedure
,	O
deteriorated	B-Sign_symptom
rapidly	B-Severity
with	O
progressive	B-Lab_value
acidosis	B-Sign_symptom
,	O
oliguria	B-Sign_symptom
,	O
and	O
florid	B-Detailed_description
pulmonary	B-Biological_structure
edema	B-Sign_symptom
.	O

In	O
spite	O
of	O
the	O
very	O
high	O
risk	O
,	O
we	O
decided	O
to	O
intervene	O
surgically	O
.	O

Once	O
in	O
the	O
operating	B-Nonbiological_location
room	I-Nonbiological_location
,	O
transesophageal	B-Biological_structure
echocardiography	B-Diagnostic_procedure
confirmed	O
severe	B-Severity
mitral	B-Disease_disorder
regurgitation	I-Disease_disorder
with	O
a	O
ruptured	B-Disease_disorder
anterolateral	B-Biological_structure
papillary	I-Biological_structure
muscle	I-Biological_structure
and	O
a	O
small	B-Sign_symptom
left	B-Biological_structure
atrium	I-Biological_structure
.	O

Shortly	O
after	O
the	O
patient	O
was	O
put	O
on	O
cardiopulmonary	B-Therapeutic_procedure
bypass	I-Therapeutic_procedure
,	O
the	O
acidosis	B-Sign_symptom
resolved	O
and	O
she	O
began	O
to	O
make	O
urine	O
.	O

Excellent	O
visualization	B-Diagnostic_procedure
of	O
the	O
mitral	B-Biological_structure
valve	I-Biological_structure
was	O
obtained	O
using	O
a	O
vertical	B-Detailed_description
transseptal	I-Detailed_description
approach	I-Detailed_description
through	O
the	O
right	B-Biological_structure
atrium	I-Biological_structure
.	O

The	O
valve	O
was	O
carefully	O
inspected	B-Diagnostic_procedure
and	O
the	O
necrotic	B-Sign_symptom
ruptured	B-Disease_disorder
anterolateral	B-Biological_structure
papillary	I-Biological_structure
muscle	I-Biological_structure
was	O
seen	O
(	O
Figure	O
3	O
)	O
.	O

There	O
was	O
a	O
large	B-Severity
chunk	B-Biological_structure
of	I-Biological_structure
muscle	I-Biological_structure
attached	B-Sign_symptom
to	O
the	O
A1	B-Biological_structure
chordal	I-Biological_structure
apparatus	I-Biological_structure
.	O

The	O
anterior	B-Biological_structure
leaflet	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
mitral	I-Biological_structure
valve	I-Biological_structure
was	O
excised	B-Therapeutic_procedure
while	O
keeping	O
the	O
posterior	B-Biological_structure
leaflet	I-Biological_structure
intact	B-Sign_symptom
.	O

A	O
27	B-Distance
-	I-Distance
mm	I-Distance
St	B-Detailed_description
Jude	I-Detailed_description
Epic	I-Detailed_description
bioprosthesis	B-Therapeutic_procedure
was	O
inserted	O
(	O
Figure	O
4	O
)	O
.	O

She	O
was	O
placed	O
on	O
extracorporeal	B-Therapeutic_procedure
membrane	I-Therapeutic_procedure
oxygenation	I-Therapeutic_procedure
that	O
was	O
successfully	O
weaned	B-Therapeutic_procedure
3	O
days	O
later	O
.	O

Following	O
this	O
,	O
she	O
made	O
a	O
remarkable	O
early	B-Lab_value
recovery	B-Sign_symptom
.	O

One	O
month	O
later	O
,	O
just	O
prior	O
to	O
discharge	O
,	O
she	O
expired	O
after	O
developing	O
pneumonia	B-Disease_disorder
that	O
progressed	O
to	O
sepsis	B-Disease_disorder
with	O
multiorgan	B-Disease_disorder
failure	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
who	O
underwent	O
colonoscopy	B-Diagnostic_procedure
was	O
found	O
to	O
have	O
a	O
2	B-Distance
cm	I-Distance
sessile	B-Sign_symptom
polyp	I-Sign_symptom
that	O
was	O
located	O
10	B-Distance
cm	I-Distance
from	O
the	O
anal	B-Biological_structure
verge	I-Biological_structure
and	O
successfully	B-Therapeutic_procedure
removed	I-Therapeutic_procedure
.	O

The	O
polyp	O
was	O
a	O
tubulovillous	B-Disease_disorder
adenoma	I-Disease_disorder
with	O
focal	O
high	B-Sign_symptom
-	I-Sign_symptom
grade	I-Sign_symptom
dysplasia	I-Sign_symptom
.	O

A	O
flexible	B-Diagnostic_procedure
sigmoidoscopy	I-Diagnostic_procedure
performed	O
three	O
months	O
later	O
,	O
as	O
well	O
as	O
a	O
repeat	B-Detailed_description
colonoscopy	B-Diagnostic_procedure
one	O
year	O
after	O
the	O
initial	O
colonoscopy	O
,	O
were	O
both	O
negative	B-Lab_value
for	O
recurrence	O
.	O

A	O
colonoscopy	B-Diagnostic_procedure
performed	O
three	O
years	O
after	O
the	O
initial	O
colonoscopy	O
revealed	O
a	O
sessile	B-Sign_symptom
polyp	I-Sign_symptom
,	O
3	B-Distance
cm	I-Distance
in	O
size	O
,	O
at	O
10	B-Distance
cm	I-Distance
from	O
the	O
anal	B-Biological_structure
verge	I-Biological_structure
.	O

Biopsies	B-Diagnostic_procedure
were	O
taken	O
and	O
reported	O
to	O
be	O
fragments	O
of	O
a	O
villous	B-Disease_disorder
adenoma	I-Disease_disorder
with	O
low	B-Sign_symptom
-	I-Sign_symptom
grade	I-Sign_symptom
dysplasia	I-Sign_symptom
.	O

Due	O
to	O
the	O
previous	O
high	O
-	O
grade	O
dysplasia	O
,	O
relatively	O
rapid	O
recurrence	O
and	O
concern	O
that	O
a	O
cancer	O
may	O
have	O
been	O
missed	O
by	O
sampling	O
error	O
,	O
a	O
pelvic	B-Biological_structure
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
scan	O
and	O
an	O
endoscopic	B-Diagnostic_procedure
ultrasound	I-Diagnostic_procedure
(	O
EUS	B-Diagnostic_procedure
)	O
were	O
performed	O
before	O
definitive	O
excision	O
.	O

The	O
MRI	O
revealed	O
an	O
invasive	B-Detailed_description
rectal	B-Biological_structure
mass	B-Sign_symptom
involving	O
the	O
muscularis	B-Biological_structure
propria	I-Biological_structure
but	O
without	O
breach	O
of	O
the	O
adventitia	O
,	O
consistent	O
with	O
a	O
T2	B-Disease_disorder
rectal	I-Disease_disorder
carcinoma	I-Disease_disorder
(	O
Figure	O
1	O
)	O
.	O

No	O
pelvic	B-Biological_structure
lymphadenopathy	B-Sign_symptom
was	O
detected	O
.	O

The	O
EUS	O
revealed	O
a	O
rectal	B-Biological_structure
mass	B-Sign_symptom
involving	O
the	O
mucosa	B-Biological_structure
and	O
submucosa	B-Biological_structure
,	O
with	O
no	O
involvement	O
of	O
the	O
muscularis	O
propria	O
(	O
Figure	O
2	O
)	O
.	O

The	O
results	O
of	O
the	O
MRI	O
and	O
EUS	O
,	O
as	O
well	O
as	O
the	O
surgical	O
versus	O
endoscopic	O
resection	O
treatment	O
options	O
,	O
were	O
discussed	O
with	O
the	O
patient	O
,	O
who	O
opted	O
for	O
a	O
surgical	B-Therapeutic_procedure
resection	I-Therapeutic_procedure
.	O

The	O
patient	O
underwent	O
a	O
low	B-Therapeutic_procedure
anterior	I-Therapeutic_procedure
resection	I-Therapeutic_procedure
and	O
end	B-Therapeutic_procedure
-	I-Therapeutic_procedure
to	I-Therapeutic_procedure
-	I-Therapeutic_procedure
end	I-Therapeutic_procedure
anastomosis	I-Therapeutic_procedure
with	O
loop	B-Therapeutic_procedure
ileostomy	I-Therapeutic_procedure
.	O

Pathology	B-Diagnostic_procedure
review	I-Diagnostic_procedure
of	O
the	O
resected	B-Biological_structure
rectosigmoid	I-Biological_structure
revealed	O
a	O
villous	B-Disease_disorder
adenoma	I-Disease_disorder
with	O
low	B-Sign_symptom
-	I-Sign_symptom
grade	I-Sign_symptom
dyplasia	I-Sign_symptom
.	O

There	O
was	O
no	O
evidence	O
of	O
muscularis	B-Sign_symptom
propria	I-Sign_symptom
invasion	I-Sign_symptom
,	O
and	O
a	O
total	O
of	O
five	B-Lab_value
pericolic	B-Biological_structure
and	I-Biological_structure
two	B-Lab_value
mesorectal	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
were	O
excised	B-Therapeutic_procedure
and	O
deemed	O
benign	B-Sign_symptom
.	O

The	O
patient	O
underwent	O
ileostomy	B-Therapeutic_procedure
reversal	I-Therapeutic_procedure
five	O
months	O
later	O
.	O

He	O
remains	O
asymptomatic	B-Sign_symptom
with	O
no	O
recurrence	B-Sign_symptom
of	I-Sign_symptom
tumours	I-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
46	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
with	O
severe	B-Severity
acute	B-Detailed_description
pain	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
iliac	I-Biological_structure
fossa	I-Biological_structure
and	O
periumbilical	B-Biological_structure
region	I-Biological_structure
.	O

Ultrasound	B-Diagnostic_procedure
and	O
a	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
scan	I-Diagnostic_procedure
revealed	O
a	O
mucocele	B-Sign_symptom
in	O
the	O
vermiform	B-Biological_structure
appendix	I-Biological_structure
,	O
with	O
a	O
well	B-Detailed_description
defined	I-Detailed_description
lesion	B-Sign_symptom
located	O
at	O
the	O
mid	B-Biological_structure
zone	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
appendix	I-Biological_structure
.	O

The	O
patient	O
underwent	O
right	B-Therapeutic_procedure
hemicolectomy	I-Therapeutic_procedure
,	O
and	O
her	O
postoperative	O
clinical	O
course	O
was	O
uneventful	O
.	O

Gross	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
surgical	B-Biological_structure
specimen	I-Biological_structure
showed	O
an	O
enlarged	B-Lab_value
appendix	B-Biological_structure
,	O
which	O
was	O
filled	O
with	O
thick	B-Texture
mucinous	B-Biological_structure
material	I-Biological_structure
.	O

A	O
distinct	B-Detailed_description
lesion	O
which	O
involved	O
the	O
appendiceal	B-Biological_structure
wall	I-Biological_structure
,	O
and	O
measured	O
1	B-Distance
.	I-Distance
5	I-Distance
cm	I-Distance
maximally	O
,	O
was	O
identified	O
in	O
the	O
mid	B-Biological_structure
-	I-Biological_structure
portion	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
appendix	I-Biological_structure
.	O

There	O
was	O
no	O
evidence	O
of	O
perforation	B-Sign_symptom
,	O
extravasation	B-Sign_symptom
of	O
mucin	B-Biological_structure
into	O
the	O
periappendiceal	B-Biological_structure
tissue	I-Biological_structure
,	O
or	O
pseudomyxoma	B-Disease_disorder
peritonei	I-Disease_disorder
during	O
surgery	O
.	O

Histopathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
combined	O
GCC	B-Disease_disorder
and	O
MCA	B-Disease_disorder
of	O
the	O
vermiform	B-Biological_structure
appendix	I-Biological_structure
(	O
Figure	O
1A	O
)	O
.	O

The	O
appendiceal	B-Biological_structure
lumen	I-Biological_structure
was	O
dilated	B-Sign_symptom
and	O
lined	O
by	O
mucin	B-Sign_symptom
-	I-Sign_symptom
containing	I-Sign_symptom
columnar	B-Biological_structure
epithelial	I-Biological_structure
cells	I-Biological_structure
(	O
Figure	O
1B	O
)	O
.	O

There	O
was	O
no	O
significant	O
cytologic	B-Sign_symptom
atypia	I-Sign_symptom
,	O
and	O
no	O
mitotic	B-Sign_symptom
figures	I-Sign_symptom
were	O
identified	O
.	O

Focal	B-Sign_symptom
papillary	I-Sign_symptom
configurations	I-Sign_symptom
of	O
the	O
lining	B-Biological_structure
epithelium	I-Biological_structure
,	O
and	O
mild	B-Severity
epithelial	B-Sign_symptom
pseudostratification	I-Sign_symptom
were	O
present	O
.	O

In	O
addition	O
,	O
the	O
appendiceal	B-Biological_structure
wall	I-Biological_structure
was	O
infiltrated	O
by	O
glandular	B-Sign_symptom
structures	I-Sign_symptom
of	O
various	B-Area
sizes	I-Area
which	O
were	O
arranged	O
in	O
nests	B-Shape
and	O
tubules	B-Shape
.	O

These	O
glandular	O
structures	O
comprised	O
2	O
distinct	O
types	O
of	O
cells	O
:	O
(	O
1	O
)	O
small	B-Area
to	I-Area
intermediate	I-Area
sized	I-Area
monotonous	B-Detailed_description
neuroendocrine	B-Biological_structure
cells	I-Biological_structure
with	O
a	O
small	B-Detailed_description
amount	I-Detailed_description
of	I-Detailed_description
finely	I-Detailed_description
granular	I-Detailed_description
eosinophilic	I-Detailed_description
cytoplasm	I-Detailed_description
,	O
and	O
mild	B-Severity
cytonuclear	B-Sign_symptom
atypia	I-Sign_symptom
(	O
Figure	O
(	O
Figure1C	O
)	O
;	O
1C	O
)	O
;	O
(	O
2	O
)	O
mucin	B-Detailed_description
-	I-Detailed_description
filled	I-Detailed_description
intermediate	B-Area
sized	I-Area
cells	O
(	O
goblet	B-Biological_structure
cells	I-Biological_structure
)	O
,	O
with	O
peripherally	B-Detailed_description
located	I-Detailed_description
small	B-Area
,	O
crescent	B-Shape
-	I-Shape
like	I-Shape
hyperchromatic	B-Sign_symptom
nuclei	I-Sign_symptom
,	O
and	O
indistinct	B-Detailed_description
nucleoli	B-Biological_structure
(	O
Figure	O
(	O
Figure1D	O
)	O
.	O
1D	O
)	O
.	O

Scattered	B-Texture
infiltrating	B-Detailed_description
single	B-Detailed_description
goblet	B-Biological_structure
neoplastic	I-Biological_structure
cells	I-Biological_structure
were	O
focally	B-Sign_symptom
present	I-Sign_symptom
.	O

As	O
previously	O
described	O
[	O
1	O
]	O
the	O
tumor	B-Sign_symptom
nests	I-Sign_symptom
appeared	O
to	O
arise	O
from	O
the	O
basiglandular	B-Biological_structure
region	I-Biological_structure
of	O
the	O
intestinal	B-Biological_structure
crypts	I-Biological_structure
in	O
close	B-Detailed_description
proximity	I-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
MCA	B-Disease_disorder
(	O
Figure	O
(	O
Figure1E	O
)	O
.	O
1E	O
)	O
.	O

There	O
was	O
no	O
lymphovascular	B-Sign_symptom
invasion	I-Sign_symptom
,	O
although	O
perineural	B-Sign_symptom
and	I-Sign_symptom
intraneural	B-Sign_symptom
invasion	I-Sign_symptom
was	O
present	O
.	O

The	O
tumor	O
infiltrated	O
the	O
full	B-Biological_structure
thickness	I-Biological_structure
of	O
the	O
appendiceal	B-Biological_structure
wall	I-Biological_structure
and	O
extended	O
to	O
the	O
mesoappendix	B-Biological_structure
.	O

Ten	B-Lab_value
lymph	B-Biological_structure
nodes	I-Biological_structure
were	O
histologically	B-Diagnostic_procedure
identified	I-Diagnostic_procedure
,	O
of	O
which	O
all	O
were	O
negative	O
for	O
malignancy	B-Disease_disorder
.	O

Immunohistochemically	B-Diagnostic_procedure
(	O
Table	O
1	O
)	O
,	O
the	O
tumor	B-Sign_symptom
cells	I-Sign_symptom
of	O
the	O
GCC	B-Disease_disorder
were	O
positive	B-Lab_value
for	O
chromogranin	B-Diagnostic_procedure
,	O
synaptophysin	B-Diagnostic_procedure
,	O
and	O
serotonin	B-Diagnostic_procedure
,	O
which	O
are	O
neuroendocrine	B-Detailed_description
markers	I-Detailed_description
.	O

Diffuse	B-Lab_value
staining	I-Lab_value
for	O
cytokeratin	B-Diagnostic_procedure
(	O
CK	O
)	O
20	O
(	O
Figure	O
2	O
)	O
,	O
CK19	B-Diagnostic_procedure
,	I-Diagnostic_procedure
and	O
CD99	B-Diagnostic_procedure
was	O
also	O
present	O
.	O

The	O
Ki67	B-Diagnostic_procedure
proliferating	I-Diagnostic_procedure
index	I-Diagnostic_procedure
revealed	O
nuclear	B-Sign_symptom
staining	I-Sign_symptom
in	O
approximately	O
15	B-Lab_value
%	I-Lab_value
of	O
the	O
tumor	B-Sign_symptom
cells	I-Sign_symptom
.	O

There	O
was	O
no	O
staining	O
for	O
CK7	B-Diagnostic_procedure
.	I-Diagnostic_procedure

-DOCSTART- -X- -X- -X- O

A	O
58	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
white	O
American	O
male	O
presented	O
to	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
(	O
ED	B-Nonbiological_location
)	O
with	O
acute	B-Detailed_description
onset	I-Detailed_description
of	O
confusion	B-Sign_symptom
,	O
disorientation	B-Sign_symptom
,	O
inability	B-Sign_symptom
to	I-Sign_symptom
walk	I-Sign_symptom
steadily	I-Sign_symptom
,	O
and	O
dehydration	B-Sign_symptom
with	O
associated	O
generalized	O
weakness	B-Sign_symptom
,	O
polyuria	B-Sign_symptom
,	O
and	O
polydipsia	B-Sign_symptom
over	B-Duration
the	I-Duration
previous	I-Duration
week	I-Duration
.	O

He	O
had	O
been	O
diagnosed	O
with	O
CML	B-Disease_disorder
six	O
years	O
earlier	O
,	O
with	O
no	O
hematological	B-Sign_symptom
response	I-Sign_symptom
to	O
multiple	B-Detailed_description
chemotherapy	B-Medication
regimens	B-Detailed_description
;	O
he	O
was	O
at	O
that	O
time	O
on	O
treatment	O
with	O
allopurinol	B-Medication
and	O
awaiting	O
allogenic	B-Detailed_description
bone	B-Therapeutic_procedure
marrow	I-Therapeutic_procedure
transplant	I-Therapeutic_procedure
.	O

Vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
on	O
admission	O
to	O
the	O
ED	B-Nonbiological_location
included	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
104	B-Lab_value
bpm	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
122	B-Lab_value
/	I-Lab_value
68	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
and	O
temperature	B-Diagnostic_procedure
of	O
99	B-Lab_value
.	I-Lab_value
7	I-Lab_value
°F	I-Lab_value
(	O
37	B-Lab_value
.	I-Lab_value
6	I-Lab_value
°C	I-Lab_value
)	O
.	O

There	O
were	O
no	B-Lab_value
remarkable	I-Lab_value
findings	I-Lab_value
on	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
except	O
for	O
altered	B-Sign_symptom
mental	I-Sign_symptom
status	I-Sign_symptom
and	O
dehydration	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
evaluations	I-Diagnostic_procedure
were	O
:	O
hemoglobin	B-Diagnostic_procedure
13	B-Lab_value
.	I-Lab_value
3	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
18	B-Lab_value
.	I-Lab_value
3	I-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
neutrophils	B-Lab_value
79	I-Lab_value
.	I-Lab_value
6	I-Lab_value
%	I-Lab_value
,	O
lymphocytes	B-Lab_value
7	I-Lab_value
.	I-Lab_value
2	I-Lab_value
%	I-Lab_value
,	O
and	O
monocytes	B-Lab_value
8	I-Lab_value
.	I-Lab_value
3	I-Lab_value
%	I-Lab_value
)	O
,	O
and	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
910	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

Serum	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
:	O
calcium	B-Diagnostic_procedure
18	B-Lab_value
.	I-Lab_value
6	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
phosphate	B-Diagnostic_procedure
4	B-Lab_value
.	I-Lab_value
6	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
sodium	B-Diagnostic_procedure
135	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
potassium	B-Diagnostic_procedure
2	B-Lab_value
.	I-Lab_value
7	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
albumin	B-Diagnostic_procedure
4	B-Lab_value
.	I-Lab_value
0	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
creatinine	B-Diagnostic_procedure
2	B-Lab_value
.	I-Lab_value
2	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
0	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
alkaline	B-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
125	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
aspartate	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
41	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
alanine	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
71	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

SPEP	B-Diagnostic_procedure
was	O
negative	B-Lab_value
for	I-Lab_value
an	I-Lab_value
M	I-Lab_value
spike	I-Lab_value
.	O

Hormones	B-Diagnostic_procedure
and	I-Diagnostic_procedure
vitamins	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
:	O
PTH	B-Diagnostic_procedure
8	B-Lab_value
.	I-Lab_value
5	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
15	O
-	O
65	O
pg	O
/	O
L	O
)	O
,	O
PHTrP	B-Diagnostic_procedure
1	B-Lab_value
.	I-Lab_value
4	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
<	O
2	O
pg	O
/	O
L	O
)	O
,	O
25	B-Diagnostic_procedure
-	I-Diagnostic_procedure
OH	I-Diagnostic_procedure
vitamin	I-Diagnostic_procedure
D	I-Diagnostic_procedure
30	B-Lab_value
.	I-Lab_value
4	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
20	O
-	O
50	O
ng	O
/	O
mL	O
)	O
and	O
1,25	B-Diagnostic_procedure
OH	I-Diagnostic_procedure
vitamin	I-Diagnostic_procedure
D3	I-Diagnostic_procedure
33	B-Lab_value
.	I-Lab_value
7	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
18	O
-	O
64	O
)	O
ng	O
/	O
mL	O
.	O

Chest	B-Biological_structure
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
showed	O
diffuse	B-Detailed_description
lytic	B-Detailed_description
lesions	B-Sign_symptom
and	O
bone	B-Sign_symptom
destruction	I-Sign_symptom
throughout	O
the	O
visualized	O
thoracic	B-Biological_structure
skeleton	I-Biological_structure
,	O
concerning	O
for	O
diffuse	O
bone	B-Sign_symptom
marrow	I-Sign_symptom
involvement	I-Sign_symptom
.	O

The	O
clinical	O
history	O
and	O
biochemical	O
findings	O
led	O
to	O
a	O
diagnosis	O
of	O
CML	B-Disease_disorder
-	O
associated	O
hypercalcemia	B-Sign_symptom
in	O
the	O
context	O
of	O
a	O
blast	B-Sign_symptom
phase	I-Sign_symptom
.	O

Treatment	O
with	O
aggressive	B-Detailed_description
hydration	B-Therapeutic_procedure
with	O
0	B-Lab_value
.	I-Lab_value
9	I-Lab_value
%	I-Lab_value
saline	B-Medication
and	O
calcitonin	B-Medication
400	B-Dosage
units	I-Dosage
subcutaneous	O
was	O
administered	O
.	O

Additionally	O
,	O
zoledronic	B-Medication
acid	I-Medication
3	B-Dosage
.	I-Dosage
3	I-Dosage
mg	I-Dosage
intravenous	O
,	O
adjusted	B-Detailed_description
for	I-Detailed_description
renal	I-Detailed_description
insufficiency	I-Detailed_description
,	O
was	O
given	O
.	O

After	B-Duration
five	I-Duration
days	I-Duration
of	O
treatment	O
,	O
normalization	B-Lab_value
of	O
symptoms	B-Sign_symptom
and	O
serum	B-Diagnostic_procedure
calcium	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
achieved	O
.	O

After	O
discharge	O
from	O
the	O
hospital	B-Nonbiological_location
,	O
the	O
patient	O
continued	O
with	O
palliative	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
with	O
ponatinib	B-Medication
and	O
radiotherapy	B-Therapeutic_procedure
.	O

Acceptable	O
serum	B-Diagnostic_procedure
calcium	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
maintained	B-Lab_value
with	O
zoledronic	B-Medication
acid	I-Medication
4	B-Dosage
mg	I-Dosage
every	I-Dosage
eight	I-Dosage
weeks	I-Dosage
.	O

Despite	O
these	O
therapies	O
,	O
his	O
cancer	B-Disease_disorder
progressed	O
and	O
he	O
passed	O
away	O
approximately	O
eight	O
months	O
after	O
the	O
initial	O
admission	O
for	O
hypercalcemia	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
36	B-Age
-	I-Age
yr	I-Age
-	I-Age
old	I-Age
previously	O
healthy	O
Sri	O
Lankan	O
male	O
who	O
takes	B-Occupation
care	I-Occupation
of	I-Occupation
a	I-Occupation
horse	I-Occupation
presented	O
to	O
the	O
medical	B-Nonbiological_location
casualty	I-Nonbiological_location
ward	I-Nonbiological_location
with	O
fever	B-Sign_symptom
,	O
arthralgia	B-Sign_symptom
and	O
myalgia	B-Sign_symptom
for	O
one	B-Duration
day	I-Duration
.	O

He	O
complained	O
of	O
mild	B-Severity
dysuria	B-Sign_symptom
but	O
had	O
normal	B-Lab_value
urine	B-Diagnostic_procedure
output	I-Diagnostic_procedure
.	O

He	O
did	O
not	O
have	O
chest	B-Biological_structure
pain	B-Sign_symptom
or	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
.	O

Further	O
inquiry	O
revealed	O
that	O
he	O
was	O
treated	O
for	O
leptospirosis	O
during	O
a	O
febrile	O
illness	O
in	O
the	O
past	O
.	O

On	O
examination	B-Diagnostic_procedure
,	O
patient	O
was	O
afebrile	B-Sign_symptom
,	O
anicteric	B-Sign_symptom
.	O

His	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
90	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mmHg	I-Lab_value
and	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
76	B-Lab_value
bpm	I-Lab_value
.	O

Rest	O
of	O
the	O
examination	B-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
.	O

Initial	O
investigations	B-Diagnostic_procedure
performed	O
on	O
the	O
day	O
of	O
admission	O
revealed	O
neutrophil	B-Biological_structure
leukocytosis	B-Sign_symptom
,	O
mild	B-Severity
thrombocytopaenia	B-Sign_symptom
and	O
microscopic	B-Detailed_description
haematuria	B-Sign_symptom
(	O
Table	O
1	O
)	O
.	O

Renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
and	O
liver	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

Urine	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
revealed	O
pus	B-Lab_value
cells	I-Lab_value
05	I-Lab_value
-	I-Lab_value
06	I-Lab_value
/	I-Lab_value
hpf	I-Lab_value
,	O
red	B-Lab_value
cells	I-Lab_value
30	I-Lab_value
-	I-Lab_value
35	I-Lab_value
/	I-Lab_value
hpf	I-Lab_value
.	O

CRP	B-Diagnostic_procedure
(	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
)	O
was	O
75	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
.	O

A	O
clinical	O
diagnosis	O
of	O
leptospirosis	B-Disease_disorder
was	O
made	O
and	O
he	O
was	O
started	O
on	O
intravenous	O
penicillin	B-Medication
in	O
addition	O
to	O
adequate	O
hydration	B-Therapeutic_procedure
.	O

On	O
the	O
second	O
day	O
of	O
illness	O
,	O
he	O
developed	O
hypotension	B-Sign_symptom
with	O
tachycardia	B-Sign_symptom
and	O
dyspnoea	B-Sign_symptom
.	O

ECG	B-Diagnostic_procedure
revealed	O
sinus	B-Detailed_description
tachycardia	B-Sign_symptom
with	O
ST	B-Detailed_description
depression	I-Detailed_description
in	I-Detailed_description
leads	I-Detailed_description
V4	I-Detailed_description
-	I-Detailed_description
V6	I-Detailed_description
[	O
Figure	O
1	O
]	O
.	O

His	O
CXR	B-Diagnostic_procedure
(	O
chest	B-Diagnostic_procedure
x	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
)	O
showed	O
gross	B-Detailed_description
cardiomegaly	B-Disease_disorder
and	O
bilateral	B-Detailed_description
pulmonary	B-Biological_structure
shadows	B-Sign_symptom
[	O
Figure	O
2	O
]	O
.	O

CVP	B-Diagnostic_procedure
(	O
central	B-Diagnostic_procedure
venous	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
)	O
was	O
16	B-Lab_value
cmH2O	I-Lab_value
and	O
2D	B-Detailed_description
echocardiogram	B-Diagnostic_procedure
revealed	O
dilatation	B-Sign_symptom
of	O
all	B-Biological_structure
four	I-Biological_structure
chambers	I-Biological_structure
,	O
severe	B-Severity
global	B-Detailed_description
hypokinesia	B-Disease_disorder
and	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
20	B-Lab_value
%	I-Lab_value
.	O

Troponin	B-Diagnostic_procedure
I	I-Diagnostic_procedure
was	O
12	B-Lab_value
.	I-Lab_value
77	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
(	O
normal	O
range	O
<	O
0	O
.	O
40	O
)	O
.	O

He	O
was	O
diagnosed	O
to	O
have	O
early	B-Detailed_description
and	O
severe	B-Severity
myocarditis	B-Disease_disorder
.	O

Patient	O
was	O
transferred	O
to	O
ICU	B-Nonbiological_location
(	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
)	O
as	O
he	O
needed	O
inotropic	B-Therapeutic_procedure
support	I-Therapeutic_procedure
.	O

Intravenous	O
antibiotics	B-Medication
including	O
penicillin	B-Medication
,	O
meropenem	B-Medication
and	O
levofloxacin	B-Medication
were	O
continued	O
.	O

Patient	O
was	O
electively	O
ventilated	B-Therapeutic_procedure
on	O
the	O
3rd	O
day	O
of	O
illness	O
due	O
to	O
severe	B-Severity
respiratory	B-Disease_disorder
distress	I-Disease_disorder
.	O

On	O
the	O
same	B-Time
day	I-Time
,	O
he	O
developed	O
rapid	B-Detailed_description
atrial	B-Disease_disorder
fibrillation	I-Disease_disorder
[	O
Figure	O
3	O
]	O
unresponsive	O
to	O
digoxin	B-Medication
and	O
intravenous	O
amiodarone	B-Medication
.	O

Platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
dropped	B-Lab_value
to	O
10	B-Lab_value
×	I-Lab_value
103	I-Lab_value
μ	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
he	O
was	O
given	O
platelet	B-Therapeutic_procedure
transfusions	I-Therapeutic_procedure
to	O
prevent	O
bleeding	O
[	O
Table	O
1	O
]	O
.	O

We	O
started	O
intravenous	O
methylprednisolone	B-Medication
based	O
on	O
previous	O
studies	O
showing	O
a	O
mortality	O
benefit	O
in	O
severe	O
leptospirosis	O
complicated	O
with	O
myocarditis	O
[	O
11	O
]	O
.	O

His	O
serum	B-Biological_structure
creatinine	B-Diagnostic_procedure
increased	B-Lab_value
to	O
362	B-Lab_value
μ	I-Lab_value
mol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
by	O
the	O
5th	O
day	O
of	O
illness	O
and	O
ALT	B-Diagnostic_procedure
(	O
alanine	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
)	O
and	O
AST	B-Diagnostic_procedure
(	O
aspartate	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
)	O
were	O
markedly	O
elevated	B-Lab_value
up	O
to	O
2726	B-Lab_value
U	I-Lab_value
/	I-Lab_value
l	I-Lab_value
and	O
7438	B-Lab_value
U	I-Lab_value
/	I-Lab_value
l	I-Lab_value
respectively	O
.	O

Dengue	B-Detailed_description
and	O
Mycoplasma	B-Detailed_description
infections	B-Disease_disorder
were	O
excluded	O
.	O

Blood	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Leptospira	B-Detailed_description
IgM	I-Detailed_description
antibody	B-Diagnostic_procedure
performed	O
on	O
the	O
5th	O
day	O
of	O
illness	O
was	O
positive	B-Lab_value
(	O
IgG	B-Diagnostic_procedure
negative	B-Lab_value
)	O
.	O

Patient	O
developed	O
refractory	B-Disease_disorder
shock	I-Disease_disorder
and	O
died	O
of	O
persistent	B-Detailed_description
ventricular	B-Biological_structure
tachycardia	B-Sign_symptom
despite	O
optimal	B-Detailed_description
treatment	B-Therapeutic_procedure
in	O
the	O
ICU	B-Nonbiological_location
.	O

-DOCSTART- -X- -X- -X- O

A	O
50	B-Age
-	I-Age
year	I-Age
old	I-Age
man	O
with	O
a	O
history	O
of	O
metastatic	B-Detailed_description
mucinous	B-Detailed_description
appendiceal	B-Disease_disorder
adenocarcinoma	I-Disease_disorder
presents	O
for	O
evaluation	O
of	O
a	O
desquamating	B-Detailed_description
rash	B-Sign_symptom
on	O
his	O
face	B-Biological_structure
that	O
has	O
spread	O
to	O
his	O
scalp	B-Biological_structure
,	O
inguinal	B-Biological_structure
region	I-Biological_structure
,	O
and	O
perineum	B-Biological_structure
over	B-Duration
the	I-Duration
past	I-Duration
4	I-Duration
months	I-Duration
(	O
Figure	O
1	O
)	O
.	O

The	O
rash	B-Sign_symptom
has	O
been	O
accompanied	O
by	O
diffuse	B-Detailed_description
alopecia	B-Disease_disorder
of	O
the	O
face	B-Biological_structure
,	O
scalp	B-Biological_structure
,	O
axilla	B-Biological_structure
,	O
and	O
groin	B-Biological_structure
.	O

There	O
was	O
no	O
improvement	O
in	O
the	O
rash	B-Sign_symptom
despite	O
multiple	B-Dosage
rounds	I-Dosage
of	O
oral	O
fluconazole	B-Medication
,	O
topical	O
antibiotic	B-Medication
ointment	O
,	O
and	O
intravenous	O
antibiotics	B-Medication
.	O

Prior	O
to	O
the	O
development	O
of	O
his	O
rash	O
,	O
he	O
completed	O
neoadjuvant	B-Detailed_description
chemotherapy	B-Medication
followed	O
by	O
surgical	B-Therapeutic_procedure
resection	I-Therapeutic_procedure
.	O

He	O
underwent	O
colostomy	B-Therapeutic_procedure
after	O
he	O
failed	O
surgical	B-Therapeutic_procedure
correction	I-Therapeutic_procedure
for	O
an	O
enterocutaneous	B-Disease_disorder
fistula	I-Disease_disorder
,	O
and	O
he	O
has	O
required	O
total	B-Therapeutic_procedure
parenteral	I-Therapeutic_procedure
nutrition	I-Therapeutic_procedure
(	O
TPN	B-Therapeutic_procedure
)	O
for	O
the	O
past	B-Duration
year	I-Duration
.	O

He	O
did	O
not	O
notice	O
any	O
significant	O
changes	B-Sign_symptom
in	I-Sign_symptom
ostomy	I-Sign_symptom
output	I-Sign_symptom
during	O
this	O
time	O
.	O

Dermatological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
reveals	O
widespread	B-Detailed_description
erythematous	B-Detailed_description
plaques	B-Sign_symptom
on	O
the	O
face	B-Biological_structure
,	O
scalp	B-Biological_structure
,	O
and	O
medial	B-Biological_structure
aspect	I-Biological_structure
of	I-Biological_structure
thighs	I-Biological_structure
bilaterally	B-Detailed_description
and	O
scattered	B-Detailed_description
papules	B-Sign_symptom
with	O
scaling	B-Detailed_description
on	O
face	B-Biological_structure
,	O
scalp	B-Biological_structure
,	O
chest	B-Biological_structure
,	O
and	O
back	B-Biological_structure
.	O

Diffuse	B-Detailed_description
,	O
non	B-Detailed_description
-	I-Detailed_description
scarring	I-Detailed_description
alopecia	B-Disease_disorder
is	O
present	O
on	O
the	O
face	B-Biological_structure
,	O
scalp	B-Biological_structure
,	O
axillae	B-Biological_structure
,	O
and	O
groin	B-Biological_structure
.	O

The	O
patient	O
had	O
acquired	O
AE	B-Disease_disorder
,	O
a	O
rare	O
dermatologic	O
condition	O
caused	O
by	O
zinc	B-Disease_disorder
deficiency	I-Disease_disorder
.	O

This	O
patient	O
developed	O
acquired	B-Detailed_description
zinc	B-Disease_disorder
deficiency	I-Disease_disorder
in	O
the	O
setting	O
of	O
inadequate	B-Lab_value
zinc	B-Medication
supplementation	I-Medication
in	O
TPN	B-Therapeutic_procedure
.	O

The	O
patient	O
had	O
not	O
received	O
trace	B-Medication
elements	I-Medication
for	O
approximately	O
one	B-Duration
year	I-Duration
due	O
to	O
a	O
national	B-Other_event
shortage	I-Other_event
.	O

The	O
key	O
to	O
the	O
correct	O
diagnosis	O
of	O
acquired	O
AE	O
is	O
the	O
combination	O
of	O
desquamating	O
rash	O
coupled	O
with	O
alopecia	O
in	O
the	O
setting	O
of	O
chronic	O
supplemental	O
alimentation	O
.	O

Although	O
it	O
is	O
reasonable	O
to	O
consider	O
a	O
skin	O
biopsy	O
,	O
a	O
skin	O
biopsy	O
would	O
not	O
definitively	O
establish	O
the	O
diagnosis	O
.	O

A	O
paraneoplastic	O
panel	O
could	O
be	O
considered	O
,	O
but	O
it	O
would	O
delay	O
diagnosis	O
,	O
and	O
the	O
presentation	O
is	O
most	O
consistent	O
with	O
nutritional	O
deficiency	O
.	O

It	O
is	O
not	O
appropriate	O
to	O
start	O
a	O
topical	O
steroid	O
cream	O
until	O
a	O
diagnosis	O
is	O
determined	O
.	O

The	O
patient	O
had	O
a	O
zinc	B-Diagnostic_procedure
level	O
of	O
29	B-Lab_value
ug	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
normal	O
range	O
56	O
-	O
134	O
ug	O
/	O
dL	O
)	O
.	O

He	O
received	O
zinc	B-Medication
supplementation	I-Medication
in	O
his	O
TPN	B-Therapeutic_procedure
,	O
and	O
within	O
one	O
month	O
,	O
the	O
patient	O
had	O
complete	O
resolution	O
of	O
rash	B-Sign_symptom
and	O
fatigue	B-Sign_symptom
,	O
and	O
gradual	O
return	O
of	O
hair	B-Sign_symptom
growth	I-Sign_symptom
(	O
Figure	O
2	O
)	O
.	O

Repeat	O
zinc	B-Diagnostic_procedure
level	I-Diagnostic_procedure
following	O
supplementation	O
was	O
90	B-Lab_value
ug	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Although	O
the	O
patient	O
recovered	O
from	O
his	O
zinc	B-Disease_disorder
deficiency	I-Disease_disorder
,	O
he	O
later	O
passed	O
away	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
77	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
dysphagia	B-Sign_symptom
presented	O
with	O
a	O
two	B-Duration
-	I-Duration
week	I-Duration
history	I-Duration
of	O
rash	B-Sign_symptom
characterized	O
by	O
brown	B-Color
plaques	B-Sign_symptom
with	O
erythematous	B-Detailed_description
borders	I-Detailed_description
and	O
overlying	B-Detailed_description
thick	I-Detailed_description
scales	I-Detailed_description
involving	O
the	O
face	B-Biological_structure
and	O
a	O
prior	O
percutaneous	B-Diagnostic_procedure
endoscopic	I-Diagnostic_procedure
gastrostomy	I-Diagnostic_procedure
(	O
PEG	B-Diagnostic_procedure
)	O
tube	O
site	B-Biological_structure
(	O
Fig	O
.	O
1a	O
,	O
c	O
)	O
.	O

No	O
oral	B-Biological_structure
or	O
conjunctival	B-Biological_structure
involvement	B-Sign_symptom
was	O
present	O
.	O

She	O
had	O
been	O
receiving	O
parenteral	B-Medication
nutrition	I-Medication
for	O
two	B-Duration
months	I-Duration
following	O
removal	O
of	O
the	O
PEG	B-Diagnostic_procedure
tube	I-Diagnostic_procedure
due	O
to	O
infection	B-Disease_disorder
.	O

Although	O
the	O
differential	O
diagnosis	O
included	O
drug	B-Disease_disorder
hypersensitivity	I-Disease_disorder
,	O
autoimmune	B-Disease_disorder
disorders	I-Disease_disorder
and	O
nutritional	B-Disease_disorder
deficiency	I-Disease_disorder
,	O
the	O
rash	B-Sign_symptom
appearance	O
was	O
most	O
consistent	O
with	O
acrodermatitis	B-Disease_disorder
enteropathica	I-Disease_disorder
-	O
like	O
eruption	B-Sign_symptom
secondary	O
to	O
zinc	B-Disease_disorder
deficiency	I-Disease_disorder
.	O

Her	O
serum	B-Detailed_description
zinc	B-Diagnostic_procedure
level	O
was	O
12	B-Lab_value
mcg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
normal	O
,	O
55	O
-	O
150	O
mcg	O
/	O
dL	O
)	O
,	O
and	O
the	O
rash	B-Sign_symptom
resolved	O
within	O
one	O
week	O
of	O
parenteral	O
zinc	B-Medication
supplementation	I-Medication
(	O
Fig	O
.	O
1b	O
,	O
d	O
)	O
.	O

Zinc	O
is	O
essential	O
for	O
protein	O
synthesis	O
and	O
wound	O
healing	O
.	O

Acrodermatitis	O
enteropathica	O
presents	O
in	O
infancy	O
as	O
a	O
periorificial	O
desquamative	O
dermatitis	O
,	O
resulting	O
from	O
an	O
autosomal	O
recessive	O
mutation	O
that	O
impairs	O
zinc	O
absorption	O
.	O
A	O
similar	O
syndrome	O
may	O
occur	O
due	O
to	O
nutritional	O
zinc	O
deficiency	O
,	O
and	O
has	O
been	O
reported	O
in	O
the	O
setting	O
of	O
parenteral	O
nutrition	O
that	O
fails	O
to	O
include	O
zinc	O
supplementation	O
;	O
a	O
prompt	O
response	O
to	O
supplementation	O
helps	O
to	O
confirm	O
the	O
diagnosis	O
.	O

A	O
recent	O
national	O
shortage	O
of	O
parenteral	O
zinc	O
in	O
the	O
United	O
States	O
likely	O
contributed	O
to	O
this	O
patient	O
`	O
s	O
presentation	O
.	O

-DOCSTART- -X- -X- -X- O

Our	O
patient	O
was	O
a	O
50	B-Age
-	I-Age
year	I-Age
old	I-Age
man	O
with	O
bicuspid	B-Detailed_description
aortic	B-Sign_symptom
valve	I-Sign_symptom
insufficiency	I-Sign_symptom
and	O
ascending	B-Detailed_description
aorta	B-Sign_symptom
dilatation	I-Sign_symptom
.	O

He	O
had	O
undergone	O
a	O
free	B-Detailed_description
-	I-Detailed_description
hand	I-Detailed_description
aortic	B-Biological_structure
homograft	B-Therapeutic_procedure
implantation	I-Therapeutic_procedure
with	O
replacement	B-Therapeutic_procedure
of	O
the	O
non	B-Biological_structure
-	I-Biological_structure
coronary	I-Biological_structure
sinus	I-Biological_structure
using	O
a	O
24	B-Detailed_description
-	I-Detailed_description
mm	I-Detailed_description
homograft	I-Detailed_description
in	O
2006	O
(	O
at	O
the	O
age	O
of	O
41	O
)	O
.	O

Follow	O
-	O
up	O
evaluations	O
were	O
performed	O
every	B-Frequency
6	I-Frequency
months	I-Frequency
and	O
showed	O
mild	B-Severity
aortic	B-Sign_symptom
valve	I-Sign_symptom
insufficiency	I-Sign_symptom
.	O

After	O
8	B-Duration
years	I-Duration
of	O
follow	O
-	O
up	O
,	O
the	O
patient	O
presented	O
to	O
hospital	B-Nonbiological_location
with	O
fever	B-Sign_symptom
and	O
the	O
echocardiography	B-Diagnostic_procedure
showed	O
severe	B-Severity
aortic	B-Sign_symptom
insufficiency	I-Sign_symptom
due	O
to	O
a	O
rupture	B-Sign_symptom
of	O
one	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
cusps	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
homograft	I-Biological_structure
,	O
worsening	B-Lab_value
of	O
cardiac	B-Diagnostic_procedure
contractility	I-Diagnostic_procedure
with	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
ejection	I-Diagnostic_procedure
fraction	I-Diagnostic_procedure
(	O
LVEF	B-Diagnostic_procedure
)	O
depression	B-Lab_value
(	O
40	B-Lab_value
-	I-Lab_value
45	I-Lab_value
%	I-Lab_value
)	O
and	O
dilatation	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
left	I-Sign_symptom
ventricle	I-Sign_symptom
(	O
telediastolic	B-Lab_value
/	I-Lab_value
telesystolic	I-Lab_value
diameters	I-Lab_value
60	I-Lab_value
/	I-Lab_value
42	I-Lab_value
mm	I-Lab_value
,	O
respectively	O
)	O
.	O

The	O
patient	O
presented	O
orthopnoea	B-Sign_symptom
and	O
hypotension	B-Sign_symptom
,	O
which	O
needed	O
infusion	O
of	O
dopamine	B-Medication
and	O
diuretics	B-Medication
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
scan	O
showed	O
calcifications	B-Sign_symptom
on	O
the	O
homograft	B-Biological_structure
,	O
pleural	B-Sign_symptom
effusions	I-Sign_symptom
and	O
no	O
signs	O
of	O
pericardial	B-Sign_symptom
effusion	I-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

Since	O
the	O
Dukes	B-Diagnostic_procedure
criteria	I-Diagnostic_procedure
for	I-Diagnostic_procedure
endocarditis	I-Diagnostic_procedure
were	O
not	B-Lab_value
satisfied	I-Lab_value
,	O
the	O
final	O
diagnosis	O
was	O
an	O
early	O
structural	B-Disease_disorder
deterioration	I-Disease_disorder
of	O
the	O
homograft	B-Biological_structure
,	O
due	O
to	O
a	O
severe	B-Severity
calcification	B-Sign_symptom
process	O
.	O

The	O
operation	B-Therapeutic_procedure
was	O
performed	O
through	O
median	B-Detailed_description
resternotomy	B-Therapeutic_procedure
and	O
with	O
standard	B-Detailed_description
aorta	B-Biological_structure
-	I-Biological_structure
right	I-Biological_structure
atrium	I-Biological_structure
central	B-Therapeutic_procedure
cannulation	I-Therapeutic_procedure
for	O
the	O
extracorporeal	O
circulation	O
.	O

The	O
leaflets	B-Biological_structure
and	O
the	O
annulus	B-Biological_structure
of	O
the	O
homograft	B-Biological_structure
presented	O
severe	B-Severity
calcifications	B-Sign_symptom
and	O
no	O
signs	O
of	O
endocarditis	B-Disease_disorder
were	O
found	O
.	O

An	O
Edwards	B-Detailed_description
Intuity	I-Detailed_description
bioprosthesis	B-Therapeutic_procedure
(	O
21	O
mm	O
)	O
was	O
then	O
implanted	B-Therapeutic_procedure
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
cross	B-Therapeutic_procedure
-	I-Therapeutic_procedure
clamping	I-Therapeutic_procedure
time	O
was	O
41	B-Duration
min	I-Duration
,	O
and	O
the	O
cardiopulmonary	B-Therapeutic_procedure
bypass	I-Therapeutic_procedure
time	O
was	O
64	B-Duration
min	I-Duration
.	O

The	O
patient	O
required	O
dopamine	B-Medication
and	O
adrenaline	B-Medication
at	O
low	B-Dosage
doses	I-Dosage
for	O
bypass	O
weaning	O
.	O

No	O
complications	B-Sign_symptom
occurred	O
during	O
the	O
postoperative	B-Therapeutic_procedure
period	I-Therapeutic_procedure
.	O

Echocardiography	B-Diagnostic_procedure
before	O
the	O
discharge	O
showed	O
the	O
absence	O
of	O
paravalvular	B-Sign_symptom
leaks	I-Sign_symptom
,	O
a	O
peak	B-Diagnostic_procedure
/	I-Diagnostic_procedure
mean	I-Diagnostic_procedure
aortic	I-Diagnostic_procedure
gradient	I-Diagnostic_procedure
of	O
34	B-Lab_value
/	I-Lab_value
20	I-Lab_value
mmHg	I-Lab_value
and	O
an	O
LVEF	B-Diagnostic_procedure
of	O
33	B-Lab_value
%	I-Lab_value
.	O

Follow	O
-	O
up	O
echocardiography	B-Diagnostic_procedure
after	O
3	O
months	O
from	O
the	O
operation	O
showed	O
neither	O
leaks	B-Sign_symptom
nor	O
malfunctions	B-Sign_symptom
of	O
the	O
Edwards	B-Detailed_description
Intuity	I-Detailed_description
prosthesis	B-Biological_structure
,	O
a	O
peak	B-Diagnostic_procedure
/	I-Diagnostic_procedure
mean	I-Diagnostic_procedure
gradient	I-Diagnostic_procedure
of	O
38	B-Lab_value
/	I-Lab_value
22	I-Lab_value
mmHg	I-Lab_value
and	O
initial	B-Lab_value
recovery	I-Lab_value
of	O
the	O
LVEF	B-Diagnostic_procedure
(	O
valued	O
47	B-Lab_value
%	I-Lab_value
)	O
.	O

Patient	O
was	O
asymptomatic	B-Sign_symptom
again	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
54	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Asian	O
man	O
with	O
IgA	O
nephropathy	O
underwent	O
living	B-Detailed_description
-	I-Detailed_description
donor	I-Detailed_description
kidney	B-Therapeutic_procedure
transplantation	I-Therapeutic_procedure
14	O
years	O
previously	O
.	O

His	O
medical	B-Diagnostic_procedure
condition	I-Diagnostic_procedure
had	O
been	O
almost	B-Lab_value
stable	I-Lab_value
for	O
14	B-Duration
years	I-Duration
.	O

He	O
developed	O
multifocal	B-Detailed_description
salmon	B-Color
-	I-Color
pink	I-Color
skin	B-Biological_structure
discoloration	B-Sign_symptom
,	O
and	O
swelling	B-Sign_symptom
and	O
spontaneous	B-Detailed_description
pain	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
knee	I-Biological_structure
and	O
leg	B-Biological_structure
.	O

The	O
symptoms	O
had	O
gradually	O
expanded	O
across	O
the	O
right	B-Biological_structure
forearm	I-Biological_structure
and	O
outside	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
thigh	I-Biological_structure
.	O

He	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
the	O
evaluation	O
of	O
fever	B-Sign_symptom
(	O
39	B-Lab_value
°C	I-Lab_value
)	O
and	O
multifocal	B-Detailed_description
cellulitis	B-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

Two	O
months	O
before	O
admission	O
,	O
he	O
had	O
developed	O
chronic	B-Detailed_description
diarrhea	B-Sign_symptom
.	O

His	O
serum	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
level	O
was	O
stabilized	B-Lab_value
at	O
1	B-Lab_value
.	I-Lab_value
7	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
with	O
maintenance	O
immunosuppressive	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
comprising	O
tacrolimus	B-Medication
(	O
3	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
,	O
mycophenolate	B-Medication
mofetil	I-Medication
(	O
1500	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
,	O
and	O
prednisone	B-Medication
(	O
4	B-Dosage
mg	I-Dosage
every	I-Dosage
other	I-Dosage
day	I-Dosage
)	O
.	O

The	O
tacrolimus	B-Diagnostic_procedure
trough	I-Diagnostic_procedure
concentration	I-Diagnostic_procedure
was	O
6	B-Lab_value
.	I-Lab_value
3	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

The	O
patient	O
had	O
been	O
a	B-Occupation
dog	I-Occupation
breeder	I-Occupation
for	I-Occupation
12	I-Occupation
years	I-Occupation
.	O

On	O
admission	O
,	O
his	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
12,400	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
and	O
his	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
level	O
was	O
3	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

The	O
patient	O
was	O
initially	O
treated	O
with	O
ampicillin	B-Medication
/	I-Medication
sulbactam	I-Medication
(	O
9	B-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
intravenously	O
)	O
.	O

Two	O
days	O
after	O
the	O
initiation	O
of	O
this	O
therapy	O
,	O
he	O
was	O
afebrile	B-Sign_symptom
.	O

Four	O
days	O
later	O
,	O
an	O
automated	O
blood	B-Diagnostic_procedure
culture	I-Diagnostic_procedure
(	O
Bactec	B-Detailed_description
FX	I-Detailed_description
®	I-Detailed_description
;	O
Becton	B-Detailed_description
-	I-Detailed_description
Dickinson	I-Detailed_description
and	I-Detailed_description
Company	I-Detailed_description
,	I-Detailed_description
Sparks	I-Detailed_description
,	I-Detailed_description
MD	I-Detailed_description
,	I-Detailed_description
USA	I-Detailed_description
)	O
showed	O
positivity	B-Lab_value
for	O
gram	B-Diagnostic_procedure
-	I-Diagnostic_procedure
negative	I-Diagnostic_procedure
spiral	I-Diagnostic_procedure
bacilli	I-Diagnostic_procedure
.	O

A	O
colony	B-Detailed_description
obtained	I-Detailed_description
from	I-Detailed_description
the	I-Detailed_description
patient	I-Detailed_description
`	I-Detailed_description
s	I-Detailed_description
blood	I-Detailed_description
culture	I-Detailed_description
was	O
analyzed	O
by	O
MALDI	B-Detailed_description
-	I-Detailed_description
TOF	I-Detailed_description
MS	B-Diagnostic_procedure
(	O
Biotyper	B-Detailed_description
ver	I-Detailed_description
.	I-Detailed_description
3	I-Detailed_description
.	I-Detailed_description
0	I-Detailed_description
®	I-Detailed_description
;	O
Bruker	B-Detailed_description
Corporation	I-Detailed_description
,	I-Detailed_description
Germany	I-Detailed_description
)	O
.	O

The	O
identification	B-Lab_value
score	I-Lab_value
was	I-Lab_value
2	I-Lab_value
.	I-Lab_value
064	I-Lab_value
(	O
>	O
2	O
.	O
0	O
)	O
,	O
indicating	O
accurate	O
identification	O
of	O
H	B-Sign_symptom
.	I-Sign_symptom
cinaedi	I-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

Additional	O
evaluation	B-Diagnostic_procedure
of	O
the	O
patient	O
`	O
s	O
blood	B-Biological_structure
specifically	O
for	O
H	O
.	O

cinaedi	O
by	O
means	O
of	O
gyrase	B-Detailed_description
subunit	I-Detailed_description
B	I-Detailed_description
(	I-Detailed_description
gyrB	I-Detailed_description
)	I-Detailed_description
-	I-Detailed_description
targeted	I-Detailed_description
PCR	B-Diagnostic_procedure
assays	I-Diagnostic_procedure
(	O
using	B-Detailed_description
the	I-Detailed_description
forward	I-Detailed_description
primer	I-Detailed_description
AGGGATTCCACAAAGTGAGC	I-Detailed_description
and	I-Detailed_description
the	I-Detailed_description
reverse	I-Detailed_description
primer	I-Detailed_description
TCTTGTCCTGTGCGTTCATC	I-Detailed_description
to	I-Detailed_description
amplify	I-Detailed_description
the	I-Detailed_description
region	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
gyrB	I-Detailed_description
gene	I-Detailed_description
)	O
yielded	O
positive	B-Lab_value
results	O
.	O

We	O
performed	O
gyrB	B-Detailed_description
-	I-Detailed_description
targeted	I-Detailed_description
PCR	B-Diagnostic_procedure
using	O
a	O
single	B-Detailed_description
colony	I-Detailed_description
isolated	I-Detailed_description
from	I-Detailed_description
a	I-Detailed_description
blood	I-Detailed_description
culture	I-Detailed_description
.	O

We	O
used	O
distilled	B-Detailed_description
water	I-Detailed_description
(	I-Detailed_description
DNA	I-Detailed_description
-	I-Detailed_description
and	I-Detailed_description
DNase	I-Detailed_description
-	I-Detailed_description
free	I-Detailed_description
water	I-Detailed_description
)	I-Detailed_description
as	I-Detailed_description
a	I-Detailed_description
negative	I-Detailed_description
control	I-Detailed_description
to	O
prevent	O
contamination	O
of	O
gyrB	O
-	O
targeted	O
PCR	O
(	O
Fig	O
.	O
3	O
)	O
.	O

In	O
addition	O
,	O
we	O
performed	O
16S	B-Diagnostic_procedure
rRNA	I-Diagnostic_procedure
gene	I-Diagnostic_procedure
sequencing	I-Diagnostic_procedure
of	O
this	O
strain	O
,	O
and	O
the	O
results	O
were	O
>	O
99	O
%	O
consistent	O
with	O
the	O
existing	O
sequence	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Given	O
these	O
results	O
,	O
we	O
diagnosed	O
the	O
patient	O
with	O
H	O
.	O

cinaedi	O
bacteremia	B-Disease_disorder
with	O
cellulitis	B-Disease_disorder
.	O

We	O
examined	B-Diagnostic_procedure
the	I-Diagnostic_procedure
genomic	I-Diagnostic_procedure
heat	I-Diagnostic_procedure
shock	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	I-Diagnostic_procedure
HSP	I-Diagnostic_procedure
)	I-Diagnostic_procedure
60	I-Diagnostic_procedure
sequence	I-Diagnostic_procedure
of	O
the	O
blood	B-Detailed_description
culture	I-Detailed_description
isolate	I-Detailed_description
,	O
which	O
resulted	O
in	O
identification	O
of	O
cluster	B-Detailed_description
B	I-Detailed_description
H	B-Sign_symptom
.	I-Sign_symptom
cinaedi	I-Sign_symptom
.	O

A	O
blood	B-Diagnostic_procedure
culture	I-Diagnostic_procedure
obtained	O
at	O
11	O
days	O
was	O
positive	B-Lab_value
for	O
H	O
.	O

cinaedi	O
,	O
but	O
a	O
culture	B-Diagnostic_procedure
obtained	O
at	O
15	O
days	O
was	O
negative	B-Lab_value
.	O

The	O
patient	O
`	O
s	O
cellulitis	B-Disease_disorder
gradually	O
resolved	O
.	O

The	O
patient	O
continued	O
antibiotic	B-Medication
treatment	O
for	O
a	O
total	O
of	O
6	B-Duration
weeks	I-Duration
(	O
ampicillin	B-Medication
-	I-Medication
sulbactam	I-Medication
in	O
a	O
drip	O
for	O
2	B-Duration
weeks	I-Duration
and	O
oral	O
levofloxacin	B-Medication
for	O
4	B-Duration
weeks	I-Duration
)	O
,	O
and	O
he	O
had	O
no	O
recurrence	B-Sign_symptom
6	O
months	O
after	O
this	O
therapy	O
.	O

His	O
stool	B-Diagnostic_procedure
culture	I-Diagnostic_procedure
was	O
negative	B-Lab_value
,	O
although	O
it	O
was	O
taken	B-Detailed_description
after	I-Detailed_description
treatment	I-Detailed_description
.	O

We	O
did	O
not	O
apply	O
enteric	B-Medication
bacteria	I-Medication
elimination	I-Medication
in	O
this	O
case	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
19	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
at	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
,	O
12	B-Time
h	I-Time
after	I-Time
insertion	B-Activity
of	O
a	O
high	B-Detailed_description
pressure	I-Detailed_description
container	I-Detailed_description
with	O
tanning	O
spray	O
into	O
his	O
rectum	B-Biological_structure
.	O

A	O
plain	B-Detailed_description
abdominal	B-Biological_structure
radiograph	B-Diagnostic_procedure
(	O
Figure	O
1	O
)	O
showed	O
the	O
container	B-Sign_symptom
in	O
the	O
rectosigmoid	B-Biological_structure
region	I-Biological_structure
.	O

There	O
were	O
no	O
signs	O
of	O
perforation	B-Disease_disorder
.	O

A	O
flexible	B-Detailed_description
sigmoidoscopy	B-Diagnostic_procedure
was	O
performed	O
under	O
conscious	B-Medication
sedation	I-Medication
.	O

The	O
object	B-Sign_symptom
was	O
located	O
just	O
above	B-Biological_structure
the	I-Biological_structure
rectosigmoid	I-Biological_structure
junction	I-Biological_structure
.	O

The	O
container	O
could	O
not	O
be	O
extracted	B-Therapeutic_procedure
by	O
bimanual	B-Therapeutic_procedure
manipulation	I-Therapeutic_procedure
.	O

An	O
attempt	O
to	O
remove	B-Therapeutic_procedure
the	O
object	O
with	O
conventional	B-Detailed_description
endoscopic	I-Detailed_description
instruments	I-Detailed_description
,	O
such	O
as	O
polypectomy	B-Detailed_description
snares	I-Detailed_description
,	O
was	O
unsuccessful	B-Lab_value
.	O

The	O
sigmoidoscope	B-Diagnostic_procedure
could	O
be	O
passed	O
alongside	O
the	O
foreign	O
body	O
to	O
its	O
proximal	O
end	O
.	O

A	O
guide	B-Diagnostic_procedure
wire	I-Diagnostic_procedure
was	O
left	O
behind	O
with	O
the	O
sigmoidoscope	B-Diagnostic_procedure
removed	O
.	O

Subsequently	O
,	O
a	O
40	B-Distance
mm	I-Distance
pneumatic	B-Diagnostic_procedure
dilatation	I-Diagnostic_procedure
balloon	I-Diagnostic_procedure
(	O
Rigiflex	O
®	O
,	O
Boston	O
Scientific	O
)	O
,	O
normally	O
used	O
in	O
achalasia	O
patients	O
,	O
was	O
inserted	O
over	O
the	O
guide	B-Diagnostic_procedure
wire	I-Diagnostic_procedure
and	O
inflated	O
just	O
above	O
the	O
container	O
(	O
Figure	O
2	O
)	O
.	O

For	O
safety	O
purposes	O
,	O
the	O
sigmoidoscope	B-Diagnostic_procedure
was	O
reintroduced	O
alongside	O
the	O
catheter	O
of	O
the	O
balloon	O
to	O
allow	O
endoscopic	O
visual	O
control	O
of	O
the	O
distal	O
end	O
of	O
the	O
container	O
in	O
the	O
rectum	B-Biological_structure
.	O

Gentle	O
traction	O
was	O
exerted	O
on	O
the	O
balloon	O
catheter	O
,	O
and	O
the	O
container	O
was	O
successfully	B-Lab_value
removed	B-Therapeutic_procedure
under	O
fluoroscopic	B-Detailed_description
and	I-Detailed_description
endoscopic	I-Detailed_description
control	I-Detailed_description
(	O
Figure	O
3	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
19	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
with	O
a	O
lump	B-Sign_symptom
in	O
her	O
right	B-Biological_structure
breast	I-Biological_structure
.	O

She	O
had	O
macrocephaly	B-Disease_disorder
and	O
milimetric	B-Biological_attribute
papules	B-Sign_symptom
on	O
the	O
tongue	B-Biological_structure
giving	O
a	O
cobble	B-Texture
stone	I-Texture
appearance	O
.	O

The	O
breast	B-Biological_structure
ultrasonography	B-Diagnostic_procedure
(	O
US	B-Diagnostic_procedure
)	O
showed	O
more	B-Lab_value
than	I-Lab_value
twenty	I-Lab_value
circumscribed	B-Detailed_description
,	O
oval	B-Shape
masses	B-Disease_disorder
in	O
each	O
breast	B-Biological_structure
.	O

An	O
US	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
core	I-Detailed_description
biopsy	B-Diagnostic_procedure
was	O
performed	O
for	O
the	O
palpable	B-Detailed_description
masses	B-Disease_disorder
which	O
were	O
confirmed	O
as	O
juvenile	B-Detailed_description
fibroadenomas	B-Disease_disorder
.	O

After	O
the	O
biopsy	O
,	O
a	O
breast	B-Biological_structure
US	B-Diagnostic_procedure
was	O
done	O
as	O
follow	O
-	O
up	O
every	B-Frequency
6	I-Frequency
or	I-Frequency
12	I-Frequency
months	I-Frequency
for	O
3	B-Duration
years	I-Duration
.	O

During	O
the	O
surveillance	O
period	O
,	O
core	B-Detailed_description
biopsies	B-Diagnostic_procedure
were	O
performed	O
six	B-Quantitative_concept
times	I-Quantitative_concept
,	O
followed	O
by	O
US	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
vacuum	B-Detailed_description
-	I-Detailed_description
assisted	I-Detailed_description
core	B-Detailed_description
needle	B-Diagnostic_procedure
excisions	I-Diagnostic_procedure
or	O
surgical	B-Diagnostic_procedure
excisions	I-Diagnostic_procedure
of	O
lesions	B-Disease_disorder
with	O
increased	B-Lab_value
sizes	I-Lab_value
.	O

Pathologic	O
results	O
were	O
fibroadenoma	B-Disease_disorder
,	O
tubular	B-Disease_disorder
adenoma	I-Disease_disorder
or	O
atypical	B-Disease_disorder
ductal	I-Disease_disorder
hyperplasia	I-Disease_disorder
(	O
ADH	B-Disease_disorder
)	O
involving	O
fibroadenoma	B-Disease_disorder
.	O

At	O
the	O
age	B-Age
of	I-Age
19	I-Age
years	I-Age
,	O
the	O
patient	O
underwent	O
a	O
neck	B-Biological_structure
US	B-Diagnostic_procedure
for	O
a	O
palpable	B-Detailed_description
mass	B-Disease_disorder
in	O
the	O
left	B-Biological_structure
neck	I-Biological_structure
.	O

Several	O
indeterminate	B-Detailed_description
nodules	B-Sign_symptom
were	O
revealed	O
in	O
both	B-Lab_value
thyroid	B-Biological_structure
glands	I-Biological_structure
.	O

A	O
follow	B-Detailed_description
-	I-Detailed_description
up	I-Detailed_description
US	B-Diagnostic_procedure
revealed	O
that	O
some	B-Lab_value
of	O
those	O
nodules	B-Sign_symptom
increased	B-Lab_value
in	I-Lab_value
size	I-Lab_value
.	O

The	O
patient	O
underwent	O
a	O
total	B-Detailed_description
thyroidectomy	B-Therapeutic_procedure
and	O
the	O
pathologic	O
result	O
revealed	O
an	O
invasive	B-Detailed_description
follicular	B-Disease_disorder
carcinoma	I-Disease_disorder
in	O
the	O
left	B-Biological_structure
thyroid	I-Biological_structure
and	O
follicular	B-Disease_disorder
adenoma	I-Disease_disorder
in	O
the	O
right	B-Biological_structure
thyroid	I-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
.	O

At	O
the	O
age	O
of	O
21	O
years	O
,	O
she	O
visited	O
the	O
hospital	B-Nonbiological_location
due	O
to	O
a	O
swelling	B-Sign_symptom
of	O
her	O
left	B-Biological_structure
cheek	I-Biological_structure
.	O

Head	B-Biological_structure
and	O
neck	B-Biological_structure
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
revealed	O
a	O
vascular	B-Biological_structure
mass	B-Disease_disorder
in	O
the	O
left	B-Biological_structure
parotid	I-Biological_structure
gland	I-Biological_structure
extended	O
into	O
the	O
left	B-Biological_structure
forehead	I-Biological_structure
.	O

An	O
external	B-Biological_structure
carotid	I-Biological_structure
angiography	B-Diagnostic_procedure
confirmed	O
the	O
diagnosis	O
of	O
an	O
AVM	B-Disease_disorder
with	O
feeder	B-Biological_structure
vessel	I-Biological_structure
arising	O
from	O
the	O
left	B-Biological_structure
internal	I-Biological_structure
maxillary	I-Biological_structure
artery	I-Biological_structure
(	O
Fig	O
.	O
1B	O
)	O
.	O

A	O
partial	B-Detailed_description
embolization	B-Therapeutic_procedure
decreased	B-Lab_value
the	O
blood	B-Diagnostic_procedure
flow	I-Diagnostic_procedure
through	O
the	O
AVM	B-Disease_disorder
,	O
alleviating	O
the	O
patient	O
`	O
s	O
symptom	O
.	O

She	O
was	O
referred	O
to	O
genetic	B-Therapeutic_procedure
counseling	I-Therapeutic_procedure
under	O
the	O
suggestion	O
of	O
a	O
Cowden	B-Disease_disorder
syndrome	I-Disease_disorder
and	O
the	O
PTEN	B-Diagnostic_procedure
DNA	B-Diagnostic_procedure
sequencing	I-Diagnostic_procedure
test	I-Diagnostic_procedure
of	O
her	O
blood	B-Diagnostic_procedure
sample	I-Diagnostic_procedure
revealed	O
a	O
frameshift	B-Diagnostic_procedure
mutation	I-Diagnostic_procedure
,	O
c	B-Diagnostic_procedure
.	I-Diagnostic_procedure
301dupA	I-Diagnostic_procedure
(	O
p	B-Diagnostic_procedure
.	I-Diagnostic_procedure
I101NfsX6	I-Diagnostic_procedure
)	O
.	O

At	O
the	O
age	O
of	O
22	O
years	O
,	O
the	O
patient	O
presented	O
with	O
a	O
mass	B-Disease_disorder
with	O
increased	B-Lab_value
size	I-Lab_value
and	O
increased	B-Lab_value
vascularity	I-Lab_value
in	O
the	O
left	B-Biological_structure
breast	I-Biological_structure
.	O

An	O
US	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
vacuum	B-Detailed_description
-	I-Detailed_description
assisted	I-Detailed_description
core	B-Detailed_description
needle	B-Diagnostic_procedure
excision	I-Diagnostic_procedure
revealed	O
a	O
ductal	B-Disease_disorder
carcinoma	I-Disease_disorder
in	I-Disease_disorder
situ	I-Disease_disorder
(	O
DCIS	B-Disease_disorder
)	O
of	O
non	B-Detailed_description
-	I-Detailed_description
comedo	I-Detailed_description
type	I-Detailed_description
and	O
a	O
low	B-Lab_value
grade	I-Lab_value
involving	O
fibroadenoma	B-Disease_disorder
(	O
Fig	O
.	O
1C	O
)	O
.	O

The	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
breast	B-Biological_structure
MRI	B-Diagnostic_procedure
for	O
the	O
preoperative	O
evaluation	O
demonstrated	O
multiple	B-Lab_value
,	O
well	B-Detailed_description
-	I-Detailed_description
circumscribed	I-Detailed_description
,	O
enhancing	B-Lab_value
masses	B-Disease_disorder
in	O
both	B-Lab_value
breasts	B-Biological_structure
(	O
Fig	O
.	O
1D	O
)	O
.	O

All	B-Lab_value
masses	B-Disease_disorder
showed	O
high	B-Severity
or	O
intermediate	B-Severity
signal	B-Diagnostic_procedure
intensity	I-Diagnostic_procedure
on	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
images	I-Diagnostic_procedure
(	O
Fig	O
.	O
1E	O
)	O
.	O

Several	B-Lab_value
masses	B-Disease_disorder
showed	O
an	O
early	B-Detailed_description
rapid	I-Detailed_description
enhancement	I-Detailed_description
with	O
washout	B-Diagnostic_procedure
kinetic	I-Diagnostic_procedure
pattern	I-Diagnostic_procedure
on	O
time	B-Diagnostic_procedure
-	I-Diagnostic_procedure
signal	I-Diagnostic_procedure
intensity	I-Diagnostic_procedure
curve	I-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
,	O
which	O
tends	O
to	O
be	O
associated	O
with	O
malignancy	B-Disease_disorder
(	O
Fig	O
.	O
1F	O
)	O
.	O

A	O
bilateral	B-Detailed_description
prophylactic	I-Detailed_description
mastectomy	B-Therapeutic_procedure
with	O
immediate	B-Detailed_description
breast	B-Therapeutic_procedure
reconstruction	I-Therapeutic_procedure
was	O
performed	O
in	O
view	O
of	O
multiple	B-Lab_value
bilateral	B-Detailed_description
breast	B-Biological_structure
masses	B-Disease_disorder
with	O
suspicious	B-Detailed_description
kinetic	B-Diagnostic_procedure
features	I-Diagnostic_procedure
on	O
breast	B-Biological_structure
MRI	B-Diagnostic_procedure
and	O
a	O
high	O
risk	O
for	O
breast	B-Disease_disorder
cancer	I-Disease_disorder
of	O
Cowden	B-Disease_disorder
syndrome	I-Disease_disorder
.	O

The	O
surgical	B-Diagnostic_procedure
histopathology	I-Diagnostic_procedure
revealed	O
ADH	B-Disease_disorder
involving	O
tubular	B-Disease_disorder
adenoma	I-Disease_disorder
without	O
residual	B-Detailed_description
carcinoma	B-Disease_disorder
in	O
the	O
left	B-Biological_structure
breast	I-Biological_structure
and	O
multiple	B-Lab_value
tubular	B-Disease_disorder
adenomas	I-Disease_disorder
,	O
fibroadenomas	B-Disease_disorder
and	O
intraductal	B-Disease_disorder
papillomas	I-Disease_disorder
in	O
both	B-Lab_value
breasts	B-Biological_structure
.	O

The	O
patient	O
had	O
no	O
family	O
history	O
of	O
breast	O
cancer	O
or	O
Cowden	O
syndrome	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
11	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
boy	O
presented	O
with	O
a	O
history	O
of	O
headaches	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
that	O
had	O
been	O
present	O
for	O
several	B-Duration
months	I-Duration
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
papilledema	B-Disease_disorder
without	O
the	O
presence	O
of	O
any	O
other	O
neurological	B-Disease_disorder
deficits	I-Disease_disorder
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
revealed	O
a	O
large	B-Detailed_description
prepontine	B-Biological_structure
mass	B-Sign_symptom
with	O
dorsal	B-Detailed_description
displacement	B-Sign_symptom
of	O
the	O
brainstem	B-Biological_structure
and	O
a	O
secondary	B-Detailed_description
obstructive	B-Detailed_description
hydrocephalus	B-Disease_disorder
due	O
to	O
compression	B-Sign_symptom
of	O
the	O
aqueduct	B-Biological_structure
.	O

The	O
lesion	O
had	O
an	O
inhomogeneous	B-Detailed_description
hypointense	B-Sign_symptom
aspect	I-Sign_symptom
on	O
the	O
T1	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
image	I-Diagnostic_procedure
(	O
T1WI	B-Diagnostic_procedure
)	O
and	O
an	O
inhomogeneous	B-Detailed_description
hyperintense	B-Sign_symptom
aspect	I-Sign_symptom
on	O
the	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
image	I-Diagnostic_procedure
(	O
T2WI	B-Diagnostic_procedure
)	O
.	O

After	O
administration	O
of	O
IV	O
gadolinium	B-Medication
,	O
there	O
was	O
some	O
inhomogeneous	B-Detailed_description
enhancement	B-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
imaging	O
showed	O
no	O
bone	B-Sign_symptom
involvement	I-Sign_symptom
.	O

During	O
the	O
first	O
operation	O
,	O
a	O
ventriculoperitoneal	B-Detailed_description
shunt	B-Therapeutic_procedure
was	O
inserted	O
into	O
the	O
right	B-Biological_structure
lateral	I-Biological_structure
ventricle	I-Biological_structure
to	O
treat	O
the	O
hydrocephalus	O
.	O

A	O
careful	O
study	O
of	O
the	O
MRI	O
suggested	O
that	O
this	O
infra	O
-	O
and	O
supratentorially	O
located	O
tumour	O
might	O
be	O
resected	O
through	O
a	O
single	O
approach	O
.	O

A	O
left	B-Detailed_description
frontotemporal	B-Detailed_description
transsylvian	B-Therapeutic_procedure
approach	I-Therapeutic_procedure
was	O
performed	O
to	O
gain	O
access	O
to	O
the	O
tumour	O
.	O

The	O
tumour	B-Sign_symptom
had	O
well	B-Detailed_description
-	I-Detailed_description
defined	I-Detailed_description
margins	I-Detailed_description
and	O
was	O
entirely	O
located	O
in	O
the	O
intradural	B-Biological_structure
plane	I-Biological_structure
.	O

There	O
were	O
no	O
attachments	B-Sign_symptom
to	O
the	O
cranial	B-Biological_structure
nerves	I-Biological_structure
or	O
brainstem	B-Biological_structure
.	O

A	O
macroscopic	B-Detailed_description
complete	B-Detailed_description
resection	B-Therapeutic_procedure
was	O
performed	O
.	O

Postoperatively	O
,	O
the	O
patient	O
had	O
developed	O
a	O
left	B-Biological_structure
oculomotor	I-Biological_structure
nerve	B-Disease_disorder
palsy	I-Disease_disorder
,	O
which	O
completely	O
recovered	B-Sign_symptom
within	O
the	O
next	O
4	O
weeks	O
.	O

The	O
postoperative	O
MRI	B-Diagnostic_procedure
showed	O
a	O
complete	B-Detailed_description
removal	I-Detailed_description
of	O
the	O
tumour	B-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

After	O
careful	O
consideration	O
by	O
a	O
multidisciplinary	O
team	O
,	O
we	O
decided	O
that	O
there	O
was	O
no	O
indication	O
for	O
postoperative	O
radiation	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

At	O
follow	O
-	O
up	O
one	O
and	O
a	O
half	O
years	O
later	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
remained	O
asymptomatic	B-Sign_symptom
.	O

There	O
were	O
no	O
signs	O
of	O
tumour	B-Sign_symptom
recurrence	I-Sign_symptom
on	O
the	O
MRI	B-Diagnostic_procedure
scan	O
.	O

At	O
a	O
follow	O
-	O
up	O
of	O
more	O
than	O
6	O
years	O
after	O
treatment	O
,	O
there	O
were	O
still	O
no	O
signs	O
of	O
tumour	B-Sign_symptom
recurrence	I-Sign_symptom
on	O
the	O
MRI	B-Diagnostic_procedure
scan	O
.	O

Histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
a	O
slightly	B-Shape
lobulated	I-Shape
tumour	B-Sign_symptom
consisting	O
of	O
a	O
chondromyxoid	B-Detailed_description
matrix	I-Detailed_description
.	O

The	O
tumour	O
cells	O
showed	O
a	O
vacuolated	B-Lab_value
and	O
pale	B-Lab_value
cytoplasm	B-Diagnostic_procedure
.	O

Moderate	B-Severity
nuclear	B-Sign_symptom
polymorphism	I-Sign_symptom
was	O
observed	O
but	O
no	O
obvious	O
mitotic	B-Sign_symptom
activity	I-Sign_symptom
(	O
Fig	O
.	O
3	O
)	O
.	O

Some	O
calcifications	B-Sign_symptom
were	O
seen	O
.	O

The	O
tumour	O
cells	O
stained	O
positive	B-Lab_value
for	O
pan	B-Diagnostic_procedure
-	I-Diagnostic_procedure
keratin	I-Diagnostic_procedure
,	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
and	O
epithelial	B-Diagnostic_procedure
membrane	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
EMA	B-Diagnostic_procedure
)	O
.	O

These	O
findings	O
suggest	O
a	O
histopathological	O
diagnosis	O
of	O
chordoma	B-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
76	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Japanese	O
man	O
had	O
experienced	O
a	O
decreased	B-Sign_symptom
appetite	I-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
and	O
abdominal	B-Biological_structure
distension	B-Sign_symptom
since	O
late	O
February	O
2011	O
.	O

The	O
patient	O
passed	O
loose	B-Lab_value
,	O
soft	B-Lab_value
stools	B-Diagnostic_procedure
that	O
were	O
not	B-Lab_value
watery	I-Lab_value
once	B-Frequency
daily	I-Frequency
.	O

The	O
results	O
of	O
blood	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
performed	O
by	O
the	O
primary	B-Nonbiological_location
care	I-Nonbiological_location
physician	I-Nonbiological_location
(	O
PCP	B-Nonbiological_location
)	O
between	O
April	O
and	O
June	O
were	O
all	O
normal	B-Lab_value
,	O
but	O
upper	B-Detailed_description
and	I-Detailed_description
lower	I-Detailed_description
gastrointestinal	B-Diagnostic_procedure
endoscopy	I-Diagnostic_procedure
showed	O
atrophic	B-Detailed_description
gastritis	B-Disease_disorder
.	O

Therefore	O
,	O
we	O
assessed	O
the	O
patient	O
for	O
Helicobacter	B-Diagnostic_procedure
pylori	I-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
and	O
performed	O
the	O
rapid	B-Diagnostic_procedure
urease	I-Diagnostic_procedure
test	I-Diagnostic_procedure
and	O
a	O
histopathological	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
,	O
all	O
of	O
which	O
were	O
negative	B-Lab_value
.	O

In	O
June	O
,	O
the	O
patient	O
received	O
medication	B-Medication
from	O
a	O
mental	B-Nonbiological_location
health	I-Nonbiological_location
clinic	I-Nonbiological_location
,	O
but	O
because	O
the	O
symptoms	B-Sign_symptom
did	O
not	O
improve	O
and	O
his	O
body	B-Diagnostic_procedure
weight	I-Diagnostic_procedure
further	O
decreased	B-Lab_value
by	I-Lab_value
23	I-Lab_value
kg	I-Lab_value
,	O
he	O
stopped	O
the	O
medication	B-Medication
;	O
he	O
was	O
referred	O
to	O
our	O
department	B-Nonbiological_location
in	O
November	O
.	O

The	O
patient	O
had	O
been	O
suffering	O
from	O
hypertension	O
since	O
his	O
30s	O
.	O

Amlodipine	B-Medication
(	O
5	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
administration	O
was	O
initiated	O
in	O
2005	O
,	O
and	O
olmesartan	B-Medication
from	O
May	O
2008	O
;	O
the	O
patient	O
is	O
currently	O
receiving	O
30	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
of	O
olmesartan	O
.	O

He	O
denied	O
the	O
use	O
of	O
any	O
other	O
new	B-Medication
medications	I-Medication
or	O
nonsteroidal	B-Medication
anti	I-Medication
-	I-Medication
inflammatory	I-Medication
drugs	I-Medication
.	O

He	O
had	O
no	O
history	O
of	O
smoking	O
or	O
alcohol	O
consumption	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
that	O
the	O
patient	O
had	O
a	O
height	O
of	O
165	B-Height
cm	I-Height
,	O
a	O
body	O
weight	O
of	O
47	B-Weight
kg	I-Weight
,	O
and	O
body	B-Diagnostic_procedure
mass	I-Diagnostic_procedure
index	I-Diagnostic_procedure
of	O
17	B-Lab_value
kg	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
.	O

His	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
was	O
36	B-Lab_value
.	I-Lab_value
3	I-Lab_value
℃	I-Lab_value
;	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
101	B-Lab_value
/	I-Lab_value
min	I-Lab_value
;	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
,	O
101	B-Lab_value
/	I-Lab_value
81	I-Lab_value
mmHg	I-Lab_value
;	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
12	B-Lab_value
breaths	I-Lab_value
/	I-Lab_value
min	I-Lab_value
;	O
and	O
saturation	B-Diagnostic_procedure
from	I-Diagnostic_procedure
pulse	I-Diagnostic_procedure
oximetry	I-Diagnostic_procedure
(	O
SpO2	B-Diagnostic_procedure
)	O
was	O
98	B-Lab_value
%	I-Lab_value
.	O

The	O
patient	O
had	O
no	O
heart	B-Sign_symptom
murmur	I-Sign_symptom
,	O
third	B-Sign_symptom
heart	I-Sign_symptom
sound	I-Sign_symptom
or	O
jugular	B-Biological_structure
venous	I-Biological_structure
distension	B-Sign_symptom
.	O

The	O
patient	O
had	O
bilateral	B-Detailed_description
pitting	B-Detailed_description
edema	B-Sign_symptom
on	O
his	O
lower	B-Biological_structure
legs	I-Biological_structure
and	O
presented	O
with	O
unilateral	B-Detailed_description
gaze	B-Detailed_description
-	I-Detailed_description
evoked	I-Detailed_description
nystagmus	B-Sign_symptom
as	O
well	O
as	O
a	O
mildly	B-Severity
reduced	B-Sign_symptom
tactile	I-Sign_symptom
sensation	I-Sign_symptom
and	O
thermal	B-Detailed_description
nociception	B-Sign_symptom
in	O
the	O
toes	B-Biological_structure
and	O
dorsal	B-Biological_structure
regions	I-Biological_structure
of	I-Biological_structure
both	I-Biological_structure
feet	I-Biological_structure
.	O

Moreover	O
,	O
the	O
finger	B-Diagnostic_procedure
-	I-Diagnostic_procedure
to	I-Diagnostic_procedure
-	I-Diagnostic_procedure
nose	I-Diagnostic_procedure
test	I-Diagnostic_procedure
results	O
and	O
tandem	B-Diagnostic_procedure
gait	I-Diagnostic_procedure
were	O
poor	B-Lab_value
,	O
and	O
his	O
patellar	B-Biological_structure
and	O
Achilles	B-Biological_structure
tendon	I-Biological_structure
reflexes	B-Diagnostic_procedure
had	O
disappeared	B-Lab_value
.	O

Confabulation	B-Sign_symptom
was	O
observed	O
in	O
the	O
patient	O
,	O
and	O
the	O
revised	O
Hasegawa	B-Diagnostic_procedure
Dementia	I-Diagnostic_procedure
Scale	I-Diagnostic_procedure
(	O
HDS	B-Diagnostic_procedure
-	I-Diagnostic_procedure
R	I-Diagnostic_procedure
)	O
score	O
was	O
17	B-Lab_value
/	I-Lab_value
30	I-Lab_value
(	O
cut	O
-	O
off	O
point	O
:	O
20	O
)	O
.	O

The	O
hematologic	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
6,200	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
;	O
hemoglobin	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
12	B-Lab_value
.	I-Lab_value
5	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
;	O
mean	B-Diagnostic_procedure
corpuscular	I-Diagnostic_procedure
volume	I-Diagnostic_procedure
,	O
88	B-Lab_value
.	I-Lab_value
4	I-Lab_value
;	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
230,000	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
;	O
sodium	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
136	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
potassium	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
3	B-Lab_value
.	I-Lab_value
8	I-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
chlorine	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
103	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
iron	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
57	B-Lab_value
μg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
reference	O
value	O
:	O
64	O
-	O
187	O
μg	O
/	O
dL	O
)	O
;	O
ferritin	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
366	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
reference	O
value	O
:	O
50	O
-	O
200	O
ng	O
/	O
mL	O
)	O
;	O
B	B-Diagnostic_procedure
-	I-Diagnostic_procedure
type	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
(	O
BNP	B-Diagnostic_procedure
)	O
level	O
,	O
125	B-Lab_value
.	I-Lab_value
3	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
reference	O
value	O
:	O
-	O
18	O
.	O
4	O
pg	O
/	O
mL	O
)	O
;	O
and	O
vitamin	B-Diagnostic_procedure
B1	I-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
8	B-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
reference	O
value	O
:	O
24	O
-	O
66	O
ng	O
/	O
mL	O
)	O
.	O

An	O
electrocardiogram	B-Diagnostic_procedure
was	O
normal	B-Lab_value
and	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
rays	I-Diagnostic_procedure
showed	O
a	O
normal	B-Lab_value
cardiothoracic	B-Diagnostic_procedure
ratio	I-Diagnostic_procedure
(	O
40	B-Lab_value
.	I-Lab_value
8	I-Lab_value
%	I-Lab_value
)	O
without	O
either	O
pulmonary	B-Sign_symptom
congestion	I-Sign_symptom
or	O
pleural	B-Disease_disorder
effusion	I-Disease_disorder
.	O

Cranial	B-Biological_structure
fluid	B-Detailed_description
-	I-Detailed_description
attenuated	I-Detailed_description
inversion	I-Detailed_description
recovery	I-Detailed_description
-	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
findings	O
revealed	O
periaqueductal	B-Biological_structure
hyperintensities	B-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
;	O
therefore	O
,	O
Wernicke	B-Disease_disorder
encephalopathy	I-Disease_disorder
was	O
diagnosed	O
.	O

Moreover	O
,	O
as	O
sinus	B-Detailed_description
tachycardia	B-Sign_symptom
and	O
a	O
tendency	O
towards	O
hypotension	B-Sign_symptom
were	O
noted	O
,	O
no	O
clear	O
symptoms	O
of	O
heart	B-Disease_disorder
failure	I-Disease_disorder
or	O
dehydration	B-Sign_symptom
were	O
observed	O
;	O
it	O
was	O
thus	O
inferred	O
that	O
the	O
vitamin	B-Disease_disorder
B1	I-Disease_disorder
deficiency	I-Disease_disorder
had	O
likely	O
played	O
a	O
role	O
in	O
both	O
of	O
the	O
conditions	O
.	O

The	O
antihypertensive	B-Medication
agents	I-Medication
were	O
discontinued	O
,	O
and	O
10	O
days	O
after	O
the	O
intravenous	O
administration	O
of	O
vitamin	B-Medication
B1	I-Medication
,	O
the	O
patient	O
`	O
s	O
loss	B-Sign_symptom
of	I-Sign_symptom
appetite	I-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
and	O
gait	B-Sign_symptom
disturbance	I-Sign_symptom
disappeared	O
,	O
and	O
his	O
body	B-Diagnostic_procedure
weight	I-Diagnostic_procedure
increased	B-Lab_value
by	I-Lab_value
3	I-Lab_value
kg	I-Lab_value
.	O

Nystagmus	B-Sign_symptom
was	O
ameliorated	O
on	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
but	O
the	O
patient	O
still	O
had	O
confabulations	B-Sign_symptom
,	O
and	O
the	O
HDS	B-Diagnostic_procedure
-	I-Diagnostic_procedure
R	I-Diagnostic_procedure
score	I-Diagnostic_procedure
and	O
absence	B-Lab_value
of	O
deep	B-Biological_structure
tendon	I-Biological_structure
reflexes	B-Diagnostic_procedure
did	B-Lab_value
not	I-Lab_value
improve	I-Lab_value
.	O

Since	O
the	O
gastrointestinal	B-Sign_symptom
symptoms	I-Sign_symptom
were	O
ameliorated	O
and	O
his	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
increased	B-Lab_value
to	O
160	B-Lab_value
/	I-Lab_value
90	I-Lab_value
mmHg	I-Lab_value
,	O
the	O
PCP	B-Nonbiological_location
resumed	O
the	O
administration	O
of	O
olmesartan	B-Medication
on	O
late	O
December	O
,	O
2011	O
.	O

One	O
week	O
later	O
,	O
the	O
patient	O
complained	O
of	O
recurrent	O
decreased	B-Sign_symptom
appetite	I-Sign_symptom
and	O
nausea	B-Sign_symptom
.	O

After	O
experiencing	O
diarrhea	B-Sign_symptom
(	O
five	B-Lab_value
bowel	I-Lab_value
movements	I-Lab_value
during	I-Lab_value
a	I-Lab_value
2	I-Lab_value
-	I-Lab_value
day	I-Lab_value
period	I-Lab_value
)	O
,	O
he	O
passed	O
soft	B-Lab_value
stools	B-Diagnostic_procedure
once	B-Frequency
daily	I-Frequency
,	O
and	O
his	O
body	B-Diagnostic_procedure
weight	I-Diagnostic_procedure
decreased	B-Lab_value
to	O
47	B-Lab_value
kg	I-Lab_value
so	O
he	O
came	O
to	O
our	O
hospital	B-Nonbiological_location
again	O
3	O
weeks	O
after	O
the	O
resumption	O
of	O
olmesartan	B-Medication
for	O
treatment	O
.	O

His	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
,	O
35	B-Lab_value
.	I-Lab_value
1	I-Lab_value
℃	I-Lab_value
;	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
93	B-Lab_value
/	I-Lab_value
min	I-Lab_value
;	O
and	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
,	O
132	B-Lab_value
/	I-Lab_value
75	I-Lab_value
mmHg	I-Lab_value
.	O

The	O
neurologic	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
showed	O
no	B-Lab_value
worsening	I-Lab_value
of	O
his	O
symptoms	O
.	O

The	O
laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
sodium	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
139	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
potassium	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
2	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
and	O
chlorine	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
116	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

Hyperchloremia	B-Sign_symptom
was	O
noted	O
,	O
and	O
the	O
serum	B-Lab_value
sodium	I-Lab_value
level	I-Lab_value
minus	I-Lab_value
chloride	I-Lab_value
level	I-Lab_value
(	I-Lab_value
139	I-Lab_value
-	I-Lab_value
116	I-Lab_value
)	I-Lab_value
was	I-Lab_value
23	I-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
additionally	O
,	O
the	O
arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gas	I-Diagnostic_procedure
findings	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
pH	B-Diagnostic_procedure
,	O
7	B-Lab_value
.	I-Lab_value
25	I-Lab_value
;	O
PCO2	B-Diagnostic_procedure
,	O
25	B-Lab_value
mmHg	I-Lab_value
,	O
and	O
HCO3	B-Diagnostic_procedure
,	O
11	B-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

The	O
urinalysis	B-Diagnostic_procedure
findings	O
were	O
as	O
follows	O
:	O
sodium	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
15	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
potassium	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
13	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
chlorine	B-Diagnostic_procedure
level	I-Diagnostic_procedure
,	O
100	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
and	O
urine	B-Diagnostic_procedure
anion	I-Diagnostic_procedure
gap	I-Diagnostic_procedure
,	O
-	B-Lab_value
72	I-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
there	O
was	O
no	B-Lab_value
apparent	I-Lab_value
increase	I-Lab_value
in	O
bowel	B-Diagnostic_procedure
movements	I-Diagnostic_procedure
;	O
however	O
,	O
this	O
seemed	O
to	O
be	O
due	O
to	O
the	O
absence	B-Sign_symptom
of	I-Sign_symptom
HCO3	I-Sign_symptom
-	I-Sign_symptom
from	O
the	O
gastrointestinal	B-Biological_structure
tract	I-Biological_structure
(	O
6	O
)	O
.	O

Plain	O
abdominal	B-Biological_structure
radiography	B-Diagnostic_procedure
and	O
abdominal	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
findings	O
revealed	O
the	O
continuous	B-Detailed_description
dilation	B-Sign_symptom
of	O
the	O
entire	B-Biological_structure
intestinal	I-Biological_structure
tract	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
;	O
therefore	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
intestinal	B-Disease_disorder
pseudo	I-Disease_disorder
-	I-Disease_disorder
obstruction	I-Disease_disorder
.	O

After	O
discontinuing	O
olmesartan	B-Medication
,	O
the	O
nausea	B-Sign_symptom
and	O
body	B-Sign_symptom
weight	I-Sign_symptom
decreases	I-Sign_symptom
were	O
promptly	O
ameliorated	O
.	O

Duodenal	B-Biological_structure
biopsy	B-Diagnostic_procedure
findings	O
after	O
discontinuing	O
olmesartan	B-Medication
showed	O
that	O
the	O
inflammation	B-Sign_symptom
observed	O
before	O
discontinuation	O
as	O
well	O
as	O
the	O
fold	B-Sign_symptom
structure	I-Sign_symptom
had	O
both	O
clearly	O
ameliorated	O
(	O
Fig	O
.	O
3	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
18	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
college	B-Occupation
student	I-Occupation
was	O
referred	O
from	B-Nonbiological_location
the	I-Nonbiological_location
University	I-Nonbiological_location
Clinic	I-Nonbiological_location
for	O
having	O
low	B-Lab_value
hemoglobin	B-Diagnostic_procedure
(	O
Hg	O
4	B-Lab_value
.	I-Lab_value
7	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
)	O
.	O

He	O
was	O
completely	O
well	O
till	O
one	O
month	O
back	O
when	O
he	O
presented	O
with	O
easy	B-Detailed_description
fatigability	B-Sign_symptom
,	O
postural	B-Detailed_description
dizziness	B-Sign_symptom
,	O
palpitation	B-Sign_symptom
and	O
dyspnea	B-Sign_symptom
.	O

He	O
gave	O
history	O
of	O
30	B-Lab_value
kg	I-Lab_value
weight	B-Sign_symptom
loss	I-Sign_symptom
over	B-Duration
the	I-Duration
past	I-Duration
6	I-Duration
months	I-Duration
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
he	O
looked	O
pale	B-Sign_symptom
,	O
not	O
jaundiced	B-Sign_symptom
or	O
cyanosed	B-Sign_symptom
.	O

His	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
all	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
,	O
except	O
for	O
an	O
elevated	B-Lab_value
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
(	O
98	B-Lab_value
/	I-Lab_value
min	I-Lab_value
)	O
.	O

Cardiovascular	B-Biological_structure
,	O
respiratory	B-Biological_structure
and	O
abdominal	B-Biological_structure
examinations	B-Diagnostic_procedure
were	O
unremarkable	B-Lab_value
.	O

Primary	O
investigations	O
in	O
our	O
hospital	B-Nonbiological_location
revealed	O
low	B-Lab_value
hemoglobin	B-Diagnostic_procedure
level	O
(	O
5	B-Lab_value
.	I-Lab_value
1	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
)	O
,	O
low	B-Lab_value
iron	B-Diagnostic_procedure
(	O
<	B-Lab_value
10	I-Lab_value
ug	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
)	O
,	O
and	O
a	O
positive	B-Lab_value
occult	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
test	I-Diagnostic_procedure
.	O

A	O
provisional	O
diagnosis	O
of	O
microcytic	B-Disease_disorder
hypochromic	I-Disease_disorder
anemia	I-Disease_disorder
for	O
further	O
workup	O
was	O
made	O
.	O

Bone	B-Diagnostic_procedure
marrow	I-Diagnostic_procedure
aspirate	I-Diagnostic_procedure
and	O
trephine	B-Diagnostic_procedure
biopsy	I-Diagnostic_procedure
revealed	O
normocellular	B-Lab_value
marrow	I-Lab_value
,	O
depicting	O
normal	B-Lab_value
trilineage	I-Lab_value
hematopoiesis	I-Lab_value
.	O

Upper	B-Biological_structure
GI	I-Biological_structure
endoscopy	B-Diagnostic_procedure
showed	O
erosive	B-Detailed_description
antral	B-Biological_structure
gastritis	B-Disease_disorder
with	O
patchy	B-Detailed_description
ulcerative	B-Detailed_description
inflammation	B-Sign_symptom
.	O

Abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
showed	O
a	O
slightly	B-Severity
enlarged	B-Sign_symptom
liver	B-Biological_structure
with	O
a	O
rounded	B-Shape
echogenic	B-Detailed_description
lesion	B-Sign_symptom
in	O
the	O
anterior	B-Biological_structure
wall	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
lobe	I-Biological_structure
suggestive	O
of	O
hemangioma	B-Disease_disorder
.	O

The	O
spleen	B-Biological_structure
was	O
slightly	B-Severity
enlarged	B-Sign_symptom
and	O
normal	B-Lab_value
in	I-Lab_value
echogenicity	I-Lab_value
with	O
no	O
focal	B-Detailed_description
lesions	B-Sign_symptom
.	O

Computed	B-Diagnostic_procedure
Tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
of	O
the	O
abdomen	B-Biological_structure
and	O
pelvis	B-Biological_structure
showed	O
a	O
fairly	B-Detailed_description
large	I-Detailed_description
well	B-Detailed_description
defined	I-Detailed_description
soft	B-Detailed_description
tissue	I-Detailed_description
mass	B-Sign_symptom
located	O
in	O
the	O
anterior	B-Biological_structure
upper	I-Biological_structure
pelvis	I-Biological_structure
and	O
engulfing	O
jejunal	B-Biological_structure
loops	I-Biological_structure
causing	O
bowel	B-Biological_structure
wall	I-Biological_structure
thickening	B-Sign_symptom
.	O

The	O
patient	O
underwent	O
an	O
exploratory	O
laparotomy	B-Diagnostic_procedure
and	O
excision	B-Therapeutic_procedure
of	O
the	O
jejunal	B-Biological_structure
mass	B-Sign_symptom
.	O

Macroscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
an	O
11	B-Volume
×	I-Volume
8	I-Volume
×	I-Volume
2	I-Volume
cm	I-Volume
annular	B-Biological_structure
mass	B-Sign_symptom
located	O
within	B-Biological_structure
the	I-Biological_structure
jejunal	I-Biological_structure
wall	I-Biological_structure
ulcerating	B-Biological_structure
through	I-Biological_structure
the	I-Biological_structure
mucosa	I-Biological_structure
and	O
extending	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
serosal	I-Biological_structure
surface	I-Biological_structure
.	O

Microscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
tumor	B-Sign_symptom
situated	O
in	O
the	O
muscularis	B-Biological_structure
propria	I-Biological_structure
and	O
extending	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
mucosa	I-Biological_structure
and	O
the	O
serosa	B-Biological_structure
.	O

The	O
neoplastic	O
cells	O
were	O
arranged	O
in	O
predominantly	B-Shape
pseudoalveolar	I-Shape
pattern	I-Shape
(	O
Fig	O
.	O
1a	O
,	O
b	O
)	O
.	O

They	O
were	O
polygonal	B-Shape
in	O
shape	O
with	O
variable	B-Detailed_description
amount	I-Detailed_description
of	I-Detailed_description
eosinophilic	I-Detailed_description
to	I-Detailed_description
clear	I-Detailed_description
cytoplasm	I-Detailed_description
(	O
Fig	O
.	O
1c	O
)	O
.	O

The	O
nuclei	B-Detailed_description
were	I-Detailed_description
oval	I-Detailed_description
with	I-Detailed_description
vesicular	I-Detailed_description
chromatin	I-Detailed_description
and	I-Detailed_description
inconspicuous	I-Detailed_description
nucleoli	I-Detailed_description
.	O

Scattered	B-Detailed_description
osteoclast	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
multinucleated	B-Detailed_description
giant	B-Sign_symptom
cells	I-Sign_symptom
were	O
also	O
identified	O
(	O
Fig	O
.	O
1b	O
,	O
c	O
)	O
.	O

Frequent	B-Detailed_description
mitotic	B-Sign_symptom
figures	I-Sign_symptom
and	O
necrosis	B-Sign_symptom
were	O
noted	O
.	O

All	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
were	O
not	O
involved	B-Sign_symptom
by	I-Sign_symptom
tumor	I-Sign_symptom
.	O

Immunohistochemically	B-Diagnostic_procedure
,	O
the	O
neoplastic	O
cells	O
were	O
strongly	O
and	O
diffusely	O
positive	B-Lab_value
for	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
Fig	O
.	O
1d	O
)	O
.	O

They	O
were	O
also	O
positive	B-Lab_value
for	O
vimentin	B-Diagnostic_procedure
.	O

Melanocytic	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
(	O
HMB45	B-Diagnostic_procedure
and	O
Melan	B-Diagnostic_procedure
A	I-Diagnostic_procedure
)	O
,	O
neuroendocrine	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
(	O
chromogranin	B-Diagnostic_procedure
A	I-Diagnostic_procedure
,	O
synaptophysin	B-Diagnostic_procedure
and	O
CD56	B-Diagnostic_procedure
)	O
,	O
smooth	B-Diagnostic_procedure
muscle	I-Diagnostic_procedure
actin	I-Diagnostic_procedure
,	O
desmin	B-Diagnostic_procedure
,	O
CD34	B-Diagnostic_procedure
,	O
CD117	B-Diagnostic_procedure
,	O
cytokeratin	B-Diagnostic_procedure
and	O
LCA	B-Diagnostic_procedure
were	O
all	O
negative	B-Lab_value
in	O
the	O
neoplastic	O
cells	O
.	O

Fluorescein	B-Diagnostic_procedure
in	I-Diagnostic_procedure
situ	I-Diagnostic_procedure
hybridization	I-Diagnostic_procedure
(	O
FISH	B-Diagnostic_procedure
)	O
analysis	O
for	O
EWSR1	B-Detailed_description
break	I-Detailed_description
apart	I-Detailed_description
probe	I-Detailed_description
on	O
paraffin	B-Detailed_description
-	I-Detailed_description
embedded	I-Detailed_description
tumor	I-Detailed_description
showed	O
evidence	O
of	O
a	O
22q12	B-Sign_symptom
rearrangement	I-Sign_symptom
in	O
197	B-Lab_value
out	I-Lab_value
of	I-Lab_value
205	I-Lab_value
(	I-Lab_value
96	I-Lab_value
%	I-Lab_value
)	I-Lab_value
of	I-Lab_value
interphase	I-Lab_value
nuclei	I-Lab_value
scored	O
.	O

The	O
native	O
state	O
of	O
EWSR1	O
break	O
apart	O
probe	O
will	O
be	O
seen	O
as	O
two	O
adjacent	O
or	O
fused	O
(	O
overlapping	O
)	O
red	O
/	O
green	O
(	O
yellow	O
)	O
signals	O
.	O

However	O
,	O
EWSR1	O
gene	O
rearrangement	O
presented	O
as	O
one	O
red	O
and	O
one	O
green	O
separated	O
signal	O
(	O
Fig	O
.	O
1e	O
)	O
.	O

The	O
patient	O
did	O
not	O
receive	O
chemotherapy	B-Medication
or	O
radiotherapy	B-Therapeutic_procedure
.	O

During	O
the	O
clinical	O
follow	O
up	O
,	O
the	O
patient	O
remained	O
disease	B-Sign_symptom
free	I-Sign_symptom
for	O
3	B-Duration
years	I-Duration
until	O
he	O
presented	O
with	O
local	B-Detailed_description
recurrence	B-Sign_symptom
.	O

The	O
treatment	O
plan	O
was	O
surgical	O
resection	B-Therapeutic_procedure
but	O
the	O
patient	O
sought	O
medical	O
advice	O
in	O
a	O
different	B-Nonbiological_location
institution	I-Nonbiological_location
where	O
he	O
died	O
of	O
the	O
disease	O
a	O
year	O
later	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
54	B-Age
year	I-Age
-	I-Age
old	I-Age
diabetic	O
woman	O
complained	O
of	O
blurred	B-Sign_symptom
vision	I-Sign_symptom
in	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
for	O
5	B-Duration
days	I-Duration
without	O
scalp	B-Biological_structure
tenderness	B-Sign_symptom
or	O
headache	B-Sign_symptom
.	O

Visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
(	O
VA	B-Diagnostic_procedure
)	O
was	O
20	B-Lab_value
/	I-Lab_value
20	I-Lab_value
right	B-Biological_structure
eye	I-Biological_structure
and	O
20	B-Lab_value
/	I-Lab_value
30	I-Lab_value
left	B-Biological_structure
eye	I-Biological_structure
.	O

Intraocular	B-Diagnostic_procedure
pressures	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Funduscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
left	B-Biological_structure
optic	I-Biological_structure
nerve	I-Biological_structure
edema	B-Sign_symptom
and	O
a	O
small	B-Severity
disc	B-Biological_structure
margin	I-Biological_structure
hemorrhage	B-Sign_symptom
.	O

WBC	B-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
12,700	B-Lab_value
,	O
ESR	B-Diagnostic_procedure
was	O
7	B-Lab_value
(	O
normal	O
0	O
-	O
20	O
mm	O
/	O
hr	O
)	O
and	O
CRP	B-Diagnostic_procedure
was	O
2	B-Lab_value
.	I-Lab_value
4	I-Lab_value
(	O
normal	O
0	O
-	O
1	O
.	O
0	O
mg	O
/	O
dL	O
)	O
.	O

Three	O
days	O
later	O
,	O
she	O
noted	O
new	O
left	B-Biological_structure
eye	I-Biological_structure
pain	B-Sign_symptom
and	O
her	O
vision	B-Diagnostic_procedure
declined	O
to	O
counting	B-Lab_value
fingers	I-Lab_value
.	O

There	O
was	O
no	O
pain	B-Sign_symptom
on	B-Detailed_description
eye	I-Detailed_description
movement	I-Detailed_description
.	O

The	O
right	B-Diagnostic_procedure
pupil	I-Diagnostic_procedure
was	O
4	B-Distance
mm	I-Distance
and	O
reacted	B-Lab_value
to	I-Lab_value
light	I-Lab_value
;	O
the	O
left	B-Diagnostic_procedure
pupil	I-Diagnostic_procedure
was	O
4	B-Distance
mm	I-Distance
,	O
and	O
there	O
was	O
a	O
relative	B-Detailed_description
left	B-Biological_structure
afferent	I-Biological_structure
pupillary	I-Biological_structure
defect	B-Sign_symptom
.	O

The	O
left	B-Biological_structure
optic	I-Biological_structure
nerve	I-Biological_structure
was	O
swollen	B-Sign_symptom
with	O
a	O
few	B-Detailed_description
peripapillary	B-Biological_structure
nerve	I-Biological_structure
fiber	I-Biological_structure
layer	I-Biological_structure
hemorrhages	B-Sign_symptom
along	O
with	O
a	O
cherry	B-Color
red	I-Color
spot	B-Sign_symptom
and	O
mild	B-Severity
macular	B-Biological_structure
edema	B-Sign_symptom
consistent	O
with	O
central	B-Disease_disorder
retinal	I-Disease_disorder
artery	I-Disease_disorder
occlusion	I-Disease_disorder
;	O
there	O
were	O
no	O
posterior	B-Biological_structure
pole	I-Biological_structure
or	O
peripheral	B-Biological_structure
retinal	I-Biological_structure
hemorrhages	B-Sign_symptom
.	O

Trace	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
were	O
seen	B-Lab_value
in	O
the	O
anterior	B-Biological_structure
chamber	I-Biological_structure
,	O
but	O
not	B-Lab_value
in	O
the	O
vitreous	B-Biological_structure
fluid	I-Biological_structure
.	O

Repeat	O
WBC	B-Diagnostic_procedure
,	O
ESR	B-Diagnostic_procedure
and	O
CRP	B-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

Treponemal	B-Detailed_description
and	O
Bartonella	B-Detailed_description
antibodies	B-Diagnostic_procedure
,	O
the	O
QuantiFERON	B-Diagnostic_procedure
-	I-Diagnostic_procedure
TB	I-Diagnostic_procedure
test	I-Diagnostic_procedure
,	O
blood	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
,	O
EKG	B-Diagnostic_procedure
and	O
carotid	B-Biological_structure
Doppler	B-Detailed_description
ultrasound	B-Diagnostic_procedure
were	O
unremarkable	B-Lab_value
.	O

Brain	B-Biological_structure
contrast	B-Detailed_description
MRI	B-Diagnostic_procedure
demonstrated	O
no	B-Lab_value
optic	B-Biological_structure
nerve	I-Biological_structure
enhancement	O
.	O

Twelve	O
days	O
later	O
,	O
left	B-Biological_structure
eye	I-Biological_structure
pain	B-Sign_symptom
and	O
vision	B-Diagnostic_procedure
worsened	B-Lab_value
,	O
and	O
the	O
patient	O
complained	O
of	O
jaw	B-Biological_structure
claudication	B-Sign_symptom
and	O
scalp	B-Biological_structure
pain	B-Sign_symptom
.	O

VA	B-Diagnostic_procedure
declined	O
to	O
no	B-Lab_value
light	I-Lab_value
perception	I-Lab_value
in	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
with	O
1	B-Lab_value
+	I-Lab_value
cells	B-Diagnostic_procedure
and	I-Diagnostic_procedure
flare	I-Diagnostic_procedure
in	O
anterior	B-Biological_structure
chamber	I-Biological_structure
and	O
2	B-Lab_value
+	I-Lab_value
vitreous	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
and	I-Diagnostic_procedure
haze	I-Diagnostic_procedure
.	O

Funduscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
extensive	B-Severity
retinal	B-Biological_structure
necrosis	B-Sign_symptom
and	O
diffuse	B-Detailed_description
hemorrhages	B-Sign_symptom
with	O
multiple	B-Detailed_description
areas	I-Detailed_description
of	O
focal	B-Detailed_description
venous	B-Sign_symptom
beading	I-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
,	O
consistent	O
with	O
acute	B-Disease_disorder
retinal	I-Disease_disorder
necrosis	I-Disease_disorder
.	O

Vitreous	B-Biological_structure
fluid	I-Biological_structure
was	O
examined	O
by	O
PCR	B-Diagnostic_procedure
for	O
amplifiable	O
HSV	B-Diagnostic_procedure
,	O
VZV	B-Diagnostic_procedure
,	O
CMV	B-Diagnostic_procedure
and	O
toxoplasma	B-Diagnostic_procedure
sequences	O
and	O
returned	O
positive	B-Lab_value
for	O
VZV	B-Diagnostic_procedure
DNA	B-Detailed_description
.	O

She	O
was	O
treated	O
with	O
a	O
one	B-Frequency
-	I-Frequency
time	I-Frequency
intravitreal	O
injection	O
of	O
ganciclovir	B-Medication
2000	B-Dosage
mcg	I-Dosage
/	I-Dosage
0	I-Dosage
.	I-Dosage
5	I-Dosage
ml	I-Dosage
in	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
,	O
oral	O
acyclovir	B-Medication
800	B-Dosage
mg	I-Dosage
5	I-Dosage
times	I-Dosage
daily	I-Dosage
for	O
14	B-Duration
days	I-Duration
and	O
oral	O
prednisone	B-Medication
60	B-Dosage
mg	I-Dosage
daily	I-Dosage
for	O
7	B-Duration
days	I-Duration
followed	O
by	O
20	B-Dosage
mg	I-Dosage
for	O
7	B-Duration
days	I-Duration
.	O

Eleven	O
days	O
after	O
starting	O
treatment	O
,	O
because	O
she	O
had	O
recently	O
developed	O
jaw	B-Biological_structure
claudication	B-Sign_symptom
and	O
intermittent	B-Frequency
scalp	B-Biological_structure
pain	B-Sign_symptom
,	O
a	O
temporal	B-Biological_structure
artery	I-Biological_structure
biopsy	B-Therapeutic_procedure
was	O
performed	O
.	O

Histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
normal	B-Lab_value
(	O
Fig	O
.	O
2	O
)	O
while	O
immunohistochemical	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
demonstrated	B-Lab_value
VZV	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
in	O
the	O
arterial	B-Biological_structure
adventitia	I-Biological_structure
;	O
evaluation	O
of	O
adjacent	O
sections	O
for	O
HSV	B-Diagnostic_procedure
-	I-Diagnostic_procedure
1	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
and	O
infiltrating	B-Diagnostic_procedure
leukocytes	I-Diagnostic_procedure
(	O
CD45	O
,	O
not	O
shown	O
)	O
was	O
negative	B-Lab_value
(	O
Fig	O
.	O
3	O
)	O
.	O

Antiviral	O
therapy	O
was	O
altered	O
to	O
intravenous	O
acyclovir	B-Medication
,	O
10	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
every	I-Dosage
8	I-Dosage
h	I-Dosage
for	O
14	B-Duration
days	I-Duration
,	O
and	O
steroids	B-Medication
were	O
discontinued	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
patient	O
,	O
a	O
4	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
boy	O
,	O
was	O
diagnosed	O
as	O
having	O
Blau	B-Disease_disorder
syndrome	I-Disease_disorder
based	O
on	O
the	O
manifestation	O
of	O
typical	O
clinical	O
features	O
(	O
ankle	B-Biological_structure
and	O
wrist	B-Biological_structure
arthritis	B-Disease_disorder
/	O
tenosynovitis	B-Disease_disorder
,	O
diffuse	B-Detailed_description
eczematous	B-Biological_attribute
rash	B-Sign_symptom
,	O
and	O
uveitis	B-Disease_disorder
)	O
,	O
histologic	B-Diagnostic_procedure
evidence	O
of	O
noncaseating	B-Detailed_description
granulomas	B-Disease_disorder
,	O
and	O
a	O
heterozygous	B-Detailed_description
NOD2	B-Diagnostic_procedure
mutation	I-Diagnostic_procedure
(	O
p	B-Diagnostic_procedure
.	I-Diagnostic_procedure
R334W	I-Diagnostic_procedure
)	O
.	O

Ocular	B-Disease_disorder
involvement	I-Disease_disorder
was	O
initially	O
controlled	B-Detailed_description
by	O
topical	O
and	O
oral	O
corticosteroids	B-Medication
,	O
but	O
over	B-Duration
the	I-Duration
years	I-Duration
visual	B-Disease_disorder
impairment	I-Disease_disorder
progressed	B-Detailed_description
.	O

Other	O
manifestations	O
of	O
Blau	B-Disease_disorder
syndrome	I-Disease_disorder
(	O
arthritis	B-Disease_disorder
and	O
rash	B-Sign_symptom
)	O
subsided	B-Detailed_description
over	B-Duration
time	I-Duration
.	O

Bilateral	B-Detailed_description
panuveitis	B-Disease_disorder
progressed	B-Detailed_description
after	O
age	O
5	O
years	O
,	O
and	O
was	O
initially	O
treated	O
with	O
methotrexate	B-Medication
.	O

However	O
,	O
ocular	B-Biological_structure
inflammation	B-Disease_disorder
persisted	B-Detailed_description
despite	O
the	O
addition	O
of	O
local	B-Detailed_description
steroid	B-Medication
injections	O
and	O
repeated	B-Detailed_description
intravenous	O
(	O
IV	O
)	O
bolus	O
methylprednisolone	B-Medication
treatment	I-Medication
;	O
therefore	O
,	O
when	O
the	O
patient	O
was	O
age	O
10	O
years	O
,	O
infliximab	B-Medication
(	O
initially	O
at	O
5	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
increased	I-Dosage
to	I-Dosage
10	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
IV	I-Dosage
every	I-Dosage
4	I-Dosage
to	I-Dosage
6	I-Dosage
weeks	I-Dosage
)	O
was	O
initiated	O
.	O

Although	O
there	O
was	O
an	O
initial	O
improvement	O
,	O
1	O
year	O
after	O
this	O
treatment	O
was	O
started	O
uveitis	B-Disease_disorder
worsened	B-Severity
,	O
and	O
at	O
age	O
12	O
years	O
infliximab	B-Medication
was	O
discontinued	B-Detailed_description
.	O

Adalimumab	B-Medication
(	O
24	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
every	I-Dosage
2	I-Dosage
weeks	I-Dosage
)	O
was	O
then	O
initiated	O
and	O
the	O
dosage	O
of	O
methotrexate	B-Medication
(	O
15	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
/	I-Dosage
weekly	I-Dosage
)	O
was	O
increased	B-Lab_value
.	O

However	O
,	O
ocular	B-Disease_disorder
disease	I-Disease_disorder
remained	O
active	B-Detailed_description
.	O

Mycophenolate	B-Medication
mofetil	I-Medication
(	O
750	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
)	O
and	O
then	O
abatacept	B-Medication
(	O
10	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
month	I-Dosage
IV	O
)	O
were	O
sequentially	O
administered	O
,	O
without	B-Diagnostic_procedure
significant	I-Diagnostic_procedure
improvement	I-Diagnostic_procedure
.	O

At	O
age	O
16	O
years	O
the	O
patient	O
still	O
had	O
granulomatous	B-Disease_disorder
retinal	B-Biological_structure
lesions	B-Disease_disorder
and	O
anterior	B-Biological_structure
chamber	I-Biological_structure
inflammation	B-Disease_disorder
,	O
and	O
macular	B-Biological_structure
edema	B-Sign_symptom
developed	O
,	O
which	O
led	O
to	O
retinal	B-Disease_disorder
detachment	I-Disease_disorder
.	O

In	O
addition	O
to	O
the	O
other	O
steroid	O
therapy	O
,	O
corticosteroid	B-Medication
pulse	I-Medication
therapy	I-Medication
was	O
necessary	O
to	O
control	O
disease	O
flares	O
,	O
with	O
an	B-Lab_value
average	I-Lab_value
of	I-Lab_value
3	B-Dosage
boluses	I-Dosage
/	I-Dosage
month	I-Dosage
for	O
6	B-Duration
consecutive	I-Duration
months	I-Duration
.	O

Because	O
of	O
the	O
supposed	O
autoinflammatory	O
nature	O
of	O
Blau	O
syndrome	O
,	O
we	O
initiated	O
a	O
trial	O
of	O
IL	B-Medication
-	I-Medication
1	I-Medication
antibody	I-Medication
administration	I-Medication
(	O
2	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
month	I-Dosage
of	O
canakinumab	B-Medication
)	O
.	O

During	O
the	O
6	O
months	O
that	O
followed	O
,	O
no	O
ocular	B-Disease_disorder
flare	I-Disease_disorder
occurred	O
and	O
no	O
steroid	B-Medication
pulse	I-Medication
therapy	I-Medication
was	O
necessary	O
.	O

Concomitant	O
treatment	O
with	O
oral	O
methotrexate	B-Medication
and	O
low	B-Lab_value
-	I-Lab_value
dose	I-Lab_value
prednisone	B-Medication
(	O
0	B-Dosage
.	I-Dosage
2	I-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
remained	O
unchanged	O
.	O

Figure	O
1	O
shows	O
fluorangiograms	B-Diagnostic_procedure
before	O
treatment	O
and	O
after	O
the	O
first	O
6	O
injections	O
.	O

The	B-Medication
drug	I-Medication
was	O
well	B-Detailed_description
tolerated	I-Detailed_description
with	I-Detailed_description
no	I-Detailed_description
side	I-Detailed_description
effects	I-Detailed_description
,	O
and	O
findings	O
on	O
laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
(	O
performed	O
monthly	B-Frequency
)	O
were	O
normal	B-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

A	O
39	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Korean	O
male	O
come	O
to	O
our	O
hospital	B-Nonbiological_location
complaining	O
of	O
cough	B-Sign_symptom
,	O
myalgia	B-Sign_symptom
,	O
and	O
fever	B-Sign_symptom
that	O
had	O
lasted	B-Duration
for	I-Duration
5	I-Duration
days	I-Duration
.	O

He	O
was	O
a	O
company	B-Occupation
worker	I-Occupation
and	O
denied	O
any	O
previous	O
medical	O
histories	O
.	O

He	O
was	O
a	O
current	O
smoker	O
and	O
drank	O
alcohol	O
about	O
once	O
a	O
month	O
.	O

His	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
:	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
,	O
100	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mmHg	I-Lab_value
,	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
100	B-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
25	B-Lab_value
breaths	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
and	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
,	O
39	B-Lab_value
°C	I-Lab_value
.	O

On	O
the	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
decreased	B-Lab_value
breathing	B-Diagnostic_procedure
sound	I-Diagnostic_procedure
was	O
noted	O
in	O
the	O
right	B-Biological_structure
lower	I-Biological_structure
lung	I-Biological_structure
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
revealed	O
a	O
c	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
CRP	B-Diagnostic_procedure
)	O
level	O
of	O
119	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
a	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
level	O
of	O
1	B-Lab_value
.	I-Lab_value
8	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
and	O
alanine	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
and	O
aspartate	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
levels	O
of	O
250	B-Lab_value
and	O
172	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
respectively	O
.	O

His	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
98,000	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
,	O
while	O
his	O
white	B-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
8150	B-Lab_value
/	I-Lab_value
mm3	I-Lab_value
(	O
neutrophil	B-Lab_value
:	I-Lab_value
85	I-Lab_value
%	I-Lab_value
)	O
.	O

In	O
the	O
arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gas	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
checked	O
in	B-Detailed_description
room	I-Detailed_description
air	I-Detailed_description
,	O
pH	B-Diagnostic_procedure
,	O
PaCO2	B-Diagnostic_procedure
,	O
PaO2	B-Diagnostic_procedure
,	O
bicarbonate	B-Diagnostic_procedure
,	O
and	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
levels	O
were	O
7	B-Lab_value
.	I-Lab_value
50	I-Lab_value
,	O
34	B-Lab_value
mmHg	I-Lab_value
,	O
67	B-Lab_value
mmHg	I-Lab_value
,	O
26	B-Lab_value
.	I-Lab_value
5	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
95	B-Lab_value
%	I-Lab_value
,	O
respectively	O
.	O

A	O
test	B-Diagnostic_procedure
for	I-Diagnostic_procedure
the	I-Diagnostic_procedure
human	I-Diagnostic_procedure
immunodeficiency	I-Diagnostic_procedure
virus	I-Diagnostic_procedure
was	O
negative	B-Lab_value
.	O

Mycoplasma	B-Detailed_description
and	O
Chlamydia	B-Detailed_description
antibodies	B-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Streptococcal	B-Detailed_description
and	O
Legionella	B-Detailed_description
urinary	B-Diagnostic_procedure
antigens	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Anti	B-Detailed_description
-	I-Detailed_description
nuclear	I-Detailed_description
and	O
anti	B-Detailed_description
-	I-Detailed_description
neutrophilic	I-Detailed_description
cytoplasmic	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
were	O
also	O
negative	B-Lab_value
.	O

A	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
consolidation	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
mid	I-Biological_structure
to	I-Biological_structure
lower	I-Biological_structure
lung	I-Biological_structure
fields	I-Biological_structure
.	O

Chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
showed	O
consolidation	B-Sign_symptom
with	O
surrounding	B-Texture
ground	I-Texture
glass	I-Texture
opacity	I-Texture
in	O
the	O
right	B-Biological_structure
middle	I-Biological_structure
lobe	I-Biological_structure
with	O
a	O
small	B-Severity
amount	I-Severity
of	O
pleural	B-Disease_disorder
effusion	I-Disease_disorder
in	O
the	O
right	B-Biological_structure
hemithorax	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Abdominal	B-Biological_structure
sonography	B-Diagnostic_procedure
revealed	O
no	B-Lab_value
abnormal	I-Lab_value
finding	I-Lab_value
in	O
the	O
hepatobiliary	B-Biological_structure
system	I-Biological_structure
.	O

We	O
began	O
to	O
administer	O
4	B-Dosage
L	I-Dosage
/	I-Dosage
min	I-Dosage
of	O
oxygen	B-Medication
nasally	O
and	O
empirical	O
antibiotics	B-Medication
with	O
third	O
generation	O
cephalosporin	B-Medication
and	O
macrolide	B-Medication
following	O
a	O
diagnosis	O
of	O
community	B-Detailed_description
-	I-Detailed_description
acquired	I-Detailed_description
pneumonia	B-Disease_disorder
.	O

On	O
the	O
second	O
day	O
in	O
the	O
hospital	O
,	O
the	O
patient	O
`	O
s	O
fever	B-Sign_symptom
was	O
sustained	O
and	O
he	O
complained	O
of	O
dyspnea	B-Sign_symptom
.	O

His	O
hypoxemia	B-Sign_symptom
was	O
aggravated	O
such	O
that	O
he	O
required	O
7	B-Dosage
L	I-Dosage
/	I-Dosage
min	I-Dosage
of	O
oxygen	B-Medication
via	O
a	O
simple	O
mask	O
and	O
the	O
consolidation	B-Sign_symptom
and	O
pleural	B-Disease_disorder
effusion	I-Disease_disorder
had	O
markedly	O
progressed	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

We	O
performed	O
bronchoscopy	B-Diagnostic_procedure
and	O
thoracentesis	B-Therapeutic_procedure
.	O

Multiplex	B-Detailed_description
real	B-Diagnostic_procedure
-	I-Diagnostic_procedure
time	I-Diagnostic_procedure
reverse	I-Diagnostic_procedure
transcriptase	I-Diagnostic_procedure
polymerase	I-Diagnostic_procedure
chain	I-Diagnostic_procedure
reaction	I-Diagnostic_procedure
(	O
RT	B-Diagnostic_procedure
-	I-Diagnostic_procedure
PCR	I-Diagnostic_procedure
)	O
for	B-Detailed_description
respiratory	I-Detailed_description
viruses	I-Detailed_description
using	B-Detailed_description
bronchoalveolar	I-Detailed_description
lavage	I-Detailed_description
fluid	I-Detailed_description
was	O
positive	B-Lab_value
for	I-Lab_value
human	I-Lab_value
adenovirus	I-Lab_value
while	O
other	O
microbiological	B-Diagnostic_procedure
studies	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Pleural	B-Diagnostic_procedure
fluid	I-Diagnostic_procedure
was	O
lymphocyte	B-Lab_value
-	I-Lab_value
dominant	I-Lab_value
exudate	I-Lab_value
and	O
was	O
also	O
positive	B-Lab_value
for	I-Lab_value
human	I-Lab_value
adenovirus	I-Lab_value
.	O

Under	O
the	O
diagnosis	O
of	O
adenovirus	B-Disease_disorder
pneumonia	I-Disease_disorder
,	O
we	O
started	O
antiviral	B-Medication
therapy	I-Medication
with	O
oral	O
ribavirin	B-Medication
400	B-Dosage
mg	I-Dosage
q	I-Dosage
12	I-Dosage
h	I-Dosage
while	O
maintaining	O
antibiotics	B-Medication
.	O

On	O
hospital	O
day	O
4	O
,	O
his	O
fever	B-Sign_symptom
had	O
subsided	O
and	O
symptoms	B-Sign_symptom
were	O
much	O
improved	O
.	O

The	O
transaminase	B-Diagnostic_procedure
levels	O
,	O
CRP	B-Diagnostic_procedure
and	O
platelet	B-Diagnostic_procedure
counts	I-Diagnostic_procedure
gradually	O
normalized	B-Lab_value
(	O
Fig	O
.	O
3	O
)	O
.	O

A	O
follow	O
-	O
up	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
was	O
clear	B-Lab_value
(	O
Fig	O
.	O
2b	O
)	O
and	O
he	O
was	O
discharged	O
in	O
hospital	O
day	O
13	O
without	O
any	O
complications	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
20	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
with	O
cystic	O
fibrosis	O
was	O
transferred	O
to	O
Houston	B-Nonbiological_location
Methodist	I-Nonbiological_location
Hospital	I-Nonbiological_location
in	O
January	O
2013	O
to	O
be	O
evaluated	O
for	O
lung	B-Biological_structure
and	O
kidney	B-Biological_structure
transplant	B-Therapeutic_procedure
.	O

Patients	O
with	O
cystic	O
fibrosis	O
are	O
known	O
to	O
develop	O
chronic	O
lung	O
infections	O
that	O
adapt	O
over	O
time	O
to	O
this	O
unique	O
anatomic	O
niche	O
(	O
14	O
,	O
15	O
)	O
.	O

His	O
complicated	O
medical	O
history	O
included	O
pancreatic	O
insufficiency	O
,	O
liver	B-Biological_structure
transplantation	B-Therapeutic_procedure
in	O
2004	O
,	O
steroid	B-Medication
-	O
induced	O
diabetes	B-Disease_disorder
,	O
end	O
-	O
stage	O
renal	O
disease	O
,	O
and	O
testicular	O
cancer	O
.	O

He	O
had	O
a	O
long	O
history	O
of	O
respiratory	B-Disease_disorder
infections	I-Disease_disorder
with	O
several	O
multidrug	B-Disease_disorder
-	I-Disease_disorder
resistant	I-Disease_disorder
bacteria	I-Disease_disorder
,	O
including	O
MRSA	B-Disease_disorder
.	O

He	O
was	O
treated	O
with	O
ceftaroline	B-Medication
at	O
an	O
outside	B-Nonbiological_location
hospital	I-Nonbiological_location
immediately	O
prior	O
to	O
transfer	O
to	O
Houston	B-Nonbiological_location
Methodist	I-Nonbiological_location
Hospital	I-Nonbiological_location
.	O

The	O
patient	O
was	O
periodically	B-Frequency
hospitalized	O
from	O
January	B-Duration
to	I-Duration
July	I-Duration
2013	I-Duration
and	O
was	O
treated	O
for	O
recurrent	O
respiratory	B-Biological_structure
and	O
catheter	B-Detailed_description
-	I-Detailed_description
related	I-Detailed_description
infections	B-Disease_disorder
caused	O
by	O
MRSA	B-Disease_disorder
and	O
multidrug	B-Disease_disorder
-	I-Disease_disorder
resistant	I-Disease_disorder
Pseudomonas	I-Disease_disorder
aeruginosa	I-Disease_disorder
.	O

His	O
antibiotic	B-Medication
exposure	O
included	O
long	O
treatment	O
courses	O
with	O
various	O
agents	O
,	O
including	O
meropenem	B-Medication
,	O
ceftazidime	B-Medication
,	O
doxycycline	B-Medication
,	O
vancomycin	B-Medication
,	O
linezolid	B-Medication
,	O
cefepime	B-Medication
,	O
ciprofloxacin	B-Medication
,	O
and	O
inhaled	O
and	O
systemic	O
colistin	B-Medication
and	O
tobramycin	B-Medication
.	O

Shortly	O
after	O
being	O
readmitted	O
to	O
our	O
hospital	B-Nonbiological_location
in	O
June	O
2013	O
,	O
MRSA	B-Disease_disorder
was	O
grown	O
from	O
cultures	B-Diagnostic_procedure
of	O
blood	B-Biological_structure
and	O
respiratory	B-Biological_structure
specimens	I-Biological_structure
.	O

These	O
two	O
isolates	O
were	O
resistant	B-Lab_value
to	O
clindamycin	B-Diagnostic_procedure
,	O
linezolid	B-Diagnostic_procedure
,	O
oxacillin	B-Diagnostic_procedure
,	O
and	O
trimethoprim	B-Diagnostic_procedure
-	I-Diagnostic_procedure
sulfamethoxazole	I-Diagnostic_procedure
and	O
susceptible	B-Lab_value
to	O
minocycline	B-Diagnostic_procedure
,	O
rifampin	B-Diagnostic_procedure
,	O
and	O
vancomycin	B-Diagnostic_procedure
.	O

His	O
blood	B-Biological_structure
isolate	B-Diagnostic_procedure
grew	B-Lab_value
confluently	I-Lab_value
around	O
the	O
ceftaroline	B-Diagnostic_procedure
Etest	I-Diagnostic_procedure
strip	I-Diagnostic_procedure
,	O
yielding	O
an	O
MIC	B-Lab_value
of	I-Lab_value
>	I-Lab_value
32	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
liter	I-Lab_value
.	O

Five	B-Lab_value
additional	O
S	B-Disease_disorder
.	I-Disease_disorder
aureus	I-Disease_disorder
respiratory	B-Biological_structure
tract	I-Biological_structure
isolates	B-Diagnostic_procedure
were	O
available	O
for	O
further	O
study	O
.	O

All	O
MRSA	O
isolates	O
from	O
this	O
patient	O
had	O
a	O
small	O
-	O
colony	O
-	O
variant	O
(	O
SCV	O
)	O
phenotype	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
73	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
who	O
had	O
been	O
diagnosed	O
with	O
type	B-Disease_disorder
2	I-Disease_disorder
diabetes	I-Disease_disorder
mellitus	I-Disease_disorder
at	O
35	O
year	O
of	O
age	O
,	O
who	O
had	O
severe	B-Severity
diabetic	B-Disease_disorder
neuropathy	I-Disease_disorder
and	O
diabetic	B-Disease_disorder
-	I-Disease_disorder
ESRD	I-Disease_disorder
complained	O
of	O
respiratory	B-Sign_symptom
distress	I-Sign_symptom
and	O
sudden	B-Detailed_description
chest	B-Biological_structure
pain	B-Sign_symptom
.	O

On	O
the	O
first	O
day	O
of	O
treatment	O
,	O
he	O
visited	O
the	O
emergency	B-Nonbiological_location
room	I-Nonbiological_location
.	O

A	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
that	O
his	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
was	O
35	B-Lab_value
.	I-Lab_value
4	I-Lab_value
°C	I-Lab_value
,	O
his	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
90	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
with	O
a	O
regular	B-Lab_value
rhythm	I-Lab_value
;	O
and	O
his	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
130	B-Lab_value
/	I-Lab_value
77	I-Lab_value
mmHg	I-Lab_value
.	O

A	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
coarse	B-Detailed_description
crackles	B-Sign_symptom
on	O
bilateral	B-Detailed_description
lung	B-Diagnostic_procedure
auscultation	I-Diagnostic_procedure
.	O

The	O
laboratory	B-Diagnostic_procedure
data	I-Diagnostic_procedure
showed	O
a	O
WBC	B-Diagnostic_procedure
count	O
of	O
8,800	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
with	O
a	O
shift	B-Lab_value
to	I-Lab_value
the	I-Lab_value
left	I-Lab_value
(	O
neutrophils	B-Diagnostic_procedure
82	B-Lab_value
%	I-Lab_value
)	O
,	O
Hb	B-Diagnostic_procedure
10	B-Lab_value
.	I-Lab_value
2	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
nitrogen	I-Diagnostic_procedure
(	O
BUN	B-Diagnostic_procedure
)	O
82	B-Lab_value
.	I-Lab_value
2	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
creatinine	B-Diagnostic_procedure
(	O
Cre	B-Diagnostic_procedure
)	O
6	B-Lab_value
.	I-Lab_value
50	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
HbA1c	B-Diagnostic_procedure
5	B-Lab_value
.	I-Lab_value
9	I-Lab_value
%	I-Lab_value
,	O
creatine	B-Diagnostic_procedure
kinase	I-Diagnostic_procedure
(	O
CK	B-Diagnostic_procedure
)	O
189	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
CRP	B-Diagnostic_procedure
)	O
8	B-Lab_value
.	I-Lab_value
51	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
brain	B-Diagnostic_procedure
-	I-Diagnostic_procedure
type	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
(	O
BNP	B-Diagnostic_procedure
)	O
127	B-Lab_value
.	I-Lab_value
4	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

A	O
chest	B-Biological_structure
radiograph	B-Diagnostic_procedure
revealed	O
perihilar	B-Detailed_description
consolidations	B-Sign_symptom
and	O
air	B-Detailed_description
bronchograms	B-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

An	O
electrocardiogram	B-Diagnostic_procedure
revealed	O
ST	B-Sign_symptom
-	I-Sign_symptom
segment	I-Sign_symptom
elevation	I-Sign_symptom
and	O
poor	B-Sign_symptom
R	I-Sign_symptom
-	I-Sign_symptom
wave	I-Sign_symptom
progression	I-Sign_symptom
in	O
leads	B-Detailed_description
V1	I-Detailed_description
-	I-Detailed_description
V3	I-Detailed_description
,	O
and	O
echocardiography	B-Diagnostic_procedure
revealed	O
apical	B-Sign_symptom
and	I-Sign_symptom
ventricular	I-Sign_symptom
asynergy	I-Sign_symptom
.	O

The	O
patient	O
was	O
therefore	O
diagnosed	O
with	O
acute	B-Detailed_description
myocardial	B-Disease_disorder
infarction	I-Disease_disorder
and	O
congestive	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
.	O

Coronary	B-Biological_structure
angiography	B-Diagnostic_procedure
was	O
performed	O
,	O
revealing	O
severe	O
angiostenosis	B-Sign_symptom
in	O
the	O
septal	B-Biological_structure
branch	I-Biological_structure
.	O

PCI	B-Therapeutic_procedure
was	O
therefore	O
performed	O
.	O

The	O
patient	O
required	O
continuous	B-Detailed_description
maintenance	B-Detailed_description
dialysis	B-Therapeutic_procedure
.	O

On	O
the	O
following	O
day	O
,	O
the	O
patient	O
went	O
into	O
cardiorespiratory	B-Disease_disorder
arrest	I-Disease_disorder
and	O
cardiopulmonary	B-Therapeutic_procedure
resuscitation	I-Therapeutic_procedure
was	O
performed	O
,	O
followed	O
by	O
mechanical	B-Detailed_description
ventilation	B-Therapeutic_procedure
.	O

On	O
day	O
8	O
,	O
ventilator	B-Therapeutic_procedure
assistance	O
was	O
discontinued	O
.	O

However	O
,	O
the	O
patient	O
produced	O
an	O
increasing	B-Lab_value
volume	I-Lab_value
of	O
sputum	B-Sign_symptom
,	O
which	O
began	O
to	O
appear	O
purulent	B-Lab_value
.	O

Pseudomonas	B-Sign_symptom
aeruginosa	I-Sign_symptom
was	O
identified	O
from	O
a	O
sputum	B-Diagnostic_procedure
culture	I-Diagnostic_procedure
,	O
and	O
tazobactam	B-Medication
/	I-Medication
piperacillin	I-Medication
(	O
TAZ	B-Medication
/	I-Medication
PIPC	I-Medication
)	O
(	O
4	B-Dosage
.	I-Dosage
5g	I-Dosage
q12h	I-Dosage
)	O
was	O
administered	O
.	O

Despite	O
this	O
therapy	O
,	O
the	O
patient	O
`	O
s	O
respiratory	B-Diagnostic_procedure
condition	I-Diagnostic_procedure
worsened	B-Lab_value
and	O
a	O
chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
on	O
day	O
15	O
revealed	O
bilateral	B-Detailed_description
perihilar	B-Detailed_description
opacities	B-Sign_symptom
,	O
pleural	B-Disease_disorder
effusion	I-Disease_disorder
,	O
and	O
atelectasis	B-Disease_disorder
.	O
(	O
Fig	O
.	O
2	O
)	O
.	O

We	O
suspected	O
the	O
development	O
of	O
complications	O
such	O
as	O
microbial	B-Disease_disorder
substitution	I-Disease_disorder
,	O
pneumomycosis	B-Disease_disorder
and	O
thus	O
performed	O
sputum	B-Diagnostic_procedure
culturing	I-Diagnostic_procedure
and	O
serum	B-Diagnostic_procedure
fungal	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
tests	O
.	O

The	O
administration	O
of	O
TAZ	B-Medication
/	I-Medication
PIPC	I-Medication
was	O
changed	O
to	O
meropenem	B-Medication
(	O
0	B-Dosage
.	I-Dosage
5	I-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
.	O

On	O
day	O
16	O
,	O
the	O
patient	O
`	O
s	O
serum	B-Diagnostic_procedure
tested	O
positive	B-Lab_value
for	O
Cryptococcus	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
.	O

On	O
day	O
21	O
,	O
cryptococcal	B-Sign_symptom
bodies	I-Sign_symptom
were	O
identified	O
in	O
two	B-Detailed_description
sets	I-Detailed_description
of	O
blood	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
and	O
liposomal	B-Medication
amphotericin	I-Medication
B	I-Medication
(	O
L	B-Medication
-	I-Medication
AMB	I-Medication
)	O
(	O
3	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
was	O
administered	O
.	O

On	O
day	O
23	O
,	O
cryptococcal	B-Sign_symptom
bodies	I-Sign_symptom
were	O
identified	O
in	O
the	O
sputum	B-Diagnostic_procedure
,	O
cerebrospinal	B-Diagnostic_procedure
fluid	I-Diagnostic_procedure
,	O
and	O
bilateral	B-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
patient	O
was	O
therefore	O
diagnosed	O
with	O
disseminated	B-Detailed_description
cryptococcosis	B-Disease_disorder
.	O

On	O
day	O
25	O
,	O
brain	B-Biological_structure
CT	B-Diagnostic_procedure
revealed	O
the	O
absence	O
of	O
intracranial	B-Biological_structure
hypertension	B-Sign_symptom
and	O
a	O
brain	B-Biological_structure
abscess	B-Disease_disorder
.	O

The	O
patient	O
was	O
not	O
infected	O
with	O
human	B-Disease_disorder
immunodeficiency	I-Disease_disorder
virus	I-Disease_disorder
(	O
HIV	B-Disease_disorder
)	O
.	O

The	O
administration	O
of	O
L	B-Medication
-	I-Medication
AMB	I-Medication
(	O
3	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
day	I-Dosage
)	O
was	O
continued	O
.	O

On	O
day	O
31	O
,	O
chest	B-Biological_structure
CT	B-Diagnostic_procedure
revealed	O
a	O
solitary	B-Detailed_description
nodule	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
lingular	I-Biological_structure
segment	I-Biological_structure
for	O
the	O
first	O
time	O
,	O
which	O
was	O
suspected	O
to	O
be	O
a	O
pulmonary	B-Biological_structure
cryptococcus	B-Disease_disorder
lesion	I-Disease_disorder
(	O
Fig	O
.	O
4a	O
)	O
.	O

After	O
several	O
days	O
,	O
all	O
of	O
the	O
sputum	B-Diagnostic_procedure
,	O
blood	B-Diagnostic_procedure
,	O
bilateral	B-Detailed_description
pleural	B-Diagnostic_procedure
effusion	I-Diagnostic_procedure
,	O
and	O
cerebrospinal	B-Diagnostic_procedure
fluid	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
tested	O
negative	B-Lab_value
.	O

On	O
day	O
52	O
,	O
chest	B-Biological_structure
CT	B-Diagnostic_procedure
revealed	O
another	O
lung	B-Biological_structure
nodule	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
pulmonary	I-Biological_structure
apical	I-Biological_structure
region	I-Biological_structure
.	O

These	O
nodules	B-Sign_symptom
gradually	O
decreased	B-Lab_value
in	I-Lab_value
size	I-Lab_value
until	O
day	O
79	O
(	O
Fig	O
.	O
4b	O
and	O
c	O
)	O
.	O

Although	O
L	B-Medication
-	I-Medication
AMB	I-Medication
was	O
considered	O
effective	O
,	O
the	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
level	O
remained	O
elevated	B-Lab_value
and	O
the	O
bilateral	B-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
continuously	O
increased	O
.	O

The	O
patient	O
lost	B-Sign_symptom
consciousness	I-Sign_symptom
because	O
of	O
decreased	B-Lab_value
vital	B-Diagnostic_procedure
capacity	I-Diagnostic_procedure
with	O
increasing	O
bilateral	B-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
and	O
was	O
diagnosed	O
with	O
CO2	B-Disease_disorder
narcosis	I-Disease_disorder
.	O

The	O
patient	O
`	O
s	O
general	B-Diagnostic_procedure
condition	I-Diagnostic_procedure
deteriorated	B-Lab_value
.	O

On	O
day	O
87	O
,	O
ventricular	B-Disease_disorder
fibrillation	I-Disease_disorder
occurred	O
and	O
the	O
patient	O
died	O
.	O

Autopsy	B-Diagnostic_procedure
was	O
not	O
performed	O
.	O

At	O
a	O
later	O
date	O
,	O
the	O
Cryptococcus	B-Detailed_description
isolate	I-Detailed_description
was	O
identified	O
and	O
classified	O
as	O
Cryptococcus	B-Disease_disorder
neoformans	I-Disease_disorder
var	I-Disease_disorder
.	I-Disease_disorder
grubii	I-Disease_disorder
(	I-Disease_disorder
serotype	I-Disease_disorder
A	I-Disease_disorder
)	I-Disease_disorder
by	O
a	O
genetic	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

A	O
63	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
patient	O
without	O
smoking	B-Activity
or	O
drinking	B-Activity
history	O
was	O
admitted	O
on	O
June	O
11	O
,	O
2014	O
.	O

His	O
major	O
complaints	O
were	O
gradually	O
aggravated	O
dysphagia	B-Sign_symptom
and	O
fatigue	B-Sign_symptom
,	O
on	O
suspicion	O
of	O
obstructive	B-Disease_disorder
disease	I-Disease_disorder
in	O
upper	B-Biological_structure
digestive	I-Biological_structure
tract	I-Biological_structure
.	O

He	O
had	B-Occupation
been	I-Occupation
an	I-Occupation
athlete	I-Occupation
before	O
,	O
and	O
then	O
retired	O
in	O
good	O
physical	O
status	O
before	O
admission	O
.	O

His	O
family	O
and	O
social	O
history	O
indicated	O
nothing	O
abnormal	O
.	O

Thorough	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
his	O
skin	B-Biological_structure
,	O
oral	B-Biological_structure
mucosa	I-Biological_structure
,	O
eyes	B-Biological_structure
,	O
and	O
genital	B-Biological_structure
areas	I-Biological_structure
failed	O
to	O
identify	O
any	O
superficial	O
lesions	B-Sign_symptom
.	O

Additionally	O
,	O
laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
including	O
hepatic	B-Diagnostic_procedure
function	I-Diagnostic_procedure
,	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
,	O
and	O
serum	B-Diagnostic_procedure
tumor	I-Diagnostic_procedure
markers	I-Diagnostic_procedure
such	O
as	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
,	O
cytokeratin	B-Diagnostic_procedure
19	I-Diagnostic_procedure
fragment	I-Diagnostic_procedure
,	O
squamous	B-Diagnostic_procedure
cell	I-Diagnostic_procedure
carcinoma	I-Diagnostic_procedure
,	O
neuron	B-Diagnostic_procedure
-	I-Diagnostic_procedure
specific	I-Diagnostic_procedure
enolase	I-Diagnostic_procedure
,	O
and	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
125	I-Diagnostic_procedure
were	O
all	O
in	B-Lab_value
normal	I-Lab_value
range	I-Lab_value
.	O

Therefore	O
,	O
further	O
endoscopic	B-Detailed_description
and	O
radiological	B-Detailed_description
examinations	B-Diagnostic_procedure
were	O
carried	O
out	O
for	O
accurate	O
diagnosis	O
.	O

Endoscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
slightly	B-Color
pigmented	I-Color
,	O
irregular	B-Detailed_description
mass	B-Sign_symptom
,	O
which	O
was	O
located	O
in	O
lower	B-Biological_structure
esophagus	I-Biological_structure
,	O
measuring	O
5	B-Area
.	I-Area
0	I-Area
cm	I-Area
×	I-Area
3	I-Area
.	I-Area
0	I-Area
cm	I-Area
in	O
size	O
.	O

Fine	B-Detailed_description
needle	I-Detailed_description
biopsy	B-Diagnostic_procedure
of	O
the	O
lesion	O
revealed	O
esophageal	B-Biological_structure
melanoma	B-Disease_disorder
,	O
which	O
was	O
confirmed	O
by	O
histopathology	B-Diagnostic_procedure
.	O

Besides	O
chest	B-Biological_structure
and	O
abdomen	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
,	O
enhanced	B-Detailed_description
cranial	B-Biological_structure
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
image	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
and	O
bone	B-Biological_structure
emission	B-Diagnostic_procedure
computed	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
ECT	B-Diagnostic_procedure
)	O
showed	O
enlarged	B-Sign_symptom
mediastinal	B-Biological_structure
,	O
nd	O
also	O
celiac	B-Biological_structure
lymph	B-Biological_structure
nodes	I-Biological_structure
(	O
Fig	O
.	O
1A	O
)	O
,	O
without	O
obvious	O
involvement	B-Sign_symptom
of	O
supraclavicular	B-Biological_structure
lymph	B-Biological_structure
nodes	I-Biological_structure
.	O

Concurrently	O
,	O
the	O
CT	B-Diagnostic_procedure
showed	O
an	O
isolated	B-Detailed_description
,	O
irregular	B-Detailed_description
pulmonary	B-Biological_structure
tumor	B-Sign_symptom
(	O
Fig	O
.	O
1B	O
)	O
.	O

Positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
was	O
not	O
carried	O
out	O
,	O
because	O
it	O
was	O
not	O
covered	O
by	O
health	O
insurance	O
of	O
this	O
patient	O
.	O

Therefore	O
,	O
this	O
patient	O
was	O
clinically	B-Diagnostic_procedure
staged	I-Diagnostic_procedure
as	O
cT3NxM1	B-Lab_value
according	O
to	O
the	O
7th	B-Detailed_description
edition	I-Detailed_description
of	I-Detailed_description
American	I-Detailed_description
Joint	I-Detailed_description
Committee	I-Detailed_description
on	I-Detailed_description
Cancer	I-Detailed_description
TNM	I-Detailed_description
staging	I-Detailed_description
system	I-Detailed_description
for	O
esophageal	B-Disease_disorder
cancer	I-Disease_disorder
.	O

CT	B-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
percutaneous	B-Detailed_description
pulmonary	B-Biological_structure
biopsy	B-Diagnostic_procedure
was	O
avoided	O
,	O
with	O
the	O
aim	O
to	O
diminish	O
the	O
risk	O
of	O
tumor	O
dissemination	O
.	O

Single	B-Detailed_description
-	I-Detailed_description
stage	I-Detailed_description
resection	B-Therapeutic_procedure
of	O
the	O
esophageal	B-Biological_structure
and	O
pulmonary	B-Biological_structure
lesions	B-Sign_symptom
was	O
assumed	O
to	O
be	O
reasonable	O
after	O
multidisciplinary	O
consultation	O
,	O
which	O
was	O
approved	O
by	O
Ethical	O
Committee	O
of	O
Xuzhou	O
Central	O
Hospital	O
.	O

Because	O
the	O
prognosis	O
of	O
this	O
patient	O
probably	O
was	O
extremely	O
poor	O
without	O
targeted	B-Therapeutic_procedure
antibodies	I-Therapeutic_procedure
,	O
which	O
he	O
could	O
not	O
afford	O
for	O
financial	O
reasons	O
.	O

After	O
his	O
informed	O
consent	O
,	O
simultaneous	B-Detailed_description
Ivor	B-Detailed_description
-	I-Detailed_description
Lewis	I-Detailed_description
esophagectomy	B-Therapeutic_procedure
and	O
right	B-Detailed_description
upper	I-Detailed_description
lobectomy	B-Therapeutic_procedure
were	O
performed	O
successfully	O
,	O
under	O
general	B-Medication
anesthesia	I-Medication
,	O
after	O
double	B-Detailed_description
-	I-Detailed_description
lumen	I-Detailed_description
endotracheal	B-Detailed_description
intubation	B-Therapeutic_procedure
,	O
followed	O
by	O
systemic	B-Detailed_description
dissection	B-Therapeutic_procedure
of	O
lymph	B-Biological_structure
nodes	I-Biological_structure
located	O
in	O
mediastinum	B-Biological_structure
and	O
abdomen	B-Biological_structure
,	O
in	O
accordance	O
with	O
the	O
principles	O
of	O
oncological	O
surgery	O
.	O

The	O
operation	O
time	O
was	O
290	B-Duration
minutes	I-Duration
,	O
without	O
obvious	O
bleeding	B-Sign_symptom
during	O
the	O
surgery	O
.	O

Postoperative	O
pathological	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
of	O
the	O
specimen	O
revealed	O
pleomorphic	B-Sign_symptom
cells	I-Sign_symptom
and	O
abundant	O
melanin	B-Sign_symptom
granules	I-Sign_symptom
(	O
Fig	O
.	O
1C	O
)	O
,	O
whereas	O
immunohistochemical	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
demonstrated	O
positive	B-Lab_value
expression	I-Lab_value
of	O
human	B-Diagnostic_procedure
melanoma	I-Diagnostic_procedure
black	I-Diagnostic_procedure
45	I-Diagnostic_procedure
(	O
HMB45	B-Diagnostic_procedure
)	O
,	O
microtubule	B-Diagnostic_procedure
-	I-Diagnostic_procedure
associated	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
tau	I-Diagnostic_procedure
1	I-Diagnostic_procedure
(	O
MAPT1	B-Diagnostic_procedure
)	O
,	O
melan	B-Diagnostic_procedure
A	I-Diagnostic_procedure
and	O
S100	B-Diagnostic_procedure
,	O
and	O
negative	B-Lab_value
expression	I-Lab_value
of	O
desmin	B-Diagnostic_procedure
,	O
synaptophysin	B-Diagnostic_procedure
,	O
and	O
epithelial	B-Diagnostic_procedure
membrane	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	O
EMA	B-Diagnostic_procedure
)	O
,	O
which	O
was	O
consistent	O
with	O
melanoma	B-Disease_disorder
.	O

The	O
resection	B-Biological_structure
margin	I-Biological_structure
and	O
dissected	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
were	O
pathologically	O
tumor	B-Sign_symptom
-	O
negative	O
.	O

In	O
addition	O
,	O
molecular	B-Diagnostic_procedure
study	I-Diagnostic_procedure
of	O
the	O
patient	O
indicated	O
mutation	B-Sign_symptom
of	I-Sign_symptom
V	I-Sign_symptom
-	I-Sign_symptom
raf	I-Sign_symptom
murine	I-Sign_symptom
sarcoma	I-Sign_symptom
viral	I-Sign_symptom
oncogene	I-Sign_symptom
homolog	I-Sign_symptom
B1	I-Sign_symptom
(	O
BRAF	O
)	O
V600E	O
.	O

Based	O
on	O
these	O
findings	O
,	O
a	O
diagnosis	O
of	O
advanced	B-Severity
PMME	B-Disease_disorder
was	O
tentatively	O
established	O
as	O
stage	B-Lab_value
IV	I-Lab_value
(	O
pT3N0M1	B-Lab_value
)	O
,	O
because	O
there	O
was	O
insufficient	O
evidence	O
to	O
distinguish	O
synchronous	O
primary	O
pulmonary	O
melanoma	O
from	O
metastasis	O
for	O
this	O
patient	O
.	O

The	O
postoperative	B-Therapeutic_procedure
recovery	I-Therapeutic_procedure
was	O
mainly	B-Lab_value
uneventful	I-Lab_value
,	O
and	O
the	O
patient	O
was	O
discharged	O
14	O
days	O
after	O
surgery	O
.	O

Subsequently	O
,	O
4	B-Dosage
cycles	I-Dosage
of	O
adjuvant	B-Detailed_description
conventional	B-Detailed_description
chemotherapy	B-Medication
with	O
an	B-Dosage
interval	I-Dosage
of	I-Dosage
3	I-Dosage
weeks	I-Dosage
were	O
completed	O
,	O
with	O
controlled	O
moderate	O
toxic	O
effects	O
including	O
thrombocytopenia	B-Sign_symptom
,	O
leukopenia	B-Sign_symptom
,	O
nausea	B-Sign_symptom
,	O
vomiting	B-Sign_symptom
,	O
and	O
diarrhea	B-Sign_symptom
.	O

The	O
detailed	O
chemotherapy	O
regimen	O
is	O
as	O
follows	O
:	O
paclitaxel	B-Medication
liposome	I-Medication
for	O
injection	O
on	O
day	O
1	O
and	O
day	O
8	O
(	O
135	O
mg	O
per	O
square	O
meter	O
of	O
body	O
surface	O
area	O
;	O
Nanjing	O
Luye	O
Sike	O
Pharmaceutical	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Jiangsu	O
,	O
China	O
.	O
)	O
,	O
tegafur	B-Medication
injection	O
on	O
day	O
2	O
to	O
4	O
(	O
1000	O
mg	O
per	O
square	O
meter	O
of	O
body	O
-	O
surface	O
area	O
;	O
Shandong	O
Qilu	O
Pharmaceutical	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Jinan	O
,	O
China	O
.	O
)	O
plus	O
cis	B-Medication
-	I-Medication
platinum	I-Medication
on	O
day	O
2	O
to	O
3	O
(	O
75	O
mg	O
per	O
square	O
meter	O
of	O
body	O
-	O
surface	O
area	O
;	O
Shandong	O
Qilu	O
Pharmaceutical	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Jinan	O
,	O
China	O
)	O
.	O

This	O
patient	O
suffered	O
from	O
moderate	B-Severity
leukopenia	B-Sign_symptom
/	O
myelosuppression	B-Sign_symptom
after	O
the	O
second	O
cycle	O
of	O
TPF	O
chemotherapy	B-Medication
,	O
and	O
he	O
recovered	B-Sign_symptom
quickly	O
after	O
the	O
administration	O
of	O
granulocyte	B-Medication
colony	I-Medication
-	I-Medication
stimulating	I-Medication
factor	I-Medication
(	O
G	B-Medication
-	I-Medication
CSF	I-Medication
)	O
.	O

Concurrently	O
,	O
recombinant	O
human	B-Medication
interferon	I-Medication
alpha	I-Medication
-	I-Medication
2b	I-Medication
(	O
Harbin	O
pharmaceutical	O
group	O
biological	O
engineering	O
Co	O
.	O
,	O
Ltd	O
,	O
Harbin	O
,	O
China	O
)	O
was	O
administrated	O
via	O
hypodermic	O
injection	O
thereafter	O
(	O
6000	B-Dosage
units	I-Dosage
every	I-Dosage
3	I-Dosage
days	I-Dosage
;	O
Fig	O
.	O
2	O
)	O
,	O
lasting	O
for	B-Duration
1	I-Duration
year	I-Duration
.	O

The	O
patient	O
was	O
followed	O
up	O
continuously	O
after	O
the	O
surgery	O
.	O

Chest	B-Biological_structure
and	O
abdomen	B-Biological_structure
CT	B-Diagnostic_procedure
,	O
cranial	B-Biological_structure
MRI	B-Diagnostic_procedure
,	O
bone	B-Biological_structure
ECT	B-Diagnostic_procedure
,	O
and	O
thorough	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
were	O
carried	O
out	O
every	B-Frequency
3	I-Frequency
months	I-Frequency
.	O

Encouragingly	O
,	O
the	O
patient	O
survived	O
without	O
loco	B-Detailed_description
-	I-Detailed_description
regional	I-Detailed_description
recurrence	B-Sign_symptom
or	O
remote	B-Detailed_description
metastasis	B-Sign_symptom
during	O
the	O
follow	O
-	O
up	O
of	O
two	B-Duration
and	I-Duration
a	I-Duration
half	I-Duration
years	I-Duration
up	O
to	O
now	O
(	O
Fig	O
.	O
3	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

Our	O
24	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
non	O
-	O
smoking	O
male	O
patient	O
presented	O
with	O
repeated	B-Detailed_description
hemoptysis	B-Sign_symptom
in	O
May	O
2008	O
with	O
4	B-Duration
days	I-Duration
of	O
concomitant	B-Detailed_description
right	B-Biological_structure
thoracic	I-Biological_structure
pain	B-Sign_symptom
which	B-Detailed_description
intensified	I-Detailed_description
while	I-Detailed_description
breathing	I-Detailed_description
.	O

During	O
holidays	O
in	O
his	O
home	O
country	O
,	O
this	O
Cuban	O
patient	O
suffered	O
from	O
a	O
cold	B-Sign_symptom
with	O
fever	B-Sign_symptom
and	O
a	O
strong	B-Severity
cough	B-Sign_symptom
.	O

The	O
strong	B-Severity
dry	B-Texture
cough	O
persisted	B-Detailed_description
after	O
recovery	O
from	O
the	O
cold	O
.	O

The	O
patient	O
did	O
not	O
report	O
any	O
loss	B-Sign_symptom
of	I-Sign_symptom
weight	I-Sign_symptom
.	O

The	O
initial	O
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
of	O
the	O
thorax	B-Biological_structure
showed	O
a	O
12	B-Area
×	I-Area
4	I-Area
cm	I-Area
solid	B-Detailed_description
mass	B-Sign_symptom
paravertebral	B-Biological_structure
right	I-Biological_structure
in	O
the	O
lower	B-Biological_structure
thorax	I-Biological_structure
without	O
any	O
signs	O
of	O
metastases	B-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

The	O
bronchoscopy	B-Diagnostic_procedure
(	O
Figure	O
2	O
)	O
with	O
non	B-Detailed_description
-	I-Detailed_description
bleeding	I-Detailed_description
biopsy	B-Diagnostic_procedure
revealed	O
a	O
mass	O
of	O
the	O
lower	B-Biological_structure
right	I-Biological_structure
bronchus	I-Biological_structure
which	O
histologically	B-Diagnostic_procedure
and	O
immunohistologically	B-Diagnostic_procedure
provided	O
evidence	O
of	O
a	O
granular	B-Disease_disorder
cell	I-Disease_disorder
or	I-Disease_disorder
Abrikossoff	B-Disease_disorder
tumor	I-Disease_disorder
[	O
1	O
]	O
.	O

The	O
bronchial	B-Diagnostic_procedure
lavage	I-Diagnostic_procedure
which	O
followed	O
was	O
negative	B-Lab_value
for	O
malignant	B-Biological_structure
cells	I-Biological_structure
.	O

The	O
patient	O
was	O
discharged	O
and	O
surgical	O
intervention	O
was	O
planned	O
.	O

Four	O
days	O
after	O
discharge	O
a	O
spontaneous	B-Detailed_description
hemothorax	B-Sign_symptom
developed	O
.	O

The	O
patient	O
needed	O
to	O
be	O
readmitted	O
and	O
the	O
hemothorax	O
was	O
drained	B-Therapeutic_procedure
.	O

No	O
malignant	B-Sign_symptom
cells	I-Sign_symptom
were	O
detected	O
in	O
the	O
cytological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
drained	B-Biological_structure
liquid	I-Biological_structure
.	O

After	O
an	O
uneventful	O
course	O
and	O
decreasing	B-Lab_value
of	O
the	O
hematoma	B-Sign_symptom
,	O
the	O
tumor	B-Sign_symptom
was	O
excised	B-Therapeutic_procedure
by	O
performing	O
a	O
lower	B-Therapeutic_procedure
right	I-Therapeutic_procedure
lobectomy	I-Therapeutic_procedure
6	O
months	O
after	O
the	O
initial	O
admission	O
.	O

The	O
final	O
histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
confirmed	O
a	O
peribronchial	B-Biological_structure
and	O
infiltrating	B-Detailed_description
S100	B-Diagnostic_procedure
positive	B-Lab_value
tumor	O
supporting	O
the	O
Schwann	O
cell	O
origin	O
theory	O
with	O
very	B-Lab_value
low	I-Lab_value
growth	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
2	B-Lab_value
%	I-Lab_value
and	O
a	O
size	B-Diagnostic_procedure
of	O
15	B-Distance
mm	I-Distance
(	O
Figure	O
3	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
40	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
visited	O
the	O
Department	B-Nonbiological_location
of	I-Nonbiological_location
Obstetrics	I-Nonbiological_location
and	I-Nonbiological_location
Gynecology	I-Nonbiological_location
in	O
our	B-Nonbiological_location
hospital	I-Nonbiological_location
because	O
of	O
a	O
complaint	O
of	O
sudden	B-Detailed_description
dyspnea	B-Sign_symptom
on	B-Detailed_description
effort	I-Detailed_description
.	O

She	O
was	O
previously	O
diagnosed	O
with	O
endometriosis	B-Disease_disorder
and	O
prescribed	O
a	O
combination	B-Detailed_description
oral	O
contraceptive	B-Medication
pill	O
(	O
drospirenone	B-Medication
/	O
ethinylestradiol	B-Medication
betadex	I-Medication
,	O
trade	B-Detailed_description
name	I-Detailed_description
;	I-Detailed_description
Yaz	I-Detailed_description
™	I-Detailed_description
,	O
Bayer	B-Detailed_description
,	I-Detailed_description
Leverkusen	I-Detailed_description
,	I-Detailed_description
Germany	I-Detailed_description
)	O
.	O

Following	O
the	O
Kumamoto	B-Other_event
Earthquakes	I-Other_event
and	O
subsequent	O
aftershocks	B-Other_event
in	O
April	O
2016	O
,	O
she	O
spent	B-Activity
7	B-Duration
nights	I-Duration
in	O
a	O
vehicle	B-Nonbiological_location
.	O

She	O
noticed	O
sudden	B-Detailed_description
dyspnea	B-Sign_symptom
on	B-Detailed_description
effort	I-Detailed_description
when	O
she	O
walked	O
outside	B-Nonbiological_location
the	O
car	O
on	O
the	O
8th	O
morning	O
after	O
the	O
first	B-Other_event
earthquake	I-Other_event
.	O

Although	O
she	O
walked	B-Activity
around	I-Activity
for	O
personal	O
reasons	O
during	O
the	O
daytime	O
,	O
she	O
spent	B-Activity
nights	I-Activity
in	O
her	O
small	B-Nonbiological_location
car	I-Nonbiological_location
with	O
her	O
legs	B-Biological_structure
in	O
a	O
hanging	B-Detailed_description
position	I-Detailed_description
.	O

She	O
noticed	O
swelling	B-Sign_symptom
and	O
pain	B-Sign_symptom
in	O
her	O
left	B-Biological_structure
lower	I-Biological_structure
extremity	I-Biological_structure
,	O
and	O
her	O
serum	B-Diagnostic_procedure
D	I-Diagnostic_procedure
-	I-Diagnostic_procedure
dimer	I-Diagnostic_procedure
levels	O
were	O
13	B-Lab_value
.	I-Lab_value
2	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Deep	B-Disease_disorder
vein	I-Disease_disorder
thrombosis	I-Disease_disorder
(	O
DVT	B-Disease_disorder
)	O
was	O
suspected	O
by	O
her	O
home	B-Nonbiological_location
doctor	I-Nonbiological_location
.	O

A	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
-	O
scan	O
revealed	O
a	O
contrast	B-Sign_symptom
deficit	I-Sign_symptom
in	O
the	O
bilateral	B-Biological_structure
pulmonary	I-Biological_structure
artery	I-Biological_structure
(	O
Fig	O
.	O
2A	O
)	O
and	O
in	O
the	O
left	B-Biological_structure
lower	I-Biological_structure
extremity	I-Biological_structure
(	O
posterior	B-Detailed_description
tibial	I-Detailed_description
,	I-Detailed_description
soleus	I-Detailed_description
and	I-Detailed_description
gastrocnemius	I-Detailed_description
vein	I-Detailed_description
)	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Her	O
right	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
function	I-Diagnostic_procedure
was	O
intact	B-Lab_value
(	O
estimated	O
pulmonary	B-Diagnostic_procedure
artery	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
=	O
29	B-Lab_value
/	I-Lab_value
8	I-Lab_value
mmHg	I-Lab_value
in	O
cardiac	B-Biological_structure
ultrasound	B-Diagnostic_procedure
)	O
.	O

Her	O
plasma	B-Detailed_description
brain	B-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
and	O
high	B-Detailed_description
-	I-Detailed_description
sense	I-Detailed_description
troponin	B-Diagnostic_procedure
T	I-Diagnostic_procedure
concentration	I-Diagnostic_procedure
levels	O
were	O
97	B-Lab_value
.	I-Lab_value
2	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
and	O
0	B-Lab_value
.	I-Lab_value
0061	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
respectively	O
.	O

She	O
was	O
diagnosed	O
with	O
PTE	B-Disease_disorder
and	O
admitted	O
to	O
our	O
department	B-Nonbiological_location
.	O

On	O
admission	O
,	O
her	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
129	B-Lab_value
/	I-Lab_value
80	I-Lab_value
mmHg	I-Lab_value
and	O
her	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
72	B-Lab_value
beats	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
.	O

Her	O
degree	O
of	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
(	O
SaO2	B-Diagnostic_procedure
)	O
in	O
arterial	B-Detailed_description
blood	I-Detailed_description
gas	I-Detailed_description
was	O
97	B-Lab_value
.	I-Lab_value
7	I-Lab_value
%	I-Lab_value
.	O

Her	O
body	B-Diagnostic_procedure
mass	I-Diagnostic_procedure
index	I-Diagnostic_procedure
was	O
24	B-Lab_value
.	I-Lab_value
4	I-Lab_value
kg	I-Lab_value
/	I-Lab_value
m2	I-Lab_value
.	O

Electrocardiography	B-Diagnostic_procedure
and	O
cardiac	B-Biological_structure
ultrasound	B-Diagnostic_procedure
did	O
not	O
indicate	O
heart	B-Disease_disorder
failure	I-Disease_disorder
.	O

An	O
investigation	O
of	O
most	O
factors	B-Diagnostic_procedure
related	I-Diagnostic_procedure
to	I-Diagnostic_procedure
thrombus	I-Diagnostic_procedure
formation	I-Diagnostic_procedure
(	O
including	O
protein	B-Diagnostic_procedure
C	I-Diagnostic_procedure
,	O
protein	B-Diagnostic_procedure
S	I-Diagnostic_procedure
,	O
antithrombin	B-Diagnostic_procedure
,	O
and	O
antiphospholipid	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
)	O
revealed	O
that	O
all	O
such	O
factors	O
were	O
normal	B-Lab_value
.	O

The	O
discontinuation	O
of	O
the	O
oral	O
contraceptive	B-Medication
and	O
the	O
administration	O
of	O
rivaroxaban	B-Medication
(	O
30	B-Dosage
mg	I-Dosage
,	I-Dosage
daily	I-Dosage
)	O
,	O
a	O
direct	B-Detailed_description
oral	O
anticoagulant	B-Medication
(	O
trade	B-Detailed_description
name	I-Detailed_description
:	I-Detailed_description
Xarelto	I-Detailed_description
™	I-Detailed_description
,	O
Bayer	B-Detailed_description
)	O
was	O
initiated	O
according	B-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
results	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
EINSTEIN	I-Detailed_description
-	I-Detailed_description
PE	I-Detailed_description
trial	I-Detailed_description
(	O
3	O
)	O
.	O

After	O
7	O
days	O
,	O
a	O
follow	O
-	O
up	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
scan	O
revealed	O
a	O
reduction	O
in	O
the	O
thrombosis	B-Disease_disorder
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
patient	O
was	O
followed	O
up	O
with	O
rivaroxaban	B-Medication
.	O

The	O
patient	O
gave	O
her	O
consent	O
for	O
the	O
publication	O
of	O
this	O
study	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
68	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
referred	O
to	O
the	O
Internal	B-Nonbiological_location
Medicine	I-Nonbiological_location
Department	I-Nonbiological_location
of	O
Razi	B-Nonbiological_location
Hospital	I-Nonbiological_location
in	O
Rasht	B-Nonbiological_location
(	O
a	B-Nonbiological_location
city	I-Nonbiological_location
in	I-Nonbiological_location
the	I-Nonbiological_location
north	I-Nonbiological_location
of	I-Nonbiological_location
Iran	I-Nonbiological_location
)	O
with	O
a	O
hypogastric	B-Biological_structure
region	I-Biological_structure
discomfort	B-Sign_symptom
,	O
especially	O
in	O
the	O
right	B-Biological_structure
lower	I-Biological_structure
quadrant	I-Biological_structure
for	O
one	B-Duration
month	I-Duration
.	O

The	O
pain	O
was	O
a	O
colicky	B-Detailed_description
form	I-Detailed_description
which	O
had	O
a	B-Frequency
few	I-Frequency
episodes	I-Frequency
each	I-Frequency
day	I-Frequency
,	O
each	B-Detailed_description
episode	I-Detailed_description
lasting	I-Detailed_description
for	I-Detailed_description
4	I-Detailed_description
-	I-Detailed_description
5	I-Detailed_description
minutes	I-Detailed_description
.	O

The	O
pain	O
radiated	O
to	O
the	O
back	B-Nonbiological_location
and	O
was	O
alleviated	B-Sign_symptom
by	O
resting	B-Activity
to	I-Activity
one	I-Activity
side	I-Activity
.	O

No	O
association	O
between	O
the	O
pain	O
,	O
defecation	O
,	O
and	O
eating	O
were	O
reported	O
.	O

Furthermore	O
,	O
the	O
patient	O
complained	O
of	O
a	O
2	B-Lab_value
-	I-Lab_value
3	I-Lab_value
kg	I-Lab_value
weight	B-Sign_symptom
loss	I-Sign_symptom
over	O
the	O
last	B-Duration
one	I-Duration
month	I-Duration
followed	O
by	O
anorexia	B-Sign_symptom
.	O

However	O
,	O
no	O
symptoms	O
of	O
nausea	B-Sign_symptom
,	O
vomiting	B-Sign_symptom
,	O
fever	B-Sign_symptom
,	O
or	O
shaking	B-Sign_symptom
chills	I-Sign_symptom
were	O
demonstrated	O
.	O

He	O
was	O
first	O
admitted	O
to	O
another	B-Nonbiological_location
center	I-Nonbiological_location
for	O
a	B-Duration
week	I-Duration
,	O
then	O
was	O
referred	O
to	O
our	B-Nonbiological_location
hospital	I-Nonbiological_location
for	O
further	O
evaluation	O
.	O

The	O
patient	O
had	O
undergone	O
a	O
surgery	B-Therapeutic_procedure
for	O
prostatectomy	B-Therapeutic_procedure
seven	O
years	O
before	O
his	O
presentation	O
to	O
our	B-Nonbiological_location
center	I-Nonbiological_location
.	O

Also	O
,	O
he	O
had	O
a	O
history	O
of	O
endoscopy	B-Diagnostic_procedure
five	O
years	O
earlier	O
due	O
to	O
dyspepsia	B-Disease_disorder
,	O
which	O
was	O
found	O
to	O
be	O
Helicobacter	B-Diagnostic_procedure
pylori	I-Diagnostic_procedure
positive	B-Lab_value
at	O
that	O
time	O
and	O
which	O
was	O
eradicated	B-Sign_symptom
after	O
a	O
treatment	B-Therapeutic_procedure
course	I-Therapeutic_procedure
.	O

No	O
history	O
of	O
HIV	O
,	O
diabetes	O
,	O
smoking	O
,	O
or	O
alcohol	O
consumption	O
was	O
recorded	O
.	O

His	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
normal	B-Lab_value
at	O
the	O
time	O
of	O
admission	O
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
the	O
abdomen	B-Biological_structure
was	O
soft	B-Sign_symptom
,	O
there	O
was	O
no	O
distention	B-Sign_symptom
,	O
and	O
bowel	B-Diagnostic_procedure
sounds	I-Diagnostic_procedure
were	O
normoactive	B-Lab_value
.	O

However	O
,	O
tenderness	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
lower	I-Biological_structure
quadrant	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
abdomen	I-Biological_structure
with	O
no	B-Lab_value
rebound	B-Diagnostic_procedure
state	I-Diagnostic_procedure
was	O
noted	O
.	O

The	O
peripheral	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
is	O
shown	O
in	O
Table	O
1	O
.	O

Stool	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
urine	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
,	O
and	O
evaluation	B-Diagnostic_procedure
of	I-Diagnostic_procedure
electrolytes	I-Diagnostic_procedure
were	O
all	O
normal	B-Lab_value
.	O

An	O
abdominal	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
showed	O
a	O
well	B-Detailed_description
-	I-Detailed_description
demarcated	I-Detailed_description
and	O
homogenous	B-Detailed_description
solitary	B-Detailed_description
mass	B-Sign_symptom
in	O
the	O
cecum	B-Biological_structure
with	O
no	O
distention	B-Sign_symptom
in	O
the	O
ileum	B-Biological_structure
.	O

The	O
ileum	B-Biological_structure
wall	I-Biological_structure
was	O
thickened	B-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

A	O
colonoscopy	B-Diagnostic_procedure
revealed	O
a	O
large	B-Lab_value
mass	B-Detailed_description
like	I-Detailed_description
lesion	B-Sign_symptom
in	O
the	O
cecum	B-Biological_structure
(	O
Figure	O
2	O
)	O
;	O
during	O
the	O
procedure	O
a	O
biopsy	B-Diagnostic_procedure
was	O
taken	O
from	O
the	O
cecum	B-Biological_structure
.	O

The	O
lamina	B-Biological_structure
propria	I-Biological_structure
was	O
infiltrated	B-Sign_symptom
by	O
a	O
number	O
of	O
PMNCs	B-Biological_structure
admixed	O
by	O
some	O
eosinophils	B-Biological_structure
(	O
Figure	O
3	O
)	O
.	O

Immunohistochemical	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
was	O
positive	B-Lab_value
for	O
vimentin	B-Diagnostic_procedure
and	O
CD68	B-Diagnostic_procedure
.	O

C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Kit	I-Diagnostic_procedure
(	O
CD117	B-Diagnostic_procedure
)	O
was	O
negative	B-Lab_value
while	O
CD34	B-Diagnostic_procedure
,	O
smooth	B-Diagnostic_procedure
muscle	I-Diagnostic_procedure
actin	I-Diagnostic_procedure
(	O
SMA	B-Diagnostic_procedure
)	O
,	O
and	O
ALK	B-Diagnostic_procedure
were	O
focally	B-Lab_value
positive	I-Lab_value
.	O

There	O
were	O
no	B-Lab_value
reports	I-Lab_value
of	O
cyclin	B-Diagnostic_procedure
D1	I-Diagnostic_procedure
,	O
desmin	B-Diagnostic_procedure
,	O
or	O
pancytokeratin	B-Diagnostic_procedure
(	O
Figure	O
4	O
)	O
.	O
When	O
the	O
colonoscopy	O
was	O
performed	O
,	O
the	O
evidences	O
of	O
invasive	O
obstruction	O
lead	O
us	O
to	O
the	O
suspicion	O
of	O
a	O
malignant	B-Disease_disorder
tumor	I-Disease_disorder
.	O

After	O
pathological	O
confirmation	O
of	O
IMT	B-Disease_disorder
,	O
the	O
patient	O
was	O
referred	O
for	O
surgery	B-Therapeutic_procedure
in	O
order	O
to	O
remove	O
the	O
mass	O
.	O

On	O
surgery	O
,	O
approximately	O
40	B-Volume
mL	I-Volume
ascites	B-Sign_symptom
were	O
found	O
in	O
the	O
abdomen	B-Biological_structure
.	O

A	O
mass	B-Sign_symptom
was	O
seen	O
in	O
the	O
cecum	B-Biological_structure
with	O
ileocolic	B-Biological_structure
intussusception	B-Sign_symptom
.	O

Afterwards	O
,	O
the	O
patient	O
underwent	O
right	B-Detailed_description
hemicolectomy	B-Therapeutic_procedure
with	O
an	O
end	B-Detailed_description
-	I-Detailed_description
to	I-Detailed_description
-	I-Detailed_description
end	I-Detailed_description
anastomosis	B-Therapeutic_procedure
of	I-Therapeutic_procedure
ileocolic	I-Therapeutic_procedure
.	O

No	O
enlarge	B-Sign_symptom
lymph	B-Biological_structure
nodes	I-Biological_structure
were	O
observed	O
.	O

The	O
patient	O
was	O
discharged	O
seven	O
days	O
after	O
surgery	O
and	O
had	O
no	O
complications	B-Sign_symptom
during	O
follow	O
-	O
up	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
72	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
underwent	O
RF	B-Therapeutic_procedure
ablation	I-Therapeutic_procedure
for	O
the	O
treatment	O
of	O
a	O
metachronous	B-Detailed_description
solitary	B-Detailed_description
liver	B-Biological_structure
metastasis	B-Disease_disorder
from	O
rectal	B-Biological_structure
adenocarcinoma	B-Disease_disorder
,	O
which	O
had	O
been	O
treated	O
18	O
mo	O
before	O
with	O
preoperative	B-Detailed_description
chemoradiotherapy	B-Therapeutic_procedure
and	O
anterior	B-Therapeutic_procedure
resection	I-Therapeutic_procedure
.	O

The	O
lesion	O
was	O
located	O
in	O
segment	B-Biological_structure
VIII	I-Biological_structure
.	O

The	O
procedure	O
went	O
well	B-Lab_value
and	O
the	O
patient	O
was	O
initially	O
haemodynamically	B-Diagnostic_procedure
stable	B-Lab_value
.	O

One	B-Time
hour	I-Time
later	I-Time
her	O
condition	B-Diagnostic_procedure
suddenly	B-Severity
worsened	I-Severity
.	O

She	O
was	O
clinically	O
dizzy	B-Sign_symptom
and	O
had	O
fatigue	B-Sign_symptom
and	O
pallor	B-Sign_symptom
.	O

We	O
detected	O
hypotension	B-Sign_symptom
and	O
tachycardia	B-Sign_symptom
.	O

Emergency	O
blood	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
a	O
haemoglobin	B-Diagnostic_procedure
level	I-Diagnostic_procedure
of	O
<	B-Lab_value
7	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
and	O
markedly	O
elevated	B-Lab_value
transaminase	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
.	O

A	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
an	O
accumulation	O
of	O
intraperitoneal	B-Biological_structure
fluid	I-Biological_structure
in	O
the	O
pelvis	B-Biological_structure
and	O
two	B-Lab_value
liver	B-Biological_structure
haematomas	B-Disease_disorder
.	O

The	O
images	O
showed	O
two	B-Lab_value
liver	B-Biological_structure
lacerations	B-Sign_symptom
,	O
one	B-Detailed_description
following	I-Detailed_description
the	I-Detailed_description
path	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
needle	I-Detailed_description
(	O
Figure	O
(	O
Figure1A1A	O
-	O
-	O
C	O
)	O
C	O
)	O
and	O
another	O
,	O
unexplained	B-Detailed_description
laceration	I-Detailed_description
leading	I-Detailed_description
away	I-Detailed_description
from	I-Detailed_description
the	I-Detailed_description
first	I-Detailed_description
(	O
Figure	O
(	O
Figure2	O
)	O
.	O
2	O
)	O
.	O

The	O
patient	O
had	O
no	O
serious	O
coughing	B-Sign_symptom
or	O
hiccupping	B-Sign_symptom
after	O
the	O
RF	O
treatment	O
,	O
or	O
any	O
other	O
complications	O
that	O
might	O
have	O
caused	O
increased	O
abdominal	O
pressure	O
and	O
tumour	O
rupture	O
.	O

Subsequently	O
,	O
the	O
patient	O
received	O
a	O
blood	B-Therapeutic_procedure
transfusion	I-Therapeutic_procedure
and	O
close	B-Diagnostic_procedure
monitoring	I-Diagnostic_procedure
.	O

She	O
was	O
haemodynamically	B-Diagnostic_procedure
stable	B-Lab_value
after	O
the	O
second	B-Lab_value
blood	B-Therapeutic_procedure
transfusion	I-Therapeutic_procedure
and	O
completely	B-Sign_symptom
recovered	I-Sign_symptom
24	B-Time
h	I-Time
later	I-Time
.	O

The	O
patient	O
remained	B-Activity
in	I-Activity
bed	I-Activity
for	O
1	B-Duration
wk	I-Duration
.	O

No	O
surgical	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
was	O
required	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
70	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
gastric	B-Biological_structure
cancer	B-Disease_disorder
that	O
was	O
detected	O
during	O
screening	O
by	O
esophagogastroduodenoscopy	B-Diagnostic_procedure
(	B-Diagnostic_procedure
EGD	I-Diagnostic_procedure
)	I-Diagnostic_procedure
.	O

No	O
significant	O
medical	O
history	O
was	O
identified	O
,	O
except	O
dysuria	B-Sign_symptom
caused	B-Detailed_description
by	I-Detailed_description
bladder	I-Detailed_description
contraction	I-Detailed_description
.	O

Initial	O
laboratory	B-Diagnostic_procedure
data	O
showed	O
a	O
serum	B-Diagnostic_procedure
level	I-Diagnostic_procedure
of	I-Diagnostic_procedure
AFP	I-Diagnostic_procedure
of	O
32	B-Lab_value
.	I-Lab_value
3	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
range	O
:	O
0	O
-	O
15	O
ng	O
/	O
mL	O
)	O
,	O
but	O
no	B-Lab_value
other	I-Lab_value
abnormality	I-Lab_value
,	O
which	O
included	O
other	O
tumor	O
markers	O
,	O
such	O
as	O
,	O
carcinoembryonic	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
(	B-Diagnostic_procedure
CEA	I-Diagnostic_procedure
)	I-Diagnostic_procedure
and	O
carbohydrate	B-Diagnostic_procedure
antigen	I-Diagnostic_procedure
19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
(	B-Diagnostic_procedure
CA19	I-Diagnostic_procedure
-	I-Diagnostic_procedure
9	I-Diagnostic_procedure
)	I-Diagnostic_procedure
.	O

EGD	O
revealed	O
a	O
5	B-Distance
-	I-Distance
cm	I-Distance
ulcerofungating	B-Detailed_description
mass	B-Sign_symptom
that	O
was	O
comprised	B-Detailed_description
of	I-Detailed_description
three	I-Detailed_description
septate	I-Detailed_description
ulcers	I-Detailed_description
in	B-Biological_structure
the	I-Biological_structure
greater	I-Biological_structure
curvature	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
gastric	I-Biological_structure
antrum	I-Biological_structure
.	O

A	O
pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
endoscopic	B-Biological_structure
biopsy	I-Biological_structure
tissues	I-Biological_structure
confirmed	O
the	O
presence	O
of	O
moderately	B-Detailed_description
differentiated	I-Detailed_description
tubular	B-Detailed_description
adenocarcinoma	B-Disease_disorder
.	O

Subsequent	O
abdominopelvic	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
visualized	O
a	O
gastric	B-Biological_structure
mass	B-Sign_symptom
with	B-Detailed_description
deep	I-Detailed_description
ulceration	I-Detailed_description
in	B-Biological_structure
the	I-Biological_structure
gastric	I-Biological_structure
antrum	I-Biological_structure
with	B-Detailed_description
perigastric	I-Detailed_description
lymph	I-Detailed_description
node	I-Detailed_description
enlargement	I-Detailed_description
.	O

No	O
metastatic	B-Sign_symptom
lesions	I-Sign_symptom
were	O
observed	O
in	O
the	O
liver	B-Biological_structure
,	O
lung	B-Biological_structure
or	O
peritoneum	B-Biological_structure
,	O
and	O
chest	B-Biological_structure
radiography	B-Diagnostic_procedure
showed	O
no	B-Sign_symptom
significant	I-Sign_symptom
findings	I-Sign_symptom
.	O

Radical	B-Detailed_description
subtotal	B-Detailed_description
gastrectomy	B-Therapeutic_procedure
with	O
D2	B-Biological_structure
lymph	I-Biological_structure
node	I-Biological_structure
dissection	B-Therapeutic_procedure
and	O
Billroth	B-Detailed_description
II	I-Detailed_description
gastrojejunostomy	B-Therapeutic_procedure
were	O
performed	O
.	O

Grossly	O
,	O
the	O
resected	B-Biological_structure
specimen	I-Biological_structure
contained	O
double	B-Lab_value
lesions	B-Sign_symptom
:	O
the	O
first	O
was	O
a	B-Detailed_description
5	I-Detailed_description
.	I-Detailed_description
8	I-Detailed_description
cm	I-Detailed_description
×	I-Detailed_description
3	I-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
cm	I-Detailed_description
ulcerofungating	I-Detailed_description
mass	I-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
antrum	I-Detailed_description
,	O
with	O
extensive	B-Detailed_description
hemorrhage	I-Detailed_description
and	O
light	B-Color
gray	I-Color
fibrosis	B-Detailed_description
;	O
and	O
the	O
second	O
was	O
a	B-Detailed_description
nearby	I-Detailed_description
2	I-Detailed_description
.	I-Detailed_description
5	I-Detailed_description
cm	I-Detailed_description
×	I-Detailed_description
2	I-Detailed_description
.	I-Detailed_description
0	I-Detailed_description
cm	I-Detailed_description
ulcerative	I-Detailed_description
lesion	I-Detailed_description
(	O
Figure	O
1	O
)	O
.	O

Microscopically	O
,	O
massive	B-Lab_value
numbers	I-Lab_value
of	O
pleomorphic	B-Detailed_description
,	O
bizarre	B-Detailed_description
tumor	B-Sign_symptom
cells	I-Sign_symptom
with	O
hemorrhage	B-Detailed_description
(	I-Detailed_description
syncytiotrophoblasts	I-Detailed_description
and	I-Detailed_description
cytotrophoblasts	I-Detailed_description
)	I-Detailed_description
were	O
observed	O
in	O
the	O
first	O
lesion	O
.	O

Hematoxylin	B-Diagnostic_procedure
and	I-Diagnostic_procedure
eosin	I-Diagnostic_procedure
(	I-Diagnostic_procedure
HE	I-Diagnostic_procedure
)	I-Diagnostic_procedure
-	I-Diagnostic_procedure
stained	I-Diagnostic_procedure
tissues	I-Diagnostic_procedure
revealed	O
a	O
bubbly	B-Shape
purple	B-Color
cytoplasm	B-Biological_structure
and	O
giant	B-Lab_value
nuclei	B-Biological_structure
at	O
a	O
magnification	B-Detailed_description
of	I-Detailed_description
40	I-Detailed_description
×	I-Detailed_description
(	O
Figure	O
2A	O
)	O
and	O
100	B-Detailed_description
×	I-Detailed_description
(	O
Figure	O
2B	O
)	O
.	O

The	O
tumor	O
involved	O
the	O
proper	B-Biological_structure
muscle	I-Biological_structure
layer	I-Biological_structure
(	I-Biological_structure
T2a	I-Biological_structure
)	I-Biological_structure
and	O
metastasis	B-Sign_symptom
was	O
found	O
in	B-Biological_structure
four	I-Biological_structure
of	I-Biological_structure
56	I-Biological_structure
regional	I-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
(	O
N1	O
)	O
.	O

Immunohistochemical	B-Diagnostic_procedure
staining	I-Diagnostic_procedure
showed	O
positive	B-Lab_value
immunoreactivity	I-Lab_value
for	O
β	B-Diagnostic_procedure
-	I-Diagnostic_procedure
human	I-Diagnostic_procedure
chorionic	I-Diagnostic_procedure
gonadotropin	I-Diagnostic_procedure
(	O
HCG	O
)	O
(	O
Figure	O
3A	O
)	O
and	O
focal	B-Lab_value
positivity	I-Lab_value
for	O
AFP	B-Diagnostic_procedure
(	O
Figure	O
3B	O
)	O
.	O

These	O
findings	O
confirmed	O
the	O
presence	O
of	O
gastric	B-Biological_structure
choriocarcinoma	B-Disease_disorder
that	O
contained	O
small	O
foci	O
of	O
an	O
AFP	B-Detailed_description
-	I-Detailed_description
producing	I-Detailed_description
adenocarcinoma	B-Disease_disorder
.	O

The	O
second	O
lesion	O
was	O
moderately	O
differentiated	O
tubular	B-Biological_structure
adenocarcinoma	B-Disease_disorder
,	O
which	O
extended	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
submucosal	I-Biological_structure
layer	I-Biological_structure
(	O
T1b	O
)	O
.	O

It	O
was	O
close	O
to	O
,	O
but	O
distinct	O
from	O
the	O
first	O
lesion	O
,	O
which	O
was	O
negative	O
by	O
immunohistochemical	O
staining	O
for	O
β	O
-	O
HCG	O
and	O
AFP	O
.	O

The	O
patient	O
had	O
an	O
uneventful	B-Lab_value
postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
and	O
was	O
discharged	O
on	O
postoperative	O
day	O
9	O
.	O

Two	O
weeks	O
later	O
,	O
his	O
HCG	B-Diagnostic_procedure
level	I-Diagnostic_procedure
was	O
176	B-Lab_value
mIU	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
range	O
:	O
0	O
-	O
10	O
mIU	O
/	O
mL	O
)	O
and	O
his	O
AFP	B-Diagnostic_procedure
level	I-Diagnostic_procedure
was	O
10	B-Lab_value
.	I-Lab_value
0	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Six	B-Frequency
cycles	I-Frequency
of	O
adjuvant	B-Medication
chemotherapy	I-Medication
with	O
capecitabine	B-Medication
(	O
Xeloda	O
;	O
Hoffmann	O
-	O
La	O
Roche	O
Inc	O
.	O
,	O
Nutley	O
,	O
NJ	O
,	O
USA	O
)	O
was	O
started	O
at	O
2500	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
per	I-Dosage
day	I-Dosage
for	I-Dosage
14	I-Dosage
d	I-Dosage
/	I-Dosage
cycle	I-Dosage
.	O

After	O
two	O
cycles	O
,	O
his	O
β	B-Diagnostic_procedure
-	I-Diagnostic_procedure
HCG	I-Diagnostic_procedure
level	I-Diagnostic_procedure
had	O
declined	B-Lab_value
to	O
<	B-Lab_value
3	I-Lab_value
mIU	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
and	O
has	O
since	O
remained	O
at	O
this	O
level	O
.	O

No	O
recurrence	B-Sign_symptom
or	O
distant	B-Sign_symptom
metastasis	I-Sign_symptom
had	O
occurred	O
at	O
his	O
4	O
-	O
year	O
postoperative	O
follow	O
-	O
up	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
41	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
with	O
a	O
history	O
of	O
alcoholism	O
for	O
10	B-Duration
years	I-Duration
and	O
sober	O
for	O
the	O
last	B-Duration
3	I-Duration
years	I-Duration
,	O
recurrent	O
alcoholic	O
pancreatitis	O
,	O
and	O
no	O
known	O
liver	O
disease	O
,	O
presented	O
with	O
several	B-Detailed_description
episodes	I-Detailed_description
of	O
hematemesis	B-Sign_symptom
and	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
for	O
2	B-Duration
days	I-Duration
.	O

Esophagogastroduodenoscopy	B-Diagnostic_procedure
(	O
EGD	B-Diagnostic_procedure
)	O
,	O
performed	O
3	O
years	O
earlier	O
for	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
had	O
revealed	O
no	O
esophageal	B-Biological_structure
varices	B-Sign_symptom
,	O
gastric	B-Biological_structure
varices	B-Sign_symptom
,	O
portal	B-Biological_structure
hypertensive	B-Detailed_description
gastropathy	B-Disease_disorder
,	O
or	O
other	O
GI	B-Biological_structure
lesions	B-Sign_symptom
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
=	O
100	B-Lab_value
/	I-Lab_value
60	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
pulse	B-Diagnostic_procedure
=	O
60	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
no	O
jaundice	B-Sign_symptom
,	O
no	O
stigmata	B-Sign_symptom
of	I-Sign_symptom
chronic	I-Sign_symptom
liver	I-Sign_symptom
disease	I-Sign_symptom
,	O
a	O
soft	B-Sign_symptom
abdomen	B-Biological_structure
with	O
mild	B-Severity
epigastric	B-Biological_structure
tenderness	B-Sign_symptom
but	O
no	O
rebound	B-Detailed_description
tenderness	B-Sign_symptom
,	O
no	O
abdominal	B-Biological_structure
bruit	B-Sign_symptom
,	O
and	O
no	O
pulsatile	B-Detailed_description
abdominal	B-Biological_structure
mass	B-Sign_symptom
.	O

Rectal	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
gross	O
melena	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
revealed	O
hemoglobin	B-Diagnostic_procedure
=	O
12	B-Lab_value
.	I-Lab_value
5	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
platelets	B-Diagnostic_procedure
=	O
301,000	B-Lab_value
/	I-Lab_value
mL	I-Lab_value
,	O
INR	B-Diagnostic_procedure
(	O
international	B-Diagnostic_procedure
normalized	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
)	O
=	O
1	B-Lab_value
.	I-Lab_value
0	I-Lab_value
,	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
nitrogen	I-Diagnostic_procedure
=	O
20	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
and	O
creatinine	B-Diagnostic_procedure
=	O
1	B-Lab_value
.	I-Lab_value
1	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Serum	B-Diagnostic_procedure
aspartate	I-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
=	O
21	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
alanine	B-Diagnostic_procedure
aminotransferase	I-Diagnostic_procedure
=	O
16	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
=	O
0	B-Lab_value
.	I-Lab_value
6	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
alkaline	B-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
=	O
64	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
albumin	B-Diagnostic_procedure
=	O
4	B-Lab_value
.	I-Lab_value
4	I-Lab_value
gm	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
and	O
lipase	B-Diagnostic_procedure
=	O
32	B-Lab_value
U	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

The	O
hemoglobin	B-Diagnostic_procedure
declined	B-Lab_value
acutely	I-Lab_value
to	O
9	B-Lab_value
.	I-Lab_value
3	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Abdomino	B-Biological_structure
-	I-Biological_structure
pelvic	I-Biological_structure
computerized	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
,	O
with	O
intravenous	B-Detailed_description
contrast	I-Detailed_description
,	I-Detailed_description
revealed	O
a	O
5	B-Distance
-	I-Distance
cm	I-Distance
wide	O
,	O
irregular	B-Detailed_description
,	O
pancreatic	B-Biological_structure
/	O
peripancreatic	B-Biological_structure
mass	B-Sign_symptom
,	O
compressing	B-Sign_symptom
both	O
the	O
lesser	B-Biological_structure
curvature	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
stomach	I-Biological_structure
and	O
the	O
SV	B-Biological_structure
(	O
Fig	O
.	O
1A	O
,	O
B	O
)	O
,	O
a	O
normal	B-Lab_value
portal	B-Diagnostic_procedure
vein	I-Diagnostic_procedure
,	O
and	O
normal	B-Lab_value
liver	B-Diagnostic_procedure
parenchyma	I-Diagnostic_procedure
.	O

The	O
SV	B-Biological_structure
compression	B-Sign_symptom
was	O
pathophysiologically	B-Lab_value
significant	I-Lab_value
as	O
indicated	O
by	O
proximal	B-Biological_structure
SV	I-Biological_structure
dilatation	B-Sign_symptom
.	O

EGD	B-Diagnostic_procedure
revealed	O
in	O
the	O
proximal	B-Biological_structure
stomach	I-Biological_structure
a	O
fine	B-Detailed_description
,	O
reticular	B-Detailed_description
,	O
pale	B-Color
-	I-Color
white	I-Color
,	O
polygonal	B-Shape
,	O
mucosal	B-Biological_structure
,	O
network	B-Sign_symptom
in	O
a	O
snakeskin	B-Texture
pattern	I-Texture
,	O
and	O
characteristic	O
of	O
portal	B-Disease_disorder
hypertensive	I-Disease_disorder
gastropathy	I-Disease_disorder
that	O
was	O
actively	O
oozing	B-Sign_symptom
;	O
extensive	B-Severity
coffee	B-Texture
-	I-Texture
ground	I-Texture
,	O
blood	B-Sign_symptom
clots	I-Sign_symptom
in	O
the	O
stomach	B-Biological_structure
;	O
small	O
gastric	B-Biological_structure
cardial	B-Biological_structure
and	O
fundal	B-Biological_structure
varices	B-Sign_symptom
without	O
stigmata	B-Sign_symptom
of	I-Sign_symptom
recent	I-Sign_symptom
hemorrhage	I-Sign_symptom
(	O
SRH	B-Sign_symptom
)	O
;	O
and	O
no	O
esophageal	B-Biological_structure
varices	B-Sign_symptom
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
extrinsic	O
mass	O
produced	O
a	O
large	B-Detailed_description
,	O
round	B-Shape
bulge	B-Sign_symptom
extending	B-Biological_structure
into	I-Biological_structure
the	I-Biological_structure
lumen	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
proximal	I-Biological_structure
gastric	I-Biological_structure
body	I-Biological_structure
along	O
the	O
lesser	B-Biological_structure
curvature	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
cholangio	I-Diagnostic_procedure
-	I-Diagnostic_procedure
pancreatography	I-Diagnostic_procedure
(	O
MRCP	B-Diagnostic_procedure
)	O
revealed	O
a	O
5	B-Distance
-	I-Distance
cm	I-Distance
wide	O
,	O
enhancing	B-Detailed_description
,	O
vascular	B-Biological_structure
mass	B-Sign_symptom
likely	O
arising	B-Biological_structure
from	I-Biological_structure
the	I-Biological_structure
LGA	I-Biological_structure
and	O
located	O
between	B-Biological_structure
the	I-Biological_structure
gastric	I-Biological_structure
lesser	I-Biological_structure
curvature	I-Biological_structure
and	I-Biological_structure
distal	I-Biological_structure
pancreatic	I-Biological_structure
body	I-Biological_structure
;	O
compressing	B-Sign_symptom
the	O
stomach	B-Biological_structure
;	O
compressing	B-Sign_symptom
the	O
middle	B-Biological_structure
SV	I-Biological_structure
;	O
and	O
resulting	O
in	O
large	B-Detailed_description
collateral	B-Sign_symptom
veins	I-Sign_symptom
draining	O
the	O
SV	B-Biological_structure
into	O
the	O
superior	B-Biological_structure
mesenteric	I-Biological_structure
vein	I-Biological_structure
(	O
Fig	O
.	O
3A	O
,	O
B	O
)	O
.	O

Abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
with	O
Doppler	B-Detailed_description
studies	I-Detailed_description
demonstrated	O
large	B-Detailed_description
,	O
turbulent	B-Detailed_description
arterial	B-Biological_structure
flow	B-Sign_symptom
into	O
this	O
vascular	B-Biological_structure
mass	O
,	O
suggesting	O
a	O
large	B-Detailed_description
PA	B-Disease_disorder
(	O
Fig	O
.	O
4	O
)	O
.	O

Visceral	B-Detailed_description
arteriogram	B-Diagnostic_procedure
showed	O
a	O
5	B-Volume
.	I-Volume
3	I-Volume
×	I-Volume
2	I-Volume
.	I-Volume
2	I-Volume
-	I-Volume
cm	I-Volume
-	I-Volume
wide	I-Volume
PA	B-Disease_disorder
supplied	O
by	O
an	O
LGA	B-Biological_structure
branch	I-Biological_structure
(	O
Fig	O
.	O
5A	O
)	O
,	O
which	O
was	O
embolized	B-Therapeutic_procedure
and	O
occluded	B-Therapeutic_procedure
with	O
microcoils	B-Detailed_description
(	O
Fig	O
.	O
5B	O
)	O
.	O

Eight	O
weeks	O
later	O
,	O
the	O
patient	O
had	O
a	O
stable	B-Lab_value
hemoglobin	B-Diagnostic_procedure
level	O
with	O
no	O
further	O
GI	B-Biological_structure
bleeding	B-Sign_symptom
.	O

Abdomino	B-Biological_structure
-	I-Biological_structure
pelvic	I-Biological_structure
CT	B-Detailed_description
angiography	B-Diagnostic_procedure
demonstrated	O
the	O
PA	B-Disease_disorder
had	O
markedly	O
decreased	B-Lab_value
in	I-Lab_value
diameter	I-Lab_value
,	O
contained	B-Detailed_description
numerous	I-Detailed_description
microcoils	I-Detailed_description
,	O
and	O
had	O
no	B-Detailed_description
blood	I-Detailed_description
flow	I-Detailed_description
(	O
Fig	O
.	O
1C	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
50	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
lady	O
presented	O
with	O
complaints	O
of	O
pain	B-Sign_symptom
abdomen	B-Biological_structure
and	O
jaundice	B-Sign_symptom
for	O
one	B-Duration
and	I-Duration
a	I-Duration
half	I-Duration
months	I-Duration
;	O
she	O
also	O
complained	O
of	O
intermittent	B-Detailed_description
type	O
of	O
fever	B-Sign_symptom
in	O
the	O
last	B-Duration
1	I-Duration
week	I-Duration
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
presence	O
of	O
icterus	B-Sign_symptom
and	O
a	O
palpable	B-Detailed_description
tender	B-Detailed_description
globular	B-Shape
mass	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
hypochondrium	I-Biological_structure
measuring	O
3	B-Area
×	I-Area
3	I-Area
cm	I-Area
.	O

A	O
clinical	O
diagnosis	O
of	O
obstructive	B-Detailed_description
jaundice	B-Sign_symptom
secondary	O
to	O
periampullary	B-Disease_disorder
carcinoma	I-Disease_disorder
was	O
made	O
.	O

Ultrasonographic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
abdomen	B-Biological_structure
and	O
pelvis	B-Biological_structure
revealed	O
dilatation	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
intrahepatic	B-Biological_structure
biliary	I-Biological_structure
radicles	I-Biological_structure
(	O
IHBR	B-Biological_structure
)	O
,	O
with	O
multiple	B-Detailed_description
freely	O
mobile	B-Detailed_description
gall	B-Sign_symptom
stones	I-Sign_symptom
and	O
a	O
dilated	B-Sign_symptom
common	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
(	O
CBD	B-Biological_structure
)	O
measuring	O
1	B-Distance
.	I-Distance
8	I-Distance
cm	I-Distance
with	O
sudden	B-Detailed_description
narrowing	I-Detailed_description
at	I-Detailed_description
its	I-Detailed_description
distal	I-Detailed_description
end	I-Detailed_description
.	O

CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
showed	O
moderate	B-Severity
dilatation	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
extra	I-Sign_symptom
and	I-Sign_symptom
intrahepatic	I-Sign_symptom
biliary	I-Sign_symptom
radicles	I-Sign_symptom
,	O
cholelithiasis	B-Sign_symptom
with	O
suspicious	O
thickening	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
gall	I-Sign_symptom
bladder	I-Sign_symptom
wall	I-Sign_symptom
at	O
the	O
fundus	B-Biological_structure
,	O
and	O
a	O
distal	B-Biological_attribute
CBD	I-Biological_attribute
stricture	B-Sign_symptom
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
distant	O
metastasis	B-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
preoperative	O
diagnosis	O
of	O
periampullary	B-Disease_disorder
carcinoma	I-Disease_disorder
with	O
chronic	B-Disease_disorder
cholecystitis	I-Disease_disorder
was	O
made	O
,	O
and	O
the	O
patient	O
planned	O
for	O
a	O
pancreaticoduodenectomy	B-Therapeutic_procedure
(	O
Whipple	B-Therapeutic_procedure
`	I-Therapeutic_procedure
s	I-Therapeutic_procedure
procedure	I-Therapeutic_procedure
)	O
after	O
optimization	O
.	O

The	O
patient	O
underwent	O
a	O
classical	O
Whipple	B-Therapeutic_procedure
`	I-Therapeutic_procedure
s	I-Therapeutic_procedure
procedure	I-Therapeutic_procedure
;	O
table	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
resected	B-Biological_structure
specimen	I-Biological_structure
revealed	O
multiple	B-Detailed_description
gall	B-Sign_symptom
stones	I-Sign_symptom
in	O
the	O
gall	B-Biological_structure
bladder	I-Biological_structure
with	O
area	O
of	O
mucosal	B-Sign_symptom
thickening	I-Sign_symptom
at	O
the	O
fundus	B-Biological_structure
and	O
an	O
irregular	B-Detailed_description
circumferential	B-Detailed_description
growth	B-Sign_symptom
involving	O
the	O
intrapancreatic	B-Biological_structure
portion	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
CBD	I-Biological_structure
.	O

Postoperative	B-Therapeutic_procedure
period	I-Therapeutic_procedure
was	O
uneventful	B-Lab_value
,	O
and	O
the	O
patient	O
recovered	O
satisfactorily	B-Lab_value
.	O

Histopathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
resected	B-Biological_structure
specimen	I-Biological_structure
(	O
Figs	O
.	O
2	O
and	O
3	O
)	O
revealed	O
thickening	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
gall	I-Sign_symptom
bladder	I-Sign_symptom
wall	I-Sign_symptom
at	O
the	O
fundus	B-Biological_structure
with	O
multiple	B-Detailed_description
small	B-Detailed_description
calculi	B-Sign_symptom
,	O
the	O
largest	O
measuring	O
1	B-Distance
.	I-Distance
4	I-Distance
cm	I-Distance
(	O
Fig	O
.	O
3	O
)	O
.	O

Sections	O
studied	O
from	O
the	O
area	O
of	O
thickening	O
showed	O
features	O
suggestive	O
of	O
adenocarcinoma	B-Disease_disorder
limited	O
to	O
the	O
mucosa	B-Biological_structure
.	O

Microscopic	B-Diagnostic_procedure
sections	I-Diagnostic_procedure
obtained	O
from	O
the	O
distal	B-Biological_structure
CBD	I-Biological_structure
region	I-Biological_structure
showed	O
adenocarcinoma	B-Disease_disorder
of	O
the	O
common	B-Biological_structure
bile	I-Biological_structure
duct	I-Biological_structure
with	O
invasion	B-Detailed_description
into	O
the	O
muscular	B-Biological_structure
wall	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
duodenum	I-Biological_structure
.	O

Sections	B-Diagnostic_procedure
studied	O
from	O
the	O
resected	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
were	O
free	O
of	O
tumor	B-Sign_symptom
cells	I-Sign_symptom
.	O

A	O
pathological	O
staging	O
of	O
pT1aN0M0	B-Detailed_description
for	O
adenocarcinoma	B-Disease_disorder
of	O
the	O
gall	B-Biological_structure
bladder	I-Biological_structure
and	O
pT2N0M0	B-Detailed_description
for	O
adenocarcinoma	B-Disease_disorder
of	O
the	O
distal	B-Biological_structure
CBD	I-Biological_structure
was	O
made	O
,	O
and	O
the	O
patient	O
was	O
not	O
subjected	O
to	O
any	O
adjuvant	B-Medication
therapy	I-Medication
.	O

The	O
patient	O
was	O
disease	B-Sign_symptom
-	O
free	O
2	O
years	O
after	O
surgery	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
proband	O
(	O
II	O
-	O
2	O
in	O
Fig	O
.	O
2	O
)	O
is	O
a	O
45	B-Age
-	I-Age
year	I-Age
old	I-Age
woman	O
,	O
who	O
first	O
presented	O
to	O
our	O
university	B-Biological_structure
hospital	I-Biological_structure
at	O
the	O
age	O
of	O
35	O
and	O
was	O
referred	O
to	O
us	O
because	O
of	O
her	O
pregnancy	O
.	O

She	O
has	O
congenital	O
deafness	O
,	O
first	O
experienced	O
syncope	B-Sign_symptom
at	O
the	O
age	O
of	O
3	O
,	O
and	O
was	O
diagnosed	O
with	O
epilepsy	O
.	O

She	O
was	O
treated	O
with	O
anti	B-Medication
-	I-Medication
epilepsy	I-Medication
medications	I-Medication
;	O
however	O
,	O
she	O
subsequently	O
experienced	O
several	B-Detailed_description
instances	I-Detailed_description
of	O
syncope	B-Sign_symptom
.	O

At	O
the	O
age	O
of	O
13	O
,	O
she	O
had	O
a	O
syncope	B-Sign_symptom
event	O
,	O
and	O
was	O
suspected	O
of	O
having	O
JLNS	B-Disease_disorder
because	O
of	O
her	O
congenital	O
deafness	O
and	O
prolonged	B-Sign_symptom
QT	I-Sign_symptom
interval	I-Sign_symptom
.	O

Her	O
syncope	B-Sign_symptom
was	O
diagnosed	O
as	O
an	O
arrhythmic	B-Sign_symptom
episode	I-Sign_symptom
when	O
she	O
was	O
aware	O
of	O
tachycardia	B-Sign_symptom
and	O
as	O
epilepsy	B-Disease_disorder
when	O
she	O
was	O
not	O
.	O

She	O
also	O
had	O
a	O
subarachnoid	B-Sign_symptom
hemorrhage	I-Sign_symptom
at	O
the	O
age	O
of	O
29	O
.	O

When	O
she	O
first	O
presented	O
at	O
our	O
hospital	B-Nonbiological_location
,	O
she	O
was	O
not	O
taking	O
beta	B-Medication
-	I-Medication
blockers	I-Medication
,	O
because	O
of	O
a	O
history	O
of	O
asthma	O
,	O
but	O
was	O
taking	O
mexiletine	B-Medication
in	O
addition	O
to	O
phenytoin	B-Medication
.	O

Her	O
QTc	B-Diagnostic_procedure
was	O
found	O
to	O
be	O
prolonged	B-Lab_value
(	O
584	B-Lab_value
ms	I-Lab_value
)	O
at	O
presentation	O
and	O
administration	O
of	O
atenolol	B-Medication
was	O
initiated	O
.	O

She	O
delivered	O
her	O
baby	O
(	O
III	O
-	O
1	O
in	O
Fig	O
.	O
2	O
)	O
through	O
Caesarean	B-Therapeutic_procedure
operation	I-Therapeutic_procedure
at	O
our	O
hospital	B-Nonbiological_location
at	O
the	O
age	O
of	O
35	O
.	O

At	O
37	O
,	O
she	O
delivered	O
her	O
second	O
baby	O
(	O
III	O
-	O
2	O
in	O
Fig	O
.	O
2	O
)	O
through	O
Caesarean	B-Therapeutic_procedure
operation	I-Therapeutic_procedure
at	O
our	O
hospital	B-Nonbiological_location
.	O

Despite	O
administration	O
of	O
beta	B-Medication
-	I-Medication
blockers	I-Medication
,	O
her	O
QTc	B-Diagnostic_procedure
remained	O
prolonged	B-Lab_value
(	O
600	B-Lab_value
msec	I-Lab_value
at	O
the	O
age	O
of	O
37	O
,	O
780	B-Lab_value
msec	I-Lab_value
at	O
44	O
)	O
(	O
Figs	O
.	O
2	O
and	O
3a	O
)	O
,	O
which	O
is	O
not	O
unexpected	O
because	O
treatment	O
with	O
beta	O
-	O
blockers	O
in	O
LQTS1	O
is	O
not	O
expected	O
to	O
overtly	O
reduce	O
QTc	O
[	O
18	O
]	O
.	O

However	O
,	O
she	O
continued	O
to	O
experience	O
occasional	B-Detailed_description
syncope	B-Sign_symptom
and	O
finally	O
underwent	O
an	O
implantable	B-Therapeutic_procedure
cardioverter	I-Therapeutic_procedure
defibrillator	I-Therapeutic_procedure
(	O
ICD	B-Therapeutic_procedure
)	O
operation	O
at	O
38	O
years	O
of	O
age	O
.	O

Subsequently	O
,	O
she	O
is	O
in	O
a	O
stable	B-Sign_symptom
clinical	I-Sign_symptom
condition	I-Sign_symptom
.	O

Because	O
the	O
proband	O
was	O
suspected	O
of	O
JLNS	B-Disease_disorder
and	O
both	O
infants	O
had	O
a	O
measured	O
QTc	O
of	O
500	O
ms	O
or	O
greater	O
within	O
1	O
month	O
after	O
birth	O
,	O
beta	O
blockers	O
were	O
initiated	O
and	O
both	O
children	O
remain	O
in	O
stable	O
condition	O
at	O
ages	O
10	O
and	O
8	O
(	O
Figs	O
.	O
2	O
and	O
3b	O
,	O
c	O
)	O
.	O

QTc	O
of	O
the	O
son	O
(	O
III	O
-	O
1	O
in	O
Fig	O
.	O
2	O
)	O
was	O
measured	O
as	O
500	O
ms	O
one	O
month	O
after	O
birth	O
,	O
while	O
the	O
QTc	O
of	O
his	O
sister	O
(	O
III	O
-	O
2	O
)	O
was	O
530	O
ms	O
at	O
birth	O
.	O

The	O
father	O
(	O
I	O
-	O
1	O
)	O
and	O
mother	O
(	O
I	O
-	O
2	O
)	O
of	O
the	O
proband	O
were	O
first	O
cousins	O
.	O

There	O
is	O
no	O
history	O
of	O
sudden	O
unexplained	O
syncope	O
or	O
death	O
of	O
children	O
or	O
adults	O
in	O
the	O
immediate	O
family	O
members	O
,	O
despite	O
the	O
prolonged	O
QTc	O
of	O
the	O
children	O
.	O

Clinical	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
and	O
consultation	O
of	O
the	O
proband	O
and	O
her	O
family	O
members	O
were	O
performed	O
at	O
Chiba	B-Nonbiological_location
University	I-Nonbiological_location
Hospital	I-Nonbiological_location
.	O

Clinical	O
phenotypes	O
were	O
deduced	O
from	O
the	O
clinical	O
history	O
,	O
physical	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
,	O
and	O
ECG	B-Diagnostic_procedure
.	O

Blood	B-Diagnostic_procedure
samples	I-Diagnostic_procedure
were	O
collected	O
from	O
the	O
proband	O
and	O
her	O
family	O
members	O
following	O
genetic	O
counseling	O
,	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
prior	O
to	O
sample	O
collection	O
.	O

Genomic	B-Diagnostic_procedure
DNA	I-Diagnostic_procedure
was	O
isolated	O
from	O
peripheral	B-Biological_structure
blood	I-Biological_structure
lymphocytes	I-Biological_structure
according	O
to	O
established	O
protocols	O
at	O
our	O
laboratory	O
[	O
19	O
]	O
.	O

Entire	O
coding	O
exons	O
,	O
including	O
the	O
intronic	O
boundaries	O
of	O
the	O
genes	O
,	O
of	O
KCNQ1	B-Detailed_description
(	O
NCBI	O
ref	O
:	O
NM_000218	O
)	O
and	O
other	O
LQT	B-Detailed_description
causative	I-Detailed_description
genes	I-Detailed_description
(	O
KCNH2	B-Detailed_description
,	I-Detailed_description
SCN5A	I-Detailed_description
,	I-Detailed_description
KCNE1	I-Detailed_description
,	I-Detailed_description
KCNE2	I-Detailed_description
,	I-Detailed_description
KCNJ2	I-Detailed_description
,	I-Detailed_description
SCN4B	I-Detailed_description
,	I-Detailed_description
KCNJ5	I-Detailed_description
)	O
were	O
amplified	O
by	O
polymerase	B-Diagnostic_procedure
chain	I-Diagnostic_procedure
reaction	I-Diagnostic_procedure
(	O
PCR	B-Diagnostic_procedure
)	O
,	O
according	O
to	O
established	O
protocols	O
in	O
our	O
laboratory	O
.	O

Briefly	O
,	O
30	B-Detailed_description
-	I-Detailed_description
100	I-Detailed_description
ng	I-Detailed_description
of	I-Detailed_description
genomic	I-Detailed_description
DNA	I-Detailed_description
was	O
subjected	O
to	O
PCR	O
amplification	O
with	O
DNA	B-Detailed_description
polymerase	I-Detailed_description
(	O
PrimeSTAR	B-Detailed_description
GXL	I-Detailed_description
DNA	I-Detailed_description
Polymerase	I-Detailed_description
;	I-Detailed_description
Takara	I-Detailed_description
Bio	I-Detailed_description
Inc	I-Detailed_description
.	I-Detailed_description
,	I-Detailed_description
Kusatsu	I-Detailed_description
,	I-Detailed_description
Japan	I-Detailed_description
)	O
and	O
primer	B-Detailed_description
sets	I-Detailed_description
.	O

The	O
amplicons	B-Detailed_description
were	O
subjected	O
to	O
conventional	B-Detailed_description
sequencing	B-Diagnostic_procedure
with	O
Sanger	B-Detailed_description
sequencers	I-Detailed_description
(	O
Applied	B-Detailed_description
Biosystems	I-Detailed_description
3730	I-Detailed_description
/	I-Detailed_description
3130	I-Detailed_description
DNA	I-Detailed_description
analyzers	I-Detailed_description
;	I-Detailed_description
Thermo	I-Detailed_description
Fisher	I-Detailed_description
Scientific	I-Detailed_description
,	I-Detailed_description
Waltham	I-Detailed_description
,	I-Detailed_description
MA	I-Detailed_description
,	I-Detailed_description
USA	I-Detailed_description
)	O
.	O

The	O
sequence	O
data	O
were	O
processed	B-Detailed_description
with	I-Detailed_description
Gene	I-Detailed_description
Codes	I-Detailed_description
Sequencher	I-Detailed_description
Software	I-Detailed_description
(	O
Takara	B-Detailed_description
Bio	I-Detailed_description
Inc	I-Detailed_description
.	I-Detailed_description
)	O
and	O
mapped	B-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
human	I-Detailed_description
genome	I-Detailed_description
sequence	I-Detailed_description
(	O
build	B-Detailed_description
GRCh37	I-Detailed_description
/	I-Detailed_description
hg19	I-Detailed_description
)	O
.	O

Genetic	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
was	O
performed	O
to	O
screen	O
all	O
coding	O
exons	O
and	O
the	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
KCNQ1	B-Detailed_description
gene	I-Detailed_description
(	O
NCBI	O
ref	O
:	O
NM_000218	O
.	O
2	O
,	O
NP_000209	O
.	O
2	O
)	O
with	O
concurrent	O
screening	O
of	O
other	O
LQT	B-Detailed_description
causative	I-Detailed_description
genes	I-Detailed_description
(	O
KCNH2	B-Detailed_description
,	I-Detailed_description
SCN5A	I-Detailed_description
,	I-Detailed_description
KCNE1	I-Detailed_description
,	I-Detailed_description
KCNE2	I-Detailed_description
,	I-Detailed_description
KCNJ2	I-Detailed_description
,	I-Detailed_description
SCN4B	I-Detailed_description
,	I-Detailed_description
KCNJ5	I-Detailed_description
)	O
.	O

We	O
detected	O
a	O
novel	O
homozygous	B-Sign_symptom
nonsense	I-Sign_symptom
variant	I-Sign_symptom
,	O
NM_000218	B-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
:	I-Detailed_description
c	I-Detailed_description
.	I-Detailed_description
115G	I-Detailed_description
>	I-Detailed_description
T	I-Detailed_description
(	O
p	O
.	O
Glu39X	O
,	O
in	O
exon	O
1a	O
)	O
,	O
in	O
the	O
KCNQ1	O
gene	O
of	O
the	O
proband	O
,	O
as	O
well	O
as	O
a	O
homozygous	B-Sign_symptom
common	I-Sign_symptom
variant	I-Sign_symptom
(	O
NM_000218	B-Detailed_description
.	I-Detailed_description
2	I-Detailed_description
:	I-Detailed_description
c	I-Detailed_description
.	I-Detailed_description
1343C	I-Detailed_description
>	I-Detailed_description
G	I-Detailed_description
,	O
p	O
.	O
Pro448Arg	O
)	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

Genetic	B-Diagnostic_procedure
screening	I-Diagnostic_procedure
of	O
her	O
mother	O
(	O
I	O
-	O
2	O
)	O
and	O
children	O
(	O
III	O
-	O
1	O
and	O
III	O
-	O
2	O
)	O
revealed	O
that	O
they	O
were	O
heterozygous	O
for	O
the	O
nonsense	O
variant	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Her	O
husband	O
(	O
II	O
-	O
3	O
)	O
was	O
also	O
screened	O
and	O
found	O
to	O
be	O
heterozygous	O
for	O
the	O
common	O
variant	O
(	O
NM_000218	O
.	O
2	O
:	O
c	O
.	O
1343C	O
>	O
G	O
,	O
p	O
.	O
Pro448Arg	O
)	O
.	O

The	O
proband	O
is	O
a	O
child	O
from	O
a	O
first	O
-	O
cousin	O
marriage	O
,	O
and	O
we	O
have	O
concluded	O
the	O
homozygous	B-Sign_symptom
nonsense	I-Sign_symptom
variant	I-Sign_symptom
in	O
the	O
proband	O
is	O
the	O
cause	O
of	O
her	O
JLNS1	B-Disease_disorder
.	O

The	O
proband	O
was	O
negative	O
for	O
pathogenic	B-Sign_symptom
variants	I-Sign_symptom
in	I-Sign_symptom
other	I-Sign_symptom
LQT	I-Sign_symptom
causative	I-Sign_symptom
genes	I-Sign_symptom
,	O
including	O
the	O
KCNE1	O
gene	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
57	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Jewish	O
man	O
with	O
Crohn	O
`	O
s	O
disease	O
(	O
CD	B-Disease_disorder
)	O
of	O
the	O
ileum	B-Biological_structure
diagnosed	O
at	O
the	O
age	O
of	O
thirteen	O
,	O
presented	O
with	O
multiple	B-Detailed_description
nonmelanoma	B-Disease_disorder
skin	I-Disease_disorder
cancers	I-Disease_disorder
(	O
NMSCs	B-Disease_disorder
)	O
;	O
these	O
had	O
developed	O
over	B-Duration
the	I-Duration
past	I-Duration
16	I-Duration
years	I-Duration
coinciding	O
with	O
the	O
initiation	O
of	O
a	O
prolonged	B-Dosage
course	I-Dosage
of	O
the	O
thiopurine	B-Medication
6	B-Medication
-	I-Medication
mercaptopurine	I-Medication
(	O
mercaptopurine	B-Medication
,	O
6	B-Medication
-	I-Medication
MP	I-Medication
)	O
.	O

He	O
was	O
diagnosed	O
with	O
a	O
total	O
of	O
84	B-Lab_value
NMSC	B-Disease_disorder
:	O
72	B-Lab_value
NMSC	O
at	O
our	B-Nonbiological_location
clinic	I-Nonbiological_location
,	O
12	B-Lab_value
from	O
other	B-Nonbiological_location
clinics	I-Nonbiological_location
.	O

He	O
was	O
also	O
awaiting	O
biopsy	B-Diagnostic_procedure
and	O
removal	B-Therapeutic_procedure
for	O
additional	O
lesions	B-Sign_symptom
.	O

His	O
CD	B-Disease_disorder
was	O
initially	O
treated	O
with	O
sulfasalazine	B-Medication
and	O
intermittent	B-Frequency
steroids	B-Medication
at	O
diagnosis	O
,	O
but	O
for	O
the	O
past	B-Duration
20	I-Duration
years	I-Duration
he	O
had	O
been	O
taking	O
6	B-Medication
-	I-Medication
MP	I-Medication
daily	B-Frequency
.	O

In	O
the	O
first	B-Duration
ten	I-Duration
years	I-Duration
after	O
beginning	O
6	B-Medication
-	I-Medication
MP	I-Medication
he	O
developed	O
30	B-Lab_value
NMSC	B-Disease_disorder
;	O
14	B-Lab_value
were	O
squamous	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
(	O
SCC	B-Disease_disorder
)	O
and	O
16	B-Lab_value
were	O
basal	B-Disease_disorder
cell	I-Disease_disorder
carcinoma	I-Disease_disorder
(	O
BCC	B-Disease_disorder
)	O
.	O

The	O
patient	O
was	O
then	O
treated	B-Therapeutic_procedure
elsewhere	B-Nonbiological_location
for	O
the	O
subsequent	B-Duration
ten	I-Duration
years	I-Duration
.	O

This	O
past	O
year	O
,	O
however	O
,	O
he	O
returned	O
to	O
the	O
clinic	B-Nonbiological_location
with	O
over	O
100	B-Lab_value
new	B-Lab_value
lesions	B-Sign_symptom
suggestive	O
of	O
malignancy	B-Disease_disorder
on	O
his	O
torso	B-Biological_structure
and	O
extremities	B-Biological_structure
.	O

Subsequent	O
to	O
this	O
exam	O
,	O
he	O
had	O
42	B-Lab_value
biopsy	B-Diagnostic_procedure
-	O
proven	O
lesions	B-Sign_symptom
of	O
NMCS	B-Disease_disorder
;	O
20	B-Lab_value
were	O
SCC	B-Disease_disorder
and	O
22	B-Lab_value
were	O
BCC	B-Disease_disorder
.	O

In	O
addition	O
,	O
three	B-Lab_value
of	O
the	O
SCCs	B-Disease_disorder
were	O
moderately	B-Lab_value
differentiated	I-Lab_value
and	O
two	B-Lab_value
were	O
poorly	B-Lab_value
differentiated	I-Lab_value
and	O
some	O
of	O
his	O
larger	O
skin	B-Disease_disorder
cancers	I-Disease_disorder
have	O
necessitated	O
Mohs	B-Therapeutic_procedure
surgery	I-Therapeutic_procedure
and	O
xenografting	B-Therapeutic_procedure
.	O

The	O
largest	B-Lab_value
of	O
his	O
lesions	B-Sign_symptom
was	O
pretibial	B-Biological_structure
and	O
measured	O
64x53	B-Area
mm	I-Area
(	O
Figure	O
1	O
)	O
.	O

He	O
was	O
awaiting	O
biopsy	B-Diagnostic_procedure
for	O
many	O
other	O
suspicious	O
lesions	B-Sign_symptom
.	O

The	O
patient	O
had	O
Fitzpatrick	B-Lab_value
II	I-Lab_value
skin	B-Diagnostic_procedure
type	I-Diagnostic_procedure
and	O
admitted	O
to	O
excessive	B-Detailed_description
sun	B-Activity
exposure	I-Activity
for	O
25	B-Duration
years	I-Duration
in	O
Hawai`i	B-Nonbiological_location
.	O

Early	O
on	O
he	O
did	O
not	O
use	O
sunscreen	B-Medication
,	O
and	O
would	O
sail	B-Activity
a	O
catamaran	B-Detailed_description
during	B-Detailed_description
peak	I-Detailed_description
sun	I-Detailed_description
hours	I-Detailed_description
.	O

He	O
also	O
revealed	O
that	O
his	O
mother	O
had	O
one	B-Detailed_description
skin	I-Detailed_description
cancer	I-Detailed_description
lesion	I-Detailed_description
removed	I-Detailed_description
and	O
denied	O
ever	O
having	O
been	O
a	O
smoker	B-Activity
.	O

Within	O
the	O
past	O
year	O
he	O
discontinued	O
6	B-Medication
-	I-Medication
MP	I-Medication
and	O
began	O
using	O
mesalamine	B-Medication
(	O
Pentasa	B-Medication
)	O
and	O
later	O
adalimumab	B-Medication
(	O
Humira	B-Medication
)	O
hoping	O
to	O
attenuate	O
the	O
progression	O
of	O
NMSC	O
,	O
and	O
continued	O
to	O
have	O
monthly	B-Frequency
skin	B-Diagnostic_procedure
exams	I-Diagnostic_procedure
.	O

Overall	O
,	O
he	O
was	O
hospitalized	O
16	B-Lab_value
times	I-Lab_value
for	O
his	O
CD	B-Disease_disorder
,	O
but	O
never	O
required	O
any	O
intestinal	B-Biological_structure
resection	B-Therapeutic_procedure
.	O

Unfortunately	O
,	O
in	O
his	O
most	O
recent	O
hospitalization	O
he	O
was	O
diagnosed	O
with	O
metastatic	B-Detailed_description
adenocarcinoma	B-Disease_disorder
of	O
the	O
small	B-Biological_structure
bowel	I-Biological_structure
,	O
and	O
passed	O
away	O
shortly	O
after	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
patient	O
had	O
previously	O
undergone	O
a	O
radical	B-Detailed_description
resection	B-Therapeutic_procedure
of	O
a	O
T2bN0M0G3	B-Detailed_description
Stage	I-Detailed_description
III	I-Detailed_description
retroperitoneal	B-Disease_disorder
sarcoma	I-Disease_disorder
,	O
including	O
right	B-Detailed_description
nephrectomy	B-Therapeutic_procedure
and	O
cholecystectomy	B-Therapeutic_procedure
,	O
in	O
2002	O
.	O

Pathologic	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
demonstrated	O
a	O
25	B-Distance
cm	I-Distance
high	B-Severity
-	I-Severity
grade	I-Severity
liposarcoma	B-Disease_disorder
with	O
different	B-Detailed_description
histologic	I-Detailed_description
components	I-Detailed_description
,	O
including	O
myxoid	B-Detailed_description
,	O
round	B-Detailed_description
cell	I-Detailed_description
,	O
well	B-Detailed_description
-	I-Detailed_description
differentiated	I-Detailed_description
,	O
sclerosing	B-Detailed_description
and	O
pleomorphic	B-Detailed_description
patterns	I-Detailed_description
.	O

Surgical	B-Diagnostic_procedure
margins	I-Diagnostic_procedure
were	O
negative	B-Lab_value
as	O
the	O
tumor	B-Sign_symptom
did	O
not	O
invade	B-Sign_symptom
the	O
kidney	B-Biological_structure
,	O
and	O
since	O
the	O
renal	B-Biological_structure
vein	I-Biological_structure
and	O
ureter	B-Biological_structure
were	O
free	O
of	O
tumor	B-Sign_symptom
as	O
well	O
.	O

The	O
patient	O
did	O
not	O
undergo	O
any	O
additional	O
therapy	O
.	O

Surveillance	B-Detailed_description
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
in	O
2007	O
revealed	O
an	O
isolated	B-Detailed_description
tumor	B-Sign_symptom
recurrence	I-Sign_symptom
in	O
the	O
retroperitoneum	B-Biological_structure
.	O

An	O
exploratory	B-Detailed_description
celiotomy	B-Diagnostic_procedure
revealed	O
tumor	B-Sign_symptom
involvement	I-Sign_symptom
of	O
the	O
duodenum	B-Biological_structure
,	O
head	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
pancreas	I-Biological_structure
,	O
superior	B-Biological_structure
mesenteric	I-Biological_structure
vein	I-Biological_structure
,	O
vena	B-Biological_structure
cava	I-Biological_structure
and	O
left	B-Biological_structure
renal	I-Biological_structure
vein	I-Biological_structure
with	O
severe	B-Severity
adhesive	B-Detailed_description
changes	I-Detailed_description
,	O
leading	O
to	O
the	O
intraoperative	O
assessment	O
of	O
unresectable	B-Disease_disorder
disease	I-Disease_disorder
.	O

Subsequently	O
,	O
the	O
patient	O
underwent	O
stereotactic	B-Detailed_description
body	I-Detailed_description
radiation	B-Therapeutic_procedure
to	O
the	O
retroperitoneal	B-Biological_structure
tumor	B-Sign_symptom
in	O
five	B-Dosage
fractions	I-Dosage
for	O
a	O
total	B-Dosage
dose	I-Dosage
of	I-Dosage
30	I-Dosage
Gy	I-Dosage
,	O
without	O
complication	B-Sign_symptom
.	O

Postradiation	O
imaging	B-Diagnostic_procedure
revealed	O
near	O
complete	O
resolution	O
of	O
the	O
retroperitoneal	B-Biological_structure
mass	B-Sign_symptom
.	O

One	O
year	O
later	O
,	O
the	O
patient	O
presented	O
with	O
weight	B-Sign_symptom
loss	I-Sign_symptom
,	O
postprandial	B-Detailed_description
abdominal	B-Biological_structure
pain	B-Sign_symptom
,	O
nausea	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
.	O

Cross	B-Diagnostic_procedure
-	I-Diagnostic_procedure
sectional	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
revealed	O
a	O
7	B-Distance
cm	I-Distance
mass	B-Sign_symptom
with	O
involvement	O
of	O
the	O
third	B-Biological_structure
portion	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
duodenum	I-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
obvious	O
involvement	B-Sign_symptom
of	O
the	O
pancreatic	B-Biological_structure
head	I-Biological_structure
or	O
the	O
other	B-Biological_structure
structures	I-Biological_structure
that	O
were	O
noted	O
to	O
be	O
involved	O
during	O
the	O
previous	O
laparotomy	O
.	O

We	O
elected	O
to	O
perform	O
another	O
resection	B-Therapeutic_procedure
attempt	O
,	O
including	O
a	O
possible	O
pancreatoduodenectomy	O
or	O
retroperitoneal	O
vascular	O
resection	O
if	O
necessary	O
.	O

At	O
exploration	B-Diagnostic_procedure
,	O
the	O
residual	O
tumor	B-Sign_symptom
was	O
an	O
entirely	O
intraduodenal	B-Biological_structure
,	O
pedunculated	B-Detailed_description
mass	O
at	O
the	O
posterior	B-Biological_structure
duodenal	I-Biological_structure
wall	I-Biological_structure
distal	O
to	O
the	O
ampulla	O
that	O
filled	O
the	O
entire	O
duodenal	O
lumen	O
.	O

The	O
patient	O
underwent	O
a	O
duodenotomy	B-Therapeutic_procedure
and	O
stalk	B-Therapeutic_procedure
transection	I-Therapeutic_procedure
of	O
the	O
polypoid	B-Detailed_description
mass	B-Sign_symptom
,	O
followed	O
by	O
partial	B-Detailed_description
duodenal	B-Biological_structure
resection	B-Therapeutic_procedure
with	O
hand	B-Detailed_description
-	I-Detailed_description
sewn	I-Detailed_description
duodenojejunal	B-Biological_structure
anastomosis	B-Therapeutic_procedure
(	O
Figure	O
2	O
)	O
.	O

Surgical	B-Diagnostic_procedure
pathology	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
9	B-Distance
.	I-Distance
5	I-Distance
cm	I-Distance
recurrent	B-Detailed_description
high	B-Severity
-	I-Severity
grade	I-Severity
liposarcoma	B-Disease_disorder
with	O
polypoid	B-Detailed_description
intraluminal	I-Detailed_description
growth	I-Detailed_description
containing	O
myxoid	B-Detailed_description
,	O
round	B-Detailed_description
cell	I-Detailed_description
,	O
well	B-Detailed_description
-	I-Detailed_description
differentiated	I-Detailed_description
,	O
sclerosing	B-Detailed_description
and	O
focally	B-Detailed_description
pleomorphic	I-Detailed_description
areas	I-Detailed_description
.	O

Surgical	B-Diagnostic_procedure
margins	I-Diagnostic_procedure
were	O
negative	B-Lab_value
as	O
the	O
tumor	B-Sign_symptom
came	O
within	B-Distance
0	I-Distance
.	I-Distance
1	I-Distance
cm	I-Distance
of	O
the	O
stalk	B-Biological_structure
margin	I-Biological_structure
and	O
there	O
was	O
no	O
evidence	O
of	O
additional	O
neoplastic	B-Sign_symptom
components	I-Sign_symptom
within	O
the	O
remaining	O
resected	O
duodenum	B-Biological_structure
.	O

The	O
postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
uncomplicated	B-Lab_value
,	O
and	O
the	O
patient	O
has	O
demonstrated	O
no	O
recurrence	B-Sign_symptom
up	O
to	O
30	O
months	O
from	O
this	O
resection	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
71	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
African	O
-	O
American	O
woman	O
presented	O
to	O
the	O
hospital	O
with	O
worsening	B-Lab_value
exertional	B-Detailed_description
dyspnoea	B-Sign_symptom
associated	O
with	O
orthopnoea	B-Sign_symptom
and	O
lower	B-Biological_structure
extremity	I-Biological_structure
oedema	B-Sign_symptom
for	O
3	B-Duration
weeks	I-Duration
.	O

She	O
had	O
a	O
long	O
-	O
standing	O
history	O
of	O
hypertension	B-Sign_symptom
and	O
documented	O
G6PD	O
deficiency	O
with	O
prior	O
episodes	O
of	O
haemolysis	B-Sign_symptom
.	O

She	O
was	O
a	O
former	O
cigarette	O
smoker	O
and	O
had	O
family	O
members	O
with	O
G6PD	O
deficiency	O
,	O
hypertension	O
and	O
diabetes	O
mellitus	O
.	O

Vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
measurement	I-Diagnostic_procedure
revealed	O
a	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
150	B-Lab_value
/	I-Lab_value
73	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
70	B-Lab_value
bpm	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
24	B-Lab_value
breaths	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
temperature	B-Diagnostic_procedure
of	O
36	B-Lab_value
.	I-Lab_value
6	I-Lab_value
°C	I-Lab_value
and	O
97	B-Lab_value
%	I-Lab_value
saturation	B-Diagnostic_procedure
on	O
room	B-Detailed_description
air	I-Detailed_description
.	I-Detailed_description

She	O
was	O
comfortable	B-Sign_symptom
at	O
rest	B-Detailed_description
.	O

Her	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
distended	B-Sign_symptom
jugular	B-Biological_structure
veins	I-Biological_structure
,	O
inspiratory	B-Detailed_description
crackles	B-Sign_symptom
in	O
bilateral	B-Biological_structure
lung	I-Biological_structure
bases	I-Biological_structure
,	O
a	O
laterally	B-Lab_value
displaced	I-Lab_value
apical	B-Diagnostic_procedure
impulse	I-Diagnostic_procedure
and	O
bipedal	B-Biological_structure
oedema	B-Sign_symptom
.	O

The	O
ECG	B-Diagnostic_procedure
showed	O
left	B-Biological_structure
ventricular	I-Biological_structure
hypertrophy	B-Sign_symptom
and	O
inferolateral	B-Detailed_description
T	B-Sign_symptom
-	I-Sign_symptom
wave	I-Sign_symptom
inversions	I-Sign_symptom
.	O

Chest	B-Biological_structure
radiography	B-Diagnostic_procedure
revealed	O
cardiomegaly	B-Sign_symptom
and	O
mild	B-Severity
pulmonary	B-Biological_structure
oedema	B-Sign_symptom
.	O

The	O
metabolic	B-Diagnostic_procedure
panel	I-Diagnostic_procedure
and	O
troponin	B-Diagnostic_procedure
levels	O
were	O
normal	B-Lab_value
but	O
the	O
B	B-Diagnostic_procedure
-	I-Diagnostic_procedure
type	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
was	O
increased	B-Lab_value
at	O
826	B-Lab_value
.	I-Lab_value
5	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Echocardiography	B-Diagnostic_procedure
showed	O
a	O
dilated	B-Sign_symptom
left	B-Biological_structure
ventricle	I-Biological_structure
with	O
an	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
(	O
EF	B-Diagnostic_procedure
)	O
of	O
30	B-Lab_value
%	I-Lab_value
and	O
mild	B-Severity
right	B-Biological_structure
ventricular	I-Biological_structure
systolic	B-Disease_disorder
dysfunction	I-Disease_disorder
.	O

Coronary	B-Biological_structure
artery	I-Biological_structure
catheterisation	B-Therapeutic_procedure
revealed	O
normal	B-Lab_value
coronary	B-Diagnostic_procedure
circulation	I-Diagnostic_procedure
.	O

Ethacrynic	B-Medication
acid	I-Medication
at	O
50	B-Dosage
mg	I-Dosage
daily	I-Dosage
was	O
chosen	O
for	O
diuresis	O
.	O

She	O
improved	B-Sign_symptom
after	O
a	O
day	O
but	O
still	O
had	O
dyspnoea	B-Sign_symptom
,	O
so	O
we	O
added	O
spironolactone	B-Medication
.	O

Subsequently	O
,	O
metoprolol	B-Medication
succinate	I-Medication
and	O
losartan	B-Medication
were	O
included	O
in	O
the	O
regimen	O
.	O

Repeat	O
chest	B-Biological_structure
radiography	B-Diagnostic_procedure
showed	O
resolution	O
of	O
pulmonary	B-Biological_structure
oedema	B-Sign_symptom
.	O

The	O
patient	O
`	O
s	O
laboratory	B-Diagnostic_procedure
results	I-Diagnostic_procedure
during	O
her	O
hospital	O
stay	O
did	O
not	O
show	O
signs	O
of	O
haemolysis	B-Sign_symptom
nor	O
worsening	B-Sign_symptom
kidney	I-Sign_symptom
function	I-Sign_symptom
.	O

She	O
did	O
not	O
develop	O
ototoxicity	B-Sign_symptom
and	O
was	O
discharged	O
home	B-Nonbiological_location
asymptomatic	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
35	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
to	O
the	O
medical	B-Nonbiological_location
emergency	I-Nonbiological_location
department	I-Nonbiological_location
with	O
low	B-Severity
-	I-Severity
grade	I-Severity
fever	B-Sign_symptom
for	O
3	B-Duration
weeks	I-Duration
,	O
vomiting	B-Sign_symptom
for	O
1	B-Duration
week	I-Duration
and	O
anuria	B-Sign_symptom
for	O
3	B-Duration
days	I-Duration
.	O

She	O
also	O
reported	O
dysuria	B-Sign_symptom
and	O
breathlessness	B-Sign_symptom
for	O
1	B-Duration
week	I-Duration
.	O

There	O
was	O
no	O
history	O
of	O
decreased	B-Sign_symptom
urine	I-Sign_symptom
output	I-Sign_symptom
,	O
dialysis	B-Therapeutic_procedure
,	O
effort	B-Sign_symptom
intolerance	I-Sign_symptom
,	O
chest	B-Biological_structure
pain	B-Sign_symptom
or	O
palpitation	B-Sign_symptom
,	O
dyspnoea	B-Sign_symptom
and	O
weight	B-Sign_symptom
loss	I-Sign_symptom
.	O

Menstrual	B-Diagnostic_procedure
history	I-Diagnostic_procedure
was	O
within	B-Lab_value
normal	I-Lab_value
limit	I-Lab_value
but	O
she	O
reported	O
gradually	B-Lab_value
progressive	I-Lab_value
loss	B-Sign_symptom
of	I-Sign_symptom
appetite	I-Sign_symptom
.	O

Family	O
history	O
included	O
smoky	B-Detailed_description
urine	I-Detailed_description
in	O
her	O
younger	O
brother	O
in	O
his	O
childhood	O
,	O
who	O
died	B-Detailed_description
in	I-Detailed_description
an	I-Detailed_description
accident	I-Detailed_description
.	O

On	O
general	B-Diagnostic_procedure
survey	I-Diagnostic_procedure
,	O
the	O
patient	O
was	O
conscious	B-Sign_symptom
and	O
alert	B-Sign_symptom
.	O

She	O
was	O
dyspnoeic	B-Sign_symptom
and	O
febrile	B-Sign_symptom
.	O

Severe	B-Severity
pallor	B-Sign_symptom
was	O
present	O
with	O
mild	B-Severity
pedal	B-Biological_structure
oedema	B-Sign_symptom
.	O

Blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
180	B-Lab_value
/	I-Lab_value
100	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
and	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
116	B-Lab_value
/	I-Lab_value
min	I-Lab_value
regular	B-Lab_value
.	O

No	O
evidence	O
of	O
jaundice	B-Sign_symptom
,	O
clubbing	B-Detailed_description
cyanosis	B-Sign_symptom
or	O
lymphadenopathy	B-Disease_disorder
was	O
found	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
bibasilar	B-Biological_structure
end	B-Detailed_description
-	I-Detailed_description
inspiratory	I-Detailed_description
crepitations	B-Sign_symptom
in	O
lungs	B-Biological_structure
and	O
suprapubic	B-Biological_structure
tenderness	B-Sign_symptom
.	O

There	O
was	O
no	O
hepatosplenomegaly	B-Sign_symptom
or	O
ascites	B-Sign_symptom
.	O

Cardiac	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
normal	B-Lab_value
.	O

She	O
was	O
found	O
to	O
have	O
severe	B-Severity
bilateral	B-Detailed_description
hearing	B-Sign_symptom
loss	I-Sign_symptom
,	O
which	O
was	O
gradually	B-Lab_value
progressive	I-Lab_value
for	O
5	B-Duration
years	I-Duration
.	O

The	O
fundi	B-Biological_structure
were	O
bilaterally	B-Detailed_description
pale	B-Sign_symptom
.	O

The	O
patient	O
was	O
referred	O
to	O
the	O
department	B-Nonbiological_location
of	I-Nonbiological_location
ophthalmology	I-Nonbiological_location
for	O
a	O
comprehensive	O
eye	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
.	O

Her	O
visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
was	O
documented	O
as	O
6	B-Lab_value
/	I-Lab_value
18	I-Lab_value
in	O
both	B-Biological_structure
eyes	I-Biological_structure
with	O
no	O
obvious	O
lenticular	B-Sign_symptom
opacity	I-Sign_symptom
.	O

Slit	B-Diagnostic_procedure
-	I-Diagnostic_procedure
lamp	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
bilateral	B-Detailed_description
anterior	B-Sign_symptom
lentiglobus	I-Sign_symptom
(	O
figure	O
1	O
)	O
with	O
posterior	B-Sign_symptom
lenticonus	I-Sign_symptom
(	O
figure	O
2	O
)	O
.	O

Distant	B-Detailed_description
direct	I-Detailed_description
ophthalmoscopy	B-Diagnostic_procedure
revealed	O
oil	B-Sign_symptom
droplet	I-Sign_symptom
sign	I-Sign_symptom
(	O
a	O
suggestive	O
confirmation	O
of	O
the	O
presence	O
of	O
lenticonus	B-Sign_symptom
)	O
;	O
and	O
peripheral	B-Biological_structure
retina	I-Biological_structure
revealed	O
multiple	B-Detailed_description
yellowish	B-Color
white	I-Color
lesion	B-Sign_symptom
-	I-Sign_symptom
like	I-Sign_symptom
flecks	I-Sign_symptom
in	O
the	O
mid	B-Biological_structure
-	I-Biological_structure
periphery	I-Biological_structure
,	O
and	O
few	B-Detailed_description
blot	B-Sign_symptom
haemorrhages	I-Sign_symptom
indicative	O
of	O
hypertensive	B-Sign_symptom
changes	I-Sign_symptom
(	O
figures	O
3	O
and	O
4	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
patient	O
is	O
an	O
18	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Han	O
female	O
admitted	O
to	O
Peking	B-Nonbiological_location
Union	I-Nonbiological_location
Medical	I-Nonbiological_location
College	I-Nonbiological_location
Hospital	I-Nonbiological_location
due	O
to	O
adrenal	B-Disease_disorder
crisis	I-Disease_disorder
triggered	O
by	O
pneumonia	B-Disease_disorder
.	O

She	O
has	O
developed	O
recurrent	B-Detailed_description
respiratory	B-Biological_structure
infections	B-Disease_disorder
since	O
age	O
5	O
,	O
and	O
failed	O
to	O
respond	O
to	O
multiple	B-Detailed_description
hepatitis	B-Detailed_description
B	I-Detailed_description
virus	I-Detailed_description
(	O
HBV	B-Detailed_description
)	O
vaccinations	B-Medication
.	O

Reduced	B-Lab_value
serum	B-Detailed_description
cortisol	B-Diagnostic_procedure
and	O
ACTH	B-Diagnostic_procedure
levels	O
were	O
discovered	O
at	O
16	O
when	O
glucocorticoid	O
replacement	O
was	O
initiated	O
.	O

In	O
addition	O
,	O
hair	B-Sign_symptom
loss	I-Sign_symptom
started	O
from	O
age	O
4	O
,	O
and	O
absence	B-Sign_symptom
of	I-Sign_symptom
pubic	I-Sign_symptom
and	I-Sign_symptom
axillary	I-Sign_symptom
hair	I-Sign_symptom
was	O
noticed	O
after	O
development	B-Other_event
of	I-Other_event
regular	I-Other_event
menstruation	I-Other_event
.	O

Her	O
history	O
includes	O
nephrotic	O
syndrome	O
,	O
which	O
was	O
confirmed	O
to	O
be	O
minimal	B-Disease_disorder
change	I-Disease_disorder
nephropathy	I-Disease_disorder
by	O
renal	B-Biological_structure
biopsy	B-Diagnostic_procedure
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
at	O
admission	O
revealed	O
alopecia	B-Disease_disorder
totalis	I-Disease_disorder
,	O
oral	B-Biological_structure
candidiasis	B-Disease_disorder
,	O
hypohidrosis	B-Disease_disorder
,	O
and	O
trachyonychia	B-Sign_symptom
.	O

Facial	B-Biological_structure
or	O
dental	B-Biological_structure
abnormalities	B-Sign_symptom
was	O
not	O
noted	O
.	O

She	O
is	O
the	O
only	O
child	O
in	O
her	O
family	O
.	O

Symptom	O
and	O
signs	O
of	O
the	O
above	O
disorders	O
were	O
not	O
identified	O
among	O
her	O
nonconsanguineous	O
parents	O
.	O

Initial	O
immunologic	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
revealed	O
remarkable	O
panhypogammaglobulinemia	B-Sign_symptom
and	O
reduced	B-Lab_value
cell	B-Diagnostic_procedure
counts	I-Diagnostic_procedure
of	O
B	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
,	O
T	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
,	O
and	O
natural	B-Diagnostic_procedure
killer	I-Diagnostic_procedure
(	I-Diagnostic_procedure
NK	I-Diagnostic_procedure
)	I-Diagnostic_procedure
cells	I-Diagnostic_procedure
(	O
Table	O
(	O
Table1	O
)	O
.	O
1	O
)	O
.	O

CD4	B-Diagnostic_procedure
/	I-Diagnostic_procedure
CD8	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
,	O
as	O
well	O
as	O
expression	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	O
various	O
T	B-Diagnostic_procedure
-	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
activation	I-Diagnostic_procedure
markers	I-Diagnostic_procedure
were	O
in	O
normal	B-Lab_value
range	I-Lab_value
,	O
except	O
increased	B-Lab_value
proportion	B-Diagnostic_procedure
of	I-Diagnostic_procedure
CD8	I-Diagnostic_procedure
+	I-Diagnostic_procedure
/	I-Diagnostic_procedure
HLA	I-Diagnostic_procedure
-	I-Diagnostic_procedure
DR	I-Diagnostic_procedure
+	I-Diagnostic_procedure
subset	I-Diagnostic_procedure
.	O

Antinuclear	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
(	O
ANA	B-Diagnostic_procedure
)	O
and	O
antineutrophil	B-Diagnostic_procedure
cytoplasmic	I-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
(	O
ANCA	B-Diagnostic_procedure
)	O
were	O
negative	B-Lab_value
.	O

When	O
regular	O
hydrocortisone	B-Medication
replacement	I-Medication
was	O
suspended	O
,	O
her	O
8:00	B-Time
am	I-Time
serum	B-Detailed_description
cortisol	B-Diagnostic_procedure
was	O
measured	O
at	O
0	B-Lab_value
.	I-Lab_value
93	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
with	O
ACTH	B-Diagnostic_procedure
<	B-Lab_value
5	I-Lab_value
.	I-Lab_value
00	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Serum	B-Detailed_description
levels	O
of	O
other	O
anterior	B-Diagnostic_procedure
pituitary	I-Diagnostic_procedure
hormones	I-Diagnostic_procedure
,	O
as	O
well	O
as	O
serum	B-Detailed_description
and	O
urine	B-Detailed_description
osmolality	B-Diagnostic_procedure
were	O
within	B-Lab_value
reference	I-Lab_value
range	I-Lab_value
.	O

Both	O
antiperoxidase	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
and	O
antithyroglobulin	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

She	O
had	O
positive	B-Lab_value
antiprotein	B-Diagnostic_procedure
tyrosine	I-Diagnostic_procedure
phosphatase	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
,	O
with	O
fasting	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
glucose	I-Diagnostic_procedure
at	O
5	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
with	O
contrast	B-Detailed_description
suggested	O
a	O
normal	B-Lab_value
pituitary	B-Diagnostic_procedure
.	O

She	O
was	O
diagnosed	O
with	O
CVID	B-Disease_disorder
,	O
isolated	B-Disease_disorder
ACTH	I-Disease_disorder
deficiency	I-Disease_disorder
,	O
and	O
ectodermal	B-Disease_disorder
dysplasia	I-Disease_disorder
.	O

Symptoms	O
of	O
fever	B-Sign_symptom
,	O
cough	B-Sign_symptom
,	O
and	O
vomiting	B-Sign_symptom
cleared	O
with	O
antibiotics	B-Medication
and	O
stress	B-Detailed_description
-	I-Detailed_description
dose	I-Detailed_description
hydrocortisone	B-Medication
treatment	O
.	O

Intravenous	B-Medication
immunoglobulin	I-Medication
(	O
IVIG	B-Medication
)	O
therapy	O
was	O
suggested	O
but	O
denied	O
by	O
the	O
parents	O
.	O

At	O
follow	O
-	O
up	O
1	O
year	O
after	O
her	O
discharge	O
,	O
she	O
reported	O
no	O
infection	B-Disease_disorder
events	O
during	B-Duration
the	I-Duration
previous	I-Duration
year	I-Duration
as	O
she	O
stayed	O
at	O
home	B-Nonbiological_location
and	O
avoided	O
outdoor	B-Activity
activities	I-Activity
.	O

Her	O
glucocorticoid	B-Medication
replacement	I-Medication
was	O
withdrawn	O
4	O
months	O
after	O
discharge	O
,	O
and	O
she	O
has	O
only	O
received	O
traditional	B-Medication
Chinese	I-Medication
medicine	I-Medication
ever	O
since	O
.	O

Lymphocyte	B-Diagnostic_procedure
subsets	I-Diagnostic_procedure
test	I-Diagnostic_procedure
done	O
at	O
the	O
follow	O
-	O
up	O
documented	O
increased	B-Lab_value
levels	O
of	O
B	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
and	O
T	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
,	O
while	O
NK	B-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
remained	O
below	B-Lab_value
normal	I-Lab_value
limit	I-Lab_value
.	O

To	O
assess	O
her	O
NK	O
-	O
cell	O
activity	O
,	O
a	O
flow	B-Diagnostic_procedure
cytometric	I-Diagnostic_procedure
procedure	I-Diagnostic_procedure
was	O
done	O
following	O
previously	O
described	O
method	O
.	O
[	O
10,11	O
]	O
Effector	O
to	O
target	O
cell	O
ratio	O
was	O
set	O
at	O
10:1	O
.	O

Less	O
apoptosis	O
of	O
target	O
cell	O
line	O
(	O
12	O
.	O
43	O
%	O
,	O
reference	O
range	O
15	O
.	O
11	O
-	O
26	O
.	O
91	O
%	O
)	O
was	O
observed	O
when	O
cocultured	O
with	O
patient	O
`	O
s	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
indicating	O
a	O
deficient	O
NK	O
-	O
cell	O
cytotoxicity	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
30	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
(	O
65	O
kg	O
)	O
underwent	O
rhinoplasty	B-Therapeutic_procedure
under	O
general	B-Medication
anaesthesia	I-Medication
,	O
which	O
was	O
induced	O
using	O
a	O
combination	O
of	O
a	O
bolus	O
of	O
Remifentanyl	B-Medication
(	O
0	B-Dosage
.	I-Dosage
5	I-Dosage
μg	I-Dosage
/	I-Dosage
kg	I-Dosage
)	O
and	O
Propofol	B-Medication
2	B-Dosage
mg	I-Dosage
/	I-Dosage
kg	I-Dosage
.	O

Muscle	B-Disease_disorder
paralysis	I-Disease_disorder
was	O
obtained	O
with	O
Cisatracurium	B-Medication
(	O
0	B-Dosage
.	I-Dosage
15	I-Dosage
μg	I-Dosage
/	I-Dosage
kg	I-Dosage
)	O
.	O

Transoral	B-Detailed_description
intubation	B-Therapeutic_procedure
was	O
performed	O
with	O
a	O
Macintosh	B-Therapeutic_procedure
blade	I-Therapeutic_procedure
(	O
No	B-Detailed_description
.	I-Detailed_description
3	I-Detailed_description
)	O
and	O
a	O
size	O
7	B-Detailed_description
mm	I-Detailed_description
diameter	I-Detailed_description
reinforced	B-Detailed_description
tracheal	B-Therapeutic_procedure
tube	I-Therapeutic_procedure
was	O
easily	O
and	O
gently	O
placed	O
in	O
the	O
trachea	B-Biological_structure
,	O
on	O
the	O
first	O
attempt	O
and	O
was	O
then	O
fixed	O
to	O
the	O
right	B-Biological_structure
corner	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
mouth	I-Biological_structure
.	O

No	O
problems	B-Disease_disorder
were	O
encountered	O
during	O
laryngoscopy	B-Therapeutic_procedure
and	O
intubation	O
.	O

The	O
cuff	O
of	O
the	O
tube	O
was	O
inflated	O
with	O
a	O
pressure	B-Lab_value
≤	I-Lab_value
20	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
.	O

No	O
adjustment	B-Therapeutic_procedure
of	I-Therapeutic_procedure
cuff	I-Therapeutic_procedure
volume	I-Therapeutic_procedure
was	O
made	O
intra	O
-	O
operatively	O
.	O

N2O	B-Medication
was	O
not	O
used	O
for	O
inhalation	O
anaesthesia	O
.	O

The	O
throat	B-Therapeutic_procedure
pack	I-Therapeutic_procedure
was	O
placed	O
in	O
the	O
pharynx	B-Biological_structure
to	O
avoid	O
the	O
passage	O
of	O
blood	O
in	O
the	O
aero	O
-	O
digestive	O
tract	O
.	O

General	B-Medication
anaesthesia	I-Medication
was	O
maintained	O
with	O
Sevofluorane	B-Medication
in	O
oxygen	O
/	O
air	O
and	O
Remifentanyl	B-Medication
in	O
continuous	O
infusion	O
0	B-Dosage
.	I-Dosage
25	I-Dosage
μg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
min	I-Dosage
.	O

Moderate	B-Severity
arterial	B-Sign_symptom
hypotension	I-Sign_symptom
was	O
maintained	O
with	O
a	O
cuff	O
systolic	B-Diagnostic_procedure
artery	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
approximately	O
90	B-Lab_value
mmHg	I-Lab_value
.	O

The	O
operation	O
was	O
carried	O
out	O
in	O
a	O
semi	B-Therapeutic_procedure
-	I-Therapeutic_procedure
supine	I-Therapeutic_procedure
position	I-Therapeutic_procedure
with	O
the	O
head	B-Detailed_description
slightly	I-Detailed_description
inclined	I-Detailed_description
forward	I-Detailed_description
and	O
laterally	O
and	O
trunk	B-Detailed_description
slightly	I-Detailed_description
elevated	I-Detailed_description
.	O

Duration	O
of	O
the	O
operation	B-Therapeutic_procedure
was	O
100	B-Duration
minutes	I-Duration
.	O

The	O
patient	O
was	O
extubated	B-Therapeutic_procedure
,	O
after	O
removal	O
of	O
the	O
throat	B-Therapeutic_procedure
pack	I-Therapeutic_procedure
without	O
problems	B-Disease_disorder
.	O

The	O
following	O
day	O
the	O
patient	O
complained	O
of	O
difficulty	B-Sign_symptom
in	I-Sign_symptom
swallowing	I-Sign_symptom
,	O
dysphonia	B-Sign_symptom
and	O
hoarseness	B-Sign_symptom
.	O

Examination	B-Diagnostic_procedure
revealed	O
deviation	B-Sign_symptom
of	O
the	O
tongue	B-Biological_structure
to	O
the	O
right	B-Detailed_description
side	I-Detailed_description
and	O
vocal	B-Biological_structure
cord	I-Biological_structure
paralysis	B-Disease_disorder
,	O
expression	O
of	O
hypoglossal	B-Biological_structure
and	O
recurrent	B-Detailed_description
laryngeal	B-Biological_structure
nerve	B-Disease_disorder
injury	I-Disease_disorder
without	O
local	B-Detailed_description
oedema	B-Sign_symptom
or	O
haematoma	B-Sign_symptom
.	O

The	O
movements	B-Diagnostic_procedure
of	O
the	O
pharynx	B-Biological_structure
and	O
soft	B-Biological_structure
palate	I-Biological_structure
were	O
normal	B-Lab_value
.	O

Meticulous	O
neurological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
including	O
also	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRN	B-Diagnostic_procedure
)	O
revealed	O
no	O
other	O
evidence	O
of	O
central	B-Biological_structure
or	O
cranial	B-Biological_structure
nerve	B-Sign_symptom
involvement	I-Sign_symptom
.	O

Conservative	O
management	O
included	O
steroids	B-Medication
,	O
vitamins	B-Medication
together	O
with	O
speech	B-Detailed_description
and	O
swallowing	B-Detailed_description
therapy	B-Therapeutic_procedure
.	O

Full	B-Lab_value
recovery	I-Lab_value
of	O
lingual	B-Biological_structure
and	O
laryngeal	B-Biological_structure
functions	B-Diagnostic_procedure
was	O
obtained	O
within	O
four	O
months	O
after	O
surgery	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
21	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
to	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
with	O
a	O
rash	B-Sign_symptom
on	O
his	O
arms	B-Biological_structure
and	O
neck	B-Biological_structure
(	O
figure	O
1	O
)	O
.	O

It	O
had	O
developed	O
over	B-Duration
the	I-Duration
course	I-Duration
of	I-Duration
36	I-Duration
h	I-Duration
from	O
discrete	B-Detailed_description
`	I-Detailed_description
pin	I-Detailed_description
prick	I-Detailed_description
`	I-Detailed_description
areas	I-Detailed_description
of	O
erythema	B-Sign_symptom
into	O
a	O
maculopapular	B-Detailed_description
rash	B-Sign_symptom
with	O
vesicles	B-Detailed_description
(	O
figure	O
2	O
)	O
.	O

It	O
covered	O
his	O
forearms	B-Biological_structure
from	O
the	O
dorsal	B-Biological_structure
aspect	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
hands	I-Biological_structure
to	O
the	O
flexor	B-Biological_structure
surface	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
elbows	I-Biological_structure
.	O

It	O
was	O
also	O
beginning	O
to	O
develop	O
around	O
his	O
neck	B-Biological_structure
(	O
figure	O
3	O
)	O
.	O

He	O
described	O
the	O
rash	B-Sign_symptom
as	O
itchy	B-Detailed_description
and	O
painful	B-Detailed_description
,	O
and	O
was	O
feeling	B-Diagnostic_procedure
`	O
under	B-Lab_value
the	I-Lab_value
weather	I-Lab_value
`	O
.	O

The	O
patient	O
had	O
no	O
previous	O
dermatological	O
or	O
other	O
medical	O
history	O
of	O
note	O
.	O

He	O
took	O
no	O
medication	B-Medication
.	O

He	O
worked	B-Occupation
in	I-Occupation
a	I-Occupation
supermarket	I-Occupation
handling	I-Occupation
food	I-Occupation
items	I-Occupation
but	O
there	O
was	O
no	O
history	O
of	O
occupational	O
chemical	O
exposure	O
.	O

He	O
had	O
not	O
recently	O
had	O
any	O
change	O
in	O
washing	O
powder	O
or	O
personal	O
hygiene	O
products	O
.	O

Physiological	B-Diagnostic_procedure
observations	I-Diagnostic_procedure
were	O
entirely	O
normal	B-Lab_value
and	O
systemic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
unremarkable	B-Lab_value
.	O

Closer	O
examination	B-Diagnostic_procedure
of	O
the	O
rash	B-Sign_symptom
revealed	O
that	O
it	O
was	O
present	O
only	O
on	O
skin	B-Biological_structure
exposed	B-Activity
to	I-Activity
the	I-Activity
sun	I-Activity
when	O
wearing	B-Activity
a	I-Activity
short	I-Activity
-	I-Activity
sleeved	I-Activity
shirt	I-Activity
;	O
the	O
most	O
striking	O
feature	O
was	O
the	O
`	B-Other_entity
V	I-Other_entity
`	I-Other_entity
shape	I-Other_entity
on	I-Other_entity
the	I-Other_entity
patient	I-Other_entity
`	I-Other_entity
s	I-Other_entity
chest	I-Other_entity
in	O
keeping	O
with	O
the	O
neck	O
line	O
of	O
a	O
polo	O
shirt	O
.	O

On	O
further	O
questioning	O
the	O
patient	O
described	O
a	O
period	O
of	O
time	O
48	O
h	O
prior	O
to	O
presentation	O
(	O
and	O
12	O
h	O
prior	O
to	O
the	O
development	O
of	O
the	O
rash	B-Sign_symptom
)	O
spent	O
strimming	B-Activity
the	I-Activity
grass	I-Activity
under	O
the	O
hedges	O
in	O
his	O
garden	O
.	O

Blood	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
including	O
full	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
urea	B-Diagnostic_procedure
and	O
electrolytes	B-Diagnostic_procedure
,	O
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
test	I-Diagnostic_procedure
and	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
reactive	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
were	O
all	O
within	B-Lab_value
normal	I-Lab_value
reference	I-Lab_value
ranges	I-Lab_value
.	O

The	O
list	O
of	O
potential	O
differential	O
diagnoses	O
for	O
a	O
maculopapular	O
rash	O
is	O
long	O
,	O
but	O
given	O
the	O
distribution	O
of	O
the	O
rash	O
and	O
the	O
history	O
of	O
plant	O
material	O
exposure	O
a	O
diagnosis	O
of	O
phytophotodermatitis	B-Disease_disorder
was	O
made	O
.	O

The	O
patient	O
was	O
discharged	O
with	O
chlorphenamine	B-Medication
,	O
simple	B-Medication
analgesia	I-Medication
and	O
the	O
advice	B-Other_event
to	I-Other_event
wear	I-Other_event
a	I-Other_event
long	I-Other_event
-	I-Other_event
sleeved	I-Other_event
t	I-Other_event
-	I-Other_event
shirt	I-Other_event
and	I-Other_event
sunscreen	I-Other_event
when	O
gardening	O
in	O
the	O
future	O
.	O

The	O
rash	B-Sign_symptom
resolved	O
over	O
a	O
period	B-Duration
of	I-Duration
3	I-Duration
weeks	I-Duration
.	O

It	O
remained	O
pruritic	B-Detailed_description
throughout	O
healing	O
but	O
the	O
associated	O
pain	B-Sign_symptom
settled	O
over	B-Duration
a	I-Duration
few	I-Duration
days	I-Duration
.	O

Residual	O
scarring	B-Sign_symptom
is	O
beginning	O
to	O
fade	O
2	O
months	O
after	O
presentation	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
58	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
had	O
been	O
suffering	O
from	O
general	B-Sign_symptom
fatigue	I-Sign_symptom
and	O
severe	B-Severity
anemia	B-Sign_symptom
for	O
several	B-Duration
months	I-Duration
.	O

His	O
hemoglobin	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
were	O
6	B-Lab_value
.	I-Lab_value
6	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
(	O
normal	O
range	O
:	O
12	O
-	O
16	O
g	O
/	O
dl	O
)	O
.	O

He	O
had	O
no	O
medical	O
history	O
and	O
did	O
not	O
take	O
any	O
medicine	O
.	O

Esophagogastroduodenoscopy	B-Diagnostic_procedure
and	O
colonoscopy	B-Diagnostic_procedure
did	O
not	O
reveal	O
any	O
significant	O
bleeding	B-Sign_symptom
.	O

Abdominal	B-Biological_structure
computer	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
revealed	O
a	O
2	B-Distance
-	I-Distance
cm	I-Distance
hypervascular	B-Detailed_description
tumor	B-Sign_symptom
in	O
the	O
small	B-Biological_structure
intestine	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Oral	O
DBE	B-Diagnostic_procedure
detected	O
a	O
2	B-Distance
-	I-Distance
cm	I-Distance
-	I-Distance
diameter	I-Distance
reddish	B-Color
,	O
submucosal	B-Biological_structure
tumor	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
lesion	B-Sign_symptom
with	O
surface	B-Detailed_description
ulceration	I-Detailed_description
in	O
the	O
jejunum	B-Biological_structure
,	O
approximately	O
20	B-Biological_structure
cm	I-Biological_structure
away	I-Biological_structure
from	I-Biological_structure
the	I-Biological_structure
Treitz	I-Biological_structure
ligament	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

We	O
did	O
not	O
perform	O
biopsy	B-Diagnostic_procedure
because	O
it	O
can	O
be	O
difficult	O
to	O
stop	O
bleeding	O
in	O
the	O
case	O
of	O
hypervascular	O
lesions	O
.	O

Under	O
the	O
diagnosis	O
of	O
a	O
small	B-Disease_disorder
bowel	I-Disease_disorder
tumor	I-Disease_disorder
,	O
gastrointestinal	B-Disease_disorder
stromal	I-Disease_disorder
tumor	I-Disease_disorder
(	O
GIST	B-Disease_disorder
)	O
,	O
malignant	B-Disease_disorder
lymphoma	I-Disease_disorder
,	O
or	O
cancer	B-Disease_disorder
,	O
we	O
performed	O
laparoscopic	B-Detailed_description
-	I-Detailed_description
assisted	I-Detailed_description
segmental	B-Detailed_description
resection	B-Therapeutic_procedure
of	O
the	O
jejunum	B-Biological_structure
with	O
the	O
dissection	B-Detailed_description
of	I-Detailed_description
lymph	I-Detailed_description
nodes	I-Detailed_description
.	O

Examination	B-Diagnostic_procedure
of	O
the	O
resected	B-Detailed_description
tumor	B-Sign_symptom
showed	O
that	O
it	O
measured	O
19	B-Area
×	I-Area
16	I-Area
mm	I-Area
in	O
diameter	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Histology	B-Diagnostic_procedure
revealed	O
the	O
proliferation	B-Sign_symptom
of	I-Sign_symptom
blood	I-Sign_symptom
capillaries	I-Sign_symptom
and	O
granulation	B-Sign_symptom
tissue	I-Sign_symptom
,	O
which	O
was	O
consistent	O
with	O
PG	B-Disease_disorder
(	O
Fig	O
.	O
4	O
)	O
.	O

The	O
patient	O
was	O
discharged	O
on	O
postoperative	O
day	O
9	O
without	O
complication	B-Sign_symptom
and	O
his	O
anemia	B-Sign_symptom
improved	B-Lab_value
gradually	O
without	O
the	O
need	O
for	O
oral	B-Medication
iron	I-Medication
after	O
surgery	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
24	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Azeri	O
male	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
blurred	B-Sign_symptom
vision	I-Sign_symptom
in	O
both	B-Biological_structure
eyes	I-Biological_structure
.	O

He	O
was	O
diagnosed	O
with	O
achondroplasia	O
in	O
early	O
childhood	O
.	O

He	O
was	O
born	O
at	O
term	O
with	O
normal	O
birth	O
weight	O
.	O

There	O
was	O
no	O
history	O
of	O
hereditary	O
ocular	O
or	O
systemic	O
disease	O
.	O

This	O
patient	O
had	O
characteristic	B-Sign_symptom
features	I-Sign_symptom
of	I-Sign_symptom
achondroplasia	I-Sign_symptom
(	O
i	O
.	O
e	O
.	O
,	O
short	O
stature	O
,	O
lumbar	O
lordosis	O
,	O
short	O
proximal	O
long	O
bones	O
,	O
large	O
hands	O
,	O
frontal	O
bossing	O
,	O
and	O
flat	O
nasal	O
bridge	O
)	O
[	O
Figure	O
1	O
]	O
.	O

His	O
height	O
was	O
108	B-Height
cm	I-Height
.	O

Best	O
corrected	B-Detailed_description
visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
was	O
20	B-Lab_value
/	I-Lab_value
70	I-Lab_value
in	O
the	O
right	B-Biological_structure
eye	I-Biological_structure
with	O
−	B-Lab_value
0	I-Lab_value
.	I-Lab_value
75	I-Lab_value
+	I-Lab_value
1	I-Lab_value
.	I-Lab_value
25	I-Lab_value
×	I-Lab_value
60	I-Lab_value
°	I-Lab_value
and	O
20	B-Lab_value
/	I-Lab_value
70	I-Lab_value
in	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
with	O
OS	B-Biological_structure
:	O
+0	B-Lab_value
.	I-Lab_value
25	I-Lab_value
+	I-Lab_value
0	I-Lab_value
.	I-Lab_value
50	I-Lab_value
×	I-Lab_value
130	I-Lab_value
°	I-Lab_value
.	O

Pupils	B-Biological_structure
were	O
equal	B-Detailed_description
in	I-Detailed_description
size	I-Detailed_description
,	O
round	B-Detailed_description
and	O
reactive	B-Detailed_description
to	I-Detailed_description
light	I-Detailed_description
with	O
no	O
reverse	B-Sign_symptom
afferent	I-Sign_symptom
pupillary	I-Sign_symptom
defect	I-Sign_symptom
.	O

Ocular	B-Diagnostic_procedure
motility	I-Diagnostic_procedure
was	O
normal	B-Lab_value
in	O
both	B-Biological_structure
eyes	I-Biological_structure
and	O
slit	B-Diagnostic_procedure
lamp	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
.	O

The	O
intraocular	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
12	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
by	O
Goldmann	B-Detailed_description
applanation	I-Detailed_description
tonometry	I-Detailed_description
.	O

Central	B-Diagnostic_procedure
corneal	I-Diagnostic_procedure
thickness	I-Diagnostic_procedure
values	I-Diagnostic_procedure
of	O
the	O
right	B-Biological_structure
and	I-Biological_structure
left	B-Biological_structure
eyes	I-Biological_structure
were	O
,	O
561	B-Lab_value
and	I-Lab_value
557	B-Lab_value
μ	I-Lab_value
,	O
respectively	O
.	O

Dilated	B-Diagnostic_procedure
fundus	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
well	B-Detailed_description
-	I-Detailed_description
demarcated	I-Detailed_description
circular	B-Shape
macular	B-Biological_structure
lesion	B-Sign_symptom
in	O
both	B-Biological_structure
eyes	I-Biological_structure
.	O

In	O
the	O
right	B-Biological_structure
eye	I-Biological_structure
,	O
this	O
lesion	B-Sign_symptom
was	O
approximately	O
2	B-Distance
.	I-Distance
5	I-Distance
disc	I-Distance
diameters	I-Distance
(	I-Distance
DD	I-Distance
)	I-Distance
in	I-Distance
width	I-Distance
and	O
2	B-Distance
.	I-Distance
7	I-Distance
DD	I-Distance
in	I-Distance
length	I-Distance
.	O

In	O
the	O
left	B-Biological_structure
eye	I-Biological_structure
,	O
this	O
lesion	B-Sign_symptom
was	O
approximately	O
2	B-Distance
.	I-Distance
5	I-Distance
DD	I-Distance
in	I-Distance
width	I-Distance
and	O
2	B-Distance
.	I-Distance
8	I-Distance
DD	I-Distance
in	I-Distance
length	I-Distance
.	O

The	O
border	B-Detailed_description
of	O
the	O
lesions	B-Sign_symptom
was	O
pigmented	B-Detailed_description
.	O

Underlying	O
choroidal	B-Biological_structure
and	O
overlying	O
retinal	B-Biological_structure
vasculature	B-Biological_structure
appeared	O
normal	B-Lab_value
.	O

In	O
addition	O
,	O
a	O
stalk	B-Sign_symptom
of	I-Sign_symptom
tissue	I-Sign_symptom
emanated	O
from	B-Biological_structure
the	I-Biological_structure
optic	I-Biological_structure
disc	I-Biological_structure
and	O
coursed	O
into	B-Biological_structure
the	I-Biological_structure
vitreous	I-Biological_structure
[	O
Figure	O
2	O
]	O
.	O

Fluorescein	B-Detailed_description
angiography	B-Diagnostic_procedure
of	O
the	O
posterior	B-Biological_structure
segment	I-Biological_structure
and	O
optical	B-Diagnostic_procedure
coherence	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
of	O
the	O
optic	B-Biological_structure
nerve	I-Biological_structure
head	I-Biological_structure
(	O
Stratus	O
;	O
Carl	O
Zeiss	O
GmbH	O
,	O
Jena	O
,	O
Germany	O
)	O
were	O
performed	O
[	O
Figures	O
[	O
Figures3	O
and	O
4	O
]	O
.	O

Due	O
to	O
the	O
background	O
maculopathy	O
,	O
the	O
patient	O
could	O
not	O
appropriately	O
fixate	O
on	O
the	O
target	O
during	O
image	O
acquisition	O
resulting	O
in	O
slightly	O
decentered	O
fluorescein	O
angiography	O
images	O
[	O
Figure	O
3	O
]	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
70	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
presented	O
to	O
the	O
Emergency	B-Nonbiological_location
Department	I-Nonbiological_location
with	O
palpitations	B-Sign_symptom
,	O
dyspnea	B-Sign_symptom
and	O
anterior	B-Detailed_description
epistaxis	B-Sign_symptom
.	O

She	O
had	O
a	O
3	B-Duration
years	I-Duration
history	O
of	O
atrial	B-Disease_disorder
fibrillation	I-Disease_disorder
and	O
chronic	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
NYHA	B-Lab_value
class	I-Lab_value
III	I-Lab_value
.	O

She	O
was	O
treated	O
with	O
aspirin	B-Medication
100	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
an	O
irregular	B-Lab_value
pulse	B-Diagnostic_procedure
of	O
148	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
130	B-Lab_value
/	I-Lab_value
100	I-Lab_value
mmHg	I-Lab_value
,	O
pansystolic	B-Detailed_description
mitral	B-Biological_structure
murmur	B-Sign_symptom
of	O
2	B-Lab_value
/	I-Lab_value
6	I-Lab_value
grade	I-Lab_value
,	O
murmur	B-Sign_symptom
of	O
tricuspid	B-Biological_structure
regurgitation	B-Detailed_description
of	O
3	B-Lab_value
/	I-Lab_value
6	I-Lab_value
grade	I-Lab_value
,	O
lower	B-Biological_structure
extremities	I-Biological_structure
swelling	B-Sign_symptom
.	O

The	O
oto	B-Diagnostic_procedure
-	I-Diagnostic_procedure
rhino	I-Diagnostic_procedure
-	I-Diagnostic_procedure
laryngology	I-Diagnostic_procedure
exam	I-Diagnostic_procedure
conclusion	O
was	O
of	O
anterior	B-Detailed_description
epistaxis	B-Sign_symptom
.	O

The	O
12	B-Detailed_description
-	I-Detailed_description
lead	I-Detailed_description
electrocardiogram	B-Diagnostic_procedure
revealed	O
atrial	B-Disease_disorder
fibrillation	I-Disease_disorder
,	O
inferior	B-Detailed_description
ischemia	B-Sign_symptom
.	O

Her	O
International	B-Diagnostic_procedure
Normalized	I-Diagnostic_procedure
Ratio	I-Diagnostic_procedure
(	O
INR	B-Diagnostic_procedure
)	O
was	O
of	O
1,24	B-Lab_value
.	O

The	O
two	B-Detailed_description
-	I-Detailed_description
dimensional	I-Detailed_description
transthoracic	B-Biological_structure
echocardiography	B-Diagnostic_procedure
showed	O
the	O
thickening	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
mitral	I-Sign_symptom
valves	I-Sign_symptom
with	O
a	O
moderate	B-Severity
mitral	B-Sign_symptom
insufficiency	I-Sign_symptom
and	O
a	O
mobile	B-Detailed_description
round	B-Shape
mass	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
atrium	I-Biological_structure
,	O
heterogeneous	B-Detailed_description
,	O
inhomogeneous	B-Detailed_description
,	O
of	O
18	B-Distance
mm	I-Distance
in	O
size	O
,	O
attached	B-Detailed_description
with	I-Detailed_description
a	I-Detailed_description
narrow	I-Detailed_description
stalk	I-Detailed_description
to	O
the	O
interatrial	B-Biological_structure
septum	I-Biological_structure
.	O

It	O
showed	O
a	O
tumor	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
movement	I-Detailed_description
with	I-Detailed_description
a	I-Detailed_description
cardiac	I-Detailed_description
cycle	I-Detailed_description
,	O
reaching	O
the	O
mitral	B-Biological_structure
annular	I-Biological_structure
plane	I-Biological_structure
(	O
Figure	O
1	O
,	O
Figure	O
2	O
)	O
.	O

Also	O
,	O
echocardiography	B-Diagnostic_procedure
showed	O
tricuspid	B-Sign_symptom
insufficiency	I-Sign_symptom
with	O
a	O
maximum	B-Diagnostic_procedure
gradient	I-Diagnostic_procedure
of	O
30	B-Lab_value
mmHg	I-Lab_value
,	O
intact	B-Sign_symptom
interatrial	I-Sign_symptom
septum	I-Sign_symptom
,	O
akinesia	B-Sign_symptom
of	O
two	B-Biological_structure
thirds	I-Biological_structure
of	I-Biological_structure
basal	I-Biological_structure
inferior	I-Biological_structure
wall	I-Biological_structure
,	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
42	B-Lab_value
%	I-Lab_value
.	O

There	O
was	O
no	O
mass	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
atrial	I-Biological_structure
appendage	I-Biological_structure
.	O

The	O
two	B-Detailed_description
-	I-Detailed_description
dimensional	I-Detailed_description
transesophageal	B-Biological_structure
echocardiography	B-Diagnostic_procedure
confirmed	O
the	O
presence	O
of	O
the	O
intraatrial	B-Biological_structure
mass	B-Sign_symptom
.	O

Epistaxis	B-Sign_symptom
was	O
considered	O
to	O
be	O
due	O
to	O
heart	B-Disease_disorder
failure	I-Disease_disorder
and	O
the	O
increased	B-Lab_value
venous	B-Sign_symptom
pressure	I-Sign_symptom
.	O

The	O
patient	O
was	O
referred	O
to	O
the	O
cardiovascular	B-Nonbiological_location
surgery	I-Nonbiological_location
clinic	I-Nonbiological_location
,	O
but	O
she	O
refused	O
surgery	B-Therapeutic_procedure
.	O

Anticoagulation	B-Therapeutic_procedure
with	O
fraxiparine	B-Medication
of	O
0,6	B-Dosage
ml	I-Dosage
/	I-Dosage
day	I-Dosage
was	O
started	O
and	O
continued	O
for	B-Duration
3	I-Duration
weeks	I-Duration
,	O
after	O
cessation	O
of	O
epistaxis	B-Sign_symptom
by	O
nasal	B-Therapeutic_procedure
tamponament	I-Therapeutic_procedure
.	O

After	O
3	O
weeks	O
the	O
echocardiography	B-Diagnostic_procedure
was	O
repeated	O
,	O
with	O
no	O
remnant	O
mass	B-Sign_symptom
in	O
the	O
left	O
atrium	O
.	O

The	O
conclusion	O
was	O
that	O
the	O
mass	O
must	O
have	O
been	O
a	O
thrombus	B-Sign_symptom
that	O
has	O
melted	O
away	O
.	O

In	O
this	O
particular	O
case	O
,	O
the	O
left	O
intraatrial	O
thrombus	O
may	O
have	O
been	O
due	O
to	O
the	O
presence	O
of	O
atrial	O
fibrillation	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
61	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Chinese	O
woman	O
complained	O
of	O
dizziness	B-Sign_symptom
for	O
3	B-Duration
weeks	I-Duration
and	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
after	O
a	O
bifrontal	B-Biological_structure
mass	B-Sign_symptom
was	O
found	O
radiologically	B-Diagnostic_procedure
.	O

Other	O
than	O
dizziness	B-Sign_symptom
,	O
the	O
patient	O
presented	O
no	O
signs	B-Sign_symptom
or	I-Sign_symptom
symptoms	I-Sign_symptom
that	I-Sign_symptom
are	I-Sign_symptom
commonly	I-Sign_symptom
associated	I-Sign_symptom
with	I-Sign_symptom
neurological	I-Sign_symptom
disease	I-Sign_symptom
,	O
such	O
as	O
headache	B-Sign_symptom
,	O
vomiting	B-Sign_symptom
,	O
sensory	B-Sign_symptom
disturbances	I-Sign_symptom
,	O
altered	B-Sign_symptom
consciousness	I-Sign_symptom
,	O
or	O
seizures	B-Sign_symptom
.	O

Except	O
for	O
a	O
20	O
-	O
year	O
history	O
of	O
hypertension	O
,	O
which	O
was	O
properly	O
controlled	O
with	O
angiotensin	B-Medication
-	I-Medication
converting	I-Medication
enzyme	I-Medication
inhibitors	I-Medication
,	O
the	O
patient	O
was	O
otherwise	O
healthy	B-Sign_symptom
.	O

No	O
special	O
circumstances	O
were	O
identified	O
regarding	O
her	O
personal	O
or	O
family	O
history	O
,	O
and	O
the	O
patient	O
was	O
found	O
to	O
be	O
normal	B-Lab_value
upon	O
neurological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
.	O

Plain	B-Detailed_description
and	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
of	O
the	O
head	B-Biological_structure
showed	O
a	O
space	B-Detailed_description
-	I-Detailed_description
occupying	I-Detailed_description
lesion	B-Sign_symptom
in	O
the	O
bifrontal	B-Biological_structure
lobe	I-Biological_structure
,	O
mainly	B-Biological_structure
on	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
side	I-Biological_structure
,	O
clinging	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
sagittal	I-Biological_structure
sinus	I-Biological_structure
and	O
the	O
cerebral	B-Biological_structure
falx	I-Biological_structure
.	O

The	O
5	B-Volume
.	I-Volume
7	I-Volume
×	I-Volume
5	I-Volume
.	I-Volume
0	I-Volume
×	I-Volume
5	I-Volume
.	I-Volume
0	I-Volume
cm	I-Volume
dural	O
-	O
based	O
mass	O
growing	O
across	B-Biological_structure
the	I-Biological_structure
sagittal	I-Biological_structure
midline	I-Biological_structure
revealed	O
isointensity	B-Sign_symptom
on	O
the	O
T1	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
image	I-Diagnostic_procedure
and	O
a	O
slight	O
hyperintensity	B-Sign_symptom
on	O
the	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
image	I-Diagnostic_procedure
and	O
was	O
homogenously	O
enhanced	O
with	O
a	O
characteristic	B-Detailed_description
`	I-Detailed_description
dural	I-Detailed_description
-	I-Detailed_description
tail	I-Detailed_description
`	I-Detailed_description
sign	I-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
.	O

Diagnosis	O
of	O
a	O
parasagittal	B-Detailed_description
-	I-Detailed_description
parafalcine	I-Detailed_description
meningioma	B-Disease_disorder
was	O
made	O
,	O
and	O
a	O
craniotomic	B-Detailed_description
meningioma	O
resection	B-Therapeutic_procedure
was	O
chosen	O
as	O
treatment	O
.	O

The	O
blood	B-Diagnostic_procedure
cell	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
;	O
coagulation	B-Diagnostic_procedure
function	I-Diagnostic_procedure
,	O
liver	B-Diagnostic_procedure
and	I-Diagnostic_procedure
renal	I-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	O
;	O
urinalysis	B-Diagnostic_procedure
;	O
chest	B-Biological_structure
x	B-Diagnostic_procedure
-	I-Diagnostic_procedure
rays	I-Diagnostic_procedure
and	O
electrocardiogram	B-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

The	O
albumin	B-Diagnostic_procedure
was	O
36	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
the	O
total	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
(	O
TBil	B-Diagnostic_procedure
)	O
was	O
12	B-Lab_value
.	I-Lab_value
2	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
the	O
direct	B-Diagnostic_procedure
bilirubin	I-Diagnostic_procedure
(	O
DBil	B-Diagnostic_procedure
)	O
was	O
4	B-Lab_value
.	I-Lab_value
1	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

Alanine	B-Diagnostic_procedure
transaminase	I-Diagnostic_procedure
(	O
ALT	B-Diagnostic_procedure
)	O
was	O
17	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
the	O
international	B-Diagnostic_procedure
normalized	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
(	O
INR	B-Diagnostic_procedure
)	O
for	O
coagulation	O
values	O
was	O
1	B-Lab_value
.	I-Lab_value
02	I-Lab_value
.	O

Because	O
of	O
the	O
patient	O
`	O
s	O
advanced	O
age	O
and	O
history	O
of	O
hypertension	O
,	O
we	O
performed	O
an	O
echocardiograph	B-Diagnostic_procedure
and	O
a	O
blood	B-Diagnostic_procedure
gas	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
and	O
tested	O
her	O
creatine	B-Diagnostic_procedure
kinase	I-Diagnostic_procedure
levels	O
and	O
pulmonary	B-Diagnostic_procedure
functions	I-Diagnostic_procedure
.	O

The	O
results	O
revealed	O
no	B-Lab_value
surgical	I-Lab_value
contraindications	I-Lab_value
.	O

Written	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
.	O

Five	B-Dosage
hundred	I-Dosage
milligrams	I-Dosage
of	O
VPA	B-Medication
twice	B-Dosage
per	I-Dosage
day	I-Dosage
was	O
initiated	O
3	O
days	O
before	O
the	O
operation	O
.	O

The	O
patient	O
tolerated	O
the	O
administration	O
well	O
.	O

A	O
craniotomy	B-Therapeutic_procedure
was	O
then	O
performed	O
with	O
a	O
radical	O
tumor	B-Therapeutic_procedure
resection	I-Therapeutic_procedure
(	O
Simpson	O
II	O
)	O
.	O

The	O
tumor	O
was	O
pink	B-Color
and	O
solid	B-Detailed_description
and	O
had	O
a	O
moderate	B-Detailed_description
blood	I-Detailed_description
supply	I-Detailed_description
,	O
and	O
its	O
texture	O
was	O
medium	B-Texture
.	O

Thirty	B-Time
minutes	I-Time
before	I-Time
the	I-Time
end	I-Time
of	I-Time
surgery	I-Time
,	O
800	B-Dosage
mg	I-Dosage
of	O
VPA	B-Medication
was	O
administered	O
by	O
intravenous	O
infusion	O
.	O

After	O
the	O
operation	O
,	O
the	O
patient	O
regained	O
consciousness	B-Sign_symptom
within	B-Time
30	I-Time
minutes	I-Time
and	O
scored	O
15	B-Lab_value
on	O
the	O
Glasgow	B-Diagnostic_procedure
coma	I-Diagnostic_procedure
scale	I-Diagnostic_procedure
(	O
GCS	B-Diagnostic_procedure
)	O
.	O

Two	O
hours	O
later	O
as	O
she	O
was	O
being	O
transported	O
back	O
to	O
her	O
ward	B-Nonbiological_location
,	O
the	O
patient	O
underwent	O
UGH	B-Disease_disorder
.	O

The	O
vomitus	B-Sign_symptom
(	O
approximately	B-Volume
50	I-Volume
mL	I-Volume
)	O
was	O
composed	O
of	O
coffee	B-Color
-	I-Color
colored	I-Color
blood	B-Detailed_description
.	O

Excluding	O
the	O
possible	O
etiology	O
of	O
endotracheal	B-Biological_structure
intubation	B-Detailed_description
damage	B-Sign_symptom
,	O
we	O
diagnosed	O
the	O
patient	O
as	O
experiencing	O
acute	B-Detailed_description
erosive	B-Detailed_description
-	I-Detailed_description
hemorrhagic	I-Detailed_description
gastritis	B-Disease_disorder
,	O
a	O
reaction	O
to	O
the	O
craniotomy	B-Detailed_description
injury	B-Sign_symptom
.	O

The	O
patient	O
was	O
given	O
omeprazole	B-Medication
to	O
inhibit	O
gastric	O
acid	O
secretion	O
,	O
and	O
the	O
hematemesis	B-Sign_symptom
ceased	O
.	O

The	O
patient	O
was	O
administered	O
VPA	B-Medication
(	O
1200	B-Dosage
mg	I-Dosage
,	O
intravenously	O
)	O
during	O
the	O
first	O
2	O
postoperative	O
days	O
.	O

Because	O
of	O
her	O
stomach	O
and	O
intestine	O
functional	O
recovery	O
,	O
the	O
VPA	B-Medication
dosage	O
was	O
changed	O
to	O
500	B-Dosage
mg	I-Dosage
via	O
oral	O
administration	O
twice	B-Dosage
a	I-Dosage
day	I-Dosage
.	O

A	O
brain	B-Biological_structure
MRI	B-Diagnostic_procedure
was	O
performed	O
on	O
postoperative	O
day	O
3	O
,	O
and	O
it	O
revealed	O
that	O
the	O
tumor	B-Sign_symptom
was	O
radically	O
removed	O
and	O
the	O
operative	B-Diagnostic_procedure
field	I-Diagnostic_procedure
was	O
clean	B-Lab_value
(	O
Fig	O
.	O
2A	O
and	O
B	O
)	O
.	O

A	O
subsequent	O
paraffin	B-Detailed_description
histological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
confirmed	O
the	O
diagnosis	O
of	O
meningioma	B-Disease_disorder
.	O

At	O
3	B-Time
am	I-Time
on	O
postoperative	O
day	B-Time
4	I-Time
,	O
the	O
patient	O
was	O
suddenly	O
found	O
in	O
a	O
deep	B-Severity
coma	B-Disease_disorder
.	O

Her	O
pupils	B-Sign_symptom
were	I-Sign_symptom
dilated	I-Sign_symptom
to	O
3	B-Distance
.	I-Distance
0	I-Distance
mm	I-Distance
and	O
round	B-Shape
,	O
and	O
the	O
light	B-Diagnostic_procedure
reflex	I-Diagnostic_procedure
was	O
sensitive	B-Lab_value
.	O

The	O
neurological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
,	O
and	O
her	O
vital	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
stable	B-Lab_value
;	O
however	O
,	O
her	O
mental	B-Diagnostic_procedure
state	I-Diagnostic_procedure
gradually	B-Lab_value
changed	I-Lab_value
to	O
a	O
deep	B-Lab_value
coma	B-Disease_disorder
(	O
GCS	B-Diagnostic_procedure
=	O
8	B-Lab_value
)	O
,	O
which	O
we	O
believed	O
was	O
caused	O
by	O
intracranial	B-Biological_structure
lesions	B-Sign_symptom
.	O

A	O
computerized	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
of	O
the	O
brain	B-Biological_structure
was	O
immediately	O
performed	O
;	O
however	O
,	O
it	O
failed	B-Lab_value
to	I-Lab_value
reveal	I-Lab_value
any	I-Lab_value
abnormalities	I-Lab_value
,	O
such	O
as	O
severe	B-Severity
brain	B-Biological_structure
swelling	B-Sign_symptom
,	O
intracranial	B-Disease_disorder
hemorrhage	I-Disease_disorder
,	O
or	O
cerebral	B-Disease_disorder
infarction	I-Disease_disorder
(	O
Fig	O
.	O
2C	O
)	O
.	O

Because	O
a	O
possible	O
cerebral	B-Disease_disorder
infarction	I-Disease_disorder
could	O
not	O
be	O
excluded	O
within	B-Time
24	I-Time
hours	I-Time
,	O
glucocorticoid	B-Medication
,	O
mannitol	B-Medication
,	O
and	O
a	O
vasodilator	B-Medication
were	O
used	O
.	O

The	O
patient	O
`	O
s	O
routine	O
laboratory	B-Diagnostic_procedure
results	I-Diagnostic_procedure
for	O
blood	B-Biological_structure
cell	I-Biological_structure
,	O
liver	B-Biological_structure
,	O
and	O
renal	B-Biological_structure
functions	B-Diagnostic_procedure
were	O
in	O
relatively	B-Lab_value
normal	I-Lab_value
ranges	I-Lab_value
.	O

The	O
albumin	B-Diagnostic_procedure
was	O
33	B-Lab_value
g	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
the	O
TBil	B-Diagnostic_procedure
was	O
13	B-Lab_value
.	I-Lab_value
3	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
the	O
DBil	B-Diagnostic_procedure
was	O
4	B-Lab_value
.	I-Lab_value
5	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

ALT	B-Diagnostic_procedure
was	O
12	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
the	O
INR	B-Diagnostic_procedure
for	O
coagulation	O
values	O
was	O
1	B-Lab_value
.	I-Lab_value
01	I-Lab_value
.	O

Because	O
of	O
her	O
history	O
of	O
UGH	O
,	O
we	O
checked	O
her	O
blood	B-Diagnostic_procedure
ammonia	I-Diagnostic_procedure
levels	O
and	O
performed	O
a	O
fecal	B-Diagnostic_procedure
occult	I-Diagnostic_procedure
blood	I-Diagnostic_procedure
test	I-Diagnostic_procedure
and	O
blood	B-Diagnostic_procedure
gas	I-Diagnostic_procedure
analysis	I-Diagnostic_procedure
.	O

Her	O
blood	O
ammonia	O
was	O
elevated	B-Lab_value
(	O
181	B-Lab_value
.	I-Lab_value
6	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
;	O
normal	O
range	O
is	O
11	O
-	O
32	O
μmol	O
/	O
L	O
)	O
,	O
whereas	O
the	O
fecal	O
occult	O
blood	O
test	O
was	O
positive	B-Lab_value
.	O

Thus	O
,	O
considering	O
her	O
history	O
and	O
elevated	O
blood	O
ammonia	O
,	O
she	O
was	O
diagnosed	O
with	O
UGH	B-Disease_disorder
-	O
induced	O
hepatic	B-Disease_disorder
encephalopathy	I-Disease_disorder
,	O
and	O
the	O
oral	O
administration	O
of	O
VPA	B-Medication
was	O
changed	O
to	O
intravenous	O
administration	O
to	O
prevent	O
seizures	O
.	O

Lactulose	B-Medication
,	O
vitamin	B-Medication
B	I-Medication
,	O
and	O
L	B-Medication
-	I-Medication
arginine	I-Medication
were	O
administered	O
,	O
clysis	B-Therapeutic_procedure
with	O
vinegar	B-Detailed_description
was	O
performed	O
,	O
and	O
the	O
patient	O
was	O
fasted	B-Therapeutic_procedure
.	O

The	O
patient	O
`	O
s	O
blood	B-Diagnostic_procedure
ammonia	I-Diagnostic_procedure
level	O
fluctuated	B-Lab_value
(	O
144	B-Lab_value
.	I-Lab_value
8	I-Lab_value
-	I-Lab_value
207	I-Lab_value
.	I-Lab_value
7	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
and	O
she	O
remained	O
unconscious	B-Sign_symptom
during	O
the	O
following	B-Duration
3	I-Duration
days	I-Duration
.	O

Because	O
of	O
the	O
unremarkable	O
progress	B-Lab_value
in	O
the	O
patient	O
`	O
s	O
mental	B-Diagnostic_procedure
state	I-Diagnostic_procedure
and	O
blood	B-Diagnostic_procedure
ammonia	I-Diagnostic_procedure
level	O
,	O
we	O
held	O
a	O
multidisciplinary	O
conference	O
to	O
discuss	O
diagnosis	O
and	O
treatment	O
,	O
initially	O
considering	O
hemodialysis	O
or	O
peritoneal	O
dialysis	O
.	O

After	O
the	O
multidisciplinary	O
discussion	O
,	O
a	O
suspected	O
diagnosis	O
of	O
VHE	B-Disease_disorder
was	O
finally	O
made	O
,	O
even	O
though	O
the	O
blood	B-Diagnostic_procedure
VPA	I-Diagnostic_procedure
level	O
was	O
within	O
the	O
normal	B-Lab_value
range	I-Lab_value
.	O

We	O
decided	O
to	O
stop	O
VPA	B-Medication
administration	O
before	O
performing	O
any	O
dialysis	O
and	O
administered	O
levetiracetam	O
instead	O
of	O
VPA	O
.	O

The	O
patient	O
`	O
s	O
blood	O
VPA	O
and	O
ammonia	O
levels	O
were	O
then	O
routinely	O
monitored	O
.	O

The	O
patient	O
`	O
s	O
mental	B-Diagnostic_procedure
state	I-Diagnostic_procedure
began	O
to	O
improve	B-Lab_value
from	O
the	O
first	B-Time
24	I-Time
hours	I-Time
of	O
VPA	O
discontinuation	O
,	O
and	O
she	O
achieved	O
complete	B-Detailed_description
consciousness	B-Sign_symptom
within	O
48	O
hours	O
(	O
GCS	B-Diagnostic_procedure
=	O
15	B-Lab_value
)	O
.	O

The	O
ammonia	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
in	O
her	O
blood	B-Biological_structure
decreased	B-Lab_value
dramatically	O
and	O
returned	O
to	O
normal	B-Lab_value
within	O
4	O
days	O
(	O
Fig	O
.	O
3	O
)	O
.	O

On	O
postoperative	O
day	O
15	O
(	O
8	O
days	O
after	O
the	O
discontinuation	O
of	O
VPA	O
)	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
no	O
complications	B-Sign_symptom
.	O

The	O
follow	O
-	O
up	O
interviews	O
in	O
postoperative	O
month	O
5	O
witnessed	O
her	O
full	B-Detailed_description
consciousness	B-Sign_symptom
and	O
non	O
-	O
recurrence	B-Sign_symptom
of	O
the	O
primary	B-Detailed_description
tumor	I-Detailed_description
(	O
Fig	O
.	O
2D	O
)	O
.	O

The	O
patient	O
`	O
s	O
GCS	B-Diagnostic_procedure
score	O
was	O
15	B-Lab_value
,	O
and	O
she	O
reported	O
enjoying	O
a	O
satisfying	B-Lab_value
quality	B-Diagnostic_procedure
of	I-Diagnostic_procedure
postoperative	I-Diagnostic_procedure
life	I-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

In	O
January	O
2009	O
,	O
a	O
57	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
emergently	O
presented	O
with	O
acute	B-Detailed_description
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
.	O

She	O
had	O
a	O
1	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
progressive	B-Detailed_description
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
and	O
a	O
gradual	B-Lab_value
decrease	I-Lab_value
in	O
exercise	B-Diagnostic_procedure
capacity	I-Diagnostic_procedure
secondary	O
to	O
mild	B-Severity
dyspnea	B-Sign_symptom
.	O

She	O
reported	O
no	O
additional	B-Sign_symptom
symptoms	I-Sign_symptom
.	O

At	O
age	O
40	O
,	O
she	O
had	O
been	O
diagnosed	O
with	O
a	O
stage	B-Lab_value
IIA	I-Lab_value
,	O
T1bN1	B-Lab_value
,	O
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
breast	B-Disease_disorder
cancer	I-Disease_disorder
.	O

Initial	O
treatment	O
had	O
included	O
a	O
lumpectomy	B-Therapeutic_procedure
and	O
axillary	B-Biological_structure
node	B-Therapeutic_procedure
dissection	I-Therapeutic_procedure
.	O

She	O
subsequently	O
underwent	O
4	B-Dosage
cycles	I-Dosage
of	O
DOX	B-Medication
therapy	I-Medication
(	O
75	B-Dosage
mg	I-Dosage
/	I-Dosage
m2	I-Dosage
)	O
,	O
followed	O
by	O
8	B-Dosage
cycles	I-Dosage
of	O
cyclophosphamide	B-Medication
,	O
methotrexate	B-Medication
,	O
and	O
5	B-Medication
-	I-Medication
fluorouracil	I-Medication
.	O

Multigated	B-Diagnostic_procedure
acquisition	I-Diagnostic_procedure
scans	I-Diagnostic_procedure
before	O
and	O
after	O
chemotherapy	B-Medication
showed	O
normal	B-Lab_value
cardiac	B-Diagnostic_procedure
function	I-Diagnostic_procedure
.	O

After	O
chemotherapy	B-Medication
,	O
she	O
underwent	O
left	B-Biological_structure
whole	I-Biological_structure
-	I-Biological_structure
breast	I-Biological_structure
radiation	B-Therapeutic_procedure
with	O
an	O
axillary	B-Detailed_description
boost	I-Detailed_description
.	O

Because	O
the	O
tumor	B-Sign_symptom
had	O
been	O
estrogen	B-Detailed_description
receptor	I-Detailed_description
-	I-Detailed_description
positive	I-Detailed_description
,	O
her	O
subsequent	O
medical	O
regimen	O
consisted	O
only	O
of	O
anti	B-Medication
-	I-Medication
estrogen	I-Medication
therapy	I-Medication
.	O

She	O
took	O
tamoxifen	B-Medication
for	O
5	B-Duration
years	I-Duration
,	O
and	O
,	O
ever	O
since	O
,	O
the	O
aromatase	O
inhibitor	O
letrozole	B-Medication
.	O

In	O
the	O
17	B-Duration
years	I-Duration
after	I-Duration
chemotherapy	O
,	O
she	O
had	O
been	O
active	B-Sign_symptom
and	O
in	O
relatively	B-Lab_value
good	I-Lab_value
health	B-Diagnostic_procedure
.	O

In	O
addition	O
to	O
her	O
other	O
symptoms	O
,	O
she	O
now	O
presented	O
with	O
tachycardia	B-Sign_symptom
,	O
tachypnea	B-Sign_symptom
,	O
and	O
hypertension	B-Sign_symptom
.	O

She	O
had	O
marked	O
jugular	B-Biological_structure
venous	I-Biological_structure
distention	B-Sign_symptom
,	O
an	O
S3	B-Sign_symptom
,	O
pulmonary	B-Sign_symptom
rales	I-Sign_symptom
,	O
and	O
trace	B-Severity
peripheral	B-Detailed_description
edema	B-Sign_symptom
.	O

Initial	O
laboratory	B-Diagnostic_procedure
values	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
except	O
for	O
an	O
elevated	B-Lab_value
level	O
of	O
N	B-Diagnostic_procedure
-	I-Diagnostic_procedure
terminal	I-Diagnostic_procedure
pro	I-Diagnostic_procedure
-	I-Diagnostic_procedure
brain	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
(	O
>	B-Lab_value
2,000	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
)	O
.	O

Results	O
of	O
investigation	O
into	O
the	O
new	O
-	O
onset	O
cardiomyopathy	B-Disease_disorder
included	O
normal	B-Lab_value
cardiac	B-Diagnostic_procedure
enzyme	I-Diagnostic_procedure
levels	O
,	O
an	O
electrocardiogram	B-Diagnostic_procedure
(	O
ECG	B-Diagnostic_procedure
)	O
that	O
revealed	O
no	O
ischemic	B-Sign_symptom
changes	I-Sign_symptom
,	O
and	O
a	O
coronary	B-Biological_structure
angiogram	B-Diagnostic_procedure
of	O
normal	B-Lab_value
appearance	O
.	O

The	O
ECG	B-Diagnostic_procedure
showed	O
sinus	B-Detailed_description
tachycardia	B-Sign_symptom
with	O
frequent	B-Frequency
premature	B-Sign_symptom
ventricular	I-Sign_symptom
complexes	I-Sign_symptom
,	O
left	B-Sign_symptom
-	I-Sign_symptom
axis	I-Sign_symptom
deviation	I-Sign_symptom
,	O
left	B-Biological_structure
atrial	I-Biological_structure
enlargement	B-Sign_symptom
,	O
and	O
low	B-Detailed_description
-	I-Detailed_description
voltage	I-Detailed_description
QRS	B-Sign_symptom
complexes	I-Sign_symptom
with	O
nonspecific	B-Detailed_description
ST	B-Sign_symptom
changes	I-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

A	O
2	B-Detailed_description
-	I-Detailed_description
dimensional	I-Detailed_description
echocardiogram	B-Diagnostic_procedure
revealed	O
a	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
ejection	I-Diagnostic_procedure
fraction	I-Diagnostic_procedure
(	O
LVEF	B-Diagnostic_procedure
)	O
of	O
0	B-Lab_value
.	I-Lab_value
20	I-Lab_value
,	O
severe	B-Severity
diffuse	B-Detailed_description
left	B-Biological_structure
ventricular	I-Biological_structure
(	O
LV	B-Biological_structure
)	O
hypokinesis	B-Sign_symptom
,	O
and	O
a	O
mildly	B-Severity
dilated	B-Sign_symptom
left	B-Biological_structure
atrium	I-Biological_structure
.	O

To	O
better	O
define	O
the	O
cause	O
of	O
the	O
LV	O
systolic	O
dysfunction	O
,	O
cardiovascular	B-Diagnostic_procedure
magnetic	I-Diagnostic_procedure
resonance	I-Diagnostic_procedure
(	O
CMR	B-Diagnostic_procedure
)	O
was	O
performed	O
.	O

It	O
confirmed	O
the	O
LVEF	B-Diagnostic_procedure
of	O
0	B-Lab_value
.	I-Lab_value
20	I-Lab_value
.	O

The	O
T2	B-Diagnostic_procedure
-	I-Diagnostic_procedure
weighted	I-Diagnostic_procedure
sequence	I-Diagnostic_procedure
showed	O
slow	B-Lab_value
flow	B-Diagnostic_procedure
secondary	O
to	O
LV	B-Biological_structure
dysfunction	B-Disease_disorder
,	O
and	O
no	O
myocardial	B-Biological_structure
edema	B-Sign_symptom
(	O
Fig	O
.	O
2A	O
)	O
.	O

Late	B-Detailed_description
gadolinium	B-Diagnostic_procedure
enhancement	I-Diagnostic_procedure
disclosed	O
diffuse	B-Detailed_description
myocardial	B-Biological_structure
thinning	B-Sign_symptom
and	O
no	O
scarring	B-Sign_symptom
(	O
Fig	O
.	O
2B	O
)	O
.	O

The	O
patient	O
was	O
treated	B-Therapeutic_procedure
medically	I-Therapeutic_procedure
.	O

Her	O
symptoms	B-Sign_symptom
progressively	O
improved	B-Lab_value
during	O
therapy	B-Therapeutic_procedure
,	O
which	O
consisted	O
of	O
a	O
β	B-Medication
-	I-Medication
blocker	I-Medication
,	O
an	O
angiotensin	B-Medication
-	I-Medication
converting	I-Medication
enzyme	I-Medication
inhibitor	I-Medication
,	O
digoxin	B-Medication
,	O
and	O
a	O
diuretic	B-Medication
.	O

The	O
therapy	O
was	O
slowly	O
tapered	B-Lab_value
,	O
and	O
her	O
LVEF	B-Diagnostic_procedure
increased	B-Lab_value
from	O
0	B-Lab_value
.	I-Lab_value
20	I-Lab_value
to	O
0	B-Lab_value
.	I-Lab_value
55	I-Lab_value
during	O
an	O
8	B-Duration
-	I-Duration
month	I-Duration
period	I-Duration
.	O

All	O
medications	B-Medication
except	O
for	O
low	B-Dosage
-	I-Dosage
dose	I-Dosage
metoprolol	B-Medication
were	O
discontinued	B-Lab_value
after	O
1	O
year	O
,	O
and	O
she	O
remained	O
asymptomatic	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
60	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Caucasian	O
woman	O
with	O
no	O
significant	O
medical	O
history	O
developed	O
exercise	B-Sign_symptom
intolerance	I-Sign_symptom
,	O
fatigue	B-Sign_symptom
and	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
on	O
exertion	B-Detailed_description
over	O
the	O
several	B-Duration
months	I-Duration
prior	I-Duration
to	O
her	O
presentation	O
to	O
our	O
outpatient	B-Nonbiological_location
clinic	I-Nonbiological_location
.	O

At	O
the	O
time	O
of	O
presentation	O
,	O
she	O
also	O
reported	O
of	O
dry	B-Detailed_description
cough	B-Sign_symptom
,	O
orthopnea	B-Sign_symptom
,	O
paroxysmal	B-Detailed_description
nocturnal	B-Detailed_description
dyspnoea	B-Sign_symptom
,	O
generalised	B-Detailed_description
weakness	B-Sign_symptom
and	O
intermittent	B-Detailed_description
numbness	B-Sign_symptom
of	O
her	O
hands	B-Biological_structure
and	O
feet	B-Biological_structure
.	O

Social	O
history	O
was	O
negative	O
for	O
smoking	B-Activity
,	O
alcohol	B-Activity
or	O
illicit	B-Activity
drugs	I-Activity
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
,	O
except	O
for	O
jugular	B-Biological_structure
venous	I-Biological_structure
distension	B-Sign_symptom
,	O
audible	O
S1	B-Sign_symptom
and	I-Sign_symptom
S2	I-Sign_symptom
sounds	I-Sign_symptom
,	O
bilateral	B-Detailed_description
crackles	B-Sign_symptom
on	O
lung	B-Diagnostic_procedure
auscultation	I-Diagnostic_procedure
and	O
bilateral	B-Detailed_description
pitting	B-Detailed_description
oedema	B-Sign_symptom
.	O

Chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
cardiomegaly	B-Sign_symptom
,	O
pulmonary	B-Sign_symptom
oedema	I-Sign_symptom
and	O
small	B-Severity
-	I-Severity
sized	I-Severity
bilateral	B-Detailed_description
pleural	B-Sign_symptom
effusions	I-Sign_symptom
.	O

A	O
12	B-Detailed_description
-	I-Detailed_description
lead	I-Detailed_description
ECG	B-Diagnostic_procedure
demonstrated	O
normal	B-Lab_value
sinus	B-Diagnostic_procedure
rhythm	I-Diagnostic_procedure
,	O
low	B-Sign_symptom
-	I-Sign_symptom
voltage	I-Sign_symptom
complexes	I-Sign_symptom
and	O
extreme	B-Severity
right	B-Sign_symptom
-	I-Sign_symptom
axis	I-Sign_symptom
deviation	I-Sign_symptom
(	O
figure	O
1	O
)	O
.	O

Transthoracic	B-Diagnostic_procedure
echocardiogram	I-Diagnostic_procedure
(	O
TTE	B-Diagnostic_procedure
)	O
demonstrated	O
asymmetric	B-Detailed_description
biventricular	B-Biological_structure
hypertrophy	B-Sign_symptom
with	O
preserved	B-Lab_value
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
60	B-Lab_value
%	I-Lab_value
,	O
elevated	B-Lab_value
right	B-Biological_structure
-	I-Biological_structure
ventricular	I-Biological_structure
systolic	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
36	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
and	O
abnormal	B-Lab_value
myocardial	B-Diagnostic_procedure
texture	I-Diagnostic_procedure
,	O
described	O
as	O
`	O
granular	B-Texture
sparkling	I-Texture
`	O
(	O
figure	O
2	O
)	O
.	O

Coronary	B-Biological_structure
CT	B-Diagnostic_procedure
angiogram	I-Diagnostic_procedure
demonstrated	O
normal	B-Lab_value
coronary	B-Biological_structure
arteries	I-Biological_structure
.	O

Subsequently	O
,	O
cardiac	B-Biological_structure
MRI	B-Diagnostic_procedure
demonstrated	O
early	B-Detailed_description
and	O
diffuse	B-Detailed_description
subendocardial	B-Biological_structure
delayed	B-Sign_symptom
enhancement	I-Sign_symptom
,	O
concerning	O
for	O
infiltrative	B-Disease_disorder
myocardial	I-Disease_disorder
disease	I-Disease_disorder
and	O
for	O
diffuse	B-Detailed_description
biventricular	B-Biological_structure
hypertrophy	B-Sign_symptom
,	O
with	O
normal	B-Lab_value
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
(	O
figure	O
3	O
)	O
.	O

The	O
patient	O
underwent	O
right	B-Detailed_description
heart	B-Therapeutic_procedure
catheterisation	I-Therapeutic_procedure
with	O
endomyocardial	B-Biological_structure
biopsy	B-Diagnostic_procedure
,	O
revealing	O
diffuse	B-Detailed_description
amyloidosis	B-Disease_disorder
with	O
amorphous	B-Detailed_description
proteinaceous	B-Sign_symptom
material	I-Sign_symptom
around	O
cardiac	B-Biological_structure
myocytes	I-Biological_structure
and	O
within	O
blood	B-Biological_structure
vessels	I-Biological_structure
,	O
which	O
was	O
positive	B-Lab_value
for	O
Congo	B-Diagnostic_procedure
red	I-Diagnostic_procedure
stain	I-Diagnostic_procedure
(	O
figure	O
4	O
)	O
.	O

Subsequent	O
laboratory	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
registered	O
elevated	B-Lab_value
,	O
free	B-Diagnostic_procedure
λ	I-Diagnostic_procedure
light	I-Diagnostic_procedure
chains	I-Diagnostic_procedure
(	O
86	B-Lab_value
.	I-Lab_value
3	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
:	O
5	O
.	O
7	O
-	O
26	O
.	O
3	O
mg	O
/	O
L	O
)	O
)	O
and	O
positive	B-Lab_value
Bence	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Jones	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
0	B-Lab_value
.	I-Lab_value
37	I-Lab_value
g	I-Lab_value
/	I-Lab_value
24	I-Lab_value
h	I-Lab_value
)	O
in	O
the	O
urine	B-Detailed_description
.	O

Bone	B-Biological_structure
marrow	I-Biological_structure
biopsy	B-Diagnostic_procedure
revealed	O
greater	B-Lab_value
than	I-Lab_value
10	I-Lab_value
%	I-Lab_value
infiltration	B-Diagnostic_procedure
of	O
CD19	B-Detailed_description
−	I-Detailed_description
CD56	I-Detailed_description
+	I-Detailed_description
CD138	I-Detailed_description
+	I-Detailed_description
plasma	I-Detailed_description
cells	I-Detailed_description
with	O
reversal	B-Lab_value
of	O
marrow	B-Diagnostic_procedure
κ	I-Diagnostic_procedure
/	I-Diagnostic_procedure
λ	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
(	O
<	B-Lab_value
1:2	I-Lab_value
,	O
normal	O
:	O
2:1	O
)	O
,	O
consistent	O
with	O
MM	B-Disease_disorder
.	O

The	O
patient	O
was	O
eventually	O
diagnosed	O
with	O
systemic	B-Detailed_description
AL	B-Detailed_description
amyloidosis	B-Disease_disorder
with	O
advanced	B-Severity
,	O
stage	B-Detailed_description
III	I-Detailed_description
,	O
cardiac	B-Biological_structure
amyloidosis	B-Disease_disorder
due	O
to	O
underlying	O
MM	B-Disease_disorder
.	O

Given	O
her	O
advanced	B-Severity
cardiac	B-Biological_structure
amyloidosis	B-Disease_disorder
,	O
the	O
patient	O
was	O
deemed	O
a	O
poor	O
candidate	O
for	O
autologous	B-Therapeutic_procedure
stem	I-Therapeutic_procedure
-	I-Therapeutic_procedure
cell	I-Therapeutic_procedure
transplantation	I-Therapeutic_procedure
.	O

The	O
patient	O
was	O
started	O
on	O
systemic	B-Detailed_description
chemotherapy	B-Medication
with	O
melphalan	B-Medication
and	O
dexamethasone	B-Medication
.	O

Despite	O
receiving	O
standard	O
therapy	O
for	O
heart	O
failure	O
-	O
including	O
diuretics	B-Medication
,	O
β	B-Medication
-	I-Medication
blockers	I-Medication
and	O
ACE	B-Medication
inhibitors	I-Medication
-	O
the	O
patient	O
`	O
s	O
condition	B-Diagnostic_procedure
continued	O
to	O
worsen	B-Lab_value
and	O
she	O
succumbed	O
to	O
sudden	B-Disease_disorder
cardiac	I-Disease_disorder
death	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

The	O
patient	O
was	O
a	O
38	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Caucasian	O
man	O
of	O
Spanish	O
origin	O
.	O

His	O
height	O
was	O
165	B-Height
cm	I-Height
and	O
his	O
parents	O
were	O
cousins	O
.	O

Both	O
parents	O
were	O
of	O
normal	B-Detailed_description
height	I-Detailed_description
and	O
neither	B-Detailed_description
showed	I-Detailed_description
any	I-Detailed_description
minor	I-Detailed_description
anomalies	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
EvC	I-Detailed_description
syndrome	I-Detailed_description
spectrum	I-Detailed_description
.	O

The	O
patient	O
had	O
two	O
healthy	B-Detailed_description
sisters	O
.	O

His	O
morphological	B-Diagnostic_procedure
features	I-Diagnostic_procedure
were	O
:	O
(	O
a	O
)	O
normal	B-Sign_symptom
mouth	I-Sign_symptom
opening	I-Sign_symptom
with	O
missing	B-Sign_symptom
lower	I-Sign_symptom
incisors	I-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
;	O
(	O
b	O
)	O
small	B-Sign_symptom
chest	I-Sign_symptom
,	O
as	O
determined	O
by	O
a	O
cardiothoracic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
;	O
and	O
(	O
c	O
)	O
disproportionately	O
short	B-Sign_symptom
extremities	I-Sign_symptom
with	O
one	B-Detailed_description
additional	B-Sign_symptom
postaxial	I-Sign_symptom
digit	I-Sign_symptom
on	O
each	B-Biological_structure
hand	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

Although	O
no	O
sensory	B-Sign_symptom
-	I-Sign_symptom
motor	I-Sign_symptom
deficit	I-Sign_symptom
was	O
noted	O
,	O
the	O
patient	O
presented	O
with	O
mild	B-Detailed_description
mental	B-Disease_disorder
retardation	I-Disease_disorder
.	O

Genetic	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
in	O
his	O
early	O
infancy	O
showed	O
a	O
previously	O
reported	O
homozygous	B-Detailed_description
nonsense	B-Detailed_description
mutation	B-Sign_symptom
c	B-Detailed_description
.	I-Detailed_description
1195	I-Detailed_description
C1T	I-Detailed_description
,	I-Detailed_description
p	I-Detailed_description
.	I-Detailed_description
Arg399X	I-Detailed_description
of	I-Detailed_description
EvC2	I-Detailed_description
,	O
resulting	O
in	O
loss	B-Detailed_description
of	I-Detailed_description
function	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
protein	I-Detailed_description
.	O
(	O
5	O
)	O
His	O
parents	O
were	O
heterozygous	B-Detailed_description
carriers	I-Detailed_description
of	O
the	O
mutation	O
.	O

In	O
1998	O
,	O
the	O
patient	O
underwent	O
successful	O
ostium	B-Biological_structure
primum	I-Biological_structure
atrial	B-Therapeutic_procedure
septal	I-Therapeutic_procedure
defect	I-Therapeutic_procedure
closure	I-Therapeutic_procedure
through	O
a	O
midsternotomy	B-Therapeutic_procedure
.	O

He	O
re	O
-	O
presented	O
with	O
embolic	B-Detailed_description
cerebral	B-Biological_structure
ictus	B-Sign_symptom
in	O
2007	O
,	O
and	O
cavotricuspid	B-Biological_structure
isthmus	I-Biological_structure
ablation	B-Therapeutic_procedure
for	O
common	B-Detailed_description
atrial	B-Disease_disorder
flutter	I-Disease_disorder
was	O
performed	O
successfully	O
.	O

There	O
were	O
no	O
serious	B-Severity
aftereffects	B-Sign_symptom
.	O

During	O
a	O
routine	O
examination	B-Diagnostic_procedure
in	O
2012	O
,	O
a	O
high	B-Detailed_description
-	I-Detailed_description
pitched	I-Detailed_description
systolic	B-Detailed_description
murmur	B-Sign_symptom
was	O
discovered	O
.	O

Electrocardiography	B-Diagnostic_procedure
showed	O
sinus	B-Lab_value
rhythm	I-Lab_value
with	O
hemiblock	B-Disease_disorder
and	O
right	B-Disease_disorder
bundle	I-Disease_disorder
branch	I-Disease_disorder
block	I-Disease_disorder
,	O
while	O
echocardiography	B-Diagnostic_procedure
revealed	O
a	O
dilated	B-Sign_symptom
and	O
hypertrophic	B-Sign_symptom
left	B-Biological_structure
ventricle	I-Biological_structure
.	O

These	O
abnormalities	O
produced	O
a	O
flow	B-Sign_symptom
that	O
was	O
directed	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
atrial	I-Biological_structure
appendage	I-Biological_structure
,	O
leading	O
to	O
severe	O
mitral	B-Sign_symptom
valve	I-Sign_symptom
regurgitation	I-Sign_symptom
.	O

The	O
patient	O
`	O
s	O
systolic	B-Detailed_description
pulmonary	B-Diagnostic_procedure
artery	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
50	B-Lab_value
mmHg	I-Lab_value
and	O
his	O
aortic	B-Sign_symptom
valve	I-Sign_symptom
was	I-Sign_symptom
normal	I-Sign_symptom
.	O

His	O
medical	O
treatment	O
included	O
ramipril	B-Medication
,	O
duloxetine	B-Medication
,	O
alprazolam	B-Medication
and	O
acenocumarol	B-Medication
.	O

The	O
patient	O
was	O
scheduled	O
for	O
mitral	B-Therapeutic_procedure
valve	I-Therapeutic_procedure
surgery	I-Therapeutic_procedure
.	O

In	O
the	O
operating	O
theatre	O
,	O
the	O
patient	O
`	O
s	O
right	B-Biological_structure
femoral	I-Biological_structure
artery	I-Biological_structure
was	O
cannulated	B-Therapeutic_procedure
.	O

A	O
right	B-Detailed_description
thoracotomy	B-Therapeutic_procedure
was	O
performed	O
on	O
the	O
fourth	B-Biological_structure
intercostal	I-Biological_structure
space	I-Biological_structure
and	O
bicaval	B-Detailed_description
cannulation	B-Therapeutic_procedure
was	O
established	O
.	O

Both	B-Detailed_description
veins	I-Detailed_description
were	I-Detailed_description
excluded	I-Detailed_description
.	O

The	O
operation	O
used	O
a	O
normothermic	B-Detailed_description
cardiopulmonary	B-Therapeutic_procedure
bypass	I-Therapeutic_procedure
without	B-Detailed_description
cross	I-Detailed_description
-	I-Detailed_description
clamping	I-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
aorta	I-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
beating	I-Detailed_description
heart	I-Detailed_description
.	O

To	O
avoid	O
air	O
embolisms	O
,	O
continuous	B-Therapeutic_procedure
carbon	I-Therapeutic_procedure
dioxide	I-Therapeutic_procedure
(	I-Therapeutic_procedure
CO2	I-Therapeutic_procedure
)	I-Therapeutic_procedure
field	I-Therapeutic_procedure
flooding	I-Therapeutic_procedure
was	O
applied	O
using	O
a	O
CarbonAid	B-Detailed_description
CO2	I-Detailed_description
diffuser	I-Detailed_description
(	O
Cardia	B-Detailed_description
Innovation	I-Detailed_description
AB	I-Detailed_description
,	I-Detailed_description
Stockholm	I-Detailed_description
,	I-Detailed_description
Sweden	I-Detailed_description
)	O
.	O

The	O
attempt	O
to	O
perform	O
a	O
mitral	B-Therapeutic_procedure
valve	I-Therapeutic_procedure
repair	I-Therapeutic_procedure
was	O
unsuccessful	O
and	O
a	O
bileaflet	B-Detailed_description
mechanical	I-Detailed_description
valve	I-Detailed_description
(	O
no	B-Detailed_description
.	I-Detailed_description
29	I-Detailed_description
)	O
was	O
implanted	B-Therapeutic_procedure
.	O

No	O
complications	B-Sign_symptom
associated	B-Detailed_description
with	I-Detailed_description
anaesthesia	I-Detailed_description
occurred	O
.	O

The	O
patient	O
`	O
s	O
postoperative	B-Therapeutic_procedure
recovery	I-Therapeutic_procedure
was	O
uneventful	B-Lab_value
and	O
he	O
was	O
discharged	O
on	O
postoperative	O
day	O
10	O
.	O

After	O
two	B-Duration
years	I-Duration
of	O
follow	O
-	O
up	O
,	O
echocardiography	B-Diagnostic_procedure
revealed	O
optimal	B-Lab_value
function	I-Lab_value
of	O
the	O
mitral	B-Biological_structure
valve	I-Biological_structure
and	O
a	O
decrease	B-Lab_value
in	O
systolic	B-Detailed_description
pulmonary	B-Diagnostic_procedure
artery	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
(	O
30	B-Lab_value
mmHg	I-Lab_value
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
71	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
known	O
diastolic	B-Detailed_description
congestive	B-Disease_disorder
heart	I-Disease_disorder
failure	I-Disease_disorder
(	B-Disease_disorder
CHF	I-Disease_disorder
)	I-Disease_disorder
presented	O
to	O
the	O
ER	B-Nonbiological_location
with	O
exacerbation	B-Detailed_description
of	O
CHF	B-Disease_disorder
and	O
a	O
decreased	B-Lab_value
level	B-Sign_symptom
of	I-Sign_symptom
consciousness	I-Sign_symptom
.	O

Brachial	B-Biological_structure
blood	B-Sign_symptom
pressure	I-Sign_symptom
(	B-Sign_symptom
BP	I-Sign_symptom
)	I-Sign_symptom
was	O
measured	O
at	O
55	B-Lab_value
/	I-Lab_value
40	I-Lab_value
mmHg	I-Lab_value
.	O

The	O
patient	O
had	O
four	B-Lab_value
recent	B-Detailed_description
admissions	O
with	O
exacerbation	B-Detailed_description
of	O
CHF	B-Disease_disorder
.	O

Her	O
medical	O
history	O
was	O
also	O
significant	O
for	O
autoimmune	B-Detailed_description
hepatitis	B-Disease_disorder
,	O
but	O
preserved	B-Detailed_description
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
;	O
esophageal	B-Biological_structure
varices	I-Biological_structure
with	O
a	O
bleeding	B-Detailed_description
episode	I-Detailed_description
;	O
and	O
long	B-Detailed_description
-	I-Detailed_description
term	I-Detailed_description
corticosteroid	B-Medication
therapy	I-Medication
complicated	O
by	O
adrenal	B-Disease_disorder
insufficiency	I-Disease_disorder
,	O
type	B-Disease_disorder
2	I-Disease_disorder
diabetes	I-Disease_disorder
mellitus	I-Disease_disorder
and	O
osteoporosis	B-Disease_disorder
.	O

Recent	O
echocardiography	B-Diagnostic_procedure
had	O
revealed	O
moderate	B-Severity
concentric	B-Detailed_description
left	B-Biological_structure
ventricular	I-Biological_structure
hypertrophy	B-Disease_disorder
with	O
diastolic	B-Detailed_description
dysfunction	I-Detailed_description
,	O
and	O
mild	B-Severity
to	O
moderate	B-Severity
mitral	B-Disease_disorder
regurgitation	I-Disease_disorder
.	O

Cardiac	B-Diagnostic_procedure
catheterization	I-Diagnostic_procedure
in	O
a	O
recent	O
admission	O
demonstrated	O
50	B-Lab_value
%	I-Lab_value
stenosis	B-Disease_disorder
in	O
the	O
second	B-Biological_structure
diagonal	I-Biological_structure
artery	I-Biological_structure
,	O
with	O
mild	B-Severity
diffuse	B-Detailed_description
disease	O
in	O
the	O
other	B-Biological_structure
coronary	I-Biological_structure
arteries	I-Biological_structure
.	O

Right	B-Detailed_description
ventricular	I-Detailed_description
endomyocardial	I-Detailed_description
biopsy	B-Diagnostic_procedure
had	O
ruled	O
out	O
myocarditis	B-Disease_disorder
and	O
infiltrative	B-Detailed_description
cardiomyopathies	B-Disease_disorder
,	O
but	O
healing	B-Detailed_description
ischemic	B-Disease_disorder
microinfarcts	I-Disease_disorder
with	O
atheroemboli	B-Disease_disorder
were	O
observed	O
.	O

Previous	O
BP	B-Diagnostic_procedure
values	I-Diagnostic_procedure
were	O
also	O
low	B-Lab_value
;	O
systolic	B-Diagnostic_procedure
BP	I-Diagnostic_procedure
was	O
between	O
60	B-Lab_value
mmHg	I-Lab_value
and	O
65	B-Lab_value
mmHg	I-Lab_value
,	O
and	O
diastolic	B-Diagnostic_procedure
BP	I-Diagnostic_procedure
was	O
between	O
40	B-Lab_value
mmHg	I-Lab_value
and	O
45	B-Lab_value
mmHg	I-Lab_value
.	O

Following	O
intubation	B-Therapeutic_procedure
,	O
dopamine	B-Medication
was	O
started	O
for	O
hypotension	B-Therapeutic_procedure
management	I-Therapeutic_procedure
and	O
was	O
later	O
replaced	O
with	O
noradrenaline	B-Medication
.	O

The	O
patient	O
developed	O
atrial	B-Disease_disorder
flutter	I-Disease_disorder
but	O
successfully	O
converted	O
to	O
sinus	B-Sign_symptom
rhythm	I-Sign_symptom
with	O
two	B-Lab_value
direct	B-Detailed_description
current	I-Detailed_description
electric	B-Therapeutic_procedure
shocks	I-Therapeutic_procedure
.	O

Cardiology	B-Diagnostic_procedure
consultation	I-Diagnostic_procedure
resulted	O
in	O
admission	O
to	O
the	O
coronary	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
(	B-Nonbiological_location
CCU	I-Nonbiological_location
)	I-Nonbiological_location
.	O

On	O
admission	O
to	O
the	O
CCU	B-Biological_structure
,	O
BP	B-Diagnostic_procedure
was	O
measured	O
at	O
56	B-Lab_value
/	I-Lab_value
36	I-Lab_value
mmHg	I-Lab_value
in	O
the	O
left	B-Biological_structure
arm	I-Biological_structure
but	O
was	O
not	B-Lab_value
detectable	I-Lab_value
in	O
the	O
right	B-Biological_structure
arm	I-Biological_structure
.	O

An	O
arterial	B-Diagnostic_procedure
line	I-Diagnostic_procedure
was	O
inserted	O
via	O
the	O
femoral	B-Biological_structure
artery	I-Biological_structure
,	O
and	O
BP	B-Diagnostic_procedure
was	O
measured	O
at	O
191	B-Lab_value
/	I-Lab_value
92	I-Lab_value
mmHg	I-Lab_value
.	O

BP	B-Diagnostic_procedure
values	I-Diagnostic_procedure
were	O
consistently	B-Detailed_description
much	B-Severity
higher	B-Lab_value
through	B-Detailed_description
the	I-Detailed_description
femoral	I-Detailed_description
arterial	I-Detailed_description
line	I-Detailed_description
than	I-Detailed_description
the	I-Detailed_description
cuff	I-Detailed_description
on	I-Detailed_description
the	I-Detailed_description
arms	I-Detailed_description
,	O
and	O
was	O
higher	B-Lab_value
in	B-Detailed_description
the	I-Detailed_description
left	B-Biological_structure
arm	I-Biological_structure
than	I-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
right	B-Biological_structure
arm	I-Biological_structure
.	O

For	O
instance	O
,	O
on	O
the	O
first	O
day	O
post	O
-	O
CCU	O
admission	O
,	O
BP	B-Diagnostic_procedure
at	B-Time
one	I-Time
point	I-Time
was	O
measured	O
at	O
170	B-Lab_value
/	I-Lab_value
80	I-Lab_value
mmHg	I-Lab_value
through	O
the	O
arterial	O
line	O
,	O
while	O
cuff	O
readings	O
on	O
the	O
arms	O
were	O
83	B-Lab_value
/	I-Lab_value
74	I-Lab_value
mmHg	I-Lab_value
on	O
the	O
left	B-Biological_structure
and	I-Biological_structure
60	B-Lab_value
/	I-Lab_value
39	I-Lab_value
mmHg	I-Lab_value
on	I-Biological_structure
the	I-Biological_structure
right	B-Biological_structure
arm	I-Biological_structure
.	O

To	O
investigate	O
the	O
inconsistency	O
between	O
brachial	B-Biological_structure
and	O
femoral	B-Biological_structure
BP	B-Diagnostic_procedure
values	I-Diagnostic_procedure
,	O
a	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	B-Diagnostic_procedure
CT	I-Diagnostic_procedure
)	I-Diagnostic_procedure
scan	I-Diagnostic_procedure
of	O
the	O
thorax	B-Biological_structure
was	O
obtained	O
using	O
1	B-Distance
.	I-Distance
25	I-Distance
mm	I-Distance
slices	B-Diagnostic_procedure
,	O
both	O
before	O
and	O
after	O
intravenous	O
contrast	B-Diagnostic_procedure
injection	I-Diagnostic_procedure
with	O
sagittal	B-Detailed_description
and	I-Detailed_description
coronal	I-Detailed_description
planar	I-Detailed_description
reformatting	I-Detailed_description
of	O
maximum	B-Diagnostic_procedure
-	I-Diagnostic_procedure
intensity	I-Diagnostic_procedure
projection	I-Diagnostic_procedure
images	I-Diagnostic_procedure
.	O

Analysis	O
of	O
the	O
initial	B-Detailed_description
unenhanced	B-Detailed_description
CT	O
images	O
showed	O
densely	B-Severity
calcified	B-Detailed_description
plaque	B-Sign_symptom
or	O
thrombus	B-Sign_symptom
at	O
the	O
origins	B-Biological_structure
of	I-Biological_structure
both	I-Biological_structure
subclavian	I-Biological_structure
arteries	I-Biological_structure
and	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
common	I-Biological_structure
carotid	I-Biological_structure
artery	I-Biological_structure
.	O

The	O
CT	B-Diagnostic_procedure
angiogram	I-Diagnostic_procedure
showed	O
absence	O
of	O
flow	B-Sign_symptom
in	O
the	O
right	O
subclavian	O
artery	O
,	O
a	O
very	B-Severity
tight	B-Detailed_description
stenosis	B-Disease_disorder
at	O
the	O
origin	O
of	O
the	O
left	O
subclavian	O
artery	O
and	O
a	O
tight	B-Detailed_description
stenosis	B-Disease_disorder
at	O
the	O
origin	O
of	O
the	O
right	O
common	O
carotid	O
artery	O
.	O

Both	O
vertebral	O
arteries	O
showed	O
normal	B-Lab_value
calibre	B-Sign_symptom
and	O
flow	B-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

Further	B-Therapeutic_procedure
management	I-Therapeutic_procedure
following	O
the	O
insertion	O
of	O
the	O
femoral	B-Diagnostic_procedure
arterial	I-Diagnostic_procedure
line	I-Diagnostic_procedure
was	O
based	O
on	O
femoral	B-Detailed_description
BP	B-Diagnostic_procedure
readings	I-Diagnostic_procedure
with	O
diuretics	B-Medication
and	O
BP	B-Medication
-	I-Medication
lowering	I-Medication
agents	I-Medication
.	O

The	O
patient	O
was	O
eventually	O
discharged	O
in	O
stable	B-Lab_value
condition	B-Diagnostic_procedure
.	O

She	O
remained	O
stable	O
during	B-Duration
the	I-Duration
eight	I-Duration
months	I-Duration
between	I-Duration
discharge	I-Duration
and	I-Duration
the	I-Duration
time	I-Duration
the	I-Duration
present	I-Duration
report	I-Duration
was	I-Duration
written	I-Duration
,	O
without	O
further	B-Detailed_description
exacerbation	I-Detailed_description
of	O
CHF	B-Disease_disorder
or	O
related	O
ER	O
visits	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
institutional	O
review	O
board	O
(	O
Chengdu	O
Military	O
General	O
Hospital	O
)	O
approved	O
this	O
work	O
and	O
waived	O
the	O
need	O
for	O
informed	O
consent	O
.	O

In	O
2013	O
,	O
a	O
66	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
farmer	B-Occupation
with	O
a	O
history	O
of	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
and	O
hypertension	O
presented	O
to	O
the	O
Emergency	B-Nonbiological_location
Department	I-Nonbiological_location
with	O
continuous	B-Detailed_description
palpitation	B-Sign_symptom
,	O
chest	B-Sign_symptom
tightness	I-Sign_symptom
,	O
profuse	B-Severity
sweating	B-Sign_symptom
and	O
nausea	B-Sign_symptom
with	O
no	O
obvious	O
predisposing	O
causes	B-Disease_disorder
.	O

The	O
patient	O
experienced	O
a	O
sudden	B-Lab_value
drop	I-Lab_value
in	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
and	O
acute	B-Detailed_description
confusion	B-Sign_symptom
.	O

After	O
an	O
immediate	B-Detailed_description
electrical	B-Therapeutic_procedure
conversion	I-Therapeutic_procedure
,	O
his	O
consciousness	B-Sign_symptom
was	O
gradually	O
restored	O
,	O
and	O
symptoms	B-Sign_symptom
relieved	O
.	O

Then	O
,	O
this	O
patient	O
was	O
transferred	O
to	O
the	O
Department	B-Nonbiological_location
of	I-Nonbiological_location
Cardiology	I-Nonbiological_location
for	O
further	O
evaluations	B-Diagnostic_procedure
and	O
treatments	B-Therapeutic_procedure
.	O

The	O
patient	O
`	O
s	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
105	B-Lab_value
/	I-Lab_value
75	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
upon	O
admission	O
,	O
with	O
a	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
75	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
body	B-Diagnostic_procedure
temperature	I-Diagnostic_procedure
of	O
36	B-Lab_value
.	I-Lab_value
6	I-Lab_value
°C	I-Lab_value
and	O
respiration	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
18	B-Lab_value
times	I-Lab_value
/	I-Lab_value
min	I-Lab_value
.	O

The	O
heart	B-Biological_structure
border	I-Biological_structure
extended	B-Sign_symptom
to	B-Lab_value
the	I-Lab_value
left	I-Lab_value
,	O
with	O
the	O
apical	B-Diagnostic_procedure
impulse	I-Diagnostic_procedure
located	O
in	O
the	O
left	B-Lab_value
5th	I-Lab_value
intercostal	I-Lab_value
space	I-Lab_value
,	O
1	B-Distance
.	I-Distance
0	I-Distance
cm	I-Distance
lateral	I-Distance
to	I-Distance
the	I-Distance
midclavicular	I-Distance
line	I-Distance
.	O

The	O
patient	O
had	O
a	O
history	O
of	O
hypertension	B-Disease_disorder
over	O
30	B-Duration
years	I-Duration
without	O
regular	O
antihypertensive	B-Medication
medication	I-Medication
.	O

The	O
highest	B-Detailed_description
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
170	B-Lab_value
/	I-Lab_value
110	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

There	O
was	O
no	O
family	O
history	O
of	O
early	O
coronary	O
artery	O
disease	O
or	O
sudden	O
cardiac	O
death	O
.	O

He	O
did	O
not	O
smoke	B-Activity
cigarettes	I-Activity
or	O
use	B-Activity
illicit	I-Activity
drugs	I-Activity
,	O
and	O
rarely	O
consumed	B-Activity
alcohol	I-Activity
.	O

He	O
also	O
reported	O
no	O
known	O
contacts	O
with	O
sick	O
persons	O
and	O
no	O
recent	O
travel	O
.	O

Twelve	B-Detailed_description
-	I-Detailed_description
lead	I-Detailed_description
surface	B-Detailed_description
electrocardiogram	B-Diagnostic_procedure
(	O
ECG	B-Diagnostic_procedure
)	O
of	O
VT	B-Disease_disorder
indicated	O
that	O
the	O
origin	O
of	O
VT	O
was	O
at	O
the	O
boundary	B-Biological_structure
between	I-Biological_structure
right	B-Biological_structure
ventricular	I-Biological_structure
outflow	I-Biological_structure
tract	I-Biological_structure
(	O
RVOT	B-Biological_structure
)	O
and	O
tricuspid	B-Biological_structure
valve	I-Biological_structure
.	O

When	O
VT	B-Disease_disorder
increased	B-Lab_value
to	O
150	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
or	I-Lab_value
higher	I-Lab_value
,	O
no	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
were	O
found	O
in	O
the	O
precordial	B-Diagnostic_procedure
leads	I-Diagnostic_procedure
(	O
Figure1A	O
and	O
B	O
)	O
.	O

In	O
contrast	O
,	O
when	O
VT	B-Disease_disorder
decreased	B-Lab_value
to	O
120	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
or	I-Lab_value
lower	I-Lab_value
,	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
appeared	O
in	O
leads	B-Diagnostic_procedure
V1	I-Diagnostic_procedure
-	I-Diagnostic_procedure
V2	I-Diagnostic_procedure
(	O
Figure1C	O
)	O
.	O

Notably	O
,	O
the	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
preceded	B-Lab_value
QRS	I-Lab_value
waves	I-Lab_value
in	O
leads	B-Diagnostic_procedure
V1	I-Diagnostic_procedure
-	I-Diagnostic_procedure
V2	I-Diagnostic_procedure
,	O
while	O
endocardiac	B-Diagnostic_procedure
tracing	I-Diagnostic_procedure
confirmed	O
that	O
the	O
corresponding	O
local	B-Lab_value
potential	I-Lab_value
originating	O
from	O
RVOT	B-Biological_structure
appeared	O
prior	B-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
ventricular	I-Detailed_description
rhythm	I-Detailed_description
(	O
Figure	O
(	O
Figure1D	O
)	O
.	O
1D	O
)	O
.	O

Sinus	B-Detailed_description
ECG	B-Diagnostic_procedure
in	O
the	O
year	O
of	O
2013	O
suggested	O
a	O
slight	B-Lab_value
left	I-Lab_value
deviation	I-Lab_value
of	O
electric	B-Diagnostic_procedure
axis	I-Diagnostic_procedure
,	O
with	O
a	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
87	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
and	O
flat	B-Lab_value
T	I-Lab_value
waves	I-Lab_value
in	O
lead	B-Diagnostic_procedure
II	I-Diagnostic_procedure
.	O

T	B-Sign_symptom
wave	I-Sign_symptom
inversions	I-Sign_symptom
were	O
found	O
in	O
leads	B-Diagnostic_procedure
III	I-Diagnostic_procedure
,	I-Diagnostic_procedure
avF	I-Diagnostic_procedure
and	I-Diagnostic_procedure
V1	I-Diagnostic_procedure
-	I-Diagnostic_procedure
V3	I-Diagnostic_procedure
,	O
meanwhile	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
were	O
found	O
following	B-Lab_value
QRS	I-Lab_value
complex	I-Lab_value
in	O
leads	B-Diagnostic_procedure
V1	I-Diagnostic_procedure
-	I-Diagnostic_procedure
V3	I-Diagnostic_procedure
(	O
Figure	O
(	O
Figure2B	O
)	O
.	O
2B	O
)	O
.	O

When	O
the	O
lead	B-Diagnostic_procedure
avR	I-Diagnostic_procedure
was	O
amplified	B-Detailed_description
,	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
were	O
also	O
found	O
behind	B-Lab_value
QRS	I-Lab_value
waves	I-Lab_value
(	O
Figure	O
2C	O
)	O
.	O

Atrial	B-Biological_structure
premature	B-Sign_symptom
beats	I-Sign_symptom
appeared	O
occasionally	B-Frequency
.	O

Moreover	O
,	O
ventricular	B-Biological_structure
premature	B-Sign_symptom
beats	I-Sign_symptom
were	O
also	O
found	O
to	O
originate	O
from	O
the	O
right	B-Biological_structure
ventricular	I-Biological_structure
apex	I-Biological_structure
,	O
with	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
appearing	O
behind	B-Lab_value
QRS	I-Lab_value
waves	I-Lab_value
(	O
Figure	O
(	O
Figure2B	O
)	O
.	O
2B	O
)	O
.	O

In	O
contrast	O
,	O
sinus	B-Biological_structure
ECG	B-Diagnostic_procedure
obtained	O
in	O
the	O
year	O
of	O
1999	O
revealed	O
similar	O
left	B-Lab_value
deviation	I-Lab_value
of	O
electric	B-Diagnostic_procedure
axis	I-Diagnostic_procedure
,	O
flat	B-Sign_symptom
T	I-Sign_symptom
waves	I-Sign_symptom
and	O
T	B-Sign_symptom
wave	I-Sign_symptom
inversions	I-Sign_symptom
,	O
but	O
absence	O
of	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
(	O
Figure	O
(	O
Figure2A	O
)	O
.	O
2A	O
)	O
.	O

Data	O
from	O
biochemical	B-Diagnostic_procedure
assays	I-Diagnostic_procedure
were	O
as	O
follows	O
:	O
cardiac	B-Diagnostic_procedure
troponin	I-Diagnostic_procedure
I	I-Diagnostic_procedure
level	O
was	O
0	B-Lab_value
.	I-Lab_value
714	I-Lab_value
μg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
0	O
-	O
0	O
.	O
06	O
μg	O
/	O
L	O
)	O
,	O
serum	B-Diagnostic_procedure
B	I-Diagnostic_procedure
-	I-Diagnostic_procedure
type	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
level	O
was	O
466	B-Lab_value
.	I-Lab_value
530	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
range	O
,	O
0	O
-	O
100	O
pg	O
/	O
mL	O
)	O
,	O
serum	B-Diagnostic_procedure
d	I-Diagnostic_procedure
-	I-Diagnostic_procedure
dimer	I-Diagnostic_procedure
level	O
was	O
8	B-Lab_value
.	I-Lab_value
14	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
0	O
-	O
0	O
.	O
55	O
mg	O
/	O
L	O
)	O
,	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
level	O
was	O
11	B-Lab_value
.	I-Lab_value
69	I-Lab_value
mmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
2	O
.	O
90	O
-	O
7	O
.	O
20	O
mmol	O
/	O
L	O
)	O
,	O
serum	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
level	O
was	O
144	B-Lab_value
.	I-Lab_value
00	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
44	O
-	O
133	O
μmol	O
/	O
L	O
)	O
,	O
serum	B-Diagnostic_procedure
uric	I-Diagnostic_procedure
acid	I-Diagnostic_procedure
level	O
was	O
611	B-Lab_value
.	I-Lab_value
40	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
100	O
-	O
432	O
μmol	O
/	O
L	O
)	O
,	O
and	O
endogenous	B-Diagnostic_procedure
creatinine	I-Diagnostic_procedure
clearing	I-Diagnostic_procedure
value	O
was	O
57	B-Lab_value
.	I-Lab_value
90	I-Lab_value
mL	I-Lab_value
/	I-Lab_value
min	I-Lab_value
(	O
normal	O
range	O
,	O
>	O
80	O
mL	O
/	O
min	O
)	O
.	O

Echo	B-Diagnostic_procedure
data	O
revealed	O
remarkably	B-Severity
enlarged	B-Sign_symptom
right	B-Biological_structure
atrium	I-Biological_structure
and	O
right	B-Biological_structure
ventricle	I-Biological_structure
,	O
and	O
widened	B-Sign_symptom
ROVT	B-Biological_structure
.	O

Uncoordinated	B-Sign_symptom
motions	I-Sign_symptom
of	O
the	O
left	B-Biological_structure
and	I-Biological_structure
right	I-Biological_structure
ventricular	I-Biological_structure
walls	I-Biological_structure
were	O
also	O
detected	O
.	O

Moreover	O
,	O
we	O
also	O
found	O
aortic	B-Biological_structure
valve	I-Biological_structure
degradation	B-Sign_symptom
with	O
slight	B-Severity
regurgitation	B-Sign_symptom
,	O
slight	B-Severity
mitral	B-Biological_structure
regurgitation	B-Sign_symptom
,	O
and	O
moderate	B-Severity
to	I-Severity
severe	I-Severity
tricuspid	B-Biological_structure
regurgitation	B-Sign_symptom
.	O

The	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
function	I-Diagnostic_procedure
was	O
reduced	B-Lab_value
to	O
55	B-Lab_value
%	I-Lab_value
(	O
Figure	O
3A	O
and	O
B	O
)	O
.	O

The	O
coronary	B-Diagnostic_procedure
angiogram	I-Diagnostic_procedure
revealed	O
no	O
vascular	B-Disease_disorder
stenosis	I-Disease_disorder
(	O
Figure	O
3C	O
-	O
E	O
)	O
.	O

Based	O
on	O
the	O
above	O
-	O
mentioned	O
examinations	O
,	O
this	O
patient	O
met	O
at	O
least	O
2	O
major	O
criteria	O
,	O
the	O
bilateral	O
ventricular	O
dilation	O
and	O
the	O
existence	O
of	O
epsilon	O
waves	O
,	O
providing	O
diagnostic	O
support	O
for	O
ARVC	B-Disease_disorder
.	O

A	O
diet	B-Therapeutic_procedure
with	O
low	B-Detailed_description
salt	I-Detailed_description
and	O
low	B-Detailed_description
fat	I-Detailed_description
was	O
suggested	O
.	O

The	O
patient	O
was	O
also	O
treated	O
with	O
metoprolol	B-Medication
succinate	I-Medication
sustained	O
-	O
release	O
tablets	O
(	O
23	B-Dosage
.	I-Dosage
75	I-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
,	O
amiodarone	B-Medication
(	O
200	B-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
,	O
furosemide	B-Medication
(	O
20	B-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
i	O
.	O
v	O
.	O
)	O
,	O
and	O
compound	B-Detailed_description
α	B-Medication
-	I-Medication
ketoacid	I-Medication
tablets	O
(	O
2	B-Dosage
.	I-Dosage
52	I-Dosage
g	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
.	O

Moreover	O
,	O
VTs	B-Disease_disorder
with	O
different	B-Detailed_description
morphologies	I-Detailed_description
and	I-Detailed_description
cycle	I-Detailed_description
lengths	I-Detailed_description
were	O
found	O
during	O
radiofrequency	B-Therapeutic_procedure
ablation	I-Therapeutic_procedure
(	O
Figure	O
4	O
)	O
.	O

The	O
substrate	B-Diagnostic_procedure
voltage	I-Diagnostic_procedure
mapping	I-Diagnostic_procedure
revealed	O
that	O
the	O
anterior	B-Biological_structure
wall	I-Biological_structure
of	I-Biological_structure
RVOT	I-Biological_structure
was	O
wrapped	O
by	O
circular	B-Shape
scar	B-Sign_symptom
(	O
Figure	O
5A	O
)	O
.	O

Considering	O
the	O
association	O
of	O
VT	O
with	O
scar	O
areas	O
,	O
substrate	B-Therapeutic_procedure
ablation	I-Therapeutic_procedure
was	O
chosen	O
for	O
this	O
patient	O
.	O

The	O
residual	O
potentials	O
in	O
the	O
scar	O
areas	O
were	O
searched	O
,	O
and	O
then	O
linear	B-Detailed_description
and	O
focal	B-Detailed_description
ablations	B-Therapeutic_procedure
were	O
performed	O
(	O
Figure	O
5B	O
)	O
.	O

Neither	O
programmed	B-Detailed_description
stimulation	B-Diagnostic_procedure
nor	O
induced	B-Detailed_description
stimulation	B-Diagnostic_procedure
could	O
induce	O
VT	B-Disease_disorder
after	O
the	O
procedure	O
was	O
completed	O
,	O
indicating	O
the	O
success	O
of	O
operation	O
.	O

The	O
ECG	B-Diagnostic_procedure
after	O
radiofrequency	O
ablation	O
showed	O
sinus	B-Sign_symptom
rhythm	I-Sign_symptom
,	O
with	O
a	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
61	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
T	B-Sign_symptom
wave	I-Sign_symptom
inversions	I-Sign_symptom
in	O
leads	B-Diagnostic_procedure
III	I-Diagnostic_procedure
and	I-Diagnostic_procedure
avF	I-Diagnostic_procedure
,	O
and	O
epsilon	B-Sign_symptom
waves	I-Sign_symptom
and	O
T	B-Sign_symptom
wave	I-Sign_symptom
inversions	I-Sign_symptom
in	O
leads	B-Diagnostic_procedure
V1	I-Diagnostic_procedure
-	I-Diagnostic_procedure
V3	I-Diagnostic_procedure
(	O
Figure	O
2D	O
)	O
.	O

This	O
patient	O
was	O
discharged	O
from	O
hospital	B-Nonbiological_location
on	O
day	O
9	O
with	O
a	O
regimen	O
of	O
metoprolol	B-Medication
succinate	I-Medication
sustained	O
-	O
release	O
tablets	O
(	O
23	B-Dosage
.	I-Dosage
75	I-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
,	O
amiodarone	B-Medication
hydrochloride	I-Medication
tablets	O
(	O
200	B-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
,	O
spironolactone	B-Medication
tablets	O
(	O
40	B-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
,	O
and	O
fosinopril	B-Medication
sodium	I-Medication
tablets	O
(	O
10	B-Dosage
mg	I-Dosage
daily	I-Dosage
,	O
p	O
.	O
o	O
.	O
)	O
.	O

The	O
patient	O
was	O
followed	O
up	O
3	O
months	O
after	O
discharge	O
.	O

He	O
had	O
no	O
recurrent	O
palpitation	B-Sign_symptom
,	O
chest	B-Biological_structure
tightness	B-Sign_symptom
,	O
profuse	B-Severity
sweating	B-Sign_symptom
or	O
nausea	B-Sign_symptom
.	O

Although	B-Other_entity
ARVC	I-Other_entity
was	I-Other_entity
the	I-Other_entity
main	I-Other_entity
diagnosis	I-Other_entity
at	I-Other_entity
the	I-Other_entity
time	I-Other_entity
of	I-Other_entity
this	I-Other_entity
patient	I-Other_entity
`	I-Other_entity
s	I-Other_entity
initial	I-Other_entity
presentation	I-Other_entity
,	I-Other_entity
it	I-Other_entity
is	I-Other_entity
essential	I-Other_entity
in	I-Other_entity
such	I-Other_entity
cases	I-Other_entity
to	I-Other_entity
perform	I-Other_entity
a	I-Other_entity
reassessment	I-Other_entity
for	I-Other_entity
the	I-Other_entity
presence	I-Other_entity
of	I-Other_entity
structural	I-Other_entity
heart	I-Other_entity
disease	I-Other_entity
,	I-Other_entity
which	I-Other_entity
can	I-Other_entity
evolve	I-Other_entity
over	I-Other_entity
time	I-Other_entity
.	O

-DOCSTART- -X- -X- -X- O

A	O
33	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
with	O
left	B-Biological_structure
flank	I-Biological_structure
dull	B-Detailed_description
ache	B-Sign_symptom
.	O

On	O
the	O
abdominal	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
,	O
a	O
solid	B-Detailed_description
renal	B-Biological_structure
mass	B-Sign_symptom
in	O
the	O
upper	B-Biological_structure
portion	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
kidney	I-Biological_structure
was	O
identified	O
.	O

The	O
mass	O
was	O
measured	O
2	B-Volume
.	I-Volume
8	I-Volume
cm	I-Volume
×	I-Volume
2	I-Volume
.	I-Volume
8	I-Volume
cm	I-Volume
×	I-Volume
2	I-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
in	O
size	O
,	O
was	O
well	B-Detailed_description
-	I-Detailed_description
defined	I-Detailed_description
.	O

The	O
patient	O
had	O
no	O
other	B-Sign_symptom
abnormal	I-Sign_symptom
findings	I-Sign_symptom
,	O
such	O
as	O
suspected	O
distant	B-Detailed_description
metastasis	B-Sign_symptom
or	O
lymph	B-Biological_structure
node	I-Biological_structure
metastasis	B-Sign_symptom
.	O

Radical	B-Detailed_description
nephrectomy	B-Therapeutic_procedure
was	O
performed	O
on	O
14	O
/	O
9	O
/	O
2005	O
.	O

On	O
gross	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
the	O
nephrectomy	B-Detailed_description
specimen	I-Detailed_description
measured	O
11	B-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
×	I-Volume
6	I-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
×	I-Volume
4	I-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
and	O
the	O
tumor	O
was	O
a	O
solid	B-Detailed_description
,	O
grayish	B-Color
-	I-Color
brown	I-Color
mass	O
measured	O
3	B-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
×	I-Volume
2	I-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
×	I-Volume
2	I-Volume
.	I-Volume
2	I-Volume
cm	I-Volume
in	O
size	O
.	O

Histologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
demonstrated	O
trabecular	B-Lab_value
and	I-Lab_value
ribbonlike	I-Lab_value
patterns	I-Lab_value
with	O
minimal	B-Lab_value
fibrotic	I-Lab_value
stroma	I-Lab_value
.	O

The	O
cytoplasm	B-Diagnostic_procedure
was	O
granular	B-Lab_value
and	O
eosinophilic	B-Lab_value
with	O
uniform	B-Lab_value
round	I-Lab_value
to	I-Lab_value
oval	I-Lab_value
nuclei	I-Lab_value
with	O
finely	B-Lab_value
stippled	I-Lab_value
chromatin	I-Lab_value
and	O
inconspicuous	B-Lab_value
nucleoli	I-Lab_value
.	O

Mitoses	B-Diagnostic_procedure
were	O
not	B-Lab_value
found	I-Lab_value
(	O
0	B-Lab_value
per	I-Lab_value
10	I-Lab_value
high	I-Lab_value
-	I-Lab_value
power	I-Lab_value
fields	I-Lab_value
)	O
on	O
H&E	B-Diagnostic_procedure
stain	I-Diagnostic_procedure
.	O

The	O
final	O
pathologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
well	B-Detailed_description
-	I-Detailed_description
differentiated	I-Detailed_description
neuroendocrine	B-Disease_disorder
(	I-Disease_disorder
carcinoid	I-Disease_disorder
)	I-Disease_disorder
tumor	I-Disease_disorder
confined	O
to	O
the	O
kidney	B-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Immunohistochemical	B-Diagnostic_procedure
stains	I-Diagnostic_procedure
demonstrated	O
labeling	B-Lab_value
with	O
chromogranin	B-Diagnostic_procedure
,	O
neuron	B-Diagnostic_procedure
-	I-Diagnostic_procedure
specific	I-Diagnostic_procedure
enolase	I-Diagnostic_procedure
and	O
synaptophysin	B-Diagnostic_procedure
(	O
Fig	O
.	O
2	O
)	O
,	O
and	O
the	O
proliferation	B-Diagnostic_procedure
index	I-Diagnostic_procedure
was	O
less	B-Lab_value
than	I-Lab_value
2	I-Lab_value
%	I-Lab_value
as	O
measured	O
by	O
immunohistochemistry	B-Diagnostic_procedure
for	I-Diagnostic_procedure
Ki	I-Diagnostic_procedure
-	I-Diagnostic_procedure
67	I-Diagnostic_procedure
.	O

Further	O
radiation	B-Therapeutic_procedure
and	O
chemotherapy	B-Medication
were	O
not	O
received	O
.	O

Nine	O
years	O
after	O
radical	O
nephrectomy	O
,	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
of	O
the	O
abdomen	B-Biological_structure
demonstrated	O
a	O
2	B-Area
cm	I-Area
×	I-Area
1	I-Area
.	I-Area
8	I-Area
cm	I-Area
cyst	B-Detailed_description
mass	B-Sign_symptom
in	O
the	O
right	B-Biological_structure
liver	I-Biological_structure
and	O
multiple	B-Detailed_description
high	B-Sign_symptom
density	I-Sign_symptom
shadow	I-Sign_symptom
in	O
gallbladder	B-Biological_structure
.	O

No	O
enlarged	B-Sign_symptom
lymph	B-Biological_structure
nodes	I-Biological_structure
were	O
found	O
in	O
the	O
abdominal	B-Biological_structure
cavity	I-Biological_structure
.	O

Cholecystectomy	B-Therapeutic_procedure
and	O
extirpation	B-Therapeutic_procedure
for	O
hepatic	B-Disease_disorder
cyst	I-Disease_disorder
were	O
performed	O
by	O
laparoscopy	B-Therapeutic_procedure
surgery	I-Therapeutic_procedure
.	O

Histologic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
demonstrated	O
trabecular	B-Lab_value
and	I-Lab_value
glandlike	I-Lab_value
growth	I-Lab_value
(	O
Fig	O
.	O
3	O
)	O
,	O
moderate	B-Lab_value
and	I-Lab_value
uniform	I-Lab_value
nuclei	I-Lab_value
and	O
mitoses	B-Diagnostic_procedure
were	B-Lab_value
n`t	I-Lab_value
found	I-Lab_value
(	O
0	B-Lab_value
per	I-Lab_value
10	I-Lab_value
high	I-Lab_value
-	I-Lab_value
power	I-Lab_value
fields	I-Lab_value
)	O
.	O

Advanced	B-Detailed_description
immunohistochemistry	B-Diagnostic_procedure
revealed	O
that	O
the	O
lesion	O
was	O
positive	B-Lab_value
for	O
synaptophysin	B-Diagnostic_procedure
(	O
Fig	O
.	O
4	O
)	O
and	O
CD56	O
,	O
but	O
negative	B-Lab_value
for	O
chromogranin	B-Diagnostic_procedure
and	O
neuron	B-Diagnostic_procedure
-	I-Diagnostic_procedure
specific	I-Diagnostic_procedure
enolase	I-Diagnostic_procedure
.	O

These	O
features	O
are	O
supported	O
in	O
a	O
neuroendocrine	B-Disease_disorder
tumor	I-Disease_disorder
.	O

Due	O
to	O
the	O
similar	O
pathologic	O
characteristics	O
between	O
the	O
primary	O
renal	O
carcinoid	O
tumor	O
and	O
liver	O
tumor	O
.	O

The	O
final	O
pathology	O
report	O
indicated	O
a	O
carcinoid	B-Disease_disorder
tumor	I-Disease_disorder
of	O
the	O
left	B-Biological_structure
kidney	I-Biological_structure
with	O
liver	B-Biological_structure
metastasis	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

The	O
patient	O
is	O
a	O
57	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
who	O
had	O
noted	O
a	O
rapidly	B-Lab_value
enlarging	I-Lab_value
mass	B-Sign_symptom
on	O
the	O
left	B-Biological_structure
side	I-Biological_structure
of	I-Biological_structure
her	I-Biological_structure
neck	I-Biological_structure
in	O
2010	O
.	O

She	O
underwent	O
a	O
total	B-Detailed_description
thyroidectomy	B-Therapeutic_procedure
and	O
central	B-Biological_structure
neck	I-Biological_structure
dissection	B-Therapeutic_procedure
,	O
which	O
revealed	O
a	O
3	B-Distance
.	I-Distance
8	I-Distance
-	I-Distance
cm	I-Distance
anaplastic	B-Detailed_description
thyroid	B-Disease_disorder
cancer	I-Disease_disorder
arising	O
in	O
a	O
background	O
of	O
an	O
oncocytic	B-Detailed_description
variant	I-Detailed_description
of	O
poorly	B-Detailed_description
differentiated	I-Detailed_description
thyroid	B-Disease_disorder
cancer	I-Disease_disorder
(	O
Fig	O
.	O
1A	O
,	O
and	O
Fig	O
.	O
S1	O
in	O
Supplementary	O
Appendix	O
1	O
,	O
available	O
with	O
the	O
full	O
text	O
of	O
this	O
article	O
at	O
NEJM	O
.	O
org	O
)	O
.	O

Resection	B-Diagnostic_procedure
margins	I-Diagnostic_procedure
were	O
positive	B-Lab_value
,	O
and	O
3	B-Lab_value
of	I-Lab_value
12	I-Lab_value
lymph	B-Biological_structure
nodes	I-Biological_structure
were	O
involved	B-Sign_symptom
.	O

At	O
3	O
weeks	O
after	O
surgery	O
,	O
the	O
serum	B-Detailed_description
thyroglobulin	B-Diagnostic_procedure
level	O
was	O
17	B-Lab_value
.	I-Lab_value
2	I-Lab_value
ng	I-Lab_value
per	I-Lab_value
milliliter	I-Lab_value
,	O
with	O
undetectable	B-Lab_value
thyroglobulin	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
.	O

The	O
patient	O
received	O
concurrent	O
radiation	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
and	O
weekly	O
carboplatin	B-Medication
and	O
paclitaxel	B-Medication
chemotherapy	B-Medication
.	O

The	O
serum	B-Detailed_description
thyroglobulin	B-Diagnostic_procedure
level	O
at	O
4	O
weeks	O
after	O
the	O
completion	O
of	O
chemotherapy	O
and	O
radiation	O
therapy	O
was	O
12	B-Lab_value
.	I-Lab_value
0	I-Lab_value
ng	I-Lab_value
per	I-Lab_value
milliliter	I-Lab_value
.	O

Restaging	O
scans	B-Diagnostic_procedure
obtained	O
3	O
months	O
later	O
revealed	O
a	O
new	O
,	O
right	B-Biological_structure
-	I-Biological_structure
sided	I-Biological_structure
hilar	I-Biological_structure
mass	B-Sign_symptom
(	O
Fig	O
.	O
1C	O
)	O
,	O
and	O
the	O
patient	O
enrolled	O
in	O
a	O
phase	B-Detailed_description
2	I-Detailed_description
clinical	O
trial	O
of	O
everolimus	B-Medication
,	O
which	O
was	O
administered	O
at	O
a	O
dose	O
of	O
10	B-Dosage
mg	I-Dosage
daily	I-Dosage
.	O

Within	O
6	O
months	O
,	O
follow	O
-	O
up	O
scans	B-Diagnostic_procedure
showed	O
that	O
the	O
lesion	O
had	O
greatly	O
diminished	B-Sign_symptom
in	I-Sign_symptom
size	I-Sign_symptom
(	O
from	O
3	B-Area
.	I-Area
0	I-Area
by	I-Area
2	I-Area
.	I-Area
6	I-Area
cm	I-Area
to	O
1	B-Area
.	I-Area
1	I-Area
by	I-Area
0	I-Area
.	I-Area
8	I-Area
cm	I-Area
)	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

After	O
18	B-Duration
months	I-Duration
of	O
a	O
sustained	O
response	B-Sign_symptom
to	O
everolimus	B-Medication
,	O
scans	B-Diagnostic_procedure
revealed	O
progressive	B-Disease_disorder
disease	I-Disease_disorder
(	O
Fig	O
.	O
1E	O
)	O
.	O

The	O
patient	O
underwent	O
a	O
mediastinoscopy	B-Diagnostic_procedure
with	O
removal	B-Therapeutic_procedure
of	O
an	O
enlarged	B-Sign_symptom
lymph	B-Biological_structure
node	I-Biological_structure
,	O
which	O
contained	O
metastatic	B-Detailed_description
anaplastic	B-Detailed_description
thyroid	B-Disease_disorder
cancer	I-Disease_disorder
(	O
Fig	O
.	O
1B	O
,	O
and	O
Fig	O
.	O
S1	O
in	O
Supplementary	O
Appendix	O
1	O
)	O
.	O

Whole	B-Detailed_description
-	I-Detailed_description
exome	I-Detailed_description
sequencing	B-Diagnostic_procedure
was	O
performed	O
on	O
biopsy	B-Diagnostic_procedure
samples	O
of	O
the	O
pretreatment	B-Detailed_description
and	I-Detailed_description
resistant	I-Detailed_description
tumors	I-Detailed_description
as	O
well	O
as	O
on	O
a	O
blood	B-Detailed_description
sample	I-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

A	O
woman	O
in	O
her	O
early	B-Age
70s	I-Age
presented	O
to	O
our	O
emergency	B-Nonbiological_location
room	I-Nonbiological_location
30	B-Time
min	I-Time
after	I-Time
her	O
husband	O
expired	O
with	O
8	B-Lab_value
/	I-Lab_value
10	I-Lab_value
,	O
substernal	B-Biological_structure
chest	B-Biological_structure
pain	B-Sign_symptom
with	O
concurrent	O
diaphoresis	B-Sign_symptom
and	O
dyspnoea	B-Sign_symptom
.	O

The	O
patient	O
`	O
s	O
husband	O
had	O
an	O
out	B-Detailed_description
-	I-Detailed_description
of	I-Detailed_description
-	I-Detailed_description
hospital	I-Detailed_description
cardiac	I-Detailed_description
arrest	I-Detailed_description
earlier	B-Time
that	I-Time
day	I-Time
and	O
was	O
brought	B-Detailed_description
to	I-Detailed_description
our	I-Detailed_description
emergency	I-Detailed_description
room	I-Detailed_description
and	O
subsequently	O
admitted	B-Detailed_description
to	I-Detailed_description
the	I-Detailed_description
coronary	I-Detailed_description
care	I-Detailed_description
unit	I-Detailed_description
.	O

He	O
had	O
recurrent	B-Detailed_description
ventricular	I-Detailed_description
fibrillation	I-Detailed_description
and	O
could	B-Detailed_description
not	I-Detailed_description
be	I-Detailed_description
successfully	I-Detailed_description
resuscitated	I-Detailed_description
.	O

The	O
patient	O
`	O
s	O
medical	O
history	O
included	O
hypertension	O
and	O
hypothyroidism	O
.	O

She	O
denied	O
having	O
had	O
a	O
similar	O
episode	O
of	O
pain	O
.	O

She	O
had	O
regular	O
appointments	O
with	O
her	O
primary	O
care	O
physician	O
.	O

Her	O
medication	B-Medication
included	O
oral	O
furosemide	B-Medication
20	B-Dosage
mg	I-Dosage
and	O
levothyroxine	B-Medication
100	B-Dosage
µg	I-Dosage
,	O
both	O
once	B-Dosage
daily	I-Dosage
.	O

She	O
denied	O
allergies	O
.	O

On	O
presentation	O
,	O
the	O
patient	O
was	O
afebrile	B-Sign_symptom
,	O
with	O
a	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
105	B-Lab_value
/	I-Lab_value
55	I-Lab_value
,	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
93	B-Lab_value
bpm	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
20	B-Lab_value
/	I-Lab_value
min	I-Lab_value
and	O
an	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
of	O
98	B-Lab_value
%	I-Lab_value
on	O
room	B-Detailed_description
air	I-Detailed_description
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
she	O
was	O
in	O
significant	B-Severity
distress	B-Sign_symptom
due	O
to	O
pain	B-Sign_symptom
.	O

Her	O
skin	B-Diagnostic_procedure
was	O
warm	B-Lab_value
and	O
moist	B-Lab_value
,	O
with	O
minimal	B-Lab_value
crackles	I-Lab_value
in	O
bilateral	B-Diagnostic_procedure
bases	I-Diagnostic_procedure
,	O
regular	B-Lab_value
rate	B-Diagnostic_procedure
and	I-Diagnostic_procedure
rhythm	I-Diagnostic_procedure
,	O
2	B-Lab_value
/	I-Lab_value
6	I-Lab_value
systolic	I-Lab_value
murmur	B-Sign_symptom
of	B-Detailed_description
the	I-Detailed_description
apex	I-Detailed_description
without	I-Detailed_description
radiation	I-Detailed_description
,	O
no	O
rubs	B-Sign_symptom
,	O
elevated	B-Lab_value
jugular	B-Biological_structure
vein	I-Biological_structure
distention	B-Sign_symptom
of	O
8	B-Distance
cm	I-Distance
,	O
strong	B-Lab_value
peripheral	B-Detailed_description
pulses	B-Diagnostic_procedure
and	O
no	O
peripheral	B-Detailed_description
oedema	B-Sign_symptom
.	O

The	O
abdomen	B-Diagnostic_procedure
was	O
soft	B-Lab_value
,	O
non	B-Lab_value
-	I-Lab_value
tender	I-Lab_value
,	O
non	B-Lab_value
-	I-Lab_value
distended	I-Lab_value
,	O
with	B-Lab_value
bowel	I-Lab_value
sounds	I-Lab_value
,	O
and	O
the	O
patient	O
was	O
alert	B-Sign_symptom
and	O
oriented	B-Sign_symptom
without	O
focal	B-Detailed_description
neurological	B-Sign_symptom
deficits	I-Sign_symptom
.	O

The	O
complete	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
basic	B-Diagnostic_procedure
metabolic	I-Diagnostic_procedure
panel	I-Diagnostic_procedure
and	O
coagulation	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

The	O
cardiac	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
were	O
increased	B-Lab_value
with	O
a	O
troponin	B-Diagnostic_procedure
I	I-Diagnostic_procedure
of	O
2	B-Lab_value
.	I-Lab_value
59	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
(	O
normal	O
range	O
0	O
.	O
015	O
-	O
0	O
.	O
045	O
ng	O
/	O
mL	O
)	O
,	O
creatine	B-Diagnostic_procedure
phosphokinase	I-Diagnostic_procedure
of	O
84	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
26	O
-	O
192	O
U	O
/	O
L	O
)	O
.	O

ECG	B-Diagnostic_procedure
on	O
admission	O
revealed	O
normal	B-Lab_value
sinus	B-Diagnostic_procedure
rhythm	I-Diagnostic_procedure
with	O
2	B-Lab_value
-	I-Lab_value
3	I-Lab_value
mm	I-Lab_value
ST	I-Lab_value
segment	I-Lab_value
elevations	I-Lab_value
in	I-Lab_value
leads	I-Lab_value
V2	I-Lab_value
-	I-Lab_value
V3	I-Lab_value
and	O
Q	B-Lab_value
waves	I-Lab_value
in	I-Lab_value
leads	I-Lab_value
V1	I-Lab_value
-	I-Lab_value
V3	I-Lab_value
,	O
suggestive	O
of	O
anterior	B-Biological_structure
wall	I-Biological_structure
infarct	B-Disease_disorder
(	O
figure	O
2	O
)	O
.	O

An	O
echocardiogram	B-Diagnostic_procedure
revealed	O
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
ejection	I-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
30	B-Lab_value
-	I-Lab_value
35	I-Lab_value
%	I-Lab_value
with	O
mild	B-Severity
concentric	B-Detailed_description
left	B-Biological_structure
ventricular	I-Biological_structure
hypertrophy	B-Sign_symptom
,	O
akinesis	B-Sign_symptom
of	O
the	O
apex	B-Biological_structure
and	O
2	B-Biological_structure
/	I-Biological_structure
3	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
inferoseptum	I-Biological_structure
and	O
apical	B-Biological_structure
inferior	I-Biological_structure
-	I-Biological_structure
anterior	I-Biological_structure
wall	I-Biological_structure
segments	I-Biological_structure
,	O
suggesting	O
ischaemic	B-Sign_symptom
damage	I-Sign_symptom
at	O
the	O
left	B-Biological_structure
anterior	I-Biological_structure
descending	I-Biological_structure
artery	I-Biological_structure
distribution	O
versus	O
takotsubo	B-Disease_disorder
cardiomyopathy	I-Disease_disorder
(	O
figures	O
3	O
and	O
4	O
)	O
.	O

The	O
patient	O
received	O
aspirin	B-Medication
162	B-Dosage
mg	I-Dosage
and	O
prasugrel	B-Medication
60	B-Dosage
mg	I-Dosage
,	O
and	O
was	O
taken	O
to	O
the	O
cardiac	B-Nonbiological_location
catheterisation	I-Nonbiological_location
laboratory	I-Nonbiological_location
.	O

The	O
angiogram	B-Diagnostic_procedure
showed	O
non	B-Detailed_description
-	I-Detailed_description
obstructive	I-Detailed_description
coronary	B-Disease_disorder
artery	I-Disease_disorder
disease	I-Disease_disorder
with	O
luminal	B-Biological_structure
irregularities	B-Sign_symptom
(	O
figures	O
5	O
and	O
6	O
)	O
.	O

The	O
left	B-Diagnostic_procedure
ventriculography	I-Diagnostic_procedure
showed	O
an	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
35	B-Lab_value
%	I-Lab_value
with	O
akinesis	B-Sign_symptom
of	O
apical	B-Biological_structure
wall	I-Biological_structure
and	O
hyperkinesis	B-Sign_symptom
of	O
basal	B-Biological_structure
segments	I-Biological_structure
(	O
figures	O
7	O
and	O
8	O
)	O
.	O

The	O
patient	O
remained	O
haemodynamically	B-Diagnostic_procedure
stable	B-Lab_value
and	O
was	O
started	O
on	O
oral	O
heart	B-Medication
failure	I-Medication
medications	I-Medication
,	O
including	O
lisinopril	B-Medication
2	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
daily	I-Dosage
and	O
metoprolol	B-Medication
tartrate	I-Medication
12	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
two	I-Dosage
times	I-Dosage
a	I-Dosage
day	I-Dosage
.	O

Her	O
pain	B-Sign_symptom
and	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
resolved	O
and	O
she	O
was	O
discharged	O
home	B-Nonbiological_location
after	O
48	O
h	O
of	O
hospitalisation	O
in	O
stable	B-Lab_value
condition	B-Diagnostic_procedure
.	O

A	O
repeat	O
echocardiogram	B-Diagnostic_procedure
2	O
months	O
later	O
showed	O
resolution	O
of	O
her	O
cardiomyopathy	B-Disease_disorder
and	O
an	O
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
of	O
65	B-Lab_value
-	I-Lab_value
70	I-Lab_value
%	I-Lab_value
,	O
with	O
normal	B-Lab_value
left	B-Diagnostic_procedure
ventricular	I-Diagnostic_procedure
motion	I-Diagnostic_procedure
.	O

-DOCSTART- -X- -X- -X- O

A	O
63	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
no	O
known	O
cardiac	O
history	O
presented	O
with	O
a	O
sudden	B-Detailed_description
onset	I-Detailed_description
of	O
dyspnea	B-Sign_symptom
requiring	O
intubation	B-Therapeutic_procedure
and	O
ventilatory	B-Therapeutic_procedure
support	I-Therapeutic_procedure
out	B-Nonbiological_location
of	I-Nonbiological_location
hospital	I-Nonbiological_location
.	O

She	O
denied	O
preceding	O
symptoms	O
of	O
chest	B-Biological_structure
discomfort	B-Sign_symptom
,	O
palpitations	B-Sign_symptom
,	O
syncope	B-Sign_symptom
or	O
infection	B-Disease_disorder
.	O

The	O
patient	O
was	O
afebrile	B-Sign_symptom
and	O
normotensive	B-Sign_symptom
,	O
with	O
a	O
sinus	B-Detailed_description
tachycardia	B-Sign_symptom
of	O
140	B-Lab_value
beats	I-Lab_value
/	I-Lab_value
min	I-Lab_value
.	O

The	O
cardiorespiratory	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
remarkable	O
for	O
an	O
elevated	B-Lab_value
jugular	B-Diagnostic_procedure
venous	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
at	O
the	O
angle	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
jaw	I-Biological_structure
,	O
a	O
left	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
third	B-Sign_symptom
heart	I-Sign_symptom
sound	I-Sign_symptom
and	O
bibasilar	B-Detailed_description
crackles	B-Sign_symptom
in	O
both	B-Biological_structure
lung	I-Biological_structure
fields	O
.	O

The	O
complete	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
electrolytes	B-Diagnostic_procedure
and	O
cardiac	B-Diagnostic_procedure
biomarkers	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

An	O
initial	O
electrocardiogram	B-Diagnostic_procedure
revealed	O
ST	B-Sign_symptom
depression	I-Sign_symptom
in	O
leads	B-Diagnostic_procedure
V2	I-Diagnostic_procedure
to	I-Diagnostic_procedure
V6	I-Diagnostic_procedure
,	O
suggestive	O
of	O
anterolateral	B-Disease_disorder
ischemia	I-Disease_disorder
(	O
Figure	O
1	O
)	O
.	O

A	O
chest	B-Biological_structure
radiograph	B-Diagnostic_procedure
demonstrated	O
pulmonary	B-Biological_structure
vascular	B-Sign_symptom
congestion	I-Sign_symptom
consistent	O
with	O
a	O
diagnosis	O
of	O
pulmonary	B-Disease_disorder
edema	I-Disease_disorder
(	O
Figure	O
2	O
)	O
.	O

An	O
echocardiographic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
normal	B-Lab_value
cardiac	B-Diagnostic_procedure
dimensions	I-Diagnostic_procedure
,	O
normal	B-Lab_value
wall	B-Diagnostic_procedure
motion	I-Diagnostic_procedure
and	O
mild	B-Severity
diastolic	B-Disease_disorder
dysfunction	I-Disease_disorder
with	O
an	O
early	B-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
to	I-Diagnostic_procedure
late	I-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
transmitral	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
of	O
less	B-Lab_value
than	I-Lab_value
1	I-Lab_value
,	O
prolonged	B-Lab_value
deceleration	B-Diagnostic_procedure
time	I-Diagnostic_procedure
(	O
250	B-Lab_value
ms	I-Lab_value
)	O
and	O
a	O
reduced	B-Lab_value
early	B-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
annular	I-Diagnostic_procedure
velocity	I-Diagnostic_procedure
of	O
the	O
lateral	B-Biological_structure
mitral	I-Biological_structure
valve	I-Biological_structure
annulus	I-Biological_structure
.	O

Following	O
aggressive	B-Lab_value
diuresis	B-Therapeutic_procedure
and	O
requiring	O
minimal	B-Lab_value
ventilatory	B-Therapeutic_procedure
support	I-Therapeutic_procedure
,	O
the	O
patient	O
was	O
extubated	B-Therapeutic_procedure
one	O
day	O
following	O
her	O
initial	O
presentation	O
.	O

Within	B-Time
1	I-Time
h	I-Time
of	O
extubation	O
,	O
the	O
patient	O
developed	O
recurrent	B-Detailed_description
pulmonary	B-Disease_disorder
edema	I-Disease_disorder
clinically	O
and	O
radiographically	B-Diagnostic_procedure
,	O
requiring	O
mechanical	B-Therapeutic_procedure
ventilation	I-Therapeutic_procedure
.	O

Cardiac	B-Diagnostic_procedure
catheterization	I-Diagnostic_procedure
was	O
performed	O
and	O
revealed	O
normal	B-Lab_value
coronary	B-Biological_structure
arteries	I-Biological_structure
.	O

On	O
day	O
4	O
of	O
the	O
coronary	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
admission	O
,	O
the	O
patient	O
failed	O
a	O
repeat	O
attempt	O
at	O
extubation	B-Therapeutic_procedure
.	O

A	O
computed	B-Diagnostic_procedure
tomographic	I-Diagnostic_procedure
scan	O
revealed	O
a	O
4	B-Area
cm	I-Area
×	I-Area
9	I-Area
cm	I-Area
multinodular	B-Detailed_description
goiter	B-Disease_disorder
extending	O
into	O
the	O
mediastinum	B-Biological_structure
and	O
suspected	O
associated	O
tracheal	B-Biological_structure
stenosis	B-Sign_symptom
(	O
Figure	O
3	O
)	O
.	O

With	O
a	O
diagnosis	O
of	O
NPPE	B-Disease_disorder
secondary	O
to	O
an	O
enlarged	B-Severity
goiter	B-Disease_disorder
,	O
the	O
patient	O
underwent	O
surgical	B-Therapeutic_procedure
intervention	I-Therapeutic_procedure
for	O
a	O
thyroidectomy	B-Therapeutic_procedure
.	O

Intraoperative	B-Detailed_description
bronchoscopy	B-Diagnostic_procedure
revealed	O
tracheal	B-Biological_structure
stenosis	B-Sign_symptom
of	O
greater	B-Lab_value
than	I-Lab_value
50	I-Lab_value
%	I-Lab_value
.	O

The	O
postoperative	B-Diagnostic_procedure
course	I-Diagnostic_procedure
was	O
uncomplicated	B-Lab_value
,	O
and	O
three	O
months	O
following	O
discharge	O
,	O
the	O
patient	O
returned	O
to	O
her	O
previous	B-Detailed_description
activity	I-Detailed_description
level	I-Detailed_description
without	O
subjective	O
dyspnea	B-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

We	O
present	O
the	O
case	O
of	O
a	O
22	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
who	O
was	O
diagnosed	O
in	O
childhood	O
with	O
type	O
IIb	O
VHL	O
,	O
with	O
known	O
multiple	O
retinal	O
angiomas	O
,	O
pancreatic	O
cysts	O
,	O
and	O
spinal	O
and	O
cerebellar	O
hemangioblastomas	O
.	O

She	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
complaining	O
of	O
progressive	B-Detailed_description
dyspnea	B-Sign_symptom
and	O
palpitations	B-Sign_symptom
.	O

On	O
examination	B-Diagnostic_procedure
,	O
her	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
159	B-Lab_value
/	I-Lab_value
119	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
and	O
her	O
pulse	B-Diagnostic_procedure
was	O
123	B-Lab_value
bpm	I-Lab_value
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
systolic	B-Detailed_description
murmur	B-Sign_symptom
at	O
the	O
mitral	B-Biological_structure
focus	I-Biological_structure
with	O
irradiation	B-Biological_structure
to	I-Biological_structure
the	I-Biological_structure
axilla	I-Biological_structure
and	O
pulmonary	B-Sign_symptom
rales	I-Sign_symptom
.	O

Electrocardiography	B-Diagnostic_procedure
revealed	O
no	B-Lab_value
remarkable	I-Lab_value
findings	I-Lab_value
,	O
except	O
for	O
sinus	B-Detailed_description
tachycardia	B-Sign_symptom
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
an	O
elevated	B-Lab_value
N	B-Detailed_description
-	I-Detailed_description
terminal	I-Detailed_description
pro	B-Diagnostic_procedure
-	I-Diagnostic_procedure
brain	I-Diagnostic_procedure
natriuretic	I-Diagnostic_procedure
peptide	I-Diagnostic_procedure
and	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
signs	O
of	O
pulmonary	B-Sign_symptom
interstitial	I-Sign_symptom
edema	I-Sign_symptom
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
Department	B-Biological_structure
of	I-Biological_structure
Cardiology	I-Biological_structure
with	O
the	O
diagnosis	O
of	O
acute	B-Detailed_description
decompensated	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
.	O

Transthoracic	B-Detailed_description
echocardiography	B-Diagnostic_procedure
showed	O
a	O
dilated	B-Sign_symptom
left	B-Biological_structure
ventricle	I-Biological_structure
with	O
severely	B-Lab_value
depressed	I-Lab_value
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
due	O
to	O
generalized	B-Detailed_description
hypokinesia	B-Sign_symptom
and	O
a	O
mild	B-Severity
mitral	B-Sign_symptom
regurgitation	I-Sign_symptom
(	O
fig	O
.	O
1a	O
)	O
.	O

During	O
admission	O
,	O
the	O
patient	O
had	O
several	B-Detailed_description
episodes	I-Detailed_description
of	O
paroxysmal	B-Detailed_description
dyspnea	B-Sign_symptom
despite	O
treatment	O
with	O
β	B-Medication
-	I-Medication
blockers	I-Medication
and	O
diuretics	B-Medication
.	O

Due	O
to	O
the	O
clinical	O
suspicion	O
of	O
adrenal	B-Disease_disorder
gland	I-Disease_disorder
disease	I-Disease_disorder
,	O
24	B-Detailed_description
-	I-Detailed_description
hour	I-Detailed_description
urinary	B-Biological_structure
catecholamine	B-Diagnostic_procedure
and	O
metanephrine	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
were	O
requested	O
.	O

Cardiac	B-Biological_structure
MRI	B-Diagnostic_procedure
was	O
performed	O
in	O
order	O
to	O
complete	O
the	O
cardiomyopathy	B-Diagnostic_procedure
study	I-Diagnostic_procedure
,	O
and	O
confirmed	O
the	O
echocardiographic	O
findings	O
as	O
well	O
as	O
revealed	O
an	O
incidental	O
finding	O
of	O
a	O
great	B-Detailed_description
left	B-Biological_structure
renal	I-Biological_structure
mass	B-Sign_symptom
.	O

The	O
24	O
-	O
hour	O
urine	O
laboratory	O
tests	O
showed	O
markedly	B-Lab_value
elevated	I-Lab_value
levels	O
of	O
norepinephrine	B-Diagnostic_procedure
,	O
total	B-Diagnostic_procedure
catecholamines	I-Diagnostic_procedure
,	O
normetanephrine	B-Diagnostic_procedure
and	O
metanephrine	B-Diagnostic_procedure
with	O
normal	O
epinephrine	B-Diagnostic_procedure
values	O
:	O
24	O
-	O
hour	O
norepinephrine	O
468	B-Lab_value
μg	I-Lab_value
(	O
normal	O
range	O
:	O
23	O
-	O
105	O
)	O
,	O
24	O
-	O
hour	O
epinephrine	O
13	B-Lab_value
μg	I-Lab_value
(	O
normal	O
range	O
:	O
4	O
-	O
20	O
)	O
,	O
24	O
-	O
hour	O
total	O
catecholamines	O
658	B-Lab_value
μg	I-Lab_value
(	O
normal	O
range	O
:	O
217	O
-	O
575	O
)	O
,	O
24	O
-	O
hour	O
normetanephrine	O
2,988	B-Lab_value
μg	I-Lab_value
(	O
normal	O
range	O
:	O
105	O
-	O
354	O
)	O
,	O
24	O
-	O
hour	O
total	O
metanephrine	O
3,013	B-Lab_value
μg	I-Lab_value
(	O
normal	O
range	O
:	O
0	O
-	O
1,000	O
)	O
.	O

Therefore	O
,	O
an	O
abdominal	B-Biological_structure
MRI	B-Diagnostic_procedure
was	O
performed	O
,	O
which	O
showed	O
the	O
presence	O
of	O
two	B-Detailed_description
cystic	B-Detailed_description
masses	B-Sign_symptom
(	O
fig	O
.	O
2	O
)	O
located	O
at	O
the	O
left	B-Biological_structure
hypochondrium	I-Biological_structure
.	O

Surgical	B-Detailed_description
resection	B-Therapeutic_procedure
of	O
both	O
masses	O
was	O
performed	O
(	O
after	O
α	B-Therapeutic_procedure
-	I-Therapeutic_procedure
blockade	I-Therapeutic_procedure
with	O
phenoxybenzamine	B-Medication
and	O
β	B-Therapeutic_procedure
-	I-Therapeutic_procedure
blockade	I-Therapeutic_procedure
with	O
propranolol	B-Medication
)	O
through	O
a	O
laparoscopic	B-Therapeutic_procedure
approach	I-Therapeutic_procedure
,	O
confirming	O
the	O
diagnosis	O
of	O
pheochromocytoma	B-Disease_disorder
and	O
clear	B-Detailed_description
cell	I-Detailed_description
renal	B-Therapeutic_procedure
carcinoma	I-Therapeutic_procedure
on	O
histology	B-Diagnostic_procedure
.	O

During	O
follow	O
-	O
up	O
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
and	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
values	O
normalized	B-Lab_value
(	O
124	B-Lab_value
/	I-Lab_value
77	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
78	B-Lab_value
bpm	I-Lab_value
)	O
,	O
24	B-Detailed_description
-	I-Detailed_description
hour	I-Detailed_description
urinary	B-Biological_structure
catecholamine	B-Diagnostic_procedure
values	O
returned	O
to	O
normal	B-Lab_value
range	I-Lab_value
(	O
norepinephrine	B-Diagnostic_procedure
69	B-Lab_value
μg	I-Lab_value
/	O
24	O
h	O
,	O
total	B-Diagnostic_procedure
catecholamine	I-Diagnostic_procedure
221	B-Lab_value
μg	I-Lab_value
/	O
24	O
h	O
,	O
normetanephrine	B-Diagnostic_procedure
202	B-Lab_value
μg	I-Lab_value
/	O
24	O
h	O
and	O
total	B-Diagnostic_procedure
metanephrine	I-Diagnostic_procedure
259	B-Lab_value
μg	I-Lab_value
/	O
24	O
h	O
)	O
and	O
the	O
patient	O
had	O
no	O
new	O
episodes	O
of	O
palpitations	B-Sign_symptom
or	O
dyspnea	B-Sign_symptom
.	O

Six	O
months	O
after	O
surgical	O
resection	O
,	O
echocardiography	B-Diagnostic_procedure
was	O
repeated	O
and	O
showed	O
a	O
left	B-Biological_structure
ventricle	I-Biological_structure
with	O
normal	B-Sign_symptom
diameters	I-Sign_symptom
and	O
preserved	B-Lab_value
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
(	O
fig	O
.	O
1b	O
)	O
.	O

Genetic	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
revealed	O
a	O
germline	B-Sign_symptom
mutation	I-Sign_symptom
(	O
exon	B-Detailed_description
3	I-Detailed_description
deletion	I-Detailed_description
)	O
of	O
the	O
VHL	B-Detailed_description
tumor	I-Detailed_description
suppressor	I-Detailed_description
gene	I-Detailed_description
on	O
the	O
short	B-Detailed_description
arm	I-Detailed_description
of	I-Detailed_description
chromosome	I-Detailed_description
3	I-Detailed_description
.	O

As	O
the	O
patient	O
had	O
no	O
family	O
history	O
of	O
VHL	O
,	O
it	O
was	O
concluded	O
that	O
it	O
was	O
a	O
de	B-Detailed_description
novo	I-Detailed_description
mutation	I-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

A	O
49	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
was	O
admitted	O
to	O
the	O
Department	B-Nonbiological_location
of	I-Nonbiological_location
Radiology	I-Nonbiological_location
of	O
the	O
Second	B-Nonbiological_location
Affiliated	I-Nonbiological_location
Hospital	I-Nonbiological_location
of	I-Nonbiological_location
Zhejiang	I-Nonbiological_location
University	I-Nonbiological_location
in	O
October	O
2004	O
with	O
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
pain	B-Sign_symptom
and	O
weight	B-Sign_symptom
loss	I-Sign_symptom
.	O

She	O
was	O
a	O
hepatitis	B-Disease_disorder
B	I-Disease_disorder
virus	O
carrier	O
.	O

Her	O
α	B-Diagnostic_procedure
-	I-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
level	O
was	O
1185	B-Lab_value
.	I-Lab_value
3	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
.	O

Ultrasonography	B-Diagnostic_procedure
and	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
revealed	O
a	O
10	B-Distance
-	I-Distance
cm	I-Distance
mass	B-Sign_symptom
in	O
the	O
posterior	B-Biological_structure
segments	I-Biological_structure
of	O
the	O
right	B-Biological_structure
liver	I-Biological_structure
lobe	I-Biological_structure
.	O

A	O
1	B-Distance
.	I-Distance
5	I-Distance
-	I-Distance
cm	I-Distance
mass	B-Sign_symptom
was	O
also	O
found	O
in	O
the	O
left	B-Biological_structure
lateral	I-Biological_structure
segment	I-Biological_structure
.	O

These	O
clinical	O
signs	O
indicated	O
that	O
the	O
patient	O
had	O
inoperable	B-Detailed_description
HCC	B-Disease_disorder
and	O
Child	B-Detailed_description
-	I-Detailed_description
Pugh	I-Detailed_description
class	I-Detailed_description
A	I-Detailed_description
cirrhosis	B-Disease_disorder
.	O

TACE	B-Therapeutic_procedure
was	O
offered	O
to	O
the	O
patient	O
.	O

Angiogram	B-Diagnostic_procedure
demonstrated	O
no	O
obvious	O
hepatic	B-Biological_structure
arterio	B-Sign_symptom
-	I-Sign_symptom
venous	I-Sign_symptom
shunt	I-Sign_symptom
,	O
but	O
multiple	B-Detailed_description
smaller	B-Detailed_description
masses	B-Sign_symptom
in	O
both	B-Biological_structure
lobes	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
liver	I-Biological_structure
.	O

An	O
emulsion	O
of	O
oxaliplatin	B-Medication
,	O
pirarubicin	B-Medication
,	O
hydroxycamptothecin	B-Medication
and	O
lipiodol	B-Medication
were	O
prepared	O
,	O
35	B-Dosage
mL	I-Dosage
and	O
3	B-Dosage
mL	I-Dosage
of	O
the	O
mixture	B-Medication
were	O
administered	O
intra	O
-	O
arterially	O
to	O
the	O
right	B-Biological_structure
and	I-Biological_structure
left	I-Biological_structure
hepatic	I-Biological_structure
artery	I-Biological_structure
,	O
respectively	O
.	O

The	O
patient	O
experienced	O
right	B-Biological_structure
upper	I-Biological_structure
quadrant	I-Biological_structure
pain	B-Sign_symptom
after	O
TACE	O
and	O
had	O
an	O
uneventful	B-Lab_value
recovery	B-Diagnostic_procedure
.	O

One	O
month	O
later	O
,	O
a	O
second	B-Detailed_description
TACE	B-Therapeutic_procedure
procedure	O
was	O
performed	O
via	O
the	O
right	B-Biological_structure
hepatic	I-Biological_structure
artery	I-Biological_structure
and	O
40	B-Dosage
mL	I-Dosage
of	O
the	O
mixture	O
was	O
administered	O
.	O

On	O
the	O
next	O
day	O
,	O
she	O
experienced	O
sudden	B-Detailed_description
acute	B-Detailed_description
dyspnoea	B-Sign_symptom
and	O
the	O
peripheral	B-Diagnostic_procedure
oxygen	I-Diagnostic_procedure
saturation	I-Diagnostic_procedure
decreased	B-Lab_value
to	O
90	B-Lab_value
%	I-Lab_value
.	O

The	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
showed	O
some	O
increased	B-Detailed_description
reticular	B-Detailed_description
shadows	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
lung	I-Biological_structure
,	O
especially	O
in	O
the	O
lower	B-Biological_structure
zones	I-Biological_structure
,	O
and	O
a	O
chest	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
revealed	O
multiple	B-Detailed_description
iodized	B-Detailed_description
oil	B-Detailed_description
-	I-Detailed_description
like	I-Detailed_description
high	B-Detailed_description
-	I-Detailed_description
density	I-Detailed_description
materials	B-Sign_symptom
in	O
parenchyma	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
lung	I-Biological_structure
(	O
Figure	O
1	O
)	O
.	O

After	O
10	B-Dosage
mg	I-Dosage
dexamethasone	B-Medication
i	O
.	O
v	O
.	O
and	O
other	O
supportive	B-Therapeutic_procedure
therapies	I-Therapeutic_procedure
were	O
administered	O
,	O
the	O
respiratory	O
symptom	O
was	O
attenuated	O
.	O

Two	O
days	O
later	O
,	O
the	O
patient	O
suffered	O
from	O
a	O
serious	B-Severity
headache	B-Sign_symptom
and	O
transient	B-Detailed_description
consciousness	B-Sign_symptom
loss	I-Sign_symptom
,	O
accompanying	O
nausea	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
followed	O
by	O
confusion	B-Sign_symptom
,	O
lower	B-Biological_structure
extremity	I-Biological_structure
weakness	B-Sign_symptom
.	O

Non	B-Detailed_description
-	I-Detailed_description
contrast	I-Detailed_description
enhanced	I-Detailed_description
CT	B-Diagnostic_procedure
scanning	O
showed	O
multiple	B-Detailed_description
disseminated	B-Detailed_description
hyper	B-Detailed_description
-	I-Detailed_description
intense	I-Detailed_description
lesions	B-Sign_symptom
in	O
the	O
brain	B-Biological_structure
,	O
consistent	O
with	O
deposition	B-Sign_symptom
of	O
iodized	B-Detailed_description
oil	I-Detailed_description
(	O
Figure	O
2	O
)	O
.	O

One	O
week	O
later	O
,	O
her	O
respiratory	B-Biological_structure
and	O
neurologic	B-Biological_structure
symptoms	B-Sign_symptom
disappeared	O
completely	O
,	O
and	O
she	O
was	O
discharged	O
.	O

The	O
patient	O
also	O
consequently	O
completed	O
the	O
other	B-Detailed_description
three	I-Detailed_description
TACE	B-Therapeutic_procedure
procedures	O
,	O
during	O
which	O
no	O
similar	B-Detailed_description
symptoms	B-Sign_symptom
occurred	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
64	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
was	O
found	O
lying	B-Activity
down	I-Activity
after	O
10	B-Duration
-	I-Duration
12	I-Duration
hours	I-Duration
of	O
binge	B-Activity
drinking	I-Activity
.	O

She	O
was	O
taken	O
to	O
an	O
outlying	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
(	O
ED	B-Nonbiological_location
)	O
,	O
and	O
subsequently	O
transferred	O
to	O
our	O
hospital	B-Nonbiological_location
with	O
mental	B-Sign_symptom
status	I-Sign_symptom
changes	I-Sign_symptom
and	O
respiratory	B-Sign_symptom
distress	I-Sign_symptom
and	O
hypoxia	B-Sign_symptom
for	O
further	O
management	O
.	O

She	O
had	O
a	O
past	O
history	O
of	O
rheumatoid	O
arthritis	O
,	O
congestive	O
heart	O
failure	O
,	O
controlled	O
hypertension	O
,	O
and	O
alcoholism	O
.	O

She	O
smoked	O
two	O
packs	O
a	O
day	O
for	O
the	O
past	O
50	O
years	O
.	O

On	O
presentation	O
,	O
she	O
had	O
a	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
176	B-Lab_value
/	I-Lab_value
80	I-Lab_value
mm	I-Lab_value
/	I-Lab_value
Hg	I-Lab_value
,	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
of	O
80	B-Lab_value
bpm	I-Lab_value
,	O
respirations	B-Diagnostic_procedure
24	B-Lab_value
bpm	I-Lab_value
,	O
temperature	B-Diagnostic_procedure
98	B-Lab_value
°F	I-Lab_value
(	O
36	B-Lab_value
.	I-Lab_value
7	I-Lab_value
°C	I-Lab_value
)	O
.	O

Arterial	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
gases	I-Diagnostic_procedure
on	O
room	B-Detailed_description
air	I-Detailed_description
showed	O
a	O
pH	B-Diagnostic_procedure
of	O
7	B-Lab_value
.	I-Lab_value
30	I-Lab_value
,	O
PaCO2	B-Diagnostic_procedure
60	B-Lab_value
,	O
PaO2	B-Diagnostic_procedure
61	B-Lab_value
mm	I-Lab_value
/	I-Lab_value
Hg	I-Lab_value
,	O
H	B-Diagnostic_procedure
−	I-Diagnostic_procedure
CO3	I-Diagnostic_procedure
29	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
saturation	B-Diagnostic_procedure
92	B-Lab_value
%	I-Lab_value
which	O
improved	O
to	O
95	B-Lab_value
%	I-Lab_value
with	O
oxygen	B-Therapeutic_procedure
by	O
a	O
high	B-Detailed_description
flow	I-Detailed_description
non	I-Detailed_description
-	I-Detailed_description
rebreather	I-Detailed_description
mask	I-Detailed_description
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
she	O
was	O
lethargic	B-Sign_symptom
,	O
disoriented	B-Sign_symptom
,	O
dysarthritic	B-Sign_symptom
,	O
but	O
without	O
neurological	B-Sign_symptom
focalization	I-Sign_symptom
.	O

Scattered	B-Detailed_description
expiratory	B-Sign_symptom
wheezes	I-Sign_symptom
were	O
noted	O
bilaterally	B-Biological_structure
along	O
with	O
normal	B-Lab_value
heart	B-Diagnostic_procedure
sounds	I-Diagnostic_procedure
.	O

The	O
remaining	O
results	O
of	O
her	O
physical	O
examination	O
and	O
routine	O
laboratory	B-Diagnostic_procedure
results	I-Diagnostic_procedure
were	O
unremarkable	B-Lab_value
with	O
the	O
exception	O
of	O
a	O
leukocyte	B-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
14,000	B-Lab_value
/	I-Lab_value
dL	I-Lab_value
with	O
88	B-Lab_value
%	I-Lab_value
neutrophils	I-Lab_value
.	O

Repeated	O
vitals	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
consistent	O
with	O
a	O
normal	B-Lab_value
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
but	O
evidence	O
of	O
tachycardia	B-Sign_symptom
in	O
the	O
monitor	O
.	O

Repeated	O
ABG	B-Diagnostic_procedure
`	I-Diagnostic_procedure
s	I-Diagnostic_procedure
on	O
the	O
non	B-Therapeutic_procedure
-	I-Therapeutic_procedure
rebreather	I-Therapeutic_procedure
mask	I-Therapeutic_procedure
showed	O
:	O
pH	B-Diagnostic_procedure
7	B-Lab_value
.	I-Lab_value
22	I-Lab_value
,	O
PaCO2	B-Diagnostic_procedure
78	B-Lab_value
,	O
PaO2	B-Diagnostic_procedure
140	B-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
H	B-Diagnostic_procedure
−	I-Diagnostic_procedure
CO3	I-Diagnostic_procedure
30	B-Lab_value
mEq	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
hemoglobin	B-Diagnostic_procedure
SaO2	I-Diagnostic_procedure
97	B-Lab_value
%	I-Lab_value
.	O

In	O
the	O
ED	B-Nonbiological_location
she	O
was	O
started	O
on	O
IV	O
steroids	B-Medication
and	O
antibiotics	B-Medication
for	O
a	O
COPD	B-Disease_disorder
exacerbation	B-Detailed_description
.	O

As	O
part	O
of	O
the	O
diagnostic	B-Diagnostic_procedure
workup	I-Diagnostic_procedure
,	O
she	O
underwent	O
a	O
chest	B-Biological_structure
x	B-Diagnostic_procedure
ray	I-Diagnostic_procedure
that	O
did	O
not	O
show	O
any	O
infiltrates	B-Sign_symptom
or	O
any	O
major	O
abnormal	B-Sign_symptom
findings	I-Sign_symptom
.	O

The	O
ECG	B-Diagnostic_procedure
was	O
only	O
significant	O
for	O
sinus	B-Biological_structure
tachycardia	B-Sign_symptom
.	O

Given	O
the	O
negative	O
findings	O
on	O
chest	O
x	O
ray	O
,	O
sinus	O
tachycardia	O
on	O
ECG	O
,	O
and	O
an	O
increased	O
A	O
-	O
a	O
gradient	O
,	O
the	O
patient	O
was	O
sent	O
for	O
a	O
spiral	B-Detailed_description
chest	B-Biological_structure
CT	B-Diagnostic_procedure
with	B-Detailed_description
contrast	I-Detailed_description
to	O
rule	O
out	O
a	O
pulmonary	B-Biological_structure
embolism	B-Disease_disorder
.	O

During	O
CT	O
about	O
100	B-Volume
-	I-Volume
150	I-Volume
mL	I-Volume
of	O
air	O
was	O
inadvertently	O
injected	O
through	O
the	O
right	B-Biological_structure
antecubital	I-Biological_structure
vein	I-Biological_structure
using	O
a	O
power	B-Detailed_description
contrast	I-Detailed_description
injector	I-Detailed_description
(	O
estimated	O
by	O
the	O
technician	O
and	O
approximation	O
of	O
volumes	O
on	O
available	O
imaging	O
)	O
.	O

Concurrent	B-Detailed_description
imaging	B-Diagnostic_procedure
(	O
CT	O
)	O
showed	O
a	O
significant	B-Severity
amount	B-Sign_symptom
of	I-Sign_symptom
air	I-Sign_symptom
in	O
the	O
right	B-Biological_structure
atrium	I-Biological_structure
and	O
right	B-Biological_structure
ventricular	I-Biological_structure
cavity	I-Biological_structure
(	O
Figure	O
1	O
)	O
,	O
and	O
air	B-Sign_symptom
mixed	I-Sign_symptom
with	I-Sign_symptom
contrast	I-Sign_symptom
in	O
the	O
main	B-Biological_structure
pulmonary	I-Biological_structure
artery	I-Biological_structure
and	O
its	O
proximal	B-Biological_structure
branches	I-Biological_structure
divisions	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
pulmonary	I-Biological_structure
circulation	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

Concurrently	O
,	O
a	O
filling	B-Sign_symptom
defect	I-Sign_symptom
was	O
noted	O
in	O
the	O
right	B-Biological_structure
lower	I-Biological_structure
lobe	I-Biological_structure
artery	I-Biological_structure
consistent	O
with	O
pulmonary	B-Biological_structure
thromboembolism	B-Disease_disorder
(	O
Figures	O
3	O
,	O
,4	O
)	O
.	O
4	O
)	O
.	O

The	O
patient	O
maintained	O
hemodynamic	B-Diagnostic_procedure
stability	I-Diagnostic_procedure
with	O
Trendelenburg	B-Therapeutic_procedure
,	O
and	O
left	B-Therapeutic_procedure
lateral	I-Therapeutic_procedure
decubitus	I-Therapeutic_procedure
positioning	I-Therapeutic_procedure
(	O
Durant	B-Therapeutic_procedure
`	I-Therapeutic_procedure
s	I-Therapeutic_procedure
maneuver	I-Therapeutic_procedure
)	O
,	O
and	O
supportive	B-Therapeutic_procedure
care	I-Therapeutic_procedure
alone	O
and	O
she	O
was	O
transferred	O
to	O
the	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
(	O
ICU	B-Nonbiological_location
)	O
for	O
observation	O
.	O

Her	O
respiratory	B-Sign_symptom
distress	I-Sign_symptom
worsened	O
,	O
and	O
she	O
was	O
placed	O
temporarily	O
on	O
non	B-Therapeutic_procedure
-	I-Therapeutic_procedure
invasive	I-Therapeutic_procedure
positive	I-Therapeutic_procedure
pressure	I-Therapeutic_procedure
ventilation	I-Therapeutic_procedure
(	O
NIPPV	B-Therapeutic_procedure
)	O
without	O
improvement	B-Sign_symptom
and	O
a	B-Time
few	I-Time
hours	I-Time
later	I-Time
she	O
was	O
intubated	B-Therapeutic_procedure
and	O
placed	O
on	O
mechanical	B-Therapeutic_procedure
ventilation	I-Therapeutic_procedure
.	O

Intravenous	O
full	B-Detailed_description
dose	I-Detailed_description
heparin	B-Medication
infusion	O
(	O
initial	B-Dosage
bolus	I-Dosage
,	I-Dosage
80	I-Dosage
units	I-Dosage
/	I-Dosage
kg	I-Dosage
,	I-Dosage
followed	I-Dosage
by	I-Dosage
18	I-Dosage
units	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
hour	I-Dosage
)	O
was	O
initiated	O
for	O
treatment	O
of	O
concurrent	O
thromboembolism	B-Disease_disorder
.	O

Echocardiography	B-Diagnostic_procedure
did	O
not	O
show	O
any	O
evidence	O
of	O
right	B-Sign_symptom
or	I-Sign_symptom
left	I-Sign_symptom
ventricular	I-Sign_symptom
failure	I-Sign_symptom
.	O

Subsequent	O
echocardiography	B-Diagnostic_procedure
done	O
24	B-Time
hours	I-Time
later	I-Time
did	O
not	O
show	O
any	O
evidence	O
of	O
intracardiac	B-Biological_structure
air	B-Sign_symptom
and	O
complete	O
resolution	O
of	O
the	O
air	O
embolism	B-Disease_disorder
.	O

During	B-Duration
the	I-Duration
next	I-Duration
48	I-Duration
hours	I-Duration
,	O
she	O
remained	O
hemodynamically	B-Diagnostic_procedure
stable	B-Lab_value
with	O
no	O
requirements	O
of	O
vasoactive	B-Medication
agents	I-Medication
.	O

She	O
was	O
finally	O
extubated	B-Therapeutic_procedure
48	O
hours	O
after	O
the	O
initial	O
presentation	O
.	O

She	O
was	O
later	O
discharged	O
home	B-Nonbiological_location
on	O
warfarin	B-Medication
with	O
subsequent	O
outpatient	O
follow	O
-	O
up	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
84	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
patient	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
disease	O
and	O
right	O
coronary	O
artery	O
(	O
RCA	O
)	O
stenting	O
was	O
admitted	O
to	O
our	O
university	B-Nonbiological_location
hospital	I-Nonbiological_location
in	O
February	O
2012	O
because	O
of	O
progressive	B-Detailed_description
dyspnoea	B-Sign_symptom
and	O
recurring	B-Detailed_description
syncopes	B-Sign_symptom
.	O

Cardiological	B-Diagnostic_procedure
work	I-Diagnostic_procedure
-	I-Diagnostic_procedure
up	I-Diagnostic_procedure
revealed	O
a	O
grade	B-Lab_value
III	I-Lab_value
severe	B-Severity
symptomatic	B-Detailed_description
aortic	B-Disease_disorder
stenosis	I-Disease_disorder
.	O

Due	O
to	O
relevant	O
comorbidities	O
(	O
logistic	B-Diagnostic_procedure
EuroSCORE	I-Diagnostic_procedure
of	O
19	B-Lab_value
points	I-Lab_value
)	O
and	O
severe	B-Severity
femoral	B-Biological_structure
arteriopathy	B-Disease_disorder
,	O
he	O
was	O
scheduled	O
for	O
trans	B-Detailed_description
-	I-Detailed_description
subclavian	I-Detailed_description
TAVI	B-Therapeutic_procedure
.	O

After	O
successful	O
implantation	O
of	O
a	O
CoreValve	B-Detailed_description
prosthesis	I-Detailed_description
(	O
Medtronic	B-Detailed_description
)	O
[	O
Medtronic	B-Detailed_description
World	I-Detailed_description
Headquarters	I-Detailed_description
Medtronic	I-Detailed_description
Parkway	I-Detailed_description
Minneapolis	I-Detailed_description
,	I-Detailed_description
Minnesota	I-Detailed_description
,	I-Detailed_description
USA	I-Detailed_description
]	O
(	O
diameter	B-Detailed_description
31	I-Detailed_description
mm	I-Detailed_description
)	O
and	O
initial	O
discharge	O
,	O
he	O
was	O
referred	O
back	O
to	O
the	O
hospital	B-Biological_structure
because	O
of	O
dyspnoea	B-Sign_symptom
due	O
to	O
bilateral	B-Detailed_description
pleural	B-Disease_disorder
effusions	I-Disease_disorder
.	O

Transoesophageal	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
TEE	B-Diagnostic_procedure
)	O
showed	O
a	O
severe	B-Severity
mitral	B-Sign_symptom
regurgitation	I-Sign_symptom
(	O
MR	B-Sign_symptom
)	O
,	O
which	O
was	O
subsequently	O
treated	O
by	O
interventional	B-Detailed_description
mitral	B-Therapeutic_procedure
valve	I-Therapeutic_procedure
repair	I-Therapeutic_procedure
using	O
the	O
MitraClip	B-Biological_structure
(	O
Abbott	B-Detailed_description
Vascular	I-Detailed_description
,	I-Detailed_description
Abbott	I-Detailed_description
Laboratories	I-Detailed_description
,	I-Detailed_description
Abbott	I-Detailed_description
Park	I-Detailed_description
,	I-Detailed_description
Illinois	I-Detailed_description
,	I-Detailed_description
U	I-Detailed_description
.	I-Detailed_description
S	I-Detailed_description
.	I-Detailed_description
A	I-Detailed_description
.	I-Detailed_description
)	O
and	O
procedurally	O
dependent	O
atrial	B-Therapeutic_procedure
septal	I-Therapeutic_procedure
defect	I-Therapeutic_procedure
(	I-Therapeutic_procedure
ASD	I-Therapeutic_procedure
)	I-Therapeutic_procedure
closure	I-Therapeutic_procedure
AMPLATZER	B-Detailed_description
™	I-Detailed_description
PFO	I-Detailed_description
Occluder	I-Detailed_description
(	O
St	O
.	O

Jude	O
Medical	O
GmbH	O
,	O
Helfmann	O
-	O
Park	O
7	O
,	O
Eschborn	O
,	O
Germany	O
)	O
.	O

Two	O
weeks	O
after	O
secondary	B-Detailed_description
discharge	O
,	O
the	O
patient	O
developed	O
progressive	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
in	O
combination	O
with	O
acute	B-Detailed_description
renal	B-Disease_disorder
failure	I-Disease_disorder
.	O

Immediate	B-Detailed_description
echocardiography	B-Diagnostic_procedure
revealed	O
a	O
moderate	B-Severity
-	I-Severity
to	I-Severity
-	I-Severity
severe	I-Severity
aortic	B-Sign_symptom
regurgitation	I-Sign_symptom
and	O
recurrent	B-Detailed_description
severe	B-Severity
MR	B-Sign_symptom
.	O

Valvular	B-Sign_symptom
defects	I-Sign_symptom
resulted	O
from	O
a	O
slight	B-Severity
but	I-Severity
significant	I-Severity
aortic	B-Sign_symptom
valve	I-Sign_symptom
prosthesis	I-Sign_symptom
migration	I-Sign_symptom
towards	O
the	O
left	B-Biological_structure
ventricular	I-Biological_structure
outflow	I-Biological_structure
tract	I-Biological_structure
,	O
which	O
had	O
caused	O
aortic	B-Sign_symptom
paravalvular	I-Sign_symptom
leakage	I-Sign_symptom
and	O
partial	B-Detailed_description
posterior	B-Detailed_description
mitral	B-Sign_symptom
leaflet	I-Sign_symptom
detachment	I-Sign_symptom
(	O
Fig	O
.	O
1	O
)	O
.	O

As	O
a	O
consequence	O
of	O
these	O
findings	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
cardiac	B-Nonbiological_location
surgery	I-Nonbiological_location
department	I-Nonbiological_location
.	O

Preoperative	O
coronary	B-Biological_structure
angiography	B-Diagnostic_procedure
revealed	O
a	O
progression	O
of	O
the	O
coronary	B-Disease_disorder
artery	I-Disease_disorder
disease	I-Disease_disorder
.	O

Consequently	O
the	O
patient	O
was	O
scheduled	O
for	O
conventional	B-Detailed_description
aortic	B-Biological_structure
and	O
mitral	B-Biological_structure
valve	B-Therapeutic_procedure
replacement	I-Therapeutic_procedure
,	O
as	O
well	O
as	O
coronary	B-Therapeutic_procedure
artery	I-Therapeutic_procedure
bypass	I-Therapeutic_procedure
surgery	I-Therapeutic_procedure
.	O

The	O
operation	O
was	O
performed	O
via	O
median	B-Therapeutic_procedure
sternotomy	I-Therapeutic_procedure
.	O

On	O
initialization	O
of	O
cardiopulmonary	B-Therapeutic_procedure
bypass	I-Therapeutic_procedure
,	O
the	O
ascending	B-Biological_structure
aorta	I-Biological_structure
was	O
opened	B-Therapeutic_procedure
for	O
exploration	B-Detailed_description
of	I-Detailed_description
the	I-Detailed_description
aortic	I-Detailed_description
valve	I-Detailed_description
(	O
Fig	O
.	O
2A	O
)	O
.	O

After	O
careful	O
removal	B-Therapeutic_procedure
of	O
the	O
CoreValve	B-Detailed_description
prosthesis	I-Detailed_description
,	O
an	O
Edwards	B-Detailed_description
Perimount	I-Detailed_description
aortic	B-Detailed_description
valve	I-Detailed_description
prosthesis	I-Detailed_description
(	O
diameter	B-Detailed_description
25	I-Detailed_description
mm	I-Detailed_description
)	O
was	O
implanted	B-Therapeutic_procedure
.	O

After	O
vein	B-Therapeutic_procedure
-	I-Therapeutic_procedure
grafting	I-Therapeutic_procedure
of	O
the	O
circumflex	B-Biological_structure
coronary	I-Biological_structure
artery	I-Biological_structure
,	O
the	O
mitral	B-Biological_structure
valve	I-Biological_structure
was	O
explored	B-Detailed_description
via	I-Detailed_description
the	I-Detailed_description
left	I-Detailed_description
atrium	I-Detailed_description
and	O
excised	B-Therapeutic_procedure
with	O
the	O
attached	B-Detailed_description
clip	I-Detailed_description
.	O

Thereafter	O
,	O
an	O
Edwards	B-Detailed_description
Perimount	I-Detailed_description
mitral	B-Detailed_description
valve	I-Detailed_description
prosthesis	I-Detailed_description
(	O
diameter	B-Detailed_description
31	I-Detailed_description
mm	I-Detailed_description
)	O
was	O
implanted	B-Therapeutic_procedure
.	O

More	O
recently	O
,	O
the	O
atrial	B-Therapeutic_procedure
septal	I-Therapeutic_procedure
occluder	I-Therapeutic_procedure
was	I-Therapeutic_procedure
removed	I-Therapeutic_procedure
prior	O
to	O
direct	O
closure	B-Therapeutic_procedure
of	O
the	O
resulting	O
septal	B-Sign_symptom
defect	I-Sign_symptom
with	O
a	O
single	B-Detailed_description
-	I-Detailed_description
suture	I-Detailed_description
line	I-Detailed_description
(	O
Fig	O
.	O
2B	O
)	O
.	O

Intraoperative	B-Detailed_description
echocardiography	B-Diagnostic_procedure
revealed	O
adequate	B-Lab_value
function	I-Lab_value
of	I-Lab_value
both	I-Lab_value
prostheses	I-Lab_value
and	O
the	O
operation	O
was	O
completed	O
in	O
the	O
usual	O
manner	O
.	O

During	O
the	O
postoperative	O
phase	O
,	O
the	O
patient	O
recovered	B-Sign_symptom
well	B-Lab_value
from	O
surgery	O
although	O
hospitalization	O
was	O
prolonged	O
by	O
transient	B-Detailed_description
renal	B-Disease_disorder
failure	I-Disease_disorder
and	O
recurring	B-Detailed_description
pleural	B-Disease_disorder
effusions	I-Disease_disorder
.	O

After	O
a	O
month	O
of	O
postoperative	B-Therapeutic_procedure
care	I-Therapeutic_procedure
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	B-Nonbiological_location
to	O
rehabilitation	B-Therapeutic_procedure
in	O
a	O
good	B-Lab_value
condition	B-Diagnostic_procedure
,	O
without	O
signs	B-Sign_symptom
for	I-Sign_symptom
heart	I-Sign_symptom
failure	I-Sign_symptom
.	O

At	O
follow	O
-	O
up	O
three	O
months	O
after	O
surgery	O
,	O
the	O
patient	O
was	O
still	O
in	O
a	O
cardiopulmonary	B-Lab_value
stable	I-Lab_value
condition	B-Diagnostic_procedure
,	O
undergoing	O
additional	O
physiotherapy	B-Therapeutic_procedure
.	O

-DOCSTART- -X- -X- -X- O

A	O
3	B-Age
-	I-Age
month	I-Age
-	I-Age
old	I-Age
infant	O
from	O
the	O
UAE	O
with	O
a	O
genetically	O
-	O
confirmed	O
diagnosis	O
of	O
Jarcho	O
-	O
Levin	O
syndrome	O
and	O
dependent	O
on	O
mechanical	O
ventilation	O
since	O
birth	O
was	O
admitted	O
to	O
our	O
centre	B-Nonbiological_location
for	O
the	O
implantation	B-Therapeutic_procedure
of	I-Therapeutic_procedure
VEPTRs	I-Therapeutic_procedure
.	O

We	O
received	O
an	O
intubated	B-Therapeutic_procedure
patient	O
,	O
mechanically	B-Detailed_description
ventilated	B-Therapeutic_procedure
in	O
a	O
volume	B-Detailed_description
-	I-Detailed_description
controlled	I-Detailed_description
mode	I-Detailed_description
,	O
with	O
a	O
0	B-Lab_value
.	I-Lab_value
30	I-Lab_value
-	I-Lab_value
0	I-Lab_value
.	I-Lab_value
45	I-Lab_value
fraction	I-Lab_value
of	I-Lab_value
inspired	I-Lab_value
oxygen	I-Lab_value
(	O
FiO2	O
)	O
(	O
peak	B-Lab_value
inspiratory	I-Lab_value
pressures	I-Lab_value
(	I-Lab_value
PIP	I-Lab_value
)	I-Lab_value
of	I-Lab_value
23	I-Lab_value
-	I-Lab_value
45	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
,	O
positive	B-Lab_value
end	I-Lab_value
-	I-Lab_value
expiratory	I-Lab_value
pressure	I-Lab_value
(	I-Lab_value
PEEP	I-Lab_value
)	I-Lab_value
of	I-Lab_value
7	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
,	O
backup	B-Lab_value
respiratory	I-Lab_value
rate	I-Lab_value
(	I-Lab_value
RR	I-Lab_value
)	I-Lab_value
of	I-Lab_value
34	I-Lab_value
)	O
.	O

A	O
chest	B-Biological_structure
X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
of	O
the	O
thorax	B-Biological_structure
was	O
performed	O
on	O
admission	O
(	O
figure	O
1A	O
)	O
,	O
and	O
a	O
month	O
after	O
the	O
first	O
surgery	B-Therapeutic_procedure
(	O
figure	O
1B	O
)	O
,	O
showing	O
improvement	O
of	O
the	O
bilateral	B-Detailed_description
posterior	B-Detailed_description
atelectasis	B-Disease_disorder
in	O
the	O
base	B-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
lungs	I-Biological_structure
.	O

Owing	O
to	O
the	O
difficulty	O
of	O
progressing	O
in	O
the	O
weaning	O
process	O
from	O
mechanical	O
ventilation	O
after	O
the	O
VEPTRs	O
were	O
implanted	O
to	O
expand	O
the	O
thorax	O
,	O
a	O
bronchoscopy	B-Therapeutic_procedure
was	O
performed	O
,	O
showing	O
bronchomalacia	B-Disease_disorder
predominantly	O
in	O
both	B-Biological_structure
upper	I-Biological_structure
lobar	I-Biological_structure
bronchi	I-Biological_structure
.	O

As	O
prolonged	B-Detailed_description
mechanical	B-Detailed_description
ventilation	B-Therapeutic_procedure
was	O
expected	O
,	O
a	O
tracheostomy	B-Therapeutic_procedure
was	O
previously	O
performed	O
.	O

After	O
an	O
initial	O
CT	B-Diagnostic_procedure
scan	O
(	O
figure	O
2A	O
)	O
,	O
a	O
follow	O
-	O
up	O
CT	B-Diagnostic_procedure
scan	O
(	O
figure	O
2B	O
)	O
a	O
month	O
after	O
the	O
surgery	O
showed	O
a	O
resolution	O
of	O
the	O
posterior	B-Detailed_description
-	I-Detailed_description
basal	I-Detailed_description
atelectasis	B-Disease_disorder
,	O
coinciding	O
with	O
a	O
decrease	B-Lab_value
of	O
FiO2	B-Diagnostic_procedure
to	O
0	B-Lab_value
.	I-Lab_value
21	I-Lab_value
.	O

Postoperatively	O
,	O
the	O
patient	O
was	O
on	O
the	O
Servo	B-Detailed_description
-	I-Detailed_description
i	I-Detailed_description
ventilator	B-Therapeutic_procedure
in	O
a	O
volume	B-Detailed_description
-	I-Detailed_description
controlled	I-Detailed_description
mode	I-Detailed_description
and	O
needed	O
variable	B-Detailed_description
PIPs	B-Diagnostic_procedure
between	B-Lab_value
25	I-Lab_value
and	I-Lab_value
45	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
and	O
PEEP	B-Diagnostic_procedure
values	O
of	O
7	B-Lab_value
-	I-Lab_value
11	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
.	O

During	O
the	O
attempts	O
to	O
wean	O
the	O
patient	O
off	O
the	O
ventilator	O
in	O
the	O
following	O
months	O
,	O
he	O
was	O
unable	O
to	O
activate	O
the	O
inspiratory	O
flow	O
trigger	O
and	O
required	O
significant	O
sedoanalgesia	B-Medication
to	O
adapt	O
to	O
the	O
ventilator	O
due	O
to	O
repeated	O
episodes	O
of	O
desaturation	B-Sign_symptom
,	O
on	O
some	O
occasions	O
with	O
bradycardia	B-Sign_symptom
,	O
associated	O
to	O
bronchial	B-Disease_disorder
collapse	I-Disease_disorder
.	O

He	O
continued	O
to	O
have	O
asynchrony	B-Sign_symptom
which	O
required	O
boluses	O
of	O
sedation	B-Medication
in	O
addition	O
to	O
existing	O
medications	O
.	O

He	O
initially	O
received	O
fentanyl	B-Medication
and	O
midazolam	B-Medication
through	O
a	O
continuous	O
infusion	O
pump	O
with	O
progressive	B-Dosage
increase	I-Dosage
in	I-Dosage
the	I-Dosage
doses	I-Dosage
as	O
well	O
as	O
continuous	B-Dosage
cisatracurium	B-Medication
as	O
a	O
muscular	B-Medication
relaxant	I-Medication
to	O
adapt	O
to	O
mechanical	O
ventilation	O
(	O
figure	O
3	O
)	O
.	O

As	O
clinical	B-Sign_symptom
stabilisation	I-Sign_symptom
was	O
achieved	O
,	O
the	O
muscular	B-Medication
relaxant	I-Medication
was	O
withdrawn	O
and	O
a	O
progressive	B-Dosage
decrease	I-Dosage
of	O
sedation	B-Medication
was	O
initiated	O
along	O
with	O
a	O
change	O
in	O
the	O
drug	O
regimen	O
.	O

During	O
this	O
period	O
,	O
the	O
patient	O
developed	O
an	O
ocular	B-Sign_symptom
flutter	I-Sign_symptom
which	O
was	O
attributed	O
to	O
a	O
pharmacological	O
cause	O
after	O
neurological	O
alterations	O
were	O
ruled	O
out	O
with	O
normal	B-Lab_value
EEG	B-Diagnostic_procedure
,	O
ophthalmoscopy	B-Diagnostic_procedure
,	O
metabolic	B-Diagnostic_procedure
workup	I-Diagnostic_procedure
and	O
cranial	B-Biological_structure
MRI	B-Diagnostic_procedure
.	O

At	O
5	O
months	O
of	O
age	O
,	O
the	O
NAVA	B-Therapeutic_procedure
mode	I-Therapeutic_procedure
started	O
to	O
improve	B-Lab_value
the	O
patient	O
`	O
s	O
adaptation	B-Diagnostic_procedure
to	I-Diagnostic_procedure
the	I-Diagnostic_procedure
ventilator	I-Diagnostic_procedure
through	O
the	O
use	O
of	O
a	O
neural	B-Therapeutic_procedure
trigger	I-Therapeutic_procedure
.	O

The	O
NAVA	B-Therapeutic_procedure
catheter	I-Therapeutic_procedure
additionally	O
costs	B-Detailed_description
around	I-Detailed_description
$	I-Detailed_description
200	I-Detailed_description
per	I-Detailed_description
catheter	I-Detailed_description
;	O
according	B-Other_entity
to	I-Other_entity
the	I-Other_entity
manufacturer	I-Other_entity
it	I-Other_entity
should	I-Other_entity
be	I-Other_entity
changed	I-Other_entity
every	I-Other_entity
5	I-Other_entity
days	I-Other_entity
.	O

It	O
was	O
required	O
for	B-Duration
7	I-Duration
months	I-Duration
;	O
nevertheless	O
the	O
catheters	B-Therapeutic_procedure
were	I-Therapeutic_procedure
changed	I-Therapeutic_procedure
every	B-Frequency
15	I-Frequency
days	I-Frequency
without	O
observing	O
a	O
deterioration	B-Sign_symptom
of	I-Sign_symptom
the	I-Sign_symptom
Edi	I-Sign_symptom
signal	I-Sign_symptom
.	O

According	B-Other_entity
to	I-Other_entity
the	I-Other_entity
literature	I-Other_entity
,	I-Other_entity
Jarcho	I-Other_entity
-	I-Other_entity
Levin	I-Other_entity
syndrome	I-Other_entity
does	I-Other_entity
not	I-Other_entity
appear	I-Other_entity
with	I-Other_entity
mental	I-Other_entity
retardation	I-Other_entity
and	I-Other_entity
life	I-Other_entity
expectancy	I-Other_entity
is	I-Other_entity
pretty	I-Other_entity
long	I-Other_entity
,	I-Other_entity
so	I-Other_entity
ethically	I-Other_entity
,	I-Other_entity
we	I-Other_entity
considered	I-Other_entity
that	I-Other_entity
this	I-Other_entity
patient	I-Other_entity
should	I-Other_entity
have	I-Other_entity
an	I-Other_entity
opportunity	I-Other_entity
to	I-Other_entity
overcome	I-Other_entity
his	I-Other_entity
thoracic	I-Other_entity
insufficiency	I-Other_entity
if	I-Other_entity
it	I-Other_entity
were	I-Other_entity
technically	I-Other_entity
possible	I-Other_entity
.	O

Tachypnoea	B-Sign_symptom
was	O
initially	O
observed	O
with	O
a	O
RR	B-Diagnostic_procedure
of	O
55	B-Lab_value
without	O
other	O
signs	O
of	O
increase	O
in	O
his	O
work	B-Sign_symptom
of	I-Sign_symptom
breathing	I-Sign_symptom
and	O
his	O
RR	B-Diagnostic_procedure
eventually	O
returned	O
to	O
normal	B-Lab_value
for	O
his	O
age	O
(	O
40	B-Lab_value
)	O
over	O
the	O
next	O
few	O
days	O
.	O

The	O
synchrony	B-Sign_symptom
achieved	O
with	O
the	O
ventilator	B-Therapeutic_procedure
allowed	O
a	O
progressive	O
decrease	O
of	O
the	O
sedoanalgesia	B-Medication
he	O
received	O
until	O
it	O
was	O
completely	O
withdrawn	O
in	O
10	O
days	O
;	O
and	O
the	O
need	O
for	O
extra	O
boluses	O
of	O
sedation	B-Medication
was	O
reduced	O
to	O
zero	O
.	O

Concurrently	O
to	O
the	O
reduction	O
of	O
sedation	O
,	O
his	O
ocular	B-Sign_symptom
flutter	I-Sign_symptom
disappeared	O
and	O
he	O
showed	O
significant	O
progress	B-Lab_value
in	O
his	O
psychomotor	B-Diagnostic_procedure
development	I-Diagnostic_procedure
.	O

The	O
settings	O
used	O
were	O
:	O
NAVA	B-Lab_value
level	I-Lab_value
of	I-Lab_value
1	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
/	I-Lab_value
µV	I-Lab_value
,	O
PEEP	B-Lab_value
11	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
,	O
Edi	B-Lab_value
trigger	I-Lab_value
0	I-Lab_value
.	I-Lab_value
5	I-Lab_value
µV	I-Lab_value
.	O

The	O
patient	O
had	O
tidal	B-Diagnostic_procedure
volumes	I-Diagnostic_procedure
(	O
Vt	B-Diagnostic_procedure
)	O
of	O
6	B-Lab_value
-	I-Lab_value
7	I-Lab_value
mL	I-Lab_value
/	I-Lab_value
kg	I-Lab_value
(	O
figure	O
3	O
)	O
.	O

After	O
10	O
days	O
on	O
the	O
NAVA	B-Therapeutic_procedure
mode	I-Therapeutic_procedure
,	O
he	O
did	O
not	O
require	O
any	O
type	O
of	O
sedation	B-Medication
and	O
the	O
sporadic	O
episodes	O
of	O
bronchial	B-Disease_disorder
collapse	I-Disease_disorder
were	O
resolved	O
with	O
a	O
quick	O
increase	O
of	O
PEEP	B-Diagnostic_procedure
to	O
20	B-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
or	O
manual	B-Detailed_description
ventilation	B-Therapeutic_procedure
with	O
the	O
self	B-Detailed_description
-	I-Detailed_description
inflating	I-Detailed_description
bag	I-Detailed_description
.	O

Once	O
he	O
was	O
stabilised	O
on	O
the	O
NAVA	B-Therapeutic_procedure
mode	I-Therapeutic_procedure
,	O
his	O
PIPs	B-Diagnostic_procedure
oscillated	O
between	B-Lab_value
15	I-Lab_value
and	I-Lab_value
45	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
with	O
a	O
NAVA	B-Lab_value
level	I-Lab_value
of	I-Lab_value
0	I-Lab_value
.	I-Lab_value
4	I-Lab_value
and	O
Edi	B-Diagnostic_procedure
peaks	I-Diagnostic_procedure
between	B-Lab_value
15	I-Lab_value
and	I-Lab_value
100	I-Lab_value
µV	I-Lab_value
.	O

A	O
posterior	B-Detailed_description
pulmonary	B-Biological_structure
CT	B-Diagnostic_procedure
scan	O
performed	O
2	O
months	O
after	O
the	O
first	O
surgery	O
,	O
1	O
month	O
after	O
starting	O
NAVA	O
and	O
prior	O
to	O
the	O
first	O
thoracic	O
expansion	O
,	O
showed	O
a	O
significant	O
reduction	O
in	O
the	O
posterobasal	B-Detailed_description
atelectases	B-Disease_disorder
previously	O
observed	O
(	O
figure	O
2B	O
)	O
.	O

When	O
he	O
turned	O
1	O
year	O
old	O
,	O
after	O
several	O
attempts	O
with	O
different	B-Therapeutic_procedure
devices	I-Therapeutic_procedure
Trilogy	B-Detailed_description
100	I-Detailed_description
(	I-Detailed_description
Philips	I-Detailed_description
)	I-Detailed_description
,	O
Astral	B-Detailed_description
150	I-Detailed_description
(	I-Detailed_description
ResMed	I-Detailed_description
)	I-Detailed_description
,	O
the	O
patient	O
finally	O
tolerated	O
mechanical	B-Detailed_description
ventilation	B-Therapeutic_procedure
with	O
a	O
home	B-Detailed_description
ventilator	I-Detailed_description
(	O
Monnal	B-Detailed_description
T	I-Detailed_description
-	I-Detailed_description
50	I-Detailed_description
,	I-Detailed_description
Air	I-Detailed_description
Liquide	I-Detailed_description
)	O
in	O
a	O
volume	B-Detailed_description
assisted	I-Detailed_description
/	I-Detailed_description
controlled	I-Detailed_description
mode	I-Detailed_description
with	I-Detailed_description
the	I-Detailed_description
following	I-Detailed_description
settings	I-Detailed_description
:	O
Vt	B-Lab_value
80	I-Lab_value
mL	I-Lab_value
(	I-Lab_value
9	I-Lab_value
mL	I-Lab_value
/	I-Lab_value
kg	I-Lab_value
)	I-Lab_value
,	O
PEEP	B-Lab_value
10	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
,	O
flow	B-Lab_value
trigger	I-Lab_value
0	I-Lab_value
.	I-Lab_value
5	I-Lab_value
L	I-Lab_value
/	I-Lab_value
min	I-Lab_value
.	O

His	O
PIPs	B-Diagnostic_procedure
were	O
around	B-Lab_value
30	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
.	O

He	O
did	O
not	O
tolerate	B-Sign_symptom
a	O
decrease	B-Lab_value
of	O
PEEP	B-Diagnostic_procedure
below	B-Lab_value
9	I-Lab_value
cm	I-Lab_value
H2O	I-Lab_value
or	O
short	B-Detailed_description
disconnections	I-Detailed_description
from	O
the	O
ventilator	B-Therapeutic_procedure
.	O

Currently	O
,	O
the	O
patient	O
is	O
19	O
months	O
old	O
,	O
is	O
able	B-Sign_symptom
to	I-Sign_symptom
walk	I-Sign_symptom
and	O
his	O
neurodevelopment	B-Diagnostic_procedure
seems	O
to	O
be	O
normal	B-Lab_value
.	O

-DOCSTART- -X- -X- -X- O

A	O
female	O
outpatient	O
in	O
her	O
50s	O
had	O
routinely	O
visited	O
our	O
hospital	B-Nonbiological_location
because	O
of	O
liver	O
cirrhosis	O
resulting	O
from	O
hepatitis	O
B	O
virus	O
and	O
biliary	O
duct	O
stones	O
.	O

At	O
65	B-Age
years	I-Age
of	I-Age
age	I-Age
,	O
she	O
suffered	O
from	O
HCC	B-Disease_disorder
with	O
BCLC	B-Lab_value
early	I-Lab_value
stage	I-Lab_value
A	I-Lab_value
.	O

Her	O
liver	B-Diagnostic_procedure
function	I-Diagnostic_procedure
was	O
well	B-Lab_value
preserved	I-Lab_value
,	O
and	O
Child	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Pugh	I-Diagnostic_procedure
score	I-Diagnostic_procedure
was	O
A	B-Lab_value
.	O

She	O
underwent	O
left	B-Detailed_description
lateral	I-Detailed_description
segmentectomy	B-Therapeutic_procedure
for	O
HCC	B-Disease_disorder
,	O
without	O
other	B-Therapeutic_procedure
preoperative	I-Therapeutic_procedure
treatments	I-Therapeutic_procedure
.	O

Histopathological	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
revealed	O
bridging	B-Detailed_description
fibrosis	B-Disease_disorder
and	O
pseudolobule	B-Disease_disorder
formation	I-Disease_disorder
.	O

Serum	B-Biological_structure
levels	O
of	O
alpha	B-Diagnostic_procedure
-	I-Diagnostic_procedure
fetoprotein	I-Diagnostic_procedure
(	O
AFP	B-Diagnostic_procedure
)	O
and	O
protein	B-Diagnostic_procedure
induced	I-Diagnostic_procedure
by	I-Diagnostic_procedure
vitamin	I-Diagnostic_procedure
K	I-Diagnostic_procedure
absence	I-Diagnostic_procedure
-	I-Diagnostic_procedure
II	I-Diagnostic_procedure
normalized	B-Lab_value
after	O
primary	O
resection	O
(	O
Figure	O
1	O
)	O
.	O

In	O
imaging	B-Diagnostic_procedure
studies	I-Diagnostic_procedure
,	O
no	O
LN	B-Biological_structure
metastasis	B-Sign_symptom
was	O
detected	O
at	O
the	O
time	O
of	O
primary	O
resection	O
of	O
HCC	O
.	O

Two	O
and	O
a	O
half	O
years	O
postoperatively	O
,	O
the	O
patient	O
`	O
s	O
AFP	B-Diagnostic_procedure
level	I-Diagnostic_procedure
increased	B-Lab_value
dramatically	I-Lab_value
to	O
780	B-Lab_value
.	I-Lab_value
2	I-Lab_value
ng	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
.	O

A	O
lobular	B-Shape
lesion	B-Sign_symptom
with	O
fine	B-Detailed_description
enhancement	I-Detailed_description
was	O
detected	O
by	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
.	O

The	O
tumor	O
measured	O
27	B-Distance
mm	I-Distance
in	I-Distance
diameter	I-Distance
and	O
was	O
located	O
caudally	B-Biological_structure
on	I-Biological_structure
the	I-Biological_structure
left	I-Biological_structure
kidney	I-Biological_structure
.	O

In	O
contrast	B-Detailed_description
-	I-Detailed_description
enhanced	I-Detailed_description
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
,	O
the	O
tumor	O
showed	O
strong	B-Detailed_description
enhancement	B-Sign_symptom
in	O
the	O
arterial	B-Biological_structure
phase	I-Biological_structure
(	O
Figure	O
2A	O
,	O
2B	O
)	O
and	O
a	O
relatively	B-Detailed_description
low	I-Detailed_description
density	B-Sign_symptom
in	O
the	O
portal	B-Biological_structure
phase	I-Biological_structure
(	O
Figure	O
2C	O
,	O
2D	O
)	O
.	O

These	O
enhancement	O
findings	O
appeared	O
consistent	O
with	O
a	O
typical	B-Detailed_description
HCC	B-Disease_disorder
pattern	O
.	O

Detailed	O
imaging	O
studies	O
of	O
both	O
magnetic	O
resonance	O
imaging	O
and	O
computed	O
tomography	O
were	O
performed	O
in	O
this	O
case	O
because	O
a	O
very	O
rare	O
metastatic	O
LN	O
initially	O
seemed	O
to	O
be	O
debatable	O
and	O
we	O
needed	O
to	O
rule	O
out	O
exclusion	O
diagnoses	O
.	O

Three	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
proved	O
that	O
the	O
tumor	O
was	O
fed	B-Biological_structure
by	I-Biological_structure
a	I-Biological_structure
main	I-Biological_structure
vessel	I-Biological_structure
from	I-Biological_structure
the	I-Biological_structure
inferior	I-Biological_structure
mesenteric	I-Biological_structure
artery	I-Biological_structure
(	O
red	O
arrow	O
)	O
and	O
by	O
an	O
accessory	B-Biological_structure
feeder	I-Biological_structure
from	I-Biological_structure
the	I-Biological_structure
superior	I-Biological_structure
mesenteric	I-Biological_structure
artery	I-Biological_structure
(	O
Figure	O
3	O
)	O
.	O

Fluorine	B-Diagnostic_procedure
-	I-Diagnostic_procedure
18	I-Diagnostic_procedure
-	I-Diagnostic_procedure
fluorodeoxyglucose	I-Diagnostic_procedure
positron	I-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
FDG	B-Diagnostic_procedure
-	I-Diagnostic_procedure
PET	I-Diagnostic_procedure
)	O
and	O
positron	B-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
-	I-Diagnostic_procedure
computed	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
did	O
not	O
detect	O
the	O
tumor	O
(	O
Figure	O
4	O
)	O
,	O
although	O
we	O
thought	O
positron	O
emission	O
tomography	O
-	O
computed	O
tomography	O
was	O
helpful	O
to	O
identify	O
other	O
metastatic	O
tumors	O
.	O

Further	O
imaging	O
findings	O
revealed	O
no	O
other	O
intrahepatic	B-Biological_structure
or	O
extrahepatic	B-Biological_structure
metastasis	B-Sign_symptom
.	O

Based	O
on	O
the	O
tumor	O
location	O
,	O
the	O
clinical	O
diagnosis	O
was	O
solitary	B-Detailed_description
metastasis	B-Sign_symptom
to	O
a	O
mesocolic	B-Biological_structure
LN	I-Biological_structure
or	O
HCC	B-Disease_disorder
dissemination	B-Detailed_description
.	O

Determining	O
the	O
ideal	O
therapeutic	O
strategy	O
for	O
solitary	O
but	O
extrahepatic	O
rare	O
metastasis	O
was	O
difficult	O
.	O

Although	O
rapid	O
growth	O
was	O
a	O
critical	O
concern	O
in	O
this	O
case	O
,	O
the	O
tumor	B-Sign_symptom
was	O
solitary	B-Detailed_description
and	O
not	O
accompanied	O
by	O
other	B-Detailed_description
metastases	B-Sign_symptom
.	O

Considering	O
both	O
diagnostic	O
and	O
therapeutic	O
viewpoints	O
,	O
we	O
finally	O
chose	O
surgical	B-Therapeutic_procedure
resection	I-Therapeutic_procedure
in	O
this	O
case	O
.	O

No	O
disseminative	B-Sign_symptom
nodules	I-Sign_symptom
,	O
lymphadenopathy	B-Disease_disorder
,	O
or	O
ascites	B-Sign_symptom
was	O
observed	O
during	O
surgery	O
.	O

The	O
tumor	O
was	O
located	O
in	O
the	O
mesocolon	B-Biological_structure
nearly	O
at	B-Biological_structure
the	I-Biological_structure
wall	I-Biological_structure
of	I-Biological_structure
the	I-Biological_structure
descending	I-Biological_structure
colon	I-Biological_structure
,	O
and	O
partial	O
resection	O
of	O
the	O
descending	B-Biological_structure
colon	I-Biological_structure
with	O
regional	B-Biological_structure
mesocolon	I-Biological_structure
was	O
performed	O
.	O

The	O
patient	O
`	O
s	O
postoperative	B-Therapeutic_procedure
course	I-Therapeutic_procedure
was	O
uneventful	B-Lab_value
,	O
and	O
she	O
was	O
discharged	O
on	O
postoperative	O
day	O
8	O
.	O

Serum	B-Biological_structure
levels	O
of	O
tumor	B-Diagnostic_procedure
marker	I-Diagnostic_procedure
decreased	B-Lab_value
immediately	I-Lab_value
after	O
surgery	O
(	O
Figure	O
1	O
)	O
.	O

Macroscopically	B-Diagnostic_procedure
,	O
the	O
mesocolic	O
tumor	O
was	O
a	O
solid	B-Lab_value
and	O
elastic	B-Lab_value
mass	O
with	O
a	O
smooth	B-Texture
surface	I-Texture
(	O
Figure	O
5A	O
)	O
.	O

A	O
yellowish	B-Color
nodule	B-Sign_symptom
was	O
encapsulated	B-Detailed_description
in	I-Detailed_description
the	I-Detailed_description
cut	I-Detailed_description
surface	I-Detailed_description
(	O
Figure	O
5B	O
)	O
.	O

The	O
enlarged	B-Detailed_description
LN	I-Detailed_description
contained	O
metastatic	B-Detailed_description
HCC	B-Disease_disorder
with	O
a	O
ductal	B-Detailed_description
structure	I-Detailed_description
(	O
Figure	O
6A	O
)	O
,	O
and	O
immunohistochemically	B-Diagnostic_procedure
,	O
the	O
tumor	O
was	O
positive	B-Lab_value
for	O
AFP	B-Diagnostic_procedure
and	O
negative	B-Lab_value
for	O
CK	B-Diagnostic_procedure
-	I-Diagnostic_procedure
20	I-Diagnostic_procedure
,	O
which	O
was	O
consistent	O
with	O
the	O
pattern	O
of	O
primary	B-Detailed_description
HCC	B-Disease_disorder
(	O
Figure	O
6B	O
)	O
.	O

The	O
histopathological	O
diagnosis	O
was	O
metastatic	B-Detailed_description
HCC	B-Disease_disorder
to	O
a	O
mesocolic	B-Biological_structure
LN	I-Biological_structure
.	O

As	O
of	O
the	O
writing	O
of	O
this	O
report	O
,	O
the	O
patient	O
has	O
remained	O
free	O
of	O
recurrence	B-Sign_symptom
for	O
13	O
months	O
after	O
the	O
second	O
surgery	O
,	O
and	O
has	O
also	O
been	O
carefully	O
followed	O
up	O
.	O

No	O
adjuvant	B-Medication
therapies	I-Medication
have	O
been	O
performed	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
5	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Caucasian	O
male	B-Age
presented	O
to	O
the	O
Children	B-Nonbiological_location
`	I-Nonbiological_location
s	I-Nonbiological_location
Emergency	I-Nonbiological_location
Department	I-Nonbiological_location
with	O
epistaxis	B-Sign_symptom
,	O
bleeding	B-Sign_symptom
from	O
the	O
dental	B-Therapeutic_procedure
extraction	I-Therapeutic_procedure
site	B-Biological_structure
and	O
a	O
widespread	B-Detailed_description
purpuric	B-Detailed_description
rash	B-Sign_symptom
,	O
secondary	O
to	O
acute	B-Detailed_description
idiopathic	B-Detailed_description
thrombocytopenia	B-Sign_symptom
.	O

Two	O
days	O
prior	O
to	O
this	O
,	O
he	O
developed	O
a	O
generalised	B-Detailed_description
chickenpox	B-Sign_symptom
rash	I-Sign_symptom
.	O

While	O
in	O
the	O
department	O
it	O
was	O
noted	O
that	O
his	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
ranged	O
between	B-Lab_value
50	I-Lab_value
and	I-Lab_value
60	I-Lab_value
beats	I-Lab_value
per	I-Lab_value
min	I-Lab_value
,	O
he	O
was	O
otherwise	O
haemo	B-Sign_symptom
-	I-Sign_symptom
dynamically	I-Sign_symptom
stable	I-Sign_symptom
with	O
a	O
normal	B-Lab_value
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
and	O
oxygen	B-Diagnostic_procedure
saturations	I-Diagnostic_procedure
in	O
air	B-Detailed_description
.	O

He	O
had	O
a	O
short	B-Detailed_description
systolic	B-Detailed_description
murmur	B-Sign_symptom
grade	B-Lab_value
2	I-Lab_value
/	I-Lab_value
6	I-Lab_value
at	O
the	O
left	B-Biological_structure
sternal	I-Biological_structure
border	I-Biological_structure
.	O

He	O
had	O
no	O
clinical	O
evidence	O
of	O
myocarditis	B-Disease_disorder
or	O
heart	B-Disease_disorder
failure	I-Disease_disorder
.	O

He	O
had	O
extensive	B-Severity
generalised	B-Detailed_description
petechiae	B-Sign_symptom
and	O
purpuric	B-Detailed_description
rash	B-Sign_symptom
(	O
figure	O
1	O
)	O
secondary	O
to	O
acute	B-Detailed_description
thrombocytopenia	B-Sign_symptom
presumed	O
to	O
be	O
due	O
to	O
varicella	B-Disease_disorder
infection	I-Disease_disorder
.	O

Apparently	O
he	O
was	O
healthy	B-Sign_symptom
prior	O
to	O
this	O
admission	O
.	O

There	O
was	O
no	O
history	O
of	O
maternal	O
lupus	O
.	O

An	O
ECG	B-Diagnostic_procedure
was	O
performed	O
which	O
showed	O
complete	B-Severity
heart	B-Disease_disorder
block	I-Disease_disorder
(	O
figure	O
2	O
)	O
.	O

He	O
was	O
admitted	O
to	O
the	O
high	B-Nonbiological_location
dependency	I-Nonbiological_location
unit	I-Nonbiological_location
for	O
close	B-Detailed_description
overnight	B-Duration
monitoring	B-Therapeutic_procedure
.	O

The	O
presumed	O
diagnosis	O
was	O
complete	O
heart	B-Disease_disorder
block	I-Disease_disorder
secondary	O
to	O
varicella	B-Disease_disorder
infection	I-Disease_disorder
.	O
1	O
2	O
The	O
initial	O
investigation	O
showed	O
normal	B-Lab_value
electrolytes	B-Diagnostic_procedure
,	O
calcium	B-Diagnostic_procedure
,	O
phosphate	B-Diagnostic_procedure
,	O
glucose	B-Diagnostic_procedure
and	O
magnesium	B-Diagnostic_procedure
levels	O
.	O

The	O
full	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
showed	O
a	O
normal	B-Lab_value
haemoglobin	B-Diagnostic_procedure
and	O
white	B-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
.	O

But	O
the	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
low	B-Lab_value
that	O
is	O
,	O
13	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
l	I-Lab_value
.	O

The	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
normalised	B-Lab_value
within	O
10	O
days	O
without	O
any	O
intervention	B-Therapeutic_procedure
.	O

The	O
antinuclear	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
titres	O
and	O
the	O
autoimmune	B-Diagnostic_procedure
screen	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Maternal	O
autoimmune	B-Detailed_description
screen	I-Detailed_description
was	I-Detailed_description
negative	I-Detailed_description
.	O

The	O
echocardiogram	B-Diagnostic_procedure
showed	O
a	O
structurally	B-Sign_symptom
normal	I-Sign_symptom
heart	B-Biological_structure
and	O
follow	O
-	O
up	O
24	O
h	O
tape	O
showed	O
persistence	O
of	O
complete	B-Severity
heart	B-Disease_disorder
block	I-Disease_disorder
.	O

Following	O
these	O
investigations	O
a	O
diagnosis	O
of	O
congenital	B-Detailed_description
complete	B-Severity
heart	B-Disease_disorder
block	I-Disease_disorder
was	O
made	O
.	O

On	O
follow	O
-	O
up	O
after	O
6	O
months	O
his	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
remains	O
between	B-Lab_value
50	I-Lab_value
and	I-Lab_value
60	I-Lab_value
beats	I-Lab_value
per	I-Lab_value
min	I-Lab_value
,	O
but	O
he	O
remains	O
asymptomatic	B-Sign_symptom
without	O
any	O
intervention	B-Therapeutic_procedure
.	O

The	O
need	O
for	O
a	O
pacemaker	B-Therapeutic_procedure
is	O
being	O
considered	O
on	O
follow	O
-	O
up	O
.	O

The	O
incidental	O
finding	O
of	O
complete	O
heart	O
block	O
was	O
congenital	O
in	O
aetiology	O
with	O
no	O
association	O
with	O
varicella	O
infection	O
or	O
acute	O
thrombocytopenia	O
.	O

This	O
case	O
highlights	O
that	O
asymptomatic	O
late	O
-	O
presenting	O
congenital	O
complete	O
heart	O
block	O
must	O
be	O
considered	O
as	O
a	O
differential	O
diagnosis	O
in	O
children	O
presenting	O
with	O
asymptomatic	O
bradycardia	O
to	O
the	O
emergency	O
department	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
44	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Chinese	O
man	O
with	O
a	O
7	O
pack	O
-	O
year	O
smoking	B-Activity
history	O
was	O
referred	O
to	O
Shanghai	B-Nonbiological_location
Pulmonary	I-Nonbiological_location
Hospital	I-Nonbiological_location
in	O
February	O
2013	O
for	O
a	O
left	B-Biological_structure
upper	I-Biological_structure
lobe	I-Biological_structure
lung	B-Biological_structure
mass	B-Sign_symptom
with	O
multiple	B-Detailed_description
bilateral	B-Detailed_description
intrapulmonary	B-Biological_structure
metastases	B-Sign_symptom
,	O
left	B-Detailed_description
pleural	B-Disease_disorder
effusion	I-Disease_disorder
,	O
and	O
2R	B-Lab_value
/	I-Lab_value
4R	I-Lab_value
/	I-Lab_value
10L	I-Lab_value
/	I-Lab_value
11L	I-Lab_value
lymphadenopathy	B-Disease_disorder
.	O

Pleural	B-Biological_structure
fluid	I-Biological_structure
cytology	B-Diagnostic_procedure
revealed	O
adenocarcinoma	B-Disease_disorder
and	O
Scorpion	B-Diagnostic_procedure
Amplification	I-Diagnostic_procedure
Refractory	I-Diagnostic_procedure
Mutation	I-Diagnostic_procedure
system	I-Diagnostic_procedure
(	O
AmoyDx	B-Detailed_description
Co	I-Detailed_description
.	I-Detailed_description
,	I-Detailed_description
Xiamen	I-Detailed_description
,	I-Detailed_description
China	I-Detailed_description
)	O
.	O

showed	O
no	O
detectable	O
epidermal	B-Sign_symptom
growth	I-Sign_symptom
factor	I-Sign_symptom
receptor	I-Sign_symptom
mutation	I-Sign_symptom
.	O

He	O
commenced	O
chemotherapy	B-Medication
with	O
gemcitabine	B-Medication
and	O
cisplatin	B-Medication
.	O

However	O
,	O
after	O
a	O
single	O
cycle	O
,	O
his	O
symptoms	B-Sign_symptom
worsened	O
and	O
imaging	O
confirmed	O
progressive	B-Detailed_description
disease	B-Disease_disorder
.	O

A	O
second	O
opinion	O
was	O
requested	O
from	O
the	O
University	B-Nonbiological_location
of	I-Nonbiological_location
Colorado	I-Nonbiological_location
and	O
a	O
computed	B-Detailed_description
tomography	I-Detailed_description
-	I-Detailed_description
guided	I-Detailed_description
biopsy	B-Diagnostic_procedure
of	O
the	O
left	B-Biological_structure
upper	I-Biological_structure
lobe	I-Biological_structure
lesion	B-Sign_symptom
was	O
performed	O
to	O
permit	O
additional	O
molecular	O
testing	O
.	O

In	O
the	O
interim	O
,	O
the	O
patient	O
commenced	O
pemetrexed	B-Medication
and	O
nedaplatin	B-Medication
.	O

Unfortunately	O
,	O
after	O
two	O
cycles	O
his	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
worsened	O
,	O
with	O
evidence	O
of	O
further	B-Sign_symptom
progression	I-Sign_symptom
on	O
his	O
scans	B-Diagnostic_procedure
(	O
Fig	O
.	O
1A	O
)	O
.	O

Molecular	O
testing	O
on	O
his	O
repeat	O
biopsy	B-Diagnostic_procedure
specimen	O
revealed	O
no	O
mutations	B-Sign_symptom
by	O
SNaPshot	B-Detailed_description
multiplex	I-Detailed_description
PCR	B-Diagnostic_procedure
testing	I-Diagnostic_procedure
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
)	O
.	O

However	O
,	O
although	O
technically	O
negative	O
,	O
the	O
ALK	B-Detailed_description
break	I-Detailed_description
-	I-Detailed_description
apart	I-Detailed_description
FISH	B-Diagnostic_procedure
test	I-Diagnostic_procedure
showed	O
an	O
atypical	B-Lab_value
negative	I-Lab_value
pattern	I-Lab_value
.	O

Specifically	O
,	O
68	B-Lab_value
%	I-Lab_value
of	I-Lab_value
cells	I-Lab_value
demonstrated	I-Lab_value
single	I-Lab_value
copies	I-Lab_value
of	I-Lab_value
the	I-Lab_value
5	I-Lab_value
′	I-Lab_value
ALK	I-Lab_value
signal	I-Lab_value
and	O
numerous	B-Lab_value
cells	I-Lab_value
with	I-Lab_value
doublets	I-Lab_value
of	I-Lab_value
the	I-Lab_value
5	I-Lab_value
′	I-Lab_value
ALK	I-Lab_value
signal	I-Lab_value
combined	I-Lab_value
with	I-Lab_value
one	I-Lab_value
3	I-Lab_value
′	I-Lab_value
ALK	I-Lab_value
signal	I-Lab_value
(	O
Fig	O
.	O
2A	O
)	O
.	O

Subsequently	O
,	O
confirmatory	O
diagnostic	B-Diagnostic_procedure
assays	I-Diagnostic_procedure
demonstrated	O
ALK	B-Lab_value
protein	I-Lab_value
expression	I-Lab_value
by	O
IHC	B-Diagnostic_procedure
using	O
the	O
D5F3	B-Detailed_description
antibody	I-Detailed_description
(	O
Cell	B-Detailed_description
Signaling	I-Detailed_description
Technology	I-Detailed_description
Inc	I-Detailed_description
.	I-Detailed_description
,	I-Detailed_description
Danvers	I-Detailed_description
,	I-Detailed_description
MA	I-Detailed_description
;	O
H	O
score	O
=	O
150	O
;	O
Fig	O
.	O
2B	O
)	O
and	O
the	O
presence	B-Lab_value
of	I-Lab_value
an	I-Lab_value
echinoderm	I-Lab_value
microtubule	I-Lab_value
-	I-Lab_value
associated	I-Lab_value
protein	I-Lab_value
-	I-Lab_value
like	I-Lab_value
4	I-Lab_value
(	I-Lab_value
EML4	I-Lab_value
)	I-Lab_value
-	I-Lab_value
ALK	I-Lab_value
transcript	I-Lab_value
(	O
E13	O
;	O
A20	O
)	O
by	O
RT	B-Diagnostic_procedure
-	I-Diagnostic_procedure
PCR	I-Diagnostic_procedure
(	O
Fig	O
.	O
2C	O
)	O
.	O

The	O
patient	O
then	O
received	O
crizotinib	B-Medication
(	O
250	B-Dosage
mg	I-Dosage
twice	I-Dosage
daily	I-Dosage
)	O
as	O
third	O
-	O
line	O
therapy	O
in	O
May	O
2013	O
with	O
an	O
impressive	O
symptomatic	B-Sign_symptom
improvement	I-Sign_symptom
and	O
CT	O
response	O
after	O
1	O
month	O
of	O
therapy	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

He	O
remains	O
on	O
treatment	O
with	O
crizotinib	B-Medication
with	O
no	O
evidence	O
of	O
progression	B-Sign_symptom
as	O
of	O
September	O
2013	O
.	O

-DOCSTART- -X- -X- -X- O

In	O
2013	O
,	O
a	O
50	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
patient	O
visited	O
hospital	B-Nonbiological_location
complaining	O
of	O
local	B-Detailed_description
bone	B-Biological_structure
pain	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
leg	I-Biological_structure
.	O

On	O
August	O
14	O
,	O
2013	O
,	O
the	O
patient	O
underwent	O
a	O
left	B-Biological_structure
distal	I-Biological_structure
femoral	I-Biological_structure
tumor	B-Sign_symptom
en	B-Detailed_description
bloc	I-Detailed_description
resection	B-Therapeutic_procedure
and	O
reconstruction	B-Therapeutic_procedure
with	O
a	O
modular	B-Detailed_description
femoral	I-Detailed_description
prosthetic	I-Detailed_description
system	I-Detailed_description
.	O

Pathology	B-Diagnostic_procedure
diagnosis	I-Diagnostic_procedure
confirmed	O
osteoblastic	B-Detailed_description
osteosarcoma	B-Disease_disorder
(	O
Fig	O
.	O
2	O
)	O
.	O

One	B-Dosage
cycle	I-Dosage
of	O
neoadjuvant	B-Detailed_description
chemotherapy	B-Medication
and	O
4	B-Dosage
cycles	I-Dosage
of	O
adjuvant	B-Detailed_description
chemotherapy	B-Medication
with	O
MAP	B-Medication
regimen	I-Medication
(	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
methotrexate	B-Medication
,	O
cisplatin	B-Medication
,	O
and	O
doxorubicin	B-Medication
)	O
were	O
administered	O
.	O

In	O
January	O
2015	O
,	O
a	O
mass	B-Sign_symptom
was	O
found	O
on	O
the	O
left	B-Biological_structure
upper	I-Biological_structure
crus	I-Biological_structure
area	I-Biological_structure
.	O

Tumor	O
recurrence	B-Sign_symptom
was	O
confirmed	O
by	O
biopsy	B-Diagnostic_procedure
on	O
January	O
23	O
,	O
2015	O
.	O

However	O
,	O
only	O
an	O
upper	B-Biological_structure
femur	I-Biological_structure
amputation	B-Therapeutic_procedure
was	O
carried	O
out	O
,	O
as	O
the	O
patient	O
refused	O
hip	B-Biological_structure
joint	B-Therapeutic_procedure
replacement	I-Therapeutic_procedure
.	O

After	O
wound	B-Therapeutic_procedure
healing	I-Therapeutic_procedure
,	O
the	O
patient	O
went	O
back	O
to	O
his	O
normal	O
life	O
in	O
the	O
help	O
of	O
artificial	B-Therapeutic_procedure
limb	I-Therapeutic_procedure
,	O
but	O
refused	O
to	O
receive	O
further	O
chemotherapy	B-Medication
due	O
to	O
concerns	O
regarding	O
the	O
chemotherapy	O
toxicities	O
such	O
as	O
nausea	O
,	O
vomiting	O
,	O
leucopenia	O
,	O
deadlimb	O
,	O
and	O
headache	O
.	O

About	O
half	O
a	O
year	O
after	O
the	O
amputation	O
,	O
the	O
patient	O
got	O
occasional	B-Detailed_description
cough	B-Sign_symptom
and	O
chest	B-Biological_structure
tightness	B-Sign_symptom
.	O

Then	O
a	O
thin	B-Detailed_description
chest	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
was	O
performed	O
on	O
July	O
15	O
,	O
2015	O
.	O

The	O
CT	O
results	O
revealed	O
multiple	B-Detailed_description
pulmonary	B-Biological_structure
nodules	B-Sign_symptom
(	O
Table	O
1	O
)	O
,	O
considering	O
the	O
possibility	O
of	O
metastases	B-Sign_symptom
.	O

The	O
patient	O
still	O
rejected	O
further	O
chemotherapy	B-Medication
.	O

Immunophenotype	B-Diagnostic_procedure
was	O
suggestive	O
of	O
CD31	B-Detailed_description
+	I-Detailed_description
and	O
CD34	B-Detailed_description
+	I-Detailed_description
tumor	B-Sign_symptom
cells	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Furthermore	O
,	O
most	O
cells	O
showed	O
strong	B-Lab_value
positive	I-Lab_value
staining	B-Diagnostic_procedure
for	I-Diagnostic_procedure
VEGFR	I-Diagnostic_procedure
-	I-Diagnostic_procedure
2	I-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

Apatinib	B-Medication
was	O
administered	O
at	O
a	O
dose	O
of	O
500	B-Dosage
mg	I-Dosage
daily	I-Dosage
.	O

Half	O
a	O
month	O
later	O
,	O
the	O
symptoms	B-Sign_symptom
disappeared	O
,	O
but	O
a	O
progressive	B-Detailed_description
wound	B-Sign_symptom
necrosis	I-Sign_symptom
appeared	O
.	O

A	O
debridement	B-Therapeutic_procedure
surgery	I-Therapeutic_procedure
was	O
finally	O
conducted	O
and	O
an	O
enlarged	B-Sign_symptom
lymph	B-Biological_structure
node	I-Biological_structure
near	B-Biological_structure
iliac	I-Biological_structure
vessels	I-Biological_structure
was	O
resected	B-Therapeutic_procedure
on	O
February	O
24	O
,	O
2016	O
(	O
Fig	O
.	O
(	O
Fig	O
.	O
4	O
)	O
.	O
4	O
)	O
.	O

The	O
result	O
of	O
pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
an	O
inflammatory	B-Detailed_description
hyperplasia	B-Sign_symptom
lymph	B-Biological_structure
node	I-Biological_structure
.	O

Apatinib	B-Medication
administration	O
was	O
stopped	O
during	O
the	O
3	B-Duration
weeks	I-Duration
of	O
wound	B-Therapeutic_procedure
healing	I-Therapeutic_procedure
period	O
.	O

The	O
thin	B-Detailed_description
chest	B-Biological_structure
CT	B-Diagnostic_procedure
was	O
performed	O
7	O
and	O
11	O
months	O
following	O
apatinib	O
administration	O
.	O

At	O
the	O
7	O
-	O
month	O
follow	O
-	O
up	O
time	O
point	O
,	O
2	B-Lab_value
out	I-Lab_value
of	I-Lab_value
5	I-Lab_value
measurable	I-Lab_value
and	O
9	B-Lab_value
out	I-Lab_value
of	I-Lab_value
17	I-Lab_value
non	I-Lab_value
-	I-Lab_value
measurable	I-Lab_value
lesions	B-Sign_symptom
disappeared	O
,	O
but	O
1	B-Lab_value
new	I-Lab_value
measurable	I-Lab_value
nodule	B-Sign_symptom
and	O
6	B-Lab_value
new	I-Lab_value
non	I-Lab_value
-	I-Lab_value
measurable	I-Lab_value
lesions	B-Sign_symptom
were	O
observed	O
(	O
Table	O
1	O
,	O
Fig	O
.	O
5	O
)	O
,	O
which	O
considered	O
PD	B-Lab_value
according	O
to	O
the	O
Response	B-Diagnostic_procedure
Evaluation	I-Diagnostic_procedure
Criteria	I-Diagnostic_procedure
in	I-Diagnostic_procedure
Solid	I-Diagnostic_procedure
Tumors	I-Diagnostic_procedure
(	O
RECIST	B-Diagnostic_procedure
)	O
1	B-Detailed_description
.	I-Detailed_description
1	I-Detailed_description
standard	O
.	O

However	O
,	O
at	O
the	O
11	O
-	O
month	O
follow	O
-	O
up	O
time	O
point	O
,	O
a	O
total	O
of	O
9	B-Lab_value
lesions	B-Sign_symptom
disappeared	O
,	O
including	O
1	B-Lab_value
measurable	I-Lab_value
nodule	I-Lab_value
and	O
2	B-Lab_value
non	I-Lab_value
-	I-Lab_value
measurable	I-Lab_value
lesions	I-Lab_value
presented	O
before	O
apatinib	O
treatment	O
as	O
well	O
as	O
6	B-Lab_value
non	I-Lab_value
-	I-Lab_value
measureable	I-Lab_value
lesions	I-Lab_value
presented	O
7	O
months	O
after	O
apatinib	O
treatment	O
.	O

No	O
new	O
lesion	O
was	O
raised	O
.	O

After	O
target	O
lesion	B-Detailed_description
measurement	B-Diagnostic_procedure
according	O
to	O
the	O
RECIST	B-Diagnostic_procedure
1	I-Diagnostic_procedure
.	I-Diagnostic_procedure
1	I-Diagnostic_procedure
standard	I-Diagnostic_procedure
,	O
it	O
was	O
narrowly	O
considered	O
PR	B-Lab_value
.	O

The	O
toxicities	O
the	O
patient	O
experienced	O
included	O
mild	B-Severity
hand	B-Disease_disorder
-	I-Disease_disorder
foot	I-Disease_disorder
syndrome	I-Disease_disorder
and	O
slight	B-Severity
high	B-Sign_symptom
blood	I-Sign_symptom
pressure	I-Sign_symptom
.	O

Both	O
were	O
well	B-Lab_value
controlled	I-Lab_value
after	I-Lab_value
appropriate	I-Lab_value
treatment	I-Lab_value
.	O

No	O
severe	B-Severity
toxicities	B-Sign_symptom
and	O
other	O
treatment	B-Detailed_description
-	I-Detailed_description
related	I-Detailed_description
adverse	B-Sign_symptom
events	I-Sign_symptom
were	O
observed	O
.	O

The	O
patient	O
continued	O
to	O
use	O
apatinib	B-Medication
as	O
maintenance	O
therapy	O
without	O
major	O
toxic	B-Sign_symptom
effects	I-Sign_symptom
,	O
and	O
went	O
back	O
to	O
normal	O
life	O
,	O
even	O
driving	B-Activity
an	O
automatic	B-Detailed_description
car	I-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

A	O
34	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
Hispanic	O
male	O
without	O
significant	O
past	O
medical	O
history	O
presented	O
to	O
our	O
hospital	B-Nonbiological_location
with	O
a	O
one	B-Duration
month	I-Duration
history	O
of	O
cough	B-Sign_symptom
;	O
productive	O
of	O
whitish	B-Color
sputum	B-Sign_symptom
.	O

At	O
presentation	O
,	O
he	O
denied	O
fever	B-Sign_symptom
,	O
chills	B-Sign_symptom
,	O
night	B-Sign_symptom
sweats	I-Sign_symptom
,	O
chest	B-Biological_structure
pain	B-Sign_symptom
,	O
hemoptysis	B-Sign_symptom
,	O
back	B-Biological_structure
pain	B-Sign_symptom
,	O
recent	B-Detailed_description
travel	O
or	O
sick	B-Detailed_description
contacts	O
.	O

He	O
reported	O
that	O
he	O
had	O
approximately	O
a	O
15	B-Lab_value
-	I-Lab_value
20	I-Lab_value
pound	I-Lab_value
weight	B-Sign_symptom
loss	I-Sign_symptom
during	O
the	O
last	B-Duration
six	I-Duration
months	I-Duration
.	O

He	O
denied	O
smoking	B-Activity
,	O
socially	O
drank	B-Activity
alcohol	I-Activity
,	O
and	O
had	O
unprotected	B-Detailed_description
sexual	B-Activity
intercourse	I-Activity
with	O
multiple	B-Detailed_description
partners	I-Detailed_description
in	O
the	O
past	O
.	O

On	O
admission	O
,	O
his	O
temperature	B-Diagnostic_procedure
was	O
97	B-Lab_value
.	I-Lab_value
9	I-Lab_value
°F	I-Lab_value
;	O
heart	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
85	B-Lab_value
beats	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
,	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
was	O
16	B-Lab_value
breaths	I-Lab_value
per	I-Lab_value
minute	I-Lab_value
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
107	B-Lab_value
/	I-Lab_value
66	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
and	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
was	O
100	B-Lab_value
%	I-Lab_value
on	O
room	B-Detailed_description
air	I-Detailed_description
.	O

Examination	B-Diagnostic_procedure
showed	O
oral	B-Biological_structure
thrush	B-Sign_symptom
,	O
decreased	B-Lab_value
breath	B-Diagnostic_procedure
sounds	I-Diagnostic_procedure
and	O
crackles	B-Sign_symptom
on	O
the	O
right	B-Biological_structure
lower	I-Biological_structure
lung	I-Biological_structure
base	I-Biological_structure
.	O

No	O
cutaneous	B-Biological_structure
lesions	B-Sign_symptom
were	O
reported	O
and	O
the	O
rest	O
of	O
clinical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
.	O

His	O
complete	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
count	I-Diagnostic_procedure
(	O
CBC	B-Diagnostic_procedure
)	O
showed	O
hemoglobin	B-Diagnostic_procedure
of	O
9	B-Lab_value
.	I-Lab_value
7	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
WBCs	B-Diagnostic_procedure
2	B-Lab_value
.	I-Lab_value
3	I-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
platelets	B-Diagnostic_procedure
of	O
164	B-Lab_value
×	I-Lab_value
109	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

His	O
creatinine	B-Diagnostic_procedure
was	O
0	B-Lab_value
.	I-Lab_value
62	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
,	O
and	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
nitrogen	I-Diagnostic_procedure
was	O
10	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
.	O

Radiograph	B-Diagnostic_procedure
of	O
the	O
chest	B-Biological_structure
showed	O
extensive	B-Severity
right	B-Biological_structure
and	O
left	B-Biological_structure
perihilar	B-Biological_structure
opacity	B-Sign_symptom
more	B-Biological_structure
on	I-Biological_structure
the	I-Biological_structure
right	I-Biological_structure
side	I-Biological_structure
,	O
and	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
of	O
the	O
chest	B-Biological_structure
showed	O
a	O
right	B-Biological_structure
sided	I-Biological_structure
large	B-Severity
perihilar	B-Biological_structure
mass	B-Sign_symptom
(	O
Figure	O
1	O
)	O
with	O
multiple	B-Detailed_description
thoracic	B-Biological_structure
and	O
lumbar	B-Biological_structure
vertebrae	B-Biological_structure
,	O
ribs	B-Biological_structure
,	O
and	O
sternal	B-Biological_structure
tiny	B-Severity
lytic	B-Detailed_description
lesions	B-Sign_symptom
consistent	O
with	O
bony	B-Biological_structure
metastasis	B-Disease_disorder
(	O
Figure	O
2	O
)	O
.	O

Blood	B-Biological_structure
and	O
sputum	B-Biological_structure
cultures	B-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Tuberculosis	B-Disease_disorder
was	O
ruled	O
out	O
by	O
three	B-Detailed_description
consecutive	I-Detailed_description
negative	B-Lab_value
sputum	B-Diagnostic_procedure
smears	I-Diagnostic_procedure
for	O
acid	B-Detailed_description
fast	I-Detailed_description
bacilli	I-Detailed_description
and	O
a	O
negative	B-Lab_value
QUANTIferon	B-Diagnostic_procedure
gold	I-Diagnostic_procedure
test	I-Diagnostic_procedure
.	O

He	O
tested	O
positive	B-Lab_value
for	O
human	B-Disease_disorder
immunodeficiency	I-Disease_disorder
virus	I-Disease_disorder
(	O
HIV	B-Disease_disorder
)	O
and	O
his	O
CD4	B-Diagnostic_procedure
counts	I-Diagnostic_procedure
came	O
back	O
at	O
7	B-Lab_value
cells	I-Lab_value
/	I-Lab_value
uL	I-Lab_value
.	O

He	O
was	O
started	O
on	O
prophylaxis	B-Therapeutic_procedure
with	O
bactrim	B-Medication
80	B-Dosage
-	I-Dosage
160	I-Dosage
mg	I-Dosage
daily	I-Dosage
and	O
azithromycin	B-Medication
1200	B-Dosage
mg	I-Dosage
weekly	I-Dosage
for	O
opportunistic	O
infections	O
.	O

Bronchoscopy	B-Diagnostic_procedure
with	O
biopsy	B-Diagnostic_procedure
was	O
performed	O
but	O
was	O
unrevealing	B-Lab_value
and	O
he	O
underwent	O
a	O
video	B-Detailed_description
assisted	I-Detailed_description
mediastinoscopy	B-Diagnostic_procedure
with	O
biopsies	B-Diagnostic_procedure
of	O
the	O
right	B-Biological_structure
hilar	I-Biological_structure
mass	B-Sign_symptom
.	O

Pathology	B-Diagnostic_procedure
showed	O
spindle	B-Sign_symptom
cells	I-Sign_symptom
positive	B-Lab_value
for	O
CD34	B-Diagnostic_procedure
,	O
BCL2	B-Diagnostic_procedure
,	O
vimentin	B-Diagnostic_procedure
,	O
and	O
HHV	B-Diagnostic_procedure
-	I-Diagnostic_procedure
8	I-Diagnostic_procedure
with	O
diffuse	B-Detailed_description
positivity	B-Lab_value
for	O
CD31	B-Diagnostic_procedure
diagnostic	O
of	O
KS	B-Disease_disorder
.	O

He	O
started	O
treatment	O
with	O
HAART	B-Medication
in	O
the	O
form	O
of	O
emtricitabine	B-Medication
and	I-Medication
tenofovir	I-Medication
disoproxil	I-Medication
fumarate	I-Medication
200	B-Lab_value
/	I-Lab_value
300	I-Lab_value
mg	I-Lab_value
and	O
dolutegravir	B-Medication
50	B-Lab_value
mg	I-Lab_value
.	O

The	O
patient	O
was	O
actively	B-Detailed_description
involved	I-Detailed_description
in	O
decisions	O
regarding	O
management	B-Detailed_description
options	I-Detailed_description
.	O

He	O
favored	O
HAART	B-Medication
isolated	O
regimen	O
without	O
additional	B-Medication
chemotherapy	I-Medication
.	O

His	O
condition	O
showed	O
continuing	O
clinical	B-Sign_symptom
improvement	I-Sign_symptom
;	O
a	O
repeat	O
CT	B-Diagnostic_procedure
scan	O
of	O
the	O
chest	B-Biological_structure
at	O
three	O
months	O
showed	O
profound	O
regression	B-Sign_symptom
of	O
the	O
disease	O
with	O
disappearance	O
of	O
most	O
of	O
the	O
lesions	B-Sign_symptom
(	O
Figure	O
3	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
18	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
with	O
a	O
history	O
of	O
a	O
palpable	B-Detailed_description
lump	B-Sign_symptom
in	O
the	O
presternal	B-Biological_structure
area	I-Biological_structure
,	O
which	O
was	O
found	O
incidentally	O
after	O
weight	B-Sign_symptom
reduction	I-Sign_symptom
.	O

The	O
patient	O
had	O
no	O
other	O
relevant	O
medical	O
or	O
trauma	O
history	O
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
,	O
the	O
lesion	O
was	O
found	O
to	O
be	O
a	O
nonmovable	B-Detailed_description
,	O
firm	B-Texture
mass	B-Sign_symptom
with	O
no	O
tenderness	B-Sign_symptom
or	O
associated	O
skin	B-Sign_symptom
changes	I-Sign_symptom
,	O
detected	O
at	O
the	O
midline	B-Biological_structure
position	I-Biological_structure
over	I-Biological_structure
the	I-Biological_structure
sternum	I-Biological_structure
(	O
at	O
the	O
manubrium	B-Biological_structure
level	I-Biological_structure
)	O
.	O

There	O
was	O
no	O
visible	O
fistulous	B-Sign_symptom
opening	I-Sign_symptom
or	O
discharge	B-Sign_symptom
from	O
the	O
lesion	O
.	O

On	O
ultrasonography	B-Diagnostic_procedure
,	O
we	O
detected	O
a	O
well	B-Detailed_description
-	I-Detailed_description
circumscribed	I-Detailed_description
,	O
oval	B-Shape
,	O
anechoic	B-Lab_value
mass	B-Sign_symptom
,	O
with	O
posterior	B-Detailed_description
acoustic	I-Detailed_description
enhancement	I-Detailed_description
,	O
that	O
measured	O
about	O
3	B-Volume
.	I-Volume
3	I-Volume
×	I-Volume
1	I-Volume
.	I-Volume
7	I-Volume
×	I-Volume
3	I-Volume
.	I-Volume
1	I-Volume
cm	I-Volume
,	O
and	O
was	O
located	O
in	O
the	O
subcutaneous	B-Biological_structure
fat	I-Biological_structure
layer	I-Biological_structure
over	O
the	O
sternum	B-Biological_structure
.	O

In	O
the	O
dependent	B-Biological_structure
portion	I-Biological_structure
of	O
the	O
mass	O
was	O
an	O
internal	B-Detailed_description
,	O
well	B-Detailed_description
-	I-Detailed_description
circumscribed	I-Detailed_description
,	O
heterogeneously	B-Detailed_description
hypoechoic	B-Lab_value
,	O
egg	B-Shape
-	I-Shape
shaped	I-Shape
lesion	B-Sign_symptom
(	O
Fig	O
.	O
1A	O
and	O
B	O
)	O
showing	O
a	O
movement	B-Detailed_description
according	I-Detailed_description
to	I-Detailed_description
patient	I-Detailed_description
movement	I-Detailed_description
.	O

The	O
mass	O
could	O
be	O
compressed	B-Lab_value
using	O
the	O
linear	B-Therapeutic_procedure
transducer	I-Therapeutic_procedure
(	O
Fig	O
.	O
2A	O
and	O
B	O
)	O
.	O

A	O
color	B-Detailed_description
Doppler	B-Diagnostic_procedure
study	I-Diagnostic_procedure
showed	O
no	O
vascularity	B-Sign_symptom
within	O
the	O
cystic	O
mass	O
or	O
the	O
internal	B-Detailed_description
hypoechoic	B-Lab_value
lesion	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

Surgical	B-Therapeutic_procedure
excision	I-Therapeutic_procedure
of	O
the	O
mass	B-Sign_symptom
was	O
performed	O
without	O
postoperative	B-Disease_disorder
complications	I-Disease_disorder
.	O

Grossly	O
,	O
the	O
excised	O
mass	O
was	O
a	O
well	B-Lab_value
-	I-Lab_value
defined	I-Lab_value
,	O
ovoid	B-Shape
,	O
cystic	B-Lab_value
mass	O
gray	B-Color
-	I-Color
tan	I-Color
in	O
color	O
.	O

On	O
section	O
,	O
it	O
was	O
found	O
to	O
be	O
a	O
unilocular	B-Lab_value
cyst	B-Sign_symptom
filled	O
with	O
whitish	B-Color
mucous	B-Sign_symptom
material	I-Sign_symptom
.	O

Microscopically	O
,	O
the	O
mass	O
was	O
lined	O
with	O
ciliated	O
pseudostratified	O
columnar	O
epithelium	O
suggestive	O
of	O
respiratory	O
type	O
-	O
mucosa	O
(	O
Fig	O
.	O
3	O
)	O
.	O

There	O
was	O
nonspecific	B-Lab_value
collagenous	B-Detailed_description
fibrosis	B-Sign_symptom
around	O
the	O
cyst	O
.	O

The	O
differential	O
diagnosis	O
of	O
subcutaneous	O
cyst	O
included	O
epidermal	B-Disease_disorder
inclusion	I-Disease_disorder
cyst	I-Disease_disorder
,	O
thyroglossal	B-Disease_disorder
duct	I-Disease_disorder
cyst	I-Disease_disorder
,	O
branchial	B-Disease_disorder
cleft	I-Disease_disorder
cyst	I-Disease_disorder
,	O
and	O
dermoid	B-Disease_disorder
cyst	I-Disease_disorder
.	O

There	O
was	O
no	O
histological	B-Sign_symptom
evidence	I-Sign_symptom
of	O
squamous	B-Detailed_description
epithelium	I-Detailed_description
,	O
keratin	B-Detailed_description
,	O
thyroid	B-Detailed_description
tissue	I-Detailed_description
,	O
or	O
skin	B-Detailed_description
appendage	I-Detailed_description
in	O
the	O
cystic	O
wall	O
of	O
the	O
present	O
case	O
.	O

The	O
mass	O
was	O
diagnosed	O
as	O
a	O
bronchogenic	B-Disease_disorder
cyst	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
68	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
referred	O
by	O
his	O
optometrist	O
to	O
HES	B-Nonbiological_location
with	O
suspected	O
LTG	B-Disease_disorder
due	O
to	O
repeatedly	B-Detailed_description
irregular	I-Detailed_description
visual	B-Diagnostic_procedure
field	I-Diagnostic_procedure
test	I-Diagnostic_procedure
results	I-Diagnostic_procedure
,	O
advanced	B-Detailed_description
optic	B-Diagnostic_procedure
disc	I-Diagnostic_procedure
cupping	I-Diagnostic_procedure
,	O
normal	B-Lab_value
intraocular	B-Diagnostic_procedure
pressures	I-Diagnostic_procedure
(	O
IOPs	B-Diagnostic_procedure
)	O
and	O
a	O
family	O
history	O
of	O
glaucoma	O
.	O

The	O
patient	O
subjectively	O
felt	O
that	O
vision	B-Sign_symptom
in	O
his	O
`	O
good	B-Detailed_description
`	O
left	B-Biological_structure
eye	I-Biological_structure
(	O
LE	B-Biological_structure
)	O
,	O
which	O
normally	O
had	O
a	O
visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
of	O
6	B-Lab_value
/	I-Lab_value
6	I-Lab_value
N5	I-Lab_value
,	O
started	O
to	O
deteriorate	B-Detailed_description
6	O
months	O
earlier	O
;	O
at	O
the	O
point	O
of	O
referral	O
it	O
was	O
best	O
corrected	O
to	O
6	B-Lab_value
/	I-Lab_value
7	I-Lab_value
.	I-Lab_value
5	I-Lab_value
N6	I-Lab_value
.	O

His	O
right	B-Biological_structure
eye	I-Biological_structure
(	O
RE	B-Biological_structure
)	O
was	O
known	O
to	O
be	O
amblyopic	B-Disease_disorder
with	O
a	O
visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
of	O
6	B-Lab_value
/	I-Lab_value
18	I-Lab_value
N12	I-Lab_value
.	O

His	O
medical	O
history	O
included	O
considerable	O
risk	O
factors	O
for	O
systemic	B-Detailed_description
vasculopathy	B-Disease_disorder
,	O
such	O
as	O
hypertension	O
,	O
hypercholesterolaemia	O
,	O
50	B-Lab_value
pack	I-Lab_value
-	I-Lab_value
years	I-Lab_value
of	O
smoking	O
and	O
type	O
2	O
diabetes	O
with	O
no	O
diabetic	O
retinopathy	O
.	O

Despite	O
detailed	O
questioning	O
,	O
he	O
denied	O
any	O
new	B-Sign_symptom
systemic	I-Sign_symptom
symptoms	I-Sign_symptom
apart	O
from	O
experiencing	O
increased	B-Lab_value
lethargy	B-Sign_symptom
.	O

Clinical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
at	O
HES	B-Nonbiological_location
revealed	O
advanced	B-Detailed_description
bilateral	I-Detailed_description
cupped	B-Diagnostic_procedure
optic	I-Diagnostic_procedure
discs	I-Diagnostic_procedure
with	O
a	O
cup	B-Diagnostic_procedure
-	I-Diagnostic_procedure
to	I-Diagnostic_procedure
-	I-Diagnostic_procedure
disc	I-Diagnostic_procedure
ratio	I-Diagnostic_procedure
right	B-Detailed_description
0	B-Lab_value
.	I-Lab_value
9	I-Lab_value
(	O
90	B-Lab_value
%	I-Lab_value
)	O
and	O
left	B-Detailed_description
0	B-Lab_value
.	I-Lab_value
8	I-Lab_value
(	O
80	B-Lab_value
%	I-Lab_value
;	O
figure	O
1	O
)	O
.	O

Furthermore	O
,	O
the	O
findings	O
from	O
the	O
referring	B-Detailed_description
optometrist	O
of	O
equal	O
and	O
reactive	O
pupils	O
,	O
normal	B-Lab_value
eye	B-Diagnostic_procedure
movements	I-Diagnostic_procedure
and	O
IOPs	O
in	O
mid	B-Age
-	I-Age
teens	I-Age
were	O
confirmed	O
.	O

Computerised	B-Diagnostic_procedure
perimetry	I-Diagnostic_procedure
showed	O
constricted	B-Detailed_description
visual	B-Diagnostic_procedure
fields	I-Diagnostic_procedure
in	O
both	B-Lab_value
eyes	B-Biological_structure
,	O
albeit	O
with	O
considerably	B-Lab_value
raised	I-Lab_value
false	B-Diagnostic_procedure
-	I-Diagnostic_procedure
negative	I-Diagnostic_procedure
error	I-Diagnostic_procedure
rates	I-Diagnostic_procedure
in	B-Lab_value
excess	I-Lab_value
of	I-Lab_value
30	I-Lab_value
%	I-Lab_value
(	O
figure	O
2A	O
)	O
.	O

Since	O
this	O
can	O
be	O
a	O
result	O
of	O
poor	B-Severity
concentration	B-Sign_symptom
and	O
attention	B-Sign_symptom
span	I-Sign_symptom
with	B-Detailed_description
testing	I-Detailed_description
compounded	I-Detailed_description
,	O
especially	O
with	O
an	O
amblyopic	B-Disease_disorder
RE	B-Biological_structure
,	O
the	O
field	B-Diagnostic_procedure
test	I-Diagnostic_procedure
was	O
repeated	O
4	O
weeks	O
later	O
with	B-Detailed_description
similar	I-Detailed_description
results	I-Detailed_description
(	O
figure	O
2B	O
)	O
.	O

At	O
this	O
visit	O
,	O
the	O
patient	O
experienced	O
further	B-Lab_value
deterioration	I-Lab_value
of	O
his	O
`	O
good	B-Detailed_description
`	O
LE	B-Biological_structure
.	O

Visual	B-Diagnostic_procedure
acuities	I-Diagnostic_procedure
measured	O
6	B-Lab_value
/	I-Lab_value
24	I-Lab_value
(	I-Lab_value
loss	B-Detailed_description
of	I-Detailed_description
one	I-Detailed_description
Snellen	I-Detailed_description
line	I-Detailed_description
)	I-Lab_value
N36	I-Lab_value
in	O
his	O
amblyopic	B-Disease_disorder
RE	B-Biological_structure
,	O
and	O
6	B-Lab_value
/	I-Lab_value
18	I-Lab_value
(	I-Lab_value
loss	B-Detailed_description
of	I-Detailed_description
two	I-Detailed_description
Snellen	I-Detailed_description
lines	I-Detailed_description
)	I-Lab_value
N36	I-Lab_value
in	O
his	O
LE	B-Biological_structure
,	O
which	O
now	O
also	O
showed	O
depressed	B-Lab_value
colour	B-Diagnostic_procedure
vision	I-Diagnostic_procedure
.	O

An	O
urgent	B-Detailed_description
scan	B-Diagnostic_procedure
of	O
the	O
patient	O
`	O
s	O
head	B-Biological_structure
and	O
orbit	B-Biological_structure
was	O
requested	O
to	O
rule	O
out	O
a	O
compressive	B-Detailed_description
lesion	B-Disease_disorder
and	O
blood	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
was	O
carried	O
out	O
to	O
screen	O
for	O
other	B-Diagnostic_procedure
causes	I-Diagnostic_procedure
of	I-Diagnostic_procedure
optic	B-Disease_disorder
neuropathy	I-Disease_disorder
including	O
vitamin	B-Diagnostic_procedure
B12	I-Diagnostic_procedure
,	O
folate	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
and	O
inflammatory	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
.	O

MRI	B-Diagnostic_procedure
revealed	O
a	O
large	B-Biological_attribute
mass	B-Disease_disorder
centred	O
at	O
the	O
pituitary	B-Biological_structure
fossa	I-Biological_structure
measuring	O
approximately	O
4	B-Volume
.	I-Volume
5	I-Volume
cm	I-Volume
×	I-Volume
5	I-Volume
.	I-Volume
1	I-Volume
cm	I-Volume
×	I-Volume
4	I-Volume
.	I-Volume
8	I-Volume
cm	I-Volume
(	O
figure	O
3A	O
-	O
C	O
)	O
extending	O
into	O
the	O
suprasellar	B-Biological_structure
cistern	I-Biological_structure
and	O
infrasellar	B-Biological_structure
sphenoid	I-Biological_structure
sinuses	I-Biological_structure
.	O

The	O
optic	B-Biological_structure
chiasm	I-Biological_structure
and	O
both	B-Lab_value
optic	B-Biological_structure
nerves	I-Biological_structure
were	O
displaced	B-Detailed_description
superiorly	I-Detailed_description
and	O
compressed	B-Detailed_description
on	I-Detailed_description
both	I-Detailed_description
sides	I-Detailed_description
.	O

The	O
mass	B-Disease_disorder
showed	O
heterogeneous	B-Detailed_description
T1	B-Diagnostic_procedure
and	I-Diagnostic_procedure
T2	B-Diagnostic_procedure
signals	I-Diagnostic_procedure
with	O
multiple	B-Lab_value
fluid	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
most	O
likely	O
due	O
to	O
previous	O
haemorrhage	O
and	O
low	O
-	O
signal	O
components	O
suggesting	O
calcifications	B-Disease_disorder
.	O

The	O
appearance	O
was	O
probably	O
due	O
to	O
a	O
craniopharyngioma	B-Disease_disorder
or	O
haemorrhagic	B-Detailed_description
pituitary	B-Disease_disorder
adenoma	I-Disease_disorder
.	O

The	O
patient	O
was	O
referred	O
urgently	O
to	O
the	O
neurosurgery	B-Nonbiological_location
unit	I-Nonbiological_location
and	O
was	O
found	O
to	O
have	O
markedly	B-Lab_value
raised	I-Lab_value
prolactin	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
of	O
greater	B-Lab_value
than	I-Lab_value
200	I-Lab_value
000	I-Lab_value
mIU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
confirming	O
the	O
diagnosis	O
of	O
a	O
giant	B-Severity
prolactinoma	B-Disease_disorder
.	O

In	O
cooperation	O
with	O
the	O
local	B-Nonbiological_location
endocrinology	I-Nonbiological_location
service	I-Nonbiological_location
,	O
he	O
was	O
started	O
on	O
cabergoline	B-Medication
500	B-Dosage
µg	I-Dosage
and	O
dexamethasone	B-Medication
8	B-Dosage
mg	I-Dosage
.	O

Within	O
a	O
week	O
this	O
led	O
to	O
a	O
dramatic	B-Lab_value
improvement	I-Lab_value
of	O
the	O
patient	O
`	O
s	O
visual	B-Diagnostic_procedure
fields	I-Diagnostic_procedure
and	I-Diagnostic_procedure
acuities	I-Diagnostic_procedure
to	O
6	B-Lab_value
/	I-Lab_value
18	I-Lab_value
RE	B-Biological_structure
and	O
to	O
6	B-Lab_value
/	I-Lab_value
9	I-Lab_value
LE	B-Biological_structure
.	O

His	O
prolactin	B-Diagnostic_procedure
levels	I-Diagnostic_procedure
showed	O
a	O
similar	O
dramatic	B-Lab_value
response	I-Lab_value
with	I-Lab_value
levels	I-Lab_value
coming	I-Lab_value
down	I-Lab_value
to	O
336	B-Lab_value
mIU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

Three	O
months	O
later	O
his	O
visual	B-Diagnostic_procedure
acuity	I-Diagnostic_procedure
in	O
his	O
RE	B-Biological_structure
and	O
LE	B-Biological_structure
were	O
6	B-Lab_value
/	I-Lab_value
18	I-Lab_value
and	O
6	B-Lab_value
/	I-Lab_value
5	I-Lab_value
,	O
respectively	O
,	O
and	O
visual	B-Diagnostic_procedure
field	I-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
striking	B-Detailed_description
recovery	I-Detailed_description
with	O
almost	B-Detailed_description
normal	I-Detailed_description
results	I-Detailed_description
(	O
figure	O
2C	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
51	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
G1P1	O
Caucasian	O
female	O
with	O
lifelong	O
neurogenic	O
bladder	O
secondary	O
to	O
spina	O
bifida	O
occulta	O
was	O
referred	O
for	O
symptoms	O
of	O
constipation	B-Sign_symptom
and	O
(	O
FI	B-Sign_symptom
)	O
.	O

She	O
averaged	O
one	O
Bristol	B-Diagnostic_procedure
Type	I-Diagnostic_procedure
1	B-Lab_value
-	I-Lab_value
2	I-Lab_value
stool	B-Activity
every	B-Frequency
5	I-Frequency
days	I-Frequency
requiring	O
frequent	B-Detailed_description
manual	B-Therapeutic_procedure
disimpaction	I-Therapeutic_procedure
.	O

Additionally	O
,	O
she	O
reported	O
twice	B-Frequency
weekly	I-Frequency
episodes	O
of	O
urgent	B-Severity
fecal	B-Sign_symptom
seepage	I-Sign_symptom
,	O
which	O
required	O
the	O
use	O
of	O
daily	B-Frequency
continence	B-Therapeutic_procedure
pads	I-Therapeutic_procedure
.	O

Her	O
symptoms	O
did	O
not	O
improve	O
with	O
the	O
addition	O
of	O
psyllium	B-Medication
and	O
bisacodyl	B-Medication
suppositories	O
.	O

A	O
defecography	B-Diagnostic_procedure
suggested	O
atrophy	B-Sign_symptom
of	O
the	O
puborectalis	B-Biological_structure
and	O
poor	B-Sign_symptom
squeeze	I-Sign_symptom
with	O
EAS	B-Biological_structure
muscle	I-Biological_structure
atrophy	B-Sign_symptom
.	O

Anorectal	B-Diagnostic_procedure
manometry	I-Diagnostic_procedure
(	O
ARM	B-Diagnostic_procedure
)	O
showed	O
a	O
normal	B-Lab_value
resting	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
with	O
no	O
augmentation	B-Sign_symptom
of	I-Sign_symptom
squeeze	I-Sign_symptom
pressure	I-Sign_symptom
,	O
consistent	O
with	O
weak	B-Disease_disorder
EAS	I-Disease_disorder
(	O
Figure	O
1	O
)	O
.	O

During	O
bearing	B-Activity
down	I-Activity
,	O
fixed	B-Sign_symptom
perineal	I-Sign_symptom
descent	I-Sign_symptom
was	O
noted	O
with	O
the	O
inability	B-Lab_value
to	I-Lab_value
widen	I-Lab_value
the	O
posterior	B-Diagnostic_procedure
anorectal	I-Diagnostic_procedure
angle	I-Diagnostic_procedure
and	O
poor	B-Lab_value
evacuation	B-Diagnostic_procedure
of	I-Diagnostic_procedure
contrast	I-Diagnostic_procedure
with	O
straining	B-Sign_symptom
,	O
consistent	O
with	O
DD	B-Disease_disorder
.	O

With	O
pushing	B-Activity
,	O
ARM	B-Diagnostic_procedure
similarly	O
demonstrated	O
type	B-Lab_value
IV	I-Lab_value
DD	B-Disease_disorder
,	O
which	O
is	O
classified	O
as	O
inability	O
to	O
generate	O
adequate	O
propulsive	O
forces	O
along	O
with	O
absent	O
or	O
incomplete	O
relaxation	O
of	O
the	O
anal	O
sphincter	O
[	O
8	O
]	O
(	O
Figure	O
2	O
)	O
.	O

Reflex	B-Diagnostic_procedure
and	I-Diagnostic_procedure
sensory	I-Diagnostic_procedure
testing	I-Diagnostic_procedure
indicated	O
an	O
intact	B-Lab_value
rectoanal	B-Diagnostic_procedure
inhibitory	I-Diagnostic_procedure
reflex	I-Diagnostic_procedure
and	O
rectal	B-Biological_structure
hypersensitivity	B-Sign_symptom
.	O

The	O
patient	O
failed	O
management	B-Sign_symptom
with	O
home	B-Detailed_description
and	O
conventional	B-Detailed_description
biofeedback	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

Following	O
a	O
successful	O
trial	O
of	O
temporary	B-Detailed_description
SNS	B-Therapeutic_procedure
with	O
improvement	O
in	O
FI	B-Sign_symptom
symptoms	O
by	O
75	B-Lab_value
%	I-Lab_value
,	O
the	O
patient	O
had	O
a	O
permanent	B-Detailed_description
SNS	B-Therapeutic_procedure
placed	O
.	O

One	O
year	O
later	O
,	O
the	O
patient	O
reports	O
sustained	O
improvement	O
in	O
constipation	B-Sign_symptom
and	O
FI	B-Sign_symptom
symptoms	O
.	O

-DOCSTART- -X- -X- -X- O

An	O
82	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
was	O
admitted	O
in	O
our	O
outside	B-Nonbiological_location
hospital	I-Nonbiological_location
`	I-Nonbiological_location
s	I-Nonbiological_location
emergency	I-Nonbiological_location
room	I-Nonbiological_location
due	O
to	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
and	O
faint	B-Sign_symptom
.	O

He	O
had	O
a	O
previous	O
history	O
of	O
auricular	B-Sign_symptom
fibrillation	I-Sign_symptom
in	O
treatment	O
with	O
a	O
dicumarinic	O
anticoagulant	O
and	O
a	O
previous	O
episode	O
of	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
which	O
was	O
diagnosed	O
as	O
spontaneous	B-Detailed_description
mesenchimal	B-Disease_disorder
haematoma	I-Disease_disorder
and	O
treated	B-Therapeutic_procedure
non	I-Therapeutic_procedure
operatively	I-Therapeutic_procedure
.	O

He	O
denied	O
any	O
kind	O
of	O
trauma	B-Sign_symptom
,	O
and	O
had	O
no	O
hematemesis	B-Sign_symptom
or	O
melena	B-Sign_symptom
.	O

At	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
the	O
patient	O
was	O
stable	B-Lab_value
and	O
suffered	O
from	O
intense	B-Severity
pain	B-Sign_symptom
at	O
the	O
right	B-Biological_structure
lower	I-Biological_structure
abdomen	I-Biological_structure
with	O
no	O
defense	O
.	O

Blood	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
a	O
haemoglobin	B-Diagnostic_procedure
level	I-Diagnostic_procedure
of	O
10	B-Lab_value
g	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
.	O

Coagulation	B-Diagnostic_procedure
was	O
altered	B-Lab_value
as	O
expected	O
.	O

CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
showed	O
massive	B-Severity
hemoperitoneum	B-Sign_symptom
(	O
Figure	O
1	O
)	O
and	O
the	O
already	O
known	O
mesenteric	B-Disease_disorder
hematoma	I-Disease_disorder
(	O
Figure	O
2	O
)	O
.	O

Assuming	O
the	O
diagnosis	O
of	O
expansive	B-Detailed_description
mesenteric	B-Disease_disorder
hematoma	I-Disease_disorder
plus	O
ongoing	B-Detailed_description
bleeding	B-Sign_symptom
a	O
laparotomy	B-Therapeutic_procedure
was	O
performed	O
.	O

During	O
first	O
exploration	O
,	O
3	B-Volume
liters	I-Volume
of	O
fresh	B-Sign_symptom
and	I-Sign_symptom
old	I-Sign_symptom
blood	I-Sign_symptom
clots	I-Sign_symptom
were	O
found	O
.	O

At	O
90	B-Distance
cm	I-Distance
from	I-Distance
the	O
ileocecal	B-Biological_structure
valve	I-Biological_structure
a	O
torsionated	B-Detailed_description
and	O
perforated	B-Detailed_description
meckel	B-Disease_disorder
diverticulum	I-Disease_disorder
with	O
intradiverticular	B-Biological_structure
bleeding	B-Sign_symptom
was	O
found	O
(	O
Figure	O
3	O
)	O
and	O
a	O
diverticular	B-Biological_structure
resection	B-Therapeutic_procedure
was	O
performed	O
.	O

The	O
postoperatory	B-Therapeutic_procedure
was	O
uneventful	B-Lab_value
and	O
the	O
patient	O
was	O
discharged	O
home	O
at	O
the	O
9th	O
postoperative	O
day	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
48	B-Age
year	I-Age
-	I-Age
old	I-Age
female	O
presented	O
with	O
vaginal	B-Biological_structure
bleeding	B-Sign_symptom
and	O
abnormal	B-Lab_value
Pap	B-Diagnostic_procedure
smears	I-Diagnostic_procedure
.	O

Upon	O
diagnosis	O
of	O
invasive	B-Detailed_description
non	B-Detailed_description
-	I-Detailed_description
keratinizing	I-Detailed_description
SCC	B-Disease_disorder
of	O
the	O
cervix	B-Biological_structure
,	O
she	O
underwent	O
a	O
radical	B-Detailed_description
hysterectomy	B-Therapeutic_procedure
with	O
salpingo	B-Therapeutic_procedure
-	I-Therapeutic_procedure
oophorectomy	I-Therapeutic_procedure
which	O
demonstrated	O
positive	B-Sign_symptom
spread	I-Sign_symptom
to	O
the	O
pelvic	B-Biological_structure
lymph	I-Biological_structure
nodes	I-Biological_structure
and	O
the	O
parametrium	B-Biological_structure
.	O

Pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
that	O
the	O
tumour	O
also	O
extensively	O
involved	O
the	O
lower	B-Biological_structure
uterine	I-Biological_structure
segment	I-Biological_structure
.	O

5	O
months	O
after	O
this	O
surgery	O
,	O
the	O
woman	O
underwent	O
external	B-Detailed_description
beam	I-Detailed_description
radiotherapy	B-Therapeutic_procedure
and	O
intracavitary	B-Detailed_description
brachytherapy	B-Therapeutic_procedure
.	O

Two	O
years	O
later	O
,	O
the	O
patient	O
presented	O
with	O
a	O
three	B-Duration
-	I-Duration
month	I-Duration
history	O
of	O
a	O
productive	B-Detailed_description
cough	B-Sign_symptom
,	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
,	O
and	O
a	O
2	B-Duration
-	I-Duration
3	I-Duration
week	I-Duration
history	O
of	O
progressive	B-Detailed_description
exertional	B-Detailed_description
dyspnea	B-Sign_symptom
.	O

X	B-Diagnostic_procedure
-	I-Diagnostic_procedure
rays	I-Diagnostic_procedure
of	O
the	O
chest	B-Biological_structure
demonstrated	O
a	O
reticular	O
nodular	O
pattern	O
,	O
and	O
CT	B-Diagnostic_procedure
scans	I-Diagnostic_procedure
revealed	O
multiple	O
bilateral	B-Detailed_description
patchy	I-Detailed_description
areas	I-Detailed_description
of	O
ground	B-Texture
glass	I-Texture
opacity	I-Texture
scarring	B-Sign_symptom
with	O
focal	O
areas	O
of	O
subsegmental	B-Detailed_description
atelectasis	B-Sign_symptom
within	O
both	B-Biological_structure
lungs	I-Biological_structure
.	O

A	O
differential	O
diagnosis	O
included	O
interstitial	B-Detailed_description
pneumonia	B-Disease_disorder
versus	O
non	B-Detailed_description
-	I-Detailed_description
cardiogenic	I-Detailed_description
edema	B-Sign_symptom
.	O

The	O
woman	O
underwent	O
a	O
bronchoscopy	B-Diagnostic_procedure
,	O
left	B-Detailed_description
thoracoscopy	B-Diagnostic_procedure
,	O
and	O
an	O
open	B-Detailed_description
wedge	I-Detailed_description
left	B-Biological_structure
lung	I-Biological_structure
biopsy	B-Diagnostic_procedure
.	O

Pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
of	O
the	O
left	B-Biological_structure
lung	I-Biological_structure
biopsy	O
confirmed	O
the	O
presence	O
of	O
neoplastic	B-Sign_symptom
sheets	I-Sign_symptom
of	I-Sign_symptom
cells	I-Sign_symptom
classically	O
distributed	O
along	B-Biological_structure
the	I-Biological_structure
septal	I-Biological_structure
vessels	I-Biological_structure
,	O
perivascular	B-Biological_structure
,	O
peribronchial	B-Biological_structure
,	O
and	O
subpleural	B-Biological_structure
lymphatics	B-Biological_structure
.	O

Subpleural	B-Biological_structure
nodules	B-Sign_symptom
were	O
also	O
identified	O
with	O
the	O
presence	O
of	O
neoplastic	O
cells	O
distending	O
the	O
subpleural	B-Biological_structure
lymphatics	I-Biological_structure
confirming	O
LC	B-Disease_disorder
(	O
Figures	O
1A	O
,	O
1B	O
,	O
1C	O
)	O
.	O

On	O
immunohistochemical	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
,	O
the	O
lesional	O
cells	O
were	O
strongly	O
positive	B-Lab_value
to	O
p16	B-Diagnostic_procedure
(	O
Figure	O
1D	O
)	O
,	O
high	B-Diagnostic_procedure
and	I-Diagnostic_procedure
low	I-Diagnostic_procedure
molecular	I-Diagnostic_procedure
weight	I-Diagnostic_procedure
keratins	I-Diagnostic_procedure
(	O
Figure	O
1E	O
)	O
,	O
cytokeratin	B-Diagnostic_procedure
-	I-Diagnostic_procedure
7	I-Diagnostic_procedure
(	O
CK7	O
)	O
(	O
Figure	O
1F	O
)	O
,	O
CK19	B-Diagnostic_procedure
,	O
and	O
pan	B-Diagnostic_procedure
keratin	I-Diagnostic_procedure
,	O
and	O
negative	B-Lab_value
to	O
CK20	B-Diagnostic_procedure
,	O
p63	B-Diagnostic_procedure
,	O
and	O
EGFR	B-Diagnostic_procedure
.	O

Based	O
on	O
these	O
findings	O
,	O
she	O
was	O
diagnosed	O
to	O
have	O
lymphangitic	B-Disease_disorder
carcinomatosis	I-Disease_disorder
in	O
the	O
lung	B-Biological_structure
metastatic	B-Sign_symptom
from	O
SCC	B-Disease_disorder
of	O
the	O
cervix	B-Biological_structure
.	O

She	O
was	O
started	O
on	O
chemotherapy	B-Medication
(	O
Carbo	B-Medication
/	O
Taxol	B-Medication
)	O
with	O
corticosteroids	B-Medication
while	O
in	O
the	O
hospital	O
,	O
and	O
was	O
discharged	O
ten	O
days	O
later	O
.	O

Post	O
-	O
treatment	O
improvement	B-Lab_value
of	O
clinical	B-Sign_symptom
symptoms	I-Sign_symptom
was	O
paralleled	O
by	O
radiographic	B-Diagnostic_procedure
imaging	I-Diagnostic_procedure
that	O
showed	O
marked	O
interval	O
improvement	B-Lab_value
of	O
the	O
nodular	B-Sign_symptom
opacifications	I-Sign_symptom
and	O
the	O
interstitial	B-Sign_symptom
thickening	I-Sign_symptom
that	O
had	O
previously	O
been	O
noted	O
.	O

Despite	O
this	O
improvement	O
,	O
she	O
subsequently	O
died	O
13	O
months	O
after	O
the	O
initial	O
diagnosis	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
35	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
to	O
the	O
ear	B-Nonbiological_location
,	I-Nonbiological_location
nose	I-Nonbiological_location
and	I-Nonbiological_location
throat	I-Nonbiological_location
outpatient	I-Nonbiological_location
department	I-Nonbiological_location
with	O
headache	B-Sign_symptom
and	O
a	O
blocked	B-Sign_symptom
left	I-Sign_symptom
-	I-Sign_symptom
sided	I-Sign_symptom
nasal	I-Sign_symptom
canal	I-Sign_symptom
with	O
epistaxis	B-Sign_symptom
for	O
2	B-Duration
years	I-Duration
.	O

Medical	O
history	O
revealed	O
secondary	B-Detailed_description
amenorrhoea	B-Sign_symptom
for	O
the	O
past	O
19	B-Duration
years	I-Duration
with	O
regression	B-Sign_symptom
of	I-Sign_symptom
secondary	I-Sign_symptom
sexual	I-Sign_symptom
characteristics	I-Sign_symptom
with	O
no	O
galactorrhoea	B-Sign_symptom
.	O

Physical	B-Diagnostic_procedure
and	O
ophthalmological	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

Nasal	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
left	B-Biological_structure
-	I-Biological_structure
sided	I-Biological_structure
choanal	B-Biological_structure
mass	B-Sign_symptom
.	O

As	O
the	O
mass	O
was	O
bleeding	B-Detailed_description
on	I-Detailed_description
palpation	I-Detailed_description
,	O
imaging	B-Diagnostic_procedure
was	O
advised	O
prior	O
to	O
performing	O
a	O
biopsy	O
.	O

MRI	B-Diagnostic_procedure
of	O
the	O
head	B-Biological_structure
showed	O
a	O
sellar	B-Biological_structure
and	O
infra	B-Biological_structure
-	I-Biological_structure
sellar	I-Biological_structure
mass	B-Sign_symptom
extending	B-Biological_structure
into	I-Biological_structure
the	I-Biological_structure
nasopharynx	I-Biological_structure
(	O
figure	O
1	O
)	O
.	O

The	O
patient	O
was	O
then	O
referred	O
to	O
the	O
endocrinologist	B-Nonbiological_location
for	O
further	O
hormonal	B-Diagnostic_procedure
investigation	I-Diagnostic_procedure
.	O

Her	O
serum	B-Diagnostic_procedure
prolactin	I-Diagnostic_procedure
was	O
very	B-Lab_value
high	I-Lab_value
-	O
7443	B-Lab_value
µg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
N	O
<	O
20	O
)	O
.	O

Other	B-Diagnostic_procedure
pituitary	I-Diagnostic_procedure
hormones	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
limits	I-Lab_value
.	O

A	O
final	O
diagnosis	O
of	O
giant	B-Disease_disorder
prolactinoma	I-Disease_disorder
was	O
made	O
and	O
the	O
patient	O
was	O
prescribed	O
cabergoline	B-Medication
0	B-Dosage
.	I-Dosage
25	I-Dosage
mg	I-Dosage
twice	I-Dosage
per	I-Dosage
week	I-Dosage
with	O
the	O
associated	O
risks	O
explained	O
in	O
advance	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
47	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
female	O
patient	O
presented	O
progressively	B-Detailed_description
worsening	I-Detailed_description
pain	B-Sign_symptom
in	O
the	O
chest	B-Biological_structure
wall	I-Biological_structure
,	O
back	B-Biological_structure
,	O
and	O
bilateral	B-Biological_structure
lower	I-Biological_structure
extremities	I-Biological_structure
as	O
well	O
as	O
muscle	B-Sign_symptom
weakness	I-Sign_symptom
.	O

She	O
did	O
not	O
have	O
a	O
family	O
history	O
of	O
bone	O
disease	O
or	O
fractures	O
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
unremarkable	B-Lab_value
excluding	B-Detailed_description
bone	I-Detailed_description
and	I-Detailed_description
muscular	I-Detailed_description
abnormalities	I-Detailed_description
.	O

Bone	B-Biological_structure
scintigraphy	B-Diagnostic_procedure
using	B-Detailed_description
technetium	I-Detailed_description
-	I-Detailed_description
99m	I-Detailed_description
methylenediphosphate	I-Detailed_description
showed	O
increased	O
uptake	B-Sign_symptom
in	O
the	O
shoulder	B-Biological_structure
,	O
multiple	B-Biological_structure
ribs	I-Biological_structure
,	O
thoracic	B-Biological_structure
and	I-Biological_structure
lumbar	I-Biological_structure
spines	I-Biological_structure
,	O
bilateral	B-Biological_structure
sacroiliac	I-Biological_structure
joints	I-Biological_structure
,	O
left	B-Biological_structure
ilium	I-Biological_structure
,	O
and	O
left	B-Biological_structure
foot	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

Plain	B-Detailed_description
radiographs	B-Diagnostic_procedure
revealed	O
osteoporosis	B-Disease_disorder
change	O
of	O
thoracic	B-Biological_structure
and	I-Biological_structure
lumbar	I-Biological_structure
spine	I-Biological_structure
as	O
well	O
as	O
compression	B-Sign_symptom
change	O
of	O
several	B-Biological_structure
spines	I-Biological_structure
,	O
consistent	O
with	O
findings	O
of	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
and	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Decreased	B-Lab_value
bone	B-Diagnostic_procedure
mass	I-Diagnostic_procedure
was	O
presented	O
in	O
the	O
lumbar	B-Biological_structure
spine	I-Biological_structure
(	O
T	B-Lab_value
-	I-Lab_value
score	I-Lab_value
:	I-Lab_value
−	I-Lab_value
3	I-Lab_value
.	I-Lab_value
4	I-Lab_value
)	O
,	O
femoral	B-Biological_structure
neck	I-Biological_structure
(	O
T	B-Lab_value
-	I-Lab_value
score	I-Lab_value
:	I-Lab_value
−	I-Lab_value
3	I-Lab_value
.	I-Lab_value
1	I-Lab_value
)	O
,	O
and	O
hip	B-Biological_structure
(	O
T	B-Lab_value
-	I-Lab_value
score	I-Lab_value
:	I-Lab_value
−	I-Lab_value
3	I-Lab_value
.	I-Lab_value
5	I-Lab_value
)	O
.	O

Main	O
laboratory	O
data	O
are	O
shown	O
in	O
Table	O
1	O
.	O

She	O
demonstrated	O
hypophosphatemia	B-Sign_symptom
,	O
hypokalemia	B-Sign_symptom
,	O
hypouricemia	B-Sign_symptom
,	O
elevated	B-Lab_value
level	O
of	O
ALP	B-Diagnostic_procedure
,	O
C	B-Diagnostic_procedure
-	I-Diagnostic_procedure
telopeptides	I-Diagnostic_procedure
and	O
chloride	B-Diagnostic_procedure
,	O
and	O
decreased	B-Lab_value
carbon	B-Diagnostic_procedure
dioxide	I-Diagnostic_procedure
combining	I-Diagnostic_procedure
power	I-Diagnostic_procedure
.	O

The	O
urinalysis	B-Diagnostic_procedure
revealed	O
a	O
high	B-Lab_value
pH	B-Diagnostic_procedure
value	O
,	O
increased	B-Lab_value
level	O
of	O
potassium	B-Diagnostic_procedure
,	O
and	O
decreased	B-Lab_value
level	O
of	O
specific	B-Diagnostic_procedure
gravity	I-Diagnostic_procedure
,	O
chlorine	B-Diagnostic_procedure
,	O
and	O
phosphate	B-Diagnostic_procedure
.	O

Persistent	B-Detailed_description
glycosuria	B-Sign_symptom
and	O
proteinuria	B-Sign_symptom
were	O
repeatedly	O
found	O
,	O
despite	O
normal	B-Lab_value
HbA1c	B-Diagnostic_procedure
and	O
plasma	B-Diagnostic_procedure
glucose	I-Diagnostic_procedure
level	O
.	O

Other	O
laboratory	B-Diagnostic_procedure
test	I-Diagnostic_procedure
results	O
including	O
thyroid	B-Diagnostic_procedure
function	I-Diagnostic_procedure
test	O
,	O
serum	B-Diagnostic_procedure
parathyroid	I-Diagnostic_procedure
hormone	I-Diagnostic_procedure
,	O
25	B-Diagnostic_procedure
-	I-Diagnostic_procedure
hydroxyvitamin	I-Diagnostic_procedure
D	I-Diagnostic_procedure
,	O
and	O
protein	B-Diagnostic_procedure
electrophoresis	I-Diagnostic_procedure
were	O
within	B-Lab_value
normal	I-Lab_value
range	I-Lab_value
.	O

In	O
addition	O
,	O
all	O
of	O
serum	B-Diagnostic_procedure
tumor	I-Diagnostic_procedure
markers	I-Diagnostic_procedure
were	O
negative	B-Lab_value
.	O

Due	O
to	O
limited	O
technique	O
,	O
we	O
can	O
not	O
determine	O
the	O
level	O
of	O
serum	B-Diagnostic_procedure
fibroblast	I-Diagnostic_procedure
growth	I-Diagnostic_procedure
factor	I-Diagnostic_procedure
23	I-Diagnostic_procedure
.	O

With	O
the	O
clinical	O
diagnosis	O
of	O
HO	B-Disease_disorder
,	O
fluorodeoxyglucose	B-Diagnostic_procedure
positron	I-Diagnostic_procedure
emission	I-Diagnostic_procedure
tomography	I-Diagnostic_procedure
/	O
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
18F	B-Diagnostic_procedure
-	I-Diagnostic_procedure
FDG	I-Diagnostic_procedure
PET	I-Diagnostic_procedure
/	O
CT	B-Diagnostic_procedure
)	O
and	O
technetium	B-Detailed_description
-	I-Detailed_description
99m	I-Detailed_description
octreotide	I-Detailed_description
(	O
99mTc	B-Detailed_description
-	I-Detailed_description
OCT	I-Detailed_description
)	O
scintigraphy	B-Diagnostic_procedure
were	O
performed	O
to	O
confirm	O
whether	O
the	O
occult	B-Detailed_description
causative	B-Detailed_description
tumor	B-Sign_symptom
exist	O
.	O

However	O
,	O
the	O
results	O
of	O
these	O
2	O
tests	O
were	O
negative	B-Lab_value
except	O
that	O
mild	B-Severity
uptake	B-Sign_symptom
in	O
the	O
seventh	B-Biological_structure
rib	I-Biological_structure
was	O
found	O
on	O
PET	B-Diagnostic_procedure
/	O
CT	B-Diagnostic_procedure
,	O
which	O
identified	O
no	O
evidence	O
of	O
a	O
neoplastic	B-Detailed_description
lesion	B-Sign_symptom
potentially	O
responsible	O
for	O
HO	O
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
immunological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
elevated	B-Lab_value
level	O
of	O
serum	B-Diagnostic_procedure
IgG	I-Diagnostic_procedure
,	O
IgM	B-Diagnostic_procedure
,	O
and	O
IgA	B-Diagnostic_procedure
,	O
as	O
well	O
as	O
positive	B-Lab_value
antinuclear	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
SSA	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
,	O
and	O
rheumatic	B-Diagnostic_procedure
factor	I-Diagnostic_procedure
.	O

Subsequently	O
,	O
Schirmer	B-Diagnostic_procedure
test	I-Diagnostic_procedure
was	O
abnormal	B-Lab_value
and	O
lip	B-Biological_structure
biopsy	B-Diagnostic_procedure
supported	O
the	O
diagnosis	O
of	O
SS	B-Disease_disorder
(	O
Fig	O
.	O
3	O
)	O
.	O

Eventually	O
,	O
this	O
patient	O
was	O
diagnosed	O
with	O
HO	B-Disease_disorder
secondary	O
to	O
SS	B-Disease_disorder
,	O
and	O
she	O
was	O
then	O
treated	O
with	O
alkalinization	B-Therapeutic_procedure
(	O
citrate	B-Medication
4	B-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
and	O
potassium	B-Medication
citrate	I-Medication
3	B-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
for	O
2	B-Duration
weeks	I-Duration
)	O
,	O
steroids	B-Medication
(	O
prednisone	B-Medication
20	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
for	O
1	B-Duration
month	I-Duration
,	O
10	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
for	O
4	B-Duration
months	I-Duration
)	O
,	O
neutral	B-Medication
phosphate	I-Medication
(	O
1	B-Dosage
.	I-Dosage
0	I-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
for	O
5	B-Duration
months	I-Duration
)	O
,	O
calcium	B-Medication
supplements	I-Medication
(	O
600	B-Dosage
mg	I-Dosage
/	I-Dosage
day	I-Dosage
for	O
5	B-Duration
months	I-Duration
)	O
,	O
and	O
together	O
with	O
activated	B-Medication
vitamin	I-Medication
D	I-Medication
(	O
0	B-Dosage
.	I-Dosage
5	I-Dosage
g	I-Dosage
/	I-Dosage
day	I-Dosage
for	O
5	B-Duration
months	I-Duration
)	O
.	O

So	O
far	O
,	O
she	O
recovered	B-Sign_symptom
uneventfully	O
with	O
relieved	O
pain	B-Sign_symptom
and	O
increased	B-Lab_value
serum	B-Diagnostic_procedure
phosphorus	I-Diagnostic_procedure
level	O
.	O

This	O
case	O
report	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
West	O
China	O
Hospital	O
of	O
Sichuan	O
University	O
,	O
Chengdu	O
,	O
China	O
,	O
and	O
the	O
written	O
informed	O
consent	O
was	O
obtained	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
23	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
a	O
history	O
of	O
carnitine	O
deficiency	O
presented	O
with	O
exertional	B-Detailed_description
dyspnea	B-Sign_symptom
and	O
fatigue	B-Sign_symptom
.	O

She	O
was	O
first	O
diagnosed	O
with	O
nonischemic	B-Detailed_description
cardiomyopathy	B-Disease_disorder
at	O
age	O
10	O
years	O
,	O
when	O
she	O
presented	O
with	O
symptoms	O
of	O
congestive	B-Detailed_description
heart	B-Disease_disorder
failure	I-Disease_disorder
and	O
transthoracic	O
echocardiography	O
(	O
TTE	B-Diagnostic_procedure
)	O
revealed	O
severe	B-Severity
left	B-Disease_disorder
ventricular	I-Disease_disorder
(	I-Disease_disorder
LV	B-Disease_disorder
)	I-Disease_disorder
dysfunction	I-Disease_disorder
.	O

At	O
that	O
time	O
,	O
her	O
total	O
carnitine	O
level	O
was	O
<	B-Lab_value
3	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
25	O
-	O
69	O
μmol	O
/	O
L	O
)	O
,	O
and	O
her	O
free	O
carnitine	O
level	O
was	O
<	B-Lab_value
3	I-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
,	O
16	O
-	O
60	O
μmol	O
/	O
L	O
)	O
.	O

The	O
cardiomyopathy	O
was	O
attributed	O
to	O
carnitine	O
deficiency	O
.	O

After	O
5	B-Duration
months	I-Duration
of	O
therapy	O
with	O
carnitine	O
supplements	O
,	O
her	O
total	O
carnitine	O
and	O
free	O
carnitine	O
levels	O
had	O
increased	O
to	O
86	B-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
48	B-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
respectively	O
,	O
and	O
her	O
left	B-Biological_structure
ventricular	I-Biological_structure
systolic	B-Diagnostic_procedure
function	I-Diagnostic_procedure
had	O
normalized	B-Lab_value
,	O
with	O
fractional	O
shortening	O
of	O
34	B-Lab_value
.	I-Lab_value
7	I-Lab_value
%	I-Lab_value
.	O

At	O
the	O
current	O
admission	O
,	O
the	O
patient	O
reported	O
that	O
,	O
over	B-Duration
the	I-Duration
past	I-Duration
10	I-Duration
years	I-Duration
,	O
she	O
had	O
only	O
been	O
intermittently	B-Detailed_description
compliant	I-Detailed_description
with	O
her	O
carnitine	B-Medication
supplement	I-Medication
regimen	I-Medication
,	O
and	O
that	O
,	O
approximately	O
6	O
months	O
before	O
presentation	O
,	O
her	O
total	B-Diagnostic_procedure
carnitine	I-Diagnostic_procedure
and	I-Diagnostic_procedure
free	B-Diagnostic_procedure
carnitine	I-Diagnostic_procedure
levels	I-Diagnostic_procedure
had	O
dropped	O
to	O
18	B-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
17	B-Lab_value
μmol	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
respectively	O
.	O

She	O
underwent	O
TTE	B-Diagnostic_procedure
followed	O
by	O
cardiac	B-Diagnostic_procedure
magnetic	I-Diagnostic_procedure
resonance	I-Diagnostic_procedure
(	O
CMR	B-Diagnostic_procedure
)	O
with	O
gadolinium	B-Diagnostic_procedure
enhancement	I-Diagnostic_procedure
.	O

The	O
TTE	B-Diagnostic_procedure
showed	O
normal	B-Lab_value
LV	B-Diagnostic_procedure
function	I-Diagnostic_procedure
and	O
mild	B-Severity
,	O
concentric	B-Detailed_description
LV	B-Disease_disorder
hypertrophy	I-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

Results	O
of	O
CMR	B-Diagnostic_procedure
confirmed	O
normal	B-Lab_value
LV	B-Diagnostic_procedure
size	I-Diagnostic_procedure
and	I-Diagnostic_procedure
function	I-Diagnostic_procedure
but	O
showed	O
focal	B-Detailed_description
increased	B-Lab_value
wall	B-Diagnostic_procedure
thickness	I-Diagnostic_procedure
at	O
the	O
basal	B-Biological_structure
and	I-Biological_structure
mid	B-Biological_structure
lateral	I-Biological_structure
wall	I-Biological_structure
(	O
end	B-Diagnostic_procedure
-	I-Diagnostic_procedure
diastolic	I-Diagnostic_procedure
thickness	I-Diagnostic_procedure
,	O
1	B-Distance
.	I-Distance
6	I-Distance
cm	I-Distance
)	O
(	O
Fig	O
.	O
2	O
)	O
with	O
patchy	B-Detailed_description
delayed	B-Diagnostic_procedure
gadolinium	I-Diagnostic_procedure
enhancement	I-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
)	O
.	O

On	O
the	O
basis	O
of	O
the	O
patient	O
`	O
s	O
family	O
history	O
of	O
sudden	O
cardiac	O
death	O
,	O
abnormal	B-Lab_value
myocardial	B-Diagnostic_procedure
structure	I-Diagnostic_procedure
,	O
and	O
underlying	O
disease	O
process	O
,	O
a	O
dual	B-Detailed_description
-	I-Detailed_description
chamber	I-Detailed_description
implantable	B-Therapeutic_procedure
cardioverter	I-Therapeutic_procedure
-	I-Therapeutic_procedure
defibrillator	I-Therapeutic_procedure
was	O
placed	O
for	O
primary	O
prevention	O
of	O
sudden	O
cardiac	O
death	O
from	O
both	O
bradyarrhythmias	O
and	O
tachyarrhythmias	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
38	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
presented	O
to	O
our	O
Emergency	B-Nonbiological_location
Department	I-Nonbiological_location
with	O
severe	B-Severity
abdominal	B-Biological_structure
pain	B-Sign_symptom
.	O

She	O
had	O
no	O
history	O
of	O
drug	O
use	O
or	O
constipation	O
.	O

She	O
said	O
that	O
she	O
had	O
intermittent	B-Detailed_description
bloody	B-Detailed_description
diarrhea	B-Sign_symptom
.	O

Physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
rebound	B-Detailed_description
tenderness	B-Sign_symptom
and	O
guarding	B-Sign_symptom
over	O
the	O
abdomen	B-Biological_structure
.	O

Stool	B-Diagnostic_procedure
microscopy	I-Diagnostic_procedure
was	O
negative	B-Lab_value
for	O
amoeba	B-Diagnostic_procedure
trophozoites	I-Diagnostic_procedure
or	O
any	O
parasites	B-Diagnostic_procedure
.	O

Fecal	B-Diagnostic_procedure
occult	I-Diagnostic_procedure
blood	I-Diagnostic_procedure
was	O
found	B-Lab_value
.	O

Sedimentation	B-Diagnostic_procedure
was	O
27	B-Lab_value
mm	I-Lab_value
/	I-Lab_value
s	I-Lab_value
,	O
CRP	B-Diagnostic_procedure
(	O
nephelometry	B-Diagnostic_procedure
)	O
was	O
65	B-Lab_value
.	I-Lab_value
6	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
normal	O
range	O
0	O
-	O
5	O
)	O
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
nuclear	I-Diagnostic_procedure
antibody	I-Diagnostic_procedure
was	O
0	B-Lab_value
.	I-Lab_value
4	I-Lab_value
(	O
0	O
-	O
0	O
.	O
8	O
negative	O
)	O
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ds	I-Diagnostic_procedure
DNA	I-Diagnostic_procedure
<	B-Lab_value
10	I-Lab_value
(	O
<	O
20	O
negative	O
)	O
,	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
14	B-Lab_value
.	I-Lab_value
98	I-Lab_value
(	O
normal	O
range	O
4	O
-	O
10	O
)	O
,	O
hemoglobin	B-Diagnostic_procedure
level	O
was	O
10	B-Lab_value
.	I-Lab_value
9	I-Lab_value
,	O
neutro	B-Diagnostic_procedure
-	I-Diagnostic_procedure
phil	I-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
13	B-Lab_value
.	I-Lab_value
14	I-Lab_value
,	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
was	O
473	B-Lab_value
(	O
100	O
-	O
300	O
)	O
,	O
urea	B-Diagnostic_procedure
level	O
was	O
17	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
BUN	B-Diagnostic_procedure
level	O
was	O
7	B-Lab_value
.	I-Lab_value
94	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
creatinine	B-Diagnostic_procedure
level	O
was	O
0	B-Lab_value
.	I-Lab_value
56	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
,	O
AST	B-Diagnostic_procedure
was	O
20	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
ALT	B-Diagnostic_procedure
was	O
24	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
.	O

HIV	B-Diagnostic_procedure
was	O
negative	B-Lab_value
.	O

Abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
scanning	O
showed	O
free	B-Sign_symptom
fluid	I-Sign_symptom
at	O
the	O
right	B-Biological_structure
paracolic	I-Biological_structure
,	O
perihepatic	B-Biological_structure
,	O
left	B-Biological_structure
paracolic	I-Biological_structure
gutters	B-Biological_structure
and	O
pelvis	B-Biological_structure
.	O

Upon	O
detection	O
of	O
air	B-Sign_symptom
-	I-Sign_symptom
fluid	I-Sign_symptom
level	I-Sign_symptom
and	O
free	B-Sign_symptom
air	I-Sign_symptom
under	B-Biological_structure
the	I-Biological_structure
diaphragm	I-Biological_structure
on	O
erect	B-Detailed_description
abdominal	B-Biological_structure
x	B-Diagnostic_procedure
-	I-Diagnostic_procedure
ray	I-Diagnostic_procedure
,	O
emergency	B-Detailed_description
laparotomy	B-Therapeutic_procedure
was	O
performed	O
.	O

In	O
the	O
operation	O
,	O
multiple	B-Detailed_description
perforation	B-Sign_symptom
areas	O
were	O
found	O
in	O
the	O
sigmoid	B-Biological_structure
colon	I-Biological_structure
,	O
descending	B-Biological_structure
colon	I-Biological_structure
,	O
and	O
transverse	B-Biological_structure
colon	I-Biological_structure
.	O

Wide	B-Detailed_description
resection	B-Therapeutic_procedure
of	O
the	O
transverse	B-Biological_structure
colon	I-Biological_structure
with	O
descending	B-Biological_structure
and	I-Biological_structure
sigmoid	I-Biological_structure
colon	I-Biological_structure
resection	B-Therapeutic_procedure
was	O
undertaken	O
(	O
Figure	O
1	O
)	O
.	O

Pathergy	B-Diagnostic_procedure
test	I-Diagnostic_procedure
was	O
positive	B-Lab_value
.	O

The	O
patient	O
had	O
recurrent	O
oral	B-Biological_structure
and	O
genital	B-Biological_structure
aphthous	B-Detailed_description
ulcers	B-Disease_disorder
4	B-Lab_value
-	I-Lab_value
5	I-Lab_value
times	I-Lab_value
within	O
the	O
past	O
year	O
.	O

Eye	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
results	O
were	O
normal	B-Lab_value
.	O

Computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
revealed	O
extensive	B-Detailed_description
thrombus	B-Disease_disorder
within	O
the	O
inferior	B-Biological_structure
vena	I-Biological_structure
cava	I-Biological_structure
extending	O
through	O
the	O
right	B-Biological_structure
and	I-Biological_structure
middle	I-Biological_structure
hepatic	I-Biological_structure
vein	I-Biological_structure
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
received	O
corticosteroid	B-Medication
,	O
anticoagulant	B-Medication
,	O
and	O
immunosuppressive	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
.	O

Our	O
patient	O
is	O
still	O
alive	B-Sign_symptom
and	O
healthy	B-Sign_symptom
53	O
weeks	O
later	O
(	O
Figure	O
3	O
)	O
.	O

In	O
macroscopy	B-Diagnostic_procedure
,	O
the	O
transverse	B-Diagnostic_procedure
colon	I-Diagnostic_procedure
was	O
50	B-Distance
cm	I-Distance
and	O
sigmoid	B-Lab_value
and	O
descending	B-Diagnostic_procedure
colon	I-Diagnostic_procedure
specimens	I-Diagnostic_procedure
were	O
27	B-Distance
cm	I-Distance
in	O
length	O
.	O

Specimens	B-Diagnostic_procedure
of	I-Diagnostic_procedure
both	I-Diagnostic_procedure
colon	I-Diagnostic_procedure
segments	I-Diagnostic_procedure
were	O
4	B-Distance
cm	I-Distance
in	O
diameter	O
.	O

Perforation	B-Disease_disorder
areas	O
were	O
evident	O
in	O
the	O
serosal	B-Biological_structure
surface	I-Biological_structure
.	O

Colonic	B-Biological_structure
wall	I-Biological_structure
and	O
bowel	B-Biological_structure
mucosa	I-Biological_structure
was	O
edematous	B-Sign_symptom
and	O
hyperemic	B-Sign_symptom
.	O

Plicae	B-Diagnostic_procedure
were	O
regular	B-Lab_value
in	O
their	O
course	O
.	O

There	O
were	O
3	B-Lab_value
roundish	B-Shape
,	O
punched	B-Detailed_description
-	I-Detailed_description
out	I-Detailed_description
perforations	B-Disease_disorder
in	O
the	O
transverse	B-Biological_structure
colon	I-Biological_structure
and	O
4	B-Lab_value
in	O
the	O
descending	B-Biological_structure
and	I-Biological_structure
sigmoid	I-Biological_structure
colon	I-Biological_structure
,	O
which	O
were	O
somewhat	O
separate	B-Detailed_description
from	I-Detailed_description
the	I-Detailed_description
colonic	I-Detailed_description
wall	I-Detailed_description
,	O
with	O
the	O
largest	B-Distance
being	I-Distance
2	I-Distance
cm	I-Distance
in	O
diameter	O
(	O
Figure	O
4	O
)	O
.	O

There	O
were	O
multiple	B-Detailed_description
ulcers	B-Disease_disorder
(	O
the	O
largest	B-Distance
was	I-Distance
1	I-Distance
cm	I-Distance
in	O
diameter	O
)	O
in	O
different	O
locations	O
,	O
which	O
were	O
not	B-Detailed_description
merging	I-Detailed_description
together	I-Detailed_description
,	O
and	O
were	O
somewhat	B-Detailed_description
separate	I-Detailed_description
from	I-Detailed_description
the	I-Detailed_description
surrounding	I-Detailed_description
mucosa	I-Detailed_description
via	I-Detailed_description
a	I-Detailed_description
certain	I-Detailed_description
limit	I-Detailed_description
,	O
covered	B-Detailed_description
with	I-Detailed_description
exudate	I-Detailed_description
and	O
surrounded	B-Detailed_description
by	O
a	O
hyperemic	B-Sign_symptom
region	I-Sign_symptom
.	O

There	O
were	O
no	O
macroscopic	B-Sign_symptom
lymph	I-Sign_symptom
nodes	I-Sign_symptom
in	O
the	O
serosa	B-Biological_structure
.	O

Numerous	O
samples	O
were	O
taken	O
from	O
ulcerated	O
and	O
perforated	O
regions	O
and	O
normal	O
mucosa	O
.	O

The	O
samples	O
were	O
submitted	O
for	O
routine	O
microscopic	B-Diagnostic_procedure
tissue	I-Diagnostic_procedure
follow	I-Diagnostic_procedure
-	I-Diagnostic_procedure
up	I-Diagnostic_procedure
.	O

Hematoxylin	B-Diagnostic_procedure
-	I-Diagnostic_procedure
eosin	I-Diagnostic_procedure
,	O
tissue	B-Diagnostic_procedure
Giemsa	I-Diagnostic_procedure
and	O
PAS	B-Diagnostic_procedure
-	I-Diagnostic_procedure
stained	I-Diagnostic_procedure
slides	I-Diagnostic_procedure
were	O
prepared	O
for	O
examination	O
.	O

In	O
microscopic	O
examination	O
,	O
there	O
were	O
neutrophil	B-Biological_structure
leukocyte	I-Biological_structure
and	O
lymphocyte	B-Biological_structure
reaction	B-Sign_symptom
around	O
and	O
within	O
the	O
walls	B-Biological_structure
and	I-Biological_structure
lumens	I-Biological_structure
of	I-Biological_structure
arterioles	I-Biological_structure
,	O
and	O
venules	B-Sign_symptom
around	O
the	O
perforated	B-Detailed_description
and	O
ulcerated	B-Detailed_description
lesions	B-Sign_symptom
(	O
Figures	O
5	O
and	O
and6	O
)	O
.	O
6	O
)	O
.	O

There	O
were	O
well	B-Detailed_description
-	I-Detailed_description
organized	I-Detailed_description
thrombi	B-Sign_symptom
and	O
intimal	B-Sign_symptom
proliferation	I-Sign_symptom
within	O
some	B-Biological_structure
vessels	I-Biological_structure
(	O
Figures	O
7	O
and	O
and8	O
)	O
.	O
8	O
)	O
.	O

There	O
was	O
marked	O
acute	B-Detailed_description
peritonitis	B-Disease_disorder
.	O

Surface	B-Diagnostic_procedure
epithelium	I-Diagnostic_procedure
and	O
colonic	B-Diagnostic_procedure
crypts	I-Diagnostic_procedure
were	O
regular	B-Lab_value
within	O
the	O
colonic	B-Biological_structure
mucosa	I-Biological_structure
apart	O
from	O
the	O
ulcerated	O
or	O
perforated	O
lesions	O
.	O

Samples	O
were	O
free	O
of	O
parasites	B-Disease_disorder
or	O
their	O
eggs	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
proband	O
is	O
a	O
19	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
,	O
first	O
child	O
of	O
healthy	O
unrelated	O
parents	O
.	O

Her	O
family	O
history	O
was	O
unremarkable	O
.	O

She	O
was	O
born	O
at	O
term	O
after	O
a	O
normal	O
pregnancy	O
.	O

The	O
perinatal	B-Diagnostic_procedure
period	I-Diagnostic_procedure
was	O
uneventful	B-Lab_value
and	O
her	O
early	B-Diagnostic_procedure
development	I-Diagnostic_procedure
was	O
referred	O
to	O
as	O
normal	B-Lab_value
,	O
but	O
after	O
1	O
year	O
of	O
age	O
,	O
psychomotor	B-Disease_disorder
delay	I-Disease_disorder
became	O
evident	B-Severity
.	O

She	O
started	O
walking	B-Activity
autonomously	B-Detailed_description
at	O
22	O
months	O
,	O
with	O
poor	B-Lab_value
balance	B-Diagnostic_procedure
and	O
frequent	B-Frequency
falls	B-Sign_symptom
.	O

At	O
3	O
years	O
of	O
age	O
,	O
she	O
developed	O
a	O
demyelinating	B-Disease_disorder
sensorimotor	I-Disease_disorder
neuropathy	I-Disease_disorder
and	O
a	O
brain	B-Biological_structure
MRI	B-Diagnostic_procedure
disclosed	O
supratentorial	B-Biological_structure
leukodystrophy	B-Disease_disorder
.	O

During	O
her	O
childhood	O
,	O
the	O
clinical	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
remained	O
stable	B-Lab_value
.	O

At	O
10	O
years	O
,	O
her	O
walking	B-Disease_disorder
difficulties	I-Disease_disorder
worsened	B-Lab_value
,	O
and	O
limb	B-Biological_structure
weakness	B-Sign_symptom
and	O
tremor	B-Sign_symptom
ensued	O
.	O

The	O
neurological	B-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
showed	O
dysarthria	B-Sign_symptom
,	O
dysmetria	B-Sign_symptom
,	O
ataxic	B-Lab_value
gait	B-Diagnostic_procedure
and	O
hyporeflexia	B-Sign_symptom
in	O
the	O
four	B-Biological_structure
limbs	I-Biological_structure
with	O
muscle	B-Disease_disorder
wasting	I-Disease_disorder
.	O

She	O
was	O
able	O
to	O
walk	B-Activity
alone	B-Detailed_description
only	B-Lab_value
for	I-Lab_value
a	I-Lab_value
few	I-Lab_value
steps	I-Lab_value
with	O
an	O
ataxic	B-Lab_value
gait	B-Diagnostic_procedure
.	O

Mild	B-Severity
cognitive	B-Disease_disorder
impairment	I-Disease_disorder
was	O
documented	O
(	O
IQ	B-Diagnostic_procedure
75	B-Lab_value
,	O
WISC	B-Detailed_description
-	I-Detailed_description
R	I-Detailed_description
scale	I-Detailed_description
)	O
.	O

Histological	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
of	O
a	O
muscle	B-Biological_structure
biopsy	B-Diagnostic_procedure
showed	O
hypo	B-Sign_symptom
/	I-Sign_symptom
atrophy	I-Sign_symptom
of	O
fibres	B-Biological_structure
.	O

The	O
clinical	B-Diagnostic_procedure
evolution	I-Diagnostic_procedure
was	O
slowly	B-Lab_value
progressive	I-Lab_value
.	O

At	O
her	O
last	O
follow	O
-	O
up	O
examination	O
,	O
at	O
19	O
years	O
of	O
age	O
,	O
she	O
was	O
able	O
to	O
walk	B-Activity
alone	B-Detailed_description
only	O
with	O
ankle	B-Detailed_description
-	I-Detailed_description
foot	I-Detailed_description
orthotic	B-Therapeutic_procedure
aids	I-Therapeutic_procedure
and	O
had	O
developed	O
a	O
marked	B-Severity
dorsal	B-Biological_structure
-	I-Biological_structure
lumbar	I-Biological_structure
scoliosis	B-Disease_disorder
.	O

Other	O
clinical	B-Diagnostic_procedure
signs	I-Diagnostic_procedure
were	O
stable	B-Lab_value
.	O

Neurophysiological	B-Diagnostic_procedure
studies	I-Diagnostic_procedure
confirmed	O
worsening	B-Lab_value
of	O
her	O
mixed	B-Detailed_description
axonal	B-Biological_structure
demyelinating	B-Disease_disorder
peripheral	I-Disease_disorder
neuropathy	I-Disease_disorder
.	O

Brain	B-Biological_structure
and	O
spinal	B-Biological_structure
cord	I-Biological_structure
MRI	B-Diagnostic_procedure
showed	O
mild	B-Severity
extension	B-Lab_value
of	O
signal	B-Sign_symptom
abnormalities	I-Sign_symptom
and	O
extensive	B-Severity
cavitations	B-Sign_symptom
in	O
the	O
cerebral	B-Biological_structure
white	I-Biological_structure
matter	I-Biological_structure
;	O
the	O
cerebellum	B-Biological_structure
and	O
brainstem	B-Biological_structure
were	O
spared	B-Sign_symptom
but	O
the	O
spinal	B-Biological_structure
cord	I-Biological_structure
was	O
thin	B-Sign_symptom
with	O
no	O
obvious	O
focal	B-Detailed_description
lesions	B-Sign_symptom
(	O
figure	O
1A	O
)	O
.	O

Plasma	B-Diagnostic_procedure
lactate	I-Diagnostic_procedure
was	O
2	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mM	I-Lab_value
(	O
n	O
.	O
v	O
.	O
<	O
2	O
.	O
1	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
36	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
white	O
woman	O
at	O
40	B-Lab_value
week	I-Lab_value
of	O
gestation	O
was	O
admitted	O
to	O
a	O
local	B-Nonbiological_location
obstetric	I-Nonbiological_location
clinic	I-Nonbiological_location
for	O
elective	B-Detailed_description
repeated	B-Detailed_description
cesarean	B-Therapeutic_procedure
delivery	I-Therapeutic_procedure
due	O
to	O
slanting	B-Detailed_description
position	I-Detailed_description
of	O
the	O
fetus	O
.	O

Both	O
her	O
previous	O
and	O
current	O
pregnancy	O
were	O
uncomplicated	O
.	O

Her	O
past	O
medical	O
history	O
was	O
unremarkable	O
and	O
no	O
family	O
history	O
of	O
cardiac	O
disease	O
was	O
reported	O
.	O

The	O
caesarean	B-Therapeutic_procedure
delivery	I-Therapeutic_procedure
was	O
performed	O
following	O
the	O
administration	O
of	O
standard	B-Detailed_description
spinal	B-Biological_structure
anesthesia	B-Medication
.	O

During	O
surgery	O
the	O
patient	O
became	O
hypotensive	B-Sign_symptom
and	O
ephedrine	B-Medication
was	O
injected	O
to	O
maintain	O
her	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
in	O
the	O
normal	B-Lab_value
range	I-Lab_value
.	O

Three	B-Time
hours	I-Time
after	I-Time
delivery	O
of	O
healthy	B-Detailed_description
male	B-Detailed_description
infant	O
,	O
the	O
patient	O
complained	O
of	O
nausea	B-Sign_symptom
,	O
increasing	O
dyspnoea	B-Sign_symptom
and	O
palpitations	B-Sign_symptom
.	O

On	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
tachycardia	B-Sign_symptom
with	O
ventricular	B-Biological_structure
extra	B-Sign_symptom
systoles	I-Sign_symptom
and	O
pulmonary	B-Biological_structure
rales	B-Sign_symptom
were	O
detected	O
.	O

Her	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
80	B-Lab_value
/	I-Lab_value
40	I-Lab_value
mmHg	I-Lab_value
and	O
demanded	O
the	O
administration	O
of	O
inotropic	B-Medication
agents	I-Medication
(	O
initially	O
continuous	O
infusion	O
of	O
norepinephrine	B-Medication
0	B-Dosage
.	I-Dosage
5	I-Dosage
mg	I-Dosage
/	I-Dosage
h	I-Dosage
followed	O
by	O
dobutamine	B-Medication
7	B-Dosage
μg	I-Dosage
/	I-Dosage
kg	I-Dosage
/	I-Dosage
min	I-Dosage
)	O
.	O

Owing	O
to	O
worsening	B-Lab_value
of	O
oxygen	B-Diagnostic_procedure
saturation	I-Diagnostic_procedure
up	B-Lab_value
to	I-Lab_value
70	I-Lab_value
%	I-Lab_value
and	O
gradual	B-Severity
deterioration	B-Sign_symptom
of	I-Sign_symptom
consciousness	I-Sign_symptom
,	O
mechanical	B-Therapeutic_procedure
ventilation	I-Therapeutic_procedure
was	O
applied	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
.	O

Chest	B-Biological_structure
X	B-Diagnostic_procedure
ray	I-Diagnostic_procedure
indicated	O
pulmonary	B-Disease_disorder
congestion	I-Disease_disorder
.	O

Emergency	B-Detailed_description
computer	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
excluded	O
pulmonary	B-Disease_disorder
thromboembolism	I-Disease_disorder
(	O
PE	B-Disease_disorder
)	O
and	O
confirmed	O
severe	B-Severity
pulmonary	B-Disease_disorder
oedema	I-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
patient	O
received	O
loop	B-Medication
diuretic	I-Medication
,	O
furosemide	B-Medication
,	O
at	O
initial	O
daily	B-Dosage
dose	I-Dosage
80	I-Dosage
mg	I-Dosage
,	O
which	O
was	O
progressively	B-Lab_value
reduced	I-Lab_value
.	O

The	O
diuretic	O
was	O
discontinued	O
after	O
12	O
days	O
of	O
treatment	O
.	O

The	O
electrocardiogram	B-Diagnostic_procedure
disclosed	O
sinus	B-Sign_symptom
tachycardia	I-Sign_symptom
with	O
ST	B-Sign_symptom
-	I-Sign_symptom
segment	I-Sign_symptom
elevation	I-Sign_symptom
of	O
1,5	B-Lab_value
mm	I-Lab_value
with	O
negative	B-Sign_symptom
T	I-Sign_symptom
waves	I-Sign_symptom
in	O
aVL	B-Diagnostic_procedure
and	O
ST	B-Sign_symptom
-	I-Sign_symptom
segment	I-Sign_symptom
depression	I-Sign_symptom
of	O
1	B-Lab_value
mm	I-Lab_value
in	O
II	B-Diagnostic_procedure
,	O
III	B-Diagnostic_procedure
,	O
aVF	B-Diagnostic_procedure
,	O
V5	B-Diagnostic_procedure
-	I-Diagnostic_procedure
V6	I-Diagnostic_procedure
(	O
Fig	O
.	O
2	O
)	O
.	O

Laboratory	B-Diagnostic_procedure
tests	I-Diagnostic_procedure
showed	O
elevated	B-Lab_value
troponin	B-Diagnostic_procedure
up	B-Lab_value
to	I-Lab_value
908	I-Lab_value
pg	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
(	O
normal	O
value	O
<	O
14	O
pg	O
/	O
ml	O
)	O
,	O
NT	B-Diagnostic_procedure
-	I-Diagnostic_procedure
pro	I-Diagnostic_procedure
BNP	I-Diagnostic_procedure
6236	B-Lab_value
pg	I-Lab_value
/	I-Lab_value
ml	I-Lab_value
(	O
normal	O
value	O
<	O
125	O
pg	O
/	O
ml	O
)	O
.	O

The	O
bedside	B-Detailed_description
transthoracic	B-Diagnostic_procedure
echocardiography	I-Diagnostic_procedure
(	O
TTE	B-Diagnostic_procedure
)	O
revealed	O
severe	B-Severity
left	B-Biological_structure
ventricular	I-Biological_structure
(	O
LV	B-Biological_structure
)	O
systolic	B-Disease_disorder
dysfunction	I-Disease_disorder
.	O

Therefore	O
the	O
patient	O
was	O
transferred	O
to	O
Intensive	B-Biological_structure
Cardiac	I-Biological_structure
Therapy	I-Biological_structure
Clinic	I-Biological_structure
.	O

Repeated	O
TTE	B-Diagnostic_procedure
showed	O
LV	B-Biological_structure
ejection	B-Diagnostic_procedure
fraction	I-Diagnostic_procedure
30	B-Lab_value
%	I-Lab_value
with	O
hypokinesis	B-Sign_symptom
of	O
the	O
mid	B-Detailed_description
and	I-Detailed_description
basal	I-Detailed_description
segments	I-Detailed_description
of	O
posterior	B-Biological_structure
,	I-Biological_structure
anterior	I-Biological_structure
and	I-Biological_structure
lateral	I-Biological_structure
wall	I-Biological_structure
with	O
preserved	B-Lab_value
contractility	B-Diagnostic_procedure
of	O
the	O
apical	B-Biological_structure
segments	I-Biological_structure
.	O

Urgent	B-Detailed_description
coronary	B-Diagnostic_procedure
angiography	I-Diagnostic_procedure
presented	O
normal	B-Lab_value
coronary	B-Biological_structure
arteries	I-Biological_structure
.	O

The	O
diagnosis	O
of	O
inverted	B-Detailed_description
stress	B-Detailed_description
-	I-Detailed_description
induced	I-Detailed_description
cardiomyopathy	B-Disease_disorder
was	O
set	O
upon	O
the	O
overall	O
clinical	O
data	O
.	O

After	O
3	O
days	O
the	O
patient	O
was	O
weaned	O
from	O
respirator	B-Therapeutic_procedure
and	O
extubated	B-Therapeutic_procedure
.	O

Following	O
hemodynamic	B-Diagnostic_procedure
improvement	B-Lab_value
,	O
inotropic	B-Medication
agents	I-Medication
were	O
tapered	O
gradually	O
.	O

Both	O
TTE	B-Diagnostic_procedure
and	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
Figs	O
.	O
3	O
and	O
4	O
)	O
performed	O
on	O
the	O
fifth	O
day	O
showed	O
complete	B-Lab_value
recovery	I-Lab_value
of	O
myocardial	B-Diagnostic_procedure
function	I-Diagnostic_procedure
.	O

The	O
patient	O
was	O
discharged	O
after	O
15	O
days	O
in	O
good	B-Lab_value
overall	B-Diagnostic_procedure
condition	I-Diagnostic_procedure
.	O

At	O
12	O
-	O
month	O
follow	O
-	O
up	O
she	O
remained	O
asymptomatic	B-Sign_symptom
with	O
no	O
echocardiographic	B-Sign_symptom
abnormalities	I-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
54	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
woman	O
with	O
stage	B-Detailed_description
IV	I-Detailed_description
NSCLC	B-Disease_disorder
was	O
treated	O
with	O
carboplatin	B-Medication
and	O
paclitaxel	B-Medication
without	B-Detailed_description
disease	I-Detailed_description
response	I-Detailed_description
.	O

Molecular	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
of	O
tumor	B-Diagnostic_procedure
tissue	I-Diagnostic_procedure
was	O
unavailable	B-Detailed_description
at	O
that	O
time	O
.	O

However	O
,	O
her	O
demographic	O
profile	O
(	O
Asian	O
,	O
minimal	B-Severity
smoking	O
history	O
,	O
non	B-Detailed_description
-	I-Detailed_description
small	I-Detailed_description
cell	I-Detailed_description
histology	O
)	O
predicted	O
her	O
disease	O
would	O
harbor	O
EGFR	B-Diagnostic_procedure
TKI	I-Diagnostic_procedure
sensitive	I-Diagnostic_procedure
cells	I-Diagnostic_procedure
[	O
2	O
]	O
.	O

Therefore	O
,	O
she	O
then	O
initiated	O
standard	B-Detailed_description
daily	B-Dosage
dosing	I-Dosage
of	O
erlotinib	B-Medication
(	O
150	B-Lab_value
mg	I-Lab_value
)	O
and	O
her	O
disease	O
responded	B-Detailed_description
.	O

Twenty	O
-	O
eight	O
months	O
later	O
,	O
she	O
acquired	O
resistance	B-Other_event
to	O
erlotinib	B-Medication
with	O
progression	B-Detailed_description
of	O
disease	O
systemically	B-Detailed_description
.	O

Following	O
further	O
progression	O
through	O
an	O
experimental	B-Detailed_description
angiogenesis	B-Medication
inhibitor	I-Medication
,	O
she	O
initiated	O
pemetrexed	B-Medication
and	O
resumed	O
standard	O
dose	O
erlotinib	O
.	O

After	O
initial	O
response	O
,	O
11	O
months	O
later	O
,	O
her	O
disease	O
again	O
progressed	B-Detailed_description
.	O

DNA	B-Biological_structure
was	O
extracted	O
from	O
biopsy	B-Diagnostic_procedure
of	O
a	O
progressing	B-Detailed_description
lung	B-Biological_structure
lesion	B-Disease_disorder
and	O
examined	O
using	O
established	O
techniques	O
for	O
analysis	O
of	O
EGFR	B-Diagnostic_procedure
mutations	I-Diagnostic_procedure
[	O
5	O
]	O
.	O

Direct	B-Diagnostic_procedure
sequencing	I-Diagnostic_procedure
of	O
exons	B-Detailed_description
18	I-Detailed_description
-	I-Detailed_description
21	I-Detailed_description
encoding	O
the	O
kinase	B-Detailed_description
domain	I-Detailed_description
of	O
EGFR	B-Diagnostic_procedure
revealed	O
the	O
L858R	B-Diagnostic_procedure
mutation	I-Diagnostic_procedure
associated	O
with	O
EGFR	B-Detailed_description
TKI	I-Detailed_description
sensitivity	I-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
[	O
2	O
]	O
.	O

It	O
also	O
demonstrated	O
the	O
T790M	B-Diagnostic_procedure
mutation	I-Diagnostic_procedure
associated	O
with	O
acquired	B-Detailed_description
EGFR	I-Detailed_description
TKI	I-Detailed_description
resistance	I-Detailed_description
(	O
Fig	O
.	O
1	O
)	O
[	O
2	O
]	O
.	O

She	O
also	O
developed	O
headaches	B-Sign_symptom
and	O
there	O
was	O
a	O
high	O
clinical	O
suspicion	O
of	O
CNS	B-Biological_structure
metastases	B-Disease_disorder
despite	O
negative	B-Lab_value
imaging	B-Diagnostic_procedure
(	O
not	O
shown	O
)	O
.	O

She	O
refused	O
a	O
lumbar	B-Therapeutic_procedure
puncture	I-Therapeutic_procedure
.	O

She	O
initiated	O
empiric	B-Detailed_description
temozolomide	B-Medication
plus	O
standard	B-Detailed_description
dose	I-Detailed_description
erlotinib	B-Medication
(	O
150	B-Dosage
mg	I-Dosage
daily	I-Dosage
)	O
for	O
presumed	O
CNS	B-Disease_disorder
disease	I-Disease_disorder
,	O
but	O
after	B-Time
one	I-Time
cycle	I-Time
her	O
headaches	B-Sign_symptom
worsened	B-Lab_value
,	O
and	O
she	O
developed	O
nausea	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
concerning	O
for	O
CNS	B-Disease_disorder
metastases	I-Disease_disorder
with	O
associated	O
raised	B-Lab_value
intracranial	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
.	O

Magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	B-Diagnostic_procedure
MRI	I-Diagnostic_procedure
)	I-Diagnostic_procedure
of	O
the	O
brain	B-Biological_structure
now	O
demonstrated	O
LM	B-Disease_disorder
(	O
Fig	O
.	O
2	O
)	O
confirmed	O
by	O
CSF	B-Diagnostic_procedure
cytology	I-Diagnostic_procedure
(	O
not	O
shown	O
)	O
.	O

By	O
direct	B-Detailed_description
sequencing	B-Diagnostic_procedure
,	O
DNA	B-Biological_structure
from	O
CSF	B-Diagnostic_procedure
cells	I-Diagnostic_procedure
harbored	O
L858R	B-Diagnostic_procedure
predicting	O
EGFR	B-Diagnostic_procedure
TKI	I-Diagnostic_procedure
sensitivity	I-Diagnostic_procedure
(	O
Fig	O
.	O
3	O
,	O
left	O
panel	O
)	O
but	O
not	O
the	O
T790M	B-Diagnostic_procedure
resistance	I-Diagnostic_procedure
mutation	I-Diagnostic_procedure
(	O
data	O
not	O
shown	O
)	O
.	O

Because	O
the	O
result	O
for	O
T790M	B-Diagnostic_procedure
was	O
negative	B-Lab_value
in	O
this	O
sample	O
,	O
we	O
performed	O
a	O
more	B-Lab_value
sensitive	I-Lab_value
fluorescence	B-Detailed_description
detection	I-Detailed_description
PCR	B-Detailed_description
-	I-Detailed_description
based	I-Detailed_description
assay	B-Diagnostic_procedure
that	O
takes	O
advantage	O
of	O
a	O
PCR	B-Diagnostic_procedure
restriction	I-Diagnostic_procedure
fragment	I-Diagnostic_procedure
length	I-Diagnostic_procedure
polymorphism	I-Diagnostic_procedure
generated	O
by	O
the	O
specific	O
missense	O
mutation	O
(	O
Fig	O
.	O
3	O
,	O
right	O
panel	O
,	O
arrow	O
,	O
positive	O
control	O
)	O
[	O
6	O
]	O
.	O

That	O
result	O
was	O
also	O
negative	B-Lab_value
,	O
as	O
only	O
the	O
wild	B-Diagnostic_procedure
type	I-Diagnostic_procedure
peak	I-Diagnostic_procedure
was	O
detected	O
(	O
Fig	O
.	O
3	O
,	O
right	O
panel	O
,	O
bottom	O
)	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
the	O
LM	O
remained	O
sensitive	O
to	O
an	O
EGFR	O
TKI	O
if	O
sufficiently	O
high	O
concentrations	O
of	O
drug	O
could	O
be	O
achieved	O
in	O
the	O
CSF	O
.	O

The	O
erlotinib	O
concentration	O
required	O
to	O
inhibit	O
growth	O
of	O
cell	O
lines	O
harboring	O
L858R	O
by	O
50	O
%	O
(	O
IC50	O
)	O
is	O
100	O
nM	O
(	O
nM	O
)	O
[	O
2	O
]	O
.	O

Standard	O
dose	O
erlotinib	O
(	O
150	O
mg	O
daily	O
)	O
achieves	O
3000	O
nM	O
in	O
plasma	O
[	O
7	O
]	O
,	O
but	O
CSF	O
concentrations	O
of	O
EGFR	O
TKIs	O
are	O
as	O
low	O
as	O
1	O
%	O
plasma	O
levels	O
below	O
the	O
IC50	O
[	O
3	O
,	O
8	O
]	O
.	O

Increasing	O
the	O
daily	O
dose	O
of	O
gefitinib	O
to	O
enhance	O
CSF	O
penetration	O
has	O
been	O
an	O
effective	O
strategy	O
[	O
3	O
]	O
,	O
but	O
gefitinib	O
is	O
no	O
longer	O
available	O
in	O
the	O
United	O
States	O
following	O
failure	O
in	O
phase	O
III	O
NSCLC	O
trials	O
.	O

An	O
analogous	O
increase	O
of	O
the	O
daily	O
erlotinib	O
dose	O
above	O
150	O
-	O
200	O
mg	O
daily	O
induces	O
unacceptable	O
toxicity	O
.	O

However	O
,	O
weekly	O
high	O
-	O
dose	O
erlotinib	O
up	O
to	O
2000	O
mg	O
is	O
tolerable	O
[	O
4	O
]	O
.	O

Pharmacokinetic	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
of	O
CSF	B-Biological_structure
from	O
another	O
patient	O
with	O
NSCLC	B-Disease_disorder
LM	B-Disease_disorder
(	O
not	O
shown	O
)	O
treated	O
with	O
1500	B-Dosage
mg	I-Dosage
erlotinib	B-Medication
weekly	I-Dosage
demonstrated	O
a	O
peak	B-Diagnostic_procedure
plasma	I-Diagnostic_procedure
concentration	I-Diagnostic_procedure
of	O
11,300	B-Lab_value
nM	I-Lab_value
with	O
a	O
concurrent	O
CSF	B-Diagnostic_procedure
concentration	I-Diagnostic_procedure
of	O
130	B-Lab_value
nM	I-Lab_value
.	O

Therefore	O
,	O
such	O
high	O
dose	O
weekly	O
administration	O
of	O
erlotinib	O
achieved	O
a	O
CSF	O
concentration	O
exceeding	B-Detailed_description
the	I-Detailed_description
IC50	I-Detailed_description
.	O

Therefore	O
,	O
to	O
increase	O
CSF	O
penetrance	O
over	O
standard	O
daily	O
erlotinib	O
dosing	O
in	O
this	O
patient	O
,	O
we	O
initiated	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
weekly	I-Dosage
erlotinib	B-Medication
at	O
1000	B-Lab_value
mg	I-Lab_value
then	O
1200	B-Lab_value
mg	I-Lab_value
;	O
persistent	B-Detailed_description
nausea	B-Sign_symptom
precluded	O
higher	O
doses	O
.	O

Pharmacokinetic	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
was	O
not	O
undertaken	O
in	O
this	O
patient	O
.	O

After	O
1	O
month	O
there	O
was	O
a	O
partial	B-Diagnostic_procedure
radiographic	I-Diagnostic_procedure
response	I-Diagnostic_procedure
of	O
LM	B-Disease_disorder
on	O
brain	B-Biological_structure
MRI	B-Diagnostic_procedure
(	O
Fig	O
.	O
2b	O
)	O
and	O
after	O
2	O
months	O
in	O
the	O
cauda	B-Biological_structure
equina	I-Biological_structure
(	O
not	O
shown	O
)	O
.	O

However	O
,	O
hydrocephalus	B-Disease_disorder
and	O
persistent	B-Detailed_description
symptoms	B-Sign_symptom
referable	O
to	O
increased	B-Lab_value
intracranial	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
led	O
to	O
a	O
VP	B-Therapeutic_procedure
shunt	I-Therapeutic_procedure
and	O
whole	B-Biological_structure
-	I-Biological_structure
brain	I-Biological_structure
radiation	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
,	O
after	O
which	O
she	O
resumed	O
treatment	O
with	O
1500	B-Dosage
mg	I-Dosage
weekly	I-Dosage
erlotinib	B-Medication
.	O

One	O
month	O
later	O
,	O
progressive	B-Detailed_description
intra	B-Disease_disorder
-	I-Disease_disorder
thoracic	I-Disease_disorder
disease	I-Disease_disorder
led	O
to	O
initiation	O
of	O
cetixumab	B-Medication
and	O
erlotinib	B-Medication
was	O
continued	O
but	O
changed	O
to	O
low	B-Dosage
dose	I-Dosage
(	I-Dosage
100	B-Lab_value
mg	I-Lab_value
)	I-Dosage
daily	I-Dosage
.	O

She	O
survived	B-Sign_symptom
14	O
months	O
following	O
the	O
diagnosis	O
of	O
CNS	B-Disease_disorder
disease	I-Disease_disorder
.	O

-DOCSTART- -X- -X- -X- O

A	O
65	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
was	O
referred	O
to	O
our	O
hospital	B-Nonbiological_location
for	O
evaluation	O
of	O
stuttering	B-Detailed_description
chest	B-Biological_structure
pain	B-Sign_symptom
for	O
10	B-Duration
days	I-Duration
,	O
and	O
he	O
was	O
a	O
common	B-Occupation
worker	I-Occupation
.	O

There	O
was	O
no	B-Lab_value
positive	I-Lab_value
finding	I-Lab_value
from	O
the	O
relevant	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
.	O

He	O
has	O
no	O
medical	O
,	O
family	O
,	O
and	O
psychosocial	O
history	O
including	O
co	O
-	O
morbidities	O
,	O
and	O
relevant	O
genetic	O
information	O
.	O

His	O
electrocardiogram	B-Diagnostic_procedure
showed	O
T	B-Sign_symptom
-	I-Sign_symptom
wave	I-Sign_symptom
inversion	I-Sign_symptom
over	O
leads	B-Detailed_description
V1	I-Detailed_description
to	I-Detailed_description
V4	I-Detailed_description
(	O
Figure	O
1	O
)	O
.	O

Coronary	B-Diagnostic_procedure
angiography	I-Diagnostic_procedure
showed	O
90	B-Lab_value
%	I-Lab_value
stenosis	B-Sign_symptom
in	O
the	O
mid	B-Biological_structure
-	I-Biological_structure
left	I-Biological_structure
anterior	I-Biological_structure
descending	I-Biological_structure
coronary	I-Biological_structure
artery	I-Biological_structure
(	O
LAD	B-Biological_structure
)	O
,	O
which	O
was	O
stented	B-Therapeutic_procedure
(	O
Figure	O
2	O
)	O
.	O

T	B-Detailed_description
-	I-Detailed_description
wave	I-Detailed_description
still	O
inversion	B-Sign_symptom
over	O
leads	B-Detailed_description
V1	I-Detailed_description
to	I-Detailed_description
V4	I-Detailed_description
after	O
the	O
percutaneous	B-Therapeutic_procedure
coronary	I-Therapeutic_procedure
intervention	I-Therapeutic_procedure
(	O
PCI	B-Therapeutic_procedure
)	O
(	O
Figure	O
3	O
)	O
.	O

The	O
patient	O
discharged	O
after	O
the	O
PCI	O
in	O
5	O
days	O
and	O
recharged	O
in	O
the	O
hospital	B-Nonbiological_location
because	O
of	O
a	O
palpation	B-Sign_symptom
.	O

His	O
electrocardiogram	B-Diagnostic_procedure
demonstrated	O
ventricular	B-Disease_disorder
tachycardia	I-Disease_disorder
(	O
Figure	O
4	O
)	O
,	O
and	O
severe	B-Severity
hypertension	B-Sign_symptom
,	O
remarkable	O
blood	B-Sign_symptom
pressure	I-Sign_symptom
fluctuation	I-Sign_symptom
between	B-Lab_value
224	I-Lab_value
/	I-Lab_value
76	I-Lab_value
and	I-Lab_value
70	I-Lab_value
/	I-Lab_value
50	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

Although	O
several	O
antihypertensive	B-Medication
drugs	I-Medication
were	O
used	O
,	O
ventricular	B-Disease_disorder
tachycardia	I-Disease_disorder
still	O
occurred	O
on	O
him	O
for	O
2	B-Detailed_description
times	I-Detailed_description
,	O
each	O
was	O
preceded	O
by	O
a	O
period	O
of	O
blood	B-Sign_symptom
pressure	I-Sign_symptom
fluctuation	I-Sign_symptom
and	O
burst	O
out	O
concomitantly	O
at	O
the	O
peak	O
of	O
a	O
hypertension	B-Disease_disorder
crisis	I-Disease_disorder
.	O

The	O
patient	O
felt	O
abdominal	B-Biological_structure
pain	B-Sign_symptom
and	O
his	O
abdominal	B-Biological_structure
ultrasound	B-Diagnostic_procedure
showed	O
suspicious	O
right	B-Biological_structure
adrenal	I-Biological_structure
gland	I-Biological_structure
tumor	B-Sign_symptom
.	O

Enhanced	B-Detailed_description
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
of	O
adrenal	B-Biological_structure
gland	I-Biological_structure
conformed	O
that	O
there	O
was	O
a	O
tumor	B-Sign_symptom
in	O
right	B-Biological_structure
adrenal	I-Biological_structure
gland	I-Biological_structure
accompanied	O
by	O
an	O
upset	B-Lab_value
level	O
of	O
aldosterone	B-Diagnostic_procedure
(	O
Figure	O
5	O
)	O
.	O

The	O
tumor	B-Sign_symptom
was	O
removed	B-Therapeutic_procedure
by	O
laparoscope	B-Therapeutic_procedure
,	O
and	O
pathological	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
showed	O
pheochromocytoma	B-Disease_disorder
(	O
Figure	O
6	O
)	O
.	O

After	O
the	O
surgery	O
,	O
the	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
turned	O
normal	B-Lab_value
gradually	O
.	O

There	O
was	O
no	O
T	B-Sign_symptom
-	I-Sign_symptom
wave	I-Sign_symptom
inversion	I-Sign_symptom
in	O
lead	B-Detailed_description
V1	I-Detailed_description
-	I-Detailed_description
V4	I-Detailed_description
(	O
Figure	O
7	O
)	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
37	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
African	O
American	O
female	O
with	O
a	O
past	O
medical	O
history	O
significant	O
for	O
stage	B-Lab_value
1	I-Lab_value
sarcoidosis	B-Disease_disorder
presented	O
to	O
our	O
facility	B-Nonbiological_location
with	O
a	O
chief	O
complaint	O
of	O
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
.	O

Ten	O
years	O
prior	O
,	O
she	O
presented	O
with	O
bilateral	B-Detailed_description
uveitis	B-Disease_disorder
and	O
lupus	B-Sign_symptom
pernio	I-Sign_symptom
(	O
LP	B-Sign_symptom
)	O
on	O
her	O
right	B-Biological_structure
ear	I-Biological_structure
and	O
was	O
subsequently	O
diagnosed	O
with	O
sarcoidosis	B-Disease_disorder
.	O

She	O
was	O
successfully	B-Lab_value
treated	B-Therapeutic_procedure
for	O
these	O
conditions	O
and	O
her	O
sarcoidosis	B-Disease_disorder
remained	O
quiescent	B-Lab_value
until	O
three	O
years	O
ago	O
,	O
when	O
,	O
at	O
an	O
outside	B-Nonbiological_location
institution	I-Nonbiological_location
,	O
she	O
was	O
discovered	O
to	O
have	O
laryngeal	B-Biological_structure
involvement	B-Sign_symptom
.	O

She	O
was	O
treated	B-Therapeutic_procedure
with	O
prednisone	B-Medication
60	B-Dosage
mg	I-Dosage
daily	I-Dosage
for	O
several	B-Duration
months	I-Duration
and	O
eventually	O
tapered	O
to	O
10	B-Dosage
mg	I-Dosage
daily	I-Dosage
.	O

Her	O
sarcoidosis	B-Disease_disorder
remained	O
well	B-Lab_value
-	I-Lab_value
controlled	I-Lab_value
on	O
this	O
maintenance	B-Dosage
dose	I-Dosage
of	O
prednisone	B-Medication
until	O
six	O
months	O
prior	O
,	O
at	O
which	O
time	O
she	O
self	B-Lab_value
-	I-Lab_value
discontinued	I-Lab_value
her	O
prednisone	B-Medication
in	O
favor	O
of	O
the	O
homeopathic	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
Nopalea	B-Medication
cactus	I-Medication
juice	I-Medication
,	O
which	O
unsubstantially	O
claimed	O
to	O
have	O
anti	O
-	O
inflammatory	O
properties	O
[	O
4	O
]	O
.	O

Subsequently	O
,	O
she	O
developed	O
dyspnea	B-Sign_symptom
on	B-Detailed_description
exertion	I-Detailed_description
progressing	O
to	O
dyspnea	B-Sign_symptom
at	B-Detailed_description
rest	I-Detailed_description
.	O

During	O
this	O
time	O
her	O
voice	B-Activity
became	O
increasingly	O
hoarse	B-Sign_symptom
and	O
she	O
experienced	O
frequent	B-Frequency
episodes	O
of	O
difficulty	B-Sign_symptom
swallowing	I-Sign_symptom
.	O

In	O
our	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
,	O
her	O
physical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
was	O
concerning	O
for	O
respiratory	B-Sign_symptom
distress	I-Sign_symptom
as	O
she	O
presented	O
with	O
inspiratory	B-Sign_symptom
stridor	I-Sign_symptom
and	O
hoarseness	B-Sign_symptom
.	O

She	O
also	O
had	O
chronic	B-Lab_value
-	I-Lab_value
appearing	I-Lab_value
,	O
indurated	B-Lab_value
lesions	B-Sign_symptom
on	O
her	O
right	B-Biological_structure
ear	I-Biological_structure
.	O

Given	O
that	O
she	O
had	O
signs	O
of	O
upper	B-Disease_disorder
airway	I-Disease_disorder
disease	I-Disease_disorder
for	O
impending	B-Lab_value
respiratory	B-Disease_disorder
failure	I-Disease_disorder
,	O
an	O
emergent	B-Detailed_description
bedside	B-Detailed_description
laryngoscopy	B-Diagnostic_procedure
was	O
performed	O
,	O
revealing	O
an	O
obstructed	B-Disease_disorder
airway	B-Biological_structure
with	O
the	O
epiglottis	B-Biological_structure
retroflexed	B-Sign_symptom
over	O
the	O
glottis	B-Biological_structure
and	O
significant	B-Lab_value
edema	B-Sign_symptom
in	O
the	O
arytenoids	B-Biological_structure
and	O
aryepiglottic	B-Biological_structure
folds	I-Biological_structure
.	O

She	O
was	O
immediately	O
treated	O
with	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
intravenous	O
dexamethasone	B-Medication
and	O
taken	O
emergently	O
to	O
the	O
operating	B-Nonbiological_location
room	I-Nonbiological_location
(	O
OR	B-Nonbiological_location
)	O
to	O
secure	B-Therapeutic_procedure
her	O
airway	B-Biological_structure
for	O
concern	O
for	O
complete	B-Lab_value
upper	B-Biological_structure
airway	I-Biological_structure
obstruction	B-Disease_disorder
,	O
which	O
was	O
confirmed	O
with	O
direct	B-Diagnostic_procedure
visualization	I-Diagnostic_procedure
of	O
her	O
larynx	B-Biological_structure
in	O
the	O
OR	B-Nonbiological_location
.	O

She	O
was	O
intubated	B-Therapeutic_procedure
for	O
a	O
surgical	B-Therapeutic_procedure
airway	I-Therapeutic_procedure
,	O
and	O
after	O
taking	O
biopsies	B-Diagnostic_procedure
from	O
the	O
lingual	B-Biological_structure
surface	I-Biological_structure
of	O
her	O
epiglottis	B-Biological_structure
,	O
a	O
#	B-Detailed_description
4	I-Detailed_description
cuffed	I-Detailed_description
Shiley	B-Detailed_description
™	O
tracheostomy	B-Therapeutic_procedure
was	O
placed	O
.	O

Her	O
respiratory	B-Diagnostic_procedure
status	I-Diagnostic_procedure
immediately	O
stabilized	B-Lab_value
,	O
was	O
extubated	B-Therapeutic_procedure
,	O
and	O
transferred	O
to	O
our	O
medical	B-Nonbiological_location
intensive	I-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
.	O

Her	O
tracheostomy	B-Therapeutic_procedure
was	O
exchanged	O
to	O
a	O
#	B-Detailed_description
4	I-Detailed_description
cuffless	I-Detailed_description
Shiley	B-Detailed_description
on	O
postoperative	O
day	O
5	O
.	O

During	O
this	O
time	O
she	O
was	O
transitioned	O
from	O
intravenous	O
dexamethasone	B-Medication
to	O
prednisone	B-Medication
60	B-Dosage
mg	I-Dosage
daily	I-Dosage
.	O

Biopsies	B-Diagnostic_procedure
ultimately	O
revealed	O
non	B-Detailed_description
-	I-Detailed_description
necrotizing	I-Detailed_description
epithelioid	B-Detailed_description
granulomas	B-Sign_symptom
consistent	O
with	O
sarcoidosis	B-Disease_disorder
(	O
Figure	O
1	O
)	O
.	O

She	O
was	O
prescribed	O
this	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
prednisone	B-Medication
for	O
three	B-Duration
months	I-Duration
,	O
and	O
after	O
receiving	O
education	O
for	O
self	B-Therapeutic_procedure
-	I-Therapeutic_procedure
tracheostomy	I-Therapeutic_procedure
care	I-Therapeutic_procedure
,	O
she	O
was	O
discharged	O
home	B-Nonbiological_location
.	O

At	O
her	O
subsequent	O
one	O
-	O
month	O
and	O
three	O
-	O
month	O
follow	O
-	O
up	O
visits	O
,	O
she	O
denied	O
any	O
further	O
respiratory	B-Sign_symptom
issues	I-Sign_symptom
.	O

Repeat	O
laryngoscopies	B-Diagnostic_procedure
showed	O
significant	O
improvement	B-Lab_value
in	O
the	O
edema	B-Sign_symptom
in	O
the	O
arytenoids	B-Biological_structure
and	O
aryepiglottic	B-Biological_structure
folds	I-Biological_structure
,	O
but	O
the	O
epiglottis	B-Biological_structure
continued	O
to	O
obscure	B-Disease_disorder
the	O
glottis	B-Biological_structure
despite	O
therapy	O
with	O
high	B-Dosage
-	I-Dosage
dose	I-Dosage
prednisone	B-Medication
.	O

Methotrexate	B-Medication
was	O
initiated	O
while	O
prednisone	B-Medication
was	O
tapered	O
to	O
10	B-Dosage
mg	I-Dosage
daily	I-Dosage
;	O
however	O
,	O
this	O
regimen	O
failed	O
and	O
her	O
prednisone	B-Medication
dosage	O
was	O
increased	O
to	O
20	B-Dosage
mg	I-Dosage
daily	I-Dosage
to	O
reduce	O
edema	O
.	O

Because	O
she	O
declined	O
surgical	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
,	O
she	O
will	O
continue	O
with	O
medical	B-Therapeutic_procedure
management	I-Therapeutic_procedure
with	O
immunosuppressive	B-Therapeutic_procedure
therapy	I-Therapeutic_procedure
to	O
facilitate	O
eventual	O
de	O
-	O
cannulation	O
.	O

-DOCSTART- -X- -X- -X- O

A	O
7	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
boy	O
with	O
Goldenhar	O
syndrome	O
with	O
post	O
-	O
natal	O
genetic	O
diagnosis	O
was	O
referred	O
to	O
our	O
Department	B-Nonbiological_location
of	I-Nonbiological_location
Radiology	I-Nonbiological_location
for	O
imaging	B-Diagnostic_procedure
study	I-Diagnostic_procedure
of	O
the	O
temporal	B-Biological_structure
bone	I-Biological_structure
.	O

The	O
patient	O
underwent	O
a	O
3D	B-Diagnostic_procedure
-	I-Diagnostic_procedure
CT	I-Diagnostic_procedure
scan	I-Diagnostic_procedure
.	O

Brilliance	B-Diagnostic_procedure
CT	I-Diagnostic_procedure
-	I-Diagnostic_procedure
64	I-Diagnostic_procedure
-	I-Diagnostic_procedure
channel	I-Diagnostic_procedure
(	O
Philips	B-Nonbiological_location
Medical	I-Nonbiological_location
Systems	I-Nonbiological_location
,	I-Nonbiological_location
Amsterdam	I-Nonbiological_location
,	I-Nonbiological_location
The	I-Nonbiological_location
Netherlands	I-Nonbiological_location
)	O
was	O
employed	O
.	O

The	O
protocol	O
generated	O
120	B-Lab_value
kV	I-Lab_value
and	O
a	O
current	O
of	O
150	B-Lab_value
mA	I-Lab_value
.	O

Slice	B-Diagnostic_procedure
thickness	I-Diagnostic_procedure
of	O
the	O
images	O
was	O
1	B-Distance
-	I-Distance
mm	I-Distance
with	O
a	O
0	B-Distance
.	I-Distance
5	I-Distance
-	I-Distance
mm	I-Distance
increment	B-Diagnostic_procedure
.	O

Images	B-Diagnostic_procedure
in	O
DICOM	B-Detailed_description
format	I-Detailed_description
were	O
processed	B-Detailed_description
on	I-Detailed_description
a	I-Detailed_description
PC	I-Detailed_description
using	I-Detailed_description
commercial	I-Detailed_description
software	I-Detailed_description
,	O
obtaining	O
a	O
three	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
reconstruction	I-Diagnostic_procedure
of	O
skeletal	B-Biological_structure
structures	I-Biological_structure
.	O

The	O
3	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
reconstruction	I-Diagnostic_procedure
of	O
the	O
skin	B-Biological_structure
plans	I-Biological_structure
showed	O
hypoplasia	B-Disease_disorder
of	O
the	O
auricle	B-Biological_structure
that	O
on	O
the	O
right	B-Detailed_description
side	I-Detailed_description
consisted	O
of	O
a	O
simple	B-Detailed_description
dysmorphic	B-Sign_symptom
rough	I-Sign_symptom
.	O

The	O
left	B-Biological_structure
auricle	I-Biological_structure
had	O
regular	B-Lab_value
dimensions	B-Diagnostic_procedure
and	O
morphology	B-Diagnostic_procedure
.	O

Atresia	B-Disease_disorder
of	O
the	O
right	B-Biological_structure
auditory	I-Biological_structure
conduit	I-Biological_structure
and	O
a	O
normal	B-Lab_value
left	B-Biological_structure
auditory	I-Biological_structure
conduit	I-Biological_structure
were	O
observed	B-Diagnostic_procedure
.	O

The	O
upper	B-Detailed_description
images	B-Diagnostic_procedure
showed	O
partial	B-Severity
ossification	B-Other_event
of	O
the	O
cranium	B-Biological_structure
typical	B-Detailed_description
in	I-Detailed_description
paediatric	I-Detailed_description
age	I-Detailed_description
.	O

Description	O
of	O
the	O
profile	O
:	O
typical	B-Detailed_description
II	I-Detailed_description
class	I-Detailed_description
very	B-Severity
convex	B-Diagnostic_procedure
profile	I-Diagnostic_procedure
with	O
interposition	B-Detailed_description
of	O
the	O
inferior	B-Biological_structure
lip	I-Biological_structure
and	O
a	O
reduced	B-Lab_value
neck	B-Biological_structure
-	I-Biological_structure
chin	I-Biological_structure
angle	I-Biological_structure
.	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Skeletal	B-Diagnostic_procedure
studies	I-Diagnostic_procedure
show	O
that	O
the	O
mandibular	B-Biological_structure
condyle	I-Biological_structure
,	I-Biological_structure
ramus	I-Biological_structure
and	I-Biological_structure
corpus	I-Biological_structure
were	O
shorter	B-Detailed_description
on	I-Detailed_description
the	I-Detailed_description
affected	I-Detailed_description
side	I-Detailed_description
.	O

Tilting	B-Detailed_description
of	O
oral	B-Biological_structure
rhyme	I-Biological_structure
,	O
occlusal	B-Biological_structure
plane	I-Biological_structure
and	O
mandibular	B-Biological_structure
plane	I-Biological_structure
were	O
evident	O
.	O

Number	B-Disease_disorder
or	I-Disease_disorder
form	B-Disease_disorder
abnormalities	I-Disease_disorder
were	O
not	O
found	O
during	O
mixed	B-Diagnostic_procedure
dentition	I-Diagnostic_procedure
.	O

Mandibular	B-Biological_structure
condyles	I-Biological_structure
and	O
temporo	B-Biological_structure
-	I-Biological_structure
mandibular	I-Biological_structure
joints	I-Biological_structure
seemed	O
to	O
be	O
asymmetric	B-Detailed_description
,	O
and	O
in	O
particular	O
the	O
right	B-Biological_structure
condyle	I-Biological_structure
was	O
deformed	B-Biological_attribute
,	O
shorter	B-Lab_value
and	I-Lab_value
wider	B-Lab_value
than	I-Lab_value
the	I-Lab_value
other	I-Lab_value
side	I-Lab_value
(	O
mandibular	B-Biological_structure
condyle	I-Biological_structure
dimensions	B-Diagnostic_procedure
were	O
11	B-Area
×	I-Area
7	I-Area
mm	I-Area
right	B-Detailed_description
and	O
14	B-Area
×	I-Area
7	I-Area
mm	I-Area
left	B-Detailed_description
)	O
.	O

The	O
3	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
reconstruction	I-Diagnostic_procedure
of	O
the	O
skeleton	B-Biological_structure
planes	I-Biological_structure
showed	O
the	O
different	O
morphology	B-Diagnostic_procedure
of	O
the	O
right	B-Biological_structure
and	I-Biological_structure
left	B-Biological_structure
hemimandibula	I-Biological_structure
.	O

Mandibular	B-Biological_structure
3	B-Diagnostic_procedure
-	I-Diagnostic_procedure
dimensional	I-Diagnostic_procedure
reconstruction	I-Diagnostic_procedure
showed	O
in	O
detail	O
the	O
shift	B-Detailed_description
of	O
the	O
medial	B-Biological_structure
axis	I-Biological_structure
to	O
the	O
hypoplastic	B-Disease_disorder
right	B-Detailed_description
side	I-Detailed_description
and	O
the	O
asymmetry	B-Detailed_description
of	O
the	O
right	B-Biological_structure
mandibular	I-Biological_structure
condyles	I-Biological_structure
that	O
appears	O
dysmorphic	B-Detailed_description
short	B-Lab_value
and	O
wide	B-Lab_value
in	O
axial	B-Detailed_description
and	O
coronal	B-Detailed_description
scansions	B-Diagnostic_procedure
(	O
Figs	O
.	O
2	O
,	O
3	O
)	O
.	O

The	O
study	O
of	O
the	O
temporal	B-Biological_structure
bone	I-Biological_structure
showed	O
on	O
the	O
right	B-Detailed_description
side	I-Detailed_description
an	O
external	B-Biological_structure
auditory	I-Biological_structure
canal	I-Biological_structure
atresia	B-Disease_disorder
,	O
hypoplasia	B-Disease_disorder
of	O
tympanic	B-Biological_structure
cavity	I-Biological_structure
that	O
was	O
not	O
pneumatized	B-Disease_disorder
and	O
occupied	B-Detailed_description
by	I-Detailed_description
dense	I-Detailed_description
materials	I-Detailed_description
from	I-Detailed_description
soft	I-Detailed_description
parts	I-Detailed_description
.	O

No	O
pneumatization	B-Disease_disorder
was	O
present	O
in	O
right	B-Biological_structure
mastoid	I-Biological_structure
cells	I-Biological_structure
.	O

Left	B-Biological_structure
external	I-Biological_structure
auditory	I-Biological_structure
canal	I-Biological_structure
dimensions	B-Diagnostic_procedure
and	O
morphology	B-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

The	O
left	B-Biological_structure
tympanic	I-Biological_structure
cavity	I-Biological_structure
was	O
normally	B-Detailed_description
formed	I-Detailed_description
and	O
totally	B-Detailed_description
occupied	I-Detailed_description
by	I-Detailed_description
dense	I-Detailed_description
materials	I-Detailed_description
from	I-Detailed_description
soft	I-Detailed_description
tissues	I-Detailed_description
.	O

Both	O
right	B-Biological_structure
and	I-Biological_structure
left	B-Biological_structure
ears	I-Biological_structure
presented	O
minor	B-Severity
hypoplasia	B-Disease_disorder
of	O
auricle	B-Biological_structure
bones	I-Biological_structure
in	O
the	O
right	B-Detailed_description
side	I-Detailed_description
.	O

In	O
agreement	O
with	O
the	O
resolution	O
of	O
our	O
instrument	O
,	O
normal	B-Detailed_description
representation	I-Detailed_description
of	O
the	O
malleus	B-Biological_structure
head	I-Biological_structure
that	O
seemed	O
articulated	O
with	O
a	O
dysmorphic	B-Sign_symptom
rough	I-Sign_symptom
of	O
a	O
deformed	B-Detailed_description
incus	B-Biological_structure
was	O
observed	O
;	O
it	O
was	O
impossible	B-Detailed_description
to	I-Detailed_description
see	I-Detailed_description
the	O
staples	B-Biological_structure
.	O

The	O
left	B-Biological_structure
malleus	I-Biological_structure
and	O
incus	B-Biological_structure
were	O
visible	B-Detailed_description
and	O
appeared	O
to	O
be	O
articulated	B-Detailed_description
in	I-Detailed_description
an	I-Detailed_description
abnormal	I-Detailed_description
manner	I-Detailed_description
(	O
reduce	B-Detailed_description
contact	I-Detailed_description
surface	I-Detailed_description
)	O
;	O
the	O
staples	B-Biological_structure
was	O
difficult	B-Detailed_description
to	I-Detailed_description
observe	I-Detailed_description
but	O
seemed	O
to	O
have	O
regular	B-Detailed_description
morphology	B-Diagnostic_procedure
.	O

Dimensions	B-Diagnostic_procedure
and	O
morphology	B-Diagnostic_procedure
of	O
cochlea	B-Biological_structure
semicircular	I-Biological_structure
canals	I-Biological_structure
,	I-Biological_structure
vestibulum	I-Biological_structure
and	I-Biological_structure
utriculum	I-Biological_structure
were	O
unaltered	B-Detailed_description
(	O
Figs	O
.	O
4	O
-	O
7	O
)	O
.	O

In	O
conclusion	O
,	O
through	O
3D	B-Diagnostic_procedure
-	I-Diagnostic_procedure
CT	I-Diagnostic_procedure
valuation	I-Diagnostic_procedure
of	O
this	O
young	O
patient	O
we	O
observed	O
asymmetry	B-Detailed_description
of	O
the	O
condyles	B-Biological_structure
;	O
in	O
particular	O
,	O
the	O
right	B-Biological_structure
condyle	I-Biological_structure
was	O
dysmorphic	B-Detailed_description
,	O
short	B-Lab_value
and	O
wide	B-Lab_value
;	O
the	O
auricle	B-Biological_structure
of	O
the	O
right	B-Biological_structure
external	I-Biological_structure
ear	I-Biological_structure
was	O
hypoplastic	B-Disease_disorder
,	O
only	O
a	O
dysmorphic	B-Sign_symptom
rough	I-Sign_symptom
was	O
present	O
;	O
the	O
right	B-Biological_structure
middle	I-Biological_structure
ear	I-Biological_structure
had	O
a	O
hypoplastic	B-Disease_disorder
tympanic	B-Biological_structure
cavity	I-Biological_structure
;	O
the	O
right	B-Biological_structure
internal	I-Biological_structure
ear	I-Biological_structure
has	O
an	O
atresic	B-Disease_disorder
auditory	B-Biological_structure
conduit	I-Biological_structure
.	O

-DOCSTART- -X- -X- -X- O

A	O
48	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
man	O
presented	O
at	O
our	O
hospital	B-Nonbiological_location
complaining	O
of	O
intracranial	B-Biological_structure
bruits	B-Sign_symptom
.	O

The	O
cranial	B-Diagnostic_procedure
nerve	I-Diagnostic_procedure
and	O
laboratory	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

A	O
DVAF	B-Disease_disorder
was	O
considered	O
,	O
conventional	B-Diagnostic_procedure
digital	I-Diagnostic_procedure
subtraction	I-Diagnostic_procedure
angiography	I-Diagnostic_procedure
was	O
performed	O
,	O
which	O
showed	O
a	O
Cognard	B-Disease_disorder
II	I-Disease_disorder
DVAF	I-Disease_disorder
in	O
the	O
location	O
of	O
right	B-Biological_structure
hypoglossal	I-Biological_structure
canal	I-Biological_structure
(	O
HC	B-Biological_structure
)	O
.	O

The	O
DVAF	O
was	O
fed	O
by	O
the	O
meningeal	B-Biological_structure
branches	I-Biological_structure
of	O
the	O
bilateral	B-Biological_structure
ascending	I-Biological_structure
pharyngeal	I-Biological_structure
arteries	I-Biological_structure
,	O
and	O
the	O
right	B-Biological_structure
anterior	I-Biological_structure
condylar	I-Biological_structure
veins	I-Biological_structure
within	O
the	O
hypoglossal	B-Biological_structure
canal	I-Biological_structure
that	O
was	O
the	O
fistulous	B-Sign_symptom
point	I-Sign_symptom
mainly	O
drained	B-Detailed_description
into	I-Detailed_description
the	I-Detailed_description
jugular	I-Detailed_description
vein	I-Detailed_description
.	O

Endovascular	B-Therapeutic_procedure
treatment	I-Therapeutic_procedure
was	O
insisted	O
upon	O
by	O
the	O
patient	O
because	O
of	O
the	O
associated	O
intolerable	B-Detailed_description
intracranial	B-Biological_structure
bruit	O
.	O

Treatment	O
was	O
performed	O
by	O
transarterial	B-Therapeutic_procedure
approach	I-Therapeutic_procedure
under	O
general	B-Medication
anesthesia	I-Medication
using	O
a	O
biplane	B-Therapeutic_procedure
angiographic	I-Therapeutic_procedure
unit	I-Therapeutic_procedure
.	O

Standard	B-Therapeutic_procedure
coaxial	I-Therapeutic_procedure
techniques	I-Therapeutic_procedure
were	O
used	O
.	O

The	O
guide	B-Therapeutic_procedure
catheter	I-Therapeutic_procedure
was	I-Therapeutic_procedure
navigated	I-Therapeutic_procedure
into	O
the	O
left	B-Biological_structure
ascendingtrawt	I-Biological_structure
pharyngeal	I-Biological_structure
artery	I-Biological_structure
.	O

Marathon	B-Therapeutic_procedure
flow	I-Therapeutic_procedure
directed	I-Therapeutic_procedure
catheter	I-Therapeutic_procedure
(	I-Therapeutic_procedure
eV3	I-Therapeutic_procedure
)	I-Therapeutic_procedure
was	I-Therapeutic_procedure
subsequently	I-Therapeutic_procedure
navigated	I-Therapeutic_procedure
over	O
a	O
Mirage	O
.	O
008	O
microwire	O
(	O
eV3	O
)	O
to	O
reach	O
as	O
near	O
as	O
possible	O
to	O
the	O
fistula	B-Sign_symptom
.	O

The	O
microcatheter	B-Therapeutic_procedure
was	I-Therapeutic_procedure
flushed	I-Therapeutic_procedure
with	O
10	B-Volume
mL	I-Volume
of	O
normal	B-Biological_structure
saline	I-Biological_structure
.	O

The	O
dead	O
space	O
of	O
the	O
microcatheter	B-Therapeutic_procedure
was	I-Therapeutic_procedure
subsequently	I-Therapeutic_procedure
filled	I-Therapeutic_procedure
with	O
dimethyl	B-Medication
sulfoxide	I-Medication
(	O
DMSO	O
)	O
.	O

Onyx	B-Medication
-	I-Medication
18	I-Medication
was	O
then	O
injected	B-Therapeutic_procedure
over	O
two	B-Duration
minutes	I-Duration
to	O
fill	O
the	O
microcatheter	O
and	O
to	O
replace	O
the	O
DMSO	O
in	O
the	O
dead	O
space	O
.	O

The	O
injection	B-Therapeutic_procedure
was	I-Therapeutic_procedure
stopped	I-Therapeutic_procedure
until	O
unwanted	O
flow	O
into	O
branches	O
of	O
the	O
right	O
ascending	O
pharyngeal	O
artery	O
was	O
observed	O
.	O

The	O
follow	B-Detailed_description
-	I-Detailed_description
up	I-Detailed_description
angiogram	B-Diagnostic_procedure
showed	O
no	O
residual	B-Sign_symptom
shunt	I-Sign_symptom
(	O
Figure	O
1	O
)	O
.	O

The	O
intracranial	B-Biological_structure
bruits	B-Sign_symptom
disappeared	O
immediately	O
after	O
the	O
operation	O
.	O

For	O
the	O
toxicity	O
of	O
DMSO	O
,	O
10	B-Dosage
mg	I-Dosage
dexamethasone	B-Medication
was	O
intravenously	O
injected	O
for	O
three	B-Duration
days	I-Duration
.	O

On	O
the	O
second	O
day	O
after	O
endovascular	O
treatment	O
,	O
the	O
patient	O
complainted	O
of	O
difficulty	B-Sign_symptom
moving	I-Sign_symptom
his	I-Sign_symptom
tongue	I-Sign_symptom
to	O
the	O
left	O
.	O

Cranial	B-Biological_structure
nerve	I-Biological_structure
examination	B-Diagnostic_procedure
was	O
only	O
significant	O
for	O
a	O
right	B-Sign_symptom
hypoglossal	I-Sign_symptom
nerve	I-Sign_symptom
palsy	I-Sign_symptom
.	O

The	O
patient	O
was	O
discharged	O
from	O
our	O
hospital	B-Nonbiological_location
four	O
days	O
after	O
treatment	O
without	O
continuative	B-Medication
pharmacotherapy	I-Medication
.	O

At	O
two	O
months	O
follow	O
-	O
up	O
,	O
the	O
patient	O
`	O
s	O
main	O
complaint	O
were	O
difficulty	O
swallowing	O
(	O
dysphagia	B-Sign_symptom
)	O
and	O
slurred	O
speech	O
(	O
dysarthria	B-Sign_symptom
)	O
.	O

In	O
addition	O
,	O
his	O
tongue	B-Lab_value
deviated	I-Lab_value
toward	I-Lab_value
the	I-Lab_value
right	I-Lab_value
during	O
tongue	B-Diagnostic_procedure
protrusion	I-Diagnostic_procedure
,	O
and	O
marked	B-Detailed_description
right	B-Detailed_description
-	I-Detailed_description
sided	I-Detailed_description
hemiatrophy	B-Sign_symptom
was	O
observed	O
(	O
Figure	O
2	O
)	O
.	O

The	O
cranial	B-Biological_structure
nerve	I-Biological_structure
examation	B-Diagnostic_procedure
showed	O
right	O
hypoglossal	O
nerve	O
palsy	O
persisted	O
.	O

We	O
telephone	O
the	O
patient	O
at	O
three	O
months	O
follow	O
-	O
up	O
and	O
requested	O
a	O
vocal	B-Diagnostic_procedure
cord	I-Diagnostic_procedure
evaluation	I-Diagnostic_procedure
by	O
an	O
ENT	O
specialist	O
in	O
a	O
local	B-Nonbiological_location
hospital	I-Nonbiological_location
.	O

Vocal	B-Biological_structure
cord	I-Biological_structure
paralysis	B-Sign_symptom
was	O
not	O
found	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
vagus	B-Biological_structure
nerve	I-Biological_structure
dysfunction	B-Sign_symptom
.	O

Oral	B-Medication
Vitamin	I-Medication
B12	I-Medication
was	O
used	O
and	O
his	O
prognosis	O
was	O
still	O
at	O
a	O
long	O
follow	O
-	O
up	O
.	O

-DOCSTART- -X- -X- -X- O

The	O
36	B-Age
-	I-Age
year	I-Age
-	I-Age
old	I-Age
male	O
patient	O
in	O
this	O
case	O
had	O
a	O
6	B-Duration
-	I-Duration
year	I-Duration
history	O
of	O
diffuse	B-Detailed_description
cutaneous	B-Biological_structure
SSc	B-Disease_disorder
(	O
Fig	O
.	O
1	O
)	O
and	O
had	O
not	O
received	O
regular	O
follow	O
-	O
up	O
or	O
medication	B-Medication
therapy	O
.	O

He	O
had	O
experienced	O
malaise	B-Sign_symptom
,	O
poor	B-Sign_symptom
appetite	I-Sign_symptom
,	O
and	O
progressive	B-Detailed_description
shortness	B-Sign_symptom
of	I-Sign_symptom
breath	I-Sign_symptom
for	O
1	B-Duration
month	I-Duration
and	O
oligouria	B-Sign_symptom
for	O
3	B-Duration
days	I-Duration
.	O

He	O
was	O
admitted	O
to	O
our	O
hospital	B-Nonbiological_location
with	O
renal	B-Disease_disorder
failure	I-Disease_disorder
and	O
pulmonary	B-Biological_structure
edema	B-Sign_symptom
.	O

In	O
the	O
emergency	O
department	O
,	O
his	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
,	O
pulse	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
,	O
and	O
respiratory	B-Diagnostic_procedure
rate	I-Diagnostic_procedure
were	O
174	B-Lab_value
/	I-Lab_value
127	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
88	B-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
and	O
22	B-Lab_value
/	I-Lab_value
min	I-Lab_value
,	O
respectively	O
.	O

Laboratory	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
revealed	O
the	O
following	O
values	O
:	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
7730	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
(	O
3500	O
-	O
11,000	O
/	O
μL	O
)	O
;	O
hemoglobin	B-Diagnostic_procedure
,	O
8	B-Lab_value
.	I-Lab_value
6	I-Lab_value
g	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
12	O
-	O
16	O
g	O
/	O
dL	O
)	O
:	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
,	O
87000	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
(	O
150,000	O
-	O
400,000	O
/	O
μL	O
)	O
;	O
blood	B-Diagnostic_procedure
urea	I-Diagnostic_procedure
nitrogen	I-Diagnostic_procedure
,	O
78	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
6	O
-	O
21	O
mg	O
/	O
dL	O
)	O
;	O
creatinine	B-Diagnostic_procedure
,	O
8	B-Lab_value
.	I-Lab_value
9	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
1	O
.	O
1	O
-	O
1	O
.	O
5	O
mg	O
/	O
dL	O
)	O
;	O
calcium	B-Diagnostic_procedure
,	O
8	B-Lab_value
.	I-Lab_value
2	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
8	O
.	O
8	O
-	O
10	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
phosphorus	B-Diagnostic_procedure
,	O
5	B-Lab_value
.	I-Lab_value
4	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
2	O
.	O
7	O
-	O
4	O
.	O
5	O
mg	O
/	O
dL	O
)	O
;	O
haptoglobin	B-Diagnostic_procedure
,	O
<	B-Lab_value
6	I-Lab_value
.	I-Lab_value
56	I-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
(	O
30	O
-	O
200	O
mg	O
/	O
dL	O
)	O
;	O
and	O
lactate	B-Diagnostic_procedure
dehydrogenase	I-Diagnostic_procedure
,	O
547	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
(	O
106	O
-	O
211	O
U	O
/	O
L	O
)	O
.	O

A	O
routine	O
urinalysis	B-Diagnostic_procedure
revealed	O
a	O
proteinuria	B-Lab_value
score	I-Lab_value
of	I-Lab_value
2	I-Lab_value
+	I-Lab_value
(	O
200	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dL	I-Lab_value
)	O
,	O
white	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
3	B-Lab_value
-	I-Lab_value
5	I-Lab_value
/	I-Lab_value
high	I-Lab_value
power	I-Lab_value
field	I-Lab_value
,	O
and	O
red	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
cell	I-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
25	B-Lab_value
-	I-Lab_value
50	I-Lab_value
/	I-Lab_value
high	I-Lab_value
power	I-Lab_value
field	I-Lab_value
.	O

The	O
autoimmune	B-Diagnostic_procedure
profile	I-Diagnostic_procedure
indicated	O
an	O
antinuclear	B-Diagnostic_procedure
antibody	I-Diagnostic_procedure
level	O
of	O
1:320	B-Lab_value
(	O
speckles	B-Lab_value
;	I-Lab_value
normal	I-Lab_value
,	O
<	B-Lab_value
1:40	I-Lab_value
)	O
.	O

Tests	O
for	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Scl70	I-Diagnostic_procedure
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
double	I-Diagnostic_procedure
-	I-Diagnostic_procedure
stranded	I-Diagnostic_procedure
DNA	I-Diagnostic_procedure
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
Ro	I-Diagnostic_procedure
,	O
anti	B-Diagnostic_procedure
-	I-Diagnostic_procedure
La	I-Diagnostic_procedure
,	O
and	O
anticardiolipin	B-Diagnostic_procedure
antibodies	I-Diagnostic_procedure
were	O
all	O
negative	B-Lab_value
.	O

Kidney	B-Biological_structure
echogram	B-Diagnostic_procedure
showed	O
a	O
decreased	B-Sign_symptom
bilateral	I-Sign_symptom
kidney	I-Sign_symptom
size	I-Sign_symptom
without	O
hydronephrosis	B-Sign_symptom
.	O

Despite	O
the	O
chronic	O
changes	O
visible	O
on	O
the	O
echogram	O
,	O
the	O
patient	O
had	O
developed	O
acute	O
pulmonary	B-Biological_structure
edema	B-Sign_symptom
and	O
oligouria	B-Sign_symptom
only	O
3	O
days	O
before	O
admission	O
.	O

Accordingly	O
,	O
a	O
clinical	O
diagnosis	O
of	O
acute	B-Detailed_description
-	I-Detailed_description
on	I-Detailed_description
-	I-Detailed_description
chronic	I-Detailed_description
renal	B-Disease_disorder
failure	I-Disease_disorder
was	O
made	O
.	O

A	O
further	O
diagnosis	O
of	O
SRC	B-Disease_disorder
was	O
supported	O
by	O
the	O
presence	O
of	O
renal	B-Disease_disorder
failure	I-Disease_disorder
with	O
microangiopathic	B-Detailed_description
hemolytic	B-Detailed_description
anemia	B-Sign_symptom
and	O
hypertension	B-Sign_symptom
,	O
and	O
the	O
patient	O
was	O
started	O
on	O
captopril	B-Medication
therapy	O
.	O

The	O
sustained	O
deterioration	B-Sign_symptom
in	I-Sign_symptom
renal	I-Sign_symptom
function	I-Sign_symptom
and	O
anuria	B-Sign_symptom
had	O
led	O
to	O
a	O
requirement	O
for	O
regular	B-Detailed_description
hemodialysis	B-Therapeutic_procedure
from	O
admission	O
.	O

After	O
3	O
days	O
,	O
captopril	B-Medication
was	O
changed	O
to	O
amlodipine	B-Medication
because	O
the	O
patient	O
developed	O
a	O
severe	B-Severity
,	O
intolerable	B-Detailed_description
cough	B-Sign_symptom
thought	O
to	O
be	O
associated	O
with	O
captopril	O
.	O

His	O
systolic	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
pressure	I-Diagnostic_procedure
was	O
controlled	B-Lab_value
between	B-Lab_value
140	I-Lab_value
and	I-Lab_value
180	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
.	O

At	O
approximately	O
3	O
weeks	O
after	O
the	O
initiation	O
of	O
maintenance	O
hemodialysis	O
,	O
the	O
patient	O
newly	O
developed	O
a	O
generalized	B-Detailed_description
tonic	B-Detailed_description
-	I-Detailed_description
clonic	I-Detailed_description
seizure	B-Disease_disorder
disorder	I-Disease_disorder
.	O

A	O
brain	B-Biological_structure
computed	B-Diagnostic_procedure
tomography	I-Diagnostic_procedure
(	O
CT	B-Diagnostic_procedure
)	O
scan	O
revealed	O
a	O
small	B-Severity
lacunar	B-Detailed_description
infarct	B-Disease_disorder
over	O
the	O
left	B-Biological_structure
basal	I-Biological_structure
ganglion	I-Biological_structure
without	O
intracranial	B-Biological_structure
hemorrhage	B-Disease_disorder
or	O
large	B-Severity
infarct	B-Disease_disorder
.	O

The	O
seizure	B-Sign_symptom
resolved	O
spontaneously	O
without	O
anticonvulsants	B-Medication
,	O
and	O
the	O
patient	O
was	O
finally	O
discharged	O
home	B-Nonbiological_location
without	O
incident	O
and	O
scheduled	O
for	O
regular	O
hemodialysis	B-Therapeutic_procedure
thrice	B-Frequency
weekly	I-Frequency
.	O

However	O
,	O
at	O
1	O
week	O
after	O
discharge	O
,	O
the	O
patient	O
developed	O
a	O
sudden	B-Detailed_description
-	I-Detailed_description
onset	I-Detailed_description
headache	B-Sign_symptom
and	O
vomiting	B-Sign_symptom
with	O
confusion	B-Sign_symptom
and	O
recurrence	O
of	O
the	O
generalized	B-Detailed_description
tonic	B-Detailed_description
-	I-Detailed_description
clonic	I-Detailed_description
seizure	B-Sign_symptom
.	O

He	O
presented	O
at	O
the	O
emergency	B-Nonbiological_location
department	I-Nonbiological_location
with	O
a	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
of	O
183	B-Lab_value
/	I-Lab_value
100	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
,	O
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
of	O
149,000	B-Lab_value
/	I-Lab_value
μL	I-Lab_value
,	O
serum	B-Diagnostic_procedure
LDH	I-Diagnostic_procedure
of	O
332	B-Lab_value
U	I-Lab_value
/	I-Lab_value
L	I-Lab_value
,	O
and	O
a	O
peripheral	B-Diagnostic_procedure
blood	I-Diagnostic_procedure
smear	I-Diagnostic_procedure
containing	B-Lab_value
2	I-Lab_value
-	I-Lab_value
3	I-Lab_value
schizocytes	I-Lab_value
/	I-Lab_value
HPF	I-Lab_value
(	O
Fig	O
.	O
2	O
)	O
.	O

Brain	B-Biological_structure
CT	B-Diagnostic_procedure
revealed	O
no	B-Lab_value
interval	I-Lab_value
change	I-Lab_value
,	O
and	O
lumbar	B-Diagnostic_procedure
puncture	I-Diagnostic_procedure
revealed	O
traumatic	B-Lab_value
tapping	I-Lab_value
only	I-Lab_value
.	O

Cerebrospinal	B-Biological_structure
fluid	B-Diagnostic_procedure
cultures	I-Diagnostic_procedure
were	O
negative	B-Lab_value
for	O
bacteria	B-Detailed_description
,	O
mycobacteria	B-Detailed_description
,	O
and	O
viruses	B-Detailed_description
.	O

Brain	B-Biological_structure
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
showed	O
bilateral	B-Detailed_description
hyperintensity	B-Sign_symptom
in	O
the	O
occipital	B-Biological_structure
and	I-Biological_structure
parietal	I-Biological_structure
lobes	I-Biological_structure
on	O
a	O
fluid	B-Detailed_description
-	I-Detailed_description
attenuated	I-Detailed_description
inversion	I-Detailed_description
recovery	I-Detailed_description
(	I-Detailed_description
FLAIR	I-Detailed_description
)	I-Detailed_description
sequence	I-Detailed_description
(	O
Fig	O
.	O
3	O
)	O
.	O

Finally	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
PRES	B-Disease_disorder
.	O

We	O
resumed	O
captopril	B-Medication
therapy	O
at	O
a	O
dose	O
of	O
25	B-Dosage
mg	I-Dosage
thrice	I-Dosage
daily	I-Dosage
.	O

As	O
it	O
was	O
difficult	O
to	O
differentiate	O
SRC	O
from	O
TTP	O
,	O
we	O
also	O
considered	O
plasma	O
exchange	O
treatment	O
.	O

However	O
,	O
the	O
patient	O
`	O
s	O
mental	B-Diagnostic_procedure
status	I-Diagnostic_procedure
returned	O
to	O
normal	B-Lab_value
within	O
3	O
days	O
in	O
the	O
absence	O
of	O
plasma	B-Therapeutic_procedure
exchange	I-Therapeutic_procedure
,	O
and	O
a	O
follow	O
-	O
up	O
MRI	B-Diagnostic_procedure
of	O
the	O
brain	B-Biological_structure
2	O
months	O
later	O
showed	O
complete	O
resolution	O
of	O
cerebral	B-Biological_structure
edema	B-Sign_symptom
(	O
Fig	O
.	O
4	O
)	O
.	O

Therefore	O
,	O
SRC	B-Detailed_description
-	I-Detailed_description
related	I-Detailed_description
PRES	B-Disease_disorder
was	O
confirmed	O
.	O

Although	O
the	O
patient	O
experienced	O
a	O
full	B-Sign_symptom
neurologic	I-Sign_symptom
recovery	I-Sign_symptom
,	O
his	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
did	B-Lab_value
not	I-Lab_value
improve	I-Lab_value
and	O
he	O
remained	O
dialysis	B-Therapeutic_procedure
dependent	B-Detailed_description
.	O

-DOCSTART- -X- -X- -X- O

The	O
patient	O
was	O
a	O
34	B-Age
-	I-Age
yr	I-Age
-	I-Age
old	I-Age
man	O
who	O
presented	O
with	O
complaints	O
of	O
fever	B-Sign_symptom
and	O
a	O
chronic	B-Detailed_description
cough	B-Sign_symptom
.	O

He	O
was	O
a	O
smoker	O
and	O
had	O
a	O
history	O
of	O
pulmonary	B-Biological_structure
tuberculosis	B-Disease_disorder
that	O
had	O
been	O
treated	B-Lab_value
and	I-Lab_value
cured	I-Lab_value
.	O

A	O
computed	B-Diagnostic_procedure
tomographic	I-Diagnostic_procedure
(	B-Diagnostic_procedure
CT	I-Diagnostic_procedure
)	I-Diagnostic_procedure
scan	O
revealed	O
multiple	B-Detailed_description
tiny	B-Detailed_description
nodules	B-Sign_symptom
in	O
both	B-Biological_structure
lungs	I-Biological_structure
.	O

A	O
thoracoscopic	B-Detailed_description
lung	B-Biological_structure
biopsy	B-Diagnostic_procedure
was	O
taken	O
from	O
the	O
right	B-Biological_structure
upper	I-Biological_structure
lobe	I-Biological_structure
.	O

The	O
microscopic	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
revealed	O
a	O
typical	O
LCH	B-Sign_symptom
.	O

The	O
tumor	O
cells	O
had	O
vesicular	B-Detailed_description
and	O
grooved	B-Texture
nuclei	B-Biological_structure
,	O
and	O
they	O
formed	O
small	B-Biological_attribute
aggregations	B-Biological_attribute
around	B-Biological_structure
the	I-Biological_structure
bronchioles	I-Biological_structure
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
tumor	O
cells	O
were	O
strongly	B-Severity
positive	B-Lab_value
for	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
,	O
vimentin	B-Diagnostic_procedure
,	O
CD68	B-Diagnostic_procedure
and	O
CD1a	B-Diagnostic_procedure
.	O

There	O
were	O
infiltrations	B-Biological_structure
of	O
lymphocytes	B-Biological_structure
and	O
eosinophils	B-Biological_structure
around	O
the	O
tumor	O
cells	O
.	O

With	O
performing	O
additional	O
radiologic	B-Diagnostic_procedure
examinations	I-Diagnostic_procedure
,	O
no	B-Sign_symptom
other	I-Sign_symptom
organs	I-Sign_symptom
were	I-Sign_symptom
thought	I-Sign_symptom
to	I-Sign_symptom
be	I-Sign_symptom
involved	I-Sign_symptom
.	O

He	O
quit	B-Activity
smoking	I-Activity
,	O
but	O
he	O
received	O
no	O
other	O
specific	O
treatment	O
.	O

He	O
was	O
well	B-Sign_symptom
for	B-Duration
the	I-Duration
following	I-Duration
one	I-Duration
year	I-Duration
.	O

After	O
this	O
,	O
a	O
follow	O
-	O
up	O
CT	B-Diagnostic_procedure
scan	I-Diagnostic_procedure
was	O
performed	O
and	O
it	O
showed	O
a	O
4	B-Shape
cm	I-Shape
-	I-Shape
sized	I-Shape
mass	B-Sign_symptom
in	O
the	O
left	B-Biological_structure
lower	I-Biological_structure
lobe	I-Biological_structure
,	O
in	O
addition	O
to	O
the	O
multiple	B-Detailed_description
tiny	B-Detailed_description
nodules	B-Sign_symptom
in	O
both	B-Biological_structure
lungs	I-Biological_structure
(	O
Fig	O
.	O
2	O
)	O
.	O

A	O
needle	B-Detailed_description
biopsy	B-Diagnostic_procedure
specimen	O
revealed	O
the	O
possibility	B-Sign_symptom
of	I-Sign_symptom
a	I-Sign_symptom
sarcoma	I-Sign_symptom
;	O
therefore	O
,	O
a	O
lobectomy	B-Therapeutic_procedure
was	O
performed	O
.	O

Grossly	O
,	O
a	O
4	B-Shape
cm	I-Shape
-	I-Shape
sized	I-Shape
poorly	B-Detailed_description
-	I-Detailed_description
circumscribed	I-Detailed_description
lobulated	B-Detailed_description
gray	B-Color
-	I-Color
white	I-Color
mass	B-Sign_symptom
was	O
found	O
(	O
Fig	O
.	O
3	O
)	O
,	O
and	O
there	O
were	O
a	O
few	O
small	B-Detailed_description
satellite	B-Detailed_description
nodules	B-Sign_symptom
around	O
the	O
main	O
mass	O
.	O

Microscopically	B-Diagnostic_procedure
,	O
the	O
tumor	O
cells	O
were	O
aggregated	B-Detailed_description
in	I-Detailed_description
large	I-Detailed_description
sheets	I-Detailed_description
and	O
they	O
showed	O
an	O
infiltrative	B-Biological_structure
growth	I-Biological_structure
.	O

The	O
cytologic	B-Biological_attribute
features	I-Biological_attribute
of	O
some	O
of	O
the	O
tumor	O
cells	O
were	O
similar	B-Detailed_description
to	I-Detailed_description
those	I-Detailed_description
seen	I-Detailed_description
in	I-Detailed_description
a	I-Detailed_description
typical	I-Detailed_description
LCH	I-Detailed_description
.	O

However	O
,	O
many	O
tumor	O
cells	O
showed	O
overtly	O
malignant	O
cytologic	B-Biological_attribute
features	I-Biological_attribute
such	O
as	O
pleomorphic	B-Detailed_description
/	I-Detailed_description
hyperchromatic	I-Detailed_description
nuclei	B-Biological_structure
and	O
prominent	B-Detailed_description
nucleoli	B-Biological_attribute
(	O
Fig	O
.	O
4	O
)	O
,	O
and	O
multinucleated	B-Detailed_description
tumor	B-Biological_structure
giant	I-Biological_structure
cells	I-Biological_structure
were	O
also	O
found	O
.	O

There	O
were	O
numerous	B-Detailed_description
mitotic	B-Biological_structure
figures	I-Biological_structure
ranging	O
from	O
30	B-Lab_value
to	I-Lab_value
60	I-Lab_value
per	I-Lab_value
10	I-Lab_value
high	I-Lab_value
power	I-Lab_value
fields	I-Lab_value
,	O
and	O
some	B-Detailed_description
of	I-Detailed_description
them	I-Detailed_description
were	I-Detailed_description
abnormal	I-Detailed_description
.	O

A	O
few	B-Detailed_description
foci	I-Detailed_description
of	O
typical	B-Sign_symptom
LCH	I-Sign_symptom
remained	O
around	B-Detailed_description
the	I-Detailed_description
main	I-Detailed_description
tumor	I-Detailed_description
mass	I-Detailed_description
.	O

Immunohistochemically	B-Diagnostic_procedure
,	O
the	O
tumor	O
cells	O
were	O
strongly	B-Severity
positive	B-Lab_value
for	O
S	B-Diagnostic_procedure
-	I-Diagnostic_procedure
100	I-Diagnostic_procedure
protein	I-Diagnostic_procedure
(	O
Fig	O
.	O
5	O
)	O
and	O
vimentin	B-Diagnostic_procedure
;	O
they	O
were	O
also	O
positive	B-Lab_value
for	O
CD68	B-Diagnostic_procedure
(	O
Dako	O
N1577	O
,	O
Clone	O
KPI	O
)	O
,	O
and	O
focally	B-Detailed_description
positive	B-Lab_value
for	O
CD1a	B-Diagnostic_procedure
(	O
Fig	O
.	O
6	O
)	O
,	O
and	O
they	O
were	O
negative	B-Lab_value
for	O
cytokeratin	B-Diagnostic_procedure
,	O
epithelial	B-Diagnostic_procedure
membrane	I-Diagnostic_procedure
antigen	I-Diagnostic_procedure
,	O
CD3	B-Diagnostic_procedure
,	O
CD20	B-Diagnostic_procedure
and	O
HMB45	B-Diagnostic_procedure
.	O

The	O
ultrastructural	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
failed	B-Sign_symptom
to	I-Sign_symptom
demonstrate	I-Sign_symptom
any	I-Sign_symptom
Birbeck	I-Sign_symptom
granules	I-Sign_symptom
in	O
the	O
cytoplasm	B-Biological_structure
of	O
the	O
tumor	B-Sign_symptom
cells	I-Sign_symptom
.	O

Now	O
,	O
at	O
five	O
months	O
after	O
lobectomy	O
,	O
the	O
patient	O
is	O
doing	O
well	O
with	O
no	B-Sign_symptom
significant	I-Sign_symptom
change	I-Sign_symptom
in	I-Sign_symptom
the	I-Sign_symptom
radiologic	I-Sign_symptom
findings	I-Sign_symptom
.	O

-DOCSTART- -X- -X- -X- O

A	O
woman	O
aged	B-Age
31	I-Age
years	I-Age
,	O
G2P2	O
,	O
without	O
any	O
pathological	O
past	O
history	O
,	O
with	O
good	B-Lab_value
prenatal	B-Therapeutic_procedure
care	I-Therapeutic_procedure
,	O
with	O
a	O
normal	B-Lab_value
prenatal	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
,	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
during	O
the	O
follow	O
-	O
up	O
was	O
normal	B-Lab_value
,	O
admitted	O
for	O
elective	O
caesarian	B-Therapeutic_procedure
section	I-Therapeutic_procedure
at	O
38	B-Duration
weeks	I-Duration
of	O
amenorrhea	B-Sign_symptom
.	O

During	O
realization	O
of	O
the	O
spinal	B-Biological_structure
anesthesia	B-Therapeutic_procedure
the	O
patient	O
presented	O
peak	O
of	O
the	O
hypertensive	B-Sign_symptom
(	O
180	B-Lab_value
/	I-Lab_value
100	I-Lab_value
mm	I-Lab_value
Hg	I-Lab_value
)	O
which	O
normalized	B-Lab_value
after	B-Time
a	I-Time
few	I-Time
minutes	I-Time
without	O
treatment	B-Therapeutic_procedure
.	O

In	O
post	O
-	O
partum	O
,	O
after	B-Time
12	I-Time
hours	I-Time
of	O
the	O
caesarian	O
section	O
the	O
lady	O
presented	O
a	O
severe	B-Severity
headache	B-Sign_symptom
with	O
apyrexia	B-Sign_symptom
then	O
she	O
developed	O
three	B-Detailed_description
episodes	I-Detailed_description
of	O
generalized	B-Detailed_description
tonico	B-Detailed_description
-	I-Detailed_description
clonic	I-Detailed_description
convulsions	B-Sign_symptom
.	O

The	O
1st	B-Detailed_description
convulsion	B-Sign_symptom
ceased	O
1	B-Time
min	I-Time
after	I-Time
the	O
measures	O
of	O
resuscitation	B-Therapeutic_procedure
and	O
injection	O
of	O
diazepam	B-Medication
IV	I-Medication
.	O

The	O
post	O
-	O
critical	O
clinical	B-Diagnostic_procedure
examination	I-Diagnostic_procedure
found	O
an	O
afebrile	B-Sign_symptom
patient	O
and	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
at	O
140	B-Lab_value
/	I-Lab_value
90	I-Lab_value
mmHg	I-Lab_value
and	O
with	O
Glasgow	B-Diagnostic_procedure
coma	I-Diagnostic_procedure
scale	I-Diagnostic_procedure
at	O
14	B-Lab_value
without	O
any	O
neurological	B-Sign_symptom
deficit	I-Sign_symptom
,	O
there	O
was	O
no	O
neck	B-Biological_structure
rigidity	B-Sign_symptom
,	O
diuresis	B-Sign_symptom
was	O
preserved	O
.	O

The	O
examination	B-Diagnostic_procedure
of	I-Diagnostic_procedure
urines	I-Diagnostic_procedure
by	O
urinary	B-Detailed_description
strip	I-Detailed_description
was	O
positive	B-Lab_value
(	O
+	O
+	O
+	O
)	O
.	O

The	O
2nd	B-Detailed_description
and	I-Detailed_description
3th	I-Detailed_description
convulsive	B-Sign_symptom
crisis	I-Sign_symptom
stoped	O
spontaneously	O
within	B-Time
few	I-Time
seconds	I-Time
.	O

Laboratory	B-Diagnostic_procedure
findings	I-Diagnostic_procedure
of	O
HELLP	B-Disease_disorder
syndrome	I-Disease_disorder
include	O
raised	B-Lab_value
liver	B-Diagnostic_procedure
enzymes	I-Diagnostic_procedure
(	O
ASAT	B-Diagnostic_procedure
525	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
and	O
ALAT	B-Diagnostic_procedure
214	B-Lab_value
IU	I-Lab_value
/	I-Lab_value
L	I-Lab_value
)	O
,	O
hemolysis	B-Sign_symptom
(	O
hemoglobinemia	B-Sign_symptom
in	O
7	B-Lab_value
mg	I-Lab_value
/	I-Lab_value
dl	I-Lab_value
)	O
and	O
low	B-Lab_value
platelet	B-Diagnostic_procedure
count	I-Diagnostic_procedure
(	O
44	B-Lab_value
000	I-Lab_value
platelet	I-Lab_value
/	I-Lab_value
mL	I-Lab_value
)	O
.	O

Other	O
investigations	O
included	O
the	O
renal	B-Diagnostic_procedure
function	I-Diagnostic_procedure
tests	I-Diagnostic_procedure
,	O
the	O
inflammatory	B-Diagnostic_procedure
markers	I-Diagnostic_procedure
,	O
the	O
thyroid	B-Diagnostic_procedure
hormones	I-Diagnostic_procedure
were	O
normal	B-Lab_value
.	O

The	O
viral	B-Diagnostic_procedure
serology	I-Diagnostic_procedure
was	O
negative	B-Lab_value
.	O

The	O
patient	O
was	O
transferred	O
to	O
intensive	B-Nonbiological_location
care	I-Nonbiological_location
unit	I-Nonbiological_location
;	O
she	O
was	O
treated	O
immediately	O
by	O
magnesium	B-Medication
sulfate	I-Medication
associated	O
to	O
calcium	B-Medication
channel	I-Medication
blocker	I-Medication
(	O
nicardipine	B-Medication
)	O
,	O
antiepileptic	B-Medication
(	O
phenobarbital	B-Medication
)	O
and	O
preventive	O
dose	O
of	O
low	B-Detailed_description
molecular	I-Detailed_description
weight	I-Detailed_description
heparin	B-Medication
.	O

The	O
anemia	B-Sign_symptom
and	O
thrombopenia	B-Sign_symptom
corrected	O
by	O
transfusion	B-Therapeutic_procedure
of	O
packed	B-Medication
red	I-Medication
blood	I-Medication
cells	I-Medication
and	O
platelet	B-Medication
respectively	O
.	O

The	O
magnetic	B-Diagnostic_procedure
resonance	I-Diagnostic_procedure
imaging	I-Diagnostic_procedure
(	O
MRI	B-Diagnostic_procedure
)	O
,	O
realized	O
one	B-Time
hour	I-Time
after	I-Time
the	O
first	O
episode	O
of	O
convulsion	O
showed	O
zones	B-Sign_symptom
in	O
hyposignal	B-Diagnostic_procedure
T1	I-Diagnostic_procedure
,	O
hypersignal	B-Diagnostic_procedure
T2	I-Diagnostic_procedure
and	O
flair	B-Diagnostic_procedure
sequences	I-Diagnostic_procedure
,	O
interesting	O
the	O
cerebral	B-Biological_structure
cortex	I-Biological_structure
,	O
parietal	B-Biological_structure
and	O
occipital	B-Biological_structure
sub	I-Biological_structure
-	I-Biological_structure
cortical	I-Biological_structure
and	O
the	O
white	B-Biological_structure
matter	I-Biological_structure
.	O

Intracranial	B-Biological_structure
venous	I-Biological_structure
sinuses	I-Biological_structure
were	O
permeable	B-Sign_symptom
.	O

The	O
diagnosis	O
of	O
the	O
PRES	B-Disease_disorder
syndrome	I-Disease_disorder
secondary	O
to	O
the	O
severe	B-Severity
preeclampsia	B-Disease_disorder
immediate	O
post	O
-	O
partum	O
was	O
retained	O
(	O
Figure	O
1	O
)	O
.	O

The	O
electroencephalogram	B-Diagnostic_procedure
(	O
EEG	B-Diagnostic_procedure
)	O
realized	O
in	O
the	O
second	O
day	O
did	O
not	O
showed	O
anomaly	B-Sign_symptom
.	O

The	O
evolution	O
was	O
marked	O
by	O
the	O
normalization	B-Lab_value
of	O
blood	B-Diagnostic_procedure
pressure	I-Diagnostic_procedure
,	O
the	O
normalization	B-Lab_value
of	O
the	O
neurological	B-Diagnostic_procedure
state	I-Diagnostic_procedure
and	O
of	O
the	O
biological	B-Diagnostic_procedure
analysis	I-Diagnostic_procedure
.	O

The	O
patient	O
discharged	O
in	O
good	B-Lab_value
condition	B-Diagnostic_procedure
on	O
day	O
5	O
,	O
with	O
beta	B-Medication
-	I-Medication
blocker	I-Medication
and	O
sodium	B-Medication
valproate	I-Medication
maintained	O
during	O
three	B-Duration
months	I-Duration
.	O

THE	O
MRI	B-Diagnostic_procedure
of	O
the	O
controle	O
made	O
three	O
months	O
later	O
showed	O
complete	O
resolution	O
of	O
cerebral	B-Biological_structure
edema	B-Sign_symptom
Figure	O
2	O
.	O

